<SEC-DOCUMENT>0000950123-22-001044.txt : 20230929
<SEC-HEADER>0000950123-22-001044.hdr.sgml : 20230929
<ACCEPTANCE-DATETIME>20220204170535
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-22-001044
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		29
FILED AS OF DATE:		20220204
<PUBLIC-REL-DATE>20230929
DATE AS OF CHANGE:		20220207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexeo Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001907108
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-05985
		FILM NUMBER:		22594435

	BUSINESS ADDRESS:	
		STREET 1:		430 E. 29TH STREET
		STREET 2:		FLOOR 14
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		(212) 547-9879

	MAIL ADDRESS:	
		STREET 1:		430 E. 29TH STREET
		STREET 2:		FLOOR 14
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As submitted to the Securities and Exchange Commission confidentially on February 4, 2022.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein
remains strictly confidential. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES ACT
OF 1933 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Lexeo Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Exact name of registrant as specified in its charter) </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">85-4012572</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>430 East 29<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street, Floor 14 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">547-9879</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>R. Nolan Townsend </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lexeo Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>430 East 29<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street, Floor 14 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">547-9879</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>Copies to:</I></B><B> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Eric Blanchard</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Divakar Gupta</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Peter
Byrne</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dayne Brown</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>55 Hudson
Yards</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10001</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">479-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Seo Salimi</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>William A. Magioncalda</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>620
Eighth Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10018</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">813-8800</FONT></B></P></TD></TR>
</TABLE> <center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:&nbsp;&nbsp;&nbsp;&nbsp;</B>As soon as practicable after this Registration Statement is
declared effective. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to
Rule 462(b)&nbsp;under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective
amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744;
</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Emerging&nbsp;growth&nbsp;company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends
this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#8b3f4e"><B>The information in this preliminary prospectus is not complete and may be changed.
These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities nor does it seek an offer to buy these securities
in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#8b3f4e"><B>Subject to completion, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022
</B></FONT></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; text-indent:-3%; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </I></B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g12x08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; text-indent:-3%; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is an initial public offering of shares of common stock of Lexeo Therapeutics, Inc. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. The initial public offering is expected to
be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. We intend to apply to list our common stock on the Nasdaq Global Market under the
trading symbol &#147;LXEO.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; as defined under U.S. federal
securities laws and, as such, will be subject to reduced public company reporting requirements for this prospectus and future filings. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company and a Smaller Reporting
Company.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>Investing in our common stock involves risks. See &#147;<A HREF="#toc287237_2">Risk Factors</A>&#148; beginning on
page&nbsp;14 to read about factors you should consider before buying shares of our common stock. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor
any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to Lexeo Therapeutics,
Inc.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See the section titled &#147;Underwriting&#148; for a description of the compensation payable to the underwriters. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
additional shares from us at the public offering price less the underwriting discount. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares against payment in
New York, New York on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="bottom"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>SVB&nbsp;Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Stifel</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>RBC&nbsp;Capital&nbsp;Markets</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Chardan </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Prospectus dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="toc"></A>Table of contents </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_4">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of
 Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_12">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_13">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_14">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_15">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_16">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_17">Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_18">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_19">Legal matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_21">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc287237_22">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than
those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide you. We
are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the
time of delivery of this prospectus or of any sale of the common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: We have not, and the underwriters have
not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into
possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All trademarks, trade names and service marks appearing in this prospectus are the property of their
respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>
symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Implications
of the FAST Act </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the applicable provisions of the Fixing America&#146;s Surface Transportation Act, we are not required to file our
financial information for the year ended December&nbsp;31, 2019 because we expect to file our financial information for the year ended December&nbsp;31, 2021 in our registration statement when it is first publicly filed. While the financial
information for the year ended December&nbsp;31, 2019 is otherwise required by Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> it will not be required to be included in the Form <FONT STYLE="white-space:nowrap">S-1</FONT> filing at the time
of the contemplated offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_1"></A>Prospectus summary </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights, and is qualified in its entirety by, information contained elsewhere in this prospectus. This summary does not contain all of the
information you should consider before investing in our common stock. You should read this entire prospectus carefully, especially the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; and our financial statements and the related notes thereto appearing elsewhere in this prospectus, before making an investment decision. As used in this prospectus, unless the context otherwise requires,
references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;the Company,&#148; &#147;Lexeo&#148; and &#147;Lexeo Therapeutics&#148; refer to Lexeo Therapeutics, Inc. </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage gene therapy company
focused on addressing some of the most devastating genetically defined cardiovascular and central nervous system diseases affecting both larger-rare and prevalent patient populations. We are advancing a deep and diverse pipeline of <FONT
STYLE="white-space:nowrap">AAV-based</FONT> gene therapy candidates utilizing our modular approach that integrates clinically validated technology, a disease area strategy targeting defined patient
<FONT STYLE="white-space:nowrap">sub-populations</FONT> most likely to benefit from our gene therapy candidates, and high-quality, scalable manufacturing, which is designed to overcome many of the challenges facing the field of gene therapy. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to initiate a Phase 1/2 clinical trial in <FONT STYLE="white-space:nowrap">mid-2022</FONT> for our most advanced cardiovascular program, LX2006 for
the treatment of patients with the cardiac manifestation of Friedreich&#146;s ataxia, or FA cardiomyopathy, and we expect to report initial biomarker data by the end of 2022. Our lead central nervous system, or CNS, product candidate, LX1001, is in
an ongoing Phase 1/2 trial for the treatment of apolipoprotein E4, or APOE4, associated Alzheimer&#146;s disease. We have initially observed an increase in expression levels of the protective protein, APOE2, and a reduction in core Alzheimer&#146;s
disease biomarkers in the low dose cohort of this ongoing trial. We expect to report initial biomarker data from the <FONT STYLE="white-space:nowrap">mid-dose</FONT> cohort by the end of 2022. Utilizing a step-wise, capital-efficient development
approach, we are leveraging early <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> functional and biomarker data to build a pipeline of gene therapy programs targeting cardiovascular indications and
Alzheimer&#146;s disease for genetically defined populations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our integrated, modular approach enables us to optimize our strategy to pursue larger-rare
and prevalent genetically defined indications in specific sub-populations of patients. Our gene therapy candidates utilize the vector construct, dose and route of administration that we believe will result in the most favorable biodistribution and
safety profile for our product candidate for each disease. Our most advanced cardiovascular and CNS programs use the AAVrh10 vector due to its high transduction efficiency in both myocardial cells and neurons, potentially lower toxicity given its
ability to utilize lower doses compared to other well-established adeno-associated virus, or AAV, serotypes, and lower <FONT STYLE="white-space:nowrap">pre-existing</FONT> immunity. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By specifically tailoring our technological approach to each targeted disease, we believe we can design our programs to achieve the highest likelihood of
having therapeutic impact. We target genetically defined indications in specific <FONT STYLE="white-space:nowrap">sub-populations</FONT> of patients that may be most amenable to gene therapy. These target indications offer the potential to show
therapeutic impact through functional endpoints or biomarkers, have high unmet need and large market opportunities, have demonstrated promising preclinical data, and have organized patient advocacy groups and identifiable patient populations. We
believe targeting cardiac and CNS diseases can be enhanced by our current approach utilizing AAVrh10 as well as ongoing discovery efforts to identify a next-generation vector technology with the best potential therapeutic profile. Finally, we
continuously seek to bolster our pipeline through relationships with academic institutions, which provide us access to cutting edge gene therapy research that we will utilize in the discovery and development of next generation gene therapy
candidates. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Our pipeline </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing a deep and diverse pipeline of cardiovascular and CNS therapeutic programs for larger-rare and prevalent diseases. We retain exclusive
worldwide development and commercialization rights to all of our product candidates and programs. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g30r12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lead cardiovascular programs </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are seeking to develop a number of disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases that have significant unmet need
and no approved treatments addressing the underlying genetic cause of the disease. These programs include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>LX2006</I> is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional frataxin,
or <I>FXN, </I>gene<I> </I>for the treatment of FA cardiomyopathy. FA cardiomyopathy is the most common cause of mortality in patients with Friedreich&#146;s ataxia and affects approximately 5,600 patients in the United States. LX2006 is designed to
promote the expression of the protein frataxin to restore normal mitochondrial function and energy production in myocardial cells. In preclinical studies, LX2006 demonstrated improvement in cardiac function and survival in a severe <I>FXN</I>
knockout mouse model as well as restoration of cardiac function and reversal of the disease abnormalities of FA cardiomyopathy in a partial <I>FXN</I> knockout mouse model. Our investigational new drug application, or IND, for LX2006 was cleared by
the U.S. Food and Drug Administration, or FDA, in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. We expect to initiate an open-label, dose-escalation Phase 1/2 clinical trial in patients with
FA cardiomyopathy in <FONT STYLE="white-space:nowrap">mid-2022,</FONT> and we expect to report interim biomarker data by the end of 2022. The FDA has granted Rare Pediatric Disease designation and Orphan Drug designation to LX2006 for the treatment
of Friedreich&#146;s ataxia. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>LX2020</I> is an AAVrh10-based gene therapy candidate designed to intravenously deliver a fully
functional<I>&nbsp;PKP2</I><I></I>&nbsp;gene to cardiac muscle for the treatment of arrhythmogenic right ventricular cardiomyopathy, or ARVC, caused by mutations in the <I>PKP2</I> gene. <I>PKP2</I> mutations are associated with approximately 75% of
all genetic cases of ARVC, and we estimate they affect more than 70,000 patients in the United States. <I>PKP2</I> mutations can cause replacement of heart muscle with fibrotic tissue and fatty deposits, and severe abnormal heart rhythms, or
arrhythmias, that cause cardiac dysfunction and can result in sudden cardiac death. LX2020 is designed to increase desmosomal PKP2 protein levels, reassemble desmosomes and restore myocardial cell
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
function. In our preclinical studies, LX2020 resulted in fewer arrhythmias and increased survival. We intend to submit an IND for LX2020 in 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lead CNS programs </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing a pipeline of CNS
focused gene therapies that includes a portfolio of approaches to treat the genetics underlying Alzheimer&#146;s disease as well as a program designed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, or CLN2 Batten disease. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>LX1001</I> is an AAVrh10-based gene therapy candidate designed to deliver via
<FONT STYLE="white-space:nowrap">one-time</FONT> administration into the cerebrospinal fluid, or CSF, an <I>APOE2</I> gene for the treatment of <I>APOE4 </I>homozygous patients with Alzheimer&#146;s disease. Alzheimer&#146;s disease is the leading
cause of cognitive decline in late adult life and characterized by complex underlying pathology in the CNS. <I>APOE4</I> homozygous individuals are approximately 15 times more likely to develop Alzheimer&#146;s disease than the general population,
and it is estimated that there are 900,000 <I>APOE4</I> homozygous patients with Alzheimer&#146;s disease in the United States alone. Currently, there are no approved disease-modifying treatments for Alzheimer&#146;s disease. LX1001 is designed to
express the protective <I>APOE2</I> gene in the CNS of <I>APOE4</I> homozygous patients in order to halt or slow the progression of Alzheimer&#146;s disease. LX1001 is being evaluated in an ongoing open-label, dose-escalation Phase 1/2 clinical
trial and we have observed a decline in Alzheimer&#146;s disease CSF biomarkers, such as total tau and phosphorylated tau, in the first two patients with <FONT STYLE="white-space:nowrap">12-month</FONT> data in the
<FONT STYLE="white-space:nowrap">low-dose</FONT> cohort in the trial. We have also reported data demonstrating expression of the protective APOE2 protein in all four patients in the <FONT STYLE="white-space:nowrap">low-dose</FONT> cohort with <FONT
STYLE="white-space:nowrap">follow-up</FONT> data. We expect to report initial biomarker data from the <FONT STYLE="white-space:nowrap">mid-dose</FONT> cohort by the end of 2022. LX1001 has been granted fast track designation by the FDA.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>LX1004</I> is an AAVrh10-based gene therapy candidate designed to deliver via intracisternal injection a fully
functional <I>CLN2</I> gene to the CNS in order to restore the enzyme tripeptidyl peptidase 1, or TPP1, the secreted protein that is deficient in CLN2 Batten disease patients. This disease is an autosomal recessive lysosomal storage disorder causing
loss of cognitive and motor function, blindness, seizures, and ultimately death in childhood, with approximately 900 cases estimated in the United States and European Union. In a completed Phase 1/2 clinical trial, LX1004 was administered via
intraparenchymal injection and demonstrated an increase in TPP1 levels leading to a slower decline of motor and language function at 18 months post treatment in treated patients compared to natural history controls. We anticipate receiving feedback
from the FDA on the design of our potentially pivotal Phase 2/3 clinical trial in the second half of 2022, and we intend to initiate the clinical trial in the first half of 2023. The FDA has granted Rare Pediatric Disease designation and Orphan Drug
designation to LX1004 for the treatment of CLN2 Batten disease. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional programs </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within our cardiovascular pipeline, we are concurrently advancing several additional <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy programs to
treat other targets in myocardial cells that are dysregulated in various types of cardiomyopathy, including LX2021 to restore Connexin 43, or Cx43, in patients with ARVC, and LX2022 to treat hypertrophic cardiomyopathy, or HCM, due to mutations in
the <I>TNNI3</I> gene. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also building a portfolio of approaches to treat the genetics underlying Alzheimer&#146;s disease. Our Alzheimer&#146;s
disease portfolio includes LX1020, which is designed to deliver both the protective <I>APOE2</I> gene and microRNA, or miRNA, to suppress the expression of the deleterious <I>APOE4</I> gene, and LX1021, which is designed to deliver a
Christchurch-modified <I>APOE2</I> gene. The Christchurch mutation has been shown in individuals to be effective at protecting patients against Alzheimer&#146;s disease even in the presence of significant amyloid pathology. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Our approach </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our integrated modular approach enables us to optimize our strategy to pursue larger-rare and prevalent genetically defined indications in specific
sub-populations of patients, and is comprised of our technology approach, our disease area strategy, our manufacturing process and academic collaborations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our technology approach </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our approach to
technology confers the following advantages: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>High Transduction Efficiency and Biodistribution</B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp; The AAVrh10 vector has
proven to be effective at transducing myocardial cells and neurons, which we believe makes it optimal for delivery and expression of transgenes for the treatment of the cardiovascular and CNS diseases we are currently targeting.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Reduced Toxicity</B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp; The cardiac tropism allows AAVrh10 to be systemically
administered at lower doses than many other <FONT STYLE="white-space:nowrap">AAV-based</FONT> therapies targeting cardiovascular or other systemic diseases. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Reduced <FONT STYLE="white-space:nowrap">Pre-Existing</FONT> Neutralizing
Antibodies.</I><I>&nbsp;&nbsp;&nbsp;&nbsp; </I>Among the naturally occurring and commonly used AAV serotypes, AAVrh10 has been shown to have among the lowest levels of <FONT STYLE="white-space:nowrap">pre-existing</FONT> neutralizing antibodies.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Optimized Expression.</I>&nbsp;&nbsp;&nbsp;&nbsp; We are collaborating with our academic partners to develop
novel solutions to optimize the therapeutic efficacy of our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our disease area strategy </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We employ a strategy to select targets in indications that have relatively large patient populations, high unmet need and technically feasible treatment
profiles. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our disease area strategy </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g34p78.jpg" ALT="LOGO">
 </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We target diseases with the following characteristics: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><I>Defined <FONT STYLE="white-space:nowrap">sub-populations</FONT> in indications that may be effectively
treated by gene therapy.</I><B></B><I>&nbsp;&nbsp;&nbsp;&nbsp; </I>We select targets that correspond to populations with a specific genetic profile and clearly defined disease phenotype, increasing the homogeneity of our studied patient populations
and the likelihood of efficacy. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Indications with potential to demonstrate early evidence of meaningful clinical
benefit.</I>&nbsp;&nbsp;&nbsp;&nbsp; We pursue clearly defined biomarkers, as well as functional endpoints, that can potentially provide early <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> and
inform clinical development decisions, and may also facilitate accelerated approval pathways. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Present opportunity to address high unmet medical need.</I>&nbsp;&nbsp;&nbsp;&nbsp; We are focused on
genetically defined cardiovascular and CNS conditions where there is no currently approved treatment or where we believe our therapeutic candidates will have a meaningful improvement relative to existing standards of care. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Significant market opportunity.&nbsp;&nbsp;&nbsp;&nbsp;</B>We seek indications with significant commercial
opportunities beyond those typically associated with gene therapy companies targeting rare monogenic diseases. Our cardiac pipeline and our Alzheimer&#146;s disease portfolio target either larger-rare or prevalent patient populations.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Targets that have demonstrated promising preclinical data.</B>&nbsp;&nbsp;&nbsp;&nbsp;We have leveraged our
relationships with academic institutions including Weill Cornell Medical College, or Weill Cornell Medicine, and the University of California, San Diego, or UCSD, to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire product candidates
with established proof of concept in relevant animal models across a wide range of indications. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Targeted disease areas best treated by optimal vector technologies.&nbsp;&nbsp;&nbsp;&nbsp;</B>Our initial
gene therapy candidates utilize the AAVrh10 vector due its high transduction efficiency and biodistribution profile. For future indications, we will pursue the optimal vector technology to address the diseases of interest while ensuring sufficient
preclinical or clinical validation for any novel approaches. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Readily identifiable patient groups.&nbsp;&nbsp;&nbsp;&nbsp; </B>Our goal is to accelerate patient recruitment
for our clinical trials and increase the likelihood of commercial success of our potential products by focusing on diseases with established patient advocacy groups and university researchers who maintain registries of potentially eligible patients.
Where possible, we are also leveraging existing natural history studies which can help us to better define the target patient phenotypes associated with the disease. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our manufacturing approach </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing gene
therapy candidates for larger-rare and prevalent disease patient populations, which require a high-quality process that can produce vector in relatively large quantities while utilizing established biologics manufacturing infrastructure. We use a
baculovirus/Sf9 expression system to manufacture our gene therapy candidates due to its scalability and efficiency. Our manufacturing platform infects Sf9 cells at high densities in suspension cell culture with a capsid baculovirus and a transgene
baculovirus. The output is coupled with a chromatography-based purification process which allows for efficient AAV purification, resulting in higher vector yield, fewer empty AAV capsids, reduced incorporation of
<FONT STYLE="white-space:nowrap">non-transgene</FONT> DNA impurities and lower levels of process residuals than traditionally used plasmid HEK adherent cell culture approaches. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Academic collaborations </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our foundational science stems
from partnerships and exclusive licenses with leading academic laboratories at Weill Cornell Medicine and UCSD, two preeminent institutions on the cutting edge of gene therapy research. We </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
believe our ongoing work with these institutions, as well as any potential new or expanded collaborations, will continue to be a valuable aspect of our efforts as we seek to further discover and
develop novel gene therapies for devastating diseases. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Our company and team </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are led by pioneers and experts with decades of collective experience in genetic medicine, rare disease drug development, manufacturing and
commercialization. Our scientific founder and Chief Scientific Advisor, Ronald&nbsp;G. Crystal, M.D., is a world leader in gene therapy research and development and currently serves as Professor and Chairman of Weill Cornell Medicine&#146;s
Department of Genetic Medicine and Director of the Belfer Gene Therapy Core Facility. Our Chief Executive Officer, R. Nolan Townsend, has spent more than a decade working in global biopharmaceutical commercial organizations. Most recently, he led
Pfizer&#146;s U.S. rare disease commercial business unit, where he oversaw the successful U.S. launch of blockbuster rare cardiovascular product (tafamidis) Vyndaqel/Vyndamax. With over 20 years in the biopharmaceutical industry,&nbsp;Jay&nbsp;A.
Barth, M.D., our Executive Vice President and Chief Medical Officer, previously held leadership roles at Amicus Therapeutics, Inc. and PTC Therapeutics, Inc. and had clinical oversight of the initial approvals of Galafold, for the treatment of Fabry
disease, and Translarna, the first approved treatment for Duchenne muscular dystrophy. Our Chief Technical Officer, Paul McCormac, Ph.D., has more than 20 years of experience in the field of gene therapy and biologics chemistry, manufacturing, and
controls, or CMC, and previously led gene therapy CMC and vector supply strategy for Pfizer&#146;s rare disease business and research units. Our Chairman, Steven Altschuler, M.D., is currently Managing Director at Ziff Capital Investments and was
formerly Chairman of the gene therapy pioneer Spark Therapeutics, Inc., which was responsible for the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> gene therapy, voretigene neparvovec-rzyl (Luxturna), and was acquired by Roche Holding
AG in 2019 for $4.3&nbsp;billion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have raised $183.7&nbsp;million in capital from premier institutional investors, including funds
affiliated with D1 Capital Partners, Eventide Healthcare&nbsp;&amp; Life Sciences Fund, Janus Henderson Investors, Longitude Capital, Lundbeckfonden Ventures, Omega Funds and PBM Capital. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Our strategy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our vision is a world where gene therapies
resolve the burden of disease, transforming the lives of patients. The key elements of our strategy to achieve this vision are to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Focus on genetically defined cardiovascular and CNS indications of high unmet need and substantial commercial
potential. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Target development efforts at disease pathologies and defined
<FONT STYLE="white-space:nowrap">sub-populations</FONT> of patients most likely to benefit from our gene therapy candidates. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pursue a step-wise and capital-efficient development approach for advancing our programs through the clinic and
regulatory approval. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand our cardiovascular pipeline capabilities through the discovery and development of next-generation gene
therapy technologies. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage and expand upon our partnerships and exclusive licenses with world class academic institutions.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Utilize a scalable, unified manufacturing platform across all current and future programs. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Build a fully integrated gene therapy company and selectively evaluate strategic opportunities to maximize the
impact of our pipeline. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Risks associated with our business </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in the section
titled &#147;Risk Factors&#148; and include, among others: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant losses since our inception. We expect to incur losses over the next several years
and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and no history of commercializing products, which may make it difficult for
an investor to evaluate the success of our business to date and to assess our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will need substantial additional funding to meet our financial
obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business is dependent on our ability to advance our current and future product candidates through preclinical
studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are developing novel gene therapy product candidates, which makes it difficult to predict the time, cost and
potential success of product candidate development. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is
rigorous, complex, uncertain and subject to change, we neither predict the geographic areas in which we could obtain regulatory approval nor the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we
may develop. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and
involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time consuming
and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical
trials. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and our contract manufacturers are subject to significant regulation with respect to manufacturing our
products. The third-party manufacturing facilities on which we rely, and any manufacturing facility that we may have in the future, may have limited capacity or fail to meet the applicable stringent regulatory requirements. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that
result in delays in the development or commercialization of our product candidates or otherwise harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss
of these third-party suppliers or their inability to supply us with adequate materials could harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product
candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
costs or necessitate the abandonment or limitation of the development of some of our product candidates. We may also identify safety and efficacy concerns after the approval of a product
candidate which can result in negative consequences to our business and results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain or protect intellectual property rights related to any of our product candidates, we
may not be able to compete effectively in our market. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future success depends on our ability to retain key executives and advisors and to attract, retain and
motivate qualified personnel. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Implications of being an emerging growth company and a smaller reporting company </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For so long as we remain
an emerging growth company, we may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced obligations with respect to financial data, including only being required to present two years of audited
financial statements, in addition to any required unaudited interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
disclosure;</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exception from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended;</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#146;s report on financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions
until we no longer qualify as an emerging growth company. We will cease to qualify as an emerging growth company on the date that is the earliest of: (i)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the
completion of this offering, (ii)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in total annual gross revenues, (iii)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; under the
rules of the U.S. Securities and Exchange Commission, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June&nbsp;30<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over the prior three-year period. We may choose to take
advantage of some but not all of these reduced reporting burdens. We have taken advantage of certain reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different than you might obtain from other
public companies in which you hold equity interests. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised
accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure
requirements available to emerging growth companies. As a result of the accounting </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may
make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide in this prospectus may be different than the information you may receive from other public companies
in which you hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may result in a less active trading market for our common stock and higher
volatility in our share price. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our shares held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most recently
completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our shares held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $250&nbsp;million or
(ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our shares held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $700 million. If we
are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting
company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-K&nbsp;and,</FONT> similar to emerging growth companies, smaller
reporting companies have reduced disclosure obligations regarding executive compensation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Corporate information </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2017, we were formed as a Delaware limited liability company under the name LEXEO Therapeutics, LLC. In November 2020, we converted into a Delaware
corporation and were renamed Lexeo Therapeutics, Inc. Our principal executive offices are located at 430 East 29<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street, Floor 14, New York, New York 10016, and our telephone number is (212) <FONT
STYLE="white-space:nowrap">547-9879.</FONT> Our website address is <I>www.lexeotx.com</I>. The information contained on, or accessible through, our website is not incorporated by reference into this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="toc287237_1a"></A>The offering </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="59%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock offered by us</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Underwriters&#146; option to purchase additional shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock to be outstanding immediately after this offering</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
(or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise in full their option to purchase additional shares).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Use of proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, (or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise in full their option to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock), assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is
the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this offering, together with our
existing cash, to advance the clinical development of LX2006, LX1001 and LX1004, to fund the development of our other product candidates and discovery efforts, and for working capital and other general corporate purposes. See the section titled
&#147;Use of Proceeds&#148; for additional information.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Risk factors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You should read the section titled &#147;Risk Factors&#148; for a discussion of factors you should consider carefully, together with all the other information included in this prospectus, before deciding to invest in our common
stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposed Nasdaq Global Market symbol</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#147;LXEO&#148;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 after giving effect to the conversion of all
outstanding shares of our convertible preferred stock into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, and excludes: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon
the exercise of options under our 2021 Equity Incentive Plan, or the Existing Plan, granted subsequent to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 at a weighted-average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for
future issuance under the Existing Plan as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022, which shares will cease to be available for issuance at the time our 2022 Stock Incentive Plan, or the 2022 Plan, becomes
effective and will be added to, and become available for issuance under, the 2022 Plan; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for
future issuance under our 2022 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2022 Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for
future issuance under our 2022 Employee Stock Purchase Plan, or the ESPP, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the
ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information contained in this prospectus, including the number of shares of common stock that will
be outstanding after this offering, assumes or gives effect to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of all outstanding shares of our preferred stock on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, which will occur upon the closing of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stock</FONT></FONT> split of our common stock effected on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation upon the closing of this
offering; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options referred to above after
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="toc287237_1b"></A>Summary financial data </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following tables set forth our summary financial data for the years ended December&nbsp;31, 2020 and 2021. We have derived the statement of operations
and comprehensive loss data for the year ended December&nbsp;31, 2020 and 2021 and the balance sheet as of December&nbsp;31, 2021 from our audited financial statements included elsewhere in this prospectus. In the opinion of management, the
unaudited data reflects all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation of the financial information in those statements. </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read the following summary data together with our financial statements and the related notes thereto included elsewhere in this prospectus and the
section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; The summary financial data in this section are not intended to replace our financial statements and are
qualified in their entirety by our financial statements and related notes included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that should be expected in the future. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">518,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Operating expenses:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,318,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,106,264</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,587,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(422,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest Expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other expense, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(565,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,152,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss and comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,152,788</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">(0.34</TD>
<TD NOWRAP VALIGN="top">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares outstanding used in computation of net loss per common share,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">15,270,957</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average number of shares outstanding used in computation of net loss per common
share, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:7.5pt">Unaudited pro forma net loss per share, basic and diluted, is calculated giving effect to the automatic
conversion of the convertible preferred stock into shares of common stock. Unaudited pro forma net loss per share does not include the shares expected to be sold and related proceeds to be received in this offering. Unaudited pro forma net loss per
share for the year ended December&nbsp;31, 2020 and 2021 was calculated using the weighted-average number of shares of common stock outstanding, including the pro forma effect of the automatic conversion of all outstanding
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:7.5pt">
shares of our convertible preferred stock into shares of our common stock, as if the initial public offering had occurred at the beginning of the period or their issuance dates, if later.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro<BR>forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro forma<BR>as&nbsp;adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma column reflects the conversion of all of the outstanding preferred shares of our redeemable convertible preferred stock into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock upon completion of this offering. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted column reflects the pro forma adjustments set forth above and the sale of &nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting fees and commissions and estimated
offering expenses payable by us. This pro forma as adjusted information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the pro
forma as adjusted amount of each of cash, working capital, total assets and total stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as
set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions. Each increase or decrease of 1.0&nbsp;million in the number of shares we are offering would increase or
decrease the pro forma as adjusted amount of each of cash, working capital, total assets and total stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed
initial public offering price per share and after deducting the estimated underwriting discounts and commissions. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. See our financial statements appearing elsewhere in this prospectus. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_2"></A>Risk factors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all
of the other information in this prospectus, including our financial statements and related notes, before deciding whether to purchase shares of our common stock. The risks and uncertainties described below are not the only ones we face. Additional
risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks are realized, our business, financial condition, results of operations and
prospects could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part or all of your investment. </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Risks related to our financial position and capital needs </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain
profitability. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant net losses, and we expect to continue to incur significant expenses and operating
losses for the foreseeable future. For the fiscal years ended December&nbsp;31, 2020 and 2021, we incurred a net loss of $5.2 and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively, and we had an accumulated
deficit of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as of December&nbsp;31, 2021. We have financed our operations with approximately $183.7 in gross proceeds raised in our private placements of preferred stock
through August 2021. We have no products approved for commercialization and have never generated any revenue from product sales. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are still in the early
clinical stages of development of our product candidates, and only one of our product candidates has completed a Phase 1/2 clinical trial. We expect to continue to incur significant expenses and operating losses over the next several years. Our
operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to advance the preclinical and clinical development of our product candidates and discovery programs;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and complete additional clinical trials of our current and future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approval for any product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to develop our gene therapy product candidate pipeline; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scale up our clinical and regulatory capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">work with our third party manufacturing partners to produce material in accordance with current good
manufacturing practices, or cGMP, for clinical trials or potential commercial sales; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish, either alone or with a third party, a commercialization infrastructure and scale up manufacturing and
distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio and patent claims; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical, quality control, regulatory, manufacturing, scientific and administrative personnel;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our
product development and planned future commercialization efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting and other expenses in operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have not generated any revenue from the commercialization of our product candidates. To become and remain profitable, we must succeed in developing
and eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates,
obtaining regulatory approval, and manufacturing, marketing and selling any product candidates for which we may obtain regulatory approval, as well as discovering and developing additional product candidates. We are only in the preliminary stages of
most of these activities and all of our product candidates are in early clinical trials or preclinical development. We may never succeed in these activities and, even if we do, may never generate any revenue or revenue that is significant enough to
achieve profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our
failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our
operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history
and no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage gene therapy company with a limited operating history. We commenced substantive business operations in 2020, and our operations to date
have been largely focused on organizing and staffing our company, business planning, raising capital and entering into collaboration and license agreements for conducting preclinical and clinical research and development activities for our product
candidates and gene therapy pipeline. To date, we have not yet demonstrated our ability to successfully initiate or complete internally sponsored clinical trials, complete pivotal clinical trials, manufacture a product on a commercial scale, or
arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could
be if we had a longer operating history or a history of successfully developing and commercializing products. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful,
we will need substantial additional funding to meet our financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth
strategy. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will require substantial future capital in order to complete planned and future clinical development for our lead product candidates,
preclinical development for our other product candidates, and potential commercialization of these product candidates, if any are approved. We expect our spending levels to significantly increase in connection with our planned clinical trials of our
lead product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. Furthermore, upon
the closing of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to
raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate certain of our clinical trials, our research and development programs or other operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, we had cash of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We believe that the anticipated net proceeds from this offering, together with our existing cash, will be sufficient to fund our operating expenses and capital requirements
through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. Changes may occur beyond our
control that would cause us to consume our available capital before that time, including changes in and progress of our development activities, acquisitions of additional product candidates, and changes in regulation. Our future capital requirements
will depend on many factors, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of and investment in ongoing and future development of our gene therapy product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, costs and results of discovery, preclinical development, laboratory testing and clinical
trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we develop, <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other product
candidates and technologies in our gene therapy product candidate pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of process development and manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT>
activities associated with our product candidates and other programs as we advance them through preclinical and clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of, and development requirements for, product candidates that we may pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount growth and associated costs as we expand our research and development capabilities and establish a
commercial infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of establishing and maintaining commercial-scale cGMP manufacturing capabilities, either internally or
with third parties; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales
and distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain additional collaborations on favorable terms, if at all;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of any collaborations that we may establish and our license agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of milestones or occurrence of other developments that trigger payments under our collaboration
agreement or any additional collaboration agreements we may enter into; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will require additional capital to achieve our business objectives. Additional funds may not be available on a timely basis, on favorable terms, or at all,
and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Further, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and
the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including new variants of the virus, such as the
Delta and Omicron variants. If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our growth strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require
us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial revenue, we may
finance our cash needs through a combination of equity offerings, government or private party grants, debt financings and license and collaboration agreements. We do not currently have any committed external source of funds. To the extent that we
raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common
stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or
declaring dividends. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with
third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or product candidates, grant licenses on terms that may not be favorable to us or commit to future payment streams. If we are unable to raise
additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we
would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Risks related to the development of our product candidates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain
marketing approval and ultimately commercialize them. If we are unable or experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have invested a significant portion of our time and financial resources in the development of our product candidates and technology platforms. Our business
is dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize LX2006, LX1001, LX1004 and any other product candidates in a timely manner.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of our product candidates and programs will require additional preclinical and clinical development, regulatory approval and significant marketing
efforts, and we will be required to obtain manufacturing supply and expertise and to build a commercial organization or successfully outsource commercialization before we generate any revenue from product sales. We do not have any products that are
approved for commercial sale, and we may never be able to develop or commercialize marketable products. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue from our product
candidates, which we do not expect to occur for several years, if ever, will depend heavily on the successful development, regulatory approval and eventual commercialization of our product candidates. The success of our lead product candidates, or
any other product candidates that we develop or otherwise may acquire will depend on several factors, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies
and minimally efficacious dose studies in animals, where applicable, under FDA&#146;s good laboratory practices, or GLPs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability or development of suitable animal disease models for nonclinical studies to enable us to proceed
into clinical development or support the submission of a marketing application; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effective investigational new drug applications, or INDs, from the U.S. Food and Drug Administration, or FDA, or
comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment and completion of clinical trials, including under the FDA&#146;s current Good Clinical
Practices, or cGCPs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of arrangements with third-party manufacturers for, our commercial manufacturing processes for any
of our product candidates that receive regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of timely marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launch of commercial sales of products, if approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of the benefits and use of our products, including method of administration, if and when approved, by
patients, the medical community and third-party payors, for their approved diseases; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of adverse events experienced with any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability, perceived advantages, cost, safety and efficacy of alternative therapies for any product
candidate, and any diseases for such product candidate, that we develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to produce our product candidates on a commercial scale; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attainment and maintenance of patent, trademark and trade secret protection and regulatory exclusivity for our
product candidates and otherwise protecting our rights in our intellectual property portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintenance of compliance with regulatory requirements, including cGMPs, and complying effectively with other
procedures; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attainment and maintenance of third-party coverage and adequate reimbursement and patients&#146; willingness to
pay <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of such coverage and adequate reimbursement; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintenance of a continued acceptable safety, tolerability and efficacy profile of our products following
approval. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience
significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for any product candidate we develop, we may not be able to
continue our operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are developing novel gene therapy product candidates, which makes it difficult to predict the time, cost and potential
success of product candidate development. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future success depends on the efficacious development of a novel therapeutic approach. To date, very
few products that utilize gene transfer have been approved in the United States or Europe. There have been a limited number of clinical trials using AAVrh10. Only two <FONT STYLE="white-space:nowrap">AAV-based</FONT> product candidates are currently
approved by the FDA, and both of these use a different vector than our current product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be certain that our AAVrh10-based gene
therapy product candidates or any future product candidates utilizing other vector constructs will successfully complete preclinical studies and clinical trials. We may not be successful in developing product candidates that avoid triggering
toxicities or other side effects in preclinical studies or clinical trials. Our intravenous, intracisternal, intrathecal and intraparenchymal routes of administration may cause unforeseen side effects or present other challenges. Any such results
could impact our ability to develop a product candidate, including our ability to enroll patients in our clinical trials. As a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our approach to gene therapy,
or any similar or competitive programs, will result in the identification, development, and regulatory approval of any product candidate, or that other gene therapy programs will not be considered better or more attractive. There can be no assurance
that any development problems we experience in the future related to our current gene therapy product candidates or any of our research programs will not cause significant delays or unanticipated costs, or that such development problems can be
solved. We may also experience delays and challenges in achieving sustainable, reproducible, and scalable production. Any of these factors may prevent us from completing our preclinical studies or clinical trials or commercializing any product
candidates we may develop on a timely or profitable basis, if at all. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because gene therapy is novel and the regulatory landscape that governs any
product candidates we may develop is rigorous, complex, uncertain and subject to change, we can predict neither the geographic areas in which we could obtain regulatory approval nor the time and cost of obtaining regulatory approval, if we receive
it at all, for any product candidates we may develop. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulatory requirements that will govern any novel gene therapy product candidates we
develop are not entirely clear and are subject to change. The novel nature of our capsids makes it further difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United
States, the European Union or other jurisdictions. Within the broader genetic medicine field, very few therapeutic products have received marketing authorization from the FDA or the European Medicines Agency, or EMA. Even with respect to gene
therapies, the regulatory landscape is still developing. Regulatory requirements governing gene therapy products have changed frequently and will likely continue to change in the future. Moreover, there is substantial overlap in those responsible
for regulation of existing gene therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of
gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates
will need to meet safety and efficacy standards applicable to any new biologic being pursued for a given disease under the regulatory framework administered by the FDA. In addition to FDA oversight and oversight by institutional review boards, or
IRBs, certain human clinical trials involving recombinant or synthetic nucleic acid molecules are subject to oversight of institutional biosafety committees, or IBCs, as set forth in the NIH Guidelines. Under the NIH Guidelines, recombinant and
synthetic nucleic acids are defined as: (i)&nbsp;molecules that are constructed by joining nucleic acid molecules and that can replicate in a living cell (i.e., recombinant nucleic acids); (ii) nucleic acid molecules that are chemically or by other
means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules (i.e., synthetic nucleic acids); or (iii)&nbsp;molecules that result from the replication of
those described in (i)&nbsp;or (ii). Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing
recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a
clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other
institutions not otherwise subject to the NIH Guidelines voluntarily follow them. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the
initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The same applies in the European Union. The EMA&#146;s Committee for Advanced Therapies, or CAT, is
responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products. Advanced-therapy medicinal products include gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines. The role of the
CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the EMA. In the European Union, the development and evaluation of a gene therapy product must be considered
in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy products and require that we comply with these new guidelines. As a result, the procedures and
standards applied to gene therapy products may be applied to any gene therapy product candidate we may develop, but that remains uncertain at this point. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adverse developments in preclinical studies or clinical trials conducted by others in the field of gene therapy and gene regulation products may cause the FDA,
the EMA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing gene regulation technologies, either of which could harm our business. In addition, the
clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and
intended use and market of the potential products. The regulatory approval process for product candidates such as ours can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product
candidates. Further, as we are developing novel potential treatments for diseases in which, in some cases, there is little clinical experience with potential new endpoints and methodologies, there is heightened risk that the FDA, the EMA or other
regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. In addition, we may not be able to identify or develop
appropriate animal disease models to enable or support planned clinical development. Any natural history studies that we may rely upon in our clinical development may not be accepted by the FDA, EMA or other regulatory authorities. Regulatory
agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene regulation technology in a timely manner or under technically or commercially feasible conditions. In addition,
regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products. Further, approvals by one regulatory agency may not be indicative of what other
regulatory agencies may require for approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulatory review committees and advisory groups described above and any new guidelines they promulgate
may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and
commercialization of these treatment candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and
advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop. These additional processes may result in a review and approval
process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact
our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and
implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our product candidates are in preclinical or early clinical development, and the risk of failure is high. The preclinical studies, clinical trials and
manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other
countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and
clinical trials that our product candidates are both safe and effective for use in each target disease. In particular, because our product candidates are subject to regulation as biologics, we will need to demonstrate that they are safe and of
sufficient purity and potency for use in their target diseases. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and is subject to uncertainty. We cannot guarantee that any clinical trials will be
initiated on schedule, conducted as planned or completed on schedule, if at all. To date, clinical trials of LX1001 and LX1004 have been initiated and conducted by our collaborators, and we have not successfully initiated or completed any clinical
trial that we have internally sponsored. Failure can occur at any time during the clinical trial process. Even if our ongoing and future clinical trials are completed as planned, we cannot be certain that their results will support the safety and
effectiveness of our product candidates for their targeted diseases or support continued clinical development of such product candidates. Our future clinical trial results may not be successful. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, even if such trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as
we do, and more trials could be required before we submit our product candidates for approval. This is particularly true for clinical trials in very rare diseases, such as Batten disease, where the very small patient population makes it difficult or
impossible to conduct two traditional, adequate and well-controlled studies, and therefore the FDA or comparable foreign regulatory authorities are often required to exercise flexibility in approving therapies for such diseases. Moreover, results
acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or
foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience delays in initiating and conducting clinical trials of our lead product candidates and we do not know whether our clinical trials will
begin on time, need to be redesigned, recruit and enroll patients on time or be completed on schedule, or at all. Events that may prevent successful or timely completion of clinical development include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other <I>in vivo </I>or <I>in vitro </I>data to
support the initiation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in sourcing or qualifying ancillaries required for administration of our clinical drug product (such as
vials, stoppers, or tubing); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain
product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement with the FDA, EMA or other regulatory authorities as to the design or implementation
of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory approval to commence a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reaching an agreement on acceptable terms with clinical trial sites or prospective contract research
organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining IRB approval for each clinical trial site; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruiting suitable patients to participate in a clinical trial in a timely manner; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">having patients complete a clinical trial or return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites, CROs or other third parties deviating from trial protocol or dropping out of a trial;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform our planned clinical trials in accordance with the FDA&#146;s cGCP requirements, or applicable
regulatory guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing patient-safety concerns that arise during the course of a trial, including occurrence of adverse
events associated with the product candidate that are viewed to outweigh its potential benefits; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding a sufficient number of clinical trial sites; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of product candidate for use in clinical trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval
or commercialize our product candidates or significantly increase the cost of such trials, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience changes in regulatory requirements or guidance, or receive feedback from regulatory authorities
that requires us to modify the design of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or
regulators may require us, to conduct additional clinical trials or abandon development programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations
to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, our investigators or regulators may suspend or terminate clinical trials of our product candidates for
various reasons, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the
participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates may be greater than we anticipate and we may not have funds
to cover the costs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our
product candidates may be insufficient or inadequate; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as
we anticipate; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical
trials in ways they view as advantageous to them but that are suboptimal for us. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional clinical
trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully initiate or complete clinical trials of our product candidates or other testing, if the results of these trials or tests
are not positive or are only modestly positive or if there are safety concerns, we may: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur unplanned costs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval in some countries and not in others; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval for diseases or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety
warnings, including boxed warnings or Risk Evaluation and Mitigation Strategies, or REMS; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to additional post-marketing testing requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have the product removed from the market after obtaining marketing approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by
the Data Safety Monitoring Board for such trial or by the FDA, EMA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or
adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our product candidates will require extensive clinical testing before we are prepared to submit a biologics license application, or BLA, or marketing
authorization application, or MAA, for regulatory approval. We cannot predict with any certainty if or when we might complete the clinical development for our product candidates and submit a BLA or MAA for regulatory approval of any of our product
candidates or whether any such BLA or MAA will be approved. We may also seek feedback from the FDA, EMA or other regulatory authorities on our clinical development program, and the FDA, EMA or such regulatory authorities may not provide such
feedback on a timely basis, or such feedback may not be favorable, which could further delay our development programs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict with any
certainty whether or when we might complete a given clinical trial. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product
candidates could be harmed, and our ability to generate revenues from our product candidates may be delayed or lost. In addition, any delays in our clinical trials could increase our costs, slow down the development and approval process and
jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and results of operations. In addition, many of the factors that cause, or lead to, a delay in the
commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time
consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The time required to obtain approval or other marketing authorizations by the FDA, EMA and comparable foreign authorities is unpredictable, and it typically
takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, and the type and amount of clinical
data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that we may
never obtain regulatory approval for any product candidates we may seek to develop in the future. Neither we nor any collaborator is permitted to market any biologic product candidates in the United States until we receive regulatory approval of a
BLA from the FDA, and we cannot market it in the European Union until we receive approval for a MAA from the EMA, or other required regulatory approval in other countries. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we must demonstrate with substantial evidence from
well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe, effective and of sufficient purity for their intended uses. Results from preclinical studies and clinical
trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may
also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or after approval, or it may object to elements of our clinical development programs, or require changes to our manufacturing
approaches. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes
and are commercialized. The lengthy approval and marketing authorization process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval and marketing authorization to market our
product candidates, which would significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have invested a significant
portion of our time and financial resources in the development of our product candidates and technology platforms. Our business is dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval
for, and, if approved, successfully commercialize LX2006, LX1001, LX1004 and any other product candidates in a timely manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we eventually
complete clinical testing and receive approval of a BLA or foreign marketing application for any of our product candidates, the FDA, EMA or the applicable foreign regulatory agency may grant approval or other marketing authorization contingent on
the performance of costly additional clinical trials, including post-marketing clinical trials. The FDA, EMA or the applicable foreign regulatory agency also may approve or authorize for marketing a product candidate for a more limited disease or
patient population than we originally request, and the FDA, EMA or applicable foreign regulatory agency may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate.
Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the FDA, EMA and other regulatory authorities may change their policies, issue additional regulations or revise existing regulations, or take
other actions, which may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide
adequate data to demonstrate the efficacy and safety of a product candidate. Preclinical tests and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side
effects of product candidates at various doses and schedules. Success in preclinical or animal studies and early clinical trials does not ensure that later large-scale efficacy and safety trials will be successful nor does it predict final results.
For example, we may be unable to identify suitable animal disease models for our product candidates, which could delay or frustrate our ability to proceed into clinical trials or obtain marketing approval. In addition, the preclinical studies
conducted by Stelios Therapeutics, Inc. and UCSD for our product candidates LX2020, LX2021 and LX2022 employed an AAV9-based formulation and studies using this vector may not be predictive of future testing we intend to conduct using an
AAVrh10-based formulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in
preclinical studies or having successfully advanced through initial clinical trials. The Phase 1/2 clinical trial of LX1004 for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, or CLN2 Batten disease, employed an
intraparenchymal route of administration. We are planning to pursue an intracisternal route of administration in our anticipated potentially pivotal Phase 2/3 clinical trial of LX1004 and results from the Phase 1/2 clinical trial may not be
indicative of future trials that we conduct using a different route of administration. Furthermore, the clinical trial of LX1004, as well as our other past and most future clinical trials, involve or will involve a small patient population. Because
of the small sample sizes studied in our trials thus far, the results of these trials may not be indicative of results of future clinical trials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, some of our ongoing and planned clinical trials utilize, or may utilize, an &#147;open-label&#148; trial design. An &#147;open-label&#148;
clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the
investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when
they are receiving treatment. Open-label clinical trials may be subject to a &#147;patient bias&#148; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition,
open-label clinical trials may be subject to an &#147;investigator bias&#148; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information
of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied
in a controlled environment with a placebo or active control. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay,
limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could
negatively impact our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary results from our
clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary results from our clinical trials. Interim results
from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or
<FONT STYLE="white-space:nowrap">top-line</FONT> results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim
and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock
to fluctuate significantly. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates,
or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or
limitation of the development of some of our product candidates. We may also identify safety and efficacy concerns after the approval of a product candidate which can result in negative consequences to our business and results of operations.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and
expensive preclinical testing and clinical trials that our product candidates are safe, effective and of sufficient purity for use in each target disease, and failures can occur at any stage of testing. Preclinical studies and clinical trials often
fail to demonstrate safety or efficacy of the product candidate studied for the target disease. While we have developed our AAVrh10-mediated gene therapy product candidates to leverage the low seropositivity of AAVrh10, any gene therapy product
based on viral vectors carries the risks of immunogenicity, elevated liver enzymes and insertional oncogenesis, which is the process whereby the insertion of a functional gene near a gene that is important in cell growth or division results in
uncontrolled cell division, which could potentially enhance the risk of malignant transformation. In one of our preclinical studies of LX2006, we observed one case of hepatocellular carcinoma, or HCC, in a muscle creatine kinase, or MCK, mouse at 10
months post-treatment. Although a large body of available data suggests that HCC observed in mice after AAV treatment is unlikely to translate to risks for humans, any future instances of HCC in our clinical trials could result in delays or the
abandonment of our trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early
after administration, which, while not necessarily adverse to the patient&#146;s health, could substantially limit the effectiveness of the treatment. For example, in previous third-party clinical trials involving AAV capsids for gene therapy, some
subjects experienced the development of a <FONT STYLE="white-space:nowrap">T-cell</FONT> antibody response, whereby after the vector is within the target cell types, the cellular immune response system triggers the removal of transduced cell types
by activated <FONT STYLE="white-space:nowrap">T-cells.</FONT> If any of our product candidates demonstrate a similar effect, we may decide or be required to perform additional preclinical studies or to halt or delay further clinical development of
our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to side effects caused by the product candidate, the administration process or related procedures also can cause
adverse side effects. Our central nervous system, or CNS, product candidates are designed to be delivered either via intracisternal or parenchymal administration. While the intracisternal and parenchymal methods of administration have been available
for some years, their use for gene therapies is new and no gene therapy is currently approved for these methods of administration. Intracisternal administration may have greater risk and/or be perceived as having greater risk than more common
methods of administration, such as intravenous injection, while parenchymal administration involves neurosurgery and carries all risks attendant with such a procedure. These risks include allergic reaction to anesthesia, bleeding or swelling in the
brain, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seizures, stoke, coma and infection. Other gene therapy product candidates in clinical development utilizing intracisternal or parenchymal delivery could also generate data that could adversely
affect the clinical, regulatory or commercial perception of our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If adverse events occur, either as a result of the product candidate
or administration process, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse events were not caused by the drug or administration process or related procedures, the FDA, EMA or foreign regulatory
authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted diseases. Even if we are able to demonstrate that all future serious adverse events are not product-related, such
occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates,
the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product
candidates, and may harm our business, financial condition and prospects significantly. Furthermore, negative results in our development of LX2006, LX1001 or LX1004 could be interpreted as a failure to achieve proof of concept for our technology and
result in the abandonment of other development programs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, gene therapy is still a relatively new approach to disease treatment and additional
adverse side effects could develop. There also is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the
genetic material. If our product candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses in which the side effects
or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. The FDA or an IRB may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we
conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated. Such findings could further result in regulatory authorities failing to provide marketing authorization
for our product candidates or limiting the scope of the approved disease, if approved. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the
product candidate. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if one or more of our product candidates receives marketing approval, and we or others identify undesirable side effects
caused by such products or the administration procedure, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approvals of such product; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the labels; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to
patients or other requirements subject to a REMS; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to achieve or maintain third-party payor coverage and adequate reimbursement; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation and physician or patient acceptance of our products may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or foreign regulatory
agency in a timely manner or at all. Moreover, any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations
and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some of the diseases we initially seek to treat have low prevalence and it may be difficult to
identify and enroll patients with these diseases. If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients. Patient enrollment, a significant factor in
the timing of clinical trials, is affected by many factors, including the size and nature of the patient population and competition for patients with other trials. Genetic diseases generally, and especially the rare disease for which some of our
product candidates are designed to target, have low incidence and prevalence. In particular, because we are focused on patients with specific genetic mutations, our ability to enroll eligible patients may be limited or enrollment may be slower than
we anticipate. For example, we estimate that there are approximately 8,000 people in the United States who have Friedreich&#146;s ataxia and that approximately 70% of these patients will develop the cardiac manifestation of Friedreich&#146;s ataxia,
or FA cardiomyopathy, and accordingly it may be difficult for us to identify and timely recruit a sufficient number of eligible patients to conduct our clinical trials. Even for more prevalent conditions such as Alzheimer&#146;s disease, it may be
difficult to recruit patients to clinical trials due to the number of approved products and clinical trials being conducted in this indication. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our trials
may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient
number of eligible patients to participate in these trials as required by the FDA, EMA or other foreign regulatory authorities. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Subject enrollment is
affected by other factors including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the eligibility criteria for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the patient population and process for identifying patients; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the perceived risks and benefits of the product candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate being
studied in relation to other available therapies, including any new drugs that may be approved for the diseases we are investigating; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the novelty of gene therapy as a modality for treatment of our target indications; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of competing commercially available therapies and other competing therapeutic candidates&#146;
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the clinical trials before completion of
their treatment; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential disruptions caused by the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic (including
new variants of the virus, such as the Delta and Omicron variants), including difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies
that may be implemented, and other factors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity and availability of clinical trial sites for prospective patients. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our inability to enroll a sufficient number of patients for clinical trials would result in significant
delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and
limit our ability to obtain additional financing. Furthermore, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we will have limited influence over their performance. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such
patients in our clinical trials. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek orphan drug designation or rare pediatric drug designation for some of our product candidates and we
may be unsuccessful, or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity, for product candidates for which we obtain orphan drug designation. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some jurisdictions, including the United States, may designate drugs or biologics intended to treat relatively small patient
populations as orphan drug products. Under the Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than
200,000 individuals in the United States, or a patient population of 200,000 or more in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, orphan drug designation entitles a party to potential financial incentives such as tax advantages and user fee waivers. Opportunities for
grant funding toward clinical trial costs may also be available for clinical trials of drugs or biologics for rare diseases, regardless of whether the drugs or biologics are designated for the orphan use. In addition, if a drug or biologic with an
orphan drug designation subsequently receives the first marketing approval for the disease for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity, which precludes the FDA from approving another
marketing application for the same drug and disease for that time period, except in limited circumstances. If our competitors are able to obtain orphan drug exclusivity prior to us, for products that constitute the &#147;same drug&#148; and treat
the same diseases as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similarly, in the European Union, the European Commission, upon the recommendation of the EMA&#146;s Committee for Orphan Medicinal Products, grants orphan
drug designation to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions and either the prevalence of the condition is not more than 5 in 10,000
persons in the European Union or, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug. In each case, there must be no satisfactory method of
diagnosis, prevention or treatment of the condition that has been authorized, or, if such a method exists, the product in question must be of significant benefit to those affected by such condition. In the European Union, orphan drug designation
entitles a party to financial incentives such as reduction of fees or fee waivers. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have obtained from the FDA orphan drug designation for LX1004 for
treatment of CLN2 Batten disease and LX2006 for treatment of Friedreich&#146;s ataxia. We may seek orphan designation for some or all of our product candidates in orphan indications in which there is a medically plausible basis for the use of these
product candidates. However, we may be unsuccessful in obtaining orphan drug designation and may be unable to maintain the benefits associated with such designations. Even if we obtain orphan drug exclusivity for any of our product candidates, that
exclusivity may not effectively protect those product candidates from competition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
because different drugs can be approved for the same condition, and orphan drug exclusivity does not prevent the FDA from approving the same or a different drug in another indication. Even after
an orphan drug is granted orphan exclusivity and approved, the FDA can subsequently approve a later application for the same drug for the same condition before the expiration of the seven-year exclusivity period if the FDA concludes that the later
drug is clinically superior in that it is shown to be safer in a substantial portion of the target populations, more effective or makes a major contribution to patient care. On August&nbsp;3, 2017, Congress passed the FDA Reauthorization Act of
2017, or FDARA. FDARA, among other things, codified the FDA&#146;s preexisting regulatory interpretation, to require that a drug Sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug
for the same rare disease in order to receive orphan drug exclusivity. The law reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical
superiority. Moreover, in the Consolidated Appropriations Act of 2021, Congress did not further change this interpretation when it clarified that the interpretation codified in FDARA would apply in cases where FDA issued an orphan designation before
the enactment of FDARA but where product approval came after the enactment of FDARA. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the disease for which it received
orphan designation. Moreover, orphan-drug-exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to manufacture sufficient quantities of
the product to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval
process. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect
our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fast track, breakthrough therapy, or regenerative medicine advanced therapy designation by the FDA may not actually lead to a faster development or
regulatory review or approval process, and does not assure FDA approval of our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek fast track, breakthrough therapy or
regenerative medicine advanced therapy, or RMAT, designation from the FDA for some or all of our product candidates but we may be unable to obtain such designations or to maintain the benefits associated with such designations. FDA&#146;s fast
track, breakthrough therapy, and RMAT designation programs are intended to expedite the development of certain qualifying products candidates intended for the treatment of serious diseases and conditions. If a product candidate is intended for the
treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the product&#146;s potential to address an unmet medical need for this condition, the sponsor may apply for FDA fast track designation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A product candidate may be designated as a breakthrough therapy if it is intended, alone or in combination with one or more other drugs or biologics to treat a
serious or life-threatening condition and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For product candidates that
have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in
ineffective control regimens. Biologics designated as breakthrough therapies by the FDA may also be eligible for accelerated approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A product candidate
may receive RMAT designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate has
the potential to address an unmet medical need for such condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
RMAT designation allows companies developing regenerative medicine therapies to work more closely and frequently with the FDA, and RMAT-designated product candidates may be eligible for priority
review and accelerated approval. FDA has confirmed that gene therapies, including genetically modified cells, that lead to a sustained effect on cells or tissues may meet the definition of a regenerative medicine therapy. For product candidates that
have received an RMAT designation, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control
regimens. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have received fast track designation for LX1001 for the treatment of patients with early Alzheimer&#146;s disease who are <I>APOE4</I>
homozygous, to slow disease progression. While we may seek fast track, breakthrough and/or RMAT designation for some or all of our product candidates, there is no guarantee that we will be successful in obtaining any such designation. Even if we do
obtain such designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. A fast track, breakthrough, or RMAT designation does not ensure that the product candidate will receive
marketing approval or that approval will be granted within any particular timeframe. In addition, the FDA may withdraw fast track, breakthrough, or RMAT designation if it believes that the designation is no longer supported by data from our clinical
development program. Fast track, breakthrough and/or RMAT designation alone do not guarantee qualification for the FDA&#146;s priority review procedures. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have received rare pediatric disease designation from the FDA for LX2006 for the treatment of Friedreich&#146;s ataxia and LX1004 for the treatment
of neuronal ceroid lipofuscinosis type 2 (CLN2) disease and we may seek such designation for certain other product candidates. However, a marketing application for these product candidates, if approved, may not meet the eligibility criteria for a
rare pediatric disease priority review voucher. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have received rare pediatric disease designation from the FDA for LX2006 for the treatment of
Friedreich&#146;s ataxia and LX1004 for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease and we may seek rare pediatric disease designation for certain of our other product candidates. The FDA defines &#147;rare pediatric
disease&#148; as a (i)&nbsp;serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and
adolescents; and (ii)&nbsp;a rare disease or condition within the meaning of the Orphan Drug Act. Designation of a product candidate as a product for a rare pediatric disease does not guarantee that a marketing application for such product candidate
will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Under the U.S. Federal Food, Drug, and Cosmetic Act, or FDCA, we will need to request a rare pediatric disease priority
review voucher in our original marketing application for our product candidates for which we have received rare pediatric disease designation. The FDA may determine that a marketing application for any such product candidates, if approved, do not
meet the eligibility criteria for a priority review voucher, including for the following reasons: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rare pediatric disease for which received such designation no longer meets the definition of a rare pediatric
disease; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the marketing application contains an active ingredient (including any ester or salt of the active ingredient)
that has been previously approved in a marketing application; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the marketing application is not deemed eligible for priority review; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the marketing application does not rely on clinical data derived from studies examining a pediatric population
and dosages of the product intended for that population (that is, if the marketing application does not contain sufficient clinical data to allow for adequate labeling for use by the full range of affected pediatric patients); or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the marketing application is approved for a different adult indication than the rare pediatric disease for which
our product candidates are designated. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the current statutory sunset provisions, after September&nbsp;30, 2024, the FDA may only
award a priority review voucher, or PRV, for an approved rare pediatric disease product application if the sponsor has&nbsp;rare pediatric disease designation&nbsp;for the drug or biologic that is the subject of such application, and that
designation was granted by September&nbsp;30, 2024. After September&nbsp;30, 2026, the FDA may not award any rare pediatric disease priority review vouchers. However, it is possible the authority for FDA to award rare pediatric disease priority
review vouchers will be further extended by Congress. As such, if we do not obtain approval of a marketing application for LX2006 or LX1004 in patients with Friedreich&#146;s ataxia or CLN2 disease, respectively, on or before September&nbsp;30,
2026, and if the priority review voucher program is not extended by Congressional action, we may not receive a priority review voucher. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Where
appropriate, we may seek approval from the FDA, EMA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies
or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA or comparable regulatory
authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, EMA or such other regulatory authorities may seek to withdraw accelerated approval. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where possible, we may pursue accelerated development strategies in areas of high medical need. We may seek an accelerated approval pathway for one or more of
our therapeutic candidates from the FDA, EMA or comparable foreign regulatory authorities. Under the accelerated approval provisions in the FDCA and the FDA&#146;s implementing regulations, the FDA may grant accelerated approval to a therapeutic
candidate that is designed to treat a serious or life-threatening condition, generally provides a meaningful therapeutic benefit over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict
clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA considers a clinical benefit to be a
positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement,
radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on
irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new product over
available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#146;s agreement to conduct,
in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. If such post-approval studies fail to confirm the product&#146;s clinical benefit, the FDA may withdraw its approval of
the product. In addition, the FDA currently requires, unless otherwise informed by the agency, <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials for products receiving Accelerated Approval, which could adversely impact
the timing of the commercial launch of the product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to seeking accelerated approval, we would seek feedback from the FDA, EMA or comparable foreign
regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for
accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, EMA or comparable foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so.
Furthermore, if we decide to submit an application for accelerated approval, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA, EMA or other comparable foreign
regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently
converted by FDA to full approval. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our therapeutic candidate would result in a longer time period to commercialization of such therapeutic
candidate, could increase the cost of development of such therapeutic candidate and could harm our competitive position in the marketplace. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of
our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA determines that a product candidate is intended to treat a serious disease or condition and, if approved, would
provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of such disease or condition, the FDA may designate the product candidate for priority review. A priority review designation means that the
goal for the FDA to review a marketing application is six months from filing of the application, rather than the standard review period of ten months. We may request priority review for certain of our product candidates. The FDA has broad discretion
with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may disagree and decide not to grant it. Moreover, a
priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee
approval within the <FONT STYLE="white-space:nowrap">six-month</FONT> review cycle or thereafter. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a
particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and management resources, we must focus on development programs and product candidates that we identify for specific
diseases. As such, currently we are primarily focused on the development of LX2006, LX1001 and LX1004. As a result, we may forego or delay pursuit of opportunities with other product candidates. Our resource allocation decisions may cause us to fail
to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific diseases may not yield any commercially viable products. If we do not
accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would
have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in
our efforts to build a pipeline of additional product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business model is centered on developing therapies for patients with both
rare and prevalent cardiac and central nervous system diseases by establishing focused selection criteria to select, develop and advance product candidates that we believe will have a high probability of technical and regulatory success through
development into commercialization. We may not be able to continue to identify and develop new product candidates. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable
for clinical development. For example, they may be shown to have harmful side effects or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product
candidates based upon our approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require
or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the clinical development of our product candidates for certain indications, we may work with collaborators to develop or obtain access to
<I>in vitro</I> companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our product candidates. To be successful, we or our collaborators will need to address a number of
scientific, technical, regulatory and logistical challenges. The FDA and comparable foreign regulatory authorities regulate <I>in vitro</I> companion diagnostics as medical devices and, under that regulatory framework, will likely require the
conduct of clinical trials to demonstrate the safety and effectiveness of any diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization. The FDA generally will require approval or
clearance of the diagnostic at the same time that the FDA approves the therapeutic product if the FDA determines that safe and effective use of a therapeutic product depends on an <I>in vitro </I>companion diagnostic. The clearance or approval of a
companion diagnostic as part of the product label will also limit the use of the product candidate to patients who have met the screening criteria tested for by the companion diagnostic. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may require
such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve
issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early
clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future
collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic candidates themselves, including issues with
achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these
product candidates, or experience delays in doing so, the development of these product candidates may be adversely affected, these product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of
these product candidates that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling
or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to
enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which
could adversely affect and/or delay the development or commercialization of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations may be adversely affected by the evolving and ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> global pandemic. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business and operations may be adversely affected by the effects of the evolving <FONT
STYLE="white-space:nowrap">COVID-19</FONT> virus, which was declared by the World Health Organization as a global pandemic, including the current global resurgences as a result of the Delta and Omicron variants and other future resurgences. The
ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in travel and other restrictions in order to reduce the spread of the disease, including public health directives and orders in the United States and the European Union
that, among other things and for various periods of time, directed individuals to shelter at their places of residence, directed businesses and governmental agencies to cease <FONT STYLE="white-space:nowrap">non-essential</FONT> operations at
physical locations, prohibited certain <FONT STYLE="white-space:nowrap">non-essential</FONT> gatherings and events and ordered cessation of <FONT STYLE="white-space:nowrap">non-essential</FONT> travel. Future remote work policies and similar
government orders or other restrictions on the conduct of business operations related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may negatively impact productivity; disrupt our ongoing research and development activities and
our clinical programs and timelines; and cause disruptions to our supply chain, to the administrative functions of clinical trial sites and to the operations of our other partners, the magnitude of which will depend, in part, on the length and
severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In the event that government authorities were to enhance current restrictions, our employees who currently are not telecommuting may no
longer be able to access our facilities, including our laboratories, and our operations may be further limited or curtailed. Further, such orders also may impact the availability or cost of materials, which would disrupt our supply chain and
manufacturing efforts and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities. We may also face difficulties in obtaining access to manufacturing slots for our product candidates. For example, since the
beginning of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, three vaccines for <FONT STYLE="white-space:nowrap">COVID-19</FONT> have received Emergency Use Authorization by the FDA, and two of those later received marketing approval.
Additional vaccines may be authorized or approved in the future. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign
legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have experienced delays in patient enrollment and certain follow up visits in the Phase 1/2 clinical trial of LX1001, and we may experience additional
disruptions related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in the future that could severely impact our ongoing and planned clinical trials, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, difficulties or a suspension in clinical site initiation, including difficulties in recruiting clinical
site investigators and clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, difficulties or interruptions in shipping and delivering in a timely manner supplies, samples or products
required for our clinical trials due to the impact of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the United States Postal Service, FedEx, United Parcel Service and/or other commercial shipping organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, difficulties or interruptions in obtaining the raw materials and other resources needed for our
operations, including due to <FONT STYLE="white-space:nowrap">government-led</FONT> diversion, reprioritization or appropriation of such resources; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruptions or delays in patient enrollment or patient visits on trial due to quarantines, perceived risks of
in person visits or limited facility and healthcare professional availability; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or interruptions in third-party or collaborator services, including due to
<FONT STYLE="white-space:nowrap">government-led</FONT> diversion, reprioritization or appropriation of such services; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruptions in our ability to manufacture and deliver drug supply for trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
outbreak that may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, and the ability or
willingness of subjects to travel to trial sites due to limitations on travel imposed or recommended by federal or state governments, employers and others; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials,
including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA, EMA or other regulatory authorities, which may impact review
and approval timelines; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to accept data from clinical trials in these affected geographies. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including new variants of the virus such as the Delta and Omicron variants, which has caused a
broad impact globally, may materially affect us economically. While the overall economic impact brought by, and the duration of, <FONT STYLE="white-space:nowrap">COVID-19</FONT> may be difficult to assess or predict, the ongoing pandemic could
result in further disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> could materially affect our business and the value of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to rapidly evolve. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our business and operations, including our clinical development and regulatory
efforts, will depend on future developments that are highly uncertain and cannot be predicted with confidence at the time of this prospectus, such as the duration of the outbreak, the duration and effect of business disruptions, the occurrence of
global resurgences as a result of the Delta and Omicron variants and other future resurgence, and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the
United States and other countries to contain and treat the disease. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a
whole. However, these impacts could adversely affect our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, to the
extent the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#147;Risk
Factors&#148; section. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Risks related to the manufacturing of our product candidates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The third-party manufacturing
facilities on which we rely, and any manufacturing facility that we may have in the future, may have limited capacity or fail to meet the applicable stringent regulatory requirements. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have relationships with a limited number of suppliers for the manufacturing of all components of our product candidates. However, if we experience
slowdowns or problems with our manufacturing partners and are unable to establish or scale our internal manufacturing capabilities, we will need to continue to contract with manufacturers that can produce the preclinical, clinical and commercial
supply of our products. Each supplier </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain and we may be unable to license such intellectual property rights on
reasonable commercial terms or to transfer or sublicense the intellectual property rights we may have with respect to such activities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All entities
involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for components of our product candidates, are subject to extensive regulation. Components of a finished therapeutic
product approved for commercial sale or used in late-stage clinical trials in the United States and European Union must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record
keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents
or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a
BLA or MAA on a timely basis. Our potential manufacturing facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection
for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing
facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted, and they could put a hold on one or
more of our clinical trials if the facilities of our contract development and manufacturing organizations do not pass such audit or inspections. If these facilities do not pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> plant inspection,
FDA approval of the products will not be granted. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulatory authorities also may, at any time following approval of a product for sale, inspect or
audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs
independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent
suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could harm our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things,
refusal to approve a pending application for a new drug product or biologic product, or revocation of a <FONT STYLE="white-space:nowrap">pre-existing</FONT> approval. As a result, our business, financial condition and results of operations may be
harmed. Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be qualified through a BLA and/or MAA supplement which could
result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our
desired clinical and commercial timelines. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or
commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully, if approved. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure
one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing
problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacture
of gene therapy products is technically complex and necessitates substantial expertise and capital investment. Production difficulties caused by unforeseen events may delay the availability of material for our clinical studies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on third party manufacturers to manufacture our product candidates for preclinical studies and clinical trials. The manufacturers of pharmaceutical
products must comply with strictly enforced cGMP requirements, state and federal regulations, as well as foreign requirements when applicable. Any failure of us or our contract manufacturing organizations, or CMOs, to adhere to or document
compliance to such regulatory requirements could lead to a delay or interruption in the availability of our product candidate materials for clinical trials or enforcement action from the FDA, EMA or foreign regulatory authorities. If we or our
manufacturers were to fail to comply with the requirements of the FDA, EMA or other regulatory authority, it could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or
withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurances that our third party manufacturers will be able to meet our timetable and requirements. If any third party with whom we contract
fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different third party manufacturer, which we may not be able to do
on reasonable terms, if at all. In either scenario, our clinical trials and future commercial supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our product
candidates may be unique or proprietary to the original third party manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a <FONT STYLE="white-space:nowrap">back-up</FONT>
or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that
comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidates according to the
specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates or commercialize our products, if
approved, in a timely manner or within budget. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to arrange for alternative third-party manufacturing sources on commercially reasonable
terms or in a timely manner, we may be delayed in the development of our product candidates. Our dependence upon others for the manufacture of our product candidates may also adversely affect our future profit margins and our ability to
commercialize any product candidates that receive regulatory approval on a timely and competitive basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates require processing steps
that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as our modified virus generally cannot be fully characterized. As a
result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Although we believe that the manufacture of our product candidates may be simplified due to their shared raw materials and
other similarities, we cannot be certain that this will be the case and we may be required to develop manufacturing methods that ultimately differ significantly between product candidates, which would require that we invest substantial time and
capital to develop suitable manufacturing methods. Our program materials are manufactured using technically complex processes requiring specialized equipment and facilities, highly specific raw materials,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cell types and reagents, and other production constraints. Our production process also requires a number of highly specific raw materials, cell types and reagents with limited suppliers. Even
though we aim to have backup supplies of raw materials, cell types and reagents whenever possible, we cannot be certain they will be sufficient if our primary sources are unavailable. A shortage of a critical raw material, cell line, or reagent, or
a technical issue during manufacturing may lead to delays in clinical development or commercialization plans. We are particularly susceptible to any shortages, delays or our inability to obtain suitable raw materials for our lead product candidates.
Any changes in the manufacturing of components of the raw materials we use could result in unanticipated or unfavorable effects in our manufacturing processes, resulting in delays. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if any of our product candidates obtain approval, the FDA, EMA and other regulatory authorities may require us to submit samples of any lot of any
approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, EMA or other regulatory authorities may require that we not distribute a lot until the agency authorizes its
release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product
recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their
inability to supply us with adequate materials could harm our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on third-party suppliers for all of the materials and components
required for the production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing,
availability, and delivery schedules. There is substantial demand and limited supply for certain of the raw materials used to manufacture gene therapy products. As a small company, our negotiation leverage is limited and we are likely to get lower
priority than our competitors that are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality
requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find
a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including
limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any
contamination or interruption in our manufacturing process, shortages of raw materials or failure of our suppliers of viruses to deliver necessary components could result in delays in our clinical development or marketing schedules. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the nature of gene therapy manufacturing, there is a risk of contamination occurring during the manufacturing process. Any contamination could adversely
affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Some of the raw materials required in our manufacturing process are derived from biologic sources. Such
raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could
adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could adversely affect our development timelines and our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or
delay. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization,
it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and product characteristics. Such changes carry the risk that they will not
achieve our intended objectives. Any such changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered
processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay the initiation and completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more
clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue. In addition, we may be required to make significant changes to our upstream and downstream
processes across our pipeline, which could delay the development of our future product candidates. Regulatory agencies, and in particular the FDA and EMA, have demonstrated increased caution in their regulation of gene therapies, including increased
scrutiny related to chemistry, manufacturing and control, or CMC, issues. This increased regulatory scrutiny around gene therapy CMC may result in us being required to conduct additional preclinical studies or clinical trials with respect to any of
our product candidates, which may result in delays and increased costs in the development or commercialization of our product candidates and ultimately could lead to the failure to obtain approval for any gene therapy product. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Risks related to the commercialization of our product candidates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients,
third-party payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our product candidates receive marketing
approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our product candidates do not achieve an adequate level of acceptance, we may not generate
significant revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy, safety and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements of the FDA or foreign regulatory authorities, including any
limitations or warnings contained in a product&#146;s approved labeling, including any black box warning or REMS; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new treatments, such as gene therapy as a novel modality
for treatment of our target indications and of physicians to prescribe these treatments; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to hire and retain a sales force in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of coverage and adequate reimbursement for our product candidates, once approved, from
third-party payors and government authorities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our products together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative public opinion of gene therapy and increased regulatory scrutiny of gene therapy and genetic research may adversely impact the development or
commercial success of our current and future product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our potential therapeutic products involve introducing genetic material into a
patient&#146;s cells via intrathecal and intravenous administration. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy and gene regulation for the prevention or
treatment of human diseases. Public attitudes may be influenced by claims that gene therapy and gene regulation are unsafe, unethical or immoral, and consequently, our products may not gain the acceptance of the public or the medical community.
Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we
may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair
the development and commercialization of our product candidates or demand for any products once approved. In 2021, sponsors of other clinical trials involving gene therapies have announced imposition of clinical holds by FDA to evaluate safety
issues arising during the trials. Among the risks in any gene therapy product based on viral vectors are the risks of immunogenicity, elevated liver enzymes and insertional oncogenesis. If any of our vectors demonstrate a similar effect, we may
decide or be required to halt or delay further clinical development of any product candidates that utilize that vector. Adverse events in our or others&#146; clinical trials, even if not ultimately attributable to our product candidates, and the
resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that
are approved and a decrease in demand for any such product candidates. The risk of cancer remains a concern for gene therapy and we cannot assure that it will not occur in any of our planned or future clinical trials or in any clinical trials
conducted by other companies. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry
the genetic material. In addition, for our regulated gene replacement therapy candidates which require that the expression of a therapeutic transgene be tightly regulated, such as LX1020, we may inadvertently cause overexpression, which could lead
to numerous issues, including safety and toxicity concerns. Furthermore, these regulatory gene replacement therapy candidates require the insertion of microRNA, or miRNA, targets into the viral genome, which is a technology that to our knowledge is
not present in any approved gene therapy products. If any such adverse events occur, commercialization of our product candidates or further advancement of our clinical trials could be halted or delayed, which would have a negative impact on our
business and operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The affected populations for our other product candidates may be smaller than we or third parties currently project, which
may affect the addressable markets for our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently focus our research and product development on several indications that
are orphan diseases. However, our projections of the number of people who have the diseases we are seeking to treat, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates,
are estimates based on our knowledge and understanding of these diseases. These estimates may prove to be incorrect and new studies may further reduce the estimated incidence or prevalence of this disease.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The number of patients in the United States, the European Union and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our product candidate or
patients may become increasingly difficult to identify and access, all of which would adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total addressable market opportunity for our product candidates will ultimately depend upon a number of factors including the diagnosis and treatment
criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient access and product pricing and reimbursement. Incidence and prevalence estimates are frequently based on information
and assumptions that are not exact and may not be appropriate, and the methodology is forward-looking and speculative. The process we have used in developing an estimated incidence and prevalence range for the indications we are targeting has
involved collating limited data from multiple sources. Accordingly, the incidence and prevalence estimates included in this prospectus should be viewed with caution. Further, the data and statistical information used in this prospectus, including
estimates derived from them, may differ from information and estimates made by our competitors or from current or future studies conducted by independent sources. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete
effectively. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drug development, particularly in the gene therapy field, is highly competitive and subject to rapid and significant technological
advancements. As a significant unmet medical need exists in the cardiovascular and CNS disease areas, there are several large and small pharmaceutical companies focused on delivering therapeutics for the treatment of these diseases, including those
that we are initially targeting. It is likely that additional drugs will become available in the future for the treatment of our target diseases. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
aware that our competitors are developing product candidates for the treatment of diseases that our product candidates will target. With respect to LX2006, we are aware of preclinical gene therapy programs in development at Novartis International
AG, or Novartis, PTC Therapeutics, Inc., Aavanti Bio, Inc., Lacerta Therapeutics, Inc. and those being developed in collaborations between Voyager Therapeutics, Inc., and Neurocrine Biosciences, Inc. and between Takeda Pharmaceutical Company Limited
and StrideBio, Inc. Among other treatment modalities for Friedreich&#146;s ataxia, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, <FONT STYLE="white-space:nowrap">CTI-1601,</FONT> and that Reata
Pharmaceuticals, Inc. is developing late-clinical-stage candidate omaveloxolone. With respect to our portfolio of gene therapy programs for the treatment of homozygous <I>APOE4</I>-associated Alzheimer&#146;s disease, we are aware that uniQure, N.V.
is pursuing <FONT STYLE="white-space:nowrap">AMT-240,</FONT> a preclinical gene therapy candidate for autosomal dominant Alzheimer&#146;s disease intended to silence the toxic variant while expressing the protective variant and Novartis has a gene
therapy for Alzheimer&#146;s disease which is in the early preclinical stages of development. Many large and small pharmaceutical companies and academic institutions are developing potential treatments for the condition given the significant unmet
need and the large population suffering from Alzheimer&#146;s disease. There are multiple FDA-approved treatments for Alzheimer&#146;s disease, including donepezil (Aricept), memantine (Namenda), and aducanumab (Aduhelm), which was recently approved
under accelerated approval and will require confirmatory data to verify clinical benefit. Finally, we are aware that Voyager Therapeutics, Inc. and Taysha Gene Therapies, Inc. are pursuing Alzheimer&#146;s disease treatments and have early-stage
discovery efforts ongoing based on vectorized antibodies and <FONT STYLE="white-space:nowrap">tau-specific</FONT> miRNA shuttles, respectively. With respect to LX1004, the FDA approved BioMarin Pharmaceutical, Inc.&#146;s treatment for CLN2 Batten
disease, cerliponase alfa (Brineura) in 2017. Brineura is an enzyme replacement therapy which requires chronic twice monthly infusions directly into the cerebrospinal fluid, or CSF, via intraventricular injections. In addition to Brineura, REGENXBIO
Inc. is developing two preclinical gene therapy candidates to treat the CNS and ocular manifestations of CLN2 Batten disease. With respect to LX2020, Tenaya Therapeutics Inc. is developing a preclinical
<FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy candidate designed to deliver a functional <I>PKP2</I> gene to patients with arrhythmogenic right ventricular cardiomyopathy, or ARVC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our existing or potential competitors have substantially greater financial, technical and human
resources than we do and significantly greater experience in the discovery and development of product candidates, as well as in obtaining regulatory approvals of those product candidates in the United States and in foreign countries. Our current and
potential future competitors may also have significantly more experience commercializing drugs, particularly gene therapy and other biologics, that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology
industries could result in even more resources being concentrated among a small number of our competitors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will face competition from other drugs or
from other <FONT STYLE="white-space:nowrap">non-drug</FONT> products currently approved or that will be approved in the future in the cardiac and neurology fields, including for the treatment of diseases and diseases in the therapeutic categories we
intend to target. Therefore, our ability to compete successfully will depend largely on our ability to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop and commercialize drugs that are superior to other products in the market; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrate through our clinical trials that our product candidates are differentiated from existing and future
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract qualified scientific, product development and commercial personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain patent or other proprietary protection for our medicines; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain required regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain coverage and adequate reimbursement from, and negotiate competitive pricing with, third-party payors; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new
medicines. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The availability of our competitors&#146; products could limit the demand, and the price we are able to charge, for any
product candidate we develop. The inability to compete with existing or subsequently introduced drugs would have an adverse impact on our business, financial condition and prospects. In addition, the reimbursement structure of approved gene
therapies by other companies could impact the anticipated reimbursement structure of our gene therapies, if approved, and our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to
<FONT STYLE="white-space:nowrap">in-license</FONT> novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy,
convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving regulatory and marketing
approval for, or commercializing, drugs before we do, which would have an adverse impact on our business and results of operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product
candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval
pathway for biologics that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product
may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12- year period of exclusivity, another company may still market a competing version of the reference product if the FDA
approves a full BLA for the competing product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is
still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any
such processes could have an adverse effect on the future commercial prospects for our biologics. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is a risk that any of our product candidates
approved as a biological product under a BLA would not qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will
not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity
provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for <FONT
STYLE="white-space:nowrap">non-biologics</FONT> is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing our
candidates, if approved, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The success of our product candidates will depend significantly on coverage and adequate reimbursement or the willingness of patients, commercial and
government payors to pay for these procedures. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our success depends on obtaining and maintaining coverage and adequate reimbursement for
our product candidates, including LX2006, LX1001, and LX1004, and the extent to which patients will be willing to pay <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> for such products, in the absence of
reimbursement for all or part of the cost. In the United States and in other countries, patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their
treatment. The availability of coverage and adequacy of reimbursement for our products by third-party payors, including government health care programs (e.g., Medicare, Medicaid, TRICARE), managed care providers, private health insurers, health
maintenance organizations and other organizations is essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates. Third-party payors often rely upon Medicare coverage policy and
payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis. One payor&#146;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage, and adequate reimbursement. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, an agency
within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors determine which products and procedures they will cover and establish reimbursement levels. Even if a third-party payor covers a particular
product or procedure, the resulting reimbursement payment rates may not be adequate. Patients who are treated <FONT STYLE="white-space:nowrap">in-office</FONT> for a medical condition generally rely on third-party payors to reimburse all or part of
the costs associated with the procedure, including costs associated with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products used during the procedure, and may be unwilling to undergo such procedures in the absence of such coverage and adequate reimbursement. Physicians may be unlikely to offer procedures for
such treatment if they are not covered by insurance and may be unlikely to purchase and use our product candidates, if approved, for our stated diseases unless coverage is provided and reimbursement is adequate. In addition, for products
administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Further, coverage policies and <FONT
STYLE="white-space:nowrap">third-party</FONT> reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the
future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that a procedure is
safe, effective and medically necessary; appropriate for the specific patient; cost-effective; supported by peer-reviewed medical journals; included in clinical practice guidelines; and neither cosmetic, experimental, nor investigational. Further,
increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not
cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the
medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health plans or government
healthcare programs. Our product candidates may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the
product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. We expect to experience pricing pressures from third-party payors in connection
with the potential sale of any of our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign governments also have their own healthcare reimbursement systems, which vary
significantly by country and region, and we cannot be sure that coverage and adequate reimbursement will be made available with respect to the treatments in which our products are used under any foreign reimbursement system. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that LX2006, LX1001, LX1004, or any other product candidates, if approved for sale in the United States or in other countries, will
be considered medically reasonable and necessary, that it will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available or that reimbursement policies and practices in the United
States and in foreign countries where our products are sold will not adversely affect our ability to sell our product candidates profitably, if they are approved for sale. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may
develop. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will
face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or drugs caused injuries, we will incur substantial liabilities. Regardless of
merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates or drugs that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards paid to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced resources of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We may need to
increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or
in an amount adequate to satisfy any liability that may arise. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Risks related to our dependence on third parties </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Currently, we rely on our collaborations with Cornell University for many of our preclinical and clinical research and development programs, including
for discovering, developing and conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for portions of our near-term future pipeline. Failure or delay of Cornell University to fulfill all or part of its obligations to us under the
agreement, a breakdown in collaboration between the parties or a complete or partial loss of this relationship would materially harm our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our company was founded with a collaboration between us, Cornell University, and Ronald G. Crystal, M.D., Professor and Chairman of Weill Cornell
Medicine&#146;s Department of Genetic Medicine. Our collaboration with Cornell University is critical to our business and in May 2020, we entered into two separate license agreements with Cornell University for preclinical research and development
collaborations and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license rights to patents for certain products and technologies. In June 2019, Cornell University completed the first clinical trial for LX1004. As part of our second license
agreement, Cornell assigned the IND for LX1004 to us. As part of our first license agreement, we assumed oversight for the conduct of the Phase 1/2 clinical trial of LX1001 that was initiated by Cornell University at the end of 2019. Pursuant to
these license agreements, we are obligated to diligently proceed with the development, manufacture, and sale of licensed products. Our collaboration with Cornell University provides us with the opportunity to expand our pipeline into several
additional cardiac and CNS disease targets. In February 2021, we further expanded our collaboration and entered into a Research Collaboration Agreement with Cornell University to enable discovery and preclinical research aimed at expanding our
cardiovascular pipeline. If Cornell University delays or fails to perform its obligations under this collaboration agreement, disagrees with our interpretation of the terms of the collaboration or our discovery plan or terminates any of our existing
license and collaboration agreements, our pipeline of product candidates would be significantly adversely affected and our prospects will be materially harmed. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We intend to continue to rely on third parties to conduct a significant portion of our existing clinical trials and potential future clinical trials for
product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have engaged CROs to conduct our ongoing clinical trials. We expect to continue to rely on third parties, including clinical data management organizations,
medical institutions and clinical investigators, to conduct those clinical trials and any future clinical trials. Any of these third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any
time for convenience. If any of our relationships with these third parties terminate, we may not be able to timely enter into arrangements with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
alternative third parties or to do so on commercially reasonable terms, if at all. Switching or adding a CRO involves substantial cost and requires management time and focus. In addition, there
is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our
CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. Further, the performance of
our CROs may also be interrupted by the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including due to travel or quarantine policies, heightened exposure of CRO staff who are healthcare providers to <FONT
STYLE="white-space:nowrap">COVID-19</FONT> or prioritization of resources toward the pandemic. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, any third parties conducting our clinical
trials will not be our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our clinical programs. If these third parties do
not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical
protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. Consequently, our
results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on these parties for execution of our preclinical studies and clinical trials, and generally do not control their activities. Our reliance on these
third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted
in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with cGCP regulations, for conducting, recording and reporting the results of clinical trials to assure that data and reported
results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a
government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. If we or any of our CROs or other third parties, including trial sites, fail to
comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our
marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with cGCP regulations. In addition, our clinical trials must be
conducted with product produced under cGMP conditions. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation
in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of
interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result
in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of LX2006, LX1001, LX1004, or any other product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also expect to rely on other third parties to store and distribute product supplies for our clinical
trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential revenue.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek collaborations with <FONT STYLE="white-space:nowrap">non-academic</FONT> third parties for the development or commercialization of our
product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek third-party collaborators for the development and commercialization of our product candidates, including for the commercialization of any of our
product candidates that are approved for marketing outside the United States. Our likely collaborators for any such arrangements include regional and national pharmaceutical companies and biotechnology companies. If we enter into any additional such
arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from
these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates pose the following risks to us: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory
approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that
divert resources or create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with
their own product candidates or drugs, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve
regulatory approval may not commit sufficient resources to the marketing and distribution of such products; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the
preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in
litigation or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or
their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation
and potential liability; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required
to raise additional capital to pursue further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration
agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our
product development or commercialization program could be delayed, diminished or terminated. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate
collaborators. Whether we reach a definitive agreement for any collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the
proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential
market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology,
which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar
diseases that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there
have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail
the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our
expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may
not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Risks related to intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are
unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product
candidates including LX2006, LX1001, LX1004 and other programs, their respective components, formulations, therapies, methods used to manufacture them and methods treatment. We currently do not have any patents or patent applications covering our
LX1004 or LX1001 product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to obtain and maintain patent and other intellectual property
protection in the United States and in other countries with respect to our proprietary technology and product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot offer any assurances about which of our patent applications will issue, the breadth of any
resulting patent or whether any of the issued patents will be found invalid and unenforceable or will be threatened by third parties. We cannot offer any assurances that the breadth of our granted patents will be sufficient to stop a competitor from
developing and commercializing a product, including a biosimilar product that would be competitive with one or more of our product candidates. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us
after patent issuance could deprive us of rights necessary for the successful commercialization of any of our product candidates. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product
candidate under patent protection could be reduced. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive and time-consuming. We may not be able to prepare, file
and prosecute all necessary or desirable patent applications at a commercially reasonable cost or in a timely manner or in all jurisdictions. It is also possible that we may fail to identify patentable aspects of inventions made in the course of
development and commercialization activities before it is too late to obtain patent protection on them. We may not be able to obtain or maintain patent applications and patents due to the subject matter claimed in such patent applications and
patents being in the public domain. In some cases, the work of certain academic researchers in the gene therapy field has entered the public domain, which may preclude our ability to obtain patent protection for certain inventions relating to such
work. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific
collaborators, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent
protection. Consequently, we would not be able to prevent any third party from using any technology that is in the public domain to compete with our product candidates. Moreover, depending on the terms of any future
<FONT STYLE="white-space:nowrap">in-licenses</FONT> to which we may become a party, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology <FONT
STYLE="white-space:nowrap">in-licensed</FONT> from third parties. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in
recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of any patent rights are highly uncertain. Our owned and licensed pending and future patent applications may not
result in issued patents which protect our technology or product candidates, effectively prevent others from commercializing competitive technologies and product candidates or otherwise provide any competitive advantage. In fact, patent applications
may not issue as patents at all. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties
from competing with us, or otherwise provide us with any competitive advantage. Any patents that we hold or <FONT STYLE="white-space:nowrap">in-license</FONT> may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently,
we do not know whether any of our technologies and product candidates will be protectable or remain protected by valid and enforceable patents. In addition, our existing patents and any future patents we obtain may not be sufficiently broad to
prevent others from using our technology or from developing competing technologies and products and the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after
issuance. Any failure to obtain, maintain or defend our patents and other intellectual property could have a material adverse effect on our business, financial conditions, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority or
entitlement disputes. We may be required to disclaim part or all of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim.
There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. Since patent
applications in the United States and other countries are confidential for a period of time after filing, at any moment in time, we cannot be certain that we were in the past or will be in the future the first to file any patent application related
to our product candidates. For example, some patent applications in the United States may be maintained in secrecy until the patents are issued. Further, publications in the scientific literature often lag behind actual discoveries. Consequently, we
cannot be certain that others have not filed patent applications for technology covered by our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents or our pending applications, or that we or, if applicable, a licensor were
the first to invent or first to file an application for the technology. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our patents or
patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form, preparation, prosecution,
or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from
third parties, which may have an adverse impact on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the protection provided by our patent estate, we rely on trade secret
protection and confidentiality agreements to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is not amenable to patent protection. Although we generally require all of our employees to assign their inventions to us, and all
of our employees, consultants, advisors and any third parties who have access to our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology to enter into confidentiality agreements, we cannot provide any assurances
that all such agreements have been duly executed, or that our trade secrets and other confidential proprietary information will not be disclosed. In addition, while we have undertaken reasonable efforts to ensure such agreements are enforceable and
that employees and third parties comply with their obligations thereunder, these agreements may be found insufficient by a court of law or may be breached, or we may not enter into sufficient agreements with such individuals in the first instance,
in either case potentially resulting in the unauthorized use or disclosure of our trade secrets and other intellectual property, including to our competitors, which could cause us to lose any competitive advantage resulting from this intellectual
property. Individuals not subject to invention assignment agreements may make adverse ownership claims to our current and future intellectual property. Moreover, our competitors may independently develop knowledge, methods and <FONT
STYLE="white-space:nowrap">know-how</FONT> equivalent to our trade secrets. Competitors could purchase our products, if approved, and replicate some or all of the competitive advantages we derive from our development efforts for technologies on
which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or
information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. Enforcing a claim that a third-party entity illegally obtained and is using any
of our trade secrets is expensive and time-consuming, and the outcome is unpredictable, and we may not be able to obtain adequate remedies for such breaches. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and
electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, our agreements or security measures may be breached, and we may not have adequate remedies for any breach. Also, if
the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary
information. For example, the FDA is considering whether to make additional information publicly available on a routine basis, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the
future. If we are unable to prevent material disclosure of the <FONT STYLE="white-space:nowrap">non-patented</FONT> intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable
trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and if we do not obtain protection
under the Hatch-Waxman Amendments and similar <FONT STYLE="white-space:nowrap">non-United</FONT> States legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire
before or shortly after such candidates are commercialized. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our United States patents may be eligible for limited patent term
extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension of up to five
years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of
14 years from the date of product approval. Only one patent may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not receive an extension if we
fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain
patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner.
As a result, our revenue from applicable products could be reduced and could have a material adverse effect on our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We <FONT
STYLE="white-space:nowrap">in-license</FONT> key intellectual property necessary for the development of each of our current product candidates. If we fail to comply with our obligations in our current and future intellectual property licenses with
third parties, resulting in the termination of such licenses, we could lose rights that are important to our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are heavily reliant upon
licenses to certain patent rights and proprietary technology for the development of each of our current product candidates. In particular, we <FONT STYLE="white-space:nowrap">in-license</FONT> key patents and patent applications from Cornell
University and Adverum Biotechnologies, Inc. related to LX2006, and we <FONT STYLE="white-space:nowrap">in-license</FONT> <FONT STYLE="white-space:nowrap">know-how</FONT> from Cornell University related to our LX1001 and LX1004 product candidates
for the treatment of Alzheimer&#146;s disease. Our license agreements impose diligence and milestone and royalty payment obligations on us, and also contain certain development requirements. If we fail to comply with our obligations, our licensors
may have the right to terminate our licenses, in which event we will not be able to develop, manufacture or market any product using the intellectual property under any such terminated agreement and may face other penalties. Such an occurrence would
materially adversely affect our business prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our licenses may not provide us with exclusive rights to use the licensed intellectual
property and technology, or may not provide us with exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product
candidates in the future. In addition, the intellectual property rights licensed to us by our licensors, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including certain intellectual property licensed by Cornell University, at least in some respects, may be used by such licensors or licensed to third parties, and such third parties may have
certain enforcement rights with respect to such intellectual property. Thus, patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against our licensors or another licensee or in
administrative proceedings brought by or against our licensors or another licensee in response to such litigation or for other reasons. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing
competitive products, including in territories covered by our licenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licenses to additional third-party technology and materials that may be required
for our development programs may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business and financial condition. In such events, we may be
required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial
basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology or product candidates. Even if we are able to obtain such additional licenses, they may be <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
thereby giving our competitors and other third parties access to the same technology licensed to us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our licensors fail to adequately protect our
licensed intellectual property, our ability to commercialize our product candidates and technology could suffer. Although we have oversight rights, Cornell University and The Regents of the University of California generally control the prosecution,
maintenance and enforcement of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications. Therefore, we cannot be certain that the prosecution, maintenance and enforcement of these patent rights will be in a manner
consistent with the best interests of our business, or in compliance with applicable laws and regulations, or will result in valid and enforceable patents and other intellectual property rights. It is possible that our licensors&#146; infringement
proceedings or defense activities may be less vigorous than had we conducted them ourselves or may not be conducted in accordance with our best interests. If we or our licensors fail to maintain such patents or patent applications, or if we or our
licensor lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be
adversely affected. In addition to the foregoing, the risks associated with patent rights that we license from third parties will also apply to patent rights we may own in the future. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, if we fail to comply with our development obligations under our license agreements, we may lose our patent rights with respect to such agreement on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">territory-by-territory</FONT></FONT> basis, which would affect our patent rights worldwide. In spite of our efforts, our current and future licensors might conclude that we have materially
breached our obligations under our license agreements and might therefore terminate such license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. Disputes
may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial and other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor
that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidates and what activities satisfy those diligence obligations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship or ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms,
we may be unable to successfully develop and commercialize the affected technology or product candidates. In addition, if any such disputes result in the termination of our intellectual property licenses, this could result in the loss of our ability
to develop and commercialize our lead product candidates, or we could lose other significant rights, experience significant delays in the development and commercialization of our other product candidates, or incur liability for damages, any of which
could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree
to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is
subject to our existing licenses and to compete with our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our future agreements with certain of our third-party research
partners may provide that improvements developed in the course of our relationship may be owned solely by either us or our third-party research partner. If we determine that rights to such improvements owned solely by a third-party research partner
or other third party with whom we collaborate are necessary to commercialize our therapeutic candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue
developing, manufacturing or marketing our drug candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our product candidates or allow
our competitors or others the chance to access technology that is important to our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination of our current or any future license agreements
would reduce or eliminate our rights under these agreements and may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important
intellectual property or technology. Any of the foregoing could prevent us from commercializing our other product candidates, which could have a material adverse effect on our operating results and overall financial condition. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, intellectual property rights that we <FONT STYLE="white-space:nowrap">in-license</FONT> in the future may be sublicenses under intellectual
property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our
license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or
amended, our ability to develop and commercialize our product candidates may be materially harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a third party may in the future bring
claims that our performance under our license agreements, including our sponsoring of clinical trials, interferes with such third party&#146;s rights under its agreement with one of our licensors. If any such claim were successful, it may adversely
affect our rights and ability to advance our product candidates as clinical candidates or subject us to liability for monetary damages, any of which would have an adverse effect on our business, financial condition, results of operations and
prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are generally also subject to all of the same risks with respect to protection of intellectual
property that we license as we are for intellectual property that we own, which are described above and below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. We may
not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presently, we have obtained rights to certain intellectual property rights through licenses from third parties to develop, manufacture and commercialize our
lead product candidates and other potential product candidates in our pipeline. Because the commercialization of our product candidates may require the use of additional intellectual property rights held by third parties, the growth of our business
likely will depend, in part, on our ability to acquire or license these intellectual property rights. Our product candidates also require specific formulations and manufacturing processes to work effectively and efficiently, and some of these rights
are held by others. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other
third-party intellectual property rights from third parties that we identify as necessary, important or more expedient to further our business operations. In addition, even if we are able to obtain such licenses, we may fail to obtain any of these
licenses at a reasonable cost or on reasonable terms, which would harm our business. Were that to happen, we may need to cease use of the product candidates and technologies covered by those third-party intellectual property rights and may need to
seek to develop alternative approaches that do not infringe, misappropriate or violate those intellectual property rights, which may entail additional costs and development delays if we are able to develop such alternatives, or which may not be
feasible. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which means that our competitors may also receive access to the same technologies licensed to us. The licensing and acquisition of
third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that
we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and
commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete such negotiations and ultimately
acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an
appropriate return on our investment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to successfully obtain rights to required third-party intellectual property or maintain the
existing intellectual property rights we have licensed, we may be required to expend significant time and resources to redesign our product candidates, or to develop or license replacement technology, all of which may not be feasible on a technical
or commercial basis, and we may have to abandon development of our product candidates, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our
rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently depend,
and will continue to depend, on our license agreements, including the license agreements with Cornell University related to LX2006 and LX1001. The agreements under which we currently license intellectual property or technology from third parties are
complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under
the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
any of our licenses or material relationships or any <FONT STYLE="white-space:nowrap">in-licenses</FONT> upon which our licenses are based are terminated or breached, we may: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lose our rights to develop and market our products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lose patent protection for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience significant delays in the development or commercialization of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not be able to obtain any other licenses on acceptable terms, if at all; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur liability for damages. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These risks apply to any agreements that we may enter into in the future for our products or for any future product candidates. If we experience any of the
foregoing, it could have a material adverse effect on our business, financial condition, results or operations and prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently
own or license any U.S. composition of matter patents or patent applications covering our LX1001 and LX1004 product candidates and we cannot be certain that any of our or licensed pending patent applications or our future owned or licensed patent
applications will result in issued patent claims covering such aspects of our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Composition-of-matter</FONT></FONT> patents on the active pharmaceutical ingredient, or API, in prescription drug products are generally considered to be the strongest form of intellectual property protection for drug
products because those types of patents provide protection without regard to any particular method of use or manufacture or formulation of the API used. We currently <FONT STYLE="white-space:nowrap">in-license</FONT> two issued U.S. patents that
relates to our LX2006 product candidate. However, we do not own or <FONT STYLE="white-space:nowrap">in-license</FONT> any composition of matter patents or patent applications in the United States or any other jurisdiction with respect to our LX1001
and LX1004 product candidates. Although we intend to file patent applications in the future that cover these product candidates, we cannot be certain that our future owned or licensed patent applications will cover our current or future product
candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Method-of-use</FONT></FONT> patents protect the use of a product for the
specified method and formulation patents cover formulations of the API. These types of patents do not prevent a competitor or other third party from developing or marketing an identical product for an indication that is outside the scope of the
patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patents, even
if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products
<FONT STYLE="white-space:nowrap">off-label,</FONT> or patients may do so themselves. Although <FONT STYLE="white-space:nowrap">off-label</FONT> use may infringe or contribute to the infringement of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">method-of-use</FONT></FONT> patents, the practice is common, and this type of infringement is difficult to prevent or prosecute. In addition, there are numerous publications and other prior art that may be relevant to our
owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patents and patent applications and may be used to challenge the validity of these owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications in litigation or other intellectual property-related proceedings. If these types of challenges are successful, our owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may be narrowed or found to be invalid and we may lose valuable intellectual property rights. Any of the foregoing could have a material adverse effect on our
business, financial conditions, prospects and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific
questions and can be uncertain. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in
other countries. Even if patents do successfully issue, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and third parties may challenge the validity, enforceability or scope of our owned and
licensed patents in courts or patent offices in the United States and abroad, which may result in those patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our owned and licensed patents and pending
patent applications, if issued, may not adequately protect our intellectual property or prevent competitors or others from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative
technologies or therapeutics in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. If the breadth or strength of protection provided by the patents and patent applications we own or license with respect to our product candidates is not
sufficient to impede such competition or is otherwise threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Any of the foregoing could have a material
adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce our
patents, which could be expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe the patents for which we have applied. To counter
infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the
defendant could counterclaim that the patent covering our product or product candidate is invalid and/or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity and/or unenforceability are common, and there are
numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. In an infringement proceeding, a court may decide that the patent claims we are asserting are invalid and/or unenforceable, or may refuse to stop the
other party from using the technology at issue on the grounds that our patent claims do not cover the technology in question. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the
context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post grant review, inter partes review and equivalent proceedings in foreign jurisdictions (for example, opposition proceedings). Such proceedings
could result in revocation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity
question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or
unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or
interpreted narrowly, could put our patent applications at risk of not issuing and could have a material adverse impact on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interference
proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patent applications. An unfavorable outcome could require us to cease using the related technology or force us to
take a license under the patent rights of the prevailing party, if available. Furthermore, our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference
proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our intellectual property rights, particularly in countries where the
laws may not protect those rights as fully as in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we establish infringement of any of our patents by a competitive product, a court may decide not to
grant an injunction against further infringing activity, thus allowing the competitive product to continue to be marketed by the competitor. It is difficult to obtain an injunction in U.S. litigation and a court could decide that the competitor
should instead pay us a &#147;reasonable royalty&#148; as determined by the court, and/or other monetary damages. A reasonable royalty or other monetary damages may or may not be an adequate remedy. Loss of exclusivity and/or competition from a
related product would have a material adverse impact on our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For certain of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
rights, such as patent rights <FONT STYLE="white-space:nowrap">in-licensed</FONT> from Cornell University and Adverum Biotechnologies Inc., we may not have the right to file a lawsuit for infringement and may have to rely on a licensor to enforce
these rights for us. If we are not able to directly assert our licensed patent rights against infringers or if a licensor does not vigorously prosecute any infringement claims on our behalf, we may have difficulty competing in certain markets where
such potential infringers conduct their business, and our commercialization efforts may suffer as a result. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we or our licensors, as the case
may be, may not be able to detect infringement against our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, which may be especially difficult for manufacturing processes or formulation patents. Even if we or our licensors detect
infringement by a third party of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, we or our licensors, as the case may be, may choose not to pursue litigation against or settlement with the third party. If we or our
licensors later sue such third party for patent infringement, the third party may have certain legal defenses available to it that otherwise would not be available but for the delay between when the infringement was first detected and when the suit
was brought. These legal defenses may make it impossible for us or our licensors to enforce our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, as the case may be, against that third party. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or
investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may
initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As our
current and future product candidates progress toward commercialization, the possibility of a patent infringement claim against us increases. We cannot provide any assurance that our current and future product candidates do not infringe other
parties&#146; patents or other proprietary rights, and competitors or other parties may assert that we infringe their proprietary rights in any event. We may become party to, or threatened with, adversarial proceedings or litigation regarding
intellectual property rights with respect to our current and future product candidates, including interference or derivation proceedings before the USPTO, or oppositions and other proceedings in foreign jurisdictions. We may be exposed to, or
threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates, manufacturing methods, formulations, administration methods and/or proprietary technologies infringe,
misappropriate or otherwise violate their intellectual property rights. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous issued patents and pending patent applications that are owned by third
parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of
infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, the claim scope that may issue from pending patent applications owned by third parties or which patents cover various types of
drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties, including our competitors, may allege
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
they have patent rights encompassing our product candidates, technologies or methods and that we are employing their proprietary technology without authorization. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we were sued for patent infringement, we would need to demonstrate that the relevant product or methods of using the product either do not infringe the
patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. In order to successfully challenge the validity of any such United States patent in federal court, we would need to
overcome a presumption of validity. As this burden is high and requires us to present clear and convincing evidence as to the invalidity of any such United States patent claim, there is no assurance that a court of competent jurisdiction would agree
with us and invalidate the claims of any such United States patent. Moreover, given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be
granted in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we may decide to initiate proceedings to challenge the validity of these or other patents in the future, we may be
unsuccessful, and courts or patent offices in the United States and abroad could uphold the validity of any such patent. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after
filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates. Regardless of
when filed, we may fail to identify relevant third-party patents or patent applications, or we may incorrectly conclude that a third-party patent is invalid or not infringed by our product candidates or activities. If a patent holder believes that
one of our product candidates infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from
<FONT STYLE="white-space:nowrap">non-practicing</FONT> entities that have no relevant drug revenue and against whom our own patent portfolio may thus have no deterrent effect. If a patent infringement suit were threatened or brought against us, we
could be forced to stop or delay research, development, manufacturing or sales of the drug or product candidate that is the subject of the actual or threatened suit. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any third-party patents are held by a court of competent jurisdiction to be valid and enforceable and to cover any of our technology or product candidates,
including the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, we could be forced, including by court order, to cease developing, manufacturing
or commercializing the infringing product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product. If we were
required to obtain a license to continue to manufacture or market the affected product, we may be required to pay substantial royalties or grant cross-licenses to our patents. We cannot, however, assure that any such license will be available on
acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property
rights, Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is
especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Furthermore, we may not be able to obtain any required license on commercially reasonable
terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally it could
include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#146; fees if we are found to have
willfully infringed a patent. A finding of infringement could prevent us from commercializing a product or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential
information or trade secrets of third parties could have a similar negative impact on our business. Furthermore, because of the substantial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by
disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business,
results of operations, financial condition and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cost to us in defending or initiating any litigation or other proceeding relating to patent
or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#146;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively
than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue
our operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed
confidential information of third parties. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We employ individuals who were previously employed at other biotechnology or biopharmaceutical
companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or our
employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#146; former employers or other third parties. We may also be subject to claims that former employers or
other third parties have an ownership interest in our future patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in
substantial cost and be a distraction to our management and other employees. Even if we are successful in defending against these types of claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur
significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments,
and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our
operating losses and reduce our resources available for development activities. Some of our competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than we can because of their substantially greater
financial resources. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship or ownership of our future patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patent applications, our future
patents, or other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates and platform discovery.
Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing
such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they
will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and litigation may be necessary to defend against these and
other claims challenging inventorship or ownership. If we fail in defending </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such
an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade
secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we rely on third parties to manufacture or commercialize our product candidates, or if we
collaborate with additional third parties for the development of such product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under
the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements
or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose
our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets
become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our
<FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially
relating to our trade secrets. Despite our efforts to protect our trade secrets, we may not be able to prevent the unauthorized disclosure or use of our technical <FONT STYLE="white-space:nowrap">know-how</FONT> or other trade secrets by the parties
to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and
disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these
agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or
disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third party illegally
obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not
adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make or use capsids, nucleic acids and vectors that are similar to the biological
compositions of our products that are the same as or similar to our product candidates but that are not covered by the claims of owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that others may circumvent our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others, including inventors or developers of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patented technologies who may become involved with competitors, may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing our intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent
applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or
unenforceable; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or our other collaboration partners might not have been the first to conceive and reduce to
practice the inventions covered by the patents or patent applications that we own, license or will own or license; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or our other collaboration partners might not have been the first to file patent applications
covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors may fail to meet obligations to the U.S. government with respect to <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications funded by U.S. government grants, leading to the loss of patent rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not result in issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to generate sufficient data to support full patent applications that protect the entire
breadth of developments in one or more of our programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no patent protection may be available with regard to formulation or method of use; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the claims of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents or patent
applications, if and when issued, may not cover our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are prior public disclosures that could invalidate our or our licensors&#146; patents;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may
later issue with claims covering our products or technology similar to ours; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or exclusively license may not provide us with any competitive advantage, or may be
held invalid or unenforceable, as a result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not exclusively license our patents and, therefore, may not have a competitive advantage if such patents
are licensed to others; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent
rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the laws of other countries may not protect our or our licensors&#146;, as the case may be, proprietary rights to
the same extent as the laws of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope
of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the United States may, under certain circumstances, force us or our licensors to grant a
license under our patents to a competitor, thus allowing the competitor to compete with us in that jurisdiction or forcing us to lower the price of our drug in that jurisdiction; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have engaged in scientific collaborations in the past and will continue to do so in the future and our
collaborators may develop adjacent or competing products that are outside the scope of our patents; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not successfully commercialize the product candidates, if approved, before our relevant patents expire;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies for which we can obtain patent protection;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that product candidates or technologies we develop may be covered by third parties&#146; patents
or other exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ownership, validity or enforceability of our or our licensors&#146; patents or patent applications may be
challenged by third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse
effect on our business. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may enjoy only limited geographical protection with respect to certain patents and we may not be able
to protect our intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing and prosecuting patent applications and defending patents covering our
product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export
otherwise infringing products to territories where we have patent protection, but enforcement rights are not as strong as that in the United States or Europe. These products may compete with our product candidates, and our future patents or other
intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may decide to abandon national and
regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents in some jurisdictions, such
as in the United States, but may issue as patents with claims of different scope or may even be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the same product
candidate or technology. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be
able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an
adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the
intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and
Europe and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of
patents, trade secrets and other intellectual property rights, which could make it difficult for us to stop the infringement of our future patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to
enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our future patents at risk of being invalidated or
interpreted narrowly and our patent applications at risk of not issuing as patents, and could provoke third parties to assert </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce
our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries
limit the enforceability of patents against government agencies or government contractors. In those countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we are forced to grant a license
to third parties with respect to any patents relevant to our business, our competitive position may be impaired. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our
patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other
government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and/or applications and any patent rights we may obtain in the
future. Furthermore, the USPTO and various <FONT STYLE="white-space:nowrap">non-United</FONT> States government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent
application process. In many cases, an inadvertent lapse of a patent or patent application can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT
STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patents or patent applications, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors
might be able to enter the market, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent laws or patent jurisprudence could
diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology
companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and genetic medicine industries involve both technological and legal complexity. Therefore, obtaining
and enforcing biotechnology and genetic medicine patents is costly, time-consuming and inherently uncertain. In addition, the Leahy-Smith America Invents Act (AIA), which was passed in September 2011, resulted in significant changes to the U.S.
patent system. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An important change introduced by the AIA is that, as of March&nbsp;16, 2013, the United States transitioned from a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party
should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system,
assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party
that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant
going forward of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities
for third parties to challenge any issued patent in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
USPTO. This applies to all of our U.S. patents, even those issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in
U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the
claim if first presented in a district court action. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims
that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation
could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#146; patent applications and the enforcement or defense of our or our licensors&#146; issued patents. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may become involved in opposition, interference, derivation, inter partes review or other proceedings challenging our or our licensors&#146; patent rights,
and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, allow third parties to
commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The
federal government retains a &#147;nonexclusive, nontransferable, irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT> license&#148; for its own benefit. The Bayh-Dole Act also provides federal agencies with
<FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;. <FONT STYLE="white-space:nowrap">March-in</FONT> rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a
&#147;nonexclusive, partially exclusive, or exclusive license&#148; to a &#147;responsible applicant or applicants.&#148; If the patent owner refuses to do so, the government may grant the license itself. Some of our licensed patents are subject to
the provisions of the Bayh-Dole Act. If our licensors fail to comply with the regulations of the Bayh-Dole Act, they could lose title to any patents subject to such regulations, which could affect our license rights under the patents and our ability
to stop others from using or commercializing similar or identical technology and products, or limit patent protection for our technology and products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain
circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain
patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could
change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In addition, the European patent system is relatively stringent in the type of
amendments that are allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents in the future
that may be important for our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current or future trademarks or trade names may be
challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we
need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such
rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation
proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business
may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these
agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have
registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA
(or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would
qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a
subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to
market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade
names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in
question. In this case, we could ultimately be forced to cease use of such trademarks. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Risks related to legal and regulatory compliance matters
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers, healthcare providers, including physicians, and third-party payors are subject, directly or indirectly, to
federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face
substantial penalties. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare providers, including physicians, and third-party payors in the United States and elsewhere will play a primary
role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors
subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the U.S. federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the
Physician Payments Sunshine Act and regulations promulgated under such laws. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs, and other interactions with healthcare professionals.
In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not limited to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, individuals or entities from
knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind in return for, or to induce, either the referral of an individual, or the purchase, lease, order or arrangement
for or recommendation of the purchase, lease, order or arrangement for any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term
&#147;remuneration&#148; has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors
are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. A person does not need
to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the ACA, signed into law in 2010, provides that the government may assert that a claim including items or services
resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including, without limitation, the federal False Claims Act,
which can be enforced by private citizens through civil whistleblower or <I>qui tam</I> actions, and the federal civil monetary penalty law which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be
presented, claims for payment or approval from the federal government, including Medicare, Medicaid and other government payors, that are false or fraudulent or knowingly making, using or causing to be made or used a false record or statement
material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the United States federal
government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other
companies have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of products for unapproved, and thus <FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional
federal criminal statutes which prohibit, among other things, a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and
willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal
Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH,
and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on health plans, healthcare clearinghouses and certain healthcare providers,
known as &#147;covered entities&#148;, and their respective HIPAA &#147;business associates&#148;, which are independent contractors that perform certain services for or on behalf of covered entities or other business associates involving the use or
disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general
new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal transparency laws, including the U.S. federal Physician Payments Sunshine Act, which requires certain
manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#146;s Health Insurance Program, with specific exceptions, to report annually to CMS information
related to: (i)&nbsp;payments or other &#147;transfers of value&#148; made </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and (ii)&nbsp;ownership and investment interests held by physicians and
their immediate family members. Effective January&nbsp;1, 2022, these reporting obligations extended to include payments and other transfers of value made, as well as ownership and investment interests held, during the previous year to certain <FONT
STYLE="white-space:nowrap">non-physician</FONT> providers, including physician assistants, nurse practitioners clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">state and foreign laws and regulations that are analogous to each of the above federal laws; state laws that
require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing; state laws that require pharmaceutical companies to comply with the
pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or that otherwise restrict payments that may be made to healthcare providers; state and local laws that
require the registration of pharmaceutical sales representatives; and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not
preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory
exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other
governmental regulations that may apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from
participating in federal and state funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, diminished profits and future earnings, reputational harm and the curtailment or restructuring of our operations, any of which could harm our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities
or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action
against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. The shifting compliance environment
and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the
requirements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA or EMA approval for any of our product candidates in the United States or European Union, we may never obtain
approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis
regarding safety and efficacy. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval by the FDA in the United States or the EMA in the European Union does not ensure approval by regulatory
authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign
regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and
could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory
approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be
reduced and our ability to realize the full market potential of any product we develop will be unrealized. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval
of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements
or experience unanticipated problems with our product candidates. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidate for which we obtain marketing approval will be subject to
ongoing regulatory requirements for, among other things, manufacturing processes, submission of post-approval clinical data and safety information, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import,
advertising, promotional activities and product tracking and tracing. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, applicable tracking
and tracing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to
physicians and recordkeeping and cGCP requirements for any clinical trials that we conduct post-approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our
product candidates or any future product candidates may also be subject to a REMS, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or requirements that we conduct potentially costly
post-marketing testing, including Phase 4 trials and surveillance to monitor the quality, safety and efficacy of the product. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing
approval. We will further be required to immediately report any serious and unexpected adverse events and certain quality or production problems with our products to regulatory authorities along with other periodic reports. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and EMA closely regulate the post-approval marketing and promotion of genetic therapy medicines to ensure they are marketed only for the approved
indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling. The FDA imposes stringent
restrictions on manufacturers&#146; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use and if we market our products for uses beyond their approved diseases, we may be subject to enforcement action for <FONT
STYLE="white-space:nowrap">off-label</FONT> marketing. Violations of the FDCA, relating to the promotion of prescription drugs for unapproved uses may lead to enforcement actions and investigations alleging violations of federal and state health
care fraud and abuse laws, as well as state consumer protection laws. The holder of an approved BLA must submit new or supplemental applications and obtain prior approval for certain changes to the approved product, product labeling, or
manufacturing process. A company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses of their products may be subject to significant civil, criminal and administrative penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, later discovery of previously unknown adverse events or other problems with our products,
manufacturers or manufacturing processes, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various
results, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on manufacturing such products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to allow entry into supply contracts, including government contracts; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning or untitled letters, or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of products; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of administrative, civil or criminal penalties or monetary fines.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA&#146;s policies, and the policies of foreign regulatory agencies, may change and additional government regulations may be
enacted that could prevent, limit or delay regulatory approval of our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also cannot predict the likelihood, nature or extent of
government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, executive orders or other actions could impose significant burdens on, or otherwise materially
delay, FDA&#146;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. If such executive actions were to impose restrictions on
FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business could be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained which would adversely affect our business, prospects and ability to achieve or sustain profitability. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative
publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our current product candidates or any future product candidates and harm our business, financial condition, results of operations and
prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our
clinical programs and obtain marketing approval of and commercialize our product candidates and may affect the prices we may set. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United
States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of
operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the ACA was enacted,
which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, <FONT STYLE="white-space:nowrap">non-deductible</FONT> fee payable by any entity that manufactures or
imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a licensure framework for follow on biologic products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of a Center for Medicare&nbsp;&amp; Medicaid Innovation at CMS to test innovative payment and
service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment,
there have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing
penalties, starting January&nbsp;1, 2019, for not complying with the ACA&#146;s individual mandate to carry health insurance, delaying the implementation of certain <FONT STYLE="white-space:nowrap">ACA-mandated</FONT> fees, and increasing the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. On June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on
procedural grounds that argued the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling,
on January&nbsp;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February&nbsp;15, 2021 and remained open
until August&nbsp;15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration
projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or
Congressional challenges in the future. It is unclear how any such challenges and the health reform measures of the Biden administration will impact the ACA and our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of
2011, among other things, led to aggregate reductions of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute will remain in effect through
2031 unless additional action is taken by Congress. However, pursuant to <FONT STYLE="white-space:nowrap">COVID-19</FONT> relief legislation, these Medicare sequester reductions have been suspended from May&nbsp;1, 2020 through December&nbsp;31,
2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers,
including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. On July&nbsp;9, 2021, President Biden issued an
executive order directing the FDA to, among other things, continue to clarify and improve the approval framework for generic drugs and biosimilars, including the standards for interchangeability of biologics, facilitate the development and approval
of biosimilar and interchangeable products, clarify existing requirements and procedures related to the review and submission of BLAs, and identify and address any efforts to impede generic drug and biosimilar competition. Additionally, on
March&nbsp;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#146;s average manufacturer price, for single source and innovator
multiple source drugs, beginning January&nbsp;1, 2024. In addition, Congress is considering additional health reform measures as part of the budget reconciliation process. It is also possible that additional governmental action is taken in response
to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and
regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their
marketed products, which has resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of
prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. For example, July 2021, the Biden administration released an executive order, &#147;Promoting Competition in the American
Economy,&#148; with multiple provisions aimed at prescription drugs. This executive order directs the FDA to, among other things, continue to clarify and improve the approval framework for biosimilars, including the standards for interchangeability
of biologics, facilitate the development and approval of biosimilar and interchangeable products, clarify existing requirements and procedures related to the review and submission of BLAs, and identify and address any efforts to impede generic drug
and biosimilar competition. In response to President Biden&#146;s executive order, on September&nbsp;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety
of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. We expect
that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our
product candidates or additional pricing pressures and could negatively affect our customers and accordingly, our financial operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Individual states
in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other
restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products
and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, similar political, economic and regulatory developments may affect our ability to
profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional
requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a
matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context.
In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and
national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product
candidates, if approved. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly
by country, and many countries have instituted price ceilings on specific products and therapies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood, nature or extent of
government regulation that may arise from future legislation or administrative action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing
requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve
or sustain profitability. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership
and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to
hire and retain key personnel, accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government
agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disruptions at
the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days
beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. Our business depends upon the ability of
the FDA to accept and review our potential regulatory filings. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material
adverse effect on our ability to advance clinical development of our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, as of May&nbsp;26, 2021, the FDA noted it is
continuing to ensure timely reviews of applications for medical products during the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign
inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection or an inspection of clinical sites is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required and due to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and travel restrictions FDA is unable to complete such required inspections during the review period.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance,
bioresearch monitoring and <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections on a prioritized basis. Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management
methods, to meet user fee commitments and goal dates. Ongoing travel restrictions and other uncertainties continue to impact oversight operations both domestic and abroad and it is unclear when standard operational levels will resume. The FDA is
continuing to complete mission-critical work, prioritize other higher-tiered inspectional needs (e.g., <FONT STYLE="white-space:nowrap">for-cause</FONT> inspections), and carry out surveillance inspections using risk-based approaches for evaluating
public health. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be
adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> public health emergency, a number of companies announced receipt of complete response letters due to the FDA&#146;s inability to complete required inspections for their applications. Regulatory
authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may experience delays in their regulatory activities. If a prolonged
government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future shutdowns of other government
agencies, such as the SEC, may also impact our business through review of our public filings and our ability to access the public markets. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates or realizing the synergies in the target diseases of
our programs, even if they are approved. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any infrastructure for the sales, marketing or distribution of our products, and the cost
of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. We expect to build a focused sales, distribution and marketing infrastructure to market our product candidates in the United States and European
Union, if approved. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate
sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution
capabilities could delay any product launch, which would adversely impact the commercialization of our product candidates. Additionally, if the commercial launch of our product candidates for which we recruit a sales force and establish marketing
capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and
marketing personnel. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not have the resources in the foreseeable future to allocate to the sales and marketing of our product candidates in certain
international markets. Therefore, our future sales in these markets will largely depend on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#146;s strategic interest in the product and such
collaborator&#146;s ability to successfully market and sell the product. We may pursue collaborative arrangements regarding the sale and marketing of LX2006, LX1001 or LX1004, if approved, for certain markets overseas; however, we cannot assure that
we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to build our own sales force or negotiate a collaborative relationship for the
commercialization of LX2006, LX1001 or LX1004, or any of our other product candidates, if approved, we may be forced to delay the potential commercialization of LX2006, LX1001 or LX1004 or any of our other product candidates or reduce the scope of
our sales or marketing activities for LX2006, LX1001 or LX1004 or any of our other product candidates. If we elect to increase our expenditures to fund commercialization activities internationally, we will need to obtain additional capital, which
may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to LX2006, LX1001 or LX1004 or any
of our other product candidates or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be
successful in commercializing LX2006, LX1001 or LX1004 or any of our other product candidates, if approved, and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have
extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we obtain approval to commercialize any products outside of the United States or the European Union, a variety of risks associated with international
operations could adversely affect our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If LX2006, LX1001 or LX1004 or any of our other product candidates are approved for
commercialization, we may seek to enter into agreements with third parties to market them in certain jurisdictions outside the United States and the European Union. We expect that we would be subject to additional risks related to international
pharmaceutical operations, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for drug and biologic approvals and rules governing drug and biologic
commercialization in foreign countries; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters
including earthquakes, typhoons, floods and fires, or from economic or political instability; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater difficulty with enforcing our contracts; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar
anti-bribery and anticorruption laws in other jurisdictions; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements
imposed by individual countries in Europe with which we will need to comply. If we are unable to successfully manage the challenges of international expansion and operations, our business and operating results could be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become
subject to fines or penalties or incur costs that could harm our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws and
regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable
materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of
contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our
resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not
provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Environmental laws
and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Risks related to employee matters and managing our growth </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and advisors and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are highly dependent on the management, development, clinical, financial and business development expertise of our executive officers, particularly R. Nolan
Townsend, our Chief Executive Officer and a member of our board of directors, Jay A. Barth, M.D., our Executive Vice President and Chief Medical Officer and Paul McCormac, Ph.D., our Chief Technical Officer, as well as on the scientific expertise of
our founder Ronald&nbsp;G. Crystal, M.D., Professor and Chairman of Weill Cornell Medicine&#146;s Department of Genetic Medicine. Each of our executive officers may currently terminate their employment with us at any time and we do not have an
employment contract with Dr.&nbsp;Crystal. We do not maintain &#147;key person&#148; insurance for any of our executives or employees. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recruiting and
retaining qualified scientific and clinical personnel and, if we progress the development of our product pipeline toward scaling up for commercialization, manufacturing and sales and marketing personnel, will also be critical to our success. The
loss of the services of our executive officers or other key employees could impede the achievement of our development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore,
replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain
regulatory approval of and commercialize gene therapy products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among
numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and
advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or
advisory contracts with other entities that may limit their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our clinical development, manufacturing and regulatory capabilities and potentially implement sales, marketing and distribution
capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2021, we had 24 full-time employees and no part-time employees. As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical product
development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and
financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth,
we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. Our choice to focus on multiple therapeutic areas may negatively affect our ability to develop adequately the specialized
capability and expertise necessary for operations. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our
business plans or disrupt our operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, collaborators, principal investigators, CROs,
suppliers and vendors may be improperly classified and may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We endeavor to properly classify our employees as exempt or <FONT STYLE="white-space:nowrap">non-exempt</FONT> with respect to wage and hour laws (including,
but not limited to, for purposes of minimum wage, overtime and applicable meal and rest periods), and we monitor and evaluate such classifications. Although there are no current, pending, or threatened claims or investigations against us asserting
that any employees have been incorrectly classified as exempt, the possibility nevertheless exists that certain job roles could be deemed to have been incorrectly classified as exempt. In addition, we endeavor to classify our workforce properly, and
we monitor and evaluate such classifications. Although there are no current, pending, or threatened claims or investigations against us asserting that any independent contractors have been incorrectly classified, the possibility nevertheless exists
that certain contractors could be deemed to be employees </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, consultants,
collaborators, principal investigators, CROs, suppliers and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct that violates FDA regulations,
including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare laws and regulations, and laws that require the true, complete and accurate reporting of
financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These
laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper
use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. In connection with this offering, we
intend to adopt a code of business conduct and ethics; however, even with such a code of conduct in place, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages,
fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar
agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our operations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CMO&#146;s, CROs&#146;,
manufacturers&#146; contractors&#146;, consultants&#146; or collaborators&#146; cybersecurity. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures,
our internal computer systems, as well as those of third parties on which we rely, are vulnerable to damage from, among other things, computer viruses, malware, unauthorized access, natural disasters, terrorism, war telecommunication and electrical
failures, system malfunctions, cyberattacks or cyber-intrusions over the Internet, attachments to emails, phishing attacks, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or
disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from
around the world have increased. If such an event were to occur and cause interruptions in our operations, it could lead to the loss, destruction, alteration, prevention of access to, disclosure, dissemination of, or damage or unauthorized access
to, our data (including trade secrets or other confidential information, intellectual property, proprietary business information and personal data) or data that is processed or maintained on our behalf, and cause interruptions in our operations,
which could result in a material disruption of our product candidate development programs. For example, the loss of preclinical study or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal,
confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary
course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees,
in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, we cannot ensure that our information technology and infrastructure will
prevent breakdowns or breaches in our or their systems or other cybersecurity incidents that cause loss, destruction, unavailability, alteration, dissemination of, or damage or unauthorized access to, our data, including personal data, assets and
other data processed or maintained on our behalf, that could have a material adverse effect upon our reputation, business, operations or financial condition. Although, to our knowledge, we have not experienced any such material security breach to
date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings,
liability under laws that protect the privacy of personal information, significant regulatory penalties, and such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical
trials, which could adversely affect our reputation and delay clinical development of our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any disruption or
security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information or personal data, we could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incur material legal claims and liability and damage to our reputation, and the further development of our product candidates could be delayed. Any such event could also compel us to comply with
federal and state breach notification laws, and foreign law equivalents, subject us to mandatory corrective action and otherwise subject us to substantial liability under laws, rules, regulations and standards that protect the privacy and security
of personal data, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notifications and <FONT STYLE="white-space:nowrap">follow-up</FONT> actions related to a data breach or other security incident could impact our reputation and
cause us to incur significant costs, including significant legal expenses and remediation costs. We expect to incur significant costs in an effort to detect and prevent security incidents, and we may face increased costs and requirements to expend
substantial resources in the event of an actual or perceived security incident. However, we cannot guarantee that we will be able to detect or prevent any such incidents, or that we can remediate any such incidents in an effective or timely manner.
Our efforts to improve security and protect data from compromise may also identify previously undiscovered instances of data breaches or other cybersecurity incidents. To the extent that any data breach, disruption or security incident were to
result in any loss, destruction, or alteration of, damage, unauthorized access to or inappropriate or unauthorized disclosure or dissemination of, our data, including personal data, or other information that is processed or maintained on our behalf,
we could be exposed to litigation and governmental investigations and inquiries, the further development and commercialization of our product candidates could be delayed and we could be subject to significant fines or penalties for any noncompliance
with applicable state, federal and foreign privacy and security laws, rules, regulations and standards. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to a variety of privacy and
data security laws, rules, regulations, policies, industry standards and contractual obligations, and our failure to comply with them could harm our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a large quantity of sensitive information, including confidential business and personal information in connection with the conduct of our clinical
trials and related to our employees, and we are subject to laws and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy and data security laws and regulations
governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws and federal and state consumer protection laws. The
legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, which may affect our business and is expected to increase our compliance costs
and exposure to liability. In the United States, numerous federal and state laws and regulations could apply to our operations or the operations of our partners, including state data breach notification laws, state health information privacy laws
and federal and state consumer protection laws and regulations, including Section&nbsp;5 of the Federal Trade Commission Act, that govern the collection, use, disclosure and protection of health-related and other personal information. In addition,
we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by the Health Information Technology for
Economic and Clinical Health Act, and the regulations promulgated thereunder. Depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use or disclose individually identifiable health information in a
manner that is not authorized or permitted by HIPAA. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Europe, the General Data Protection Regulation, or GDPR, took effect in May 2018. The GDPR governs
the collection, use, disclosure, transfer or other processing of personal data of individuals within the European Economic Area, or EEA, including clinical trial data. Among other things, the GDPR imposes requirements regarding the security of
personal data and notification of data breaches to the competent national data processing authorities, requires having lawful bases on which personal data can be processed and requires changes to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from the EEA
to the United States and other jurisdictions that the European Commission does not recognize as having &#147;adequate&#148; data protection laws; in July 2020, the Court of Justice of the European Union limited how organizations could lawfully
transfer personal data from the EEA to the United States by invalidating the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield and imposing further restrictions on the use of standard contractual clauses, which could increase our costs
and our ability to efficiently process personal data from the EEA. The GDPR imposes substantial fines for breaches and violations (up to the greater of &#128;20&nbsp;million or 4% of our consolidated annual worldwide gross revenue), and confers a
private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Relatedly, following the United Kingdom&#146;s withdrawal from the EEA and the European Union and the expiration of the Transition Period, companies must
comply with both the GDPR and the legislation similar to the GDPR as incorporated into UK national law, which provides for significant fines of up to the greater of &pound;17.5&nbsp;million or 4% of global turnover and exposes companies to two
parallel regimes with potentially divergent enforcement actions for certain violations. On January&nbsp;1, 2021, the United Kingdom became a third country for purposes of the GDPR. The relationship between the United Kingdom and the European Union
in relation to certain aspects of data protection law remains unclear, for example with respect to how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk. Pursuant to the <FONT
STYLE="white-space:nowrap">EU-UK</FONT> Trade and Cooperation Agreement of December&nbsp;24, 2020, transfers of personal data from the European Union to the United Kingdom may continue to take place without a need for additional safeguards during a
further transition period, which expires on the earlier of (i)&nbsp;the date on which an adequacy decision with respect to the United Kingdom is adopted by the European Commission; or (ii)&nbsp;the expiry of four months, which shall be extended by a
further two months unless either the European Union or the United Kingdom objects. On February&nbsp;19, 2021 the European Commission published its draft decision finding the United Kingdom to be adequate under the GDPR, though it remains unclear
whether the European Commission will formally adopt an adequacy decision with respect to the United Kingdom. In the absence of such decision, after the expiry of the additional transition period we may need to put in place additional safeguards for
transfers of personal data from the European Union to the United Kingdom, such as standard contractual clauses approved by the European Commission. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required
to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial
condition and results of operations. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly. In addition, states are constantly adopting new laws or amending existing laws, requiring attention to
frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act, or CCPA, which took effect on January&nbsp;1, 2020, became enforceable by the California Attorney General on July&nbsp;1, 2020 and has
been dubbed the first &#147;GDPR-like&#148; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed
information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt out of certain sales of personal
information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act, or CPRA, recently passed in
California and will impose additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data and opt outs for
certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
go into effect on January&nbsp;1, 2023, and additional compliance investment and potential business process changes may be required. Although the CCPA currently exempts certain health-related
information, including clinical trial data, the CCPA and the CPRA may increase our compliance costs and potential liability if we expand our operations into California. Similar laws have been proposed in other states and at the federal level and, if
passed, such laws may have potentially conflicting requirements that would make compliance challenging. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the GDPR, CCPA, CPRA and other laws,
regulations and other obligations relating to privacy and data protection imposing new and relatively burdensome obligations, and with the substantial uncertainty over the interpretation and application of these and other obligations, we may face
challenges in addressing their requirements and making necessary changes to our policies and practices and may incur significant costs and expenses in an effort to do so. We are currently in the process of developing and updating our policies and
procedures in accordance with requirements under applicable data privacy and protection laws and regulations. We do not currently have any formal data privacy policies and procedures in place and have not completed formal assessments of whether we
are in compliance with all applicable data privacy laws and regulations. Additionally, if third parties with which we work, such as vendors or service providers, violate applicable laws, rules or regulations or our policies, such violations may also
put our or our clinical trial and employee data, including personal data, at risk, which could in turn have an adverse effect on our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Risks
related to this offering, ownership of our common stock and our status as a public company </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not
develop and you may not be able to resell your shares of our common stock at or above the initial offering price, if at all. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this
offering, there has been no public market for our common stock. The initial public offering price for our common stock was determined through negotiations with the underwriters and may not be indicative of the price at which our common stock will
trade after the closing of this offering. An active trading market for our shares may never develop or be sustained following this offering. If an active market for our common stock does not develop or is not sustained, it may be difficult for you
to sell shares you purchased in this offering at an attractive price or at all. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of the shares of our common stock may be
volatile, and purchasers of our common stock could incur substantial losses. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stock price may be volatile. The stock market in general and the
market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their
common stock at or above the price paid for the shares. The market price for our common stock may be influenced by many factors, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reporting of unfavorable preclinical and clinical results; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment or results of our clinical trials of LX2006, LX1001 or LX1004 or any future clinical
trials we may conduct, or changes in the development status of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay in our regulatory filings for LX2006, LX1001 or LX1004 or any other product candidate we may develop,
and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#146;s review of such filings, including without limitation the FDA&#146;s issuance of a &#147;refusal to file&#148; letter or a request
for additional information; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results from, delays in or termination of clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to the use of LX2006, LX1001 or LX1004 or any other product
candidate; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by us or by any equity research analysts who might cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions or trends in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the
biopharmaceutical industry; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of
research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our relationships with our collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors&#146; general perception of our company and our business; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our
ability to obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation or employee or independent contractor
litigation; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stock market in general, and the market for biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often
been unrelated or disproportionate to the operating performance of these companies, including very recently in connection with the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which has resulted in decreased stock prices for
many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments
relating to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a
broad range of other risks, including those described in this section, could have a significant and material adverse impact on the market price of our common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility
in the market prices of these companies&#146; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#146;s attention and resources from our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares are restricted from immediate resale but may be
sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the
holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
outstanding based on the number of shares outstanding as of December&nbsp;31, 2021. This includes the shares that we are selling in this offering, which may be resold in the public market immediately. Following the consummation of this offering,
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares will be subject to a <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period provided
under <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements executed in connection with this offering described in &#147;Underwriting&#148; and restricted from immediate resale under the federal securities laws as described in &#147;Shares
Eligible for Future Sale.&#148; All of these shares will, however, be able to be resold after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, as well as pursuant to customary exceptions thereto or upon the waiver of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement by on behalf of the underwriters. We also intend to register shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely
sold in the public market upon issuance, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. As restrictions on resale end, the market price of our stock could decline if the holders of currently-restricted shares sell them or
are perceived by the market as intending to sell them. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of common stock in this offering, you will suffer immediate dilution
of your investment. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common stock will be substantially higher than the pro forma as adjusted net tangible
book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share after this
offering. To the extent outstanding options are exercised, you will incur further dilution. Based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the
midpoint of the estimated price range set forth on the cover page of this prospectus, you will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, representing the difference between
our pro forma as adjusted net tangible book value per share, after giving effect to this offering, and the assumed initial public offering price. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our
stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced by the research and reports that equity
research analysts publish about us and our business. As a newly public company, we have only limited research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our common stock, and such
lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The
price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us
regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our executive officers,
directors and their affiliates, if they choose to act together, have the ability to significantly influence all matters submitted to stockholders for approval and may prevent new investors from influencing significant corporate decisions.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, based on the number of common stock outstanding as of December&nbsp;31, 2021, our executive officers, directors
and stockholders who owned more than 5% of our outstanding common stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
before this offering and their respective affiliates will, in the aggregate, hold shares representing approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our
outstanding common stock. As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example,
these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other
business combination that other stockholders may desire. Any of these actions could adversely affect the market price of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of these
persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the current market price of our common stock and have held their shares for a longer
period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; and, as a result of the reduced disclosure and governance
requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies
that are not emerging growth companies, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any
golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find our common stock less attractive because we
will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting
exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the last day of the fiscal year ending after the fifth anniversary of this offering, or, if earlier, (i)&nbsp;the last day of the fiscal
year in which we have total annual gross revenue of at least $1.07&nbsp;billion, (ii)&nbsp;the date on which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th, or (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during
the prior three-year period. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition we have elected to take advantage of the extended transition period to comply with new or revised accounting
standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting
standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. As a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result of these elections, the information that we provide in this prospectus may be different than the information investors may receive from other public companies in which they hold equity
interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may result in a less active trading market for our common stock and higher volatility in our share price.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even after we no longer qualify as an emerging growth company, we may, under certain circumstances, still qualify as a &#147;smaller reporting
company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion in the use of proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree and in
ways that may not increase the value of your investment. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will have broad discretion over the use of proceeds from this offering. You may not
agree with our decisions, and our use of the proceeds may not yield any return on your investment. We expect to use the net proceeds to us from this offering, together with our existing cash, to advance the clinical development of LX2006, LX1001,
LX1004 and LX2020, to fund the development of our other product candidates and discovery programs, and for working capital and other general corporate purposes. See &#147;Use of Proceeds.&#148; In addition, we may use a portion of the proceeds from
this offering to pursue our strategy to <FONT STYLE="white-space:nowrap">in-license</FONT> or develop additional product candidates. Our failure to apply the net proceeds from this offering effectively could compromise our ability to pursue our
growth strategy and we might not be able to yield a significant return, if any, on our investment of these net proceeds. You will not have the opportunity to influence our decisions on how to use our net proceeds from this offering. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole
source of gains and you may never receive a return on your investment. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not rely on an investment in our common stock to provide
dividend income. We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of
our common stock will be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase our common stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of
the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors,
officers or employees. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the
exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a breach of fiduciary duty; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us arising under the Delaware General Corporation Law, our amended and
restated certificate of incorporation, or our amended and restated bylaws; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our restated
certificate or our amended and restated bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any claim or cause of action as to which the Delaware General Corporation Law confers jurisdiction on the Court
of Chancery of the state of Delaware; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us that is governed by the internal-affairs doctrine. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or the Exchange Act.
Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent
having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district
courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially
valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum
provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a
court in those other jurisdictions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These exclusive forum provisions may result in increased costs for investors to bring a claim. Further, these
exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our
directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional
costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our corporate
charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions in our certificate of incorporation and our bylaws that will become effective upon the closing of this offering may discourage, delay, or prevent a
merger, acquisition, or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that
investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team,
these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors such that only a portion of our directors stand for election at any
given annual stockholder meeting; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of our directors to be changed from time to time by our shareholders or our board of
directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which stockholders can remove directors from our board of directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish requirements for stockholder proposals that can be acted on at stockholder meetings;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and allow actions by our
stockholders by written consent, with certain requirements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call stockholder meetings; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to
institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, or the DGCL,
which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding
voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be subject to securities class action litigation.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of
management&#146;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>General risks </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to U.S. and certain foreign anti-corruption laws and regulations, export and import controls, sanctions and embargoes. We could face
liability and other serious consequences for violations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to anti-corruption laws and regulations, including the U.S. Foreign
Corrupt Practices Act, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act and other state and national anti-bribery laws in the countries in which we may conduct activities in the future.
Anti-corruption laws are interpreted broadly and generally prohibit companies and their employees, agents, contractors and other third-party collaborators from offering, promising, giving, or authorizing others to give anything of value, either
directly or indirectly through third parties, to any person in the public or private sector to obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions
of the corporation and to devise and maintain an adequate system of internal accounting controls. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is heavily regulated and therefore involves
significant interaction with public officials, including officials of <FONT STYLE="white-space:nowrap">non-United</FONT> States governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed
by their government, and therefore will be considered foreign officials for purposes of the FCPA. We also expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent
registrations and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual
knowledge of such activities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to export control and import laws and regulations, including the U.S. Export Administration Regulations,
U.S. Customs regulations and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls. Compliance with applicable regulatory requirements regarding the export of our
products may create delays in the introduction of our products in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of
certain products and services to countries, governments and persons targeted by U.S. sanctions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no certainty that all of our employees, agents,
suppliers, manufacturers, contractors or collaborators, or those of our affiliates, will comply with all applicable anti-corruption, export and import control, and sanctions laws and regulations, particularly given the high level of complexity of
these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain
export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in
one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our
business, prospects, operating results and financial condition. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain proper and effective internal controls, our ability to
produce accurate financial statements on a timely basis could be impaired. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the closing of this offering, we will be subject to the reporting
requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the rules and regulations of the stock market on which our common stock is listed. The Sarbanes-Oxley Act requires, among other things, that we maintain
effective disclosure controls and procedures and internal control over financial reporting. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing with our fiscal year ending December&nbsp;31, 2023,
we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting in our Form
<FONT STYLE="white-space:nowrap">10-K</FONT> filing for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. This will require that we incur substantial additional professional fees and internal costs to expand our accounting and
finance functions and that we expend significant management efforts. Prior to this offering, we have never been required to test our internal control within a specified period, and, as a result, we may experience difficulty in meeting these
reporting requirements in a timely manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may identify weaknesses in our system of internal financial and accounting controls and procedures that
could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only
reasonable, not absolute, assurance that the control system&#146;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud
will not occur or that all control issues and instances of fraud will be detected. If we fail to remediate our identified material weakness, or identify additional material weaknesses, in our internal control over financial reporting, if we are not
able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If
that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the Securities and Exchange Commission or other regulatory
authorities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in tax laws or regulations that are applied adversely to us or our customers may materially harm our business. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New tax laws, statutes, rules, regulations, or ordinances, including proposals made by the Biden administration (such as increasing the U.S. corporate income
tax rate), could be enacted at any time. Further, existing tax laws, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statutes, rules, regulations, or ordinances could be interpreted differently, changed, repealed, or modified at any time. Any such enactment, interpretation, change, repeal, or modification could
adversely affect us, possibly with retroactive effect. For example, the Tax Cuts and Jobs Act of 2017, or the Tax Act, enacted many significant changes in U.S. federal tax laws. Future guidance from the Internal Revenue Service, or the IRS, and
other tax authorities with respect to the Tax Act may adversely affect us, and certain aspects of the Tax Act could be interpreted differently, changed, repealed, or modified in future legislation, possibly with retroactive effect. One such
legislation was the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, which modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act,
or any future U.S. federal tax laws. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act, as amended by the
CARES Act or future U.S. federal tax laws, could have a material impact on the value of our deferred tax assets, result in significant <FONT STYLE="white-space:nowrap">one-time</FONT> charges, and increase our future U.S. tax expenses. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs and demands upon management as a result of being a public company. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company listed in the United States, we will incur significant additional legal, accounting and other expenses that we did not incur as a private
company, including the cost of director and officer liability insurance. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public
disclosure, including regulations implemented by the SEC and the Nasdaq Stock Market, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying
interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this
investment may result in increased general and administrative expenses and a diversion of management&#146;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws,
regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to
comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher
costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of
senior management. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will become subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are
designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods
specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the
objectives of the control system are met. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These inherent limitations include the realities that judgments in decision-making can be faulty, and that
breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by an unauthorized override of the controls. Accordingly, because of
the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_3"></A>Special note regarding forward-looking statements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained
principally in the sections titled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; &#147;Business&#148; and elsewhere in this
prospectus. In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148;
&#147;target,&#148; &#147;project,&#148; &#147;estimate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions intended to
identify statements about the future. These statements speak only as of the date of this prospectus and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events
and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include, without limitation, statements about the following: </I></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, progress and results of our preclinical studies and clinical trials of our product candidates,
including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of our planned IND submissions, initiation of planned clinical trials and timing of expected clinical
results for LX2006, LX1001, LX1004 and our other future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any submission of filings for regulatory approval of, and our ability to obtain and maintain
regulatory approvals for LX2006, LX1001, LX1004 and any other product candidates for any indication; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outbreak of the novel strain of coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT>
including new variants of the virus, such as the Delta and Omicron variants, which could adversely impact our business, including our preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify patients with the diseases treated by our product candidates, and to enroll patients in
trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the size of the patient populations, market acceptance and opportunity for and
clinical utility of our product candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our manufacturing capabilities and strategy, including the scalability and commercial viability of our
manufacturing methods and processes; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third party manufacturing partners to comply with significant regulations with respect to
manufacturing our products; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the scope of any approved indication for LX2006, LX1001, LX1004 or any other product
candidate; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to leverage our platform to identify and develop future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for or ability
to obtain additional funding before we can expect to generate any revenue from product sales; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish or maintain collaborations or strategic relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance upon intellectual property licensed from third parties and our ability to obtain such licenses on
commercially reasonable terms or at all; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect and enforce our intellectual property position for our product candidates, and the scope
of such protection; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the development of and projections relating to our competitors or our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding future revenue, expenses and needs for additional financing; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing list of risks is not exhaustive. Other sections of this prospectus may include additional factors that could harm our
business and financial performance. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of
these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein,
whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks and other information we describe in the reports we will file from time to time with the SEC after the
date of this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or
quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this
prospectus, the events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. You should refer to the &#147;Risk
Factors&#148; section of this prospectus for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this
prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_4"></A>Market and industry data </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We obtained the industry, statistical and market data in this prospectus from our own internal estimates and research as well as from industry and general
publications and research, surveys and studies conducted by third parties. All of the market data used in this prospectus involve a number of assumptions and limitations, and the sources of such data cannot guarantee the accuracy or completeness of
such information. While management is responsible for the accuracy of such data and believes that each of these studies and publications is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a
variety of important factors, including those described in the section titled &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_5"></A>Use of proceeds </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common
stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters
exercise in full their option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares), assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) the net proceeds to us from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase
(decrease) of 1.0&nbsp;million in the number of shares we are offering would increase (decrease) the net proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
by us, by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price stays the same. We do not expect that a change in the offering price or the number of shares
by these amounts would have a material effect on our intended uses of the net proceeds from this offering, although it may impact the amount of time prior to which we may need to seek additional capital. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, we had a cash balance of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million. We intend to use the
net proceeds from this offering, together with our existing cash, as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund our
ongoing and planned clinical development of LX2006 for the treatment of FA cardiomyopathy, including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund our
ongoing and planned clinical development of LX1001 for the treatment of Alzheimer&#146;s disease in <I>APOE4</I> homozygous patients, including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund our
development of LX1004 for the treatment of CLN2 Batten disease, including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the
continued development of our other programs and cardiac discovery efforts, including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for working capital and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our current operational plans and assumptions, we expect our cash, together with the net proceeds from this offering, will be sufficient to fund our
operations through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. However, we do not expect these funds will be sufficient to complete the clinical development of, or commercialize, any of our product candidates or
programs. We have based these estimates on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe opportunities may exist from time to time to expand our current business through acquisitions of complementary companies, products or technologies.
While we have no current agreements, commitments or understandings for any specific acquisitions at this time, we may also use a portion of the net proceeds for these purposes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This expected use of our existing cash and net proceeds from this offering represents our intentions based upon our current plans and business conditions,
which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, the status of and
results from clinical trials and the timing and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outcome of any regulatory submissions, as well as any collaborations that we may enter into with third parties for our drug candidates, and any unforeseen cash needs. As a result, our management
will have broad discretion in the application of the net proceeds from this offering, and investors will be relying on the judgment of our management regarding the application of those net proceeds. Pending our use of the net proceeds from this
offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_6"></A>Dividend policy </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid, and do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We currently
intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our board of
directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="toc287237_7"></A>Capitalization </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and our capitalization as of December&nbsp;31, 2021: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to: (1)&nbsp;the conversion of all outstanding shares of our preferred stock
into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock; and (2)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation upon
the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give effect to: (i)&nbsp;the pro forma adjustments described above; and
(ii)&nbsp;our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting
discounts and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This pro forma as adjusted information is illustrative only and will depend on
the actual initial public offering price and other terms of this offering determined at pricing. Our capitalization following the closing of this offering will depend on the actual initial public offering price and other terms of this offering
determined at pricing. You should read this information in conjunction with our financial statements and the related notes appearing at the end of this prospectus, the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis
of Financial Condition and Results of Operations&#148; and other financial information contained in this prospectus. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="12" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December 31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.0001 par value;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, actual; no shares authorized, no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; no shares authorized, issued or outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding,
actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro
forma;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Additional&nbsp;paid-in&nbsp;capital</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted
amount of each of cash, additional paid in capital, total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that
the number of shares offered by us, as set </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each
increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, additional paid in capital, total stockholders&#146; equity and total
capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of
shares of our common stock outstanding as of December 31, 2021 in the table above excludes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock issuable upon the exercise of options under the Existing Plan, granted subsequent to December&nbsp;31, 2021, at a weighted-average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock reserved for future issuance under the Existing Plan, which shares will cease to be available for issuance at the time the 2022 Plan becomes effective and will be added to, and become available for issuance under, the 2022 Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock reserved for future issuance under the 2022 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2022 Plan;
and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock reserved for future issuance under the 2022 Employee Stock Purchase Plan, or ESPP, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for
future issuance under the ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="toc287237_8"></A>Dilution </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial
public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2021, we had a historical net tangible book value (deficit) of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. Our historical net tangible book value (deficit) per share represents total tangible assets less total liabilities, divided
by the number of shares of our common stock outstanding as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value (deficit) as of
December&nbsp;31, 2021 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of
our common stock. Pro forma net tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to the conversion of all outstanding shares of our convertible preferred stock into an aggregate
of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, as if such conversion had occurred on December&nbsp;31, 2021. Pro forma net tangible book value per share represents pro
forma net tangible book value divided by the total number of shares outstanding as of December&nbsp;31, 2021, after giving effect to the pro forma adjustments described above. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving further effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common
stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page
of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of December&nbsp;31, 2021 would have been
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This amount represents an
immediate increase in pro forma net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors in this offering. We determine dilution by subtracting the pro forma as adjusted net tangible book value per share after
this offering from the amount of cash that a new investor paid for a share of common stock in this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates this
dilution: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in net tangible book value (deficit) per share attributable to the pro forma
transactions described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value (deficit) per share as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative only and will change based on the actual initial public offering price
and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which
is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value per share after this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and dilution in pro forma as adjusted net tangible book value per share to new investors by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discounts and commissions and estimated offering expenses payable by us. An increase of 1.0&nbsp;million shares in the number of shares we are offering would increase the pro forma as adjusted
net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and decrease the dilution per share to new investors participating in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price per share and after deducting the estimated underwriting discounts and commissions. A
decrease of 1.0&nbsp;million shares in the number of shares we are offering would decrease the pro forma as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and increase the dilution per share to new investors participating in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price per share and after deducting the estimated underwriting discounts and commissions.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares of our common stock in full, the pro forma as adjusted net tangible book value
after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase in pro forma as adjusted net tangible book value per share would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the dilution per share to new investors would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share, in each case assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of
this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of December&nbsp;31, 2021, on the pro forma as adjusted basis described above, the differences between
the number of shares purchased from us, the total consideration paid to us in cash and the average price per share that existing stockholders and new investors paid for such shares. The calculation below is based on an assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Total Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Weighted-<BR>Average<BR>Price&nbsp;Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="20" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing tables and calculations are based on the number of shares of our common stock outstanding as of December&nbsp;31,
2021, after giving effect to the conversion of all outstanding shares of our convertible preferred stock into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock,
and excludes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock issuable upon the exercise of options under the Existing Plan, granted subsequent to December&nbsp;31, 2021, at a weighted-average exercise price of $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock reserved for future issuance as of December&nbsp;31, 2021 under the Existing Plan, which shares will cease to be available for issuance at the time the 2022 Plan becomes effective and will be added to, and become available for issuance
under, the 2022 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock reserved for future issuance under the 2022 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2022 Plan;
and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock reserved for future issuance under the ESPP, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that stock options are exercised, new stock options are issued under our equity incentive plan or we issue additional
shares of common stock in the future, there will be further dilution to investors participating in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or
future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="toc287237_9"></A>Management&#146;s discussion and analysis of financial condition and results of
operations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our financial
statements and related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our
business and related financing includes forward-looking statements that involve risks and uncertainties. Many factors, including those factors set forth in the &#147;Risk Factors&#148; section of this prospectus, may materially and adversely affect
our actual results, which may differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage gene therapy company
focused on addressing some of the most devastating genetically defined cardiovascular and central nervous system diseases affecting both larger-rare and prevalent patient populations. We are advancing a deep and diverse pipeline of <FONT
STYLE="white-space:nowrap">AAV-based</FONT> gene therapy candidates utilizing our modular approach that integrates clinically validated technology, a disease area strategy targeting defined patient
<FONT STYLE="white-space:nowrap">sub-populations</FONT> most likely to benefit from our gene therapy candidates, and high-quality, scalable manufacturing, which is designed to overcome many of the challenges facing the field of gene therapy. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to initiate a Phase 1/2 clinical trial in <FONT STYLE="white-space:nowrap">mid-2022</FONT> for our most advanced cardiovascular program, LX2006 for
the treatment of patients with CNS FA cardiomyopathy, and we expect to report initial biomarker data by the end of 2022. Our lead product candidate, LX1001, is in an ongoing Phase 1/2 trial for the treatment of <I>APOE4</I>-associated
Alzheimer&#146;s disease, and we have initially observed an increase in expression levels of the protective protein, APOE2, and a reduction in core Alzheimer&#146;s disease biomarkers in the low-dose cohort of this ongoing trial. We expect to report
initial biomarker data from the <FONT STYLE="white-space:nowrap">mid-dose</FONT> cohort by the end of 2022. Utilizing a step-wise, capital-efficient development approach, we are leveraging early <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> functional and biomarker data to build a pipeline of gene therapy programs targeting cardiovascular indications and Alzheimer&#146;s disease with genetically defined populations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have devoted substantially all of our efforts to organizing and staffing our company, research and development activities, business
planning, raising capital, building our intellectual property portfolio and providing general and administrative support for these operations. To date, we have funded our operations primarily through proceeds from the sale of shares of our
convertible preferred stock. As of December&nbsp;31, 2021, we had $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million of cash. As of December&nbsp;31, 2021, we raised aggregate gross proceeds of
$183.7&nbsp;million from the sale of equity securities. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On May&nbsp;28, 2020 through August&nbsp;11, 2020, we entered into two convertible securities purchase
agreements, or the Convertible Securities Agreements, for gross proceeds of $2.6&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In November 2020, we raised $30.0&nbsp;million gross proceeds from the issuance of 29,999,996 shares of Series A
convertible preferred stock at a purchase price of $1.00 per share. In July 2021, we raised $51.0&nbsp;million gross proceeds from the additional issuance of 50,999,997 shares of Series A convertible preferred stock at a purchase price of $1.00 per
share. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In August 2021, we raised $100.1&nbsp;million gross proceeds from the issuance of 58,157,823 shares of Series B
convertible preferred stock at a purchase price of $1.72049 per share. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses since the
commencement of our operations. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eventual commercialization of one or more of our current gene therapy candidates or any future gene therapy candidates.&nbsp;Our net losses for the years ended December&nbsp;31, 2020 and 2021
were $5.2&nbsp;million and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, respectively, and our accumulated deficit was $5.5&nbsp;million at December&nbsp;31, 2020. We expect to continue to
incur significant losses for the foreseeable future as we advance our current and future product candidates through preclinical and clinical development, continue to build our operations and transition to operating as a public company. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to incur net operating losses for at least the next several years, and we expect our research and development expenses, general and
administrative expenses, and capital expenditures will continue to increase. We expect our expenses and capital requirements will increase significantly in connection with our ongoing activities as we: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our ongoing and planned research and development of LX2006, LX1001, and LX1004, and other product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate preclinical studies and clinical trials for any additional product candidates, including LX2020, LX2021,
LX2022, LX1020 and LX1021, that we may pursue in the future; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to discover and develop additional product candidates and further expand our clinical product pipeline;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">invest in capital equipment in order to expand our research and development and manufacturing activities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire and retain additional clinical, scientific, quality control, regulatory, and manufacturing
management and administrative personnel; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add clinical, operational, financial and management information systems and personnel, including personnel to
support our product development; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade
secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our operations in the United States and to other geographies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting, investor relations and other general and administrative expenses associated
with operating as a public company; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure, either ourselves or in partnership with others, to
commercialize any product candidates, if approved, and related additional commercial manufacturing costs. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not generate revenue
from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur
significant expenses related to product sales, marketing and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. We will require substantial additional funding to develop our
product candidates and support our continuing operations. We may also require additional capital <FONT STYLE="white-space:nowrap">to&nbsp;pursue&nbsp;in-licenses&nbsp;or&nbsp;acquisitions</FONT> of other product candidates. We may also require
additional capital if we choose to pursue an <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing strategy. Further, following the completion of this offering we expect to incur additional costs associated with operating as a public
company. We also expect to increase the size of our administrative function to support the growth of our business. Our net losses may fluctuate significantly from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our clinical trials and
our expenses related to other research and development activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time that we can generate significant revenue from product sales or other sources, we expect to
finance our operations through the sale of equity, debt financings or other capital sources, which could include proceeds from potential collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements
with third parties, or from grants. We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may
have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our failure to obtain sufficient funds with acceptable terms could have a material adverse effect on our business, results of operations or financial
condition, including requiring us to have to delay, reduce or eliminate our product development or future commercialization efforts. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to
accurately predict the amount of increased expenses or timing, or if we will be able to achieve or maintain profitability. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to
continue our operations at planned levels and be forced to reduce or terminate our operations. We cannot provide assurance that we will ever be profitable or generate positive cash flow from operating activities. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our operations </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2020, the World Health Organization declared the outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> a global pandemic. We are subject to a
number of risks associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic, including potential delays associated with our ongoing preclinical studies and clinical trials. <FONT STYLE="white-space:nowrap">COVID-19</FONT>
may have an adverse impact on our operations, supply chains and distribution systems or those of our third-party vendors and collaborators, and increase expenses, including as a result of impacts associated with preventive and precautionary measures
that are being taken, such as restrictions on travel, quarantine polices and social distancing. We and our third-party vendors and collaborators may experience disruptions in supply of items that are essential for our research and development
activities. In addition, the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> has disrupted global healthcare and healthcare regulatory systems which could divert healthcare resources away from, or materially delay, FDA approval and
approval by other health authorities worldwide with respect to our product candidates. Furthermore, our ongoing and anticipated clinical trials may be negatively affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak. Site
initiation, patient enrollment and patient <FONT STYLE="white-space:nowrap">follow-up</FONT> visits may be delayed, for example, due to prioritization of hospital resources toward the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, travel
restrictions, the inability to access sites for initiation and monitoring, and difficulties recruiting or retaining patients in our planned clinical trials. We have experienced delays in patient enrollment and certain follow up visits in the Phase
1/2 clinical trial of LX1001. We cannot at this time predict the specific extent, duration, or full impact that the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak will have on our financial condition and operations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive license agreement with Cornell University </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;27, 2020, we entered into two exclusive license agreements with Weill Cornell Medicine. We refer to these agreements as the Cornell First License
Agreement and the Cornell Second License Agreement, and collectively as the Cornell License Agreements. The Cornell First License Agreement is for the <FONT STYLE="white-space:nowrap">in-license</FONT> of technology related to portfolios for
<I>APOE</I>, Alzheimer&#146;s disease, and <FONT STYLE="white-space:nowrap">Anti-Tau,</FONT> although our license is not restricted by such indications and it includes assignment to us of Cornell University&#146;s IND for the use of AAVrh10.hAPOE
vector to treat <I>APOE4</I> homozygous patients who are at risk for or have Alzheimer&#146;s disease. The Cornell Second License Agreement is for the <FONT STYLE="white-space:nowrap">in-license</FONT> of technology related to portfolios for CLN2
Batten disease and Friedreich&#146;s ataxia although our license is not restricted by such indications, and it includes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assignment to us of Cornell University&#146;s IND for the use of AAVrh.10CUhCLN2 to treat children with CLN2 Batten disease. Through the Cornell License Agreements, we gain access to a portfolio
of inventions, patent rights, technology, and licensed methods that we plan to develop. Under the terms of the Cornell License Agreements, we assumed all worldwide development and commercialization activities with respect to the licensed technology.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As initial consideration for the Cornell License Agreements, we paid Cornell University an upfront payment of approximately $0.15&nbsp;million and entered
into a purchase agreement for approximately $0.6&nbsp;million of convertible preferred securities, for each of the Cornell First License Agreement and Cornell Second License Agreement. In November 2020, the $1.3&nbsp;million of convertible preferred
securities were cancelled in exchange for 1,337,610 shares of Series A convertible preferred stock. As additional consideration, we are required to pay Cornell University up to $8.4&nbsp;million upon the achievement of specific clinical and
regulatory milestones under the Cornell First License Agreement and up to $4.3&nbsp;million upon the achievement of specific clinical and regulatory milestones under the Cornell Second License Agreement. Upon submitting our IND for LX2006 to the
FDA, we achieved the first clinical milestone under the Cornell Second License Agreement, and we will pay $0.1 milion to Cornell University in the first quarter of 2022 in connection with this milestone. We are also required to pay Cornell
University a flat royalty in the <FONT STYLE="white-space:nowrap">mid-single-digits</FONT> based on net sales of the products covered by the licenses, subject to certain adjustments. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the sections entitled &#147;Business&#151;First License Agreement with Cornell University&#148; and &#147;&#151;Second License Agreement with Cornell
University&#148; as well as Note 9 to the financial statements appearing elsewhere in this prospectus for more information on the Cornell License Agreements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive license agreement with Adverum Biotechnologies Inc. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;25, 2021, we entered into an exclusive license agreement, or the Adverum Agreement, with Adverum Biotechnologies, Inc., or Adverum, to <FONT
STYLE="white-space:nowrap">in-license</FONT> materials and technology related to the treatment of FA cardiomyopathy. In connection with the Adverum Agreement, we gained access to a portfolio of inventions, patent rights, technology, and licensed
methods that we will continue to develop, and we have assumed all worldwide development and commercialization activities with respect to this portfolio. Under the Adverum Agreement, we paid Adverum a $7.5&nbsp;million upfront payment in 2021. We are
obligated to pay Adverum up to $17.5&nbsp;million upon the achievement of specified development and regulatory milestones and up to $49.0&nbsp;million in commercialization and sales milestones for the products. We are obligated to pay Adverum tiered
royalties ranging from a rate in the high single-digits to 10% based on annual aggregate worldwide net sales of products, subject to reductions upon the expiration of valid claims in licensed patents and third-party licenses. No regulatory or
commercial milestones have been achieved to date under the Adverum Agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the section entitled &#147;Business&#150;License Agreement with
Adverum&#148; and Note 9 to the financial statements appearing elsewhere in this prospectus for more information on the Adverum Agreement. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research
collaboration agreement with Weill Cornell Medicine </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;2, 2021, we entered into a Research Collaboration Agreement, or the Cornell
Collaboration Agreement, with Weill Cornell Medicine, in conjunction with the Cornell License Agreements entered on May&nbsp;27, 2020. We committed to fund scientific research at Weill Cornell Medicine related to the intellectual property licensed
to us pursuant to the Cornell License Agreements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Cornell Collaboration Agreement, we will pay Weill Cornell Medicine a minimum of
$1.0&nbsp;million in three consecutive years, for an aggregate of at least $3.0&nbsp;million. During 2021, we paid Weill </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Cornell Medicine $2.3&nbsp;million, and we are required to pay Weill Cornell Medicine additional consideration of $2.0&nbsp;million for continuing research and development activities over the
following two years. With respect to each Weill Cornell Medicine invention, joint invention, and related joint results for which an Improvement, as defined in the Cornell Collaboration Agreement, applies and for which we have made an election to
amend either of the Cornell License Agreements, we have the first option to negotiate for a royalty-bearing, worldwide license to such Improvement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See
the Note 9 to the financial statements appearing elsewhere in this prospectus for more information on the Cornell Collaboration Agreement. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stelios
Therapeutics Inc. acquisition </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2021, we purchased all of the issued and outstanding capital stock of Stelios Therapeutics, Inc.,
or Stelios, for initial cash consideration of $7.0&nbsp;million, with payments of up to an additional $20.5&nbsp;million due upon the achievement of certain milestones related to the acquired assets. As of December&nbsp;31, 2021, no milestones were
achieved related to the Stelios assets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We accounted for the acquisition of Stelios as an asset acquisition pursuant to Financial Accounting Standards
Board Accounting Standards Codification Section&nbsp;805, <I>Business Combinations</I>. We acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development, or IPR&amp;D, assets from Stelios related to ARVC and TNNI3-associated
hypertrophic cardiomyopathy programs. The fair value of the IPR&amp;D acquired of $7.0&nbsp;million was charged to research and development expense as it had no alternative future use at the time of the acquisition. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive license agreement with the Regents of the University of California, San Diego </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;4, 2021, we entered into an exclusive worldwide license agreement, or the UCSD Agreement, with the Regents of UCSD to <FONT
STYLE="white-space:nowrap">in-license</FONT> materials and intellectual property related to a gene therapy for ARVC. In connection with the UCSD Agreement, we gained access to inventions, patent rights, technology, and licensed methods that we plan
to develop, and we have assumed all worldwide development and commercialization activities with respect to the licensed technology. The UCSD Agreement requires us to pay a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT
STYLE="white-space:nowrap">up-front</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> cash fee of $20,000, development and commercialization milestones in aggregate up to $5.9&nbsp;million, and
<FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-single</FONT> digit royalties based on aggregate net sales. During 2021, we did not make any payments pursuant to the UCSD Agreement. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 9 to the financial statements appearing elsewhere in this prospectus for more information on the UCSD Agreement. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Components of our results of operations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our revenue to date has been comprised of grant revenue, which are amounts earned from performing contracted research and development services.
These grants generally require us to meet certain research milestones in order to receive the funds. To date, we have not generated any revenue from product sales. If our development efforts for LX2006, LX1001, and LX1004, or any future product
candidates, are successful and result in regulatory approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from product sales, royalties or payments from such collaboration or
license agreements, or a combination of product sales and payments from such agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development
expenses consist of costs incurred for our research activities, including our discovery efforts and the preclinical and clinical development of our programs. These expenses include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, including salaries, benefits, and stock-based compensation expense for employees
engaged in research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with third parties, such as consultants, clinical investigators, contractors
and CROs that assist with (i)&nbsp;identification of potential product candidates in discovery platforms and (ii)&nbsp;the preclinical and clinical studies of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of developing and scaling our manufacturing process and manufacturing product candidates for use in our
research, preclinical studies and clinical trials, including under agreements with third parties, such as consultants, contractors, and CMOs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to maintain compliance with FDA and other regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory supplies and research materials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and
maintenance of facilities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments made under our licensing agreements with third parties; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other expenses incurred as a result of research and development activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. Nonrefundable advance payments for goods and services that will be used in future research and
development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. When third-party service providers&#146; billing terms do not coincide with our period-end, we are
required to make estimates of our obligations to those third parties incurred in a given accounting period and record accruals at the end of the period. We base these estimates on our knowledge of the research and development programs, services
performed for the period, past history for related activities and the expected duration of the third-party service contract, where applicable. If timelines or contracts are modified based upon changes in the scope of work to be performed, we modify
our estimates of accrued expenses accordingly on a prospective basis; therefore, actual results could differ from our estimates. Upfront payments under license agreements are expensed upon receipt of the license, and annual maintenance fees under
license agreements are expensed in the period in which they are incurred. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of
achievement and the related amount is reasonably estimable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our direct research and development expenses are tracked on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis and consist primarily of external costs, such as fees paid to CROs, CMOs, central laboratories and certain outside consultants in connection
with our research and discovery, preclinical development, process development, manufacturing, clinical development, clinical trials, regulatory and quality assurance activities. We do not allocate professional services costs and licensing fees and
other similar costs to specific programs because these costs are deployed across multiple programs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our
business model and account for a significant portion of our operating expenses. Product candidates in later stages of clinical development generally have higher </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect our research and
development expenses to increase substantially in absolute dollars for the foreseeable future as we advance LX2006, LX1001, LX1004, and any other future product candidates that we may develop, into and through preclinical studies and clinical trials
and pursue regulatory approvals. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently
unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as
to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future research, preclinical studies and clinical trials, regulatory developments and our
assessments as to each product candidate&#146;s commercial potential. In addition, we cannot forecast whether any of our current or future product candidates will be subject to future collaborations, when such arrangements will be secured, if at
all, and to what degree such arrangements would affect our development plans and capital requirements. We are also unable to predict when, if ever, we will generate revenue from our product candidates to offset our expenses. Our future expenses may
vary significantly each period based on factors such as: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of preclinical and clinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of preclinical and clinical programs we decide to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our current research and development programs and to establish new ones;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing an appropriate safety profile with investigational new
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology studies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful patient enrollment in, and the initiation and completion of, our ongoing and planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are
satisfactory to the FDA or any comparable foreign regulatory authority; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of regulatory approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish licensing or collaboration arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the performance of our current and potential future collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">development and timely delivery of commercial-grade therapeutics that can be used in our planned clinical trials
and for commercial launch; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercializing our product candidates, if approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profiles of our therapeutics following approval; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hiring and retaining key research and development personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of <FONT STYLE="white-space:nowrap">COVID-19</FONT> to our research and development employees,
contractors and those who may participate in our studies. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any changes in the outcome of any of these variables could mean a significant
change in the costs and timing associated with the development of our product candidates. We may never obtain regulatory approval for any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our product candidates, and, even if we do, drug commercialization takes several years and involves substantial cost. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and administrative </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative
expenses consist primarily of personnel expenses, including salaries, benefits and stock-based compensation expense, for personnel in executive, accounting, business development, legal, human resources and administrative functions. General and
administrative expenses also include corporate facility costs not otherwise included in research and development expenses, depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and
insurance, not otherwise included in research and development expenses, as well as professional fees for legal, consulting, investor and public relations, accounting and audit services. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that our general and administrative expenses will increase in the foreseeable future as we increase our headcount to support the continued research
and development of our programs and the growth of our business. We also anticipate incurring additional expenses associated with operating as a public company, including increased expenses related to audit, legal, regulatory, and <FONT
STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, and standards applicable to companies listed on a national securities
exchange, additional insurance expenses, investor relations activities and other administrative and professional services. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other income (expense)
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Loss on extinguishment of notes </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;28, 2020 and August&nbsp;11, 2020, we entered into the Convertible Securities Agreements with numerous investors to issue notes with an aggregate principal of $2.6&nbsp;million. We also entered into a third convertible securities purchase
agreement on May&nbsp;27, 2020 to retire a $1.3&nbsp;million obligation with Cornell University. This third agreement with the Convertible Securities Agreements are collectively referred to as the Notes. The Notes included an annual compound
interest rate of 6% and matured on the respective fifth anniversary of each Note, unless earlier converted. In consideration for the Notes, we received $2.6&nbsp;million in cash and retired a $1.3&nbsp;million obligation under the Cornell License
Agreements. The Notes were issued on May&nbsp;27, 2020 and August&nbsp;11, 2020, contained a conversion option feature that met the definition of a derivative and were required to be bifurcated. The initial fair value of the conversion option
feature of $0.7&nbsp;million was recorded as a separate liability, and as a reduction to the carrying value of the Notes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2020, in connection
with our issuance and sale of Series A convertible preferred stock, all of the outstanding principal and interest under the Notes and the convertible preferred securities issued to Cornell University were converted into shares of Series A
convertible preferred stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other income </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020,
we sold shares of our Series A convertible preferred stock under a purchase agreement that included provisions that obligated investors to participate in two subsequent funding events, subject to satisfaction of certain conditions set forth therein.
Each of the two funding events represented a separate tranche obligation as the conditions for each tranche of funding could be met separately and an investor could transfer part of any rights under the agreement, including the right/obligation to
participate in an individual tranche. We refer to the two funding obligations collectively as the Preferred Stock Tranche Obligation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income
includes the change in the fair value of the Preferred Stock Tranche Obligation, which was settled by us in July 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest expense </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense primarily consists of the interest on our Notes. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income taxes </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have not recorded
any income tax benefits for the net losses we have incurred in each year or for our research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss,
or NOL, carryforwards and tax credits will not be realized. As of December&nbsp;31, 2021, we had federal NOL carryforwards of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and
state NOL carryforwards of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million which may be available to offset future taxable income and begin to expire in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The total federal NOL of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million are not subject to
expiration. As of December&nbsp;31, 2021, we also had state tax research and development credit carryforwards of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to offset future tax
liabilities, which begin to expire in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. As of December&nbsp;31, 2021, we had no federal tax research and development credit carryforwards. We have
recorded a full valuation allowance against our net deferred tax assets at December&nbsp;31, 2021. As of December&nbsp;31, 2021, we had no unrecognized tax benefits. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Results of operations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the years
ended December&nbsp;31, 2020 and 2021 </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&nbsp;31, 2020 and
2021: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">518,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,318,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,106,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,587,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(422,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(565,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,152,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,152,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development expenses </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses incurred by program for the years ended December&nbsp;31, 2020 and 2021: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct external research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LX2006</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LX1001</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">919,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LX1004</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated research and development expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,603,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licenses fees and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,796,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,318,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses were $4.3&nbsp;million for the year ended December&nbsp;31, 2020 compared to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the year ended December&nbsp;31, 2021. The increase of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million was primarily due to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct external research and development expenses for LX2006 was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million for the year ended December&nbsp;31, 2021, which was primarily attributable
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We did not incur significant direct, external research and development expense for LX2006 for the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct external research and development expense for LX1001 was $0.9&nbsp;million for the year ended December&nbsp;31, 2020, compared to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the year ended December&nbsp;31, 2021. The increase of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million was primarily due to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct external research and development expenses for LX1004 was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the year ended December&nbsp;31, 2021, which was primarily attributable
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We did not incur significant direct, external research and development expense for LX1004 for the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct external research and development expenses for our other programs was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the year ended December&nbsp;31, 2021, which was primarily attributable
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We did not incur significant direct, external research and development expense for other programs for the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unallocated research and development expenses were $3.4&nbsp;million for the year ended December&nbsp;31, 2020, of which $1.6&nbsp;million was attributable to
professional fees and similar expenses and $1.8&nbsp;million was related to license fees and similar expenses. Unallocated research and development expenses were
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the year ended December&nbsp;31, 2021, of which
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million was attributable to professional fees and other and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million was related to license fees and other. The increase of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million in unallocated research and development expenses was primarily due
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and administrative expenses </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $0.8&nbsp;million for the year ended December&nbsp;31, 2020 compared to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the year ended December&nbsp;31, 2021. The increase of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million was primarily due to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Loss on extinguishment of notes </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2020, in connection with our issuance and sale of Series A convertible preferred stock, all $3.9&nbsp;million of outstanding principal and
$0.1&nbsp;million of accrued interest was converted into 4,495,719 shares of our Series A convertible preferred stock at a price ranging between <FONT STYLE="white-space:nowrap">85-100%</FONT> of $1.00 per share depending on the investor. See Note 5
to our financial statements appearing elsewhere in this prospectus for additional information. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We accounted for the conversion of the Notes as a debt
extinguishment and recognized a loss on extinguishment of notes of $1.2&nbsp;million within other income (expense), net in the statement of operations. The loss on extinguishment was calculated as the difference between the carrying value of the
Notes, net of the unamortized debt discount of $3.3&nbsp;million, and the $4.5&nbsp;million fair value of the 4,495,719 shares of Series A convertible preferred stock issued to settle the Notes. Upon conversion, the loss on extinguishment of notes
was offset by the extinguishment of the conversion option feature of $0.8&nbsp;million. See Note 3 and Note 4 to our financial statements appearing elsewhere in this prospectus for additional information. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest expense </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognized interest expense of
$0.1&nbsp;million for the year ended December&nbsp;31, 2020 related to interest accrued on the Notes prior to their extinguishment in November 2020. We did not recognize interest expense during the year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Liquidity and capital resources </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>Sources of
liquidity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative
cash flows from our operations. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our product candidates. Since our inception through December&nbsp;31, 2021, we have
funded our operations with net proceeds from sales of our convertible preferred stock and Convertible Securities Agreements of $183.7&nbsp;million. As of December&nbsp;31, 2021, we had cash of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we expect
the net proceeds from this offering, together with our existing cash, will be sufficient to fund our planned operating expenses and capital expenditure requirements
through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our total future capital requirements will depend on many factors and is subject to the risks and uncertainties set
forth in the section titled &#147;Risk Factors.&#148; Our development plans may be revised, and our estimated use of proceeds may be impacted. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>Cash
flows </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our sources and uses of cash for each of the periods presented: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,133,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,378,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,245,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2020, net cash used in operating activities consisted primarily of our net loss of $5.2&nbsp;million, partially offset
by (i) $1.3&nbsp;million retirement of the exclusive license agreement with Cornell University, (ii) $0.4&nbsp;million loss on extinguishment of the Notes, (iii) $0.1&nbsp;million accrued interest expense and (iv) $0.1&nbsp;million change on
operating assets and liabilities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing activities </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2020, there were no cash flows from investing activities. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2020, net cash provided by financing activities consisted primarily of $30.0&nbsp;million gross proceeds from the issuance of 29,999,996 shares of Series A convertible preferred stock at a purchase price of $1.00 per share, offset
by $0.2&nbsp;million of issuance costs, and $2.6&nbsp;million gross proceeds from the issuance of Convertible Securities Agreements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our primary uses of
cash are to fund our research and development activities related to our discovery programs and our preclinical and clinical product candidates, hiring personnel, raising capital and providing general and administrative support for these operations.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding requirements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our expenses
and capital requirements to increase significantly in connection with our ongoing activities, particularly as we advance our lead product candidates and other development programs. Further, following the completion of this offering, we expect to
incur additional costs associated with operating as a public company. Accordingly, we will require substantial additional funding to support our continuing operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The timing and amount of our future operating and capital requirements will largely depend on many factors, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, scope, progress, timing, results and costs of product discovery, preclinical studies and clinical
trials for our product candidates or any future candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our relationships with Weill Cornell Medicine, Adverum, UCSD, and any other key licensors
or collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, prioritization and number of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of seeking and obtaining regulatory approvals from the FDA and comparable foreign
regulatory authorities, including the potential for such authorities to require that we perform more preclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had previously been agreed
to; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations on favorable terms, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration
agreements we have or may enter into; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under
collaboration agreements, if any; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio,
including preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of securing manufacturing arrangements for commercial production; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals
to market our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and
uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and commercialize our product candidates. In addition, our product candidates, if approved, may not
achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing
to achieve our business objectives. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate significant revenue from product sales or other sources, we expect to
finance our operations through the sale of equity, debt financings, or other capital sources, which could include proceeds from potential collaborations, strategic partnerships or marketing, distribution, licensing or other similar arrangements with
third parties. However, we may be unable to raise additional funds or enter into such agreements or arrangements on favorable terms, or at all. Market volatility resulting from <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT>
or other factors could also adversely impact our ability to access capital as and when needed.&nbsp;To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted,
and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Any future debt financing and preferred equity financing, if available, may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness.
Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise funds through collaborations,
strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable
to us. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or grant rights to develop and market
product candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Contractual obligations and commitments </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations and commitments as of December&nbsp;31, 2021: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="20" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>($ in thousands)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Payments Due by Period</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Description</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Less</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>than 1</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>year</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>1 &#150; 3 years</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>3&#151;5 years</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>More&nbsp;than 5<BR>years</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Apart from the contracts with payment commitments that we have reflected in the table above, we have entered
into contracts in the normal course of business with CROs, CMOs and other third parties for preclinical research studies and testing, clinical trials and manufacturing services. These contracts do not contain any minimum purchase commitments and are
cancelable by us upon prior notice and, as a result, are not included in the table of contractual obligations and commitments above. Payments due upon cancellation consist only of payments for services provided and expenses incurred, including <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> obligations of our service providers, up to the date of cancellation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may in the future incur
potential royalty payments under license and collaboration agreements we have entered into with various entities, pursuant to which we <FONT STYLE="white-space:nowrap">have&nbsp;in-licensed&nbsp;certain</FONT> intellectual property. Due to the
uncertainty of the achievement and timing of the events requiring payment under these agreements, the amounts to be paid by us are not fixed or determinable at this time and are excluded from the table above. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet arrangements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as
defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Critical accounting policies and significant judgements and estimates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been
prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, expenses, and the disclosure of our contingent liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual
results may differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail
in Note 2 to our financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our audited financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the process
of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet
been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT> schedule or when contractual milestones are met;
however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. At each period end, we corroborate the accuracy of
these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vendors in connection with discovery and preclinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CROs in connection with preclinical studies and testing; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CMOs in connection with the process development and scale up activities and the production of materials.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record the expense and accrual related to contract research and manufacturing based on our estimates of
the services received and efforts expended considering a number of factors, including our knowledge of the progress towards completion of the research, development, and manufacturing activities; invoicing to date under contracts; communication from
the CROs, CMOs, and other companies of any actual costs incurred during the period that have not yet been invoiced; and the costs included in the contracts and purchase orders. The financial terms of these agreements are subject to negotiation, vary
from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we
estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the
amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of
services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses;
however, we cannot guarantee that such adjustments will not be made in the future. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Determination of fair value of common stock </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As there has been no public market for our common stock to date, the estimated fair value of our common stock has been determined by our board of directors as
of the date of each option grant, with input from management, considering our most recently available third-party valuations of common stock and our board of directors&#146; assessment of additional objective and subjective factors that it believed
were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public
Accountants&#146; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock
valuations were prepared using either an option pricing method, or OPM, or a hybrid method of OPM and probability-weighted expected return method, or PWERM. Both the OPM and hybrid methods use market approaches to estimate our enterprise value.
These third-party valuations were performed at various dates, which resulted in valuations of our common stock of $0.22 as of November&nbsp;20, 2020, $0.46 as of August&nbsp;11, 2021 and $1.38 as of December&nbsp;17, 2021. In addition to considering
the results of these third-party valuations, our board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we sold shares of preferred stock and the superior rights and preferences of the preferred
stock relative to our common stock at the time of each grant; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development programs, including the status and results of preclinical studies
for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical
industry; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial position, including cash on hand, and our historical and forecasted performance and operating
results; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of an active public market for our common stock and our preferred stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant changes to the key assumptions underlying the factors used could have resulted in different fair
values of common stock at each valuation date; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of our company
in light of prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the analysis of IPOs and the market performance of similar companies in the therapeutics industry.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represented management&#146;s best estimate, which involved inherent uncertainties and the
application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially different. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for
our board of directors to estimate the fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common stock will be determined based on the quoted market
price of our common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option grants </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table summarizes by grant date the number of shares subject to options granted since February&nbsp;12, 2021, the date we adopted the 2021 Equity Incentive Plan, or the Existing Plan, through December&nbsp;31, 2021, the per share exercise
price of the options, the per share fair value of our common stock on each grant date and the per share estimated fair value of the options: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number of<BR>Shares<BR>Subject to<BR>Options<BR>Granted</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per<BR>Share<BR>Exercise<BR>Price of<BR>Options</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per<BR>Share<BR>Fair<BR>Value of<BR>Common<BR>Stock on<BR>Grant<BR>Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per Share<BR>Estimated<BR>Fair<BR>Value of<BR>Options</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;16, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,304,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;9, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,791,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;19, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;22, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;5, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;12, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;14, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;17, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;4, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.38</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;9, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.38</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;15, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,679,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.38</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="16" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">At the time of the option grants approved on November&nbsp;4, November&nbsp;9 and November&nbsp;15, 2021, our board of directors had determined that the fair value of our common stock was $0.46 per share based in part
on a third-party valuation of our common stock as of August 2021. However, in December 2021, we performed a retrospective fair value assessment and concluded that the fair value of our common stock underlying the stock options that were granted on
November&nbsp;4, November&nbsp;9 and November&nbsp;15, 2021 was $1.38 per share for accounting purposes. The reassessed value was based, in part, upon a third-party valuation of our common stock prepared on a retrospective basis as of
December&nbsp;17, 2021. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Valuation of the preferred stock tranche obligation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Stock Tranche Obligation was recorded at fair value at the issuance date and a portion of the proceeds from the first closing equal to that
amount was allocated to it. At November&nbsp;20, 2020, the fair value of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Preferred Stock Tranche Obligation was valued at $3.0&nbsp;million at a value per share equivalent to $0.05 and $0.07 for the second and third closings, respectively. The Preferred Stock
Tranche Obligation was valued using a probability-weighted present value model. The valuation model considered the probability of closing each tranche, the estimated future value of the Series A convertible preferred stock to be issued at each
closing and the investment required at each closing. Future values were converted to present value using a discount rate appropriate for probability-adjusted cash flows. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2021, our board of directors and the holders of a majority of our then-outstanding Series A convertible preferred stock voted to consummate the two
subsequent funding events, resulting in the issuance of 50,999,997 shares of Series A convertible preferred stock for aggregate proceeds to us of $51.0&nbsp;million and settlement by us of the Preferred Stock Tranche Obligation. See Note 3 to our
financial statements appearing elsewhere in this prospectus for additional information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Valuation of the conversion option liabilities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed above, we issued Notes on May&nbsp;27, 2020, and August&nbsp;11, 2020. The Notes contained certain features that met the definition of a
derivative and were required to be bifurcated. We accounted for these as a single derivative comprising all the features requiring bifurcation, which we collectively refer to as the Conversion Option Liabilities. The fair value of the derivative
liability&nbsp;was estimated using a scenario-based analysis comparing the probability-weighted present value of the Note payoff at maturity with and without the bifurcated features. We considered possible outcomes available to the investors,
including a conversion into shares of convertible preferred stock that would occur in connection with a qualified financing transaction, and a mandatory conversion into shares of common stock upon a change of control. In addition to the
probabilities applied to various scenarios, the key unobservable inputs were the time to liquidity for each scenario and the discount rate. The Conversion Option Liabilities were settled during the year ended December&nbsp;31, 2020. See Note 3 to
our financial statements appearing elsewhere in this prospectus for additional information. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Emerging growth company status </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The JOBS Act permits an &#147;emerging growth company&#148; such as us to take advantage of an extended transition period to comply with new or revised
accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to &#147;opt out&#148; of such extended transition period, which means that when a standard is issued or
revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either
(i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualify as an emerging growth company. There are other exemptions and reduced reporting requirements provided by the JOBS Act that we are
currently evaluating. For example, as an &#147;emerging growth company,&#148; we are exempt from Sections&nbsp;14A(a) and (b)&nbsp;of the Securities Exchange Act of 1934, as amended, which would otherwise require us to (1)&nbsp;submit certain
executive compensation matters to shareholder advisory votes, such
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as&nbsp;&#147;say-on-pay,&#148;&nbsp;&#147;say-on-frequency,&#148;&nbsp;and</FONT></FONT></FONT></FONT> &#147;golden
parachutes;&#148; and (2)&nbsp;disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of our chief executive officer&#146;s compensation to our median employee
compensation. We also intend to rely on an exemption from the rule requiring us to provide an auditor&#146;s attestation report on our internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act. We will
continue to remain an &#147;emerging growth company&#148; until the earliest of the following: (1)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering; (2)&nbsp;the last day of the
fiscal year in which our total annual gross revenue is equal to or more than $1.07&nbsp;billion; (3)&nbsp;the date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the previous three years; or (4)&nbsp;the date on
which we are deemed to be a large accelerated filer under the rules of the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Recently issued accounting pronouncements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations and cash flows is
disclosed in Note 2 to our financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Qualitative and quantitative disclosures about market risk
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest rate risk </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020,
we had cash of $29.4&nbsp;million. As of December&nbsp;31, 2021, we had cash of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. Interest income is sensitive to changes in the general level of
interest rates. Our surplus cash has been invested in money market fund accounts and interest-bearing savings accounts. We have not entered into investments for trading or speculative purposes. Due to the conservative nature of our investment
portfolio, which is predicated on capital preservation of investments with short-term maturities, we do not believe an immediate one percentage point change in interest rates would have a material effect on the fair market value of our portfolio,
and therefore we do not expect our operating results or cash flows to be significantly affected by changes in market interest rates. As of December&nbsp;31, 2020 and 2021, we had no debt outstanding. Therefore, we are not exposed to interest rate
risk with respect to debt. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our employees and our operations are currently located in the United States. We have, from time to time, engaged with
contractors or other vendors in a currency other than the U.S. dollar. To date, we have not been exposed to significant market risk related to changes in foreign currency exchange rates. Our operations may be subject to fluctuations in foreign
currency exchange rates in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not believe that inflation has had a material effect on our business, financial condition or results of
operations. Our operations may be subject to inflation in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="toc287237_10"></A>Business </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage gene therapy company
focused on addressing some of the most devastating genetically defined cardiovascular and central nervous system diseases affecting both larger-rare and prevalent patient populations. We are advancing a deep and diverse pipeline of <FONT
STYLE="white-space:nowrap">AAV-based</FONT> gene therapy candidates utilizing our modular approach that integrates clinically validated technology, a disease area strategy targeting defined patient
<FONT STYLE="white-space:nowrap">sub-populations</FONT> most likely to benefit from our gene therapy candidates, and high-quality, scalable manufacturing, which is designed to overcome many of the challenges facing the field of gene therapy. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to initiate a Phase 1/2 clinical trial in <FONT STYLE="white-space:nowrap">mid-2022</FONT> for our most advanced cardiovascular program, LX2006 for
the treatment of patients with FA cardiomyopathy, and we expect to report initial biomarker data by the end of 2022. Our lead CNS product candidate, LX1001, is in an ongoing Phase 1/2 trial for the treatment of <I>APOE4</I>-associated
Alzheimer&#146;s disease, and we have initially observed an increase in expression levels of the protective protein, APOE2, and a reduction in core Alzheimer&#146;s disease biomarkers in the low-dose cohort of this ongoing trial. We expect to report
initial biomarker data from the <FONT STYLE="white-space:nowrap">mid-dose</FONT> cohort by the end of 2022. Utilizing a step-wise, capital-efficient development approach, we are leveraging early <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> functional and biomarker data to build a pipeline of gene therapy programs targeting cardiovascular indications and Alzheimer&#146;s disease with genetically defined populations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our integrated, modular approach enables us to optimize our strategy to pursue larger-rare and prevalent genetically defined indications in specific
sub-populations of patients. Our gene therapy candidates utilize the vector construct, dose and route of administration that we believe will result in the most favorable biodistribution and safety profile for our product candidate for each disease.
Our most advanced cardiovascular and CNS programs use the AAVrh10 vector due to its high transduction efficiency in both myocardial cells and neurons, potentially lower toxicity given its ability to utilize lower doses compared to other
well-established AAV serotypes, and lower <FONT STYLE="white-space:nowrap">pre-existing</FONT> immunity. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By specifically tailoring our technological
approach to each targeted disease, we believe we can optimize our programs to achieve the highest likelihood of having therapeutic impact. We target genetically defined indications in specific <FONT STYLE="white-space:nowrap">sub-populations</FONT>
of patients that may be most amenable to gene therapy. These targeted indications offer the potential to show therapeutic impact through functional endpoints or biomarkers, have high unmet need and large market opportunities, have demonstrated
promising preclinical data, and have organized patient advocacy groups and identifiable patient populations. We believe targeting cardiovascular and CNS diseases can be enhanced by our current approach utilizing AAVrh10 as well as ongoing discovery
efforts to identify a next-generation vector technology with the best potential therapeutic profile. Finally, we continuously seek to bolster our pipeline through relationships with academic institutions, which provide us access to cutting edge gene
therapy research that we will utilize in the discovery and development of next generation gene therapy candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>Our pipeline </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing a deep and diverse pipeline of cardiovascular and CNS therapeutic programs for larger-rare and prevalent diseases. We retain exclusive
worldwide development and commercialization rights to all of our product candidates and programs. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g30r12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lead cardiovascular programs </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are seeking to develop a number of disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases that have significant unmet need
and no approved treatments which address the underlying genetic cause of the disease. These programs include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>LX2006</B> is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional frataxin,
or <I>FXN, </I>gene<I> </I>for the treatment of FA cardiomyopathy. FA cardiomyopathy is the most common cause of mortality in patients with Friedreich&#146;s ataxia and affects approximately 5,600 patients in the United States. LX2006 is designed to
promote the expression of the protein frataxin to restore normal mitochondrial function and energy production in myocardial cells. In preclinical studies, LX2006 demonstrated improvement in cardiac function and survival in a severe <I>FXN</I>
knockout mouse model as well as restoration of cardiac function and reversal of the disease abnormalities of FA cardiomyopathy in a partial <I>FXN</I> knockout mouse model. Our IND for LX2006 was cleared by the FDA in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. We expect to initiate an open-label, dose-escalation Phase 1/2 clinical trial in patients with FA cardiomyopathy in <FONT STYLE="white-space:nowrap">mid-2022,</FONT> and
we expect to report interim biomarker data by the end of 2022. The FDA has granted Rare Pediatric Disease designation and Orphan Drug designation to LX2006 for the treatment of Friedreich&#146;s ataxia. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>LX2020</B> is an AAVrh10-based gene therapy candidate designed to intravenously deliver a fully
functional<I>&nbsp;PKP2</I><I></I>&nbsp;gene to cardiac muscle for the treatment of ARVC caused by mutations in the <I>PKP2</I> gene. <I>PKP2</I> mutations are associated with approximately 75% of all genetic cases of ARVC, and we estimate they
affect more than 70,000 patients in the United States. <I>PKP2</I> mutations can cause replacement of heart muscle with fibrotic tissue and fatty deposits, and severe abnormal heart rhythms, or arrhythmias, that cause cardiac dysfunction and can
result in sudden cardiac death. LX2020 is designed to increase desmosomal PKP2 protein levels, reassemble desmosomes and restore myocardial cell function. In our preclinical studies, LX2020 resulted in fewer arrhythmias and increased survival. We
intend to submit an IND for LX2020 in 2023. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lead CNS programs </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing a pipeline of CNS focused gene therapies that includes a portfolio of approaches to treat the genetics underlying Alzheimer&#146;s disease as
well as a program designed to treat CLN2 Batten disease. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>LX1001</I> is an AAVrh10-based gene therapy candidate designed to deliver via
<FONT STYLE="white-space:nowrap">one-time</FONT> administration into the CSF an <I>APOE2</I> gene for the treatment of <I>APOE4 </I>homozygous patients with Alzheimer&#146;s disease. Alzheimer&#146;s disease is the leading cause of cognitive decline
in late adult life and characterized by complex underlying pathology in the CNS. <I>APOE4</I> homozygous individuals are approximately 15 times more likely to develop Alzheimer&#146;s disease than the general population, and it is estimated that
there are 900,000 <I>APOE4</I> homozygous patients with Alzheimer&#146;s disease in the United States alone. Currently, there are no treatments that are approved as disease-modifying for Alzheimer&#146;s disease. LX1001 is designed to express the
protective <I>APOE2</I> gene in the CNS of <I>APOE4</I> homozygous patients in order to halt or slow the progression of Alzheimer&#146;s disease in the United States. LX1001 is being evaluated in an ongoing open-label, dose-escalation Phase 1/2
clinical trial and we have observed a decline in Alzheimer&#146;s disease CSF biomarkers, such as total tau and phosphorylated tau, in the first two patients with <FONT STYLE="white-space:nowrap">12-month</FONT> data in the <FONT
STYLE="white-space:nowrap">low-dose</FONT> cohort in the trial. We have also reported data demonstrating expression of the protective APOE2 protein in all four patients in the <FONT STYLE="white-space:nowrap">low-dose</FONT> cohort with <FONT
STYLE="white-space:nowrap">follow-up</FONT> data. We expect to report initial biomarker data from the <FONT STYLE="white-space:nowrap">mid-dose</FONT> cohort by the end of 2022. LX1001 has been granted fast track designation by the FDA.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>LX1004</I> is an AAVrh10-based gene therapy candidate designed to deliver via intracisternal injection a fully
functional <I>CLN2</I> gene to the CNS in order to restore the enzyme tripeptidyl peptidase 1, or TPP1, the secreted protein that is deficient in CLN2 Batten disease patients. This disease is an autosomal recessive lysosomal storage disorder causing
loss of cognitive and motor function, blindness, seizures, and ultimately death in childhood, with approximately 900 cases estimated in the United States and European Union. In a completed Phase 1/2 clinical trial, LX1004 was administered via
intraparenchymal injection and demonstrated an increase in TPP1 levels leading to a slower decline of motor and language function at 18 months post treatment in treated patients compared to natural history controls. We anticipate receiving feedback
from the FDA on the design of our potentially pivotal Phase 2/3 clinical trial in the second half of 2022, and we intend to initiate the clinical trial in the first half of 2023. The FDA has granted Rare Pediatric Disease designation and Orphan Drug
designation to LX1004 for the treatment of CLN2 Batten disease. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional programs </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within our cardiovascular pipeline, we are concurrently advancing several additional <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy programs to
treat other targets in myocardial cells that are dysregulated in cardiomyopathy, including LX2021 designed to restore Connexin 43, or Cx43, in patients with ARVC, and LX2022 designed to treat HCM due to mutations in the <I>TNNI3</I> gene. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also building a portfolio of approaches to treat the genetics underlying Alzheimer&#146;s disease. Our Alzheimer&#146;s disease portfolio includes
LX1020, which is designed to deliver both the protective <I>APOE2</I> gene and miRNA to suppress the expression of the deleterious <I>APOE4</I> gene, and LX1021, which is designed to deliver a Christchurch-modified <I>APOE2</I> gene. The
Christchurch mutation has been shown in individuals to be effective at protecting patients against Alzheimer&#146;s disease even in the presence of significant amyloid pathology. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>Our company and team </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were founded through a
collaboration between the world-class gene therapy research at Weill Cornell Medicine and a team of pioneering scientists, clinicians, and business leaders with deep expertise in gene </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapy. We continue to leverage our long-standing relationship with Weill Cornell Medicine through sponsored research and development efforts to progress our cardiovascular platform technology
as well as our CNS product candidates. Through our acquisition of Stelios Therapeutics, Inc., we have an ongoing collaboration with UCSD through which we sponsor research and development designed to advance our earlier stage cardiovascular pipeline.
We work with highly experienced teams at both Weill Cornell Medicine and UCSD that have deep expertise in the underlying biology of cardiovascular and CNS disorders and the patient populations that they treat. We believe our ongoing work with these
preeminent institutions, as well as any potential new or expanded collaborations, will continue to be a valuable aspect of our efforts as we seek to further discover and develop novel gene therapies for devastating diseases. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and
commercialization. Our scientific founder and Chief Scientific Advisor, Ronald&nbsp;G. Crystal, M.D., is a world leader in gene therapy research and development and currently serves as Professor and Chairman of Weill Cornell Medicine&#146;s Genetic
Medicine Department and Director of the Belfer Gene Therapy Core Facility. Dr.&nbsp;Crystal has sponsored 14 cleared gene therapy IND applications and has published more than 300 papers on gene therapy. He has more than thirty years of experience
with AAVs and vector design and expertise in CNS, cardiac, pulmonary and liver-mediated diseases. Our Chief Executive Officer, R. Nolan Townsend, has spent more than a decade working in global biopharmaceutical commercial organizations, including
leading Pfizer&#146;s $1.6&nbsp;billion international rare disease commercial business unit. Mr.&nbsp;Townsend also led Pfizer&#146;s U.S. rare disease commercial business unit, where he oversaw the successful U.S. launch of blockbuster rare
cardiovascular product (tafamidis) Vyndaqel/Vyndamax, now a $2&nbsp;billion product by revenue. He has overseen other successful rare disease product launches and been involved in business and commercial development efforts for several gene therapy
programs. Dr.&nbsp;Jay&nbsp;A. Barth, our Executive Vice President and Chief Medical Officer, has more than 20 years of experience in drug development in the biopharmaceutical industry. He was formerly the Chief Medical Officer at Amicus
Therapeutics, Inc. and Senior Vice President, Clinical Development, at PTC Therapeutics, Inc., where he had clinical oversight of the initial approvals of Galafold, for the treatment of Fabry disease, at Amicus Therapeutics, Inc., as well as
Translarna, the first approved treatment for Duchenne muscular dystrophy, at PTC Therapeutics, Inc. Our Chief Technical Officer, Paul McCormac, Ph.D., has more than 20 years of experience and a proven track record in the field of gene therapy and
biologics chemistry, manufacturing, and controls, or CMC. He previously served as Medicinal Sciences Category Lead for Pfizer Rare Disease, where he led gene therapy CMC and vector supply strategy for Pfizer&#146;s rare disease business and research
units. Our Chairman, Dr.&nbsp;Steven Altschuler, is currently Managing Director at Ziff Capital Investments and was formerly Chairman of the gene therapy pioneer Spark Therapeutics, Inc., which was responsible for the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> gene therapy, voretigene neparvovec-rzyl (Luxturna), and was acquired by Roche Holding AG in 2019 for $4.3&nbsp;billion. Our senior leadership is supported by the rest of our management team, which has
decades of experience across research, development, manufacturing and commercialization in gene therapy and rare disease both from prominent biotechnology companies and global biopharmaceutical companies that are active in the space. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have raised $183.7&nbsp;million in capital from premier institutional investors, including funds affiliated with D1 Capital Partners,
Eventide Healthcare&nbsp;&amp; Life Sciences Fund, Janus Henderson Investors, Longitude Capital, Lundbeckfonden Ventures, Omega Funds and PBM Capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Our strategy </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are building a fully integrated company with the potential to significantly advance gene therapy&#146;s impact on many of society&#146;s most challenging
genetically defined cardiovascular and CNS diseases. Our vision is a world where gene therapies resolve the burden of disease and transform the lives of patients. The key elements of our strategy to achieve this vision are
to:&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Focus on genetically-defined cardiovascular and CNS indications of high unmet need and substantial commercial
potential</I>. We are focused on genetically defined cardiovascular and CNS conditions where there is no currently approved treatment or where we believe our therapies will provide a meaningful improvement relative to existing standards of care.
Furthermore, we seek indications with commercial opportunities beyond those typically associated with gene therapy companies targeting rare monogenic diseases. Among our cardiovascular programs, LX2006 has the potential to address a prevalent pool
of approximately 5,600 FA cardiomyopathy patients in the United States, and LX2020 has the potential to address approximately 70,000 patients with ARVC caused by <I>PKP2</I> mutations. Within our CNS programs, LX1001 has the potential to address up
to approximately 900,000 patients in the United States with homozygous <I>APOE4</I>-associated Alzheimer&#146;s disease. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Target development efforts at disease pathologies and defined
<FONT STYLE="white-space:nowrap">sub-populations</FONT> of patients most likely to benefit from our therapies</I>. Our programs are designed to target either the aspect of the disease that is most amenable to gene therapy or the genetic <FONT
STYLE="white-space:nowrap">sub-populations</FONT> that we believe are most likely to respond to gene therapy. For example, in the case of LX2006, we are targeting the cardiac manifestation of the disease, because we believe it is more amenable to
gene therapy than the neurologic manifestation. In LX2020, we are targeting the <I>PKP2</I> <FONT STYLE="white-space:nowrap">sub-population</FONT> that represents approximately 75% of the genetic ARVC cases and presents a clinical phenotype amenable
to treatment. In LX1001, we are targeting homozygous <I>APOE4</I>-associated Alzheimer&#146;s disease patients, the highest risk population to develop Alzheimer&#146;s disease and the <FONT STYLE="white-space:nowrap">sub-population</FONT> most
likely to demonstrate a treatment effect from the expression of the protective APOE2<I> </I>protein. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pursue a step-wise and capital-efficient development approach for advancing our programs through the clinic
and regulatory approval</I>. We are advancing our pipeline of <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapies for cardiovascular and CNS indications. We expect to report biomarker data from the
<FONT STYLE="white-space:nowrap">low-dose</FONT> cohort in our Phase 1/2 clinical trial of LX2006 for the treatment of FA cardiomyopathy by the end of 2022. We expect to report initial biomarker data from the
<FONT STYLE="white-space:nowrap">mid-dose</FONT> cohort in our Phase 1/2 clinical trial of LX1001 for the treatment of <I>APOE4</I>-associated Alzheimer&#146;s disease by the end of 2022. We plan to leverage key learnings from our lead programs in
cardiovascular and CNS diseases to guide the development of our next-generation candidates and <FONT STYLE="white-space:nowrap">follow-on</FONT> indications. Given that there are several targets in myocardial cells that are dysregulated in
cardiomyopathy, we believe there will be readthrough to similar indications following proof of concept from our initial FA cardiomyopathy and ARVC programs. Similarly, we believe that positive clinical data from our <I>APOE4</I>-associated
Alzheimer&#146;s disease program has the potential to validate our novel approach to treating the <I>APOE4</I> homozygous <FONT STYLE="white-space:nowrap">sub-population</FONT> and can help inform the development plan of our next generation
candidates. Furthermore, we plan to leverage biomarkers for each of our development programs, potentially enabling us to rapidly validate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> action and
support further development efforts. We believe our strategy could facilitate shorter clinical trial timelines, which coupled with expedited global regulatory approval pathways, could potentially accelerate clinical development, and reduce overall
development costs. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expand our cardiovascular pipeline capabilities through the discovery and development of next-generation gene
therapy technologies</I>. We have combined our robust expertise in cardiac-targeted vector design, regulatory and clinical strategy, and disease area knowledge with our deep therapeutics pipeline to establish a leading cardiovascular gene therapy
pipeline. We have chosen to use AAVrh10 across our initial programs and will continue to evaluate the latest scientific understanding of capsid technology for each of our future </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
cardiovascular programs. We will continue to pursue the development of novel capsids, promoter technologies, routes of delivery and other next-generation capabilities to optimize the potential
therapeutic efficacy of our cardiovascular programs through our own efforts and in collaboration with others. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Leverage and expand upon our partnerships and exclusive licenses with world class academic institutions</I>.
Our foundational science stems from partnerships and exclusive licenses with leading academic laboratories at Weill Cornell Medicine and UCSD, two preeminent institutions on the cutting edge of gene therapy research. Of note, our Chief Scientific
Advisor, Ronald G. Crystal, M.D., has sponsored 14 cleared gene therapy IND applications across multiple disease areas, and researchers at UCSD led the discovery efforts of a cardiovascular gene therapy program that is expected to move into
late-stage clinical trials. We will continue to draw on the scientific expertise provided by these partnerships while evaluating new opportunities for complementary research and development with other academic collaborators. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Utilize a scalable, unified manufacturing platform across all current and future programs</I>. We plan to use
a unified manufacturing process across all current and future programs to manufacture vector for clinical and commercial use via a proprietary platform suspension baculovirus process using Sf9 cells. This production platform has demonstrated the
capability to produce high-quality, high-yield, high-potency vectors that can accommodate demand for both rare and prevalent patient populations. We are currently working with third parties for our manufacturing capabilities; however, we will
evaluate building out our own cGMP-compliant manufacturing facility as, and if, we achieve further clinical success or any of our product candidates ultimately receive marketing authorization. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Build a fully integrated gene therapy company and selectively evaluate strategic opportunities to maximize the
impact of our pipeline</I>. We aim to discover, develop, manufacture, and eventually commercialize our gene therapy candidates. Despite the larger populations in most of our target indications, we believe genetically defined patient populations
enable us to pursue a rare disease commercialization strategy characterized by targeted patient identification and facilitating an efficient patient journey through the diagnostic process, engagement with patient advocacy groups, the potential for
value-based market access efforts, and sales, account management, and field reimbursement teams focused on the small number of centers that typically diagnose and treat genetic diseases. We may seek strategic collaborations where we believe the
resources and expertise of third-party pharmaceutical or biotechnology companies could accelerate the clinical development or maximize the market potential of our product candidates, or where such collaborations could expand our internal
capabilities and platform technology. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Our approach </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>Background and successes of gene therapy </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gene
therapy is one of the most important emerging modalities, given its potential, in a single administration, to treat or cure life threatening diseases. Other <FONT STYLE="white-space:nowrap">non-genetic</FONT> medicine approaches have alleviated
certain symptoms and conditions associated with genetic diseases, but they do not directly address the underlying genetic cause of the disease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gene
therapies are designed to deliver transgenes, which are functional versions of the genes that are mutated or are the cause of deficient proteins that manifest in genetic diseases. These transgenes are utilized by the body&#146;s cellular machinery
to naturally produce functional proteins that were deficient or <FONT STYLE="white-space:nowrap">non-functional</FONT> prior to treatment. The production of these functional proteins is intended to provide consistent and durable therapeutic benefit.
Gene therapies are typically comprised of three key components: a vector&#151;a vehicle that delivers a transgene to cells in the body; a transgene&#151;a gene intended to produce a protein; and a promoter&#151;a specialized DNA sequence that
directs cells to initiate transcription. <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy has been shown to be highly effective in targeting many organ systems and has been studied in more than 3,300 patients worldwide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although gene therapies have been studied in human clinical trials for over 30 years, there are only two <FONT
STYLE="white-space:nowrap">AAV-based</FONT> gene therapy products approved by the FDA: voretigene neparvovec-rzyl (Luxturna), for the treatment of a rare ocular condition; and onasemnogene abeparvovec-xioi (Zolgensma), for the treatment of a rare
neuromuscular condition. Less than three years after its 2019 FDA approval, Zolgensma generated $1.4 billion of net product sales in 2021, highlighting the commercial viability of novel gene therapies. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>Challenges associated with gene therapies </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although substantial advances have been made in the gene therapy field, numerous challenges remain that are associated with safety, efficacy and manufacturing,
including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>High doses resulting in toxicity in systemic gene therapy</I>.&nbsp;&nbsp;&nbsp;&nbsp;Like many other drug
modalities, higher doses of gene therapies have been associated with increased toxicity. Thus far, systemic gene therapies that are intended to treat larger tissues or organ systems (such as in neuromuscular diseases) have required higher doses to
show efficacy. Adverse effects such as liver toxicity and microvascular thrombosis may arise from higher doses of gene therapy, leading to direct injury to hepatocytes and activation of aversive immune responses. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Delivery and biodistribution challenges in CNS gene
therapy</I><B><I>.</I></B><I>&nbsp;&nbsp;&nbsp;&nbsp;</I>Gene therapies for CNS indications may cause dorsal root ganglia pathology due to a preferential expression profile in dorsal root ganglia if administered to the CNS. In addition, gene
therapies administered to the CNS must overcome the issue of insufficient biodistribution to neurons and other cells of the CNS in the case of therapies that target intracellular proteins, diminishing their potential efficacy. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Lack of scalable, high-quality manufacturing</I><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Early-stage manufacture
of AAV gene therapy has traditionally relied on the use of HEK adherent and suspension cell culture using plasmid transfection and subsequent ultracentrifugation-based purification. This approach involves the use of expensive plasmids and results in
a long production cycle. Additional issues include low yield and quality of the material produced, including incorporation of <FONT STYLE="white-space:nowrap">non-transgene</FONT> DNA impurities, ratio of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">empty-to-full</FONT></FONT> capsid and efficient removal of process residuals. It has been reported that empty capsids and DNA impurities can cause innate and adaptive immune responses to AAV and even inhibit transduction
by filled capsids. Furthermore, the HEK adherent and suspension cell culture approach has proven difficult to scale up. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>Our gene
therapy approach </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our integrated modular approach enables us to optimize our strategy to pursue larger-rare and prevalent genetically defined
indications in specific sub-populations of patients. Our gene therapy candidates utilize the vector construct, dose and route of administration that we believe will result in the most favorable biodistribution profile for each disease. By
specifically tailoring our technological approach to each targeted disease, we believe we can optimize treatments to achieve the highest likelihood of having potential therapeutic impact. Our disease area strategy is focused on defined <FONT
STYLE="white-space:nowrap">sub-populations</FONT> within selected cardiovascular and CNS indications that we believe are most amenable to gene therapy. Across our portfolio, we are utilizing a scalable baculovirus/Sf9 expression system that has
demonstrated the capability to produce high-quality, high-yield, high-potency vectors that can accommodate demand for both rare and prevalent patient populations. Finally, we continuously seek to bolster our development pipeline with relationships
with academic institutions, which provide us access to cutting edge gene therapy research that we will utilize in the discovery and development of next generation gene therapy candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our technology approach </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced cardiac and CNS programs use the AAVrh10 vector due to its high transduction efficiency in both myocardial cells and neurons, higher ratio of
cardiac to liver biodistribution, potentially lower toxicity given the ability to utilize lower doses, compared to other well-established AAV serotypes, and lower <FONT STYLE="white-space:nowrap">pre-existing</FONT> immunity. We believe that our
approach to technology has the potential to confer the following advantages: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>High Transduction Efficiency and Biodistribution</I><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The AAVrh10 vector
has demonstrated successful transduction of myocardial cells and neurons, which we believe makes it optimal for delivery and expression of transgenes for the treatment of the cardiovascular and CNS diseases we are currently targeting. We have
observed organ-specific biodistribution advantages for our AAVrh10 vector. For example, we have reported vector distribution of AAVrh10 in cardiac tissue of nonhuman primates, or NHPs, that is 1.5 to 2 times greater than for AAV9. Preclinical data
from a murine model has also demonstrated that more AAVrh10 particles transduced a single brain cell than AAV9. In addition, preclinical studies have demonstrated that systemic administration of AAVrh10 promotes a ratio of cardiac-to-liver
biodistribution that is more favorable than what is known of other commonly used vector serotypes. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Reduced Toxicity</I>.&nbsp;&nbsp;&nbsp;&nbsp;The cardiac tropism allows AAVrh10 to be systemically
administered at lower doses than many other <FONT STYLE="white-space:nowrap">AAV-based</FONT> therapies targeting cardiovascular or other systemic diseases. We have selected target indications that we believe will be responsive to AAVrh10 that may
be administered at comparatively lower doses in order to potentially reduce toxicities that have been reported in clinical trials of higher-dose gene therapies. For example, we intend to use doses of low to mid x10<SUP
STYLE="font-size:85%; vertical-align:top">11</SUP> genome copies per kilogram in our Phase 1/2 clinical trial of LX2006 for the treatment of FA cardiomyopathy, compared to doses used in other systemic gene therapy programs which can exceed 1 x10<SUP
STYLE="font-size:85%; vertical-align:top">14</SUP> genome copies per kilogram. Similarly, early data suggest a lower dorsal root ganglia toxicity profile than other commonly used vectors, making it amenable for treating CNS diseases at potentially
higher doses than other vectors. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Reduced <FONT STYLE="white-space:nowrap">Pre-Existing</FONT> Neutralizing
Antibodies</I><B><I>.</I></B><I>&nbsp;&nbsp;&nbsp;&nbsp;</I>Treatments leveraging vector serotypes to which humans have <FONT STYLE="white-space:nowrap">pre-existing</FONT> immunity tend to be less effective. Among the naturally occurring and
commonly used AAV serotypes, AAVrh10 has been shown in preclinical studies to have among the lowest levels of <FONT STYLE="white-space:nowrap">pre-existing</FONT> neutralizing antibodies. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Optimized Expression</I>.&nbsp;&nbsp;&nbsp;&nbsp;We are collaborating with our academic partners to develop
tissue-specific promoters and enhancers, tissue-specific codon optimization and tissue specific miRNA-based knockdown which can be utilized to limit transgene expression in <FONT STYLE="white-space:nowrap">non-target</FONT> organs. We are also
exploring additional genetic medicine approaches to increase tissue tropism using novel capsids and developing next generation expression systems to optimize the therapeutic efficacy of our product candidates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our disease area strategy </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We employ a strategy to select targets in indications that have relatively large patient populations, high unmet need and technically feasible treatment
profiles. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our disease area strategy </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g287237g34p78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We target diseases with the following characteristics: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Defined <FONT STYLE="white-space:nowrap">sub-populations</FONT> in indications that may be effectively treated
by gene therapy</I><B><I>.</I></B><I>&nbsp;&nbsp;&nbsp;&nbsp;</I>Our disease targets are focused on defined <FONT STYLE="white-space:nowrap">sub-populations</FONT> of patients that may be effectively treated by gene therapy. We select targets that
correspond to populations with a specific genetic profile and clearly defined disease phenotype, increasing the homogeneity of our studied patient populations and increasing the potential for observing a homogeneous effect. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Indications with potential to demonstrate early evidence of meaningful clinical
benefit.</I>&nbsp;&nbsp;&nbsp;&nbsp;We pursue clearly defined biomarkers, as well as functional endpoints, that can potentially provide early <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> and
inform clinical development decisions, including the potential to pursue accelerated approval pathways. Early data regarding functional endpoints and biomarkers allows us to pursue an efficient capital allocation strategy. Certain of our clinical
trials are designed to provide initial biomarker data as early as three months from the date of treatment. In the case of LX2006 targeting FA cardiomyopathy, we are also pursuing functional and histological endpoints that may demonstrate signs of
meaningful clinical benefit as early as three months. We expect these early signals will enable us to design late-stage clinical studies with endpoints that best mirror therapeutic effects that should cure the disease. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Present opportunity to address high unmet medical need</I><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We are
focused on genetically defined cardiovascular and CNS conditions where there is no currently approved treatment or where we believe our therapeutic candidates will have a meaningful improvement relative to existing standards of care.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Significant market opportunity</I>.&nbsp;&nbsp;&nbsp;&nbsp;We seek indications with significant commercial
opportunity beyond those typically associated with gene therapy companies targeting rare monogenic diseases. Our cardiovascular gene therapy pipeline and our Alzheimer&#146;s disease gene therapy portfolio target either larger-rare disease
populations, ranging from approximately 5,600 U.S. patients, in the case of FA cardiomyopathy, to approximately 70,000 U.S patients in the case of ARVC due to <I>PKP2 </I>mutations, or prevalent diseases such as
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
homozygous <I>APOE4</I>-associated Alzheimer&#146;s disease, which has a patient population of up to approximately 900,000 in the United States. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Targets that have demonstrated promising preclinical data</I>.&nbsp;&nbsp;&nbsp;&nbsp;We have leveraged our
relationships with academic institutions including Weill Cornell Medicine and UCSD to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire product candidates with established
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in relevant animal models across a wide range of indications. We will continue to seek additional opportunities where promising preclinical data is
available. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Targeted disease areas best treated by optimal vector technologies</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our initial
gene therapy candidates utilize the AAVrh10 vector due to its biodistribution profile in myocardial cells and neurons, which allow us to pursue both cardiovascular and CNS indications. For future indications, we will pursue the optimal vector
technology to address the diseases of interest while ensuring sufficient preclinical or clinical validation for any novel approaches. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Readily identifiable patient groups</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our goal is to accelerate patient recruitment
for our clinical trials and increase the likelihood of commercial success of our potential products by focusing on diseases with established patient advocacy groups and university researchers who maintain registries of potentially eligible patients.
Where possible, we are also leveraging existing natural history studies which can help us to better define the target patient phenotypes associated with the disease. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our manufacturing approach </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing gene
therapy candidates for larger-rare and prevalent disease patient populations, which require a high-quality process that can produce vectors in relatively large quantities while utilizing traditional biologics manufacturing infrastructure. We utilize
a baculovirus/Sf9 expression system to manufacture our gene therapy candidates. Our manufacturing platform is designed to infect Sf9 cells at high densities in suspension cell culture with both an AAVrh10 and baculovirus containing the transgene.
The output is coupled with a chromatography-based purification process which allows for efficient AAV purification, resulting in higher yield, fewer empty AAV capsids, reduced incorporation of <FONT STYLE="white-space:nowrap">non-transgene</FONT>
DNA impurities and lower levels of process residuals than traditionally used plasmid HEK adherent cell culture approaches. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our baculovirus/Sf9 expression
system is designed to provide several benefits, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Ease of scalability:</I> potential to accommodate preclinical to large commercial indications;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Lower cost of goods</I>: utilizes a process that does not require expensive plasmids; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Robust yields</I>: potential for yields that can accommodate commercial demand for both larger-rare and
prevalent patient populations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Improved ratio of full capsids</I>: delivers a higher percentage of full capsids as compared to HEK systems;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Improved safety</I> <I>profile:</I> </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced plasmid DNA impurities, from 15% observed in some HEK systems to 0.2% in our process;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cellular components are <FONT STYLE="white-space:nowrap">non-replicating</FONT> in mammalian cells;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eliminates potentially immunogenic or toxic animal-derived proteins; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cells are grown under serum-free conditions, leading to reduced risk of contamination from animal-derived
products; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Equivalent potency</I>: shows levels of potency that are similar to mammalian cell lines;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Aligned with industry standards</I>: uses traditional manufacturing infrastructure and equipment widely
available in the industry; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Simpler process</I>: it does not require an adeno-virus helper. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our approach, we expect that our existing partnerships can supply material for all of our currently ongoing and planned clinical trials as well as
potential commercial production of some of our programs. We have secured relationships with Virovek, Inc. for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Bac-to-AAV&#148;</FONT></FONT> system, Millipore Corporation
for its RVN Sf9 cell line, and Fujifilm Diosynth Biotechnologies U.S.A., Inc., for viral vector process development and cGMP manufacture of viral vectors. We will own the intellectual property created by our manufacturing process development
activities or have the ability to license it and will maintain the option to transfer the process to other contract development and manufacturing companies, or CDMOs, in the future and/or to our own potential facility to ensure ongoing redundancy
and reliability. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Academic collaborations </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To support
our integrated modular approach, we have partnered with leading academic institutions who are on the cutting edge of gene therapy research. Our relationships with Weill Cornell Medicine and UCSD have provided us with access to the latest gene
therapy research. Our collaboration efforts with Weill Cornell Medicine currently focus on the discovery of second and third generation cardiac vector technology and novel cardiac transcriptional promoters, all of which have the potential to be
deployed in our early-stage research efforts. Our collaboration with UCSD focuses on preclinical candidate selection and translational research in several larger-rare cardiovascular disease indications. Both institutions are recognized leaders in
gene therapy and the collaborations are designed to best leverage their respective skill sets. We may seek additional academic collaborations where such collaborations could expand our internal capabilities and platform technology. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Our cardiovascular gene therapy programs </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
combined our robust expertise in cardiac-targeted vector design, regulatory and clinical strategy, and disease area knowledge with our pipeline to establish a leading cardiovascular gene therapy pipeline. We are developing a number of
disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases that have significant unmet need and no approved disease-modifying treatments. Our most advanced program, LX2006, is an AAVrh10-based gene therapy candidate for
the treatment of FA cardiomyopathy caused by mutations in the <I>FXN</I> gene. We are also advancing several other <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy programs to treat additional genetically defined cardiac diseases,
including LX2020 to treat ARVC caused by mutations in the <I>PKP2</I> gene, LX2021 to treat ARVC associated with Cx43 deficiency, and LX2022 to treat HCM associated with mutations in the <I>TNNI3</I> gene. We plan to leverage our experience and
learnings from LX2006 and apply them to our earlier-stage cardiac programs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>LX2006 for the treatment of FA cardiomyopathy </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing LX2006, an AAVrh10-based gene therapy candidate that is designed to deliver functional <I>FXN </I>intravenously for the treatment of FA
cardiomyopathy, to promote the expression of frataxin in order to restore normal mitochondrial function in myocardial cells. Cardiomyopathy is the most common cause of mortality in patients with Friedreich&#146;s ataxia. The FDA has granted Rare
Pediatric Disease designation and Orphan Drug designation to LX2006 for the treatment of Friedreich&#146;s ataxia. Our IND for LX2006 was cleared by the FDA
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022, and we expect to initiate an open-label, dose-escalation Phase 1/2 clinical trial in patients with FA cardiomyopathy in <FONT
STYLE="white-space:nowrap">mid-2022,</FONT> with interim biomarker data expected by the end of 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Friedreich&#146;s ataxia </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Friedreich&#146;s ataxia is a genetic, progressive, degenerative multi-system disorder with a prevalence of 1:40,000 or approximately 8,000 people in the
United States. It is estimated that approximately 70% or 5,600 of these patients will develop FA cardiomyopathy. In the European Union, Friedreich&#146;s ataxia affects approximately 11,000 people, with approximately 8,000 of these cases projected
to include FA cardiomyopathy. Friedreich&#146;s ataxia is caused by a mutation in the <I>FXN</I> gene that disrupts the normal production of the protein frataxin, which is critical to the function of mitochondria in a cell and to the maintenance of
cardiac function. Friedreich&#146;s ataxia patients with classically presenting disease have peripheral, <FONT STYLE="white-space:nowrap">non-cardiac</FONT> tissue frataxin protein levels that range from 2% to 30% of normal levels. Carriers who do
not develop symptoms of Friedreich&#146;s ataxia generally have peripheral tissue frataxin protein levels that range from 30% to 80% of normal levels. This frataxin deficiency in the mitochondria of myocardial cells causes disruption of normal
iron-sulfur cluster biosynthesis leading to mitochondrial dysfunction and deficient energy production, as shown below. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview of FA
cardiomyopathy disease mechanism </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g287237g27q99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The neurologic disease and cardiac disease are two distinct manifestations of Friedreich&#146;s ataxia. The disease is
inherited in an autosomal recessive manner, where both inherited genes are abnormal, and symptoms usually begin in childhood. Absence of fully functional frataxin leads to damage to peripheral nerves and the parts of the brain that controls movement
and balance, leading to neurological symptoms that include impaired muscle coordination, or ataxia, that worsen over time. Initial symptoms may include unsteady posture, frequent falling, and progressive difficulty in walking due to impaired ability
to coordinate voluntary movements. Affected individuals often develop slurred speech, hearing loss, scoliosis, diabetes, characteristic foot deformities, and an irregular curvature of the spine. The typical age of onset of neurological symptoms is
five to 15 years old. As the disease progresses, patients typically experience various heart conditions, including thickening of the heart muscle, or hypertrophic cardiomyopathy, and arrhythmias. Hypertrophic cardiomyopathy, fibrosis, heart failure
and arrhythmias are the cause of death in approximately <FONT STYLE="white-space:nowrap">two-thirds</FONT> of Friedreich&#146;s ataxia patients. Typical onset of the cardiac disease is 15 to 30 years old. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By the time the cardiac disease of Friedreich&#146;s ataxia emerges, the neurologic disease is generally significantly advanced and may not be amenable to gene
therapy. The optimal patient age for treatment of the neurologic disease is between five and 15 years of age while the optimal patient age for demonstrating treatment effect of the cardiac disease is 15 to 30 years of age. There are currently no
approved treatments for either the neurological or cardiac manifestations of Friedreich&#146;s ataxia. As a result, patients with Friedreich&#146;s ataxia have significant unmet need. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Neurological disease and cardiac disease are distinct manifestations of Friedreich&#146;s
ataxia with different potential therapeutic treatment windows </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g287237g28x65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our solution: LX2006 </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing LX2006 as an AAVrh10-based gene therapy delivered intravenously for the treatment of FA cardiomyopathy. LX2006 is designed to deliver the
<I>FXN</I> gene under the transcriptional control of the CAG promoter, a strong synthetic promotor frequently used in viral vectors. LX2006 utilizes AAVrh10 based on its favorable cardiac affinity and vector distribution profile observed in
preclinical studies as compared to AAV9. In preclinical studies, vector distribution in cardiac tissue with AAVrh10 has been observed to be between 1.5 to 2 times the distribution associated with the use of AAV9. In addition, there is a lower rate
of <FONT STYLE="white-space:nowrap">pre-existing</FONT> antibodies with AAVrh10 when compared to other commonly used vectors, such as AAV9 and AAV2. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LX2006 is designed to transfer the <I>FXN</I> gene to myocardial cells and increase frataxin levels in the mitochondria. The increase in frataxin levels in the
mitochondria restores mitochondrial function and energy production in cardiac myocytes, as shown below. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LX2006 is designed to deliver
functional frataxin in order to restore normal mitochondrial function </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g28y66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical studies in Friedreich&#146;s ataxia mouse models </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LX2006 has demonstrated the ability to significantly reverse the cardiac phenotype in preclinical studies. The ability to restore FXN expression levels using
an AAVrh10 vector has been established in numerous preclinical studies of Friedreich&#146;s ataxia conducted internally and by third parties. The most frequently used preclinical mouse models for Friedreich&#146;s ataxia are the MCK model which
represents the most severe phenotype of FA cardiomyopathy, and the Myosin heavy chain, <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>isoform, or <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>MyHC, model, which represents a milder phenotype. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the preclinical studies conducted by Weill Cornell Medicine utilizing the MCK model, LX2006 reduced left
ventricle mass, increased shortening fraction, or pumping ability of the heart, and increased survival, as shown in the graphic below. The MCK model completely lacks the myocardial FXN protein and untreated mice have a lifespan of approximately
11&nbsp;weeks of age due to heart failure. The untreated mouse cohort developed left ventricular hypertrophy starting at four to five weeks of age, which is associated with a rapid and progressive geometric remodeling of the heart. This cohort
exhibited decreased systolic function at eight weeks of age, which led to a severe decrease in resting cardiac output. When administered to the MCK model at three weeks, LX2006 prevented the onset of the disease. In addition, when administered at
seven weeks, LX2006 reduced hypertrophy and normalized heart function, based on shortening fraction, within five weeks, and improved survival, as shown in the graphic below. Based on these results, we believe LX2006 has the potential to improve
cardiac function and reverse the disease abnormalities in FA cardiomyopathy patients. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LX2006 improves cardiac function and survival in
severe </B><B><I>FXN</I></B><B> knockout model </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g287237g29m44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Wild type mice, n&#061;10; untreated MCK mice, n&#061;9; and treated MCK mice, n&#061;9. The treated MCK mice were given
a dose of 5.4 x10<SUP STYLE="font-size:85%; vertical-align:top">13</SUP> vg/kg at seven weeks of age. </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we have completed preclinical
studies of LX2006 using a <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>MyHC mouse model. The <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>MyHC model has myocardial frataxin protein levels that are less than 50% of normal frataxin expression levels
and present with a milder cardiac phenotype. When the mouse is given dobutamine to induce cardiac stress, the cardiac disease becomes apparent, similar to the mild phenotype in FA cardiomyopathy patients at an early stage of their cardiac disease.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The figures below show that <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>MyHC mouse models display ejection fraction and fractional shortening levels
similar to the wild type phenotype when at rest. However, when both wild type and <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>MyHC animals are stressed by the administration of dobutamine, the model demonstrated that ejection fraction and
fractional shortening levels for the <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>MyHC mice were below wild type levels. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><B>Myhc mouse model has diminished
cardiac function in response to induced stress </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g30j85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>MyHC mouse model, as demonstrated in the graphic below, intravenous
administration of LX2006 at a dose of 4 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg resulted in improvements in the cardiac phenotype as indicated by correction of dobutamine stress-induced ejection fraction and fractional
shortening as well as improvement in treadmill performance. These results show that LX2006 improves key cardiac function measures to wild type levels, helping reverse the pathology of FA cardiomyopathy and suggesting that it could potentially
improve cardiac function in Friedreich&#146;s ataxia patients. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LX2006 reverses
</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><B>MyHC cardiac phenotype in key cardiac functional measures in preclinical models </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g30k86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical dose range finding study </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Differences between Friedreich&#146;s ataxia patients and phenotypically normal carriers of Friedreich&#146;s ataxia mutations suggest that achieving
approximately 30% of normal endogenous frataxin levels would have a potential clinical beneficial effect in Friedreich&#146;s ataxia patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Seven-week-old</FONT> MCK mice were administered 5.6 x10<SUP
STYLE="font-size:85%; vertical-align:top">10 </SUP>vg/kg, 1.8 x10<SUP STYLE="font-size:85%; vertical-align:top">11 </SUP>vg/kg and 5.6 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg of LX2006 and evaluated for efficacy as a measure
of body weight improvement, survival and cardiac function, and associated myocardial FXN expression at one month post-dose. MCK mice showed a dose-dependent improvement in efficacy with LX2006. In these mice the dose of 1.8 x10<SUP
STYLE="font-size:85%; vertical-align:top">11</SUP> vg/kg resulted in trends of improvement in body weight and cardiac function survival, and the level of myocardial frataxin was 27% of normal human levels. The dose of 5.6 x10<SUP
STYLE="font-size:85%; vertical-align:top">11</SUP> vg/kg resulted in statistically significant improvements in body weight, cardiac function, and survival, and the level of myocardial frataxin expression was 73% of normal human levels. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To establish the endogenous levels in the myocardial cells of non-Friedreich&#146;s ataxia subjects, cardiac samples were obtained during autopsy from five
different individuals who did not have Friedreich&#146;s ataxia. The average level of myocardial frataxin measured in non-Friedreich&#146;s ataxia patient samples was approximately 60 ng/mg protein (represented by the upper light blue dashed line in
the figure below). In Friedreich&#146;s ataxia patients, an average of 16% of normal endogenous levels would lead to an estimate of 10 ng/mg protein in myocardial cells (represented by the lower light blue dashed line and the blue bars in the figure
below). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dose dependent FXN expression in MCK mouse model </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g31e28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the myocardial FXN expression in response to LX2006 treatment in a Friedreich&#146;s ataxia patient&#146;s stressed
heart is expected to be similar to the high level of expression in MCK mice observed upon administration of LX2006, dose selection for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study was based on
the MCK mouse data. The 1.8 x10<SUP STYLE="font-size:85%; vertical-align:top">11</SUP> vg/kg dose, which showed 27% of normal myocardial FXN expression, was identified as the minimally effective dose, and the 5.6 x10<SUP
STYLE="font-size:85%; vertical-align:top">11</SUP> vg/kg dose, which showed 73% of myocardial FXN expression, was identified as the significantly effective dose. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical expression study </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a separate NHP study
conducted at a third party lab in cynomolgus monkeys that were administered doses ranging from 5.13 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> to 7.52 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg of LX2006, the
frataxin expression in myocardial tissue at three weeks following administration exceeded the predicted therapeutic threshold and, in some cases, higher than the endogenous FXN level in humans, in the atrium, septum and right ventricle, as shown in
the figure below. This data was presented at the 2021 American Society of Gene and Cell Therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LX2006 expresses frataxin levels in NHP Cardiac Tissues that exceed predicted therapeutic
levels </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g32s77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical safety studies </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a safety study of African green monkeys, LX2006 doses of 1.2 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg and 3.9 x10<SUP
STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg resulted in dose-dependent increases in myocardial frataxin expression three months post dose. The dose of 1.2 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg resulted in FXN
expression which is 22% of normal human FXN, or hFXN, levels; while the dose of 3.9 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg resulted in FXN expression which is 45% of normal hFXN levels. Both doses demonstrated favorable
safety profiles, including no effects on cardiac pathology, physiology and echocardiography. The liver showed minimal to moderate vacuoles, or membrane-enclosed spaces in cells, not considered clinically significant, with no evidence of liver
injury. No dorsal root ganglia toxicity was observed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The safety of LX2006 was also tested in <FONT STYLE="white-space:nowrap">seven-week-old</FONT> wild
type mice administered 1.2 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP>, 3.7 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP>, and 1.2 x10<SUP STYLE="font-size:85%; vertical-align:top">13</SUP> vg/kg for one and three months,
and 5.6 x10<SUP STYLE="font-size:85%; vertical-align:top">11</SUP>, 1.8 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP>, and 5.6 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg for 10 months. Animals in the <FONT
STYLE="white-space:nowrap">one-</FONT> and three-month cohorts survived to their scheduled terminations, while those in the <FONT STYLE="white-space:nowrap">10-month</FONT> cohort had body weight loss at two time periods that necessitated early
euthanasia. The first timepoint was approximately six weeks for four of 12 males in the 5.6 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg <FONT STYLE="white-space:nowrap">10-month</FONT> cohort; the weight loss was attributed to
liver toxicity, which may have been related to high levels of liver hFXN, although hFXN levels were not determined in these mice. No adverse effects occurred in females up to three months post-dose. At 30 weeks post-dose, the remaining animals in
the high dose (5.6 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg) group and six of 12 female mice in the mid dose (1.8 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg) group had minimal to moderate hepatic changes
and weight loss necessitating early euthanasia. It is possible that both hepatic and possibly cardiac frataxin levels may have contributed to the weight loss. No dorsal root ganglia toxicity was observed at any doses in any animals. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The dose of 5.6 x10<SUP STYLE="font-size:85%; vertical-align:top">11</SUP> vg/kg in the <FONT STYLE="white-space:nowrap">10-month</FONT> cohort was generally
well tolerated with no treatment-related clinical signs, body weight changes, hematologic or clinical chemistry findings, nor histopathology findings, except for hepatocellular carcinoma, or HCC, which was observed in one of six males at 5.6 x10<SUP
STYLE="font-size:85%; vertical-align:top">11</SUP> vg/kg and in three of six males at 1.8 x10<SUP STYLE="font-size:85%; vertical-align:top">12</SUP> vg/kg. While this finding was considered adverse in the context of the study, a large body of
available data suggests that HCC observed in mice after AAV treatment is unlikely to translate to risks for humans, as it has not been observed in higher species or humans (FDA 2021). The incidence of HCC has been seen in multiple long-term mouse
studies with systemic administration of other AAVs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>LX2006 clinical development and trial design </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our IND for LX2006 was cleared by the FDA in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022, and we expect to initiate a Phase 1/2
clinical trial of LX2006 in patients with FA cardiomyopathy in <FONT STYLE="white-space:nowrap">mid-2022.</FONT> The Phase 1/2 study is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> <FONT
STYLE="white-space:nowrap">52-week,</FONT> dose-ascending, open-label trial of LX2006 in patients who have FA cardiomyopathy. LX2006 will be administered as a <FONT STYLE="white-space:nowrap">one-time</FONT> intravenous infusion to patients in at
least two dose-ascending cohorts. The trial will consist of five patients in each cohort. A potential third cohort will receive a dose that will be selected based on the dose-response relationships seen in cohort 1 and cohort 2 and an additional NHP
study that we are conducting concurrently with the first two dose cohorts in our clinical trial. There will be a long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> for patients who receive LX2006 to monitor ongoing safety for a total of
five years, per FDA requirement. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Design of phase 1/2 clinical trial of LX2006 </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g33b33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key patient inclusion criteria for the study include genotyping, abnormal cardiopulmonary exercise testing, or CPET, peak
oxygen consumption, or peak VO2, levels, left ventricular hypertrophy, abnormal cardiac strain, ejection fraction &#8805;45%, and focal fibrosis &#8804;5% of cardiac wall mass. The primary endpoint of the Phase 1/2 trial is to assess the safety and
tolerability of <FONT STYLE="white-space:nowrap">one-time</FONT> administration of LX2006 for the purpose of selecting the appropriate dose for further clinical development. The secondary endpoints assess biomarkers, including cardiac frataxin
expression levels, and preliminary functional efficacy assessments relevant in evaluating the ability of LX2006 to stop progression and improve FA cardiomyopathy. The following biomarker, functional and imaging efficacy assessments will be
conducted: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>CPET</I>:&nbsp;&nbsp;&nbsp;&nbsp;Peak VO2 and other functional measures will be performed at regular
intervals. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Cardiac MRI</I>:&nbsp;&nbsp;&nbsp;&nbsp;All patients undergo MRI scans of the heart to measure left
ventricular mass index, left ventricular ejection fraction, stroke volume, strain, and fibrosis. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Cardiac Echo</I>:&nbsp;&nbsp;&nbsp;&nbsp;All patients undergo cardiac ECHO to measure left ventricular mass
index, left ventricular ejection fraction and strain. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Cardiac biopsy</I>:&nbsp;&nbsp;&nbsp;&nbsp;Biopsies will measure, among other things, frataxin protein
expression. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Biomarkers</I>:&nbsp;&nbsp;&nbsp;&nbsp;Serum cardiac biomarkers, including troponin. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B></B><B><I>LX2020 for the treatment of ARVC caused by </I></B><B>PKP2 </B><B><I>mutations</I></B><B> </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing LX2020 as an <FONT STYLE="white-space:nowrap">AAVrh10-based</FONT> gene therapy for the treatment of ARVC caused by mutations in the
<I>PKP2</I> gene. LX2020 is designed to provide a fully functional<I>&nbsp;PKP2</I><I></I>&nbsp;gene to increase desmosomal PKP2 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
protein levels, reassemble desmosomes, and prevent cardiac arrhythmias and prevent or treat cardiac dysfunction. <I>PKP2</I> is the most frequently mutated desmosomal gene and we believe there
are more than 70,000 ARVC patients affected by the <I>PKP2</I> mutation in the United States. We intend to submit an IND to the FDA for LX2020 by the end of 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of ARVC </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARVC is a genetic heart disease
primarily characterized by myocardial cell loss and the replacement of heart muscle with fibrotic tissue and fatty deposits. ARVC can result from mutations in several desmosomal genes. These genetic mutations impair the structure and function of
cardiac desmosomes, which are membrane protein complexes engaged in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cell-to-cell</FONT></FONT> adhesion and the structural integrity of the ventricular myocardium. Lack of functioning
cardiac desmosomes can lead to myocardial cell death and fibrosis, heart dysfunction, rhythm abnormalities, and sudden death. The disease is associated with high mortality as more than 40% of ARVC patients die or have heart transplantation within 10
years of diagnosis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The figure below shows the role of the PKP2 protein in the formation of the desmosome. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview of ARVC disease mechanism caused by deficient </B><B><I>PKP2</I></B><B> Gene </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g287237g34c81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that ARVC has an estimated prevalence in the general US population between 1:2000 and 1:5000 and estimate that
over half of all ARVC patients have a genetic form of the disease. Five desmosomal genes account for nearly all genetic cases of ARVC. We are targeting the <I>PKP2</I> gene because mutations in this gene are the most common known genetic cause of
ARVC. No effective treatments or cures for ARVC exist, and thus, strategies targeted at elevating PKP2 protein levels represent a clinically relevant avenue to treat a large portion of ARVC populations. We believe that mutations in the <I>PKP2</I>
gene are associated with approximately 75% of all genetic cases of ARVC, resulting in approximately 70,000 and 95,000 ARVC patients affected by the <I>PKP2</I> mutation in the United States and European Union, respectively. Most familial cases of
the disease have an autosomal dominant pattern of inheritance, meaning one copy of an altered gene in each cell is sufficient to cause the disorder. Since having only one functioning copy of the <I>PKP2</I> gene is insufficient to produce the
wild-type phenotype, this results in a phenomenon in genetics known as haploinsufficiency. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Symptoms of the disease can include palpitations, dizziness,
heart failure and sudden death. Abnormal function of the right ventricle, fatty or fibrotic infiltrates in the myocardium, abnormal ECG, arrhythmias, or a family history of ARVC can all lead physicians to diagnose the disease. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our solution: LX2020 </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing LX2020 as an <FONT
STYLE="white-space:nowrap">AAVrh10-based</FONT> gene therapy candidate for the treatment of ARVC caused by mutations in the <I>PKP2</I> gene. LX2020 is designed to intravenously deliver a fully functional<I>&nbsp;PKP2</I><I></I>&nbsp;gene to cardiac
muscle to increase desmosomal PKP2 protein levels and restore myocardial cell function. We believe that by delivering a fully functional <I>PKP2</I> gene, LX2020 has the potential to address the underlying cause of ARVC
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for many patients, by reassembling the cardiac desmosomes, preventing cardiac arrhythmias and preventing or treating cardiac dysfunction and having a significant effect on lifespan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LX2020 is designed to deliver functional </B><I>PKP2</I><B> to restore normal desmosomal function </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g287237g35s94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical studies </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our preclinical studies have demonstrated that delivery of <I>PKP2</I> led to reassembling of the cardiac desmosome, as well as prevented arrhythmias and
cardiac dysfunction, and increased survival in a genetic mouse model of ARVC harboring <I>PKP2</I> patient genetics. The graphs below show survival data for the mice following administration of an AAV9-based <I>PKP2 </I>transgene at a dose of 5 x10<SUP
STYLE="font-size:85%; vertical-align:top">11 </SUP>vg/mouse. This was done both before severe disease onset on day two and after severe disease onset at four weeks. With early administration, we observed that 100% of the treated mice were alive at
30 weeks, while the untreated <I>PKP2-</I>homozygous mutant mice all died by approximately 25 weeks. With late administration, we observed that 100% of the treated mice were alive at 20 weeks, while only 20% of the green fluorescent protein-treated
<I>PKP2</I>-homozygous mutant mice were alive at 20 weeks at the time data were presented from the study. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Preclinical data of early and
late stage administration of AAV9-</B><B><I>PKP2</I></B><B> improved survival </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in ARVC mouse model harboring </B><I>PKP2</I><B>
patient genetics </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g35t95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on these results, we believe that the administration of AAV-<I>PKP2</I> has the potential to restore the cardiac
desmosomes and treat ARVC caused by a mutation in this gene. We further believe that early administration has the potential to prevent disease onset, improve cardiac symptoms, and prolong survival, while late administration may also have benefits in
terms of restoring desmosomes, improving cardiac function and prolonging life. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preclinical findings to date provide direction for our ongoing
development efforts. We plan to conduct further preclinical studies using an optimized AAVrh10-<I>PKP2</I> transgene in several murine models to generate additional data to better inform our clinical development plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><I></I><B>Additional cardiovascular gene therapy programs: LX2021 and LX2022 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe there are additional targets in genetically defined cardiac disease that have the potential to be addressed through
<FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapies. We plan to continue to innovate with novel capsids, promoters, and delivery methods to optimize our early-stage assets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>LX2021</I>:&nbsp;&nbsp;&nbsp;&nbsp;We are designing LX2021 to treat adults with ARVC irrespective of the underlying genetic mutation by delivering the
coding sequence for functional&nbsp;Cx43<I></I>&nbsp;protein. We believe that restoring the Cx43 protein has the potential to treat multiple genetic causes of ARVC because cardiac loss of Cx43 is a molecular deficit that is generally observed in all
ARVC populations studied. Gap junctions facilitate electrical coupling between myocardial cells. These structures are formed by connexins, and Cx43 is the protein constitutively expressed at the highest level. In patients with heart disease,
including heart failure, Cx43 can be relocalized in the lateral walls of myocardial cells and is significantly reduced at cardiac muscle cell junctions, especially in ARVC populations. Preclinical data from a desmoplankin <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> murine model, which exhibits the most severe version of ARVC, demonstrate that severely diseased ARVC mice treated with
<FONT STYLE="white-space:nowrap">AAV-based</FONT> therapy expressing Cx43, can reassemble the cardiac cell junction and desmosome as well as display significantly fewer arrhythmias, have improved cardiac function and have almost twice the survival
duration as untreated adult mice. The preclinical studies and findings to date provide direction for our ongoing development efforts. We plan to initiate <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for LX2021 by the end of 2023.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>LX2022</I>:&nbsp;&nbsp;&nbsp;&nbsp;We are designing LX2022 to treat HCM due to mutations in the <I>TNNI3</I> gene by delivering a functional
<I>TNNI3</I> gene to myocardial cells.<B> </B>With an estimated prevalence of 1:500,<B> </B>HCM is one of the most common forms of genetic cardiomyopathy and is caused by mutations that affect the cardiac sarcomere in approximately 75% of cases. It
is inherited as an autosomal dominant trait, with over 500,000 patients in the United States alone who have a genetic form of HCM. It is estimated that approximately 30,000 patients in the United States have HCM due to mutations in the thin-filament
gene <I>TNNI3</I>. In the European Union, we believe there are approximately 36,000 patients with TNNI3-associated HCM. The <I>TNNI3</I> gene encodes troponin I, a key protein in the thin filament of the sarcomere, which is involved in cardiac
contraction and relaxation. Mutations in the gene result in left ventricular hypertrophy and dysfunction, which can lead to heart failure, and increased risk of arrhythmias. Our preclinical studies and findings to date provide direction for our
ongoing development efforts. We plan to initiate <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for LX2022 by the end of 2024. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Our CNS
gene therapy programs </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><I></I><B>Our Alzheimer&#146;s disease franchise </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are building a portfolio of approaches aimed at treating the genetics underlying Alzheimer&#146;s disease. In our lead Alzheimer&#146;s disease program,
LX1001, we are initially targeting homozygous <I>APOE4</I>-associated Alzheimer&#146;s disease patients by administering AAVrh10 containing the <I>APOE2</I> gene. Our approach to treating Alzheimer&#146;s disease is predicated on the belief that
expressing the protective APOE2 in the CNS of <I>APOE4</I> homozygous patients will halt or slow the progression of Alzheimer&#146;s disease. We believe these patients represent an ideal target for gene therapy because the <I>APOE4</I> homozygous
profile is the most common genetic driver of Alzheimer&#146;s disease. We believe LX1001 is the only clinical-stage gene therapy candidate designed to treat this genetic cause of Alzheimer&#146;s disease. We plan to leverage biomarkers for LX1001 to
potentially enable us to rapidly validate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> and support further development efforts. We believe that positive clinical data from our ongoing Phase 1/2
trial has the potential to validate our novel approach to treating the <I>APOE4</I> <FONT STYLE="white-space:nowrap">sub-population</FONT> and can help inform the development plan of our next generation candidates LX1020 and LX1021 which we believe
could demonstrate an even more dramatic effect to slow or halt the progression of Alzheimer&#146;s disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current gene therapy programs under development for the treatment of Alzheimer&#146;s disease are: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>LX1001</I>:&nbsp;&nbsp;&nbsp;&nbsp;an AAVrh10-based gene therapy candidate that is designed to express the
protective APOE2 protein in the CNS of <I>APOE4</I> homozygous patients. In the ongoing Phase 1/2 clinical trial of LX1001, two patients from the first dose cohort have demonstrated decline in CSF tau biomarkers over 12 months. We have also reported
data demonstrating expression of the protective APOE2 protein in all four patients in the low-dose cohort with follow-up data. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>LX1020</I>:&nbsp;&nbsp;&nbsp;&nbsp;an AAVrh10-based gene therapy candidate that is designed to express the
protective APOE2 protein in the CNS of <I>APOE4</I> homozygous patients, while concurrently delivering miRNA to suppress the expression of the APOE4 protein. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>LX1021</I>:&nbsp;&nbsp;&nbsp;&nbsp;an AAVrh10-based gene therapy candidate that is designed to express the
Christchurch-modified APOE2 protein in the CNS of <I>APOE4</I> homozygous patients. The Christchurch mutation has been observed to protect patients against Alzheimer&#146;s disease even in the presence of significant amyloid pathology.
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>LX1001 for the treatment of homozygous APOE4-associated Alzheimer&#146;s disease </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing LX1001 to target homozygous <I>APOE4</I>-associated Alzheimer&#146;s disease patients, the highest risk population to develop
Alzheimer&#146;s disease and the <FONT STYLE="white-space:nowrap">sub-population</FONT> we believe will be the most likely to demonstrate a potential treatment effect from <I>APOE2</I>-based<I> </I>gene therapy. We anticipate reporting biomarker
data from the <FONT STYLE="white-space:nowrap">mid-dose</FONT> cohort by the end of 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview on Alzheimer&#146;s disease </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Background of Alzheimer&#146;s disease </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alzheimer&#146;s disease is a progressive neurodegenerative disorder that is the leading cause of cognitive decline in late adult life. The Alzheimer&#146;s
Association estimates that there were 6.2&nbsp;million patients living with Alzheimer&#146;s disease in 2021 in the United States alone, with costs to the nation exceeding $350&nbsp;billion. Aging of the population is expected to significantly
increase the socioeconomic burden of this disease in the coming decades, and the Alzheimer&#146;s Association further estimates that as many as 12.4 million patients in the United States could have the disease by 2050. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alzheimer&#146;s disease is characterized by a complex underlying pathology in the CNS, including accumulation of A&szlig; plaques, abnormal phosphorylation of
tau, development of tau tangles, inflammation, and progressive loss of neurons, all of which combine to precipitate a progressive decline in cognitive function. APOE, a lipid transport protein, is the major transporter of cholesterol in the brain
and is involved in synaptic integrity and plasticity, glucose metabolism, and cerebrovascular function. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Extracellular amyloid beta plaques and tau
neurofibrillary tangles are the principle pathological hallmarks of Alzheimer&#146;s disease. Therapeutics that modulate plaques and tangles historically have been the focus of substantial research and development efforts; however, there is
currently no treatment for Alzheimer&#146;s disease that is approved as disease modifying. The current standard of care for Alzheimer&#146;s disease is symptomatic therapies, such as donepezil (Aricept) and memantine (Namenda), that are viewed to
have limited benefit and do not address the underlying cause of the disease. Recently, the FDA granted accelerated approval to Biogen, Inc. for the anti-amyloid antibody intravenous infusion therapy aducanumab (Aduhelm), for the treatment of
patients with mild dementia or mild cognitive impairment stages of Alzheimer&#146;s disease. This represents a potential approval pathway for future Alzheimer&#146;s disease therapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Background on homozygous APOE4-associated Alzheimer&#146;s disease </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presence of <I>APOE4</I> is the most common genetic risk factor for Alzheimer&#146;s disease. The prevalent <I>APOE</I> alleles are <I>APOE4,</I> <I>APOE3</I>
and <I>APOE2</I>, with the <I>E4</I> allele increasing risk and reducing the age of onset and the <I>E2</I> allele decreasing risk and markedly delaying the age of onset. <I>APOE4</I> homozygous patients, individuals who have two copies of the
<I>E4</I> allele, are at the highest risk and are approximately fifteen times more likely to develop Alzheimer&#146;s disease than the general population. It is estimated that approximately 60% of Alzheimer&#146;s disease patients carry at least one
<I>APOE4</I> allele as compared with approximately 25% of <FONT STYLE="white-space:nowrap">age-matched</FONT> and healthy controls. The <I>APOE3</I> allele is believed to have a neutral impact on disease progression. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alzheimer&#146;s disease risk by </B><I>APOE</I><B> genotype (by odds ratio) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g38i49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party genetic epidemiology data from humans suggest that <I>APOE4</I> and <I>APOE2</I> are <FONT
STYLE="white-space:nowrap">co-dominant,</FONT> or both expressed, such that <I>APOE2/E4</I> heterozygous individuals have a substantially reduced risk of developing the disease as compared to <I>APOE4/E4</I> homozygous individuals. Therefore, the
expression of APOE2 appears to significantly offset the deleterious effects of the <I>APOE4</I> allele. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of the limited success in developing
therapies that effectively address A&szlig;, tau and other molecules involved in Alzheimer&#146;s disease pathology, we believe that administering the <I>APOE2</I> gene to <I>APOE4</I> homozygous patients is a promising approach because it has the
potential to address several pathways that are involved in the progression of the disease. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our solution: LX1001 </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LX1001 is an AAVrh10-based gene therapy designed to deliver the human <I>APOE2</I> gene into the CNS via <FONT STYLE="white-space:nowrap">one-time</FONT>
administration to the CSF, for the treatment of <I>APOE4 </I>homozygous patients. LX1001 is designed to express the protective APOE2 in the CNS to halt or slow the progression of Alzheimer&#146;s disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LX1001 is designed to address the genetic driver of Alzheimer&#146;s disease by delivering
</B><B><I>APOE2</I></B><B> gene into CNS of </B><I>APOE4</I><B> homozygous patients </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g39b55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on what is known regarding gene therapies delivered to the CNS, we believe LX1001 will only require a single dose
because neurons are post-mitotic, or incapable of further cell division, so there will be no dilution of extra-chromosomal LX1001 caused by cell division. APOE is a secreted protein; thus, only a fraction of neurons needs to be transduced with
LX1001 to secrete what we anticipate to be potentially efficacious levels of the protective isoform. We have designed LX1001 so that the protective isoform has the potential to be widely available to cells in the brain and able to compensate for <FONT
STYLE="white-space:nowrap">non-transduced</FONT> cells. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA granted fast track designation to LX1001 for the treatment of <I>APOE4</I> homozygous
patients with Alzheimer&#146;s disease to slow disease progression. We plan to seek other regulatory designations and consider accelerated clinical development pathways based on biomarker data that may establish early proof of mechanism and is
expected to predict clinical benefit. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical studies </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Weill Cornell Medicine has conducted preclinical studies in large and small animals that have demonstrated the potential for LX1001 to induce APOE2 expression
levels that we believe will be sufficient to halt or slow the progression of Alzheimer&#146;s disease in <I>APOE4</I> homozygous patients. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical
murine studies of LX1001 were conducted in a widely used model of brain amyloidosis (PDAPP mice) as well as a mouse model that develops APOE4-dependent amyloid deposition (APP.PS1/TRE4 mice). APP.PS1/TRE4 triple transgenic mice develop early and
robust A&szlig; and amyloid deposition, which is dramatically reduced in the absence of APOE4. Intracerebral delivery of LX1001 led to the widespread brain expression of APOE2. Studies in the APP.PS1/TRE4 model showed an approximately 80% reduction
in insoluble <FONT STYLE="white-space:nowrap">A&szlig;1-42</FONT> in the hippocampus eight weeks following intrahippocampal administration of LX1001. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An
additional preclinical study in NHPs was conducted to determine the most active and well-tolerated route of administration for LX1001 to achieve broad CNS biodistribution and therapeutic levels of the APOE2 proteins. In these studies, we utilized an
intracisternal delivery route to deliver the gene therapy vector to the CSF in order to achieve widespread biodistribution of LX1001. The intracisternal route has been shown in multiple studies in large animals to result in transgene expression
throughout the CNS and involves a minimally invasive procedure to infuse into the CSF. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To evaluate this route of delivery, at eight weeks following
intracisternal administration of total vector dose of 5 x10<SUP STYLE="font-size:85%; vertical-align:top">13</SUP> vg/ml CSF of LX1001, with the <I>APOE</I> transgene tagged with the common antibody epitope tag hemagglutinin, or <FONT
STYLE="white-space:nowrap">APOE-HA,</FONT> three NHP brains in one study were evaluated for the extent of vector <FONT STYLE="white-space:nowrap">APOE2-HA</FONT> biodistribution, mRNA transgene expression, and
<FONT STYLE="white-space:nowrap">APOE2-HA</FONT> protein expression. To visualize the extent of vector biodistribution and transgene and protein expression, a 3D representation of one centimeter<SUP STYLE="font-size:85%; vertical-align:top">
</SUP>cubes of the brain was used, as shown below in the example of one NHP. As expected for a secreted protein like APOE2, diffuse expression was observed throughout the brain. Greater-than-baseline levels of all three targets were
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
observed in most cubes throughout the CNS, as well as in the hippocampal regions, the area of the brain most relevant in Alzheimer&#146;s disease. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Biodistribution of <FONT STYLE="white-space:nowrap">APOE2-HA</FONT> vector genomic copies, transgene mRNA, and protein levels in brain of an
NHP following intracisternal administration of LX1001 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g40a28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results from this study demonstrate that <I>LX1001</I> was consistently expressed through the brain in a NHPs and
achieved broad distribution in the CNS of the animals. In addition, administration of the HA tagged version of LX1001 directly to the CNS of NHPs exhibited a favorable safety profile. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical development </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Trial design
</I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are evaluating LX1001 in an open-label, dose-ranging Phase 1/2 clinical trial in patients who are <I>APOE4</I> homozygous patients with clinical
diagnoses ranging from mild cognitive impairment to mild or moderate dementia due to Alzheimer&#146;s disease. All patients have evidence of amyloid plaque by PET scan and CSF biomarkers consistent with Alzheimer&#146;s disease. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary objective of the trial is to evaluate the safety of LX1001 administered to the CNS via injection between cervical vertebrae 1 and 2, or
intracisternal injection, and to establish a maximum tolerable dose. The trial is also designed to evaluate the conversion of the CSF from the <I>APOE4</I> homozygous profile to an <I>APOE4/E2</I> profile. Additional secondary endpoints include CSF
biomarkers, including A&szlig;42, total tau, and phosphorylated tau, amyloid PET scan, structural MRI imaging and cognitive tests. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shown below, the
clinical trial is a dose-ranging trial of LX1001 in three ascending dose cohorts (5.0 x10<SUP STYLE="font-size:85%; vertical-align:top">10</SUP>, 1.6&nbsp;x10<SUP STYLE="font-size:85%; vertical-align:top">11</SUP> and 5.0 x10<SUP
STYLE="font-size:85%; vertical-align:top">11</SUP> vg/ml), with the dose for each patient determined based on CSF volume measured by MRI. Each dose cohort will consist of approximately five patients for a total of approximately 15 patients in the
entire trial. Key patient enrollment criteria include <I>APOE4</I> homozygous genetic profile, patient age of 50 years or older, positive amyloid PET scan, CSF biomarkers consistent with Alzheimer&#146;s disease, and diagnosis that ranges from mild
cognitive impairment to mild or moderate dementia due to Alzheimer&#146;s disease. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Design of phase 1/2 clinical trial of LX1001
</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g40b29.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Trial results </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary data for cohort 1, which is the <FONT STYLE="white-space:nowrap">low-dose</FONT> group, showed increases in CSF APOE2 levels, from baseline levels
of 0, relative to their respective CSF APOE4 levels, in all four patients with follow up data at three months or longer. These results, shown below, demonstrate that the <I>APOE2</I> transgene is being expressed in the CNS in all four of these
patients. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Interim CSF APOE2/APOE4 expression data from cohort 1 </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g41l54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The two patients for whom we have <FONT STYLE="white-space:nowrap">12-month</FONT> data in cohort 1, both of whom had
moderate Alzheimer&#146;s disease at baseline, showed declines in CSF core biomarkers A&szlig;42, <FONT STYLE="white-space:nowrap">t-tau</FONT> and <FONT STYLE="white-space:nowrap">p-tau</FONT> over 12 months, as shown below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Interim CSF core biomarker data in patients with <FONT STYLE="white-space:nowrap">12-month</FONT> data </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g90n36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among all patients in cohort 1, treatment with LX1001 has been well-tolerated with no serious adverse events reported to
date. Overall, initial preliminary data in the <FONT STYLE="white-space:nowrap">low-dose</FONT> cohort suggest that LX1001 has promise as a therapeutic for <I>APOE4</I> homozygous Alzheimer&#146;s disease patients. We expect to report the initial
biomarker data from the <FONT STYLE="white-space:nowrap">mid-dose</FONT> cohort by the end of 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Next-generation gene therapy solutions for Alzheimer&#146;s disease: LX1020 and LX1021
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that positive clinical data from our ongoing Phase 1/2 trial of LX1001 has the potential to validate our novel approach to treating the
<I>APOE4</I> <FONT STYLE="white-space:nowrap">sub-population</FONT> and can help inform the development plan of our next generation candidates, LX1020 and LX1021. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LX1020: We are designing LX1020 to treat <I>APOE4</I> homozygous patients by delivering both the protective <I>APOE2</I> allele and miRNA to suppress
<I>APOE4</I>. We believe delivery of <I>APOE2</I> with concurrent suppression of <I>APOE4</I> will achieve a higher degree of conversion to the <I>APOE4/E2</I> heterozygous profile, which should lead to greater therapeutic effect. We plan to
initiate <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for LX1020 by the end of 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LX1020 is designed to add
</B><B><I>APOE2</I></B><B> gene while suppressing </B><B><I>APOE4</I></B><B> </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g42p95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LX1021</B>: We are designing LX1021 to treat <I>APOE4</I> homozygous patients by adding a Christchurch mutation-modified
<I>APOE2</I> to the CNS. The Christchurch mutation has been recognized to protect individuals against Alzheimer&#146;s disease even in the presence of significant amyloid pathology. The mechanism of this protection may relate to the fact that APOE,
in the presence of the Christchurch mutation, binds poorly to heparan sulfate proteoglycans, molecules found on the surface of neurons, which may inhibit the spread of tau between cells. We believe this approach has the potential to enhance the
protective effect of APOE2 in homozygous <I>APOE4</I>-associated Alzheimer&#146;s disease. We plan to initiate IND enabling studies for LX1021 by the end of 2024. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LX2021 is designed to add a christchurch mutation-modified </B><B><I>APOE2</I></B><B> gene </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to the CNS of </B><B><I>APOE4</I></B><B> homozygous patients </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g43r46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><I></I><B><I>LX1004 for the treatment of CLN2 Batten disease </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing LX1004, an AAVrh10-based gene therapy candidate designed to deliver a fully functional <I>CLN2</I> gene to the CNS via intracisternal
injection in order to restore TPP1, the secreted protein that is deficient in CLN2 Batten disease. The FDA has granted Rare Pediatric Disease designation and Orphan Drug designation to LX1004 for the treatment of CLN2 disease. In a Phase 1/2 trial
that was conducted by Weill Cornell Medicine under an IND that was subsequently transferred to us, LX1004 demonstrated an increase in TPP1 levels leading to a slower decline of motor and language function in treated patients compared to natural
history controls, at 18 months post treatment. We intend to initiate a pivotal Phase 2/3 trial of LX1004 in the first half of 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Batten
disease </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid
lipofuscinoses. In each form of Batten disease a defect in a specific gene interferes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with a particular neuronal function. Each defective gene is given a different number designation (ranging from <I>CLN1</I>-<I>8</I> and <I><FONT STYLE="white-space:nowrap">CLN10-14</FONT></I> for
the 13 known forms of Batten disease). The different designations have generally similar clinical features but vary in severity and the age of onset. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CLN2
Batten disease is caused by a defect in the <I>CLN2</I> gene found on chromosome 11 and affects up to approximately 900 patients in the United States and European Union. The <I>CLN2</I> gene produces TPP1, which breaks down proteins in the lysosomes
of neurons. In the case of CLN2 Batten disease, there is enzyme deficiency, resulting in neuronal degeneration from <FONT STYLE="white-space:nowrap">build-up</FONT> of <FONT STYLE="white-space:nowrap">non-degraded</FONT> proteins. Developmental
delay begins around the end of age two and children progressively lose motor and cognitive function, become unable to communicate and develop seizures and blindness. Most children with CLN2 Batten disease die between the ages of six and twelve. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no cure for the disorder. Cerliponase alfa (Brineura), an enzyme replacement therapy, is the only FDA approved treatment for CLN2 Batten disease.
Brineura requires chronic twice monthly infusions directly into the CSF via intraventricular injections. Treatment also requires that an intraventricular access device be maintained chronically, and which has been associated with infections and
other complications. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview of CLN2 Batten disease mechanism </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g287237g43z47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our solution: LX1004 </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing LX1004, an AAVrh10-based gene therapy candidate designed to deliver a fully-functional <I>CLN2</I> gene, to restore TPP1 expression in
neuronal lysosomes, in order to have a neuroprotective effect in CLN2 Batten disease, as illustrated below. TPP1 is a secreted protein and capable of cross-correcting neighboring cells with uptake mediated via the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mannose-6-receptor</FONT></FONT> pathway. We believe LX1004 has the potential to address the underlying cause of the disorder. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LX1004 is designed to deliver functional TPP1 and restored TPP1 expression in lysosomes </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g287237g44x77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical study </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
preclinical study conducted by us demonstrated that administration of LX1004 conferred a statistically significant survival benefit in <I>CLN2-</I>knockout mice, as shown in the graphic below. The conventional method for measuring the statistical
significance of a result is known as the &#147;p-value,&#148; which represents the probability that random chance caused the result (e.g., a p-value &#061; 0.001 means that there is a 0.1% or less probability that the difference between the control
group and the treatment group is purely due to random chance). Generally, a p-value less than 0.05 is considered statistically significant, and may be supportive of a finding of efficacy by regulatory authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Median ages of survival of the mice that were treated at ages seven weeks, three weeks, and two days were
168 days, 277 days, and 376 days, respectively, compared to a median age of survival of 121 days for untreated <I>CLN2-</I>knockout mice. Kaplan-Meier analysis, which is a statistical method to analyze survival data, revealed a statistically
significant survival advantage for the mice treated at three weeks of age over the mice treated at seven weeks of age (p&lt;0.001), and the survival of the mice treated at two days of age was significantly longer than both the mice treated at seven
weeks of age (p&lt;0.0001) and the mice treated at three weeks of age (p&lt;0.01). This study demonstrated that the mice treated with LX1004 at the earliest age showed the most improved median age of survival. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Preclinical study shows survival benefit of LX1004 in treated </B><I>CLN2-</I><B>knockout Mice </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g45b28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1/2 clinical trial results </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a Phase 1/2 clinical trial conducted by Weill Cornell Medicine, LX1004 was administered intraparenchymally to the CNS of eight children with CLN2 Batten
disease. Seven children had follow-up visits during the 18-month duration of the study, and of these, five children had CSF samples pre- and post-treatment. All five of those patients had increased TPP1 levels in their CSF up to 12 months,
indicating substantial expression of the protein and durability of the therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LX1004 demonstrated increases in TPP1 expression levels up to 12 months </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g06e17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, as demonstrated in the below graphic, the treated patients had a statistically significant reduction in the
rate of disease progression compared to natural history controls. The trial used the established CLN2 Clinical Rating Scale to assess efficacy. This scale was developed to assess the loss of function in CLN2 Batten disease patients that occurs over
the course of the disease. It is a four-part assessment of language, motor function, visual function, and seizures. The rate of decline in the motor &#043; language subscores of the treatment group was compared to two historical control groups of
untreated patients: the Weill Cornell Medicine natural history cohort and the European DEM Child natural history cohort. The annual rate of decline was similar in the two control groups. In contrast, the rate of decline in the treated patients was
slower than that in both control groups. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LX1004 demonstrated a slower rate of decline relative to natural history controls </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g46z92.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, the data demonstrated that LX1004 was well tolerated, with minimal serious adverse events, and
findings on brain MRI (hyperintensities at the site of the catheter tip, where the highest concentration of vector occurred) that were not considered clinically meaningful. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Future development </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on results of the Phase 1/2
clinical trial and preclinical studies, we believe that improved dosing and biodistribution could result in even greater clinical benefit in slowing or halting disease progression, in the Phase 2/3 trial compared to the Phase 1/2 trial. We plan to
pursue approaches that could improve the outcome of treatment in the potentially pivotal trial that we are currently designing. We expect to change the route of administration from intraparenchymal to intracisternal delivery, which has demonstrated
better biodistribution of transgenes and will allow for significantly higher doses. To help guide future development plans, we are conducting additional NHP studies of LX1004 administered via intracisternal injection to assess the biodistribution of
our vector and its safety profile. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate receiving feedback from the FDA on the design of our potentially pivotal Phase 2/3 clinical trial in the
second half of 2022, and we intend to initiate the clinical trial in the first half of 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on
intellectual property. This is also true for the development and commercialization of treatments for cardiovascular and neurodegenerative diseases such as Friedreich&#146;s ataxia, Alzheimer&#146;s disease, CLN2 Batten disease and broadly across
gene therapies. While we believe that our management and scientific team&#146;s deep expertise in gene therapy provides us with competitive advantages, we face competition from several sources, including large and small biopharmaceutical companies,
government agencies and academic and private research institutions. Not only must we compete with other companies that are focused on gene therapy technology, but any product candidates that we successfully develop and commercialize will compete
with existing therapies, to the extent applicable, and new therapies that may become available in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drug development, particularly in the gene
therapy field, is highly competitive and subject to rapid and significant technological advancements. A significant unmet medical need exists in each of the indications that we are targeting, and it is likely that additional drugs will become
available in the future for the treatment of these diseases. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are aware that our competitors are developing product candidates for the treatment of
diseases that our product candidates will target. With respect to LX2006, we are aware of preclinical gene therapy programs in development at Novartis, PTC Therapeutics, Inc., Aavanti Bio, Inc., Lacerta Therapeutics, Inc. and those being developed
in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. and between Takeda Pharmaceutical Company Limited and StrideBio, Inc. Among other treatment modalities for Friedreich&#146;s ataxia, we are aware that Larimar
Therapeutics, Inc. is developing a clinical stage product candidate, <FONT STYLE="white-space:nowrap">CTI-1601,</FONT> and that Reata Pharmaceuticals, Inc. is developing late-clinical-stage candidate omaveloxolone. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to our portfolio of gene therapy programs for the treatment of homozygous <I>APOE4</I>-associated Alzheimer&#146;s disease, we are aware that
uniQure, N.V. is pursuing <FONT STYLE="white-space:nowrap">AMT-240,</FONT> a preclinical gene therapy candidate for autosomal dominant Alzheimer&#146;s disease intended to silence the toxic variant while expressing the protective variant and
Novartis has a gene therapy candidate for Alzheimer&#146;s disease which is in the early preclinical stages of development. Many large and small pharmaceutical companies and academic institutions are developing potential treatments for the condition
given the significant unmet need and the large population suffering from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Alzheimer&#146;s disease. There are multiple FDA-approved treatments for Alzheimer&#146;s disease, including donepezil (Aricept), memantine (Namenda), and aducanumab (Aduhelm), which was recently
approved under accelerated approval and will require confirmatory data to verify clinical benefit. Finally, we are aware that Voyager Therapeutics, Inc. and Taysha Gene Therapies, Inc. are pursuing Alzheimer&#146;s disease treatments and have
early-stage discovery efforts ongoing based on vectorized antibodies and <FONT STYLE="white-space:nowrap">tau-specific</FONT> miRNA shuttles, respectively. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to LX1004, the FDA approved BioMarin Pharmaceutical, Inc.&#146;s treatment for CLN2 Batten disease, cerliponase alfa (Brineura) in 2017. Brineura
is an enzyme replacement therapy which requires chronic twice monthly infusions directly into the CSF via intraventricular injections. In addition to Brineura, REGENXBIO Inc. is developing two preclinical gene therapy candidates to treat the CNS and
ocular manifestations of CLN2 Batten disease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to LX2020, Tenaya Therapeutics Inc. is developing a preclinical
<FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy candidate designed to deliver a functional <I>PKP2</I> gene to patients with ARVC. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of
our existing or potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, as well as in obtaining regulatory
approvals of those product candidates in the United States and in foreign countries. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated
among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will face competition from other drugs or from other <FONT STYLE="white-space:nowrap">non-drug</FONT> products and treatments currently approved or that
will be approved in the future in the cardiovascular and neurology field, including for the treatment of diseases and diseases in the therapeutic categories we intend to target. Therefore, our ability to compete successfully will depend largely on
our ability to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop, manufacture and commercialize drugs that are superior to other products in the market;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrate through our clinical trials that our product candidates are differentiated from existing and future
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract qualified scientific, product development and commercial personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain patent or other proprietary protection for our medicines; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain required regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain coverage and adequate reimbursement from, and negotiate competitive pricing with, third-party payors; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new
medicines. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The availability of our competitors&#146; products could limit the demand, and the price we are able to charge, for any
product candidate we develop. The inability to compete with existing or subsequently introduced drugs would have an adverse impact on our business, financial condition and prospects. In addition, the reimbursement structure of currently approved or
future gene therapies by other companies could impact the anticipated reimbursement structure of our gene therapies, if <I>approved</I>, and our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel
compounds or to <FONT STYLE="white-space:nowrap">in-license</FONT> novel compounds that could make our product candidates less competitive. In addition, any new product that competes <I>with</I> an approved product must demonstrate compelling
advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving
regulatory and marketing approval for, or commercializing, drugs before we do, which would have an adverse impact on our business and results of operations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have utilized an adherent
approach to manufacture vector for <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical use. However, in October 2021, we engaged with a CDMO for process development and cGMP manufacture of our gene therapy candidates using a suspension
baculovirus/Sf9 expression system. We have partnered with Virovek, Inc. for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Bac-to-AAV&#148;</FONT></FONT> system, Millipore Corporation for its RVN Sf9 cell line, and
Fujifilm Diosynth Biotechnologies U.S.A., Inc., for viral vector process development and cGMP manufacture of our viral vectors. Our new manufacturing platform infects Sf9 cells at high densities in suspension cell culture with both an AAVrh10 and
baculovirus containing the transgene. The output is coupled with a chromatography-based purification process, allowing for efficient AAV purification. We expect that cGMP manufacture of our product candidates using this platform will begin in the
second half of this year. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our approach, we expect that our existing partnerships can supply material for all of our currently ongoing and planned
clinical trials as well as potential commercial production of some of our programs. We will own the intellectual property created by our manufacturing process development activities or have the ability to license it, and we will maintain the option
to transfer our manufacturing process to other CDMOs in the future and/or to our own potential manufacturing facility to ensure ongoing redundancy and reliability of production. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We actively seek to protect our
proprietary technology, inventions, and other intellectual property that is commercially important to the development of our business by a variety of means, for example seeking, maintaining, and defending patent rights, whether developed internally
or licensed from third parties. We also may rely on trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our proprietary technology platform, on continuing technological innovation and on
<FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen and maintain the strength of our position in the field of gene therapy that may be important for the development of our business. We also intend to seek patent
protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets, and that may be used to manufacture and develop novel gene therapy products. We are a party to license agreements that give
us rights to use specific technologies in our gene therapy products and in manufacturing our products. Additional regulatory protection may also be afforded through data exclusivity, market exclusivity and patent term extensions where available.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February&nbsp;1, 2022, we <FONT STYLE="white-space:nowrap">in-license</FONT> two U.S. patents, five pending U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, two pending U.S. provisional applications, three pending PCT applications, two foreign patents and 16 pending foreign applications. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We <FONT STYLE="white-space:nowrap">in-license</FONT> from Cornell University and Adverum Biotechnologies, Inc. two U.S. patents, two pending U.S. <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications, one pending U.S. provisional application, two foreign patents and 10 pending foreign applications that relate to our LX2006 cardiac FA program. The patents we <FONT
STYLE="white-space:nowrap">in-license</FONT> outside of the United States are granted in Mexico and New Zealand. The patent applications we <FONT STYLE="white-space:nowrap">in-license</FONT> outside of the United States are pending in Australia,
Brazil, China, Eurasia, Europe, Israel, India, Mexico and South Africa. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Not accounting for any patent term adjustment, regulatory extension or terminal disclaimers, and assuming that all annuity and/or maintenance fees are paid timely, these patents, and if granted
these patent applications, will expire in 2033. These patents and pending patent applications disclose and/or contain <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> claims to an AAV vector
encoding <I>FXN</I>, or a fragment thereof, and disclose and/or contain claims to methods of producing and methods of treatment using the AAV <I>FXN</I> vector. Cornell University co-owns these patents and patent applications with Institut National
de la Sant&eacute; et de la Recherche M&eacute;dicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universit&eacute; de Strasbourg, Universit&eacute; Paris-Saclay and Assistance
<FONT STYLE="white-space:nowrap">Publique-H&ocirc;pitaux</FONT> de Paris (APHP). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We <FONT STYLE="white-space:nowrap">in-license</FONT> from Cornell
University one pending PCT application that relates to our LX1020 Alzheimer&#146;s <FONT STYLE="white-space:nowrap">APOE2&#043;/E4-</FONT> program. Not accounting for any patent term adjustment, regulatory extension or terminal disclaimers, and
assuming that all annuity and/or maintenance fees are paid timely, if granted, patent applications claiming the priority to this PCT application, will expire in 2040. This pending PCT application discloses and/or contains <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> claims to a vector encoding human APOE2 protein and encoding one or more RNAi nucleic acid sequences for inhibition of APOE4 mRNA, and discloses and/or
contains claims to methods of producing and methods of treatment using the APOE2&#043;/APOE4- vector. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
<FONT STYLE="white-space:nowrap">in-license</FONT> from Cornell University one pending PCT application that relates to our LX1021 Alzheimer&#146;s Christchurch program. Not accounting for any patent term adjustment, regulatory extension or terminal
disclaimers, and assuming that all annuity and/or maintenance fees are paid timely, if granted, patent applications claiming the priority to this PCT application, will expire in 2040. This pending PCT application discloses and/or contains <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> claims to a vector encoding a mutated human apolipoprotein E protein, and discloses and/or contains claims to methods of producing and methods of
treatment using the mutated human apolipoprotein E vector. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>License agreements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>First license agreement with Cornell University </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May
2020, we entered into a license agreement with Cornell University, or the Cornell First License Agreement, pursuant to which we obtained a sublicensable, worldwide license under certain patents to make, use, and sell products that are covered by a
valid claim of a licensed patent, is based on the transferred IND from Cornell University, uses any licensed materials, or is produced using a licensed method, and to practice certain licensed technology, in all cases, for all human and <FONT
STYLE="white-space:nowrap">non-human</FONT> prophylactic and therapeutic uses. The technology under the license includes portfolios for APOE, Alzheimer&#146;s disease, and <FONT STYLE="white-space:nowrap">Anti-Tau,</FONT> although our license is not
restricted by such indications. The license is exclusive with respect to certain patents and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to other patents. Additionally, under the First License Agreement, Cornell University
assigned to us an IND for the use of AAVrh10.hAPOE vector to treat <I>APOE4</I> homozygous patients who are at risk or have Alzheimer&#146;s disease. Cornell University reserves the rights to practice the patents and technology for <FONT
STYLE="white-space:nowrap">non-commercial</FONT> educational and <FONT STYLE="white-space:nowrap">non-commercial</FONT> research purposes and to publish and disseminate information about inventions included in the licensed technology and licensed
patents. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are obligated to diligently proceed with the development, manufacture, and sale of licensed products, to raise certain amounts within
specified timeframes, to achieve certain development milestones within specified timeframes, to meet agreed minimum-spend requirements, and to meet other diligence obligations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Cornell First License Agreement, we paid Cornell University a license issue and assignment fee in the high six digits. We are obligated to pay
Cornell University an annual license maintenance fee ranging from the low four digits to the mid five digits, increasing annually until such time that we are commercially selling a Product. We are also obligated to pay milestone payments up to the
high seven digits for each portfolio upon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
achievement of specified development and regulatory milestones by a product in such portfolio. We are obligated to pay Cornell University a flat royalty in the
<FONT STYLE="white-space:nowrap">mid-single-digits</FONT> based on net sales of a licensed product in a country, which royalty rate increases by one percent if the licensed product is an orphan drug, subject to a reduction upon the expiration of
valid claims in licensed patents and certain reductions for third-party licenses. In addition, in certain specific instances where sales are made by a sublicensee, the royalty rate increases by a small amount. If the royalties are below certain
agreed amounts, we are required to pay Cornell University minimum annual royalties ranging from low six digits to low seven digits. The royalty term continues for each licensed product on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis beginning on the first commercial sale of such licensed product and ending on the latest of (a)&nbsp;expiration of the last valid claim in the licensed patent, (b)&nbsp;the expiration
of regulatory exclusivity, and (c)&nbsp;the launch of a generic equivalent in such country. We are also obligated to pay Cornell University a percentage of sublicensing fees ranging from low double digits to
<FONT STYLE="white-space:nowrap">mid-double</FONT> digits, decreasing over time based on when we grant a sublicense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may terminate the Cornell First License Agreement or any portfolio thereunder at any time upon advance
written notice to Cornell University. Cornell University may terminate the Cornell First License Agreement if we commit a material breach and fail to cure such breach within a specified cure period after written notice or if we challenge the
validity of a licensed patent. Upon expiration of the royalty term of a given licensed product in a country, the license becomes <FONT STYLE="white-space:nowrap">non-exclusive</FONT> and royalty-free. Upon termination of the Cornell First License
Agreement, all licenses and rights granted by either party will terminate, although we will have a period of time to sell off any remaining licensed product. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Second license agreement with Cornell University </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May
2020, we entered into a second license agreement with Cornell University, or the Cornell Second License Agreement, pursuant to which we obtained a sublicensable, worldwide license under certain patents to make, use, and sell products that are
covered by a valid claim of a licensed patent, is based on the transferred IND from Cornell University, uses any licensed materials, or is produced using a licensed method, and to practice certain licensed technology, in all cases, for all human and
<FONT STYLE="white-space:nowrap">non-human</FONT> prophylactic and therapeutic uses. The technology under the license includes portfolios for CLN2 Batten Disease and FA, although our license is not restricted by such indications. The license is
exclusive with respect to certain patents and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to other patents. Additionally, under the Second License Agreement, Cornell University assigned to us an IND for the use of
AAVrh.10CUhCLN2 to treat children with infantile neuronal ceroid lipofuscinosis (also called CLN2 Batten disease). Cornell University reserves the rights to practice the patents and technology for
<FONT STYLE="white-space:nowrap">non-commercial</FONT> educational and <FONT STYLE="white-space:nowrap">non-commercial</FONT> research purposes and to publish and disseminate information about inventions included in the licensed technology and
licensed patents. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are obligated to diligently proceed with the development, manufacture, and sale of licensed products, to raise certain amounts within
specified timeframes, to achieve certain development milestones within specified timeframes, to meet agreed minimum-spend requirements, and to meet other diligence obligations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Cornell Second License Agreement, we paid Cornell University a license issue and assignment fee in the high six digits. We are obligated to pay
Cornell University an annual license maintenance fee ranging from the low four digits to the mid five digits, increasing annually until such time that we are commercially selling a licensed product. We are also obligated to pay milestone payments up
to mid to low seven digits in two portfolios and in the mid to high six digits for a third portfolio upon the achievement of specified development and regulatory milestones by a product in such portfolio. We are obligated to pay Cornell University a
flat royalty in the <FONT STYLE="white-space:nowrap">mid-single-digits</FONT> based net sales of a licensed product in a country, which royalty rate increases by one percent if the licensed product is an orphan drug, subject to a reduction upon the
expiration of valid claims in licensed patents and certain reductions for third-party licenses. In addition, in certain specific instances where sales are made by a sublicensee, the royalty rate increases by a small amount. If the royalties are
below certain agreed amounts, we are required to pay Cornell University minimum annual royalties ranging from low six digits to low seven digits. The royalty term continues for each licensed product on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis beginning on the first commercial sale of such licensed product and ending on the latest of (a)&nbsp;expiration of the last valid claim in the licensed patent, (b)&nbsp;the expiration
of regulatory exclusivity, and (c)&nbsp;the launch of a generic equivalent in such country. We are also obligated to pay Cornell University a percentage of sublicensing fees ranging from low double digits to
<FONT STYLE="white-space:nowrap">mid-double</FONT> digits, decreasing over time based on when we grant a sublicense. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may terminate the Cornell Second
License Agreement or any portfolio thereunder at any time upon advance written notice to Cornell University. Cornell University may terminate the Cornell Second License Agreement if we commit a material breach and fail to cure such breach within a
specified cure period after written notice or if we challenge the validity of a licensed patent. Upon expiration of the royalty term of a given licensed product in a country, the license becomes <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
and royalty-free. Upon termination of the Cornell Second License Agreement, all licenses and rights granted by either party will terminate, although we will have a period of time to sell of any remaining licensed product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License agreement with Adverum </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2021, we entered into a license agreement with Adverum Biotechnologies, Inc., or the Adverum Agreement, pursuant to which we obtained an exclusive,
sublicensable, worldwide license under certain patents, <FONT STYLE="white-space:nowrap">know-how,</FONT> and other intellectual property relating to viral vector technology for gene therapy applications for the treatment of FA cardiomyopathy. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are responsible for the development, manufacture, and commercialization of gene therapy products that consist of a specific nucleic acid sequence that is
delivered by a specific gene therapy, or the Products. We are obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize the Product. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Adverum Agreement, we paid Adverum a $7.5&nbsp;million upfront payment. We are obligated to pay Adverum up to $17.5&nbsp;million upon the achievement
of specified development and regulatory milestones and up to $49&nbsp;million in commercialization and sales milestones for the Products. We are obligated to pay Adverum tiered royalties ranging from a rate in the high single-digits to 10% based on
annual aggregate worldwide net sales of Products, subject to reductions upon the expiration of valid claims in licensed patents and third-party licenses. The royalty term continues for each Product on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis beginning on the first commercial sale of such Product and ending on the latest of (a)&nbsp;expiration of the last valid claim in the licensed patent that covers the manufacture, use,
or sale of the Product in such country, (b)&nbsp;the expiration of regulatory exclusivity, and (c)&nbsp;ten years after the first commercial sale of such Product in such country. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Adverum Agreement will expire, unless earlier terminated, on the expiration of the last royalty term for a Product in a particular country. We have the
right to terminate the Adverum Agreement at any time upon advance written notice to Adverum. In addition, subject to certain conditions, either we or Adverum may terminate the Adverum Agreement upon the insolvency of the other or if the other party
commits a material breach of the agreement and fails to cure such breach within a specified cure period after written notice is provided. Additionally, Adverum may terminate the Adverum Agreement if we challenge the validity of any licensed patents.
Upon expiration of the Adverum Agreement, the license becomes royalty-free, irrevocable and perpetual. Upon termination of the Adverum Agreement, all licenses and rights granted by either party will terminate. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Government regulation </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government authorities in the
United States at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling,
packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics, including gene therapies, such as those we are developing. Generally, before a new
biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved, authorized, or cleared by the applicable
regulatory authority. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct
studies or seek approval or licensure of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. biologics regulation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, biological products are subject to regulation under the FDCA and the Public Health Service Act, or PHSA, and their implementing
regulations and other federal, state, local and foreign statutes and regulations. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or following approval may subject
an applicant to administrative actions or judicial sanctions. These actions and sanctions could include, among other actions, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold,
untitled or warning letters, voluntary or mandatory product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement
and civil or criminal fines or penalties. Our product candidates must be approved by the FDA through the Biologics License Application, or BLA, the process which is required by the FDA before biological product candidates may be marketed in the
United States and generally involves the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of extensive preclinical laboratory tests and animal studies performed in accordance with applicable
regulations, including the GLP regulations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an IRB or ethics committee at each clinical site before the trial is commenced;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations,
GCPs and other clinical trial-related regulations to establish the safety, purity and potency of the proposed biological product candidate for its intended purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of user fees for FDA review of the BLA; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-license</FONT> inspection of the
manufacturing facility or facilities at which the proposed product will be produced to assess compliance with cGMPs and to assure that the facilities, methods and controls are adequate to ensure and preserve the biological product&#146;s identity,
strength, quality and purity, and of selected clinical investigation sites to assess compliance with the GCPs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, if applicable; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval, or licensure, of a BLA to permit commercial marketing of the product for particular
indications for use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical and clinical development </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to beginning the first clinical trial with a product candidate, the product candidate must undergo rigorous preclinical testing. Preclinical studies
include laboratory evaluation of product chemistry and formulation, as well as <I>in vitro</I> and animal studies to assess safety and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to
federal and state regulations and requirements, including GLP regulations for safety/toxicology studies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An IND sponsor must submit the results of the
preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND to the FDA. An IND is a request for authorization
from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and <I>in vitro </I>studies assessing the toxicology,
pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become
effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> period, raises concerns or questions about the
proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not
result in FDA authorization to begin a clinical trial. Additionally, the review of information in an IND submission may prompt FDA to, among other things, scrutinize existing INDs and could generate requests for information or clinical holds on
other product candidates or programs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of
qualified investigators, generally physicians not employed by or under the sponsor&#146;s control, in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any
clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used in monitoring safety and the
effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for
each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed to ensure that the
risks to individuals participating in the clinical trial are minimized and are reasonable in relation to anticipated benefits. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the
submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or synthetic nucleic acid molecules are subject to oversight of IBCs as set forth in the National
Institutes for Health, or NIH, Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, or NIH Guidelines. Under the NIH Guidelines, recombinant and synthetic nucleic acids are defined as: (i)&nbsp;molecules that are
constructed by joining nucleic acid molecules and that can replicate in a living cell (i.e.,&nbsp;recombinant nucleic acids); (ii)&nbsp;nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are
chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules (i.e., synthetic nucleic acids); or (iii)&nbsp;molecules that result from the replication of those described in (i) or (ii). Specifically, under the
NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution.
The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the
research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily
follow them. A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor
may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the foreign data are applicable to the United States population and
medical practice, the trial was performed by clinical investigators of recognized competence, the trial was conducted in accordance with GCP requirements, and the data may be considered valid without the need for an on-site inspection by the FDA or
the FDA is able to validate the data through an onsite inspection if deemed necessary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of BLA approval of a product candidate, human clinical trials are typically conducted in three
sequential phases that may overlap or be combined: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 1</I>. For gene therapies in general, the investigational product is initially introduced into patients
with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if
possible, to gain early evidence on effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 2</I>. The investigational product is administered to a limited patient population to evaluate the
preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 3</I>. The investigational product is administered to an expanded patient population to further evaluate
dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit
ratio of the investigational product and to provide an adequate basis for product approval. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When these phases overlap or are combined,
the trials may be referred to as Phase 1/2 or Phase 2/3. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical
trials after a product is approved to gain more information about the product. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may
complete additional animal studies and develop additional information about the characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The
manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally,
appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical
study investigators. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious, unexpected and suspected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that
suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15
calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s
initial receipt of the information. The FDA or the sponsor may suspend a clinical study at any time on various grounds, including a finding that the research patients or patients are being exposed to an unacceptable health risk. Similarly, an IRB
can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#146;s requirements or if the biological product candidate has been associated with unexpected serious
harm to patients. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move
forward at designated checkpoints based on access to certain data from the study and may recommend halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of
efficacy. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products,
including biologics, are required to register and disclose certain clinical trial information, which is publicly available at <U>www.clinicaltrials.gov</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>BLA submission and review </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
preclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States.
The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s
chemistry, manufacturing, controls and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. No user fees are assessed on BLAs for
products designated as orphan drugs, unless the product also includes a non-orphan indication. The FDA reviews all submitted BLAs before it accepts them for filing, and may request additional information rather than accepting the BLA for filing. The
FDA has sixty days from the applicant&#146;s submission of a BLA to either issue a refusal to file letter or accept the BLA for filing, indicating that it is sufficiently complete to permit substantive review. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a BLA has been accepted for filing, the FDA&#146;s goal is to review standard applications within ten months after it accepts the application for filing,
or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information
or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent for its intended use, and whether the facility in which it is manufactured, processed, packed or held meets standards designed to
ensure and preserve the product&#146;s identity, safety, strength, quality, potency and purity. The FDA may convene an advisory committee, typically a panel that includes clinicians and other experts, to provide clinical insight on applications for
novel products or products which present difficult questions of safety or efficacy. The advisory committee will provide a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by the
recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not
approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before
approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the
deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its
drug substance will be manufactured, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete
Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter will usually describe all of the deficiencies that the FDA has identified in the
BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots
and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification,
which may include the potential requirement for additional preclinical studies or clinical trials or additional manufacturing activities. If a Complete Response Letter is issued, the applicant may either resubmit
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. The FDA may delay or refuse approval of a BLA if
applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for
which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or
potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such
as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once
approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require
one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing
studies. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited development and review programs </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or
facilitate the process for reviewing new products that meet certain criteria. Specifically, product candidates are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate
the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a fast track designated
product candidate has opportunities for frequent interactions with the FDA review team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review. A fast track designated product candidate may
also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA
agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sponsor can request the FDA to designate the product candidate for fast track status any time before receiving BLA approval, but ideally no later than the
pre-BLA meeting. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for&nbsp;breakthrough
therapy designation to expedite its development and review. A product candidate may receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs
or biologics, may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast
track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the 21st Century Cures Act, Congress amended the FDCA to facilitate an efficient development program for, and expedite review of regenerative
medicine therapies, which include cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. Gene therapies, including genetically modified cells that lead
to a durable modification of cells or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tissues may meet the definition of a Regenerative Medicine Therapy. A product candidate may be eligible for regenerative medicine therapy, or RMAT, designation if it meets the following criteria:
(1)&nbsp;it is a regenerative medicine therapy; (2)&nbsp;it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3)&nbsp;preliminary clinical evidence indicates that it has the potential to address
unmet medical needs for such a disease or condition. A sponsor may request that the FDA designate a product candidate as a RMAT concurrently with or at any time after submission of an IND. A BLA for a product candidate that has received RMAT
designation may be eligible for priority review or accelerated approval through (1)&nbsp;surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2)&nbsp;reliance upon data obtained from a meaningful number of
sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A product candidate with RMAT designation that is granted
accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health
records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review
and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it is designed to treat a serious or life threatening disease or condition and, if approved, would provide a significant improvement
in safety and effectiveness compared to available therapies. For original BLAs, priority review designation means the FDA&#146;s goal is to take action on the marketing application within six months of the
<FONT STYLE="white-space:nowrap">60-day</FONT> filing date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, a product candidate may be eligible for accelerated approval if it is designed
to treat a serious or life-threatening disease or condition and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity
or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative
treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or
mortality or other clinical benefit. FDA may withdraw approval of a product or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, for
products being considered for accelerated approval, the FDA generally requires, unless otherwise informed by the agency, <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials intended for dissemination or publication within
120 days of marketing approval, which could adversely impact the timing of the commercial launch of the product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fast track designation, breakthrough
therapy designation, RMAT designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may
later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan drug designation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug
Act, the FDA may grant orphan designation to a product candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more than
individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of disease or condition will be recovered from sales in the United States for that product candidate. Orphan drug designation must be requested before submitting a BLA. After the FDA grants
orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or
approval process. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has
such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same product for the same indication for seven years,
except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or if the holder of the orphan
drug exclusivity cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the product was designated. Orphan drug exclusivity does not prevent the FDA from
approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the
BLA application fee. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for
which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure
sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rare pediatric disease designation and
priority review vouchers </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the FDCA, as amended, the FDA incentivizes the development of product candidates that meet the definition of a
&#147;rare pediatric disease,&#148; defined to mean a serious or life-threatening disease in which the serious of life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease affects fewer than 200,000
individuals in the United States or affects 200,000 or more in the United States and for which there is no reasonable expectation that the cost of developing and making in the United States a drug for such disease or condition will be received from
sales in the United States of such drug. The sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug or biologic application after the date of
approval of the rare pediatric disease drug product. A sponsor may request rare pediatric disease designation from the FDA prior to the submission of its BLA. A rare pediatric disease designation does not guarantee that a sponsor will receive a PRV
upon approval of its BLA. Moreover, a sponsor who chooses not to submit a rare pediatric disease designation request may nonetheless receive a PRV upon approval of their marketing application if they request such a voucher in their original
marketing application and meet all of the eligibility criteria. If a PRV is received, it may be sold or transferred an unlimited number of times. Congress has extended the PRV program until September&nbsp;30, 2024, with the potential for PRVs to be
granted until September&nbsp;30, 2026. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pediatric information and pediatric exclusivity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act, or PREA, certain BLAs and certain supplements to a BLA must contain data to assess the safety and efficacy of the
product for the claimed indications in all relevant pediatric subpopulations and tosupport dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of
pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act, or FDASIA, amended the FDCA to require that a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration
submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of
the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a
deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to
an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. A biological product can also
obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods. This six-month exclusivity, which runs from the end of other exclusivity protection, may be granted based
on the voluntary completion of a pediatric study in accordance with an FDA-issued &#147;Written Request&#148; for such a study. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-approval
requirements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the
FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. As part of the manufacturing process,
the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official lot release. If the product is
subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s
tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory
standards on the safety, purity, potency and effectiveness of biologics. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are
continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and
certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers.
Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from
cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and
tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, manufacturers must continue to expend
time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA
may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of
unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical
studies to assess new safety risks; or imposition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning or untitled letters or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of existing product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal of the FDA to permit the import or export of products;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications
containing warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and
efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA
approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things,
adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those
tested by us and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across medical specialties. Physicians may believe that such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment
for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#146;s communications on the subject of
<FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and reference product exclusivity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act (BPCIA), which created an abbreviated approval pathway for biologics that
are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in
Europe. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biosimilarity, which requires that
there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical study or studies.
Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are
administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use
of the reference biologic. Complexities associated with the larger, and often more complex, structures of biologics, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated
approval pathway that are still being worked out by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years
following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed.
During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that
applicant&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as
interchangeable products. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the <FONT
STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact
and implementation of the BPCIA is subject to significant uncertainty. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign regulation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and
jurisdictions regarding quality, safety, and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need
to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to
the United States apply similarly in the context of the European Union, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to
obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay
in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other healthcare laws and
compliance requirements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by
authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the U.S. federal Anti-Kickback Statute, the civil False Claims Act, federal Health Insurance Portability and
Accountability Act of 1996, or HIPAA, and similar foreign, federal and state fraud and abuse, transparency and privacy laws. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. federal
Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or
recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value, including stock options. The U.S. federal Anti-Kickback Statute
has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and others on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common
activities from prosecution, but they are drawn narrowly, and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they
do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the U.S. federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a
statutory exception or regulatory safe harbor. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, a claim including items or services
resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Civil and criminal false claims laws, and civil monetary penalty laws, including the civil False Claims Act, which can be enforced through civil whistleblower
or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent. For
example, the civil False Claims Act prohibits any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or
statement material to a false or fraudulent claim to the federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. For example, pharmaceutical and other healthcare companies have
been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal civil and criminal liability for, among other things, knowingly and willfully executing a scheme to defraud any healthcare
benefit program, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or
private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services
relating to healthcare matters. Similar to the U.S. federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations,
impose certain requirements on HIPAA covered entities, which include certain healthcare providers, healthcare clearing houses and health plans, and individuals and entities that provide services on their behalf that involve individually identifiable
health information, known as business associates, relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal
penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs
associated with pursuing federal civil actions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value
made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective
January&nbsp;1, 2022, these reporting obligations were extended to payments and other transfers of value made during the previous year to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers, including physician assistants, nurse
practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also
subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services
reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third party payors, including private </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
insurers, or that apply regardless of payor, state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government, state and local laws which require pharmaceutical companies to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing
expenditures, state laws which require the reporting of information related to product pricing, state and local laws requiring the registration of pharmaceutical sales representatives, and state and foreign laws governing the privacy and security of
health information which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental
regulations that apply, we may be subject to penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or
similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> disgorgement, imprisonment, contractual damages, reputational harm,
diminished profits and the curtailment or restructuring of our operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and reimbursement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval.
Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare
organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are
made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ
significantly from payor to payor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement
rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical
support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For example, the FDA recently approved a monoclonal
antibody treatment for Alzheimer&#146;s disease, aducanumab (Aduhelm), which is the first Alzheimer&#146;s disease drug to be approved in nearly 20 years. However, on January&nbsp;11, 2022, CMS proposed to cover
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> monoclonal antibodies directed against amyloid for the treatment of Alzheimer&#146;s disease only for patients enrolled in some <FONT STYLE="white-space:nowrap">CMS-approved</FONT> randomized
controlled trials and trials supported by the National Institutes of Health. Since CMS&#146;s proposal, there has been pushback from drug manufacturers and patient advocacy groups to expand Medicare coverage of this class of drug for patients beyond
those enrolled in these trials. Thus, it is unclear whether Medicare coverage and reimbursement will be available for any of our product candidates for treatment of Alzheimer&#146;s disease, once approved. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, any of our product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any
product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations and financial condition. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the
higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the U.S. government, state legislatures and foreign governments have continued implementing
cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and
services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biologics, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a
third-party not to cover a product could reduce physician usage and patient demand for the product. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the United States, ensuring adequate coverage
and payment for any biological candidates we may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond
the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical
trial could be expensive and result in delays in our commercialization efforts. In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a
reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in
order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the
prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the
market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the
amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union.
The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may
further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade (arbitrage between <FONT
STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any of our products, if approved in those countries. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Healthcare reform </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is
significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these
efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded
healthcare programs, and increased governmental control of drug pricing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACA, which was enacted in March 2010, substantially changed the way
healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare
programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#146;
share of sales to federal healthcare programs. Since its enactment, there have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. For example, Congress has considered legislation that would repeal or repeal
and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, which started on January&nbsp;1, 2019, for not complying
with ACA&#146;s individual mandate to carry health insurance, delaying the implementation of certain <FONT STYLE="white-space:nowrap">ACA-mandated</FONT> fees, and increasing the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. On June&nbsp;17, 2021 the U.S. Supreme Court dismissed a
challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme
Court ruling, on January&nbsp;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February&nbsp;15, 2021 and
remained open until August&nbsp;15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid
demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to
judicial or Congressional challenges in the future. Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to
several types of Medicare providers. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031 unless additional action is taken by Congress. However, pursuant to
the CARES Act, these Medicare sequester reductions will be suspended from May&nbsp;1, 2020 through December&nbsp;31, 2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In addition, Congress is considering additional health
reform measures as part of the budget reconciliation process. It is also possible that additional governmental action is taken in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has
resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under
Medicare, and review the relationship between pricing and manufacturer patient programs. For example, in July 2021, the Biden administration released an executive order, &#147;Promoting Competition in the American Economy,&#148; with multiple
provisions aimed at prescription drugs. In response to President Biden&#146;s executive order, on September&nbsp;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out
a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive office is located in
New York, New York, where we lease a workspace for a small number of team members under a lease that can be terminated with 30 days&#146; notice of the annual renewal period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In January 2022, we entered into a lease for new facilities with a total of approximately 15,839 square feet of office and laboratory space that we will use for our administrative, research and
development and other activities beginning in May 2021, under a lease that currently expires in early 2029. We believe that our new facilities are sufficient to meet our current needs and that suitable additional space will be available as and when
needed. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Employees and human capital resources </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2021, we had 24 full-time employees and no part-time employees. Of our 24 full- and part-time employees, 18 are engaged in research and development activities. None of our employees are represented by labor unions or covered by
collective bargaining agreements. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our human capital resources objectives include, as
applicable, identifying, recruiting, retaining, incentivizing and integrating our employees. We believe our success depends on our ability to attract, retain, develop and motivate diverse highly skilled personnel. In particular, we depend upon the
personal efforts and abilities of the principal members of our senior management to partner effectively as a team, and to provide strategic direction, develop our business, manage our operations and maintain a cohesive and stable work environment.
We also rely on qualified managers and skilled employees, such as scientists, engineers and laboratory technicians, with technical expertise in operations, scientific knowledge, engineering skills and quality management experience in order to
operate our business successfully. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation program is designed to retain, motivate and, as needed, attract highly qualified employees.
Accordingly, we use a mix of competitive base salary, performance-based equity compensation awards and other employee benefits. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Legal proceedings
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any
material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_11"></A>Management </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Executive officers and directors </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
provides information regarding our current executive officers and directors, including their ages as of December&nbsp;31, 2021: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="50%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Position(s)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Nolan Townsend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay A. Barth, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President and Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul McCormac, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Technical Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Altschuler, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board of Directors</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mette Kirstine Agger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paula HJ Cholmondeley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bernard Davitian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reinaldo Diaz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="center">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the audit committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the compensation committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the nominating and corporate governance committee. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Executive officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>R. Nolan Townsend</I></B> has served as our Chief Executive Officer and as a member of our board of directors since January 2020. Before joining Lexeo,
Mr.&nbsp;Townsend was at Pfizer Inc., a global pharmaceutical company, from 2008 to December 2019, where he held several roles of increasing responsibility. Most recently, he served as President, Pfizer Rare Disease for the North America region. In
that role, Mr.&nbsp;Townsend was responsible for overseeing the division&#146;s overall strategy, cross functional organization and operating budget. Mr.&nbsp;Townsend received a B.A. in Economics from the University of Pennsylvania and an M.B.A.
from the Harvard Business School. Our board of directors believes Mr.&nbsp;Townsend is qualified to serve as a director because of his role as our Chief Executive Officer and his experience as an executive in the biopharmaceutical industry. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Jay A. Barth, M.D.</I></B> has served as our Executive Vice President and Chief Medical Officer since October 2020. Prior to joining Lexeo,
Dr.&nbsp;Barth served as the Chief Medical Officer of Amicus Therapeutics, Inc., a global pharmaceutical company, from March 2014 to October 2020. In that role, Dr.&nbsp;Barth led an organization focused on rare disease and gene therapy and oversaw
Phase 1 through Phase 4 development and clinical and regulatory activities leading to FDA, EMA, and global regulatory approvals. Dr.&nbsp;Barth began his biopharmaceutical career in 1998 at Eisai Medical Research, Inc., and since then held positions
of increasing responsibility in clinical development at several companies. Immediately prior to Amicus Therapeutics, Inc., Dr.&nbsp;Barth was Senior Vice President, Clinical Development, at PTC Therapeutics, Inc. Dr.&nbsp;Barth received a B.A. in
History from Columbia University and an M.D. from the University of Pennsylvania School of Medicine. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Paul McCormac, Ph.D.</I></B> has served as our
Chief Technical Officer since December 2021, prior to this he served as our Senior Vice President of Technical Operations since March 2021. Prior to joining Lexeo, Dr.&nbsp;McCormac was an Executive Director, Medicinal Sciences Category Lead for
Pfizer Rare Disease, a unit of Pfizer, Inc., a global pharmaceutical company, from October 2016 until March 2021. In that role, he managed chemistry, manufacturing, and controls, or CMC, for product development with a focus on Pfizer&#146;s gene
therapy CMC strategy. Prior to this, he served as Director/Team Leader for Pfizer&#146;s <FONT STYLE="white-space:nowrap">Bio-Manufacturing</FONT> Sciences group from November 2008 until October 2016. Dr.&nbsp;McCormac received a B.S. in Analytical
Science and a Ph.D. in Organic Chemistry from Dublin City University and completed a post-doctoral fellowship at Queen&#146;s University Belfast. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Steven Altschuler, M.D., </I></B>has served as the Chairman of our board of directors since January 2021. Dr.&nbsp;Altschuler has served as a Managing
Director, Healthcare Ventures, of Ziff Capital Partners, a private investment firm, since May 2018. He previously served as a consultant to the University of Miami Health Care System from September 2017 through December 2017, the Chief Executive
Officer of the University of Miami Health Care System and Executive Vice President for Healthcare at the University of Miami from January 2016 to September 2017, and the Chief Executive Officer of The Children&#146;s Hospital of Philadelphia, or
CHOP, from April 2000 until June 2015. Prior to assuming the role of Chief Executive Officer, Dr.&nbsp;Altschuler held several positions at CHOP and the Perelman School of Medicine at the University of Pennsylvania, including <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Physician-in-Chief/Chair</FONT></FONT> of Pediatrics and chief of the Division of Gastroenterology, Hepatology and Nutrition. Dr.&nbsp;Altschuler has served as a director of WW
International, Inc. since September 2012, as a director of Orchard Therapeutics plc since January 2020 and as a director of 89bio, Inc. since March 2020. He previously served as Chair of the board of directors of Spark Therapeutics, Inc. from March
2013 to December 2019 and as a director of Adtalem Global Education Inc. from May 2018 to May 2020. Dr.&nbsp;Altschuler received a B.A. in Mathematics and an M.D. from Case Western Reserve University. Our board of directors believes
Dr.&nbsp;Altschuler is qualified to serve on our board of directors based on his experience holding senior leadership positions within biotechnology companies and his role on public and private boards of directors, as well as his experience
investing in healthcare companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mette </I></B><B><I>Kirstine Agger</I></B><B><I> </I></B>has served as a member of our board of directors since
November 2020. Since 2009, Ms.&nbsp;Agger has served as a Managing Partner of Lundbeckfonden Ventures, a life sciences venture capital fund and, with its affiliates, a holder of more than 5% of our voting securities. Prior to joining Lundbeckfonden
Ventures, Ms.&nbsp;Agger <FONT STYLE="white-space:nowrap">co-founded</FONT> 7TM A/S, a biotech company engaged in therapeutic drug discovery and development, in 2000, and served as its Chief Executive Officer from founding to 2009. Ms.&nbsp;Agger
served on the board of Trevi Therapeutics, Inc., a public life sciences company, from July 2017 to June 2019 and Veloxis Pharmaceuticals A/S, a public pharmaceutical company from April 2010 to December 2019, and has served on the board of directors
of scPharmaceuticals Inc., a public pharmaceutical company, since March 2014 and Imara Inc., a public biopharmaceutical company, since January 2016. Ms.&nbsp;Agger received her M.Sc. in Biology from the University of Copenhagen and received her
M.B.A. from Henley Business School at the University of Reading. Our board of directors believe Ms.&nbsp;Agger is qualified to serve on our board of directors based on her experience holding senior leadership positions within biotechnology companies
and her role on public and private boards of directors, as well as her experience investing in healthcare companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Paula </I></B><B><I>HJ
Cholmondeley</I></B> has served as a member of our board of directors since November 2021. Ms.&nbsp;Cholmondeley has been the Chief Executive Officer of the Sorrel Group, a management consulting firm, since January 2004 and has been a part time
faculty member of the National Association of Corporate Directors, or NACD, a corporate governance association, since June 2008. Ms.&nbsp;Cholmondeley is a NACD Certified Director and has been elected to the NACD Directorship 100. She is a former
Chief Financial Officer and Certified Public Accountant. She has also held profit and loss roles as a Divisional President. Ms.&nbsp;Cholmondeley has served on the boards of directors of the Bank OZK, a regional bank headquartered in Little Rock,
Arkansas, since May 2016, of Terex Corporation, a manufacturing company since 2004, and of Nationwide Mutual Funds, an investment firm, since 2002. Ms.&nbsp;Cholmondeley holds an M.S. and a B.S. in Accounting from the Wharton School of the
University of Pennsylvania. We believe Ms.&nbsp;Cholmondeley is qualified to serve on our board of directors because of her financial leadership experience and her leadership on public boards of directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bernard Davitian </I></B>has served as a member of our board of directors since November 2020. Mr.&nbsp;Davitian has been a Partner at Omega Funds, a
life sciences-focused investment fund, since January 2020. Prior to that, Mr.&nbsp;Davitian served as Senior Vice President and Managing Director at Sanofi Ventures, the venture capital arm </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Sanofi S.A., or Sanofi, for seven years from June 2012 to October 2019. Previously, he served as the Deputy of the Global Head of Business Development at Sanofi for two years. Prior to Sanofi,
Mr.&nbsp;Davitian was Chief Financial Officer at Fovea Pharmaceuticals SA, a French biopharmaceutical R&amp;D company specializing in ophthalmology (which was acquired by Sanofi in 2009), Chief Executive Officer at Neurotech Pharmaceuticals, Inc., a
biotechnology company developing sight saving therapies for retinal diseases, Chief Financial Officer at Transgene SA, a biopharmaceutical company. Previously, he served in various capacities at Institut M&eacute;rieux, including that of Corporate
Chief Financial Officer. Prior to that, he was a senior auditor at Arthur Andersen LLP. Mr.&nbsp;Davitian has extensive experience in the life sciences and biotech industry, marked by a number of successful transactions involving financings, public
offerings and acquisitions. A Certified Public Accountant in France, Mr.&nbsp;Davitian holds an M.Sc. in Management (M.B.A. equivalent) from the EM Lyon Business School (France) and an A.M.P. from the Wharton School of Business at the University of
Pennsylvania. Our board of directors believes Mr.&nbsp;Davitian is qualified to serve as a director because of his experience and leadership in healthcare venture capital investing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reinaldo Diaz </I></B>has served as a member of our board of directors since February 2022. Mr.&nbsp;Diaz has served as a Venture Partner at Longitude
Capital, a healthcare venture capital firm since 2015, and he currently serves as the Chief Business Officer of Opna-Immuno Oncology, SA, a Longitude Capital portfolio company. Mr.&nbsp;Diaz has also served as a Managing Director of DA Advisors, LLC
since 2005, providing strategic and financial advice primarily to life science companies. From 2008 to 2018, Mr.&nbsp;Diaz served as a managing director at Auven Therapeutics, a private equity firm focusing on life science companies. From 1996 to
2005, Mr.&nbsp;Diaz served as a managing member and <FONT STYLE="white-space:nowrap">co-founder</FONT> of Diaz&nbsp;&amp; Altschul Capital Management, LLC, an asset management firm focusing on healthcare companies. Prior to that, Mr.&nbsp;Diaz
served as a managing director and head of the healthcare group at Schroder Wertheim&nbsp;&amp; Co., Inc., and in various roles at PaineWebber Development Corporation, including as president. Mr.&nbsp;Diaz currently serves on the board of directors
of the public pharmaceutical company, Inozyme Pharma, Inc., where he chairs the compensation committee. Mr.&nbsp;Diaz received a B.A. in Economics from Harvard University and an M.B.A. from Harvard Business School. Our board of directors believes
Mr.&nbsp;Diaz is qualified to serve as a director because of his experience in the life sciences industry. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Board composition </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our board of directors, which currently consists of five members. Our directors were elected to,
and currently serve on, the board pursuant to a voting agreement among us and all of our stockholders and voting rights granted by our current amended and restated certificate of incorporation. The voting agreement will terminate upon the closing of
this offering, after which there will be no further contractual obligations regarding the election of our directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with our amended and
restated certificate of incorporation that will be in effect upon the closing of this offering, our board of directors will be divided into three classes, each of which will consist, as nearly as possible, of
<FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of directors constituting our entire board and which will serve staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then
expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;I, which will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our first annual
meeting of stockholders to be held after the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;II, which will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our second annual
meeting of stockholders to be held after the closing of this offering; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;III, which will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our third annual
meeting of stockholders to be held after the closing of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws, which will become effective upon
the closing of this offering, will provide that the authorized number of directors may be changed only by resolution approved by a majority of our board of directors. Any additional directorships resulting from an increase in the number of directors
will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered
three-year terms may delay or prevent a change of our management or a change of control. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Director independence </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applicable Nasdaq rules, or the Nasdaq Listing Rules, require a majority of a listed company&#146;s board of directors to be comprised of independent directors
within one year of listing. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and corporate governance committees be independent and that
audit committee members also satisfy independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act of 1934, as amended, or the Exchange Act. The Nasdaq independence definition includes a series of
objective tests, such as that the director is not, and has not been for at least three years, one of our employees, that neither the director nor any of his family members has engaged in various types of business dealings with us and that the
director is not associated with the holders of more than 5% of our common stock. In addition, under applicable Nasdaq rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed company&#146;s board of
directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that all of our directors other
than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of
our&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directors, are &#147;independent directors&#148; as defined under applicable Nasdaq rules. In making such determination, our board of directors
considered the current and prior relationships that each such director has with our company and all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the beneficial ownership
of our capital stock by each director and the transactions described in the section titled &#147;Certain Relationships and Related Party Transactions.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Role of the board in risk oversight </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the key
functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through the board of
directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing
strategic risk exposure. Following the completion of this offering, we intend for our audit committee to have the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control
these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee will also monitor compliance with legal and regulatory requirements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Board committees </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has established
an audit committee, compensation committee and a nominating and corporate governance committee, each of which operate pursuant to a committee charter. Our board of directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may establish other committees to facilitate the management of our business. The composition and functions of each committee are described below. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit committee </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this
offering, our audit committee will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serving as chair of the audit committee. Our board of directors has determined that each of these
individuals meets the independence requirements of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, or the Exchange Act, and the applicable listing standards of Nasdaq. Each member of our audit committee
can read and understand fundamental financial statements in accordance with Nasdaq audit committee requirements. Our board of directors has also determined
that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of the
Nasdaq Listing Rules. In arriving at these determinations, the board has examined each audit committee member&#146;s scope of experience and the nature of their prior and/or current employment. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The functions of this committee include, among other things: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our board of directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as
the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and reviewing a report by the independent registered public accounting firm at least annually that
describes our internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues when required by applicable law; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe
that the composition and functioning of our audit committee will comply with all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation committee </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of
this offering, our compensation committee will consist of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serving as chair of the compensation committee. Each of these individuals is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined
in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act and is an &#147;outside director,&#148; as defined pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended, or the Code. Our board of
directors has determined that each of these individuals is &#145;&#145;independent&#148; as defined under the applicable listing standards of Nasdaq, including the standards specific to members of a compensation committee. The functions of this
committee include, among other things: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full board of
directors regarding) our overall compensation strategy and policies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to the full board of directors regarding the compensation and other terms of employment of
our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding performance goals and objectives
relevant to the compensation of our executive officers and assessing their performance against these goals and objectives; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors
regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating risks associated with our compensation policies and practices and assessing whether risks arising from
our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding the type and amount of compensation
to be paid or awarded to our <FONT STYLE="white-space:nowrap">non-employee</FONT> board members; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies with respect to votes by our stockholders to approve executive compensation to the extent
required by Section&nbsp;14A of the Exchange Act and, if applicable, determining our recommendations regarding the frequency of advisory votes on executive compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as
required by Section&nbsp;10C of the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies with respect to equity compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our
compensation policy and strategy in achieving expected benefits to us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding the terms of any employment
agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and approving our disclosures under the caption &#147;Compensation Discussion and
Analysis&#148; in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating on an annual basis the performance of the compensation committee and the compensation
committee charter. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that the composition and functioning of our compensation committee will comply with all applicable SEC and
Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and corporate
governance committee </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our nominating and corporate governance committee will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serving as chair of the nominating and corporate governance committee. Our board of directors has determined that each of these individuals is &#145;&#145;independent&#148;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as defined under the applicable listing standards of Nasdaq and SEC rules and regulations. The functions of this committee include, among other things: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, reviewing and evaluating candidates to serve on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the minimum qualifications for service on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating director performance on the board and applicable committees of the board and determining whether
continued service on our board is appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating, nominating and recommending individuals for membership on our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating nominations by stockholders of candidates for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and assessing the independence of members of our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a set of corporate governance policies and principles and recommending to our board of directors any
changes to such policies and principles; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the board of directors with respect to management succession planning;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering questions of possible conflicts of interest of directors as such questions arise; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating on an annual basis the performance of the nominating and corporate governance committee
and the nominating and corporate governance committee charter. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that the composition and functioning of our nominating and
corporate governance committee will comply with all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Compensation committee interlocks and insider participation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our directors who serve as a member of our compensation committee is, or has at any time during the past year been, one of our officers or employees.
None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any other entity that has one or more executive officers serving on our board of directors or
compensation committee. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Code of business conduct and ethics </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective upon the closing of this offering, we will adopt a Code of Business Conduct and Ethics, or the Code of Conduct, applicable to all of our employees,
executive officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. Following the closing of this offering, the full
text of the Code of Conduct will be available on our website at <I>www.lexeotx.com</I>. We intend to post on our website all disclosures that are required by law or the listing standards of the Nasdaq Stock Market concerning any amendments to, or
waivers from, any provision of the Code of Conduct. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of
this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-employee&nbsp;director</FONT> compensation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows information concerning the compensation that our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors earned during the
last completed fiscal year ended December&nbsp;31, 2021. A director who is also our employee receives no additional compensation for his or her services as a director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows information concerning the compensation that our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors earned during the last completed fiscal year ended December&nbsp;31, 2021. A director who is also our employee receives no additional compensation for his or her services as a director.
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid in Cash</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>($)(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Option&nbsp;Awards</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>($)(2)(3)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sandip Agarwala<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mette Kirstine Agger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Altschuler, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paula HJ Cholmondeley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bernard Davitian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reinaldo
Diaz<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents actual fees paid in fiscal year 2021. For Dr.&nbsp;Altschuler, this includes fees paid for board services . For Ms.&nbsp;Cholmondeley, this includes fees paid for board services. Mr.&nbsp;Agarwala,
Ms.&nbsp;Agger, Mr.&nbsp;Davitian and Mr.&nbsp;Diaz did not receive cash compensation for their service to us as <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in fiscal year 2021. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Option awards in this column are reported at the aggregate grant date fair value in accordance with FASB ASC Topic 718. Option awards under this column are discussed in greater detail below. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2021, our then <FONT STYLE="white-space:nowrap">non-employee</FONT> directors held the following option awards: </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Unexercisable</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Exercisable</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="right"><B>Exercise&nbsp;Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Expiration&nbsp;Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Sandip Agarwala</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Mette Kirstine Agger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Steven Altschuler, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/16/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,189,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Paula HJ Cholmondeley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/15/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/14/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Bernard Davitian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Reinaldo Diaz</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sandip Agarwala resigned from our board of directors effective January&nbsp;28, 2022. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reinaldo Diaz was appointed to our board of directors effective February&nbsp;2, 2022. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock option
awards </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain <FONT STYLE="white-space:nowrap">non-employee&nbsp;directors</FONT> serving on our board of directors received stock option awards
during 2021. On February&nbsp;16, 2021, Steven Altschuler, M.D. received a grant of 1,189,097 stock options, with a vesting start date of January&nbsp;5, 2021, and on November&nbsp;15, 2021, Paula Cholmondeley received a grant of 165,565 stock
options. The stock options granted to Dr.&nbsp;Altschuler and Ms.&nbsp;Cholmondeley were exercisable on the date of grant and vest with respect to 25% of the underlying shares on the first anniversary of the vesting start date and thereafter in
equal monthly installments over three years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="toc287237_12"></A>Executive compensation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our named executive officers for the period ended December&nbsp;31, 2021, consisting of our principal executive officer and the next two most highly
compensated executive officers, were: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">R. Nolan Townsend, who currently serves as our Chief Executive Officer and as a member of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jay A. Barth, M.D., who currently serves as our Executive Vice President and Chief Medical Officer; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Paul McCormac, Ph.D., who currently serves as our Chief Technical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Summary compensation table </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth
information regarding compensation awarded to, earned by and paid to our named executive officers with respect to the period ended December&nbsp;31, 2021. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name and Principal Position</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Stock<BR>Awards<BR>($)(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>Awards<BR>($)(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive&nbsp;Plan<BR>Compensation<BR>($)(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">R. Nolan Townsend</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,382,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,061,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Chief Executive Officer and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jay A. Barth, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">816,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,366,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Executive Vice President and Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Paul McCormac, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">675,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Chief Technical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stock and option awards in these columns are reported at the aggregate grant date fair value in accordance with FASB ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to our audited financial statements included elsewhere in this prospectus. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Non-equity</FONT> incentive plan compensation amounts represent actual amounts earned during 2021, but paid in 2022. The amount paid to each named executive officer is equal to a
percentage of the executive&#146;s target annual bonus pursuant to the applicable employment agreement. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Outstanding equity awards at
December&nbsp;31, 2021 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information about outstanding equity awards granted to our named executive officers that
were outstanding as of December&nbsp;31, 2021. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="16" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Option Awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Option<BR>Exercise<BR>Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Nolan Townsend</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2/16/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">11/21/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,627,848</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">(2)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2/15/2031</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/15/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/11/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,000</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/14/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay A. Barth, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/16/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/21/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,783,645</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President and Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/15/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/11/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,920,855</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/14/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul McCormac, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/22/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/22/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487,350</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/21/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Technical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/15/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/11/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,336,844</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/14/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the option awards were granted under the Existing Plan. All of the option awards were granted with a per share exercise price equal to the fair market value of one share of our common stock on the date of grant.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the 2,170,463 shares originally subject to this option were exercisable as of the date of grant, and 542,615 shares were exercised on May&nbsp;14, 2021. Of the total shares subject to this option, 25% will vest
one year after the vesting commencement date, and the remaining shares vest in 36 equal monthly installments thereafter, subject to continuous service through each applicable vesting date. All unvested shares will vest immediately prior to the
consummation of a change in control of the Company. As of December&nbsp;31, 2021, 587,833&nbsp;shares subject to this option have vested, of which 542,615 shares have been exercised and 45,218 vested shares remain unexercised. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the shares subject to these options were exercisable as of the date of grant. 25% of the total shares subject to these options will vest one year after the vesting commencement date, and the remaining shares vest
in 36 equal monthly installments thereafter, subject to continuous service through each applicable vesting date. All unvested shares will vest immediately prior to the consummation of a change in control of the Company. As of December&nbsp;31, 2021,
zero shares subject to these options have vested. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the shares subject to this option were exercisable as of the date of grant. Of the total shares subject to this option, 25% will vest one year after the vesting commencement date, and the remaining shares vest in
36 equal monthly installments thereafter, subject to continuous service through each applicable vesting date. All unvested shares will vest immediately prior to the consummation of a change in control of the Company. As of December&nbsp;31, 2021,
483,070 shares subject to this option have vested. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Agreements with our named executive officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with each of our named executive officers, setting forth the terms and conditions of such executive&#146;s
employment with us, as described below. The employment agreements generally set forth the executive officer&#146;s initial base salary, annual bonus opportunity, eligibility for employee benefits and termination benefits, and restrictive covenants.
The key terms of the employment agreements are described below. In connection with this offering, we intend to enter into amended and restated employment agreements with each of our named executive officers. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>R. Nolan Townsend </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an employment
agreement with Mr.&nbsp;Townsend, our Chief Executive Officer, in January 2020 that governs the current terms of his employment with us. In 2021, Mr.&nbsp;Townsend received a base salary of $410,833. Pursuant to the employment agreement,
Mr.&nbsp;Townsend is eligible to receive a target bonus equal to 50% of his annual base salary based upon Mr.&nbsp;Townsend&#146;s achievement of certain performance objectives agreed to by us in writing by or before January&nbsp;31 of each calendar
year during his term of employment. For 2021, Mr.&nbsp;Townsend received a bonus of $267,375. Mr.&nbsp;Townsend was granted a number of incentive units of LEXEO Therapeutics, LLC equal to 5% of the total number in the aggregate of LEXEO
Therapeutics, LLC&#146;s common units and incentive units outstanding on January&nbsp;1, 2020, subject to the terms and conditions of applicable award agreements. Mr.&nbsp;Townsend is also eligible for benefits upon an involuntary termination of his
employment with us, as described in more detail below under the section titled &#147;&#151;Potential payments upon termination or change in control.&#148; In addition, Mr.&nbsp;Townsend is eligible to participate in our regular health insurance and
other employee benefit plans, as described below as described in more detail below under the section titled &#147;&#151;Other compensation and benefits.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Jay A. Barth, M.D. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an employment
agreement with Dr. Barth, our Executive Vice President and Chief Medical Officer, in October 2020 that governs the current terms of his employment with us. In 2021, Dr. Barth received a base salary of $399,167. Pursuant to the employment agreement,
Dr. Barth is eligible to receive a target bonus equal to 40% of his annual base salary with the exact amount to be determined by our board of directors, and for 2021 Dr. Barth received a bonus of $151,200. Pursuant to the employment agreement, Dr.
Barth was also granted incentive equity awards in connection with the company&#146;s closing of certain funding rounds. The initial incentive award vests, subject to Dr. Barth&#146;s continuous employment with us and the terms and conditions of
applicable award agreements, with respect to 25% of the grant on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the effective date of the employment agreement, and with respect to the remaining 75% of the grant, monthly
thereafter in substantially equal installments for 36 months. Dr. Barth is also eligible for benefits upon an involuntary termination of his employment with us, as described in more detail below under the section titled &#147;&#151;Potential
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payments upon termination or change in control.&#148; In addition, Dr. Barth is eligible to participate in our regular health insurance and other employee benefit plans, as described below as
described in more detail below under the section titled &#147;&#151;Other compensation and benefits.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Paul McCormac, Ph.D. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an employment agreement with Dr.&nbsp;McCormac, our Chief Technical Officer, in February 2021 that governs the current terms of his employment
with us. In 2021, Dr.&nbsp;McCormac received a base salary of $256,944. Pursuant to the employment agreement, Dr.&nbsp;McCormac is eligible to receive a target bonus equal to 30% of his annual base salary with the exact amount to be determined by
our board of directors, and, for 2021, Dr.&nbsp;McCormac received a bonus of $86,625. Dr.&nbsp;McCormac was granted 487,350 options in connection with his employment with us. The options vest, subject to Dr.&nbsp;McCormac&#146;s continuous
employment with us and the terms and conditions of applicable award agreements, with respect to 25% of the grant on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of grant, and with respect to the remaining 75% of the
grant, monthly thereafter in substantially equal installments for 36 months. Dr.&nbsp;McCormac is also eligible for benefits upon an involuntary termination of his employment with us, as described in more detail below under the section titled
&#147;&#151;Potential payments upon termination or change in control.&#148; In addition, Dr.&nbsp;McCormac is eligible to participate in our regular health insurance and other employee benefit plans, as described below as described in more detail
below under the section titled &#147;&#151;Other compensation and benefits.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Potential payments upon termination or change in control </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Mr.&nbsp;Townsend&#146;s employment agreement, upon a termination of his employment by us without &#147;cause&#148; (and not due to death or
disability) or by Mr.&nbsp;Townsend for &#147;good reason&#148; (as those terms are defined in the employment agreements) and subject to his executive of a valid release of claims in favor of the company, Mr.&nbsp;Townsend is entitled to the
following payments: (i)&nbsp;any earned but unpaid annual bonus from the year prior to the year in which his termination occurs, (ii)&nbsp;accrued vacation, (iii)&nbsp;reimbursement for COBRA premiums, if applicable, for Mr.&nbsp;Townsend and his
dependents for up to 15 months, (iv)&nbsp;continuation of base salary for a period of 15 months, (v)&nbsp;continued vesting of equity awards as provided in the applicable award agreements, (vi)&nbsp;any accrued base salary or annual bonus unpaid as
of the termination date, (vii)&nbsp;any vested benefits earned under any employee benefits plan, and (viii)&nbsp;any unreimbursed business expenses incurred prior to the termination date, if otherwise reimbursable. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of Mr.&nbsp;Townsend&#146;s employment agreement, &#147;cause&#148; generally means (1)&nbsp;the willful or repeated failure or refusal by the
executive to substantially perform his material duties under the employment agreement (other than such failure resulting from the executive&#146;s incapacity due to physical or mental illness; and it being agreed that failure of the company to
achieve operating results or similar poor performance of the company shall not, in and of themselves, be deemed a failure to perform the executive&#146;s duties); (2) the plea of guilty or no contest or conviction or indictment of the executive of
any felony or any crime involving moral turpitude (other than misdemeanors for DUI or DWI); (3) the executive&#146;s commission of an act of fraud, embezzlement or material misappropriation of assets involving us or any of our subsidiaries or
affiliates; (4)&nbsp;any material breach by the executive of his obligations under the employment agreement; (5)&nbsp;any breach of any fiduciary duty owed to us or any of ours subsidiaries or affiliates under the law or under the employment
agreement or any other written agreement or written covenant with us unless the action giving rise to such breach was taken at the direction of our founder or our board of directors, as applicable, or was based on the executive&#146;s good faith
belief that such action was in the best interests of the company and/or our subsidiaries; or (6)&nbsp;any willful action under the law or under the employment agreement or any other written agreement or written covenant with the company that is
reasonably likely, in the good faith opinion of a majority of our board of directors (other than the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
executive), to result in material harm to the reputation or business prospects of the company or any of our subsidiaries or affiliates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of Mr.&nbsp;Townsend&#146;s employment agreement, &#147;good reason&#148; generally means, without the executive&#146;s written consent
(1)&nbsp;a reduction in base salary, target annual performance or benefits opportunity amount (in each case other than a reduction applied consistently to all senior executives of the company), (2) a material diminution of the executive&#146;s job
responsibilities, authority or title (regardless of whether any of the company&#146;s governing documents provide the company and/or our board of directors with the ability to materially reduce such job responsibilities, authority or title); (3) the
executive is required to report to any entity or person other than, prior to the date on which the majority of our board of directors consists of independent directors, our founder and on and after the date on which a majority of our board of
directors consists of independent directors, our board of directors or a committee thereof, (4)&nbsp;prior to an initial public offering of the company&#146;s or our successor&#146;s or parent&#146;s equity securities, the executive is removed by
the members of the company from our board of directors other than for &#147;cause&#148; or &#147;disability&#148; (as those terms are defined in the employment agreement), (5) relocation of the executive&#146;s principal worksite of more than
35&nbsp;miles from New York, New York, excluding business travel or (6)&nbsp;the company&#146;s material breach of the employment agreement or any other agreement between us and the executive, including any agreement awarding the executive equity in
the company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Dr.&nbsp;Barth&#146;s employment agreement, upon a termination of his employment by us without &#147;cause&#148; (and not due to
death or &#147;disability&#148;) or by Dr.&nbsp;Barth for &#147;good reason&#148; (as those terms are defined in the employment agreements) and subject to his execution of a valid release of claims in favor of the company, Dr.&nbsp;Barth is entitled
to the following payments: (i)&nbsp;any earned but unpaid annual bonus from the year prior to the year in which his termination occurs, (ii)&nbsp;a pro rata target annual bonus for the year of termination, (iii)&nbsp;reimbursement for COBRA
premiums, if applicable, for Dr.&nbsp;Barth and his dependents for up to 12 months, and (iv)&nbsp;continuation of base salary for a period of 12 months. In addition, all of Dr.&nbsp;Barth&#146;s incentive equity awards granted prior to the
Company&#146;s initial public offering pursuant to his employment agreement vest in connection with a Change in Control as defined in the Existing Plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Dr.&nbsp;McCormac&#146;s employment agreement, upon a termination of his employment by us without &#147;cause&#148; (and not due to death or
&#147;disability&#148;) or by Dr.&nbsp;McCormac for &#147;good reason&#148; (as those terms are defined in the employment agreements) and subject to his execution of a valid release of claims in favor of the company, Dr.&nbsp;McCormac is entitled to
the following payments: (i)&nbsp;any earned but unpaid annual bonus from the year prior to the year in which his termination occurs, (ii)&nbsp;accrued vacation, (iii)&nbsp;reimbursement for COBRA premiums, if applicable, for Dr.&nbsp;McCormac and
his dependents for up to 6 months, and (iv)&nbsp;continuation of base salary for a period of 11 months. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of Dr.&nbsp;Barth&#146;s and
Dr.&nbsp;McCormac&#146;s employment agreements, &#147;cause&#148; generally means (1)&nbsp;the willful failure or refusal by the executive to substantially perform his duties under the employment agreement (other than such failure resulting from the
executive&#146;s incapacity due to physical or mental illness); (2) the plea of guilty or no contest or conviction or indictment of the executive of any felony or any crime involving moral turpitude; (3)&nbsp;the executive&#146;s commission of an
act of fraud, embezzlement or material misappropriation of assets involving the company or any of our subsidiaries or affiliates; (4)&nbsp;any material breach by the executive of his obligations under the employment agreement; (5)&nbsp;any breach of
any fiduciary duty owed to the company or any of our subsidiaries or affiliates under the law or under the employment agreement or any other written agreement or written covenant with us or any of our subsidiaries or affiliates; or (6)&nbsp;any
willful action that is reasonably likely, in the reasonable good faith opinion of our board or directors, to result in material harm to the reputation of business prospects of the company or any of our subsidiaries or affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of Dr.&nbsp;Barth&#146;s employment agreement, &#147;good reason&#148; generally means,
without the executive&#146;s written consent, (1)&nbsp;a material reduction in his base salary (other than a reduction applied consistently to all senior executives of the company), (2) a material diminution in the executive&#146;s reporting
responsibilities, duties, authorities or responsibilities, (3)&nbsp;a relocation of the executive&#146;s principal location of employment of more than 35 miles, provided that such relation materially increases the executive&#146;s daily commute, or
(4)&nbsp;the company&#146;s other material breach of this agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of Dr.&nbsp;McCormac&#146;s employment agreement, &#147;good
reason&#148; generally means, without the executive&#146;s written consent, (1)&nbsp;a material reduction in his base salary (other than a reduction applied consistently to all senior executives of the company), or (2)&nbsp;the company&#146;s
material breach of the employment agreement. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Other compensation and benefits </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain broad-based employee benefit plans and programs for the benefit of our employees, in which our named executive officers are entitled to
participate. All of our current named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision, and accidental death and dismemberment insurance plans, in each case on the same basis as all
of our other employees. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy
certain eligibility requirements. The 401(k) plan is intended to qualify as a tax-qualified plan under the Internal Revenue Code. Our named executive officers are eligible to participate in the 401(k)&nbsp;plan on the same basis as our other
employees. The Internal Revenue Code allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the 401(k) plan. For the year ended December 31, 2021, we provided
matching contributions under our 401(k)&nbsp;plan representing 5.9% of total contributions to the 401(k) plan. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Equity incentive plans </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022 equity incentive plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors
adopted the 2022 Equity Incentive Plan, or 2022 Plan, in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022, and our stockholders approved the 2022 Plan
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022. The 2022 Plan will become effective upon the execution of the underwriting agreement for this offering. Once the 2022 Plan becomes effective, no further grants will be
made under the Existing Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our 2022 Plan provides for the grant of incentive stock options, or ISOs,
nonstatutory stock options, or NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based awards, and other awards, or collectively, awards. ISOs may be granted only to our employees, including our
officers, and the employees of our affiliates. All other awards may be granted to our employees, including our officers, <FONT STYLE="white-space:nowrap">our&nbsp;non-employee&nbsp;directors,</FONT> consultants, and the employees and consultants of
our affiliates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>.&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of common stock that may be issued under our 2022 Plan
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, which is the sum of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;new shares, plus (ii)&nbsp;the Existing Plan&#146;s available reserve,
plus (iii)&nbsp;the number of returning shares, if any, as such shares become available from time to time. In addition, the number of shares of common stock reserved for issuance under our 2022 Plan will automatically increase on January&nbsp;1 of
each year, beginning on January&nbsp;1, 2023, and continuing through and including January&nbsp;1, 2032, by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of common stock outstanding on December&nbsp;31 of the
immediately preceding calendar year, or a lesser number of shares determined by our board of directors prior to the applicable January 1. The maximum number of shares that may be issued upon the exercise of ISOs under our 2022 Plan
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares issued under our 2022 Plan will be authorized but unissued or reacquired shares of common stock.
Shares subject to awards granted under our 2022 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under our 2022 Plan.
Additionally, shares issued pursuant to awards under our 2022 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of an award or to satisfy the tax withholding obligations to an award, will become
available for future grant under our 2022 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum number of shares of common stock subject to stock awards granted under the 2022 Plan or
otherwise during any calendar year beginning in 2022 to <FONT STYLE="white-space:nowrap">any&nbsp;non-employee&nbsp;director,</FONT> taken together with any cash fees paid by us to
<FONT STYLE="white-space:nowrap">such&nbsp;non-employee&nbsp;director</FONT> during such calendar year for service on the board of directors, will not exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in total value
(calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes), or, with respect to the calendar year in which
<FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> is first appointed or elected to our board of directors, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors, or a duly authorized committee of our board, may administer our 2022 Plan. We expect
that our board of directors will delegate concurrent authority to administer our 2022 Plan to the compensation committee under the terms of the compensation committee&#146;s charter. We sometimes refer to the board of directors, or the applicable
committee with the power to administer our equity incentive plans, as the administrator. The administrator may also delegate to one or more of our officers the authority to (1)&nbsp;designate employees (other than officers) to receive specified
awards, and (2)&nbsp;determine the number of shares subject to such awards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrator has the authority to determine the terms of awards,
including recipients, the exercise, purchase or strike price of awards, if any, the number of shares subject to each award, the fair market value of a share of common stock, the vesting schedule applicable to the awards, together with any vesting
acceleration, and the form of consideration, if any, payable upon exercise or settlement of the award and the terms of the award agreements for use under our 2022 Plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, subject to the terms of the 2022 Plan, the administrator also has the power to modify outstanding awards under our 2022 Plan, including the
authority to reprice any outstanding option or stock appreciation right, cancel <FONT STYLE="white-space:nowrap">and&nbsp;re-grant&nbsp;any</FONT> outstanding option or stock appreciation right in exchange for new stock awards, cash or other
consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any materially adversely affected participant. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock options</I>.&nbsp;&nbsp;&nbsp;&nbsp;ISOs and NSOs are granted pursuant to stock option agreements adopted by the administrator. The administrator
determines the exercise price for a stock option, within the terms and conditions of the 2022 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of
grant. Options granted under the 2022 Plan vest at the rate specified in the stock option agreement as specified in the stock option agreement by the administrator. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrator determines the term of stock options granted under the 2022 Plan, up to a maximum of ten years. Unless the terms of an optionholder&#146;s
stock option agreement provide otherwise, if an optionholder&#146;s service relationship with us, or any of our affiliates, ceases for any reason other than disability, death, or cause, the optionholder may generally exercise any vested options for
a period of three months following the cessation of service. The option term may be extended in the event that either an exercise of the option or an immediate sale of shares acquired upon exercise of the option following such a termination of
service is prohibited by applicable securities laws or our insider trading policy. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain period
following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, options
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generally terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the administrator and may include
(1)&nbsp;cash, check, bank draft, or money order, (2)&nbsp;a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of common stock previously owned by the optionholder, (4)&nbsp;a net exercise of the option if it is an NSO, and
(5)&nbsp;other legal consideration approved by the administrator. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options may not be transferred to third-party financial institutions for value. Unless
the administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution or pursuant to a domestic relations order. An optionholder may designate a beneficiary, however, who may exercise the
option following the optionholder&#146;s death. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax limitations on ISOs</I>.&nbsp;&nbsp;&nbsp;&nbsp;The aggregate fair market value, determined at the
time of grant, of common stock with respect to ISOs that are exercisable for the first time by an option holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will be
treated as NSOs. No ISOs may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations, unless
(1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (2)&nbsp;the term of the ISO does not exceed five years from the date of grant. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted stock awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock awards are granted pursuant to restricted stock award agreements adopted by the
administrator. Restricted stock awards may be granted in consideration for cash, check, bank draft or money order, services rendered to us, or our affiliates or any other form of legal consideration. Common stock acquired under a restricted stock
award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the administrator. A restricted stock award may be transferred only upon such terms and conditions as set by the
administrator. Except as otherwise provided in the applicable award agreement, restricted stock awards that have not vested may be forfeited or repurchased by us upon the participant&#146;s cessation of continuous service for any reason. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted stock unit awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock unit awards are granted pursuant to restricted stock unit award agreements adopted
by the administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by
the administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise
provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant&#146;s cessation of continuous service for any reason. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock appreciation rights</I>.&nbsp;&nbsp;&nbsp;&nbsp;Stock appreciation rights are granted pursuant to stock appreciation right grant agreements adopted by
the administrator. The administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of common stock on the date of grant. Upon the exercise of a stock appreciation right,
we will pay the participant an amount equal to the product of (1)&nbsp;the excess of the per share fair market value of common stock on the date of exercise over the strike price, multiplied by (2)&nbsp;the number of shares of common stock with
respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2022 Plan vests at the rate specified in the stock appreciation right agreement as determined by the administrator. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrator determines the term of stock appreciation rights granted under the 2022 Plan, up to a maximum of ten years. Unless the terms of a
participant&#146;s stock appreciation right agreement provide otherwise, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock
appreciation right for a period of three months following the cessation of service. The stock appreciation right term may be further extended in the event that exercise of the stock appreciation right following such a termination of service is
prohibited by applicable securities laws. If a participant&#146;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the
participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12&nbsp;months in the event of disability and 18 months in the event of death. In the event of a termination for cause, stock appreciation rights
generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our 2022 Plan permits the grant of performance-based stock and cash awards. The administrator can structure
such awards so that the stock or cash will be issued or paid pursuant to such award only following the achievement of <FONT STYLE="white-space:nowrap">certain&nbsp;pre-established&nbsp;performance</FONT> goals during a designated performance period.
Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The performance goals may be based on any measure of performance selected by the board of directors. The administrator may establish performance goals on a
company-wide basis, with respect to one or more business units, divisions, affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant
indices. Unless specified otherwise (i)&nbsp;in the award agreement at the time the award is granted or (ii)&nbsp;in such other document setting forth the performance goals at the time the goals are established, the administrator will appropriately
make adjustments in the method of calculating the attainment of the performance goals as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of
changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur
&#147;infrequently&#148; as determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by us achieved performance objectives at
targeted levels during the balance of a performance period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of common stock by reason of any stock dividend or split, stock repurchase, reorganization,
recapitalization, merger, <FONT STYLE="white-space:nowrap">consolidation,&nbsp;spin-off,&nbsp;combination</FONT> or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends;
(9)&nbsp;to exclude the effects of stock-based compensation and the award of bonuses under our bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under
generally accepted accounting principles; and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The administrator may grant other awards based in whole or in part by reference to common stock. The administrator
will set the number of shares under the award and all other terms and conditions of such awards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to capital
structure</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum
number of shares reserved for issuance under the 2022 Plan; (2)&nbsp;the class and maximum number of shares by which the share reserve may increase automatically each year; (3)&nbsp;the class and maximum number of shares that may be issued upon the
exercise of ISOs; and (4)&nbsp;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;The following applies to stock awards under the 2022
Plan in the event of a corporate transaction, unless otherwise provided in a participant&#146;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the administrator at the time
of grant. Under the 2022 Plan, a corporate transaction is generally the consummation of (1)&nbsp;a sale or other disposition of all or substantially all of our assets, (2)&nbsp;a sale or other disposition of at least 50% of our outstanding
securities, (3)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation, or (4)&nbsp;a merger, consolidation, or similar transaction following which we are the surviving corporation but the shares of
common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event
of a corporate transaction, any stock awards outstanding under the 2022 Plan may be assumed, continued or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with
respect to the stock award may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue, or substitute for such stock awards, then (i)&nbsp;with respect to any
such stock awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will
be accelerated in full to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the
effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the corporate transaction), and (ii)&nbsp;any such stock awards
that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the effective time of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such
stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. In addition, the plan administrator may also provide, in its sole discretion, that the holder of a stock award that will terminate upon the
occurrence of a corporate transaction if not previously exercised will receive a payment, if any, equal to the excess of the value of the property the participant would have received upon exercise of the stock award over the exercise price otherwise
payable in connection with the stock award. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A stock award may be subject to additional acceleration of vesting and exercisability upon or after a change
in control as may be provided in an applicable award agreement or other written agreement, but in the absence of such provision, no such acceleration will occur. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>.&nbsp;&nbsp;&nbsp;&nbsp;A participant may not transfer awards under our 2022 Plan other than by will, the laws of descent and
distribution, or as otherwise provided under our 2022 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan amendment or termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board has the authority to
amend, suspend, or terminate our 2022 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the approval of our
stockholders. No ISOs may be granted after the tenth anniversary of the date our board adopted our 2022 Plan. No awards may be granted under our 2022 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022 employee stock purchase plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of
directors adopted the the ESPP on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022, and our stockholders adopted the ESPP on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. The ESPP will
become effective upon the execution of the underwriting agreement for this offering. The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees and to provide incentives for such individuals to
exert maximum efforts toward our success and that of our affiliates. The ESPP includes two components. One component is designed to allow our eligible U.S. employees to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase common stock in a manner that may qualify for favorable tax treatment under Section&nbsp;423 of the Code. In addition, purchase rights may be granted under a component that does not
qualify for such favorable tax treatment when necessary or appropriate to permit participation by our eligible employees who are foreign nationals or employed outside of the United States while complying with applicable foreign laws. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized shares.</I>&nbsp;&nbsp;&nbsp;&nbsp;The maximum aggregate number of shares of common stock that may be issued under our ESPP
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. The number of shares of common stock reserved for issuance under our ESPP will automatically increase on January&nbsp;1 of each calendar year, beginning on
January&nbsp;1, 2023 and continuing through and including January&nbsp;1, 2032, by the lesser of (1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of common stock outstanding on December&nbsp;31 of the preceding
calendar year, (2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares and (3)&nbsp;a number of shares determined by our board. Shares subject to purchase rights granted under our ESPP that terminate without having been
exercised in full will not reduce the number of shares available for issuance under our ESPP. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan
administration.</I><I></I>&nbsp;&nbsp;&nbsp;&nbsp;Our board, or a duly authorized committee thereof, will administer our ESPP. We anticipate that our board will delegate concurrent authority to administer our ESPP to the compensation committee under
the terms of the compensation committee&#146;s charter. The ESPP is implemented through a series of offerings with specific terms approved by the administrator and under which eligible employees are granted purchase rights to purchase shares of
common stock on specified dates during such offerings. Under the ESPP, we may specify offerings with durations of not more than 27 months and may specify shorter purchase periods within each offering. Each offering will have one or more purchase
dates on which shares of common stock will be purchased for our eligible employees participating in the offering. An offering under the ESPP may be terminated under certain circumstances. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Payroll deductions</I>.&nbsp;&nbsp;&nbsp;&nbsp;Generally, all regular employees, including executive officers, employed by us or by any of our designated
affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, with a maximum dollar amount as designated by the board. Unless otherwise determined by the administrator, common stock will be purchased for the
accounts of employees participating in the ESPP at a price per share equal to the lower of (a) 85% of the fair market value of a share of common stock on the first date of an offering or (b) 85% of the fair market value of a share of common stock on
the date of purchase. For the initial offering, which we expect will commence upon the execution and delivery of the underwriting agreement relating to this offering, the fair market value on the first day of the initial offering will be the price
at which shares are first sold to the public. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our employees, including executive officers, or any of our
designated affiliates may have to satisfy one or more of the following service requirements before participating in our ESPP, as determined by the administrator: (1)&nbsp;customary employment with us or one of our affiliates for more than 20 hours
per week and more than five months per calendar year, or (2)&nbsp;continuous employment with us or one of our affiliates for a minimum period of time, not to exceed two years, prior to the first date of an offering. An employee may not be granted
rights to purchase stock under our ESPP if such employee (1)&nbsp;immediately after the grant would own stock possessing 5% or more of the total combined voting power or value of common stock, or (2)&nbsp;holds rights to purchase stock under our
ESPP that would accrue at a rate that exceeds $25,000 worth of our stock for each calendar year that the rights remain outstanding. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to capital
structure</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in
property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or similar transaction, the board of directors will make appropriate adjustments to
(1)&nbsp;the number of shares reserved under the ESPP, (2)&nbsp;the maximum number of shares by which the share reserve may increase automatically each year, (3)&nbsp;the number of shares and purchase price of all outstanding purchase rights, and
(4)&nbsp;the number of shares that are subject to purchase limits under ongoing offerings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain corporate transactions,
including: (1)&nbsp;a sale of all or substantially all of our assets, (2)&nbsp;the sale or disposition of 50% of our outstanding securities, (3)&nbsp;the consummation of a merger or consolidation where we do not survive the transaction, and
(4)&nbsp;the consummation of a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the
transaction, any then-outstanding rights to purchase our stock under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company)
elects not to assume, continue, or substitute for such purchase rights, then the participants&#146; accumulated payroll contributions will be used to purchase shares of common stock within 10 business days (or such other period specified by the
board) prior to such corporate transaction and such purchase rights will terminate immediately. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the ESPP, a corporate transaction is generally the
consummation of: (1)&nbsp;a sale of all or substantially all of our assets, (2)&nbsp;the sale or disposition of more than 50% of our outstanding securities, (3)&nbsp;a merger or consolidation where we do not survive the transaction, and (4)&nbsp;a
merger or consolidation where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ESPP amendment or termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;The administrator has the authority to amend or terminate our ESPP, provided that except in
certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#146;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by applicable law or
listing requirements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 equity incentive plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors adopted the Existing Plan in February 2021, and our stockholders approved the Existing Plan in September 2021. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Existing Plan provides for the grant of ISOs, NSOs, and restricted stock awards, or collectively, stock awards.
ISOs may be granted only to our employees and the employees of any parent corporation or subsidiary corporation. All other awards may be granted to our service providers. We have granted ISOs and NSOs under the Existing Plan. As of December&nbsp;31,
2021, options to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock were outstanding with a weighted-average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and restricted stock awards to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common were outstanding,
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock remained available for future awards under the Existing Plan. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share reserve</I>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to certain capitalization adjustments, the aggregate number of shares of our common stock that has been
reserved for issuance pursuant to stock awards under the Existing Plan is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares subject to stock awards granted under our Existing Plan that expire or are forfeited or become unexercisable without having been exercised in full, or
are surrendered pursuant to an exchange program shall continue to be available under the Existing Plan for issuance pursuant to future awards. If any shares of common stock issued pursuant to a stock award are forfeited back to or repurchased by us
for at the original purchase price, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the Existing Plan. Any shares retained in satisfaction of tax withholding obligations or as
consideration for the exercise or purchase price of a stock award will again become available for issuance under the Existing Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan
</I><I>a</I><I>dministration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors administers and interprets the provisions of the Existing Plan. The board of directors may delegate its authority to a committee, or committees, of the board, referred
to as the &#147;administrator.&#148; The administrator may additionally delegate limited authority to specified directors or executive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
officers. Under our Existing Plan, the administrator has the authority to, among other things, approve award recipients, determine the numbers and types of stock awards to be granted, determine
the applicable fair market value and the provisions of each stock award, including the period of their exercisability and the vesting schedule applicable to a stock award, construe and interpret the Existing Plan and awards granted thereunder, and
prescribe, amend, modify, and rescind or terminate rules and regulations for the administration of the Existing Plan. Under the Existing Plan, the administrator may, with the consent of the majority of holders of shares entitled to vote, implement a
plan to amend outstanding awards to provide for a lower exercise price or issue new awards in exchange for the surrender and cancellation of outstanding awards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock</I><I> o</I><I>ptions</I>.&nbsp;&nbsp;&nbsp;&nbsp;ISOs and NSOs are granted under stock option agreements in such form and containing such provisions
as approved by the administrator. The administrator determines the exercise price for stock options, within the terms and conditions of the Existing Plan, provided that the exercise price of a stock option generally will not be less than 100% of the
fair market value of our common stock on the date of grant (or 110% of the fair market value for 10% stockholders as required by the Code). Stock options granted under the Existing Plan vest at the rate specified in the stock option agreements and
option rules as determined by the administrator. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrator determines the term of stock options granted under the Existing Plan, up to a maximum
of 10&nbsp;years (or five years for 10% stockholders as required by the Code). If an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than disability, death, or cause the optionholder may
generally exercise any vested options for a period of up to three months following the cessation of service, or such other period of time set forth in the option agreement. If an optionholder&#146;s service relationship with us or any of our
affiliates ceases due to death or disability (or the participant dies within three months after a termination other than for cause), then options vested as of the termination date may generally be exercised within 12 months following the date of
termination, or such other period of time set forth in the option agreement. In no event may an option be exercised beyond the expiration of its term. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to
termination for cause, the optionholder&#146;s vested options shall expire on the optionholder&#146;s termination date, or such later time as determined by the administrator. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price for shares issued under the Existing Plan are generally payable in cash, check, promissory note, surrender of previously owned shares,
consideration received through a broker-assisted (or other) cashless exercise program (whether through a broker or otherwise) implemented by us, net exercise, or other forms of consideration determined by the administrator (or any combination
thereof). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution, or,
with respect to NSOs for participants in the United States, by gift to a family member. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted stock</I>.&nbsp;&nbsp;&nbsp;&nbsp;The administrator
determines to whom an offer of restricted stock will be made, the number of shares the person may purchase, the purchase price, the restrictions to which the shares will be subject, and other terms and conditions. If a participant&#146;s service
relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through, but not limited to, a repurchase right.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to </I><I>c</I><I>apital </I><I>s</I><I>tructure</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of any stock split, reverse stock split, stock
dividend, combination, consolidation, recapitalization (including a recapitalization through a large nonrecurring cash dividend) or reclassification of the shares, subdivision of the shares, a rights offering, a reorganization, merger, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> <FONT STYLE="white-space:nowrap">split-up,</FONT> repurchase, or exchange of our common stock or other securities of ours or other significant corporate transaction, or other change affecting our common
stock, then in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Existing Plan, the administrator will adjust the number, kind and class of securities that may be delivered under
the Existing Plan and/or the number, class, kind and price of securities covered by each outstanding award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in control</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of Change in Control under the Existing Plan
shall be subject to the agreement evidencing the acquisition or other combination, which need not treat all outstanding awards in an identical manner. Such agreement, without the participant&#146;s consent, shall provide for one or more of the
following with respect to all outstanding awards: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continuation of such outstanding awards; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assumption of such outstanding awards by the surviving corporation or its parent; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the substitution by the surviving corporation or its parent of new options or other equity awards for such
awards; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cancellation of such awards in exchange for a payment to the participants equal to the excess, if any, of
(1)&nbsp;the fair market value of the shares subject to such awards as of the closing date of such Change in Control over (2)&nbsp;the exercise or purchase price paid or to be paid for the shares subject to the awards; provided that at the
discretion of the administrator, such payment may be subject to the same conditions that apply to the consideration that will be paid to holders of shares in connection with the transaction; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the opportunity for participants to exercise the options prior to the occurrence of the Change in Control and the
termination (for no consideration) upon the consummation of such Change in Control of any options not exercised prior thereto. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
Existing Plan, an Change in Control is generally defined as (i)&nbsp;the consummation of a merger or consolidation of the company with or into another entity or any other corporate reorganization, if the company&#146;s stockholders immediately prior
to such merger, consolidation or reorganization cease to directly or indirectly own immediately after such merger, consolidation or reorganization at least a majority of the combined voting power of the continuing or surviving entity&#146;s
securities outstanding immediately after such merger, consolidation or reorganization; (ii)&nbsp;the consummation of the sale, transfer or other disposition of all or substantially all of the company&#146;s assets; (iii)&nbsp;a change in the
effective control of the company; or (iv)&nbsp;the consummation of any transaction as a result of which any Person (as defined below) becomes the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under
the Exchange Act), directly or indirectly, of securities of the company representing at least fifty percent (50%) of the total voting power represented by the company&#146;s then outstanding voting securities. For purposes of this Section&nbsp;2(h),
the term &#147;Person&#148; shall have the same meaning as when used in Sections 13(d) and 14(d) of the Exchange Act but shall exclude: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trustee or other fiduciary holding securities under an employee benefit plan of the company or an affiliate of
the company; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or other entity owned directly or indirectly by the stockholders of the company in substantially
the same proportions as their ownership our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the company; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or other entity of which at least a majority of its combined voting power is owned directly or
indirectly by the company. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A transaction shall not constitute a Change in Control if its sole purpose is to change the state of the
company&#146;s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the company&#146;s securities immediately before such transactions. In addition, if any Person (as defined
above) is considered to be in effective control of the company, the acquisition of additional control of the company by the same Person will not be considered to cause a Change in Control. If required for compliance with Section&nbsp;409A of the
Code, in no event will a Change in Control be deemed to have occurred if such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction is not also a &#147;change in the ownership or effective control of&#148; the company or &#147;a change in the ownership of a substantial portion of the assets of&#148; the company as
determined under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan </I><I>A</I><I>mendment or </I><I>T</I><I>ermination</I>.&nbsp;&nbsp;&nbsp;&nbsp;The board may at any time terminate, amend or suspend the Existing
Plan and all outstanding options or restricted stock awards upon a dissolution or liquidation of us. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Limitations on liability and indemnification
matters </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our amended and restated certificate of incorporation will contain provisions that limit the liability of
our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as
directors, except liability for: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These limitations of liability do not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies
such as injunctive relief or rescission. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws that will be in effect
upon the closing of this offering will provide that we are required to indemnify our directors to the fullest extent permitted by Delaware law. Our amended and restated bylaws will also provide that, upon satisfaction of certain conditions, we are
required to advance expenses incurred by a director in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his
or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. Our amended and restated bylaws will also provide our board of directors with discretion to indemnify
our officers and employees when determined appropriate by the board. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors, and we
expect to enter into amended and restated indemnification agreements with each of our directors and enter into indemnification agreements with each of our executive officers prior to the closing of this offering. With certain exceptions, these
agreements provide for indemnification for related expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw
provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. We also maintain customary directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may
discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might
benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions.
At present, there is no pending litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought and we are not aware of any threatened litigation that may result in claims for indemnification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for our
directors, executive officers or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> sales plans </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors and executive officers may adopt written plans, known as <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> plans, in which they will
contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the director or officer when
entering into the plan, without further direction from them. The director or officer may amend a <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> plan in some circumstances and may terminate a plan at any time. Our directors and executive
officers also may buy or sell additional shares outside of a <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> plan when they are not in possession of material nonpublic information subject to compliance with the terms of our insider trading
policy. Prior to 180&nbsp;days after the date of this offering, subject to early termination, the sale of any shares under such plans would be prohibited by the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement that the director or officer
has entered into with the underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_13"></A>Certain relationships and related party transactions </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of transactions since January&nbsp;1, 2019 to which we have been a participant in which the amount involved exceeded or will
exceed $120,000, and in which any of our directors, executive officers or holders of more than 5% of our voting securities, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation
arrangements which are described under &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Agreements with Ronald G. Crystal, M.D. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consulting agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2020, we entered
into a consulting agreement, or the Crystal Consulting Agreement, with Ronald&nbsp;G. Crystal, M.D., our founder and Chief Scientific Advisor and a holder of more than 5% of our voting securities. Under the Crystal Consulting Agreement, in
consideration for an annual consulting fee of $250,000, Dr.&nbsp;Crystal will provide us with consulting services in relation to his extensive expertise in gene therapy technologies, including (a)&nbsp;consulting and advisory services with respect
to matters related to gene therapies for diseases; (b)&nbsp;participation in corporate and research and development strategy sessions; and (c)&nbsp;advising on recruiting and interviewing, or the Services. The Crystal Consulting Agreement shall
continue for five years and, unless sooner terminated in accordance with its terms, is renewable annually for one-year periods after the initial term of five years. The Crystal Consulting Agreement is terminable by either party with proper notice or
by us for cause. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock option award agreement </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2021, we granted Dr.&nbsp;Crystal an option to purchase 1,791,822 shares of our common stock at an exercise price per share of $0.22 and entered into
our standard Stock Option Award Agreement with Dr.&nbsp;Crystal, or the Crystal Option Agreement. Of the shares subject to the option, 25% will vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the closing of our third
tranche of financing from the sale of our Series A preferred convertible stock, or August&nbsp;20, 2022, and the remaining shares subject to the option will vest in 36 substantially equal installments thereafter. All of the shares subject to the
option were exercisable immediately upon grant, and any then-unvested shares subject to the option will become fully vested as of immediately prior to a change of control of Lexeo. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Private placements of our securities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series A
convertible preferred stock financing </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2020, we entered into a preferred stock purchase agreement with certain investors, including
beneficial owners of greater than 5% of our capital stock and affiliates of members of our board of directors. In connection with the initial closing of our Series A convertible preferred stock, we sold an aggregate of 34,495,725 shares of our
Series A convertible preferred stock at a purchase price of $1.00 (including approximately $4 million in principal and accrued interest on outstanding convertible promissory notes issued to certain investors, the conversion of which resulted in
issuance of 4,495,729 shares of our Series A convertible preferred stock) for aggregate gross proceeds of approximately $34&nbsp;million. In July 2021, we sold an aggregate of 50,999,997 shares of our Series A convertible preferred stock at a
purchase price of $1.00 for aggregate gross proceeds of approximately $51&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below sets forth the aggregate number of shares of Series A convertible preferred stock issued to
our related parties in this financing: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Series&nbsp;A&nbsp;Convertible<BR>Preferred Stock&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate&nbsp;Purchase<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Janus Henderson Investors(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Longitude Venture Partners IV, L.P.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omega Fund VI, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PBM LEX Holdings, LLC(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">11,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">11,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with Janus Henderson Investors hold more than 5% of our voting securities. Consists of (i) 3,643,715 shares of Series A preferred stock purchased by Janus Henderson Global Life Sciences Fund,
(ii)&nbsp;3,466,664&nbsp;shares of Series A preferred stock purchased by Janus Henderson Biotech Innovation Master Fund Limited, (iii)&nbsp;2,660,459 shares of Series A preferred stock purchased by Janus Henderson Capital Funds PLC on behalf of its
Series Janus Henderson Global Life Sciences Fund and (iv)&nbsp;229,162&nbsp;shares of Series A preferred stock purchased by Janus Henderson Horizon Fund&#151;Biotechnology Fund. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Longitude Venture Partners IV, L.P., or LVP IV, holds more than 5% of our capital stock prior to this offering. Longitude Capital Partners IV, LLC is the general partner of LVP IV. Reinaldo Diaz was designated to serve
as a member of our board of directors by LVP IV. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lundbeckfond Invest A/S, which is wholly owned by the Lundbeck Foundation, holds more than 5% of our capital stock prior to this offering. Mette Kirstine Agger is the Managing Partner of Lundbeckfonden Ventures, a
department within Lundbeckfond Invest A/S, and was designated to serve as a member of our board of directors by Lundbeckfond Invest A/S. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Omega Fund VI, L.P., or Omega Fund, holds more than 5% of our capital stock prior to this offering. Omega Fund VI GP, L.P., or Omega GP LP, is the sole general partner of the Omega Fund, and Omega Fund VI GP Manager,
Ltd. is the sole general partner of Omega GP LP. Bernard Davitian was designated to serve as a member of our board of directors by Omega Fund. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">PBM LEX Holdings, LLC, or PBM LEX, holds more than 5% of our capital stock prior to this offering. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series B convertible preferred stock financing </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
August 2021, we entered into a preferred stock purchase agreement with certain investors, including beneficial owners of greater than 5% of our capital stock, affiliates of members of our board of directors and certain of our executive officers,
pursuant to which we issued and sold to such investors an aggregate of 58,157,823 shares of our Series B convertible preferred stock at a purchase price of $1.72049 per share for aggregate gross proceeds of approximately $100&nbsp;million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below sets forth the aggregate number of shares of Series B convertible preferred stock issued to our related parties in this financing: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Series&nbsp;B&nbsp;Convertible<BR>Preferred&nbsp;Stock&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate&nbsp;Purchase<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D1 Master Holdco I LLC(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,343,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Janus Henderson Investors(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,324,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Longitude Venture Partners IV, L.P.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,906,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,615,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,499,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual Fund Series Trust, On Behalf Of Eventide Healthcare&nbsp;&amp; Life Sciences
Fund(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,718,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omega Fund VI, L.P.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,615,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,499,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul McCormac, Ph.D.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">29,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000" ALIGN="right">49,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">D1 Master Holdco I LLC, or Holdco I, holds more than 5% of our capital stock prior to this offering. Holdco I is a wholly owned subsidiary of D1 Capital Partners Master LP. D1 Capital Partners L.P. is a registered
investment adviser and serves as the investment manager of private investment vehicles and accounts, including D1 Capital Partners Master LP, and may be deemed to beneficially own the shares held by Holdco I. Daniel Sundheim indirectly controls D1
Capital Partners L.P., and may be deemed to beneficially own the shares held by Holdco I. Paula HJ Cholmondeley was designated to serve as a member of our board of directors by Holdco I. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 883,469 shares of Series B preferred stock purchased by Janus Henderson Global Life Sciences Fund and (ii) 1,441,449 shares of Series B preferred stock purchased by Janus Henderson Capital Funds PLC on
behalf of its Series Janus Henderson Global Life Sciences Fund. Entities affiliated with Janus Henderson Investors hold more than 5% of our voting securities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Longitude Venture Partners IV, L.P., or LVP IV, holds more than 5% of our capital stock prior to this offering. Longitude Capital Partners IV, LLC is the general partner of LVP IV. Reinaldo Diaz was designated to serve
as a member of our board of directors by LVP IV. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lundbeckfond Invest A/S holds more than 5% of our capital stock prior to this offering. Mette Kirstine Agger is the Managing Partner of Lundbeckfonden Ventures, a department within Lundbeckfond Invest A/S, and was
designated to serve as a member of our board of directors by Lundbeckfond Invest A/S. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mutual Fund Series Trust, on behalf of Eventide Healthcare&nbsp;&amp; Life Sciences Fund, holds more than 5% of our capital stock prior to this offering. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Omega Fund holds more than 5% of our capital stock prior to this offering. Omega GP LP is the sole general partner of the Omega Fund, and Omega Fund VI GP Manager, Ltd. is the sole general partner of Omega GP LP.
Bernard Davitian was designated to serve as a member of our board of directors by Omega Fund. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All shares are held by Paul McCormac, Ph.D., our Chief Technical Officer. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investors&#146; rights, voting
and right of first refusal agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sales of convertible preferred stock described above, we entered into an amended and
restated investors&#146; rights agreement, an amended and restated voting agreement and an amended and restated right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement containing registration rights, information rights,
voting rights and rights of first refusal, among other things, with the holders of our convertible preferred stock, including funds affiliated with D1 Capital Partners, Eventide Healthcare&nbsp;&amp; Life Sciences Fund, Janus Henderson Investors,
Longitude Capital, Lundbeckfond Invest A/S, Omega Funds and PBM Capital. These agreements will terminate upon the closing of this offering, except for the registration rights granted under our amended and restated investors&#146; rights agreement,
as more fully described in the section of this prospectus titled &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Employment
arrangements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements or offer letter agreements with certain of our executive officers. For more information
regarding such employment agreements, see &#147;Executive Compensation&#151;Employment Agreements with our Named Executive Officers.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Indemnification agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation that will be in effect upon the closing of this offering will contain provisions limiting the liability of directors, and our amended and restated bylaws will provide that we will indemnify each of our directors to the
fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation and amended and restated bylaws will also provide our board of directors with discretion to indemnify our officers and employees when determined
appropriate by the board. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we have entered into indemnification agreements with each of our directors, and we expect to enter into amended and
restated indemnification agreements with each of our directors and enter into </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">indemnification agreements with each of our executive officers prior to the
closing of this offering. For more information regarding these agreements, see &#147;Executive Compensation&#151;Limitations on Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Related person transaction policy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this
offering, we have not had a formal policy regarding approval of transactions with related parties. In connection with this offering, we have adopted a related person transaction policy that sets forth our procedures for the identification, review,
consideration and approval or ratification of related person transactions, which policy will become effective immediately upon the execution of the underwriting agreement for this offering. For purposes of our policy only, a related person
transaction will be a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director will not be covered by this policy. A
related person will be any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction
when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our audit committee, or, if
audit committee approval would be inappropriate, to another independent body of our board of directors, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts,
the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or
from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential
related-person transactions and to effectuate the terms of the policy. In addition, under our Code of Conduct that we expect to adopt prior to the closing of this offering, our employees and directors will have an affirmative responsibility to
disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of our board of directors, will take into
account the relevant available facts and circumstances including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event that the related person is a director, immediate family
member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The policy will require that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or
other independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our audit committee, or other
independent body of our board of directors, determines in the good faith exercise of its discretion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the transactions described in this section
were entered into prior to the adoption of this policy. Although we have not had a written policy for the review and approval of transactions with related persons, our board of directors has historically reviewed and approved any transaction where a
director or officer had a financial interest, including the transactions described above. Prior to approving such a transaction, the material facts as to a director&#146;s or officer&#146;s relationship or interest in the agreement or transaction
were disclosed to our board of directors. Our board of directors took this information into account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_14"></A>Principal stockholders </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding beneficial ownership of our capital stock by: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC. Under these rules, beneficial ownership includes any shares of common stock as
to which the individual or entity has sole or shared voting power or investment power. Applicable percentage ownership is based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022, after giving effect to the conversion of all of our preferred stock. In computing the number of shares beneficially owned by an individual or entity and the percentage
ownership of that person, shares of common stock subject to options held by such person that are currently exercisable or will become exercisable within 60 days of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 are
considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless noted otherwise, the address of all listed stockholders is c/o Lexeo Therapeutics, Inc., 420 East
29<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;Street, Floor 14, New York, New York 10016. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as indicated by the footnotes below, we
believe, based on information furnished to us, that each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws
where applicable.</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="3" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Percentage of Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:9pt"><B>Name of Beneficial Owner</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:9pt"><B>Before<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:9pt"><B>After<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Greater than 5% stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D1 Master Holdco I LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PBM LEX Holdings, LLC<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Janus Henderson
Investors<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Longitude Venture Partners IV,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual Fund Series Trust, on Behalf of Eventide Healthcare&nbsp;&amp; Life Sciences Fund<SUP
STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omega Fund VI, L.P<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald G. Crystal, M.D. and
affiliates<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Nolan Townsend<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay A. Barth, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul McCormac, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mette Kirstine Agger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Altschuler, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paula HJ Cholmondeley<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bernard Davitian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reinaldo Diaz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group
(eight persons)<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the shares are held by D1 Master Holdco I LLC. Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series B convertible
preferred stock. D1 Capital Partners L.P., or D1 Management Company, is a registered investment adviser and serves as the investment manager of private investment vehicles and accounts, including D1 Master Holdco I LLC, and may be deemed to
beneficially own the shares of common stock held by D1 Master Holdco I LLC. Daniel Sundheim indirectly controls the D1 Management Company and may be deemed to beneficially own the shares of common stock held by D1 Master Holdco I LLC. The business
address of each of D1 Master Holdco I LLC, D1 Capital Partners L.P. and Daniel Sundheim is 9 West 57th Street, 36th Floor, New York, New York 10019. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series A convertible preferred stock held by PBM LEX Holdings, LLC. PBM LEX
Holdings, LLC is majority owned by PBM Capital Investments II, LLC, which is managed by PBM Capital Group, LLC. Paul B. Manning is the Chief Executive Officer of PBM Capital Group, LLC, and has sole voting and investment power with respect to the
shares held by PBM LEX Holdings, LLC. The business address for each person and entity named in this footnote is 200 Garrett Street, Suite S, Charlottesville, Virginia 22902. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series A convertible preferred stock held by Janus Henderson Biotech Innovation
Master Fund Limited, (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series A convertible preferred stock held by Janus Henderson Horizon Fund &#150; Biotechnology Fund,
(iii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series A convertible preferred stock held by Janus Henderson Capital Funds PLC On Behalf Of Its Series Janus Henderson
Global Life Sciences Fund, (iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series B convertible preferred stock held by Janus Henderson Capital Funds PLC On Behalf Of
Its Series Janus Henderson Global Life Sciences Fund, (v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series A convertible preferred stock held by Janus Henderson Global
Life Sciences Fund and (vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series B convertible preferred stock held by Janus Henderson Global Life Sciences Fund. Such
shares owned by the funds may be deemed to be beneficially owned by, Janus Henderson Investors US LLC, or Janus, an investment adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser for the funds set forth above
and has the ability to make decisions with respect to the voting and disposition of the shares subject to the oversight of the board of trustees (or similar entity) of each fund. Under the terms of its management contract with each fund, Janus has
overall responsibility for directing the investments of the fund in accordance with the fund&#146;s investment objective, policies and limitations. Each fund has one or more portfolio managers appointed by and serving at the pleasure of Janus who
makes decisions with respect to the disposition of the Shares. The address for Janus and each of the foregoing entities is 151 Detroit Street, Denver, Colorado 80206. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the shares are held by Longitude Venture Partners IV, L.P. (LVP IV). Consists of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of
Series A convertible preferred stock and (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series B convertible preferred stock. Longitude Capital Partners IV, LLC (LCP
IV), is the general partner of LVP IV and may be deemed to have voting and investment power over the shares held by LVP IV. Patrick Enright and Juliet Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and investment
power over the shares held by LVP IV. Each of LCP IV, Ms.&nbsp;Tammenoms Bakker and Mr.&nbsp;Enright disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. The address for this entity is
2740 Sand Hill Road, 2nd Floor, Menlo Park, California 94025. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the shares are held by Lundbeckfond Invest A/S. Consists of (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series A convertible
preferred stock and (ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series B convertible preferred stock. Lundbeckfond Invest A/S is wholly-owned by the Lundbeck
Foundation, and the board of directors of the Lundbeckfond Foundation consists of Steffen Kragh, Lars Holmqvist, Susanne Kr&#252;ger Kj&aelig;r, Michael Kj&aelig;r, Peter Sch&#252;tze, Gunhild Waldemar, Svend Andersen, Ludovic Tranholm Otterbein,
Vagn Flink M&oslash;ller Pedersen and Kristian Funding Andersen. The board of directors of the Lundbeck Foundation also serve as the board members of Lundbeckfond Invest A/S. No individual member of the Lundbeckfond Invest A/S board of directors is
deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held by Lundbeckfond Invest A/S. The board of directors of Lundbeckfond Invest A/S makes decisions with respect to investments made by Lundbeckfond Invest A/S,
and the board of directors of Lundbeckfond Invest&nbsp;A/S and Lene Skole, the chief executive officer of Lundbeckfond Invest A/S, may be deemed to share voting and investment authority over the shares held by Lundbeckfond Invest A/S. The address of
Lundbeckfond Invest A/S is Scherfigsvej 7 <FONT STYLE="white-space:nowrap">DK-2100,</FONT> Copenhagen &Oslash;, Denmark. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the shares are held by Mutual Fund Series Trust, On Behalf of Eventide Healthcare&nbsp;&amp; Life Sciences Fund. Consists of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock issuable upon conversion of Series B convertible preferred stock. Eventide Healthcare&nbsp;&amp; Life Sciences Fund is a registered investment company for which Eventide Asset Management, LLC acts as investment advisor. Eventide Asset
Management, LLC has voting and investment power with respect to the shares. The address for this entity is c/o Eventide Asset Management, LLC, One International Place, Suite 4210, Boston, Massachusetts 02110. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the shares are held by Omega Fund. Consists of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series A convertible preferred stock
and (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series B convertible preferred stock. Omega Fund GP Manager, Ltd., or Omega Ltd., is the sole general partner of
Omega Fund VI GP, L.P., or Omega GP, which is the sole general partner of Omega Fund; and each of Omega Ltd. and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Claudio Nessi, Otello Stampacchia and Anne-Mari Paster are the
managing directors of Omega Ltd. and, as a result, may be deemed to share voting and investment power over the shares held directly by Omega Fund. Each of Dr. Stampacchia, Dr. Nessi, and Ms. Paster, and Omega Ltd. and Omega GP disclaims beneficial
ownership of the shares held by Omega Fund except to the extent of their pecuniary interest therein. The address for this entity is 888 Boylston Street, Suite 1111, Boston, Massachusetts 02199. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares held by Ronald G. Crystal, M.D., (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares held by
the Ronald G. Crystal 2021 Grantor Retained Annuity Trust over which Dr. Crystal retains sole voting and dispositive power and (iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares subject to options held by Dr.
Crystal that are exercisable within 60 days of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock and
(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares subject to options that are exercisable within 60 days
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(10)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes shares subject to options that are exercisable within 60 days of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(11)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes shares subject to options that are exercisable within 60 days of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(12)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes shares subject to options that are exercisable within 60 days of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(13)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes shares subject to options that are exercisable within 60 days of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(14)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock and (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares subject to options
that are exercisable within 60 days of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_15"></A>Description of capital stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following description of our capital stock, certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws,
as each will be in effect following the completion of this offering, and certain provisions of Delaware law are summaries. You should also refer to the amended and restated certificate of incorporation and the amended and restated bylaws, which are
filed as exhibits to the registration statement of which this prospectus is part. </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our amended and restated certificate of incorporation will authorize us to issue up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, $0.0001 par value per share, and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock, $0.0001 par value
per share, all of which shares of preferred stock will be undesignated. Our board of directors may establish the rights and preferences of the preferred stock from time to time. As of December&nbsp;31, 2021, there were
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of Series A convertible preferred stock outstanding and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of Series B convertible preferred
stock outstanding, held by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stockholders of record. All currently outstanding shares of convertible preferred stock will be converted into an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock upon the closing of this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Common stock
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each holder of our common
stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. The affirmative vote of holders of at least 66-2/3% of the voting power of all of the then-outstanding shares
of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified board, the
size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive forum. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be
applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our liquidation,
dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any
liquidation preference granted to the holders of any then-outstanding shares of preferred stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights and preferences </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common
stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the right of the holders of shares of any series of preferred stock that we may designate in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Preferred stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the closing of this offering, our board of directors will have the authority under our amended and restated certificate of incorporation, without
further action by our stockholders, to issue up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each
such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below
the number of shares of such series then outstanding. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion
rights that could adversely affect the voting power or other rights of the holders of our common stock. The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays
associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deferring or preventing a change in control of us and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. It is not possible to state the actual effect of the issuance of any
shares of preferred stock on the rights of holders of common stock until the board of directors determines the specific rights attached to that preferred stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no present plans to issue any shares of preferred stock following completion of this offering. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Options and restricted stock awards </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2021, there were options to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding and no shares of common stock had been issued pursuant to restricted stock awards. For
additional information regarding the terms of the Existing Plan, see &#147;Executive Compensation&#151;Equity Incentive Plans.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Registration
rights </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, the holders of our existing convertible preferred stock and certain holders of our existing common stock have entered into an amended and
restated investors&#146; rights agreement. The registration rights provisions of this agreement provide those holders with demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights with respect to the shares of
common stock currently held by them and issuable to them upon conversion of our convertible preferred stock in connection with our initial public offering. These shares are collectively referred to herein as registrable securities. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time beginning
180 days following the effective date of the registration statement of which this prospectus is a part, the holders of a majority of registrable securities then outstanding have the right to demand that we file a Form
<FONT STYLE="white-space:nowrap">S-1</FONT> registration statement covering registrable securities then outstanding having an aggregate offering price in excess of $10&nbsp;million. These registration rights are subject to specified conditions and
limitations, including the right of the underwriters, if any, to limit the number of shares included in any such registration under specified circumstances. Upon such a request, we are required to effect a Form
<FONT STYLE="white-space:nowrap">S-1</FONT> registration statement as soon as practicable, but in any event no later than 60 days after the date such request is given by the initiating holders. An aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be entitled to these demand registration rights. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we propose to
register any of our securities under the Securities Act either for our own account or for the account of other stockholders, the holders of registrable securities will each be entitled to notice of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration and will be entitled to include their shares of common stock in the registration statement. These piggyback registration rights are subject to specified conditions and limitations,
including the right of the underwriters to limit the number of shares included in any such registration under specified circumstances. An aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
will be entitled to these piggyback registration rights. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time after we become eligible to file&nbsp;a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> the holders of at least
10% of registrable securities then outstanding will be entitled to request to have such shares registered by us on a <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration statement. These
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights are subject to other specified conditions and limitations, including the condition that the anticipated aggregate offering price, net of certain selling expenses, is at least
$1&nbsp;million. Upon receipt of this request, the holders of registrable securities will each be entitled to participate in this registration. An aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common
stock will be entitled to these <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of registration </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to pay all expenses, including reasonable fees and expenses of one counsel to represent the selling stockholders, relating to any demand,
piggyback or <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration, other than underwriting discounts and commissions, stock transfer taxes and any additional fees of counsel for the selling stockholders, subject to specified conditions
and limitations. We are not required to pay registration expenses if a demand registration request is withdrawn at the request of a majority of holders of registrable securities to be registered, unless holders of a majority of the registrable
securities agree to forfeit their right to one demand registration. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amended and restated investors&#146; rights agreement contains customary
cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the applicable registration statement attributable to us, and the selling stockholders
are obligated to indemnify us for material misstatements or omissions in the registration statement attributable to them, subject to certain limitations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
registration rights granted under the investors&#146; rights agreement will terminate with respect to any particular stockholder upon the earlier of (a)&nbsp;the closing of a deemed liquidation event, as defined in our certificate of incorporation,
(b)&nbsp;with respect to each stockholder, at such time such stockholder is able to sell all of its shares pursuant to Rule 144 or another similar exemption under the Securities Act during a three-month period without registration and (c)&nbsp;the
fifth anniversary of the closing of this offering or such later date that is 180 days following the expiration of all deferrals of our obligations with respect to any registration rights exercised by holders of registrable securities as of such
fifth anniversary. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Anti-takeover provisions </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination
with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines a &#147;business combination&#148; to include the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation or any direct or indirect majority-owned subsidiary of the
corporation and the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder (in one transaction or a series of transactions); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation or by
any direct or indirect majority-owned subsidiary of the corporation of any stock of the corporation or of such subsidiary to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation or any direct or indirect majority-owned subsidiary of the corporation
that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as an
entity or person who, together with the person&#146;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the
corporation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and restated certificate of incorporation and amended and restated bylaws </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation to be in effect upon the completion of this offering, or our restated certificate, will provide for our
board of directors to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective
three-year terms. Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors. Our restated certificate and our amended and
restated bylaws to be effective upon the completion of this offering, or our restated bylaws, will also provide that directors may be removed by the stockholders only for cause upon the vote of 66-2/3% or more of our outstanding common stock.
Furthermore, the authorized number of directors may be changed only by resolution of the board of directors, and vacancies and newly created directorships on the board of directors may, except as otherwise required by law or determined by the board,
only be filled by a majority vote of the directors then serving on the board, even though less than a quorum. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our restated certificate of
incorporation and amended and restated bylaws our stockholders will not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the
directors standing for election, if they should so choose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our restated certificate and restated bylaws will also provide that all stockholder actions must be effected
at a duly called meeting of stockholders and will eliminate the right of stockholders to act by written consent without a meeting. Our restated bylaws will also provide that only our Chairman of the board, Chief Executive Officer or the board of
directors pursuant to a resolution adopted by a majority of the total number of authorized directors may call a special meeting of stockholders. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
restated bylaws will also provide that stockholders seeking to present proposals before a meeting of stockholders to nominate candidates for election as directors at a meeting of stockholders must provide timely advance notice in writing, and will
specify requirements as to the form and content of a stockholder&#146;s notice. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our restated certificate and restated bylaws will provide that the
stockholders cannot amend many of the provisions described above except by a vote of 66-2/3% or more of our outstanding common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in
&#147;&#151;Preferred Stock&#148; above, our restated certificate will give our board of directors the authority, without further action by our stockholders, to issue up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock in one or more series, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other
change in control. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combination of these provisions will make it more difficult for our existing stockholders to replace our board of directors as well
as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or
another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the
success of any attempt to change our control. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions are intended to enhance the likelihood of continued stability in the composition of our
board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in
proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also
inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the
proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Choice of forum </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of
incorporation will provide that the Court of Chancery of the state of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a breach of fiduciary duty; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our restated
certificate, or our amended and restated bylaws; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us that is governed by the internal affairs doctrine. </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act.
Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent
having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation will also provide that unless we consent in
writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a
venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our restated certificate of incorporation. This may
require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or
our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation
to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will further provide that the federal district courts of the United States of America will be the
exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Transfer agent and registrar </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and
registrar for our common stock is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent&#146;s address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to apply for listing of our common
stock on the Nasdaq Global Market under the trading symbol &#147;LXEO.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_16"></A>Shares eligible for future sale </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, no public market existed for our common stock. Future sales of our common stock in the public market, or the availability of such
shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal
restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to
raise equity capital in the future. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the number of shares outstanding as of December&nbsp;31, 2021, upon the closing of this offering and assuming
no exercise of the underwriters&#146; option to purchase additional shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be outstanding, assuming no outstanding options are exercised. All of
the shares of common stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, except for any shares sold to our &#147;affiliates,&#148; as that term is defined under Rule 144 under
the Securities Act. The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock held by existing stockholders are &#147;restricted securities,&#148; as that term is defined in Rule 144 under the
Securities Act. Restricted securities may be sold in the public market only if registered or if their resale qualifies for exemption from registration described below under Rule 144 promulgated under the Securities Act or another available
exemption. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below and the provisions of Rules 144 and 701 under the
Securities Act, the shares of common stock that will be deemed restricted securities after this offering will be available for sale in the public market as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">none of the existing shares will be eligible for immediate sale upon the completion of this offering; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be eligible for sale in the
public market upon expiration of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements 180&nbsp;days after the date of this prospectus, subject in certain circumstances to the volume, manner of sale and other limitations under Rule 144 and
Rule&nbsp;701 under the Securities Act, which are summarized below. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, <FONT STYLE="white-space:nowrap">non-affiliate</FONT> persons who have beneficially owned restricted shares of our common stock for at least six
months, and any affiliate of the company who owns either restricted or unrestricted shares of our common stock, are entitled to sell their securities without registration with the SEC under an exemption from registration provided by Rule 144 under
the Securities Act. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-affiliates</FONT> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any person who is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale may sell an unlimited
number of restricted securities under Rule&nbsp;144 if: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the restricted securities have been held for at least six months, including the holding period of any prior owner
other than one of our affiliates (subject to certain exceptions); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale;
and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are current in our Exchange Act reporting at the time of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any person who is not deemed to have been an affiliate of ours at the time of, or at any time during the three months preceding, a sale and has held the
restricted securities for at least one year, including the holding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period of any prior owner other than one of our affiliates, will be entitled to sell an unlimited number of restricted securities without regard to the length of time we have been subject to
Exchange Act periodic reporting or whether we are current in our Exchange Act reporting. <FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule 144.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliates </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Persons seeking to sell
restricted securities who are our affiliates at the time of, or any time during the three months preceding, a sale, would be subject to the restrictions described above. They are also subject to additional restrictions, by which such person would be
required to comply with the manner of sale and notice provisions of Rule 144 and would be entitled to sell within any three-month period only that number of securities that does not exceed the greater of either of the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares immediately after the completion of this offering based on the number of shares outstanding as of December&nbsp;31, 2021; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on the stock exchange on which our shares are listed during
the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, persons who are our
affiliates at the time of, or any time during the three months preceding, a sale may sell unrestricted securities under the requirements of Rule 144 described above, without regard to the <FONT STYLE="white-space:nowrap">six-month</FONT> holding
period of Rule 144, which does not apply to sales of unrestricted securities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rule 701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but without compliance with
certain restrictions of Rule 144, including the holding period requirement. Most of our employees, executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of
Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares. However, substantially all Rule 701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements as described below and in the section titled &#147;Underwriting&#148; and will become eligible for sale upon the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration statements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all shares of
common stock subject to outstanding stock options and common stock issued or issuable under our equity plans. We expect to file the registration statement covering shares offered pursuant to our stock plans as soon as practicable after the closing
of this offering, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by affiliates in the public market, subject to compliance
with the resale provisions of Rule 144 and expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> agreements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and substantially all of the holders of our common stock outstanding on the date of this prospectus have entered into <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters or otherwise agreed, subject to limited exceptions, that we and they will not, not to offer, pledge, announce the intention to sell, sell,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly,
or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of our common stock, or any securities convertible into, or exchangeable for or that represent the right to receive shares
of our common stock, without the prior written consent of J.P. Morgan Securities LLC and SVB Securities LLC for a period of 180 days from the date of this prospectus. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the restrictions contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, we have entered into an agreement
with the holders of our preferred stock that contains market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions imposing restrictions on the ability of such security holders to sell or otherwise transfer or dispose of any registrable
securities for a period of 180 days following the date of this prospectus. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Registration rights </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, the holders of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock,
including common stock issuable upon the conversion of our preferred stock, or their transferees, will be entitled to specified rights with respect to the registration of their registrable shares under the Securities Act, subject to certain
limitations and the expiration, waiver or termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction
under the Securities Act immediately upon effectiveness of the registration. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_17"></A>Material U.S. federal income tax consequences to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of certain material U.S. federal income tax consequences to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) of the ownership and disposition of our common stock offered pursuant to this prospectus. This discussion is not a complete analysis of all potential U.S. federal income tax
consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules under Section&nbsp;451(b) of the Code, and does not
address any U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax consequences such as estate or gift tax consequences or any tax consequences arising under any state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax
laws. This discussion is based on the Code and applicable Treasury Regulations promulgated thereunder, judicial decisions and published rulings, and administrative pronouncements of the IRS all as in effect as of the date hereof. These authorities
are subject to differing interpretations and may change, possibly retroactively, resulting in U.S. federal income tax consequences different from those discussed below. We have not requested, and do not intend to request, a ruling from the IRS with
respect to the U.S. federal income tax consequences discussed below, and there can be no assurance that the IRS or a court will agree with such tax consequences. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is further limited to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders that hold our common stock as a &#147;capital asset&#148; within
the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion also does not address all U.S. federal income tax consequences that may be relevant to a particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s particular circumstances. Finally, this discussion does not address any specific facts or circumstances that may
be relevant to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to special rules under U.S. federal income tax laws, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships, S corporations, or other entities or arrangements treated as partnerships, pass-through entities,
or disregarded entities (including hybrid entities) for U.S. federal income tax purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations&#148; within the meaning of Section 957(a) of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;passive foreign investment companies&#148; within the meaning of Section 1297(a) of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks or other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts or regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that have elected to mark securities to market; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax-exempt organizations (including private foundations), governmental organizations, or international
organizations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax-qualified retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquired our common stock through the exercise of employee stock options or otherwise as
compensation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquired our common stock through the exercise of warrants or conversion rights under convertible
instruments; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our common stock as &#147;qualified small business stock&#148; under Section 1202 of the Code
or &#147;Section 1244 stock&#148; under Section 1244 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquired our common stock in a transaction subject to the gain rollover provisions of the Code
(including Section 1045 of the Code); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;qualified foreign pension funds&#148; within the meaning of Section 897(l)(2) of the Code and entities all
of the interests of which are held by qualified foreign pension funds; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our common stock as part of a hedging or conversion transaction, straddle, a constructive sale,
or any other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a partnership (or an entity or arrangement that is treated as a
partnership for U.S. federal income tax purposes) holds our common stock, the U.S. federal income tax treatment of a partner in such partnership will generally depend on the status of the partner and the activities of the partnership. Partnerships
that hold our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of holding and disposing of our common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR
U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING, AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS AND ANY U.S. FEDERAL <FONT
STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS, OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Definition of
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is
any beneficial owner of our common stock that is not a &#147;U.S. person&#148; or a partnership (including any entity or arrangement treated as a partnership) for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal
income tax purposes, is or is treated as any of the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or any entity treated as a corporation for U.S. federal income tax purposes) created or organized
under the laws of the United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (1)&nbsp;whose administration is subject to the primary supervision of a U.S. court and which has one or
more &#147;U.S. persons&#148; within the meaning of Section&nbsp;7701(a)(30) of the Code who have the authority to control all substantial decisions of the trust or (2)&nbsp;that has a valid election in effect under applicable Treasury Regulations
to be treated as a U.S. person. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Distributions on our common stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in the section titled &#147;Dividend Policy&#148; above, we have not paid and do not anticipate paying dividends in the foreseeable future.
However, if we make cash or other property distributions on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts that exceed such current and accumulated earnings and profits and, therefore, are
not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s tax basis in our common stock, but not below
zero. Any amount distributed in excess of tax basis will be treated as gain realized on the sale or other disposition of our common stock and, therefore, treated as described in the section titled &#147;&#151;Gain on Disposition of Our Common
Stock&#148; below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding effectively connected income, backup withholding, and Sections&nbsp;1471 through 1474 of the
Code, or commonly referred to as the Foreign Account Tax Compliance Act (FATCA), dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to U.S. federal withholding tax at a rate of 30% (or such lower
rate specified by an applicable income tax treaty) of the gross amount of the dividends. To receive the benefit of a lower treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish the applicable withholding agent with a
valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or applicable successor form) certifying such
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s qualification for such rate. This certification must be provided to the applicable withholding agent before the payment of dividends and updated periodically. If the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s behalf, the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide appropriate documentation to the financial institution or agent, which then will be required to provide certification to the applicable withholding agent, either
directly or through other intermediaries. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required certification on a
timely basis, but that qualify for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock in connection with the conduct of a trade or business in the United States,
and dividends paid on our common stock are effectively connected with such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. trade or business (and are attributable to such <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder&#146;s permanent establishment in the United States, if required by an applicable tax treaty), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be exempt from U.S. federal withholding tax. To claim the exemption, the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must generally furnish a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form) to the applicable withholding agent. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, any such effectively connected dividends paid on our common stock generally will be subject to U.S. federal income tax on a net income basis at
regular U.S. federal income tax rates in the same manner as if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation
also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their tax advisors about any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Gain on disposition of our common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the
discussions below regarding backup withholding and FATCA, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to U.S. federal income tax on any gain realized on the sale or other disposition of our common stock,
unless: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct
of a trade or business in the United States and, if required by an applicable income tax treaty, is attributable to the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s permanent establishment in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the sale or other disposition, and certain other requirements are met; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a &#147;United States real property interest&#148; by reason of our status as a
United States real property holding corporation, or USRPHC, for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the sale or other disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder&#146;s holding period for our common stock, and our common stock is not regularly traded on an established securities market as defined by applicable Treasury Regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Determining whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our other trade
or business assets and our foreign real property interests. We do not believe that we are, or have been, and do not anticipate becoming, a USRPHC for U.S. federal income tax purposes, although there can be no assurance that we will not in the future
become a USRPHC. Even if we are or were to become a USRPHC, gain arising from the sale or other disposition by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock may not be subject to U.S. federal income tax if our common
stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain described in the first
bullet point above generally will be subject to U.S. federal income tax on a net income basis at regular U.S. federal income tax rates in the same manner as if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder were a resident of the United
States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively
connected earnings and profits for the taxable year, as adjusted for certain items. Gain described in the second bullet point above will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate specified by an applicable income
tax treaty) but may be offset by certain U.S.-source capital losses (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S.
federal income tax returns with respect to such losses. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their tax advisors about any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Information reporting and backup withholding </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual
reports are required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder indicating the amount of distributions on our common stock paid to such <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder and the amount of any tax withheld with respect to those distributions. These information reporting requirements apply even if no withholding was required (because the distributions were effectively connected with the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an applicable income tax treaty) and regardless of whether such distributions constitute dividends. This
information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. Backup withholding, currently at a
24% rate, generally will not apply to payments to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of dividends on or the gross proceeds of a sale or other disposition of our common stock provided that the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS
Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or certain other requirements are met. Backup withholding may apply if the payor has actual
knowledge, or reason to know, that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a U.S. person who is not an exempt recipient. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup
withholding is not an additional tax. If any amount is withheld under the backup withholding rules, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders are urged to consult their tax advisors about the possibility of and procedure for obtaining
a refund or a credit against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Foreign
account tax compliance act </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FATCA imposes a U.S. federal withholding tax of 30% on certain payments made to a &#147;foreign financial institution&#148;
(as specially defined under the FATCA rules) unless such institution enters into an agreement with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding certain U.S. account holders of such institution
(which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or an exemption applies. FATCA also generally will impose a U.S. federal withholding tax of 30% on
certain payments made to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless such entity provides the withholding agent a certification identifying certain direct and indirect U.S. owners of the entity or an exemption
applies. An intergovernmental agreement between the United States and an applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> country may modify these requirements. Under certain circumstances, a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. FATCA applies to dividends paid on our common stock and, subject to the proposed Treasury Regulations described below, also applies to
gross proceeds from sales or other dispositions of our common stock. The U.S. Treasury Department released proposed Treasury Regulations which, if finalized in their present form, would eliminate the U.S. federal withholding tax of 30% applicable to
the gross proceeds of a sale or other disposition of our common stock. In its preamble to such proposed Treasury Regulations, the U.S. Treasury Department stated that taxpayers may generally rely on the proposed Treasury Regulations until final
regulations are issued. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospective investors are urged to consult with their tax advisors about the possible implications of FATCA on their investment in
our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_18"></A>Underwriting </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC, SVB Securities LLC,
Stifel, Nicolaus&nbsp;&amp; Company, Incorporated and RBC Capital Markets, LLC are acting as joint book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the
underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and
commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RBC Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chardan Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are committed to purchase all the common stock offered by us if they purchase any shares. The underwriting
agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the common stock directly to the public at the initial public offering price set forth on the cover page of this prospectus
and to certain dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up
to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share from the initial public offering price. After the initial offering of the shares to the public, if all of the common stock is not sold at the initial public
offering price, the underwriters may change the offering price and the other selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have an option to buy up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock from us
to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30&nbsp;days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are
purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the
additional shares on the same terms as those on which the shares are being offered. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting fee is equal to the public offering price per share
of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. The following table shows the per share and total
underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Without&nbsp;Option&nbsp;to&nbsp;Purchase<BR>Additional&nbsp;Shares&nbsp;Exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>With&nbsp;Full&nbsp;Option&nbsp;to&nbsp;Purchase<BR>Additional&nbsp;Shares&nbsp;Exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal
and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on the web sites maintained by one or more
underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet
distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed that we will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to,
any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition or filing, or (ii)&nbsp;enter into
any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by
the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and SVB Securities LLC for a period of 180 days after the date of this prospectus,
other than the shares of our common stock to be sold in this offering. The restrictions on our actions, as described above, do not apply to certain transactions,
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors and executive officers, and
substantially all of our shareholders (such persons, the <FONT STYLE="white-space:nowrap">&#147;lock-up</FONT> parties&#148;) have entered into lock up agreements with the underwriters prior to the commencement of this offering pursuant to which
each <FONT STYLE="white-space:nowrap">lock-up</FONT> party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the &#147;restricted period&#148;), may not (and may not cause any of their direct or
indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and SVB Securities LLC, (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without
limitation, common stock or such other securities which may be deemed to be beneficially owned by such <FONT STYLE="white-space:nowrap">lock-up</FONT> parties in accordance with the rules and regulations of the SEC and securities which may be issued
upon exercise of a stock option or warrant (collectively with the common stock, the <FONT STYLE="white-space:nowrap">&#147;lock-up</FONT> securities&#148;)), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole
or in part, any of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise, (3)&nbsp;make any demand for, or exercise any right with respect to, the registration of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, or (4)&nbsp;publicly
disclose the intention to do any of the foregoing. Such persons or entities have further acknowledged that these undertakings preclude them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short
sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be
expected to lead to or result in, a sale or disposition or transfer (by any person or entity, whether or not a signatory to such agreement) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or
otherwise. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph and contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements between the underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions, including (a)&nbsp;transfers of
<FONT STYLE="white-space:nowrap">lock-up</FONT> securities: (i)&nbsp;as bona fide gifts, or for bona fide estate planning purposes; (ii)&nbsp;by will or intestacy; (iii)&nbsp;to any trust for the direct or indirect benefit of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party or any immediate family member, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a trustor, trustee (or <FONT STYLE="white-space:nowrap">co-trustee)</FONT> or beneficiary
of the trust or to the estate of a beneficiary of the trust; (iv)&nbsp;to a partnership, limited liability company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or other entity of which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and its immediate family members are the legal and beneficial owner of all of the outstanding equity securities
or similar interests; (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i)&nbsp;through (iv); (vi) in the case of a corporation, partnership, limited liability company,
trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or
other entity controlling, controlled by, managing or managed by or under common control with the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates or (B)&nbsp;as part of a distribution, transfer or disposition to stockholders,
partners, members, beneficiaries or other equity holders of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party; (vii)&nbsp;by operation of law; (viii)&nbsp;to us from an employee upon death, disability or termination of employment of such
employee; (ix)&nbsp;as part of a sale of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired in this offering or in open market transactions after the completion of this offering; (x)&nbsp;to us in connection with the vesting,
settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of our common stock (including &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax and
remittance payments; (xi)&nbsp;pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction approved by our board of directors and made to all shareholders involving a change in control, provided that if such
transaction is not completed, all such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities would remain subject to the restrictions in the immediately preceding paragraph; or (xii)&nbsp;to an immediate family member of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party; (b)&nbsp;exercise of the options, settlement of RSUs or other equity awards, or the exercise of warrants granted pursuant to plans described in in this prospectus, provided that any <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities received upon such exercise, vesting or settlement would be subject to restrictions similar to those in the immediately preceding paragraph; (c)&nbsp;the conversion of outstanding preferred stock,
warrants to acquire preferred stock, or convertible securities into shares of our common stock or warrants to acquire shares of our common stock, provided that any common stock or warrant received upon such conversion would be subject to
restrictions similar to those in the immediately preceding paragraph; and (d)&nbsp;the establishment by <FONT STYLE="white-space:nowrap">lock-up</FONT> parties of trading plans under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the
Exchange Act, provided that such plan does not provide for the transfer of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC and SVB Securities LLC, in their sole discretion, may release the securities subject to any of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters described above, in whole or in part at any time. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to
indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to apply to have our common stock
approved for listing on the Nasdaq Global Market under the symbol &#147;LXEO&#148;. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may engage in
stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in
progress. These stabilizing transactions may include making short sales of common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing
shares of common stock on the open market to cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares
referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in
part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may
purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that
could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also
engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in
stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of
the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may
carry out these transactions on The Nasdaq Stock Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in connection with this offering certain of the underwriters (and selling group members) may engage in passive market making transactions in our
common stock on The Nasdaq Stock Market prior to the pricing and completion of this offering. Passive market making consists of displaying bids on The Nasdaq Stock Market no higher than the bid prices of independent market makers and making
purchases at prices no higher than these independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are generally limited to a specified percentage of the passive market maker&#146;s average daily
trading volume in the common stock during a specified period and must be discontinued when such limit is reached. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market
in the absence of these transactions. If passive market making is commenced, it may be discontinued at any time. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no
public market for our common stock. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the
underwriters expect to consider a number of factors including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information set forth in this prospectus and otherwise available to the representatives;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our prospects and the history and prospects for the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our prospects for future earnings; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the general condition of the securities markets at the time of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors deemed relevant by the underwriters and us. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters can assure investors that an active trading market will develop for our common stock, or that the shares will trade in the
public market at or above the initial public offering price. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us or the underwriters that
would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this
prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable
rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or
a solicitation is unlawful. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time
to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees
and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions
in our debt or equity securities or loans, and may do so in the future. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in the european economic area </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each a &#147;Relevant State&#148;), no shares of our common stock have been offered or will be
offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares of our common stock which has been approved by the competent authority in that Relevant State or, where
appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation), except that offers of Shares may be made to the public in that Relevant State at any
time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such
offer of shares of common stock shall require the Issuer or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged
and agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of
any shares of common stock being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of
common stock acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which
may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares of common stock in any Relevant State
means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Shares, and the expression &#147;Prospectus
Regulation&#148; means Regulation (EU) 2017/1129. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in the United Kingdom </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to the United Kingdom, or the UK, no shares of our common stock have been offered or will be offered pursuant to the offering to the public in the
UK prior to the publication of a prospectus in relation to the shares of common stock which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and the Financial Services and Markets Act
2000, or the FSMA, except that offers of shares of common stock may be made to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation and the FSMA: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under the UK Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under the UK Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at any time in other circumstances falling within section 86 of the FSMA, </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of
shares of common stock shall require the issuer or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or Article 3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the UK Prospectus
Regulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each person in the UK who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented,
acknowledged and agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the UK Prospectus Regulation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of any shares of common stock being offered to a financial intermediary as that term is used in Article 5(1) of the UK Prospectus Regulation, each
such financial intermediary will be deemed to have represented, acknowledged and agreed that the Shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have
they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in the UK to qualified investors, in circumstances in which the prior consent of the
underwriters has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, the underwriters and their affiliates will rely upon the truth and
accuracy of the foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the
public&#148; in relation to any shares of our common stock in the UK means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an
investor to decide to purchase or subscribe for any shares of our common stock, the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act
2018, and the expression &#147;FSMA&#148; means the Financial Services and Markets Act 2000. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is for distribution only to persons who
(i)&nbsp;have professional experience in matters relating to investments and who qualify as investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended), or
the &#147;Financial Promotion Order,&#148; (ii) are persons falling within Article 49(2)(a) to (d) (&#147;high net worth companies, unincorporated associations etc.&#148;) of the Financial Promotion Order, (iii)&nbsp;are outside the United Kingdom,
or (iv)&nbsp;are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused
to be communicated (all such persons together being referred to as &#147;relevant persons&#148;). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in Canada </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of common stock must be made in accordance with an exemption from, or in a transaction
not subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting
Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in
connection with this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in Switzerland </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss
Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other
offering or marketing material relating to the shares of common stock or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares of common stock have been or will be filed
with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares of common stock will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the
offer of shares of common stock has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA
does not extend to acquirers of shares of common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in Hong Kong </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the laws of Hong Kong), or SFO, of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document
being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.&nbsp;32) of the laws of Hong Kong), or CO, or which do not constitute an offer to the public within the meaning of the CO. No
advertisement, invitation or document relating to the shares of common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the
contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than with respect to shares of common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and
any rules made thereunder. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in Singapore </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each joint book-running manager has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, each joint book-running manager has represented and agreed that it has not offered or sold any shares of common stock or caused the shares of common stock to be made the subject of an invitation for subscription or purchase and will not
offer or sell any shares of common stock or cause the shares of common stock to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any
other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of common stock, whether directly or indirectly, to any person in Singapore other than: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter&nbsp;289) of Singapore, as modified or amended from time to time, or the SFA) pursuant to Section&nbsp;274 of the
SFA; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified
in Section&nbsp;275 of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the shares of common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based
derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or
that trust has acquired the shares of common stock pursuant to an offer made under Section&nbsp;275 of the SFA except: </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an
offer of shares of common stock, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares of common stock are &#145;&#145;prescribed capital markets products&#146;&#146; (as defined
in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT>
Notice on Recommendations on Investment Products). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in Japan </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act.
Accordingly, none of the shares of common stock nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in
Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan,
except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the
relevant time. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in the United Arab Emirates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai
International Financial Centre, or the DIFC) other than in compliance with the laws of the United Arab Emirates (and the DIFC) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of
securities in the United Arab Emirates (including the DIFC) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or
the Dubai Financial Services Authority, or the DFSA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in Israel </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law,
5728&#151;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728&#150;1968, including, inter alia, if:
(i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors; or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First
Addendum of the Israeli Securities Law, 5728&#151;1968, subject to certain conditions, or the &#147;Qualified Investors&#148;.&nbsp;The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to
purchase securities in addition to the 35 Addressed Investors.&nbsp;We have not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&#151;1968.&nbsp;We have not
and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our shares of common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law,
5728&#151;1968.&nbsp;In particular, we may request, as a condition to be offered shares of common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor
falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968; (ii)&nbsp;which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968 regarding Qualified
Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728&#151;1968 and the regulations promulgated thereunder in connection with the offer to be issued shares of common stock;
(iv)&nbsp;that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&#151;1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a
view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#151;1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status.&nbsp;Addressed
Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in Australia </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth), or the Corporations Act; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a disclosure document for the purposes of the Corporations Act and does not purport to include the information
required of a disclosure document for the purposes of the Corporations Act; and </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(c)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available under section 708 of the Corporations Act, or Exempt
Investors. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to
subscribe for or buy the shares of common stock may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares of common stock may be distributed in Australia, except where disclosure
to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares of common stock, you represent and warrant to us
that you are an Exempt Investor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As any offer of shares of common stock under this document will be made without disclosure in Australia under Chapter
6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter&nbsp;6D.2 if none of the exemptions in section 708
applies to that resale. By applying for the shares of common stock you undertake to us that you will not, for a period of 12 months from the date of issue of the shares of common stock, offer, transfer, assign or otherwise alienate those shares of
common stock to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in China </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus
will not be circulated or distributed in the PRC and the shares of common stock will not be offered or sold, and will not be offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to
any residents of the PRC except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will
result in compliance with applicable laws and regulations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in Korea </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees
and regulations thereunder, or the FSCMA, and the shares of common stock have been and will be offered in Korea as a private placement under the FSCMA. None of the shares of common stock may be offered, sold or delivered directly or indirectly, or
offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and
the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder, or FETL. Furthermore, the purchaser of the shares of common stock shall comply with all applicable regulatory requirements (including but not limited to
requirements under the FETL) in connection with the purchase of the shares of common stock. By the purchase of the shares of common stock, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares of common stock pursuant to the applicable laws and
regulations of Korea. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in Saudi Arabia </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as
issued by the board of the Saudi Arabian Capital Market Authority, or CMA, pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as amended by resolution
number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended, or the CMA Regulations. The CMA does not make any representation as to the accuracy or completeness of this document and expressly
disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information
relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to
prospective investors in the Dubai International Financial Centre </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document relates to an Exempt Offer in accordance with the Markets Rules 2012
of the DFSA. This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or
verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to which this
document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document, you
should consult an authorized financial advisor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to its use in the DIFC, this document is strictly private and confidential and is being
distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or
indirectly to the public in the DIFC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice to prospective investors in Bermuda </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of common stock may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which
regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so
under applicable Bermuda legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_19"></A>Legal matters </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Cooley LLP, New York, New York. Certain legal matters will be passed
upon for the underwriters by Goodwin Procter LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_20"></A>Experts </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Lexeo Therapeutics, Inc. as of and for the <FONT STYLE="white-space:nowrap">one-year</FONT> period ended December&nbsp;31, 2020
have been included herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.<B> </B> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B><A NAME="toc287237_21"></A>Where you can find additional information </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to the shares of
common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information with respect to our
company and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily
complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can read our SEC filings, including the registration statement, over the internet at the SEC&#146;s website at <I>www.sec.gov</I>. Upon completion of this
offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available at
<I>www.sec.gov</I>. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also maintain a website at <I>www.lexeotx.com</I>, at which you may access these materials free of charge as soon as reasonably
practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated into, this prospectus, and the inclusion of our
website address in this prospectus is only as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B>LEXEO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="toc287237_22"></A>Index to Financial Statements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Index to Financial Statements as of and for the One-year Period Ended December 31, 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin287237_100">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin287237_101">Balance Sheet as of December 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin287237_102">Statement of Operations and Comprehensive Loss for the Year Ended December
 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin287237_103">Statement of Changes in Convertible Preferred Stock and Stockholders&#146;
 Deficit as of December 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin287237_104">Statement of Cash Flows for the Year December 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin287237_105">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="fin287237_100"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexeo Therapeutics,
Inc.: </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><I>Opinion on the Financial Statements</I><B><I> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheet of Lexeo Therapeutics, Inc. (the Company) as of December&nbsp;31, 2020, the related statements of operations and
comprehensive loss, changes in convertible preferred stock and stockholders&#146; deficit, and cash flows for the year ended December&nbsp;31, 2020, and the related notes (collectively, the financial statements). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2020, and the results of its operations and its cash flows for the year ended December&nbsp;31, 2020, in conformity with U.S.
generally accepted accounting principles. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><I>Basis for Opinion</I><B><I> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements
based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the
standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to
those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2021. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">New York, New York </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">September 8, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B>Lexeo Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="fin287237_101"></A>Balance sheet </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,373,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,406,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,409,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, convertible preferred stock&nbsp;&amp; stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,010,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,707,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock, $0.0001 par value; 85,500,000 shares authorized as of
December&nbsp;31, 2020; 34,495,725 shares issued and outstanding as of December&nbsp;31, 2020; aggregate liquidation value of $34,495,725 as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,237,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 120,000,000 shares authorized at December&nbsp;31, 2020;
16,040,884 shares issued and outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,547,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,536,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock, and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">29,409,281</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B>Lexeo Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="fin287237_102"></A>Statement of operations and comprehensive loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B>For the year ended December&nbsp;31, 2020 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">518,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,318,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,106,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,587,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(422,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(565,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,152,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,152,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted&#151;average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,270,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B>Lexeo Therapeutics Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="fin287237_103"></A>Statement of changes in convertible preferred stock and stockholders&#146; deficit </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred<BR>stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Common units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Total<BR>stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Outstanding<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balances at January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(395,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(385,537</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of common units to common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,040,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series A convertible preferred stock, net of issuance costs of $223,587</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,495,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,237,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,152,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,152,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="33" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,495,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,237,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,040,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,547,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,536,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="36" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B>Lexeo Therapeutics Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="fin287237_104"></A>Statement of cash flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B>For the year December&nbsp;31, 2020 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,152,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">422,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash&nbsp;interest</FONT> expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retirement of Cornell license obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in deferred income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,133,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(223,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,602,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,378,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,245,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,373,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash investing and financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of the Notes to Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,001,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,010,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B>Lexeo Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B><A NAME="fin287237_105"></A>Notes to financial statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>1. Description of business and basis of presentation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of business</B>&#151;LEXEO Therapeutics Inc. (&#147;LEXEO&#148; or the &#147;Company&#148;) is a clinical-stage gene therapy company focused on
addressing some of the most devastating genetically defined cardiovascular and central nervous system diseases affecting both larger-rare and prevalent patient populations. The Company is advancing a deep and diverse pipeline of <FONT
STYLE="white-space:nowrap">AAV-based</FONT> gene therapy candidates utilizing the Company&#146;s modular approach that integrates clinically validated technology, a disease area strategy targeting defined patient
<FONT STYLE="white-space:nowrap">sub-populations</FONT> most likely to benefit from the Company&#146;s therapies, and high-quality, scalable manufacturing, which is designed to overcome many of the challenges facing the field of gene therapy. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is located in New York, NY and was first formed on February&nbsp;17, 2017, as an LLC under the laws of the State of Delaware under the legal name
LEXEO Therapeutics, LLC. The Company filed and executed a certificate of conversion to corporation on November&nbsp;20, 2020, to convert the LLC to Lexeo Therapeutics, Inc., a Delaware corporation. All of the Company&#146;s tangible assets are held
in the United States (&#147;U.S.&#148;). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of presentation</B>&#151;The financial statements have been prepared in accordance with accounting
principles generally accepted in the U.S. (&#147;U.S. GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and
Accounting Standards Update (&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of
<FONT STYLE="white-space:nowrap">COVID-19</FONT></B>&#151;On March&nbsp;11, 2020, the World Health Organization declared the novel coronavirus <FONT STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> outbreak a pandemic. In response to the
outbreak, many jurisdictions, including those in which the Company is located, implemented measures to combat the outbreak, such as travel restrictions and shelter in place orders. The extent of the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak
and its impact on the Company&#146;s development activities and other third parties with whom the Company does business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020, the
Coronavirus Aid, Relief, and Economic Security Act (&#147;CARES Act&#148;) was signed into law. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary suspension of certain payment requirements for the
employer portion of Social Security taxes and the creation of certain refundable employee retention credits. These provisions of the CARES Act did not have a significant impact on the Company&#146;s financial statements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks and uncertainties</B>&#151;The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry,
including, but not limited to, successful discovery and development of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees,
protection of proprietary technology, compliance with governmental regulations, the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the ability to secure additional capital to fund operations and commercial success of its
product candidates. Any future product candidates the Company may develop will require extensive nonclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of capital, adequate
personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>2. Summary of significant accounting policies </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of estimates</B>&#151;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant
estimates relate to the accruals of research and development costs, accrual of research contract costs, and determination of fair value of the Company&#146;s convertible preferred stock and estimates of the tranche obligation liability. Management
evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on
information available as of the date of the financial statements; therefore, actual results could differ from those estimates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash</B>&#151;Cash is
recorded at cost, which approximates fair value. As of December&nbsp;31, 2020, cash consists primarily of cash on deposit with U.S. banks denominated in U.S. dollars and investments in interest bearing money market funds. The Company regularly
maintains cash balances with financial institutions which exceed Federal Deposit Insurance Corporation (&#147;FDIC&#148;) insurance limits. At December&nbsp;31, 2020, the Company had approximately $29.1&nbsp;million, in excess of FDIC insured
limits. The Company does not hold any cash equivalents, which would consist of highly liquid investments with original maturities of three months or less at the time of purchase. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounts receivable and allowance for doubtful accounts</B>&#151;Accounts receivable are recorded net of allowances for doubtful accounts. The Company does
not have any accounts receivable but in certain cases may have a grant receivable balance. For the Company to be in a receivable position related to grants, the cumulative total spend on grants would have to exceed the cumulative cash receipts in
the event there remains additional award money to be collected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Debt issuance costs</B>&#151;Costs incurred in connection with the issuance of the
Company&#146;s convertible notes have been recorded as a direct reduction against the convertible notes and amortized under the effective interest method. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Classification of convertible preferred stock</B>&#151;The holders of the Series A convertible preferred stock have certain liquidation rights in the event
of a deemed liquidation that, in certain situations, are not solely within the control of the Company and would call for the redemption of the then outstanding Series A convertible preferred stock. Therefore, the Series A convertible preferred stock
are classified outside of the stockholders&#146; deficit on the balance sheets. The carrying value of the convertible preferred stock is not subsequently remeasured to the redemption value until the contingent redemption events are considered to be
probable of occurring. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue recognition</B>&#151;On January&nbsp;1, 2020, the Company adopted ASU <FONT STYLE="white-space:nowrap">2014-09,</FONT>
Revenue from Contracts with Customers (Topic 606), on a modified retrospective basis. Topic 606 establishes a principle for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected
consideration received in exchange for those goods or services. The standard also provides guidance on the recognition of costs related to obtaining and fulfilling customer contracts. Additionally, the standard requires disclosures regarding the
nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the Company performs the
following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance
obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is
entitled to in exchange for the goods and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those
that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the
performance obligation is satisfied. As of December&nbsp;31, 2020, there is no revenue from contracts with customers. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grant revenue</B>&#151;Grants
received are recognized as grant revenue in the statement of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant revenue earned
are recognized as deferred grant revenue on the balance sheet and grant revenue earned in excess of grant payments received is recognized as grant receivable on the balance sheets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and development</B>&#151;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to
discover and develop drug candidates, including personnel expenses, allocated facility-related and depreciation expenses and third-party license fees in connection with nonclinical studies. Costs incurred in obtaining technology licenses are charged
immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and administrative</B>&#151;General and administrative expense consists primarily of the cost of employees to engage in corporate functions, such as
finance and accounting, information technology, human resources, legal and executive management. General and administrative expense also includes rent occupancy costs, office expenses, recruiting expenses, entertainment allocations, depreciation and
amortization, other general overhead costs, insurance premiums, professional service fees, and cost related to regulatory and litigation matters. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income taxes</B>&#151;Prior to November&nbsp;20, 2020, the Company was an LLC entity and elected to be treated under the Partnership provisions of the
Internal Revenue Code. Accordingly, the LLC entity was not viewed as a <FONT STYLE="white-space:nowrap">tax-paying</FONT> entity in any jurisdiction and all income and deductions of the LLC entity flowed through to the individual members and
therefore no income taxes were recorded by the Company. On November&nbsp;20, 2020, the Company elected to convert to a C Corporation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts
for income taxes under the asset and liability method pursuant to ASC 740, <I>Income Taxes</I>. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to
taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment
date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized based on all available positive and negative evidence. As of December&nbsp;31,
2020, the Company continues to maintain a full valuation allowance against its deferred tax assets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes a tax benefit only if it is
more likely than not the tax position will be sustained on examination by the local taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured
based on the largest benefit greater than 50% likelihood of being realized upon settlement with the related tax authority. The changes in recognition or measurement are reflected in the period in which the change in judgment occurs. As of
December&nbsp;31, 2020, the Company has not identified any uncertain tax positions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records interest and penalties related to unrecognized tax
benefits in the provision for income taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Segment Information</B>&#151;Operating segments are defined as components of an entity about which
separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one
reportable and operating segment, which is the business of license acquisitions, regulatory approvals, clinical trials, and commercial activity related to the current portfolio of in-licensed products. The Company&#146;s chief executive officer, who
is the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial performance. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair value measurements</B>&#151; Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are described below: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Level 1</I>&#151;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at
the measurement date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Level 2</I>&#151;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted
quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Level 3</I>&#151;Inputs are unobservable inputs for the asset or liability. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentrations of credit Risk</B>&#151;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of
cash. The Company&#146;s cash balances exceed those that are federally insured. The Company&#146;s cash is held with large financial institutions that management believes to be of high credit quality. To date, the Company has not recognized any
losses caused by uninsured balances. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Loss Per Share</B>&#151;The Company follows the <FONT STYLE="white-space:nowrap">two-class</FONT> method when
computing net income (loss) per common share as the Company has issued shares that meet the definition of participating securities. The <FONT STYLE="white-space:nowrap">two-class</FONT> method determines net income (loss) per common share for each
class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income (loss) available to common
stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its convertible preferred
stock to be participating securities as, in the event a dividend is paid on common stock, the holders of these securities would be entitled to receive dividends on a basis consistent with the common stockholders. The Company also considers the
shares issued upon the early exercise of stock options that are subject to repurchase to be participating securities because holders of such shares have <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> dividend rights in the event a dividend
is paid on common stock. There is no allocation required under the <FONT STYLE="white-space:nowrap">two-class</FONT> method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the
Company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share is computed by dividing the net income (loss) per common share by the weighted-average number of common
shares outstanding for the period. Diluted net income (loss) per common share is computed by adjusting net income (loss) to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per common share is
computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, convertible preferred stock are considered potential
dilutive common shares. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In periods in which the Company reported a net loss, diluted net loss per common share was the same as basic net loss per common
share, since dilutive common shares were not assumed to have been issued if their effect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was anti-dilutive. The Company excluded 34,495,725 potential common shares related to the conversion of Series A convertible preferred stock from the computation of diluted net loss per common
share for the year ended December&nbsp;31, 2020 because including them would have had an anti-dilutive effect. The Company reported a net loss for the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently adopted accounting pronouncements</B>&#151;In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> Income Taxes
(&#147;Topic 740&#148;): Simplifying the Accounting for Income Taxes (&#147;ASU <FONT STYLE="white-space:nowrap">2019-12&#148;),</FONT> which eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for
calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and
clarifies the accounting for transactions that result in a <FONT STYLE="white-space:nowrap">step-up</FONT> in the tax basis of goodwill. The Company early adopted ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> effective January&nbsp;1, 2019.
ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> removes the exception to the incremental approach for intra-period tax allocation in the event of a loss from continuing operations and income or gain from other items such as other comprehensive
income. The exception previously resulted in allocating a tax benefit to continuing operations and tax expense to other items, even when tax expense may have been zero. Under the simplification, no tax expense or benefit will be recorded to
continuing operations. There is no impact on the Company&#146;s financial statements for this amendment under ASU <FONT STYLE="white-space:nowrap">2019-12.</FONT> The other provisions within ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> are
not applicable to the Company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-13,</FONT> Fair Value Measurement (&#147;Topic
820&#148;)&#151;Changes to the Disclosure Requirements for Fair Value Measurement (&#147;ASU <FONT STYLE="white-space:nowrap">2018-13&#148;),</FONT> which removed the following disclosure requirements: (1)&nbsp;the amount of and reasons for
transfers between Level&nbsp;1 and Level&nbsp;2 of the fair value hierarchy; (2)&nbsp;the policy for timing of transfers between levels; and (3)&nbsp;the valuation processes for Level&nbsp;3 fair value measurements. Additionally, this update added
the following disclosure requirements: (1)&nbsp;the changes in unrealized gains and losses for the period included in other comprehensive income and loss for recurring Level&nbsp;3 fair value measurements held at the end of the reporting period;
(2)&nbsp;the range and weighted average of significant unobservable inputs used to develop Level&nbsp;3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic
average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level&nbsp;3 fair value
measurements. The Company early adopted ASU <FONT STYLE="white-space:nowrap">2018-13</FONT> on January&nbsp;1, 2019. For the new disclosures regarding the Company&#146;s Level&nbsp;3 fair value measurements, (see Note 3). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent accounting pronouncements not yet adopted</B>&#151; In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases
(&#147;Topic 842&#148;) (&#147;ASU <FONT STYLE="white-space:nowrap">2016-02&#148;),</FONT> which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and
lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification
will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less
may be accounted for similar to existing guidance for operating leases today. For <FONT STYLE="white-space:nowrap">non-public</FONT> entities, ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> is effective for annual reporting periods beginning
after December&nbsp;15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The Company is in the process of completing its review of its existing lease agreements under Topic 842 and does not expect the
adoption of ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> to have a material impact on its financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> Financial Instruments-Credit Losses (&#147;Topic 326&#148;): Measurement of
Credit Losses on Financial Instruments (&#147;ASU <FONT STYLE="white-space:nowrap">2016-13&#148;),</FONT> which requires the measurement and recognition of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expected credit losses for financial assets held at amortized cost. ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> replaces the existing incurred loss impairment model with an expected loss
methodology, which will result in more timely recognition of credit losses. ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> is effective for annual private company reporting periods, and interim periods within those years, beginning after
December&nbsp;15, 2023. The Company is currently in the process of evaluating the impact of the adoption of ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> on its financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>3. Fair value measurements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents
information about the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" COLSPAN="9" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD COLSPAN="8" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Fair value measurement at<BR>December&nbsp;31, 2020 using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,373,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,373,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">29,373,209</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">29,373,209</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,010,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,010,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">3,010,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">3,010,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s preferred stock tranche obligation (see below) is carried at fair value determined according to Level&nbsp;3
inputs in the fair value hierarchy as described below. The carrying values of other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preferred stock tranche obligation </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, the Company
obtained Series A funding from investors with two subsequent milestone closing dates. Each of the two milestones represent a separate tranche obligation as they may be exercised separately and an investor could transfer part of any rights under the
agreement, including the right/obligation to participate in an individual tranche. The tranche obligation is recorded at fair value at the issuance date and a portion of the proceeds from the first closing equal to that amount will be allocated to
the tranche obligation. At November&nbsp;20, 2020, the fair value of the tranche obligation was valued at $3.0&nbsp;million at a value per share equivalent to $0.05 and $0.07 for the second and third closings, respectively. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determined that its obligation to issue additional shares at a fixed price (i.e. the issuance price) in subsequent tranches (&#147;First
Milestone&#148; and &#147;Second Milestone&#148;) (collectively, the &#147;Milestones&#148;) following the initial closing of the Series A convertible preferred stock financings represented two freestanding financial instruments (together, the
&#147;Tranche Obligation&#148;). The Company determined that its investors would be able to transfer their initial shares but keep the right/obligation to participate in the subsequent tranches, therefore the instruments are detachable. Further, as
exercise of the tranche obligation does not result in the forfeiture of the shares issued in the initial closing, the instruments are separately exercisable. The freestanding financial instruments were classified as a liability on the Company&#146;s
balance sheets and initially recorded at fair value and will be marked to market at each reporting period through the issuance of shares at the closing of the Milestones, with changes in fair value for each reporting period recognized in other
income in the statement of operations (see Note 5). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s initial issuance of Series A convertible preferred stock in November
2020 (see Note 5) the Company recognized the Tranche Obligation at the fair value related to each issuance, which was determined based on significant inputs not observable in the market, which represented a Level&nbsp;3 measurement within the fair
value hierarchy. The initial fair value of each obligation was estimated based on results of a valuation performed. The obligation will be remeasured prior to the issuance of subsequent <B>tranches</B>, and at each subsequent reporting period, as
well as immediately prior to when the obligation is settled. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tranche Obligation was determined using the binomial pricing model, which takes into
account the probability of achievement and failure of tranche milestones and issuance of subsequent shares. The Tranche Obligation is calculated based on future Series A preferred share fair value estimated as of each milestone date, and present
valued using a risk-neutral probability-weighted framework at each milestone date. The value of the Series A convertible preferred stock price at each future milestone was estimated assuming that the expected stock price grows at the risk-free rate
on a probability-weighted basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes information about the significant unobservable inputs used in the fair value measurements
for the Tranche Obligation: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>November&nbsp;20,<BR>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">75%&nbsp;-&nbsp;90%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">75%&nbsp;-&nbsp;90%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of dissolution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10%&nbsp;-&nbsp;25%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10%&nbsp;-&nbsp;25%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to liquidity (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.11&nbsp;&#150;&nbsp;1.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.97&nbsp;&#150;&nbsp;1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10%&nbsp;-&nbsp;11%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10%&nbsp;-&nbsp;11%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tranche Obligation value is discounted back to the initial issuance date and adjusted for probability of the tranche
milestone achievement. In determining the fair values of the tranche obligations, estimates and assumptions impacting fair value include the estimated future values of the Company&#146;s Series A convertible preferred stock, discount rates,
estimated time to liquidity, and probability of tranche closing/milestone achievement. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion option liabilities </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As further described in Note 4, the Company issued Notes on May&nbsp;27, 2020, and August&nbsp;11, 2020. The Notes contained certain features that met the
definition of a derivative and were required to be bifurcated. The Company has accounted for these as a single derivative comprising all the features requiring bifurcation (the &#147;First Conversion Option Liability&#148; and the &#147;Second
Conversion Option Liability&#148;) (collectively the &#147;Conversion Option Liabilities&#148;). The fair value of the derivative liability&nbsp;was estimated using a scenario-based analysis comparing the probability-weighted present value of the
convertible promissory note payoff at maturity with and without the bifurcated features. The Company considered possible outcomes available to the investors, including a conversion upon qualified financing transaction, and a mandatory conversion
upon change of control. In addition, the probabilities applied to various scenarios, the key unobservable inputs are the time to liquidity for each scenario, and the discount rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize information about the significant unobservable inputs used in the fair value
measurements for the Conversion Option Liabilities: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First Conversion Option Liability </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>May&nbsp;27, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Conversion&nbsp;upon<BR>qualified&nbsp;financing<BR>transaction</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Mandatory<BR>conversion&nbsp;upon<BR>change&nbsp;of&nbsp;control</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of dissolution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to liquidity (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.07%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.19%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Second Conversion Option Liability </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>August&nbsp;11, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Conversion&nbsp;upon<BR>qualified&nbsp;financing<BR>transaction</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Mandatory<BR>conversion&nbsp;upon<BR>change&nbsp;of&nbsp;control</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of dissolution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to liquidity (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.99%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.60%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2020, in connection with the Company&#146;s issuance and sale of Series A convertible preferred stock, all of the
outstanding principal and accrued interest under the convertible promissory notes was automatically converted into shares of Series A convertible preferred stock and the Conversion Option Liabilities were extinguished (see Note 4). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following Level&nbsp;3 table provides a roll forward of the aggregate fair values of the Company&#146;s Conversion Option Liabilities and Tranche
Obligation: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tranche Obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,010,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Conversion Option Liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">646,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Conversion Option Liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Extinguishment of Conversion Option Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(745,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,010,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, there was no material remeasurement necessary. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>4. Convertible notes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into three
convertible securities purchase agreements (collectively, the &#147;Convertible Securities Agreements&#148;) on May&nbsp;27, 2020, May&nbsp;28, 2020, and August&nbsp;11, 2020, with numerous investors to issue notes with an aggregate principal of
$3.9&nbsp;million (the &#147;Notes&#148;). The Notes included an interest rate of 6% that compounds annually, with a maturity date of the fifth anniversary of each respective note (May&nbsp;27, 2025, May&nbsp;28, 2025, and August&nbsp;11, 2025),
unless earlier converted. The Company received $2.6&nbsp;million in cash and retired a $1.3&nbsp;million obligation for the right to use a Cornell license (see Note 9). The Notes were issued on May&nbsp;27, 2020 and August&nbsp;11, 2020, and
contained a conversion option feature. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes are accounted for in accordance with
<FONT STYLE="white-space:nowrap">ASC&nbsp;470-20,</FONT><I></I><I>&nbsp;Debt with Conversion</I><I></I><I>&nbsp;and Other Options</I> <FONT STYLE="white-space:nowrap">(&#147;ASC&nbsp;470-20&#148;)</FONT> and
<FONT STYLE="white-space:nowrap">ASC&nbsp;815-15,</FONT><I></I><I>&nbsp;Derivatives and Hedging -</I><I>&nbsp;Embedded Derivatives</I> <FONT STYLE="white-space:nowrap">(&#147;ASC&nbsp;815-15&#148;).</FONT> Under
<FONT STYLE="white-space:nowrap">ASC&nbsp;815-15,</FONT> a feature is required to be bifurcated if all three conditions are met: (1)&nbsp;economic characteristics and risks of the embedded derivative are not clearly and closely related to the
economic characteristics and risks of the host contract, (2)&nbsp;the hybrid instrument is not remeasured at fair value under otherwise applicable GAAP with changes in fair value reported in earnings as they occur, and (3)&nbsp;a separate instrument
which the same terms as the derivative would be considered a derivative instrument subject to derivative accounting (the initial net investment for the hybrid instrument should not be considered to be the initial net investment for the derivative.
The Company bifurcated the Conversion Option Liabilities as it was determined that they were required to be accounted separately as a single derivative. The initial fair value of the Conversion Option Liabilities of $0.7&nbsp;million was recorded as
a liability, and as a reduction to the carrying value of the Notes. On November&nbsp;20, 2020, upon conversion, the Company accounted for the Conversion Option Liabilities as a gain within loss on extinguishment of notes in the statement of
operations. Issuance costs related to the Notes were deemed immaterial. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt discount comprised of the initial fair value of the Conversion Option
Liabilities is amortized using the effective interest method over <FONT STYLE="white-space:nowrap">the&nbsp;two-year&nbsp;contractual</FONT> term of the Notes and presented as a direct reduction of the debt&nbsp;liability. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2020, in connection with the Company&#146;s issuance and sale of Series A convertible preferred stock, all of the outstanding principal and
interest under the Notes, totaling $4.0&nbsp;million, with interest totaling $0.1&nbsp;million recorded in interest expense in the statement of operations, was converted into 4,495,719 shares of Series A convertible preferred stock at a price
ranging between <FONT STYLE="white-space:nowrap">85-100%</FONT> of $1.00 per share depending on the investor (see Note 5). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the
conversion of the Notes as a debt extinguishment and recognized a loss on extinguishment of debt of $1.2&nbsp;million within other income (expense), net in the statement of operations. The loss on extinguishment was calculated as the difference
between the carrying value of the Notes, net of the unamortized debt discount of $3.3&nbsp;million, and the fair value of the 4,495,719 shares of Series A convertible preferred stock issued to settle the Notes of $4.5&nbsp;million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>5. Preferred stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the
Company&#146;s certificate of incorporation authorized the Company to issue 85,500,000 shares of Series A convertible preferred stock at par value of $0.0001. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;20, 2020, the Company entered into a Series A convertible preferred stock purchase agreement (the &#147;Series A Purchase Agreement&#148;)
whereby the Company issued 29,999,996 shares of Series A convertible preferred stock at $1.00 per share for an aggregate purchase price of $30.0&nbsp;million and incurred $0.2&nbsp;million of issuance costs. Additionally, on November&nbsp;20, 2020,
the Company issued 4,495,719 additional shares of Series A convertible preferred stock to the holders of the Company&#146;s Notes on conversion of the Notes (see Note 4). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Series A Purchase Agreement, the shareholders are eligible to purchase additional shares at the date of certain contractual milestone events.
The first milestone event is the successful Federal Drug Administration (&#147;FDA&#148;) clearance to proceed into human clinical studies of one of the Company&#146;s therapeutics. The second milestone event is the successful dosing of the
therapeutic in five human patients with all relevant safety data supportive of future development. As of December&nbsp;31, 2020, these milestones have not yet been achieved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company&#146;s convertible preferred stock consisted of the following:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Convertible<BR>preferred<BR>stock<BR>authorized</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Convertible<BR>preferred<BR>stock<BR>issued and<BR>outstanding</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Proceeds<BR>received</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Liquidation<BR>preference</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Common&nbsp;stock<BR>issuable&nbsp;upon<BR>conversion</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,495,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,495,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,495,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="20" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the rights and privileges of the holders of the convertible preferred stock were as follows: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting</I>&#151;Holders of preferred stock are entitled to vote together with the holders of common stock as a single class and on an as converted to common
stock basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends&#151;</I>The holders of shares of Series A convertible preferred stock are entitled to receive, when, as and if declared by the
Company&#146;s board of directors, dividends at the rate of 8% per share of preferred stock, prior and in preference to any declaration or payment of any other dividend (other than dividends on shares of common stock payable in shares of common
stock). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Deemed liquidation event</I>&#151;Each of the following events shall be considered a &#147;Deemed Liquidation Event&#148; unless the holders of
a majority of the outstanding shares of preferred stock elect otherwise by written notice sent to the Company at least five business days prior to the effective date of any such event: (a)&nbsp;a merger or consolidation in which the Company is a
constituent party or a subsidiary of the Company is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving the Company or a subsidiary in
which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or
consolidation, at least a majority of the capital stock of (1)&nbsp;the surviving or resulting company; or (2)&nbsp;if the surviving or resulting company is a wholly owned subsidiary of another company immediately following such merger or
consolidation, the parent company of such surviving or resulting corporation; or (b)&nbsp;(1) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company or any
subsidiary of the Company of all or substantially all the assets of the Company and its subsidiaries taken as a whole, or (2)&nbsp;the sale or disposition (whether by merger, consolidation or otherwise, and whether in a single transaction or a
series of related transactions) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer,
exclusive license or other disposition is to a wholly owned subsidiary of the Company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation preference&#151;</I>In the event of any voluntary or
involuntary liquidation, dissolution, or winding up of the Company, the holders of shares of preferred stock shall be entitled to be paid out of the assets of the Company or, in the case of a Deemed Liquidation Event, out of the consideration
payable to stockholders or the available proceeds, before any payment shall be made to the holders of common stock, an amount per share equal to one times $1.00 per share, plus any dividends declared but unpaid. If upon any such liquidation,
dissolution or winding up of the Company or Deemed Liquidation Event, the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of shares of preferred stock the full amount to which they shall
share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with
respect to such shares were paid in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption</I>&#151;The preferred stock does not contain a mandatory redemption provision. Upon a Deemed
Liquidation Event, the holders will be paid their preference amounts according to their priority. That is, the preferred stockholders will be entitled to an amount up to $1.00 per share, plus any accrued dividends. Accretion to redemption value will
only be required if a Deemed Liquidation Event is probable. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion</I>&#151;In the event that any holder of Series A preferred stock, does not
participate in any Milestones then each share of preferred stock held by such holder shall automatically be converted into the number of shares of common stock equal to $1.00 divided by the product of (a)&nbsp;the conversion price in effect
immediately prior to the consummation of the applicable Milestone closing and (b)&nbsp;ten. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon either (a)&nbsp;the closing of the sale of shares of
common stock to the public at a price of at least $3.00 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a
firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $50.0&nbsp;million of gross proceeds to the Company and in connection with the offering
of the common stock listed for trading on the Nasdaq Stock Market&#146;s National Market, the New York Stock Exchange or another exchange or marketplace approved by the Company&#146;s board of directors, including the approval of at least two
(2)&nbsp;preferred directors (a &#147;Qualified IPO&#148;) or (b)&nbsp;the date and time, or the occurrence of an event specified by vote or written consent of the holders of a majority of the outstanding shares of Series A convertible preferred
stock, then (i)&nbsp;all outstanding shares of preferred stock shall automatically be converted into shares of common stock at the then effective conversion rate. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>6. Common units and common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Common units
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;21, 2017, in connection with the formation of LEXEO Therapeutics, LLC (see Note 1), the Company issued 9,000 common units with a
$1.00 par value to the founding member of the Company. Each common unit represents an interest in the Company and is entitled to distributions and allocations including profit and loss, and tax priority distributions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018, the Company issued 500 additional common units with a $1.00 par value. On January&nbsp;14, 2020, and March&nbsp;6, 2020, the Company issued a total of
1,898 incentive units to the Company&#146;s chief executive officer and two scientific advisors. In November 2020, the Company modified the incentive units such that the remaining service periods were eliminated, thus the incentive units were fully
vested without further service conditions. As of November&nbsp;20, 2020, the Company had 11,398 common units outstanding at a price of $1.00 per share. On November&nbsp;20, 2020, the date of the conversion of LEXEO Therapeutics, LLC to LEXEO
Therapeutics, Inc. (see Note 1), all of the common units and incentive units in the LLC were converted into common stock of the Company. Each common unitholder and incentive unitholder received a ratable ownership-percentage in the 16,040,884 shares
of common stock issued at the time of the conversion. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Common stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company&#146;s certificate of incorporation authorized the Company to issue 120,000,000 shares of common stock with a par
value of $0.0001 per share. The voting, dividend and liquidation rights of the holders of the Company&#146;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the convertible preferred stock set forth
above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the
Company&#146;s stockholders, provided that holders of common stock are not entitled to vote on amendments to the certificate of incorporation that relate solely to the terms of the convertible preferred stock. Common stockholders are entitled to
receive dividends, if any, as may be declared by the Company&#146;s board of directors, subject to the preferential dividend rights of the convertible preferred stock. Through December&nbsp;31, 2020, no cash dividends have been declared or paid by
the Company. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>7. Income taxes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of
the Company&#146;s statutory income tax rate to the Company&#146;s effective income tax rate is as follows for the year ended December&nbsp;31, 2020: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State Taxes, net of Federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.24%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-taxable</FONT> income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.24%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in Valuation Allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18.99%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal components of the Company&#146;s deferred tax assets and liabilities at December&nbsp;31, 2020 are as follows:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Year&nbsp;ended<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">435,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">978,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(978,670</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had federal net operating loss carryforwards of approximately $1.4&nbsp;million,
which can be carried forward indefinitely. As of December&nbsp;31, 2020, the Company had state net operating loss carryforwards of approximately $1.4&nbsp;million, which begin to expire in 2040. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient
taxable income within the carryforward period. As of December&nbsp;31, 2020, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which
included the results of operations for the current and preceding years. The Company determined that it was not possible to reasonably quantify future taxable income and determined that it is more likely than not that all of the deferred tax assets
will not be realized. Accordingly, the Company maintained a full valuation allowance as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Internal Revenue Code
Section&nbsp;382, if a corporation undergoes an &#147;ownership change,&#148; the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT>
tax attributes to offset its post-change income may be limited. The Company has not completed a study to assess whether an &#147;ownership change&#148; has occurred or whether there have been multiple ownership changes since the Company became a
&#147;loss corporation&#148; as defined in Section&nbsp;382. Future changes in the Company&#146;s stock ownership, which may be outside of the Company&#146;s control, may trigger an &#147;ownership change.&#148; In addition, future equity offerings
or acquisitions that have equity as a component of the purchase price could result in an &#147;ownership change.&#148; The Company has not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conducted an &#147;ownership change&#148; analysis. If an &#147;ownership change&#148; has occurred or does occur in the future, utilization of the NOL carryforwards or other tax attributes may
be limited, which could potentially result in increased future tax liability to us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of the Company&#146;s tax liabilities involves dealing
with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which the Company operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be
recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when the Company&#146;s judgment changes as
a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company&#146;s current estimate
of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December&nbsp;31, 2020, the Company has not recorded any
uncertain tax positions in the Company&#146;s financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes interest and penalties related to unrecognized tax benefits on
the income tax expense line in the accompanying statement of operations. As of December&nbsp;31, 2020, no accrued interest or penalties are included on the related tax liability line in the balance sheet. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject
to examination by federal and state jurisdictions, where applicable. The resolution of tax matters is not expected to have a material effect on the Company&#146;s financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>8. Commitments and contingencies </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leases</B>&#151;In
January 2017, the Company entered into a lease agreement for office space at 364 E 69<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street, New York, NY, which expired January&nbsp;30, 2020. The monthly lease payments were $1,500. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2020, the Company entered into a lease agreement for office space with LaunchLabs at 430 E 29<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>
St, New York, NY. As per the terms of the lease, the Company is eligible to renew annually. Monthly lease payments of $1,295 are inclusive of license and membership fees. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contingencies&#151;</B>From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company
accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation or other
material legal proceedings. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification agreements&#151;</B> In the ordinary course of business, the Company may provide indemnification of varying
scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third
parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and will enter into indemnification agreements with its executive officers that will require the Company, among other things, to
indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is,
in many cases, unlimited. As of December&nbsp;31, 2020, the Company had not incurred any material costs as a result of such indemnifications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>9. License agreements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cornell University</B>&#151;On May 27, 2020, the Company entered into two exclusive license agreements with Cornell University (&#147;Cornell&#148;) (the
&#147;Cornell First License Agreement&#148; and the &#147;Cornell Second License Agreement,&#148; collectively &#147;the Cornell License Agreements&#148;). The Cornell First License Agreement is for the in-license of technology related to portfolios
for APOE, Alzheimer&#146;s disease, and Anti-Tau, although our license is not restricted by such indications and it includes assignment to us of Cornell&#146;s IND for the use of AAVrh10.hAPOE vector to treat <I>APOE4</I> homozygous patients who are
at risk for or have Alzheimer&#146;s disease. The Cornell Second License Agreement is for the in-license of technology related to portfolios for infantile neuronal ceroid lipofuscinosis (also called CLN2 Batten disease) and Friedreich&#146;s ataxia
although our license is not restricted by such indications, and it includes assignment to us of Cornell&#146;s IND for the use of AAVrh.10CUhCLN2 to treat children with CLN2 Batten disease. Through the Cornell License Agreements, the Company gains
access to a portfolio of inventions, patent rights, technology, and licensed methods that the Company plans to develop. Under the terms of the Cornell License Agreements, the Company has assumed all development and commercialization activities
worldwide with respect to the licensed technology. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As initial consideration for the Cornell License Agreements, the Company paid Cornell an upfront
payment in cash of $0.3&nbsp;million and issued $1.3&nbsp;million of Notes (see Note 4). In November 2020, Notes with outstanding principal of $1.3&nbsp;million were cancelled in exchange for 1,337,610 shares of Series A convertible preferred stock.
As additional consideration, the Company is required to pay Cornell up to $8.4&nbsp;million upon the achievement of specific clinical and regulatory milestones under the Cornell First License Agreement and up to $4.3&nbsp;million upon the
achievement of specific clinical and regulatory milestones under the Cornell Second License Agreement. The Company achieved the first clinical milestone under the Cornell Second License Agreement when it submitted its IND for LX2006 to the FDA. A
payment of $0.1 million is due to Cornell in connection with this milestone. The Company is also required to pay Cornell a flat royalty in the <FONT STYLE="white-space:nowrap">mid-single-digits</FONT> based on net sales of the products covered by
the licenses, subject to certain adjustments. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon expiration of the royalty term of a given licensed product in a country, the respective license becomes
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> and royalty-free. In addition, each of the Cornell License Agreements may be terminated by the Company for any reason upon 90 days&#146; advance notice to Cornell and by Cornell upon the
Company&#146;s material uncured breach, and all licenses and rights granted by either party under such agreement will concurrently terminate. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>10.
Related parties </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;27, 2020, the Company entered into two executive license agreements with and subsequently issued $1.3&nbsp;million in
Notes to Cornell (see Note 9 and Note 4). As of December&nbsp;31, 2020, Cornell owns more than 2.6% of the Company&#146;s outstanding Series A convertible preferred stock. These transactions are related party transactions. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>11. Subsequent events </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has reviewed and
evaluated subsequent events through September&nbsp;8, 2021, the date that the financial statements were available to be issued. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adverum Biotechnologies
Inc. Exclusive License Agreement</B>&#151;On January&nbsp;25, 2021, the Company entered into an exclusive license agreement with Adverum Biotechnologies Inc. (&#147;Adverum&#148;) (the &#147;Adverum Agreement&#148;) to
<FONT STYLE="white-space:nowrap">in-license</FONT> materials and technology related to the treatment of cardiomyopathy due to Friedreich&#146;s ataxia. In connection with the Adverum Agreement, the Company will gain access to a portfolio of
inventions, patent rights, technology, and licensed methods that the Company plans to develop, and the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumed all worldwide development and commercialization activities. The Company is obligated to pay Adverum up to $17.5&nbsp;million upon the achievement of specified development and regulatory
milestones and up to $49.0&nbsp;million in commercialization and sales milestones for the products. The Company is obligated to pay Adverum tiered royalties ranging from a rate in the high single-digits to 10% based on annual aggregate worldwide net
sales of products, subject to reductions upon the expiration of valid claims in licensed patents and third-party licenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Adverum Agreement remains
in effect until termination at the date of the last royalty term to expire. The Company can terminate the Adverum Agreement with 120 days written notice. The Adverum Agreement can also be terminated as a result of a patent challenge, material breach
of contractual terms, or insolvency by either party. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Weill Cornell Medical College Research Collaboration Agreement</B>&#151;On February&nbsp;2, 2021,
the Company entered into a Research Collaboration Agreement with Weill Cornell Medical College (&#147;WCM&#148;) (the &#147;WCM Agreement&#148;) in conjunction with the Cornell License Agreements entered on May&nbsp;27, 2020. The Company committed
to fund scientific research at WCM related to the intellectual property licensed to the Company pursuant to the Cornell License Agreements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
terms of the WCM Agreement, the Company will pay WCM a total of $3.0&nbsp;million over the course of three years, with equal $0.25&nbsp;million payments due each quarter starting 10 days after the execution of the WCM Agreement. With respect to each
WCM invention, joint invention, and related joint results for which an Improvement applies and the Company has made an election to amend the Agreements, the Company has the first option to negotiate in good faith with WCM for royalty-bearing,
worldwide license, under Cornell patent rights, Cornell rights, and Cornell&#146;s interest in joint patent rights, to develop, make, have made, use, offer for sale, sell, have sold, and import derived products in the field. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The WCM Agreement terminates upon the expiration of the agreed upon three-year term. In addition, the WCM Agreement may be terminated by the Company in the
event that the WCM principal investigator ceases to supervise the research and WCM is unable to or declines to find a substitute. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock based
compensation plan</B>&#151;In February 2021, the Company adopted the 2021 Equity Incentive Plan (the &#147;Plan&#148;) for the issuance of stock options to the Company&#146;s key directors, officers, employees and consultants, as a means to secure
the benefits arising from capital stock ownership. The purposes of the Plan are to promote the alignment of the interests of key directors, officers, employees and consultants with the success of the Company and to provide compensation opportunities
to attract, retain and motivate directors, officers, employees and consultants of the Company. The Plan authorizes up to 8,918,225 of shares of the Company&#146;s common stock to be issued. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stelios Therapeutics, Inc. Acquisition</B>&#151;On July&nbsp;16, 2021, the Company acquired all issued and outstanding stock of Stelios Therapeutics, Inc.,
for initial consideration of $7.0&nbsp;million, with up to an aggregate of $20.5&nbsp;million payable upon the achievement of certain development milestones. The Company accounted for the acquisition of Stelios as an asset acquisition pursuant to
Financial Accounting Standards Board Accounting Standards Codification Section 805, <I>Business Combinations</I>. The Company acquired in-process research and development, or IPR&amp;D, assets from Stelios related to arrhythmogenic right ventricular
cardiomyopathy and TNNI3-associated hypertrophic cardiomyopathy programs. The fair value of the IPR&amp;D acquired of $7.0 million was charged to research and development expense as it had no alternative future use at the time of the acquisition.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series A convertible preferred stock</B>&#151;On July&nbsp;30, 2021, the Company&#146;s board of directors and stockholders voted to waive the
milestones related to both the second and third tranches of the Series A convertible preferred stock and issued 50,999,997 shares for an aggregate consideration of $51.0&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series B convertible preferred stock</B>&#151;On August&nbsp;10, 2021, the Company entered into a Series
B convertible preferred stock purchase agreement whereby the Company issued 58,128,763 shares of Series B convertible preferred stock at $1.72 per share for an aggregate purchase price of approximately $100.1&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
</I></B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock </I></B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287237g12x08.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="bottom"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>SVB&nbsp;Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Stifel</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>RBC&nbsp;Capital&nbsp;Markets</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Chardan </B></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Through and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 (the 25th day after the date of this prospectus), all dealers that buy, sell or trade shares of our common stock, whether or not
participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or
subscriptions. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B>Part II </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><B>Information Not Required in Prospectus </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Item&nbsp;13.&nbsp;Other&nbsp;Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting
discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq
Global Market initial listing fee. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market initial listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the State of Delaware. Section&nbsp;102 of the Delaware General Corporation Law permits a corporation to eliminate the
personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged
in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the
corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person
in connection with an action, suit or proceeding to which he is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests
of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with
respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of
liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted by the Delaware General Corporation Law, our amended and restated certificate of incorporation and bylaws to be in effect upon the closing of this
offering will provide that: (i)&nbsp;we are required to indemnify our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors to the fullest extent permitted by the Delaware General Corporation Law; (ii)&nbsp;we may, in our discretion, indemnify our officers, employees and agents as set forth in the Delaware
General Corporation Law; (iii)&nbsp;we are required, upon satisfaction of certain conditions, to advance all expenses incurred by our directors in connection with certain legal proceedings; (iv)&nbsp;the rights conferred in the bylaws are not
exclusive; and (v)&nbsp;we are authorized to enter into indemnification agreements with our directors, officers, employees and agents. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with
this offering, we expect to enter into indemnification agreements with each of our directors and executive officers that require us to indemnify them against expenses, judgments, fines, settlements and other amounts that any such person becomes
legally obligated to pay (including with respect to a derivative action) in connection with any proceeding, whether actual or threatened, to which such person may be made a party by reason of the fact that such person is or was a director or officer
of us or any of our affiliates, provided such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, our best interests. The indemnification agreements will also set forth certain procedures that will
apply in the event of a claim for indemnification thereunder. We intend to enter into similar indemnification agreements with our executive officers prior to the completion of this offering. At present, no litigation or proceeding is pending that
involves any of our directors or officers regarding which indemnification is sought, nor are we aware of any threatened litigation that may result in claims for indemnification. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a directors&#146; and officers&#146; liability insurance policy. The policy insures directors and officers against unindemnified losses arising
from certain wrongful acts in their capacities as directors and officers and reimburses us for those losses for which we have lawfully indemnified the directors and officers. The policy contains various exclusions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the underwriting agreement filed as Exhibit 1.1 to this Registration Statement provides for indemnification by the underwriters of us and our
officers and directors for certain liabilities arising under the Securities Act, or otherwise. Our amended and restated investor rights agreement with certain investors also provides for cross-indemnification in connection with the registration of
our common stock on behalf of such investors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of Unregistered Securities</B><B><I>.</I></B><B> </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following list sets forth information regarding all unregistered securities sold by us since our inception through the date of the prospectus that forms a
part of this registration statement. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Limited Liability Interests </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our formation in February 2017, we issued 95 limited liability common units to our founder and 5 limited liability common units to a service
provider that is an accredited investor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2020, we issued 500 limited liability company incentive units to our chief executive officer. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020, we issued an aggregate of 206 limited liability company incentive units to two of our employees. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Common Stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2020, we
issued an aggregate of 16,040,884 shares of our common stock to five individuals and accredited investors, including our founder and our chief executive officer, in connection with the conversion of all outstanding units to shares of common stock
and the conversion of our company from a limited liability company to a corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Convertible Promissory Notes </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020, we issued a convertible promissory note to Cornell University in the principal amount of $650,000. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020, we issued a convertible promissory note to Cornell University in the principal amount of $650,000. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2020, we issued a convertible promissory note to the Alzheimer&#146;s Drug Discovery Foundation in the principal amount of $1,977,336. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, we issued a convertible promissory note to the Alchemy LP in the principal amount of $250,000. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, we issued a convertible promissory note to Thomas McWilliams in the principal amount of $250,000. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2020, we issued a convertible promissory note to Nova Venture Holdings LLC in the principal amount of $125,000. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Preferred Stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2020, we
issued an aggregate of 31,337,606 shares of our Series&nbsp;A convertible preferred stock to 13 investors at a purchase price of $1.00 per share, for aggregate cash consideration of approximately $30&nbsp;million and pursuant to the conversion of
certain convertible promissory notes and related cancellation of indebtedness of approximately $1.3&nbsp;million. We also issued an aggregate of 4,495,729 shares of our Series A convertible preferred stock to four investors at a price of $0.85 per
share, pursuant to the conversion of certain convertible promissory notes and related cancellation of indebtedness of approximately $2.7&nbsp;million. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
July 2021, we issued an aggregate of 50,999,997 shares of our Series A convertible preferred stock to 11 investors at a purchase price of $1.00 per share, for aggregate consideration of approximately $51&nbsp;million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2021, we issued an aggregate of 58,157,823 shares of our Series B convertible preferred stock to 32 investors at a purchase price of $1.72049 per
share, for aggregate consideration of over $100&nbsp;million. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances Pursuant to our Equity Plans </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From February 2017 (the date of our inception) through the date of this registration statement, we granted options under the Existing Plan to purchase an
aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, at an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, to our employees and consultants.
Of these,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares have been issued upon the exercise of options, and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;options have been forfeited, expired or
cancelled. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise
specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on Sections 3(a)(9) and&nbsp;4(a)(2) of the Securities Act (and Regulation D or Regulation S promulgated thereunder) or Rule 701
promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in
each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates
issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Item&nbsp;16.</B><B><I> </I></B><B>Exhibits and Financial Statement Schedules</B><B><I>.</I></B><B>
</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exhibits listed below are filed as part of this registration statement. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Amended and Restated Certificate of Incorporation of the Registrant (as amended and currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Bylaws of the Registrant (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Amended and Restated Certificate of Incorporation of the Registrant (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Amended and Restated Bylaws of the Registrant (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Amended and Restated Investors&#146; Rights Agreement, by and among the Registrant and certain of its stockholders, dated August&nbsp;10, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Opinion of Cooley LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10.1&#043;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2021 Equity Incentive Plan and Forms of Option Grant Notice and Agreement, Exercise Notice, Early Exercise Notice and Restricted Stock Award Notice</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10.2&#043;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022 Stock Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10.3&#043;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2022 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10.4&#043;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Form of Indemnification Agreement with Executive Officers and Directors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10.5&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">First License Agreement, dated May&nbsp;28, 2020, between LEXEO Therapeutics, LLC and Cornell University</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10.6&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Second License Agreement, dated May&nbsp;28, 2020, between LEXEO Therapeutics, LLC and Cornell University</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">10.7&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">License Agreement, dated January&nbsp;19, 2021, between Adverum Biotechnologies, Inc. and LEXEO Therapeutics, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Consent of KPMG LLP, independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Consent of Cooley LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Power of Attorney (included on signature page)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00px solid #000000">&nbsp;107*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Filing Fee Table</P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#043;</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment will be requested for portions of this agreement. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(b)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Financial Statement Schedules. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedules not listed above have been omitted because the information required
to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings</B><B><I>.</I></B><B>
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in
such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred
or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B>Signatures </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized in the City of New York, State of New York, on this&nbsp;&nbsp;&nbsp;&nbsp;day of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LEXEO THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Nolan Townsend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints R. Nolan
Townsend as his or her true and lawful agent, proxy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> with full power of substitution and resubstitution, for him or her and in his or her name,
place and stead, in any and all capacities, to (i)&nbsp;act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this registration statement together with all schedules and
exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii)&nbsp;act on, sign and file such certificates, instruments,
agreements and other documents as may be necessary or appropriate in connection therewith, (iii)&nbsp;act on and file any supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration
statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and (iv)&nbsp;take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he might or could do in person,
hereby approving, ratifying and confirming all that such agent, proxy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> or any of his substitutes may lawfully do or cause to be done by virtue
thereof. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Nolan Townsend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and Director<BR><I>(Principal Executive Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2022</TD>
<TD NOWRAP VALIGN="middle"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">R. Nolan Townsend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(Principal Financial and Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">, 2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mette Kirstine Agger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">, 2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Altschuler, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">, 2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">, 2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paula HJ Cholmondeley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">, 2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bernard Davitian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reinaldo Diaz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">, 2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g287237g06e17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g06e17.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MU/ (-4)2<G2RL[31X3,W)#1#8B4F4Z+Q19)&<X*3H]+B_]H # ,!  (1 Q$
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MJH_L,?)_\$/T*^)WU=M1?PACV=\;_#'BG\X-5_>\>Q;AGX.Z'\U4?V&/D_\
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M^$,>SOC?X8\4_G!JO[WCV+<,_!W0_FJC^PQ\G_P0_0KXG?5VU%_"&/9WQO\
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M&,8QC&,8QC&,Q_>*S^3;YN?X<-G?Z==Y.<,_=!H_X0K?Y@R)U[^9M3_N<_\
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M)DL@U2B[AC:W8:*>2TC32,+,J&.2P2Q+3M&2S(96)DY&9F4, Q+ G,^J&6O
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M;*M4HQ=2D=5)_8DE(P%(L^PI)N[L%.-7GB$D_BSLWZE =+CI:G&DU:)K&AZ
M+T<4L*<UY;L4MY*\:LJM*E=%DFC@4B.;M%*JP*XVU![=%VCGD6'5=9--Y$E?
MEJ-5>.JT[E>98WF9DB>5@7BY"&*[,??\/&,W38>:W%G:.VZUR:D+P/AS;3I?
M(&Z;FINYBQ4!R%?<A*Y-SM1";NT,G5*FDY:0<FXKM;JCJ+I813!FE6F!%5C$
M<4UUJ::1J=:K)IZP_5ZK-1BJ2U.>2@M&5$EY(6[278NH>20--SLQE/G'+2%L
MOJ5&>PEUI3H\\=N2Q'8Y5MFXC/'S2+V<>X4E$C*Q<H'(HWZ_1S)2<;"Q[R6F
M)!C$Q4<V5>2$G).T&$>P:($%1=T\>NE$FS5LBF43JKKJ$23( F.8I0$<T#-W
MK5K%RQ#5J5YK5JQ(D->M6BDGL3RR$*D4,,2M)+([$*B(K,Q( !)S&[=><-OV
MS8Y#57!NAGVS9VRGHY[;\X@O'ZBI/F"*9W8/W/I0G7*)2K*M145;,W@HD6A6
MMM1,=J/ MN=E&_Q^8?Q_&^>A]'\"^D\+:?7XG\-.N+PMILJ]M1X3I.ECBO6>
M4<RQ=A'VOB,;DHLO*LDL(<I<ETIP)13H^%OK_;\1-3/,:]7'?>U;,T(FK9F\
M](UJ*H:H* N1'7S!EY*;=-HH95%,)%D,"NW,)4JE'%5714J!MU)W)_C;) ?R
MF=>X3MTZ?@CT32>!>%]-E++ILE&OJ-K7%Y>S9]?FFYS(TJA7/B\PO1R <^JV
M2J.M[.)GAW<:N&DE-6+5$)8)2YSK$T2\N][F&\_9&\(==%TK"QAV,9"Q$4P<
M.6[=9X,?$MWD@9NV*_=NDFK9-+EFF^%3P_\ A%\+]>G0XINT*VCT9A:AT71*
MDE'3GNJCQ+<LK-9N6K4Z1R2)%V]J2& 22&"*)I)&:<V,Z4QC&,8QC&,8QC&,
M8QC&<2_XA;]4I^X;*KWCTCUY1NX^@^K-2YGU/SPQFVHSY7Y[HQC&,8RR^X;;
M-UMO7VC&72I$-,/ETI[9KV/0EHVI$:ID7CV2S%81;)+6-YVQQ).7!"&9( X1
M.X]J/(M,V';E>,1A7[%'8\]DJ'6+8;JI4]-Y&V7F?9 -QOS,HS>N"=%H:I)J
M4T])]>O4:\;Z=PI7LR4[>M-,S1V9X[$8[5X]+@WM-4I=I>GD,3K%XG!<85?K
M>PSMJIT/.V*(+#R;Y-8PHIE<(HOFJ:ZB3&:;LGI2R$6VFVA$91O%20#(QJ+H
MC1X8ZZ1SFNUY'EA221.1FWZ=0&7<A7"MY2AQLX1O*4$!NH.0O%&F:?H^N7=.
MTRZ;U6NT8YV,;R5YFC1[%"6> FM;ET^=GIRW*A\5M/"T\ 6-U45SE_-?QC&6
M<Y$E*?C]O0AF4+)%/IS9Q31UD92,E77Y34F; 64_'0XA+OX5T ^1*LHL0D73
M%1=!B(.5$AS+H?\ GJ7E.O\ XNOY4959%^W)Y4;-Y*N.]2WDAMB>F^8]S_RE
MKHK?^'GZ.&9#]J;HZKY3*>Y@OE$;@=<P)^%E;)&6Y&TN+D=S66]'0U99C#4I
M_P *FK\+CQ+EO&PB1W*F[(UPX=61Y'E,K'JT]DLLWL NE+ J=1. 34#=>)(E
M6A,RU(H?_$Q_;8^)I-7Y@6<\HID 1JVP;M6 *<H0;%]LU70Y"UR)39>7:!_M
M;Z$FG%2%7J;()+$=08U)Y]^;N3?/I/SK_-RQC&,8QC&8_O%9_)M\W/\ #AL[
M_3KO)SAG[H-'_"%;_,&1.O?S-J?]SG_P')WPW]#Q7]FL?\JED*_MV_M-ZSDJ
MO</0/5G99QRN,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&0PW_S>U=I:6)K^NM)3<>[)%46,+J379#2\V,D<@F2;V%XR0?)5\.@ =5H+
M=_/ @<CI&#6:=[A.A('3O/N#O_X_'G<' G@8XFXQJG7M0EK<(\&0)V]SBOB!
MA4I>+ @-)I\,TD#7^NX68204><-&]U)0(VL#&\6>0'*^09V_FK<%:IK\CE*1
M@N,NMY)5A$)$(8JK4;W/,G*QWK],"]5B-WDI)IBLH:/FJV/FQ9>/*3[8^?N_
MY_\ SZ<WJSX3> _!=!+I7@<TA-4UXQO7O>$?B*NL]MF8%)1H=&:-%A@;?R2\
M-6LP118IZCY-HY(Z71J=KFN1]1H=:AJE68I/RV,+!,$(]BB(@'F+&30(45W;
M@P>8[>N#*NWBPF7=+K+'.H;GL!W#;//.L:UJ_$.H3ZKKFHW-5U&RW-/<O3O8
MF?;?E0,Y/)%&#RQ0QA8HD 2)$0!11^WMG%UG!,W36/\ :TY,O!CX6/,*A43K
M%(!UG#CR@%8Z2 '2("" E6<++HI$.D4QUD\6W9\60$+SNYY47S;[=YVZD#IT
M'4D[;COR>X+X4/%6H3PRV?$]/HP>,W[("EU0DJD4?.>17DY7;M)-XXXXY'(8
MA4>A:%N.XN+LUH.SJJUKDS+LS/85=@5=%%0H(N%R).$'#Z2*<CA-JZ32<HO
M\MVW%FJV\TYC(V8+<QF$%F(1NZ[H5WV/>>H+-T(! (/0C8CKTV#B+@C1(M!F
MXBX4UB;5*-*<07X[!C>127CC9XY(Z]4@QM-"SQ/ >:&43I+R !Y &G(0LD$.
M:8BRRYNG;%&D&@21NY+U!>C$5@=#U0_#!T2]Z7X0/@^+)+D?EYN5N7^MRGE[
M]N_;;OZ=_?G5?,N_+S+S?U=QO[O=OOW=<Y&DO$OT7+AC)QSUNS442=KM'K9R
MBU51*!U4W*J*IR(*)$$#J$5,4Q"B!C  #UP58$ JP)Z@$$$@]Q&XZ[_%E0RG
M?8@[=#L0=C[A]S/:;N&[QN@[:+HNFKI%)PV<MU2+MW#=<A545T%DC&36163,
M51)5,QB*$,4Y#"40$:$$$@@@@D$$;$$=""#U!![Q@$$ @@@C<$=00>X@^<'.
M;*97&,8QC&,8QC.)?\0M^J4_<-E5[QZ1Z\HW<?0?5FI<SZGYX8S;49\K\]T8
MQC&,93%PDAC*_(J(LXB4?N$#M(N%G)1I#Q\U(+E$K>+5>O4ET">J'J':+=<Q
MR@8H)CUZA;F;EC8[(Q(V59&"*['N4D@CK[FQW]S);1*HMZE65Y[M2M'(LUN]
MI].:]9H5HV!DMI7@>)V[+<'?M8PI()<>>V&G978KV6N[?832Q-G0#7)-H27B
M&49$,G+]M)-I6$JZT5(S,:_B8I6-:J%<EF9%^L$@FZDE$G+H428U1K#/,+"R
M _:V'.BJ@+!@R1%&D5E4H#OSLWE N03MFV<;T^&*]/0).&IM,EA(U2K*:5VQ
M;O3Q5Y:LM._J\=RM1M5[MM+<R-$:%6LAK-#45XH>=K[9FYU[C&,H+:L5,SVK
M]D0=<!T:PS-"N$5 E8SSJJO33,C7I%G%@SM#%5%[6W0OED ;SS-9%U#J]DBW
M536;D.%^JR)9KO)MV:3Q,_,@E7D612V\; K(.4'=""''DD$';+4ZLT$RIOSM
M%(J;.8SS%&"[2#8H=]MG'53Y0ZC,5GAV<C.4NQ;1#:7V'?N!&T*7IJ@(56YV
M#CAR;LN^-UH3];CH^O5Z0V,TL@%=@$RJT>_=1:7CR1E9&U$[5"%,XDSM=DUZ
MAIM>)K=>'6Z\MN<R0IJ&G1TJ9CD9GD%<QDCR-U[.,!56(^?9=X+2+EZ:1:TT
MVE3QUX0DKT[KVK0= $1I@_\ 6*MVCDEFD'QG;,AFJ9L6,8QC&,8S']XK/Y-O
MFY_APV=_IUWDYPS]T&C_ (0K?Y@R)U[^9M3_ +G/_@.3OAOZ'BO[-8_Y5+(5
M_;M_:;UG)5>X>@>K.RSCE<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,L_N;?>I] 5D]JVK<8VLL3E5"-8J'%U.SSE(H"+* @VH*R4JXZF3*J
M9L@+9F50J[]PT:@=<E"0.\YMO"' W%/'>I+I?#&DV-1F!4V)U BHT8V)^W7K
MLG+7JQ[!BHD<23%3'!'+*5C,!1MW+_G!^!UXTE>)_&^0]Q[Y-HF_VPW^(5ZC
MWUYB@L@K!LGR!DCHNF#M@T!-115O:[ @*L4/'=F[N@]T]_XL[S^I/@G\"_EZ
M_+5\*7A"@[M#I.#PEH5M?-?GD1UNS0N&5XIXIY>95632J#\MG)GZ XK:8XVQ
M)V>N:R0)U\B!)Z]3IR2UVL2@F ZIY*;423,BW55*"QHN*1CH@JP>>5@#@RBQ
M^0 '</Q^?.G^._"=Q?X1+2S<0:B?$8&WHZ)1!JZ-IZ@%4%>DK,'D1"4%JT]B
MV4^UF?LPJ+(O*YU_EM]C[3JFLHTCN>=&7DG@"2'K[ "KS,PN)NPA&K4!ZD0\
MP0(J\7[&Z9A!,#J.#I(*X]BS%67=SNQ]I&O5W/Q#W-^A8]!Z=AFT<,<(ZQQ7
M::'3XA'5A.]W4K!,=&E&!S,TLI'E2<O5((^:5AY1"Q*\B1]?:QVQNQ(]KN\J
MA1 ;IF5H],3;J+'BO-415]9..2&2=(/7"2*9#G[3O4E1!46<>1 (Y3 -:U<'
M:S.(>F\,(&_+W'F<[[AB!\; ]=EVY<['K\5\'\!NNCZ!3DXA[5@FOZX\BQK;
MY%D3L*$3!X9((W=F4;K Z#D$]DR&RM;T'3=O:W5K?MFVMM9)J(:'90R+$[E=
M%(ID7#<BJZ[EG'=I4$W3HZ35%GT.[<&>*.!5*8%;\%243">S*)'4;(%W([B-
MR2J]P)V 7VQYB=^^!XBXWT6;09>'>%='ETJC=G$]Y[ BCD=@\<C)''%/9W,C
M0PJTKS[B&,0+$$(Y,>7B/52Q\?>3G#/Q&]7TF7N4M2[U'\5.0-4J;!!U8[QI
M7D#,-ZQ35D"*G;$=R-'VI*1)Z\T.\:^T)VU1;-RY38)*B3?= ECO:=JV@69D
MA6:%M3HRRLPCAMT$,LP.V^RS55?G/*>5(B0"VV=%ZQ&]2[INL01-(T<JT+:(
M 7EK6V"1=^VYBL,O(-QN\@!/+OMU?B5/=A:,X*;@U]5=5;0F4]E:+Y1['WKM
M714=6$XNL;&E*A(6)\M:I&7M=-GH>B3=LLDA*2<]%LK78&^M*"K1RP3_ -N$
M>Q7+AX07=:ISRV:Z&O=TV"G6N-*6E@694 B58ID:9(XU549HHS8G[;G7DY6X
MZT9JNEV(8Z\[":K>FM3U @6.9HRY[0O)&ZQ/)(S,ZAW$,)BY3S@KD8X52RLY
MP^XN2B\+,UY5QQ_U$4T1/HLV\LU!M1()H4[E*/?230I'94"O&HI/%1.S<-SJ
M@BL91!.!U=0FJZDH=) +UKRT+%3O,YZ%E4]-]CNHZ@[;C8F8TUB^GT6*LA-2
MOY+@!AM$HZ\I8==MQL3T(R3F1V9N,8QC&,8QC&<2_P"(6_5*?N&RJ]X](]>4
M;N/H/JS4N9]3\\,9MJ,^5^>Z,8QC&,L/NVFLY=D6UR,W5HF,@ZU9X*6/=*ZK
M9HAE&68T25>9C&:,@P5;V-D>-2;L#%]0#Y-XJP%(#J)F'!NPAE[5GB14BE1^
MVC,B!)>3=U4,I$@Y0!W\P8KMUSL/@+7)Z4YT>K0U>Y;U#5=)U"D-"U--*NSV
M])%PQ4+<SUK*2Z7.MIY; /9>+/ EGG*JP%7:YN47/M7-?;,[-&/ZJSAFXMKB
MP-&3TI"N6($B;.9HJ<SD&DPHS?I=7B;603?,7J+]BS<$\G+M>99 4 D5HE0;
M3+RR,A79)2IZ@.58>4 W,K!E4],AN)]"N:;+%J4L^DVZ^KSWI!-H=D6].J7H
MK'-=TD3HHB,])9ZSD0--6:O8@>O8GC;GRY69.:KC&,MSN%&JN-2;20O<X>L4
MA?7-W1N5D3!(5*]55:S)DL,XF"S1^B)XF(,\?E!5B]2[FX>8T<EZHGR*IE%J
ML84[286(3%'U^V2B1>S3H5/E/LO1@>O0CORS8$9KSB5RD1AE$CC;=(^1N=QN
M&&ZKN>H(Z=Q[LP)>&-=M/V_E(5I"[DU[L*:AJ3<#ZX8ZJ\-&4X5%<U@0C&\E
M+7;94U7HPUC8F8KL?0ZWK[IM$/)@S"V.V#M2M1AX;=.(8;46F[O4G@1IH18-
MGB%-7VE\LJD-:.1NR/,&YIY 7"\T08=HW/JNBRUY+P"V89F6*3L1!HK:;NGD
M\S2S,B\XV(VA392VTA!Y 5^C/-#S<,8QC&,8QF/[Q6?R;?-S_#AL[_3KO)SA
MG[H-'_"%;_,&1.O?S-J?]SG_ ,!R=\-_0\5_9K'_ "J60K^W;^TWK.2J]P]
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M;'W#C<>Z,*S,0@]3CEY6-1D%13*DP5?-4WJAE?Q14VIU07.*O_\ &!4Q$_\
MP]<;'W#C<=VXW]S?!IF(*^"+-*QI9,1*4(XSYJ#X3&3!8I0:"KZCJ9$05*'E
M]13$#AU*(#C8[;[';W?-C<;[;C?W//@LS$'?#%DE8T\D43%-'%?-3/@,0@JG
M*+0%1< )$P%0P"GU*0!./0H=<;';?8[>[YL;CNW&_N;X1F8=R\4CF\K&KR")
ME2JL47S55XD9$W:L51L14RY#)&^%4#$ 4S>X_0<;'W#C<>Z,YFDC'OS.",7[
M)Z=JIY+HK1T@Y,V5ZF#RG!45#BBIU(<.Q0"FZE,'3J4>E-C[F-P>X@Y[F,KC
M&,8QG$O^(6_5*?N&RJ]X](]>4;N/H/JS4N9]3\\,9MJ,^5^>Z,8QC&,BQS#Y
M?Z@X2Z6G=S[?EO*9M.Z.J=48*H#9]@6U9!56,JE89JF#SGKL4C+/7J@ QA8Q
M)W+22B3-JH8=GX2X2U;C/6(-'TF+=WVDM6I WBU"JK 26K+@>2B;[(@\N:4K
M%&"[#(37]?H<.:=+J%]]E7R(($([:U.02D$*GO9MMV8^3&@:1R%4Y;?@!S^U
M'X@&GDMA4(Q:W=H#TD=M'5<A()/9^@S[E(YT?PY4&9IJK3((KN*Q:$635M*M
MT7+5RVCIJ.EXF/D..^!-5X$U<T+P-BE/SR:9JD<92"] I ;R>9Q#9AW5;-9G
M9HF*LK20R12R8G"_%%#BF@+=4]E8BY4NTG8-+5E8$CKLO:0R;$PSA0L@!!"2
M))&D[\TC-FQC&1VY::^J>SN-NZ:C>)7:4)5W>N;>\F)+2UDLE9V:W9QL!(O5
M_N27K$E&NYB4511420JLB=[7[4<Y8*?BI.*?.6:N?I<\M?4*<L"UGE%B((MN
M..2N6:15':B16"+N>LB\LD8W=&5@",/4(8YZ5F.5IUC,,A8UG=)@ A)Y.0@L
MVPZ1MNCGR75E)&8EO#JKK]CR'@K%,:K\6-JUDM;6MI3[]SPY",=G:LCF$H%>
MEE4*K6H>VV)-K;K,PBVAVJ[M/T2,0PD?*=BZ3:E5VC7Y%:@\:6>&"5L1&6#1
M:!K66*]HH,LCQ1DQ1LQ!"[,69=QMOM Z0A%Q7:OKP#0R".75+8G@ ;D8\D:R
M/RR.%&Q/3E#==]M\^0]>@]/G_-U#J'7_ )AU#K_\=0_^<TC-JS&)#^'!)3!^
M14-O/E9N/>.M>2];V3$7K6,I7=:TJ":3FQF\5$EN$;+U*KM;.^EZ)6(IO5M=
MM;-,3T5589I"-VC,Y:Y"E:;$VOJGB#T],J4[&GR5W@LK)9F<I7+OV3)+*T82
M>5S+.8EC:5RY)^V/O"+H[-XXMJ_8M0W4G62!D@C0-, O:!HXP[-$@"0AV98U
M"@#R%VD=QLXH5;CM.[8O"$Z\M^Q]UK:L)?;8ZCF\*@ZB=+:MKNH]=PT9"MG+
MTC!K&UROJRTDHJ_>K2-JL=DD431\4YBX*(C]0U.6\E6$H(J],6>PB#%R&MV7
MM3NSD+S%I'"KLJA8HXU/,P9WS*=".F]B4,9)K1@[:0CE!6M E>%57<[ (G,Q
M+,6D=VW"E425N1N9^8Z/%C@8)_X=7-"5?0L2]E&''#9?H))W',W+]EY<"\53
M](\61.X;=BIC*D\E0G:H8QR]#"(C/<,.ZZ_I"J[!6U"MNH8A3O( =P#L=QTZ
MY#Z\JG1]28JI84YMB0"1Y)[B1N/Q9D#A2$+#Q8 0H :-8@8 *  (>E2#H( '
M0?<(_/D&_MV_M-ZSDNO</0/5G9 0@ )0(4"C\Y0*  /_ ,ATZ#_]YQRN.PG:
M)>PO:/O$O:':(_UB'3I^8/S?FQC'ED[>WL)V]>O;VAV]?Z^G3IUQC'ED$H%$
MA!* ]0+VAV@/O]X!TZ /O'_\C_7C&!(00 HD*)0^8HE 0#_X#IT#_P"L8P)"
M&  $A1 ON* E 0 /FZ  AT#W?U8Q@Q"&Z=Q"FZ>X.XH#T#^H.H>[_P"L8P)"
M&$!,0IA#W (E 1 /Z@ZA[L8P)"&$#&(43!TZ")0$0Z#U#H(AU#H/O#_GC&!(
M03=PD*)@^8PE 3!T^;W].ONQC'83N[NPO=_[NT.[W>X/?TZ_-[OGQC'83N[N
MPO=_[NT.[W^X??TZ_-[OGQC $(!A,!"@8>O4P% ##U^?J/3K[_S_ ->,8 A"
MB)BD*!AZ]1 H (]1ZCU$ ZCU'WC_ ,\8RR.[N0^G>.M<-9-IVV.@"KIJFBH-
M "O;18E4O<+>"@6PB^?CY@D26=F(C&,3*IGDG[)$WFA0D#OS<^"_!_Q9Q_J'
MU/X8TF>\49!;NN.QTW3T?NDO7I ((-U#,D6[V9PK"O!,XY<@D5]S YP=2PB$
MIQ$XUR/N-+.4S!NG8D.H(_\ I$4S-5H"-DFW88%$5(QB"#HPIR5T8&4;#3RC
M_P"T?I/^W\=^=V^+^"7P+=;C5?"MX1*_7Q6(@<':!;7N[5V$J7K-:3<%76S-
MVD0YJ^C3\LF3?T/QCTUQP@30NL*FV8/':)$INUR8DD[A9#%$IS'FIY5(BZB)
ME0\\D8R(QAFRQCG91K83FZU  [LZ9XX\)'%WA#NBWQ+JDD\,3LU+2JX-;2-.
M!!4+3HJQ16"'LS9F::Y(@ FLR;#+^ 0@ )0(4"C\Y0*  /\ \ATZ#_\ >5S1
M<=A.T2]A>T?>)>T.T1_K$.G3\P?F_-C&6QV3M2IZRCTC2YQ?3#_H6%J\:4B\
MQ+N#G\I($6Q0,*#8RW1,[Q8H)@8!31*X="FV4QK%J*LH+DL[>TC7J[GN&P\P
MW[R>GF&YZ':N%^#]7XJL.M)%KT*_E7]5M;QT:4:CG<O(=A)*(_*6!#S$;-(8
MH>:5;1PNL+AMN19V[=@C'0394'=<U6P5418LRCU\IS8C$,4ZSPR9A%5 P^K.
M*ADG!V+?S8G,5*TUMA+<\E =XZRDA0.NQD\Y/N^<]QY1Y.;G=XKT3@RK-HO
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MFDCG8%0&YMLR9*6IOIDT,]E+3OIC0&J((^:2T:G9AO&7E 8FP.TYV11N=]U
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MZC:>:2;A^-;$4A9Z';1S0D<CB,]L6!C?NY$$3%U#<A (3ZORF Q2F+[P, &
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M3S.SU\AYO?W]_7U7JO5].[W]OG]G3X>WM]V,;#X^OQG?\N^^%(.-48(QITW
MLT%!53(#^0*J!Q,J81,Z*Z*[4+U64^!1<Y  2@!>A" 5C;]'QGU]^%X.-<M&
M[%5-P+9J/5 I'\@DH4>AB_&X2=$<+>XP^Y950.O0?G !!C;S=?RGU[[X=0D:
M\;M6SA-P*#),$VX$?R"!BD A"?A%4'22JX]J9>IW!U3=0$PF[C&$6-O3^4Y
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M'^8X&#&8VW7?K^4[?D[L&AH\\@$H9-?UH"4P'!\^!'J1($2_R0KD&G3RP !
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M",:=-P+-NH*J1 ?R!%0.(JB(F=$=%=*!U64^!18Y/>4 +T(0"L;=-NOY3O\
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MORQ7JT(U,V>0T7ZE\QC'D=(2\A*3-AB(>!AV\G%D=.%GKQS(IIQH,I!GHO\
MD_>!32_"I8XHUSBS7)N'>!>!]/CU#B&_5,*7)1)#<L]E!/9BL5ZD%:II]NW>
MN25K311I##'79K/;01(T_P"+!MG6&R+SHGQ!-.H:^VC7Z^VGZF&L(\\DI9UW
MI&;AE63QZ-HM$&Y>RK)Z=[%V2-M#>! (Y[%2"3:33(*]"=@2<[6XM_DM\*\2
M\/:)QOX!>+GU_AF_?DH:J>)9Q673$A,L<VI"=],TR]'#6FA$-K3[&F27B;$%
MFNTM9F"2)^XOE]S?_#[+>RG%+CA(>]/7D"L8-O7V(5^9.S2#A!%6$9O$3*D6
M:2#1BU\LZ:3FH327DRHTV+=_0>YW[_C'F_CW,Z^^K'@G\"_D<.0UO"CX0H._
M7[R#V)Z%;3SZ;!&[+=EB<*R2UYIY>8,T>K4VYJN3\TWH?5&@:R2J:JIT96(\
MP)&D7B)#.9R=<I%$I7L_..A5DI9R F.*0NG!T&A#F08H-6H$0)4 #N&=%<7<
M;\4<=:D=4XHU>SJ4X+BO"Y$=*C&Y!,-&E$$K58^BANRC#RE0\[RREG-WLKFJ
M8QC&,8QC+3;,W!7-<)(,E"+S]MD^U.#J$1_*)>076,*;<RR:153LFBJO0A5S
MI**K"!RLFSM5,Z9<6S;CK@ [R2MT2%.KL3W=P/*#[I&Y_H@GIFX\+<%ZGQ.\
MDZ-'IVCU=VU#6KOVNE6C0<T@1G9%GF1-V,:NJ(.4SRP(RL;:U[4=GV)+M;SO
M9=-V9 WJ*_K9H<?N?@4S#W$&53(HH1\[, %%= 5%_-[2IR#ITE_^GML>.K+8
M8373OMUCK#_II[G./Z1]T==_Z1(\D;1J?&6E<-4IM \'\;0B1>SU+BB91]4M
M08=&%-F56KP#KV<@6/D+,U:&%_\ Q,O4\EN8VHN+L='P\N9U;ME3:;=I1=-T
MA$LA<[$Z<&!I%I!'M$U_8<2X<=C=*0>(=S@"+(0C"8?(^@-+1Q,_M0%0=['H
MH \P] \P[O/L,\O>$'PJ</<!HD=^2?6.(]0(^IO#>FDVM9U&Q.Q6)I$42/6@
MFF/+XS.I:5A(M6*W.IA/S[5#7/+33VN-T:1F^#5@O,WR1:,7D5?G]6>6F5IO
MM1NJ<AG$_"1DK%HR<4+P)-!K*R]8>U>Q$7DYAN< ,S2S"T;,KB8+R;[J" #L
M>O0]=CMMT!W&VWNYXJTO0O"1PQH?%/"5OP17=7M\=1025M9FTZ74;.E^,(Q5
MGNU*]FLL];M182.Q9T^73;P>Q:3OB7Z%.$&F+5Q_XNZIU5=W"2UL@(V9?3J#
M=R1XVBGUGLLS:5(-!RD91!<(0LR6,67;*JM%W;9PNS54:J(F'#E8/(S#N)V'
MQ@ #?S=^V_7J.[/:_@EX6U'@OP?<.<.ZLZOJ5*"U-;2.02QUIM0U"WJ)J)(I
M*/XH+0@=XV:-Y8Y'B9HV0Y3/$GA73.(]FY*3%.FI"1A][[QL6W("LN0.G#ZP
MB[7&PSZ=I=69&66;L8YY?/NIL2IHY-@V78/Z]&+,C*5Y)TO)ZIJ\VJ1Z>DJ*
MKTJ<=5Y![>RT3.L<LAZ%BL'91CFW(99&!^V$#=*&FQ:>]UHV)6U9>PJ'VL*R
M*I:-!Y@9>T?IL""@(W3<WFUWJE_5MJ[XVO8)9G,36V)JC1U?(U062-5M7:YI
MK6-K%-767,(O%T[W/;5O2KA$J+=-:_JL$DCBR.Z=8D]E9:U*M&A1*J3-)N0>
MULV)BTDP [@8$JP@'J1 &/?L,F& I/:G=@S3M$J;#;LX(8P$B)/?M*]B7?H-
MYB .FYO=F'F3C&,8QE+6B\TND-?77*VUNJM!*)RN+#-QL.FH >[HD:0<M_.,
M(_"4B7><Y^A"E$P@ YM+3=1U)^ST^A<O/OL5J5IK!7?^MV2/RC;J2VP ZD@=
M<PKNI:=IJ=IJ%^G13;<-;LPUPVW]7M73F._0!=R3T )Z9%RR<\- Q3P8FKR%
MHV=.B(II1&O:O(RJRRO7H4B+N1+$Q[H@B("95@Z> !1^$#G^ =TJ>#+BB>/M
M[L5+1JP&[6-5NQ0JJ[$[LD/C$L9Z'994C.XZ[+Y6:7<\)O"\$A@I2W=9L[D+
M!I5*69F;S!9)O%XG7NW:)Y!L>@)Z93G^W/EQL'J36'&=&DQZGN3L.XYTS Y4
MS].Q=2LD/7Y9(P%$3%*A[5( @!C]Q1!,V7[&N!-*V.L\8-J,HWYJF@5A*"1_
M1%PBW PW[RW8$[D#8CF&)[)>.]5Z:-P>FFQ-T6WK]DQD*>YS3!J3J=CN O;@
M;;G<'ER/F_>/'+^V,ZELRX6&E;:GM?3R,K&ZOK,$1&):L5G+%]) W]2SA7-F
M2<KQ$<UD8MT19^X9>85BX4Z'04VGACBO@*C)>T>A5U'0ZVJUF@FUFY9+3O*J
M2QP\W))82FR+8F>&="L22;&55W##5N*.%./;T='6+]O3M=M:59$\.C4ZH6".
M)GBEFY.>.N]Q7:"))8'#2O'N(W;JIJW0>O\ <VS^4!>1^Q-9ETY#U^ONHEM!
MJ,W$6\GY!>">5Y(JS!Z5"2= BWD%WKF4>-&K?HSBF+0KD45%4<'BC5.']&X-
M/".E:Q]7[%JTD[V1(D\=6);4=MBLL1:%"SQ+&D,<DC?;)Y)"G,H;.X8TOB'6
M>,QQ;JVCC0*]2J\"5C&T$EJ5JTE10T4@69PJRM*\\B(OVN"*,/RDK5?BD<:;
MKR.XM2+O32)R\D= 7*I\C^-KYMY)9!/;.J'XS+"%9G64;IG4MT(:;J[9LY=M
MH\\K*1;I^H"#+J7K?AO4(=/U)1;ZZ?>BET_4%/M35M+R,[; ](GY)20"W*K!
M>ISL_7*4MRBQK=+E22.Y38 ;BQ7;F51N1UD7FC ) W8$]!EU+4K.Z]TS U6Z
MP.Z'5OWC)2D5M78G&JOC;IK55ROD+)2<S;T3>3+6]O3JHY1;T.CS\94;O,UZ
M(8TU"1CT6#!649XL?)/;>2%Z@BIJK5H-0?LDLPP,JI$=BL1FE&\TT;2PI([2
ME6+-RF_)SQ5DCE6R9+1*SS4D[1H))5):0;@R")"!%$XCE9%$88; L/1\.[3F
MRN/O#726E]L.V3VUZYB+'6V:C2*AH59*C-+K93ZP:34?7R)PZ5H9ZW5JC:V&
M:>>*MD2E%'<A+/3.99]RUZW7O:M<MU05BL/'(06=QVQAC\9*-)Y?9FQVIB!V
MVC*A0J[*M-(KS5-.K5IR#)"KH-E53V0D?L P0!>T6'LQ)MONX8EF)+&:F1&2
M6,8QC&,8QC&<2_XA;]4I^X;*KWCTCUY1NX^@^K-2YGU/SPQFVHSY7Y[HQC&,
M8RQ'*7_=CY&?W$;>_P"WUAR;X9^Z/A_\-Z5_KZ^1FM?S-JWX,O\ ^EER.7A3
M_DZ.(']S->_ZKS-B\*/_ '!XL_"\_P#A3(C@?[DM _!\7K;,@F:%FU8QC++;
MYU;4-GZ_FTK%JC6>WY^M0MBG==UK:M3KUOK!+R2!?H0BRC"R@2/9G=N%"1CJ
M1(\BW*4:]?(%E&2#EPKF72LRUIT,=JQ521T2>2K+)%)V/."X#1^4=ANP4A@6
M /*Q &8UN".>%N>O#89%=X4GC21.UY&"]'Z#<^23N.A/4#,3?A[O+$INVNU4
MG".WZZ?4BN;H_P!K?)?8?"S67#YK*J2ULA3:MJ&LVU+%ZXM)R1"DK%61K#3U
MBJJT3#0]A=6";F12?FV?70GB<DIUB*PLTE3Q73X-7LZJRA8G\9EL&;81;N%9
M"Z12\SNBQHFZY Z26\92,:9)"T26?&+LNFP:>&+2+V$<(CW,GD;APKO&557+
MNQ!S.;FFYL^,8QC&,8S']XK/Y-OFY_APV=_IUWDYPS]T&C_A"M_F#(G7OYFU
M/^YS_P" Y.^&_H>*_LUC_E4LA7]NW]IO6<E5[AZ!ZL[+..5QC&,8S'=X@?!(
MW,F!UW.TV_+ZLW7IF<=3^M;NFF\.S15>KQ3QRPD%(Q9O*1ZB4G!0LK#3\<9P
M]@GS%0Z#%R5ZN4K._P#P#>&X>"&]Q!1U?0DXGX-XPHQT.(]%9HEE=84M0QSU
MULI)5G5JUZY5N4;"QPWH)U5YXC"A-F>&OAO; U;O*<Y3<L=QM=^[U=17L2MN
M449!]#5E+T[9B,X24GFK!Z[F$8IL6'AVS2%AXZ!9.)%1,)!V]07C6;?X7OY0
MV@\3\%4O!CX+>$9>!>"(K7CNHQ.\$-S4G[22?Q(UJ,L\,51K4AMVY);ENQ=F
MCKJQKQ0NEC+OC/*.,8QC&,8SP(@4!,80*4H")C"(    =1$1'W  ![Q$?< 8
MRH!)  )).P ZDD]P \Y.1FM>Y)RV3+B@Z,:(3\ZF/E35U7 #U:KI'$R9EB.1
M(H@_=$Z',FH!7#8QD^QHWE5?-11CI;;RN8*0#OW/,?\ I1#S]>YC[G>/<#'H
M.T](X(H:/1BXBX_FDT[3V >CH49*ZOJS@!@C0AEEK0G=0ZDQRA6YII:2<DDE
M5T+5%6U<WDKC9)<DW:SMG,C9]@69PFEZ5 B)E7ZJ+E\L9*'C$$"',X<*N/-,
MW(87;KTQ$T$+U:FD!+L3+._MY6ZL2>\*#ORCS>Z?.=M@->XOX]M:U7-8"OH'
M"VG1EJ^E0.E>E7KUP9.WO2_:HY6C"F1G<)7@V+HBOVDKP6OW,_:?(RU2VE.
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M>.@XQX,357MJVA.B)B(Q&O:M(RBJRON I4G4D6)8N4^HE$RK!P] I1'M*H<
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MB-O?]OK#DWPS]T?#_P"&]*_U]?(S6OYFU;\&7_\ 2RY'+PI_R='$#^YFO?\
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ML\B0PQO++(P5(T4L[,?, .I]T^8 $G8 G._9)(X8VDE=(HHUW9W(5%4><D[
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M%(F4I2@ 8&?0.&&*O%'!!%'!!#&D4,,*+'%%%&H5(XXT"HD:* J(H"JH
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MKZLDL=5*[%9J;M(TDXE=D"2Q;H8XF4%FVZ@;LN-<K7+5!M.2)(TFTYHVL-,
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M UT/I?DE4?E.8'?'1W)ROW13>+DOR0XJ;6X]<-JMNE-;<C:O7J,M\O:U956
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MHST% 24)-+K*!$O(P\RBNU-$W!U*O$WPJ<D*JRET$BAE+QDLJR*""R$J0P#
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M:HO2#_)FA)45DG ="CU4=^STA;CU$P=/3K>XH#U^+H%.GQ_D_P"<KU^+\O\
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MT5N1HH"#R;N[2/$WDR;]D'(E.\@4=F6.?2KYOC-W#W VX5:H2/UZ"H>^S+U
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M9<L4KE4*UFK8KJY(0SPR1!B!N0I=5!('4@==LX0VJU@L(+$,Q4 L(I$D*@]
M3RD[ GNW[\NMF-E_,0OC*\@ZOK_A=R>U%)4K=<U/;#XX7TT79:7I+9EUUG"%
MD6DG$D"[;-K5;D:32#(JM%7+TMGFHTS&.4;23D$F;E!8^U<)49)]7TZTLU-$
M@U"#FBFN5X;+\I5_M->219INA '9HV[ J-R",U_B*W'%IMZNT=EFFIR\KQUI
MY8%Y@RCM9T1HHNHW/.R[ ACT.^77A_$KU(E$1::FA^>9E$XYB10R7 CE:HF8
MY&R13&343U:)%""8!$AR")#%Z&*(@(#F*_#]DNY%[0]BS;;ZYIF^VY[][.^9
M"ZS!RKO5U7?8;_\ PJ_W[?\ \C.Q^4NU#] O/;Z@O*_[+,X^QZS[_P!#^?-,
M_><K]6:_O35?FJ_^PQ\I=J'Z!>>WU!>5_P!EF/8]9]_Z'\^:9^\X^K-?WIJO
MS5?_ &&/E+M0_0+SV^H+RO\ LLQ['K/O_0_GS3/WG'U9K^]-5^:K_P"PQ\I=
MJ'Z!>>WU!>5_V68]CUGW_H?SYIG[SCZLU_>FJ_-5_P#88^4NU#] O/;Z@O*_
M[+,>QZS[_P!#^?-,_><?5FO[TU7YJO\ [#'REVH?H%Y[?4%Y7_99CV/6??\
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M!>>WU!>5_P!EF/8]9]_Z'\^:9^\X^K-?WIJOS5?_ &&/E+M0_0+SV^H+RO\
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M100.(W(9PYD3H@8J&!8 '?,-K]59:T7:;M;DFB@*JS(\E<,95YU!52G(WMB
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MU&3,= Q5TBF3MF91\1=.5&+C))TRP1J]!ZZ16[8FB3BV2[:@/:N+&F2=D58
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:.X!/(NRK'!$"4KUXXH$\B-<O=D+DEC&,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g287237g12x08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g12x08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1R44&AO=&]S:&]P(#,N,  X0DE-! 0
M    ''B^<H@X0DE-! 0      #T< 5H  QLE1QP"   "   < E  "')R,S<W
M.34R' (% !Q-:6-R;W-O9G0@5V]R9" M(%))1$524RYD;V-X #A"24T$)0
M    $-[0" !!5UNL+;.IY;.G)5,X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              $S   #'          !
M                  $              QP   $S
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   $S     %)G:'1L;VYG   #
M'     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !,P    !29VAT;&]N9P   QP    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     \X0DE-! P     $AL
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MD3')P@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" !B /\# 1$  A$! Q$!_\0 'P   @,!  ,! 0$
M  H("0L'! 4& 0(#_\0 3A    8" 0("! D#$ D%     0(#! 4&!P@ "1$2
M$PH4(=05%AHB,598E[<9.947&",V.$%157)S=7B6M-;7)#-Q=X&1L;;!)3)A
MN-/_Q  = 0$  @,! 0$!            !P@!!08$ P()_\0 61$  @$$  ,#
M! @/# @%!0   0(#  0%$082(0<3,10B05$5%V%Q<Y32TQ8C,C925%56@9&5
ML;.U\ @8,S0W0E-TH:2TU"0U=I*3P</5)6)UT?%$<H*RX?_:  P# 0 "$0,1
M #\ ?XXI1Q2CBE'%*.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE'%*YMF#+5$P3
MC*ZY=R9.(5VC4& >6&PRJX>,R31H4"IM6;<H@J^E))VHWC8B-;@9U)RCQG'M
M$U'+A,@^[&8V\S&0M,9CX6N+V^G2WMX5\6D<ZVQ\$C1=O+(VECC5Y'(521Y[
MJZ@LK::[N9!%!;QM+*['H%4;T/6S'2HHZLQ"J"2!6<MO#N!?=V=@[;FJY'<Q
M\:[4^!:!3S.C.&='H<<LM\"0#42^%)1T?SEY6<>ID($C/R,D\*1)!1!NC?O@
MGA&RX-P-KB;8)).1W^1NPNFO+Z11WLI)VW=H (K="?,A1 ?.+EJY9_-SYW(R
MWLA9(A]*M8-](;=22B].A=B2\C#ZIV.O-"ZYIKA@#(^T>9Z-@[%T>>0MMXED
MV23A8%_@N!BD0%Q-6>>7135.T@J_&)N)*2< 0RADD :M4UWSEJV6V7$>>QW#
M&&O<UDF"V]I&2L8Y1)<SMYL%K"#KFFGD(1!X*"7<A$9AY<7CKK+W\%A:[,DS
M><QWRQ1#K),YZZ2-=L?2Q 506(%:.NJNM./=1\&4?!>-6G@A*E'C\(RZZ*2<
MI:[*^,#BP6R;.GXA5DYM^8ZYB"HHDP9D9Q+,4X^/9H)?S_XCSU_Q-F;W-9%^
M:XO)-B-2>ZMX% 6"VA!\(H(P$7H"QYG;;NQ-D,9CK?%6,%C:KJ*!-<Q'G2.>
MKROZW=ML?5T4= *D1S25[Z.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE'%*.*4<
M4HXI1Q2CBE'%*.*4<4HXI1Q2CBE'%*.*4<4H$0 .X^P XI23?7/ZC'ZX7):F
MKF))T%\+8AG#'N<O&.2*,LCY1CO.:N 3<-SF![5Z(95S&1I0,#62L@RLOY;M
MO'UQ\2WW8KP <)8#BG*P<N5R</+CX95(>QQL@#"0JWU%Q?#3DZYH[7D0%3/.
M@A7CWB/RZX.'LY/]$M7W=.I\VXN5\(]@]8H"2"#L-,#T(16I?9,AU5")D*=0
MZA@(0A $QSG,/8I"% !$QC&$"E* ")A$  .X\GDD*"S$*J@EF)   &R23T
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M]XK+BJYN,4LR(V^AOUU"QZZATY8$23L(L16"LS,H)"C+,E'B"/P5(Q;EU,W
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M^_H/XE^Y,_\ Q+?YZC\EMU"_LD9C_LZ'O/'MG\ _?1C?]Z;YFGT'\2_<F?\
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MC66MSU.L4[4[3$/Z_9:U+R,#/P<JV49R4/,Q+M5C)1K]JL!56[MD[05;N$5
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M26>0CQD<LWH7E7S:AR0AU#E(F4QSG,!2D* F,8QA "E*4H")C"(@   "(B(
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MY>"<.")JR%<E(B0.FDHY.BE_/[C#A>]X0SUYA;P%Q$W>V=SRE4O+&0DP7*;
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M&XO;JW@A8OW-OW(220]!)(7C=F9%)5!L*.9CK9W59_R:#!OVF<K_ -D:A_\
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MY/*V887-MAV3L&TVQ"=RC:\6KR*Z-PP\\9N1LT*T:,H-A8'LA&NY-ZSK3<D
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..I1Q2CBE'%*.*4<4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g287237g27q99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g27q99.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1)N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $E*^1I X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              70   =3          $
M                 0             '4P   70
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   70     4F=H=&QO;F<   =3
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   %T     %)G:'1L;VYG   '4P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      (/
M  $   "@    (    >   #P    ((  8  '_V/_M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    _^% ?VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z
M3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A
M+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q
M+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,BTP,BTP
M,50R,#HT,#HQ-RTP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX
M;7 Z0W)E871O<E1O;VP^5&]O;&MI="!H='1P.B\O=W=W+F%C=&EV97!D9BYC
M;VT\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E
M/C(P,C(M,#(M,#)4,3 Z-30Z-#4K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@
M(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(R+3 R+3 R5#$P.C4T.C0U
M*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q
M+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY4;V]L:VET(&AT=' Z+R]W
M=W<N86-T:79E<&1F+F-O;3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z<&1F>#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P9&9X+S$N,R\B/@H@(" @(" @(" \<&1F>#I!4%1+5D52/C$Q+C$N,"XR
M,C$S.2!0<F\@4')O9'5C=&EO;BTS,CPO<&1F>#I!4%1+5D52/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G
M92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM
M+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @
M>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX
M;7 N9&ED.C8R.#,T0D(Q13<X,T5#,3$X-D8Y0S4P,30S.40Q,$)!/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.C8T.#,T0D(Q13<X,T5#,3$X-D8Y0S4P,30S.40Q,$)!/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W!D9B!T;R!A
M<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HV,C@S
M-$)",44W.#-%0S$Q.#9&.4,U,#$T,SE$,3!"03PO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP,BTP,E0Q
M,#HU-#HS-BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C8S.#,T0D(Q13<X,T5#,3$X-D8Y
M0S4P,30S.40Q,$)!/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 R+3 R5#$P.C4T.C0U*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE
M=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@
M:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HV-#@S
M-$)",44W.#-%0S$Q.#9&.4,U,#$T,SE$,3!"03PO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP,BTP,E0Q
M,#HU-#HT-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#YU=6ED.C4U9C0W8V,R+3EC8F4M-#8Q,2UA.&(P+3$V93EE.60U
M8S8S-CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C8S.#,T0D(Q13<X
M,T5#,3$X-D8Y0S4P,30S.40Q,$)!/"]S=%)E9CII;G-T86YC94E$/@H@(" @
M(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C8R.#,T0D(Q13<X
M,T5#,3$X-D8Y0S4P,30S.40Q,$)!/"]S=%)E9CID;V-U;65N=$E$/@H@(" @
M(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-35F-#=C
M8S(M.6-B92TT-C$Q+6$X8C M,39E.64Y9#5C-C,V/"]S=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \
M<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C
M:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( '<"6 ,!$0 "$0$#$0'_Q  ?   ! P4!
M 0$             !@<( 0,$!0D""@O_Q !G$  !! $" P0%!0@+"@H#$0 !
M @,$!08'$0 2(0@3,4$4%2)180D6<8&1(R0R4Y.AL? 7,S5"5%:4P='2U1@E
M-$-2<G:VU.$F56)S>(*2E;+B&8/3)R@V-SA&1V-D='6BI+2UUO'_Q  = 0 !
M!0$! 0$              0(#! 4&!P@)_\0 51$  @( ! ,%! 8'! 4("00#
M 0(#$0 $$B$%,4$&$U%A<10B@9$RH;'!T? '%2-24Y+A,T)B\214<J+2"!8T
M0U6"DY07)34V1&-T==.#H[+4L[3#_]H # ,!  (1 Q$ /P#[RGGG0Z[]U> [
MQ>WW10&P4? ;#8;;=!T VXA)-G<\SUQJ(L15?V<9.E;.D$\N9]<6O27/QSOY
M4_S>/U[\)9\3\SAVB+^%'_+@])<_'._EE<%GQ/S.#1%_"C_EP>DN=/NSO3_Z
MT_K]N_!9\3\S@T1?PH_Y<'I+GXYW\LK@L^)^9P:(OX4?\N*^DN?CG?'?]M/Z
M[?#PX+/B?F<&B+^%'_+BGI+GX]WS_P <?/\ H\OZ>"V\3\S@[N/^%'_+BOI#
MWXU[\H1^@?[_ *N"SXGYG!HB_A1_RX._>_&O?4ZK]?MWX+/B?F<&B+^%'_+@
M](=_&O?E5<%GQ/S.#1%_"C_EP>D/?C7ORJA^@<%GQ/S.#1%_"C_EQ7TA[\:]
M^45P6?$_,X-$7\*/^7%/2'?QKWY57!9\3\S@T1?PH_Y<'I#OXU[\JKZ?U^SP
MX+/B?F<&B+^%'_+@](=_&O?E5<%GQ/S.#1%_"C_EP=^[^->_*JX+/B?F<&B+
M^%'_ "X._=_&O?E5<%GQ/S.#1%_"C_EP>D/?C7ORJOZ/S>'PX+/B?F<&B+^%
M'_+CRJ0\!^W/#J/%U7GT_P!_#D))W)Y>/IARQ1D[1QC8[A1?YWPJH:MXK!*B
M24 DDDD[D[DD_$^)_FXEQE24'?8"B=@*JN=#RQJ;#):Z$^8+'?VMKLDBIJ6Q
M,G)#@W;7) 6B/7,.#<HEVDB%$5MMWX*AP8CL=-_Z=-KWK<#K6-<8627*E&QF
MIQZ#NH>KZA8D63[1W $JY=:0W$)ZE;57'#S1ZLVRQLLEUOSK>O'\<,TEKLZ>
M8%$D[DCF=ATY<^6W6J<)Q5  <K([QZ<SC[C[\AU7FMZ0\\X^^ZH]5O/.+=<4
M2IQ:UDJ*]ZW@W\OY_P _+;#1 E$&R+NBQ_'I\,:>R@:7TQVMW\9JSUZ6-I%A
M$['8["3*:)V/0].G!WC>!^2_CBW#PG,9@7E\AFIQL;AAS$@H\C:!A1H[^1QI
M$VNAJU%*<DP%2DG921DU25 ^'4"PW\N#6_.C7C2_CBS_ ,W.*5?ZFXE6^_L>
M;K;G_<Z8V#/[$$C]HM,->W_%7M>Y_P"&:>#6W@?DN_X_?B$\$SJDAN&9Y2.8
M.6S0((\05L8S6ZS3)T;M.8VZ/'=NSC+'7KXIE$>?!WC>#?(8C/"<P-SD,T!X
MF',#[1B^*/3M0W2W1$>\36B/M$C@[QO _)?QPT\,E'/)YE?6*8?:,7_FS@9\
M(=01[Q(21]H>X-;^!^2_CAIX<XYY6<?]R;!\V<$_@=3^73_[;@UMX'_=_'!^
MKW_U:;^2;!\V<$_@=3^73_[;@UOX'_=_'!^KW_U6;^2;%I5!IZDE*F*1*AXI
M5+;!'T@O@CQ'!K;P/^[^.%_5TG^J3_\ AS8\*H].DC=2*%(\-U360-_=N9 X
M.\;P/R7"CADK<LGF#Z13G[!CQZHTUVWWQ[8>)]81]A]?I/!WC>#?(87]5S?Z
MEF?_  I_PQ9]!TMWV](Q??W>M8F_V>E\&MO _P"[^.'?JC,_]GYO_P #,?\
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MP 1'VF)RA7O'68IEEDB]I<B65V#.JDEL67RV8 DB,NEXBPD<32L9 L1B!4E
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M/PK#>[E-@(-0(%%JN][NC?PY[#K>/!A:A!,)19Q#[](2V JU)02PX^.?[AN
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MT^R8ERI<F:^ZY-D9&<E@FS,LN7B[F&1@RQZ50(2JZP$5F55+ZBJJ=*J0
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M!X*J['0[^(VJO0T?MQYP2&R^5(! .9E# V"".Z%5Y#8UO>/+/[30[_\ )_\
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M_P _7&:H4; !23>P 6_, 5SWV',DG&W9=;>0EQH\R% $'P(!WZ$'904/!25
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M<BVUCI[/?)B6+3]O1I6H;-3XZ6O6$-KF\$RHN\Q#:" '(<IW8EU1)MO]_/\
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M;RX0]/05\.?UW]N #Z5]2>IK<?UW(Q!+M-:UO44^'34\CD6E,UIPM.A)*EL
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MG?G=;'EAUZ9/9Q7CM6[J):YZSEBZU:KUNSD:G1)X>Y<T#Z&XN/QXL!$3D^<
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M8V9R"8T/V2QV4,A00"$J*2 ?  ) &WP  'OZ=>-<DDV39-GYDG^NWCC\A0
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MF=(U>R5!#,(ROPG#S<J"^$&,E:RDI0%/)"B-@H\6!!F*4F%M+5I-<_CMOTY
M7OR&')&\O]FI?R3WCSWV!O:C= \J&'"Y21N-B/>""/?Y'W<0D@$!JMEUJ-C:
M>.PW YWXG8GJS#.:WU%;<XC"BVL&/81F<EIK%IB4TEUMN=5./6=;,2E0(2_
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M47H6CL1SL"@2;>=;/)P7/<$DARG$\CPSB8S:\669Y)81FD5E]XI?L\RZ#[Y
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M;Z9X6IH\S"2 7@F N)F".=+:E7#^RO'1GH,IFHI=<6;CCD94()@DMEDRTJV
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MU&:;6E#%LVBQ:2B8A+P;WTU%>]DTDDE=;425T$D71)3W"3S7W3MMA="7>E;
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M.$\REA7.=L^)MG.R79SC$VF7-+)G> 9F8_2E@X6<H,K*Y!WFTYMP_P!%;TD
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MXE+0YKD%8W)3 LI+:/25A"2M82 I<>2#RK"5[$?@\P2KD)YD@GCEIH$N2)E
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M5+"2E@R^72Q'& ";YN=[)WMONKTQF<+X,,DY><!Y"*U;@*"![JB[YBR39.X
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M;WVZ<\830Y:VLW_Q<N*%?#ED%LD^X@GK\>GAPO(L.6QY#T/2]J^KGAO,*?\
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MT5SV#179T>X\5JLH[2'H3( ZNW$&I;!/*E2SLI2@@\CBF\,B[Z21OU%_;O\
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M"A6Q'7<;5A_<2[*NI&0%M^[1#Q2$O8J58O(E67*=MBBNAN.I"MB?9E3(BT[
M+;!) /Z]/EM]I^//'$<7_2GV>RVI.&IF^)-7N2!GA0,+K49U5JL &E9M_7$S
M].-!L'TZ+4V)$7:WZ 0;VTY7I+:E !1@, "-7)/7K'1WY'1R0[N3PI.]_5Y<
MJVZ5MTQXYVA[:<<[1LZ9J<Y?*-]'*9<E8:'+O-P9'KFVP-G88>T= !OOL/'W
M_'A,<I@X,&#@P82^0G:PPW?^,[G^J^3?K]/0=>#ZO\L,<'W:Z,#]1'B.I&%1
MP8?@X,&#^?PX,&-$%!5:WUZO3AR; [*Y[(E/+T\2D;[>77?;8\.HV?$#?R '
MWC;U-88 :'FP)LCESV-F^7J?#&:E0-HY\(+:3[]R^X1T\>O"4=(/2R/J'+[_
M (87^]S'T?$7S]?KY;XP&U U;'F79HY=M^I79*4 D]/IV\0 =_ \+I()!%$*
M21X>[?\ GTZ80 %15'?G[OC7F+KU-[#PQ>D,,3I4V&\.9M^M;8> W"@AYUX*
M2>FXW200=MAOUX52R%7'1K&VUK1^_P"VNN!EU6#R*D<_'J!S^)Y_#$:(79UH
M&3"G.S77H[EJT^F"I!2 E=D7PWS$[>R@*&X!.W4#8'B][=,I8*#=$-Y*=R?+
MI?Q%WOBO) H"E:O4!S%=>MD;'PWVK<[XDO#88AS3%CMAJ/&K8K32$@A*4I=>
M 3]2>4GS]KKU/&>;-L1]([GQ/Y_#%D;D;W0H[@T=N9'C]WGBRWL:R "5 .3(
MK@W!!4%S@\"-QU!!Y@/\G[>%(W(KD"2!6U#K6VW7\< !  VN_$$<SR-[FKVN
M^G/&'>5$>\-I D(0MM^K89W/BE2GY"@? [#9*CX>6_F.'Q,8WCD .S@CE_=(
M/4??ON/'$<@#ZE+5:D$4>MCQOKMMCDCJYH/=TK[$ZOC*=8E3&G$!MLA)YY;K
MHY5!/4J&RD]#SI.Z=QQU.5SJ2+W1:B!JZW[I /,>?E1YCPPY\KW<AD5;!VU6
M/"P-R*.WR\CAA8V&9 Y:/,>KG@X(T=.Q"@05+.V^[?CU&PZ$C?BYWB63?D!3
M&[J_*O ?5B'2;Y'Y'\]/M\<2.TBT+6N/2W>5*C5L)-A"D*5.*([?=)>+BEA;
MNP4CNTDIVWYOP4<RM@:6:SA5.[3<J*H<]Q9Y^>_]<3Y?+HSEVI0?/HIH["R-
ME\-J!QT4Q>?#@R&H^*T_>4J(J([]Y*0["8=+"'^05L=YL2)V[RVRIY34>+W?
M.&W'%<HXYX@S%F<%6#<P>>_+:]_0^?AC6!T@G;E2FO3H?0;D;@^!K&^AP(=<
MTIB%';CM+==?6E .ZWWUJ<>>6M14M;BU*.ZE*.R0$I"0 .'@ <OSX?+$9-^'
MCUZ\^IZ_D8R^%PF#@P8K_1^O\_T\&#%.#!@X,&#@P8C!VBM%^TIJ?J%I?:Z3
M:T7.F6G%)4X[$S:GQ_*W\<LKUR3J_II(S.0EI&*7S4J0K0IC5:CQQ]4V"Y7Y
MC;X]8,^ARX<._I9\EFLAEX,PN9RB9B=WD,3O&)%0#+9@1#^T0@>V'+O( #JB
M5U-@E'?-%F))(FCF:.)434JD L>]C+W:,3<(=5]X4S7L:80JB:"?*I2W#C]C
MKX+9G%,!T3DW;QSI[3V)J5G^2Z9TU%KI1X_J/4:9Y9>4%9A6I>G5-J5BM\SI
MY$]:P-4LYP)$6JAO*=K-5L[V= UKDM+239L(.Y$YR\,>89\F[P-F(T=IH)W@
ME0SMH;+PS6QV:FL'$_H-F 0D<&IM>GO9#%IG <1$J$D19%8(-0D=*  I;7>B
MGRDU9=XFQ-UP?R=>3ZNZ;X=G.98AE?H-6G0VTPA36JN3UNES^ 4-9I7F>+7>
M.)D8ID-1FV:R,DL\F5W]?1+?1%;B3-\!9)3[)W?=Y7,2PQ21VWMBS7EHVS F
M=LQ#(DE2H\40C6,47JS(T/$04J8-JGC61@P ]G*_M&6,Q 1R(1:TSZR=Z!"A
MK8G9"^5/Q2MQ3%\*[2U)&Q#&M)LQQ&5&GZQ9C;9+>9K+R74R359',RC)M([^
MP#%[776G%DM]HQ\DPE&-6&)XKD<"(_*N[R=N)]GI&DDDX>QD?,12C3EHDC6(
M1Y<-&(X\S&/<9)UWM)3())$) 56+E>(JND9G81LH/?,S:B\N[%XF)!5HB"*=
M=!4'<D]AM'&]5HN"4U9K+#Q)C-:>!25,RQPW)KS**O(UP<:HV[3(G9&18[CM
MG72K')?7R6ZM]%LM%:Q73I%P_,GRHD'F<U[,9F;*F4Q.78++&D;1W(^F.DDD
M5@L>BV&D:BRA %#-J1=YH E"!P "49F5J MK9586;V.H@5[QO#I<5\28;^57
M0"^\37P2I3KREJ,9CF4M;BE*4I7<E2E$DG=1)Z^_?A.\ V][:QSVOT]=\;<4
M^85$K,R@!%H:I"!2@ "YA0 %; >F,;U;".Y-? W/C][L=?I/HV_YCP=Z/\77
MJ.OY^>XK$OM.8_UB3Y2?_G_/VU%;!&V]? ]D<H^]V"-O=UCCH/+@[Q?!MO,?
MGEMAK9C,-_\ $R?[X_\ ^YQ3U9!\/5\';??]H9\??MZ.?U\!PG>+T##T(_/+
M;[MSA1F<R!7M,GA_UG*_'OQR^[IT/5D+_B^ -_'9ACKY]1Z. ?CPO>C_ !_,
M>?7XX7VG,?ZS)_\ N?\ ]C_/ *R"#N*^ "/ AA@$'^3]!X_IVWX.]'^/YC"'
M,YC_ %F3_P#<'V9C\^.*>JX/E7P/R#(W]V^T?J0.H)W(/A[^#O5_Q_S#\,+[
M5F/]9D\]I/\ ^QCUZM@[=:^#Y?XAGR^(8!/3W\()%'1OF!AAGS!_^)DKG_U@
M^KOC_7%#6PCXU\'IX?<&.GT?>_3ZN%[U?\?\P_##AF<P ![1)L/!_P#\_P"&
M*^K87G7P?R#/4_'[W&^WD3OP=Z/\7S'C?A?^?K@.9S)&V9D!]'\?'O\ PP>K
M86Z5)@0DK1OR+##04G?QV*6DG;PZ;[;#IL>O"=XO@?C1Z=/S]=$"SS#9LQ,0
M?I*+HUR-M(]5TH#SO;&8D+WW4&_+JD$*V V \/ #P2-@/=OUXC=@QL7X4?#H
M/\\1_LQNIDW))#'4+/,[D\^OCY=;G#<,P<&#!P8,'!@P<&#!P8,>%@[H(VZ'
MKN-_L^/3X'X^/$D>Y(\:^_#UTZ7U@D5>WB+^OPQG#%:_E$NK<D4,]P!Q<JG<
M3&0\X0=W)D!27:R>M6^Q<FPGW1^]6E0!$F,5ZMM.PLUY?Y>'7D>N*&;D]1L)
M\%C(HB$GFF4H3"LT@?OGJ:;(4P^$IZK<@V1><40EFN)(23#;Y\S7IZU^?$>>
M-I69#4V[BV(4M)ELI"Y%?(0N)9Q ? RZZ2EJ;'!/0*=90A1VY%*!!X*_S_/I
MA X) '/PVL>HN_CR\\;K@P['A2=SS  J V&Y('V@$_K[^%\K-?GIAI4'>A?F
M2/G7EY' E(&_LI!5U5R]02?PO$#Q/GMU\^$/S\+\, 4CK1ZT!1Z^%]>9W/,X
MM/1(SZ2AZ.RXE70A;:% C??;VDG@Q(KNA!1W0@V"C,I!\05((/IC12L,Q&:2
M9N+X_+)WW,FFKGB=_$DKC$DGS)/!BW%Q+B,))BXAGH[ !T9O,+8'(&I!8'0<
ML)^3I'IA+/,]@.)%6VW,BBKVE =?P5-,(*?$@D'J.G@2"7^3OBW'VAX]%_9\
M8XB/)LU,X)\P[M>VP\.?/EH'^S_I#(*BO!ZI!423W#D^* 2>O*F-+:2@>X)
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MI*3X*0X@CP .PVKN7=RQ;<UU/0 <OAB,I9I:"[4#Z>0/4D[<[PK?</(  #W
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M)C-?55K"WEI2[-L9[[$.%&02[)DO-LM)4XM*2JQ:R0J%B%9B%LTJ@LS&N04
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M%$BX[DV4)=@LY%+R&NS21)3C>-NM2FID%4M:Q<5CC;--[(#[1/--W8=%B*S
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M+'5)>/R\TK:W4;&5SYN&0-1:V=1.P)M:TWEN"XY>H8CLM-0(BQ<91&5FR@I
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MLVPBVUK)J[?'I,L.-0MQ1'D@9LI'H@GBE2)2@4(B:7C4]V:UO4@+!U!50Z2
M8><LVF11*RZXV4MS;42"&-\M@5(%;$T0:(ICO8I;I,*UOI/GK71,KUET:N-)
M&<KQO&+*B5@4&UR[6K*(<?%0<OGWT;%\6C:JTV/8KC[>21GJ:KP.K1 M(K+T
M.)3C\5U2Y1Q$QBRN:7,F)Y%<3%8\K&3)^R"&20Y9GD<QD,TS6IW+GLS]UF$[
MT@YB(1L5#*JL#F"KJ#(3:>T,$MK0#W6%T$;F/8*R#(%6\"BUKD8K02\6U=Q;
M'V(%!DPO,+I]1F^T#%I\8QBVA:CUL*OPNAB:T8PJ?1IIC*L)FD&&.U5ICZ(.
M/-XG-%QB--#/E!(RR96234\>B5H/8B[R*8&8RR'*24^NE&9E#*Y+F2)\E(RN
MHS!4,)PI"&T[TYC0HJ0#1&LX!%:F,2$,M !2S^PO":RR=F&(9^[B%FFT]/QM
M,2JN9D#&8T3,\#N*.NA4Z\PCTRX5)@^-9;IU%BH@1HRJ347*$!EJ):WE?=QC
MBQ,2Q2P"1-.ER60.Y,,Z.Q?NBX+S213DZB=<$>^H*R/;*$OKCE:,W=#4R_VL
M+?1UA=XXFBH  "1CXWCZ7=BK+< P'4/$[/6HWEUG&!UN$PLAK<+^;36+M5VH
M^I.?LNU5179*J-'A-)U"54QJNM<J8L<UKLU@-(GB#$,QQ2*:>&5<IH2*4RM&
MTO>&0F"&$ZF:.R3W6HLVH^]IWTV2++21Q2(TY=WL!PNC3;%A0#&@MT *Y7UP
MD;7Y/J]DX]18Y4:VR:--?HG-TSM;^)092G*Y^36NF>JN"9#D\&XC:E0VJ^ER
M^]U)K<^RBA?@V-M,R# ,5,7*8KE=1S,=F7C2"1Y'R@<MFUS 0O'W8C6?+3)&
M5.7)9XTR[0QOJ51'-)<9U.'8^2=DT+.4'<F.PK:M9CE0,"' "W+K*U>I$I@%
M P[]]V3+R1C6&8WB^K-C0P,(U?E:C4-+/H&;O#Z6E7G^;Y;68[5XXJS@O2)-
M)19@QA]0[D-O>XU21Z"FOL9Q+'\BIL=LJ.JG$D$DKR957,N56!W5],KN(88V
MD:0JP =XC*_=JDKEW225XW=7D.6DT@+.P*RM(H*@HJM)(P4+8)TH_=C4Q0!0
MRHK $-[3]A.YE*P]O4O5*EU$AX-!TYHZ6-,P&P9$BETWR_LWY!!D6JK?/,C$
MC);^OT#FQ,@MXB(,1^RSB18L53;=0J);V'XRH$OL^7>!IC.[E9QL^8BSZ,%T
M0QD1HV=!126(6$*6.JUBBR4T3Q.,TP:+N0C*K*]039&526$EZV.3&IA0UN'
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1&#@P8.#!@X,&#@P8.#!C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g287237g28x65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g28x65.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %?"^5A8X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             M4   =3          $                          0
M           '4P   M4                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   M4     4F=H=&QO;F<   =3    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   +5
M     %)G:'1L;VYG   '4P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      +NP    $   "@    /@   >
M '1    +GP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ /@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M&. H<+V-WM.[>YV\?H]OZ/\ UK_273@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@$$M.*P7(D<VH*!I^&7+0(,-]YY]_=O;F$Y$?<M//(8;4ZX:)3D,25*."4I
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M7+QLO+LL2&16Y:)P#D&:"RFC*'K]*=#-$K/T=ET:/*MBU[=?M&:19<S*MJM
MV]*2#RI.U)GO*326;/LN5FD*:D)M"YF:G76WE%I4JMMYK<]RBQ=*>Z3I=-V/
M-6SH5HA9\G8PM2U)S3"V4Z/658X<>DT2<N;2?9F5SMJ3*9YEUZ4Y)EAEB\0Z
M'FE-.3LFSNH!.9*;F9_T6:&3I7F%+-/R55JH";4DR4DJF,EFHQB)!(KB@4?F
M7A6>5%&)&IB(2G+[BD8A2T#LP&X[I=T2K_&'FWI=;C3[#S#[2BEUA]M3+S2A
MXR7&W E:%C6E0!&L5PCZ?T;^I[E7K5DI33CNAZ-:-2%O6RYH]H=:%E+.D3>F
M%I(0A)G+(6VN3ETZ/LSCK=GNVS-/,L.6E609!<(='I%3"?TFJU-Y"J<A%%(@
MBU"D^7)T2B*R5>(JQ-/F5(*+!0JI%7A>""=+P3;D(PZX_$@C%<>>@18T%Z'%
M?H!J*\5&![8X+I)84UHOI#;NC<\[+O3E@6O:-CS3THZ'I5V8LV;=E'79=T4O
MLN+94MLD)7=("T(6%)&=-,:2#(09"#(09"#(09"#(09"#(09"#(09"#(09"#
M(09"#(09"#(09"#(09"#(09"#(09"#(09"#(09"/)'2.BU[K?IV2YHUR?7Q;
MT8I4DJAR57J0U0I2R1JAQJN3VFSJ>ER9SR2;G%-/)Q,G31+6)=*J"/%.EE&,
M>F*$I@D&4^%!48?2K(D-&)+0M.DEJZ.LZ537MD-GNM+M:T;-38S8D>6D5/-R
M+K:W5SZTS:FG%(<8"6;A<2Z+D>?-NZ3RMOS]C6);:]'V+1T:=EYASV,D9\VM
M*3$XT)^6;<G&W!+I9Y.3#I96U,D.8>Y*4I6*U7[EK6RNDQH4T5CT])AJ6?EA
M(.HR 0G+1=H N2REEU(U!.'C964#B9$E8%DS$+P(;Z\^D/K0%(,(FZ?=*PG(
M3N.=)]!SC^QI)UW:4Z1##93EZ;ZTKAG3"/7Z+:9]U[0B0GK-T1[J5I:.2]I3
M3,Y/.V185BR5HS3LNVIIAMVUV64VL91M*UE,@)T2/*K6\9<O*4X<1D3N.DW4
MS7S4TR5I=IJ+,1E9F!<=5W-#/1B-G2$>:$R.BK2:CQ#TNF019;,))HTGP942
M72<M$BQHTX22BXF8[T1[9M!_\FDEO'MITB(.O$%\C/'97&D;:W.ZCW>]))!N
MS+:[MFE,]9[<I(27>BI6299>;LV91.2;\VF7+)G;1;FFFIA=JSA?M-]UII4Q
M..\FB[W6C31FJN@AI;4+T<0T@UBLM):Z4KKFN&9:6*:R+)[TH+M*3$AJ2"JD
M5*78$98CDWX$V+:3WB847$V !PNXX4B/PRKQ;(FI;12V-$=(+;L?15G1N?LJ
MU+!:4ZS;%JVD)QF?3:#+C2F[0><;;*.0:<"FT!9"#X0%X'S&DNG7=#TJTHLI
M>G.EQTJ<F9.U"AQVQ;%L=QEQGO%2G:6/*2J7UN@ .J=352JN%2EE1/I9772E
MH1HU/2="K3/82>9J":6R4F$8$M3A-2E,)F7"191789!,DR7YA4!=2R)PL:-Q
M8I:%"AP8H/[L0=?W/@I.SIRT.5[T9Y4,!!=47&FDH#BBE%Y3SC:?"4"  22=
M46)B;EY7D^7<N%TJ#8"%K4LI%Y5$MI6KP1B32@$=E(VDA0^I-4:@T5D>HR',
M%5:5)4KK=0I'+.*$!;E9+G--+*\N&E"$=)%8+W?R>=)QHT$K&,&$Q\V6+JL(
MB9CPH+\/2$Y+RS$V]+K;EIE3B&'C=*'5-**7 D@D^"H$5( 50E)(!,2W-RSS
MSLNV\A;S 0IUL5O-AP!2"H$#,$':*BM*B-W-AQD09"#(1K.H-8*?4N6:7($[
MKCZ0JUEJ#!I=3LLXF*J@"Y.QB69DF^"DQ(R:2-P$MQY E)=.<(*T0DG.OE'"
MKQH#1HM!BY#$J_,HF%LHOIE&#,OF\E-QD.-M%?A$%7ANH3=356-:4!(M.OM,
MJ92XL)+[H9:!!-]TH6X$B@-#<;6:F@PSC9C8\78P;]DB3OV2OV(>%#'[('J'
M_9'X%X%7>]?4=P]ZF>%/5#P9ZF>^.&OWIP-PQP[O?[^X-[P_?37N0=[W[ZNC
MD.6Y"_?17E;G*7>3O<I2YC?N7*^#>O81;Y5OE>0J>5Y/E;MU5+EZ[6]2Y6]A
M=O7J8TIC&<M9BY!D(,A$6ZE:9%!Z5Q5@C,2Y-:@O(M69-H;%E:5*;5#FF9E2
MJ,^RLY/,N2M+*0CRR9C39&CR:,>8SA^6A54M-(DCY<\=@*92,0=V,O94[,W2
MVAM*%2KLX''9AAIM,LRYR+CCBUN -@.T;"7+JE**2 4D&,1V>EF:A:U7@^W+
M7$M.K6IYQ <0A"4H)75!O%2 I*0%5(NJI*1M=&7&-I\XRDK3+,<F)<SR^I3?
M)Y5"/39*Y%83S<P2R2F>&>C2V;7T> 8B*"077X*6I14:,?+P(:E#('(A-Z,Z
M7BBY<4TZEM#JFUI:=*TMN*0H-N%NZ' A9%U905)"PDFZ5"M*B* XVI:VTK07
M&PDK0%)*T!=2@K2#>2% $I) O4-*T,=5,E3:?RBJ1$&8IP04V9'),F>HD.57
MS\$Q-IV1Y+?3H,US0ERH4$Q,2NCH)A82":B;2TPXY /*R61&YQ0)P(U3<N^Z
MD+;:<4WRS;'*!)#0>>"BTTITT;2MP(64I4H$I0I6221"GFD*N*<0%\FMT-WA
MRA;;H%K2V*K4E)4D**4D J2,U 'M9-FY G^496GN5#D51E>=)=19KEM0CIRF
MD1SR#,*:65D@Y&2EHFG+"9%,D#9>,^052!%1)O/B7.E"YF'$@N4NM+9=<9<
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M2-&B.0H,)Q^+%BQ7W8<.%#ANB\_$B/O"#KCCCH"\^^\(.NN@(B(  BT@$D
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MMFS"B9#<M,305:%GN,HE$,HEFW5EYV6>>!0I!!2V"E0Q$;MH[I\S+6?2?0Z
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M^O/.AY_,>*BS-[@7B8O[P-CD,7-_?><$'PA1@=&!N<'S !<''7_!%T7Q$!$
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M^G;#<,>O.F[C#'"'1V[=L&'C"H.JG'FK$<<=7!I%N^$3ON"(!'W'>YH']S$
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ME'"0LG!3ETBBAA<N)K5!,4HJ%+K>IRF%\@I(N(Q0!BE%ZO@D W@I5/"BYRN
M_5T?2U&>(^GK^:*\J@_1U?/#B'GMK .3 <,;CRW9O'1743SXC'"@YJ0RPZ]^
M.X;\":^80[#Q[?H$0UCB-L7 W;/G .H8"N#C//;Y\*C;CM6'9R89]6(LJ-O/
MCEVX"%#LYL,^S$PR'#'+L/%?JMK9F,<,^!OIVUU1'S?/EJK"PZ\[AG>^-\[X
M<>/I94:LJ'*FJF5,=V'JB2#KSUUK77]/!AKO@ ;.V/;4S53$G;QAQKAGN''3
MQJBU, ^,4F+@&-RZ:>&)O,5V&XZYWH;= 33KV,<OO@PW0A.>&!D2T80W$%^U
MQ%+KE2BI;%TJ222>4;/N9&"%W:F\<.3#B,UB+:ZWFZ!8 <)5=4  .3< Y0'%
M2+Q2 D8W[BS@DQ<]NW3UM1QQU=D5\<=?;%>GL.K''+JXFCJX&O##/MWQ.ZO/
MQ7'(0#5GMY-NW4&=O(PZ\MG/LV:SE7SPV=?-OPW" !SY]NG9?5GDPGHRXZLZ
MTUY9PICMSZ\>,*].4.//;<->L-H[;WUZA'%NRV4.K4=@V4IJU@8-FL;QKV;=
M0Q&W56&KS_5CLU"&.IFOT?3AMU@X:X:O3]&.S41CJAJP'S<67/UX9"+->(].
M_/H[,<P(:L#VY]'3VX9&(,]T TV92T(*%J<_* $EBHDQ=]R_2623$5X'ICFO
MO<'Q/J4*!%A&H<JRU"B05.9#<*) %^&))&+FH*HM)HO>UT#T,FM-;<;D&[[5
MGR]V8M:=2 1+2E^EQM2DE)FIE04U+)*54)<>4A33+@CSNDVD#.CUG*F%!+DT
M]>:D9<U]V?I6\X$D*##(*5OJ202+C84''$&/@$J1/DWU1G:9ZB3^OGYHG.<E
MH[,$R+RG$WTXI*BA%>C&(SX.NNPH,%R[L H3+0X)0B4A0"1* 7*%X$%S[NL^
M1D[,DY6SY"71+2<FTAB68: "&FD( 2/*))JI:U$J<65+6I2U$GYTFYAZ:=>F
M9EQ;S[ZRZZZLU6XM1J5'_P!*0 E(HE("0 +>D_VVZ7^^+)/+]DZ9VZ1:;3^Q
M=I_<$Y^BO19D_?LI]TL:O^D(X&VAC^I@WYF1]A09"#(1&_2U^T1,OX34J_2U
M(S>@T7^S<M]SVE_1<[&NM;W@]]O+_I+,20;S\;&#(09"-?'0=!66!< N O'"
MXQ!@/OOQ!?X+3@ 33KV$,SN'7 =<<LX)5TL_[-]]L\'W&7!OFC2Z7P D)Y=_
MZV1BINI54FI#A<&0$:\TY:8I<J7$7KI)43R+('* ^*N@% * MA!S)KPCQ]M?
M:V'G#=QJQ^?'T2=_&OBF'I>7+#MC?ZFGS9X\84^F(\^6'&-?HAR<V..P.?9;
M9E;..?IPPVGHVUVYURG93Y]QY]@&RM-KCQ^K(<N6W((<;-V'TG$9\U><'=#K
MI\U!JIMIS$0XN<+YV^D/HSQ;^@TRK\Q^?+".-_!^B&%^*_4TXTWT[885W5[(
M<G'GV#MRV!S[LN#QS5*+,V#@O$Q> N-CL,7-_?>=$']ZC6&!N1\,Q:^X<?NX
M\YO@CBZ#5MUHX 5_6C>N &J;R*W]B/*(Q!NC(Q;< );)N8.@B\2,;JJ7=J]@
M5@1>.)%(O/HX[6Y>;7E@UOY]U:\W3JSQB[QMIT'C5KAMZM?81UC;/8#-G;JX
M U"N6TPVZMFOBNVG4(<?GQ"UOJRLS=Z,#6OTYUAO]..%.!\T4:8B*_3J#FP^
MD?3'S:STX_,/5/SZAT8?.?6#MQ<8A8<,=G)BP\;]P-1CAMY\(#C=O(H<,=G-
MC"_)T!MOVZ,F4Y^L[*<=><-GJX!X&5(8]75EVXV8=O;GQNB./1Q\\6A('0@"
M#@0 =[X.#8L^\_"W0G3 OCNGQ%[?A?%X3#N3A@8KCO@.@UQSQA6^3<:%5@!5
M.1;IEA<N@!!^$@()\(D10W2[A< ONX()*0>577$XWKU;XU+O "Z!%V-\+WY]
M7)S6:V*8TIT:^?IK%9KKKNK#F 0OR7M?7JOYMK.D@TYZ5IJUT])U1/%>O6=O
M-J&$4[='IZ&GCK]77$<=7KZHJ/+VP^KFS%H'-QC]/3D(D\_&'T=&9A<-?5RZ
M\M6H+>5E#J[>;5GKUFOFB.?LIQT80V>FV.H?.(Y:L&'?YJUUD=6 &=,<8G9Z
MZ8ZCZ2<M6$.+CSQ[=5VG?NRPX[:1&[?GCQV5BT?!T3Q81WG=]Z'0=%Y][OG<
MC&("_O4,/ >@"\$/OA][PG(@%@<N#[[5BO)+ O4Y1JM$CDZW7KMY686!>N)&
M!'*$Y"+9 Y5!-RO)N@5/NE+S5;J<BBM+Y.(-RE:F+L.VW#DRMGCL:V>-F//G
M7+#;%T?/O[,B,\8RM!_BL7^L/<?_  <)L9[QA]J-VLQD,9*YQOU1WC68OP9"
M#(1T4T?8S,7WB5_R>8:_*^^9?^/9_.)BASZVY]HK\DQK;1Q^YZH/[S-+_P R
M$-MAI!]GK;_E>TOTUZ+$C[RD_N67_,HC<S:B,J#(09"#(09"#(09".DF,'!1
MCH1 +BY:!<#3[\.!<#4$7=T_#$'P>!X &$ #9Z+N'7O!$6R)6\'T72X%>'3D
MP%+\15: X4I6]L34C$",>: +"P;E/ ^N$I34+214C&M:7=JJ X1B?;5GR;.W
M$V1QKRY]O&^,?CC'M^B&RW+R9W#8-PMRY-&VO-SY4.T4->;.)K3C@8Z_IAAT
M^GT;>C$!!CU>KU[.O @L..?LZ:]H(;.7;VMRM.WFV<_7S1$.WHU\W$'&T<>O
M5T[SNB>/5KZ-PWP$>C9VPZF =>WC'MB*^O=U0Y,;\7'S]L&GGPIO^CC&'&7T
M\80PY^V-[^;7FT8]'&%*>G5E$^?C7S[NDQ9%0<"(?W(0 $3MXF\O///B_P!Y
MDPN9![!PQN <#<.>!O 0'_9/O-<76C5;Q]SH+U *<J[@BF:*UQ.-\K3DD1:;
M O.TN8N8W"2:\FWXX- %TI@,+EPUJ3%YVZ]7T\?$U'&'-QENWQ<X[=7S[]T5
M'H#RZ^/$0$.(&CM/FU;L 0=YB:=7GPKOQ/96'FU;.VOG%GIU[>/4(CKPU;(\
MW:0436-(^H&E7,$VZ16E)*;LCZ2\UTZEF7Z9UL7I-E9+EA(DN0%@D6+(9<N;
M+0(KIQ?4'HD0N,%R*Z]#%^$,4(D6)@%2BMP%2J!9 %2  "0!0$#  "NNE=<?
M56D6EEG=S_1GN5R-F=SKN76NJV^YM96D-IVAI+H5(6S:DU:<W;%NRCSKL\ZM
MIUQ):D6+J7+ZDF]1=VZA.]_6%(_]*S3DV?=+3%EL_DQIJKRE[?'5GMSCR'[-
M3G^2GN(?^&UF_K$/6%(_]*S3DV_=+3%GM_DQE5>4O9XZLMF</V:W/\E/<0_\
M-K-_6(>L)1OZ5>G)_K*S%^K&55Y:_P">KUP_9K<_R4]Q#_PVLW]8C\/Z R&^
M]">?TJ=.)]Z#$&)">?TE)A%Z'$&'%A"_#$4N[KXPXL5P7@L.XB1';V>&\A:P
M% +< 4FZL!:P%)O)516.(O)0:'"J4G,"*3W:5$H)[D_<.)2J\DGN:V82E5Q2
M;R?[8P5=*DU\DD:XY/6%(_\ 2LTY?]9:8OU8T5/E+_GJ]<5?LU.?Y*>XA_X;
M6;^L0]84C_TK-.7_ %EIC_5C14^4K^>KUP_9J<_R4]Q#_P -K-_6(IZPE&_I
M5Z<G^LK,7ZL::J\I?\]7KA^S6Y_DI[B'_AM9OZQ#UA*-_2KTY/\ 65F+]6,J
MKRE_SU>N'[-;G^2GN(?^&UF_K$/6$HW]*O3D_P!968OU8RJO+7_/5ZX?LUN?
MY*>XA_X;6;^L17UA2/\ TK-.7_66F/\ 5C14^4K^>KUP_9J<_P E/<0_\-K-
M_6(X#.@D@E($4R8TKM.1R%!<%]]\=):8KV ,@#@R[SSPV==="XO/"#H (B -
M4D+40A*EDD@ 7U9]>%,R=6<0>[8XD$GN4]Q  5)_]FUF_K$?%#W1.9)T4=*B
MJLF3342H=1$JE,XSA3Z2#]29L4IQ7TZ546;5QPF3BJJB^+T2-%&\<Y%A0H#D
M>.]N@AN0X<&'#^R^X*REK0R<-U/*JT@GT.NT\-P-2UGA 6KQE! )" HFZ%&@
M!)CY[^J\19Z]/- ;1LVQ;%L!&D'<7[GVDD[9M@6<Q95DHM6V5VZ]/ORTA+^Y
M,\L6VDJNWE*2RW?6M2;Q\_S6 WY-NH![;6[>,T\9H&K?3LCY7<H$DZJ"O97M
MC)J3X5;I?[XLD<GV3)8].UL:U/L7:?W!.?HKT).HG93[IE^;WPC'//''9']3
M!OS,C["@R$&0B-^EK]HB9?PFI5^EJ1F]!HO]FY;[GM+^BYV-=:WO![[>7_26
M8C_W2N?)YI[1&5UNGM62%*EZ'4%\V^)Y9F>6AGDC+M.:A3;%DXI,$GR%49=+
M&WC* 4F2$A$I>=,3V,N_L?E3SAV:"I(_ONYW(R4_;,RQ/V6NTV#9]P7&9:9[
MR<?M"0E1.+8FYZSV%("7U2ZGUOD20F._E(N2RG&]?I+-/2<DR^Q,MRZFYI*U
M(<><EQ-H:EYATRP>9EIMQ*E%L.A"&2I_DC+I-70#)#16F-;F_1UI#,\R35"G
M68%V34]26IB@E%PBZ84S+\9\Z0>+30C2[,SD9","^@F'IBE]$7HT=,B1EA)3
ME&(9*0O/Z42[,II!:TM+RIDF&)QQMF7*V%W6DA(0X%2SK\L4OIH^GO=]Y@)=
M :=<;"5G/LAU;]F2;SKPF''&0M;H2M *R3>1==0TZ"T:M'E6VW"4$N(2LE(D
M VAC91K\^-U95#=B_8U #<[QO(.?[F$!W#L2W[Z"[PO[_B(//O%K_O?#/3]9
M8- /<U8W[U1R[U21^YG"[<R(2'/AF->HU>?%2:.) %R[3W%HT!_= :WKVJO)
MX%$<&-QSSQU9WS$;9A?,-K,*#++#7EL KD:9&)-:G//7OKG6FJN=-<,0[:L?
M+QZK:F8'C7AYMVNNN(ZN*\8[M4,<-0=@'T#;4S#'6>"/6*ZXGLXQ\XK35#KY
M&GLYXCCFX$./EUAD.JVK/5MXA:-W-J.8UDZ\M>S>(G9QT4IAYL=QAQ7\EM7*
M&H,\-MF;Z>>NOF.LY8[*PW5]5<.<4J!NUX0[=L^J[3QQEVTB..,^RL6IIX77
MBEGWG+FW'<(&_;H-Q%'</8#O "(7&.'L! '/^$%JD $.52".3)\<)QJG$8B^
M=01F<Z>#%"R06\2#R@'B7M2C0X>"-94,J4UF+K7R\6O.UN7#T@U&KFWZLJUY
ML?48N:^?=KSI3GP]8ARZMO%J#7KY.AF&! SV;\R?7GUPSUY;>P#KYNJ%NW/9
MIKQT5B*<=-(;/1<1S^K#RM&WTF@&7TX^:)Y\.CG^B%L.?BUY<?/DRN/1OU9[
MNC.'KW:Z=--^4,^V ;>JPB.>&-\V9<8G9VU &6.%,H9\8#;V4).>&-<X9>CR
M@.S7Q\EV9U\_F._5NYZ0Q':.;U:\/7 =7'CB%A^D!VYX:F#7NPP-1\Q&S+'7
M ^?:,?GQUYX:HM2@B] N+PO_ +X.!<8(%GK ;C@#N] &3@!N'8MOW<'0,9Q1
M$:UBBJ4IX#7PBL?6TXWLJG,IK5!JBO@X4-^+CCX;@)NA!^N*PNYT&05B%@!>
M:B3=#?MT^?+4U(IQGL]&>N*N/3Z8#@.KF#HSU#;/' <;W:!B-?2>O+6*Y88C
M"E(DX;.,O-6HV[X;>KZL=7);&XY,V=OTX:^>NH9PX!KYQCV9'.'-GB'7VYF=
M.6![,^-<1JRSQKU\=$!'9D& 9;,[;>/;D. , VYG$Y[<J[-VS,8F)YM5/IY_
M-J.4./9GAV#;A;(,LV;MN6./KV8US.>4-^S/#@;<*9#+.'1GVXK-/7EQOK$=
M6?&ZD6KXCW[ =W0^$5-CN @ \Z\(1B0 ]WQ:\(7+BZ$ +=\ ^\__ (MA6*<D
MO 8+;\(KH1X+E1<^%48E9\2@'[I%!/NJ,3BVX:7,#X36-^G@T. 0*7P2?@87
M5QU8<E^?6/%U-;H->//3HU#?VQ<J=6'-7IUG=V1E:#_%8O\ 6'O_  X38S_C
M#[4><QD,9*YQYH[QK,7X,A!D(Z*:/L9F+[Q*_P"3S#7Y7WS+_P >S^<3%#GU
MMS[17Y)C6VCC]SU0?WF:7_F0AMGV_P#9VVJ_OM:7Z8]%B1]Y2?W++_F41N9M
M3&5!D(,A!D(,A'CO.-7ZIIG=(DR0"=?$P:<+LX2_+Y^0W%"HD4U)+J+3ZFDR
M#*)V3$FE1N1BK\[JTWP@*5'FJIA HO1JBE)82P>F*GY5$B]:E+)LQSN>.3R[
M"=]D691]]$\6[/"9SEI^TI?OMN<=M-$ZL234J0Y9\K9KBV!9ZIET\A/K>3XN
M8G9QO2=J6%HH$HZZVVJ7O3!4P4,RC@85+MR:F$]\*=HF:?FTI69H-(!=ETHC
MV(;DL>TCII@>%U'."#XPQ (/ANE^^A"YB"%@@6'=;J^Y%[_@@$8MPW%VORV+
MZ,+WCX%?)_ 5C>U4SI\*EW&M(L3)(970T-4"H1RF:TCQ1B:Y5^#XVJ,1\F%L
M;:]77C:P8MD>?&N%=6OLPK4X1C^;"F-->KMQI08POQC;+7ER7ZLO*RFX5SU9
M\].W/S0KJZ->WG^;SQ3G[=@!IZ..">V(Z>. (KYMOT^1H].SYO/#T;?G\T!Z
M.W;SM(Z^./1#C+9QZX<G)G:^70&RX<M[-'/SY5IGUG;0\U*Q-?GQSVC@=<.?
ME[?6TZ\N;CZ(B%N*]\L\[]>0]@:*[Z4SRRIV9C@PBT+"(Q#H;L7['+!> $$'
M  H5'<.O@ =\NA<7^^!OB^,"_P"X  7%THT:4JU7Q[U:NN"I'P#A=N?P;^:S
M%",2YB31SR+M!R:#2OPP,[^\I^!%V';+7MXN7#I%K9XSU;-_-CU"*X#KSZ\^
M.^L+X]5F#H[,MU-1IAVUB?3SYTWZ\<>R*=NW86GCC@1'''!B*>@[_+^FQ_;0
MGW]&U)FUO[H[]NK\I7!VG&.\]U[[$=Q7=W&[!_\ ,6E43T:J.+09"#(0V=M0
M]'8-;(@ZN?T'J@R)@R$&0@R$&0@R$:KFA<!0C"4+/B),N\-WG?8F(P7 7[@(
MWAN8A#P$'AW3^-W;;658Y--]0\-0V8I3LYSF<MFV,)UV^2D4* :<ZMM-8K6F
MX$[*_P ^CNAWW:>DSA?^&6HOYX+F+?7W<+_:;-Y?MCM/6/\ ![/IL'&R-?\
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MW:4S/LKM)IM$JMI"K--G*5-.LS4A,O2#[5HE3')S,L%(9?<9=1*SBI6:NJY
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M:\Z"M*5QRB\''9U!KYL,=889:FMC#;VGUXX:CB<=<7:;//ZZ<<Q@/1S[<<
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MQZ1JB?5QJUY=-"<XLRH.!$/[D"^)Z[XP'WGGQ>[S)A<R#P#O9C< Z&X<NYO
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MX\(@.\.C:XQ\-R+H."-GQ:XBE'#0'W,XW[M,4XC$7SL0*DUJ!A%M9H6\2/=
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MHO9I2IBPFGG$?NLZ43SE["BP)IYUM"]8Y-M !I0#./$6AIEI+:-X/VX\TTK
MM2=Z210UJBLLRVXM.HAQQ9(K>)$1]C0'#,:*8,J$ P8COC$C&(PJ$6/&?>N(
MQ(L6(5>?B/#B(O//"\\-_"O=O5I44)2A+"D(2*)2DLA*0-24AP ##( 894I'
MEE@+4I:GD+6HU4I8=4I1RJ26[Q56E:DG'FCB[S+W_C17 ,0W!T;XZ_WI@(AR
M<V35WU?%KKF1>;_KG?CNB+B/C&\20#=6-F56\0#TZL<XJ),L%KFBH7MAN#HX
M8_\ 50RPN&=]@9KZOBUY[6Q@<LUY^F("$FM'&S2N-U0QP_\ VSGC0Y4VG()0
ML&'?13EW)T0Q"X8@4 >(,]O*OJ%:MK&=,6S_ .L=4+B:5Y1&7DK!P-#@6SEF
M<MG-02A8,>^BN.K<'+Z[YE-60#8<0O<,FF^KXI?6WT_#^G="XG*^@[PE=-5/
M@:\Z5&!IOB@E"^HT5RO[$YM_JO& <88ZV7U?%KZV\OY\2$)UK1G3Q5;/M-Q.
MXX:HKWF7 ?XR6MMW)P.OO6U^< OJU-%Y7Q:^MO\ K\^OKRBFZFGCMUV75'J%
MRM-N!-->N* 4+^Z2H_\ W3G-_BH;!N.K/5C-]7Q:^MO^OSQ44)\M _[JNGX!
MVB@UY:\*]Y%P_P 9*?!.7O:WN7DU8X!K &7U?%KZV\/]>(NH/PT?S54S^TYQ
MG@*G43#O,OEWR5 <<-R<RXQ[UU<@88C@T!:OBU;Q5O#_ %_5AV@E.=]!&VZK
M,;!R>OG.. QAWF7#_&2N5\73F0Y#@5#5ARCQ@#+ZL?<E[L6\=OP_-6%U)^&C
M.F"59C,8H.O'F&XF/>?N<^]!H[!#A/N/A"GN:''AAA$!T'GH*3%L&^N0WA\"
M(Z(CN;7$0N-A;Y?[K5[VW*404A5F25T&E:!3Z3D2/&!UQ]+=RB@T5H"#=M.<
M!(! J4L'6!J(RPU9@@3Q;F<=+@R$&0CHIH^QF8OO$K_D\PU^5]\R_P#'L_G$
MQ0Y];<^T5^28UMHX_<]4']YFE_YD(;;"W_L[;7\KVE^F/18D?>4G]RR_YE$;
MF;41E09"#(09"#(1XZ4+G:@=5])&9%R!7O3B@3F=K@3G")0"I$D3;*5/Y6GC
M]BV7'RTH*\1)I6!=-19323<$FXCK=1$U*-GD]QXT[-)&.6F"9.MVU)6Y9>CL
MLRJP]"U2:+%7*"W;.G96;GYF2-IS%Z::#MJ5<?FG4*47F;/<<2VX0@RRPIB7
M\7(OV=-6L^M-HV^'U6@EXV=,R\PQ*MS DV0&B1))*6FD71R;DRA"EI-X.H(6
M[[%MR2/:1TDQ@X*,=")WON;0+]]OON0+]]0=SNGG/"![=6WH P>B[AU[P1%L
MB5KRZ*7Z^']; 4OQ%5H#@13QM=VI&-(QYJG(+K<I5'UPD(\=.9&OR=JJ X1B
M=Q[<NKMQ9-?H..;7QOSC'QP[...R'-R89B%NPY];.G;7'(&O R[(GHYL,R*<
M'/MAAK#:(>:]PL.6ST,QU'<?32AJ,]OKAAK!UZ\=W%/5#'F[!Y^OC9AT\'T=
MFZ&/1P/3V[XIVY>/MZ6GCFW<>J(AVYLV<=.4(KM[>?MR,XXPXYX0Y0\P^06C
MF/I'G$3SCT'S&+,KN0BGQ=W@!$]NG]X??>?%_O,F%S(/X.&=R#H;AP=QWOWN
M_?=OOM<6#=:K>-&J)O@ 7>5=P13-LFN)%;]\9)$6FZ7G:7*EWPKA)->3;'A@
MTHNE, :%%PYDQ=M1%R*\0\HVV!LU9:VC>.85VG;KSU1.6!VBOS:M>$4[=MOU
M-/'&SZ8CCC;]$13T'?Y>TV/[:$^_HVI,VN_='?MU?E*XW91WCNN_8CN*_P"9
MNP?_ #%I5$]&F.+QA50ZBR/2>456?:C3*FRC)Z'WEPJOJT2)#(DA43Y5+).Q
M!A0XL5YXR?.E2L)R'"?>&)&=N .@\\[!(2*DT$;BP-'[9THM65L/1^SIBU;6
MG>6[UD95*5//=[L.3+Q3?4A #;#+CBBI21=0<:T!P>3=(FD,\*-1$M*G5 *'
M:7JJB0FB"K+J 2?AI28CH"W'G,HX"M&B19&?*3&0<@S28<*ISYEPU!%]P(+K
M\14;1MS&6W Y<]-N1!.ZM?0#2RQ9>P)F:L>>=9TEE9=^S%RLE//A4S,S<])-
MV0Z>]4I1;0>L]\JLQ!<F V6UA)OD)[\U6JC1(E!4CM6J9%$Z.AP9H@'S4^RJ
M7)1I:,F>\"TQ03455<@1$,P=$"<%6<B/)\4T/>\,P]&$'&5&T95S&6WFP.,8
M#>AVESSQEV=%=(W9A$\NS5L-V'::WD6BVRIYR04TB5*TSK;(+RY520^AH%Q3
M82*Q=QZO4G+1=X,U/IX7CBB&9F"#'G66H47U-DT>!,)N8-[B*;K_  (50#19
M<,JNY[P@(YB IQ3#I*+#CO*C'$89XC#"N.S @XZC%M&BFE#B;[>C=OK1WXW9
MU]%CVBI/L@]-KD&I"\F6([\=GVW))N5KRZYMM<LE!>0I S!/6D97BJ4!*5DQ
M3C(QR&G*\%//E3L5*4(I DJPB"E#+18KY$Y%2U).4H94T$*.^04"1QUP2YJ!
M$B34'(UXKYB#&IF).;E4RZYJ5F99$VRJ8E53##K*9F72^]*J?EU.)2'F4S,M
M,2ZG6RI ?8>9*N4:6E/13$JV!Y/+O9A^^GPOE_,A;.^<6W$Y[<&SY1BI#JQA
MF@;<0+U,Z8X'4<<J1JIAW'DTG[<@C^;75OZCK$8..73V"V?-YVS!BH\]:8 U
MKOQR%3EK&&NPHY<XV:ZYURZ8X1OC>W-Q:@'BOT6#,+-4?'3S>N(-+II75GOI
MB1OILSJ1@:QQ/CX(X7Q"UN6P]&.>#5;.<Y].7&6<4H\8<:HLAVCL$1OS]+3G
M%8PJ,LZ8G7B-68V5VF/@4[H=]VGI,^_+47\\%UOK+N%T.ADV1E[8[3_1[/C%
M^JT']]7<DRK_ &/'<I'^I;^ZE.CHB"AG/#._FPZ<6[6G5S]&"/36NTZX^6EU
MH=E$TZ\]N(H8R6D]_P!ENE]_\HLD?G.F>:S8MI_8NT_N"<_17H2=>_I2O^$R
M_9,(]%(_J8M^9D?84&0@R$1OTM?M$3+^$U*OTM2,WH-%_LW+?<]I?T7.QKK6
M]X/?;R_Z2S&L].N5#DY4\IVBDZDR#)#T:K20+TIU+J].U#Y6K.]$E"=2Q6F<
M:?J;J2=/!90AGHY6?TU)0H:KPR:D5PFHI4=->-&2FST)FDR=H3[RK.GIV[9;
MM)JSK)DK:F;' FY)2K1$A:+;DDI!0E4BXZ^6^13.E3;H<NI7@Z0LE^6EFQ-2
MS%9Q'N$U.OV>S/GD)@)E#,RJDS"5!1$RE#87?,M1:"B\1(*@\F3C3NC5-)&J
M!-S\^3I*TGHR-,DW1#:JHBM*A,JY#CQW51>,&U]7A0;.E("POFC*\KP2\-26
MH\53-&HCVAMR<E+0MBTIV0E!(R<U-O/2\H$M-\BTM9*4EMA*&&B?'4RPE+#*
ME%ME(:2@1L[.8?EI&5EYE\S+[+*$.O%2U<HH#.^X5.+ %$AQQ1<< "W"5J48
MVTVJC,CSQJ#5G2:7])>I5%:!RA1!3*4]D6FT[+JO5N9)XEPQ'B5 &9")8BD.
MRA+*_#.02GJ2BQ3$<Z$&(Z^;"##B17(>]P+RG5)0TE*$X-DDEPF\2\X0;M%!
ML@"[=% :!S$JCLE@:$=S9C0*R]-M/+<TVEG;?TEM^Q)"2T4LBPYQIA%@2-A/
M.N33MJVE(+4I\VJ"A39< NJ;4E')U7<;SW2'_F3H7<?\)-:\?_VU[8YZJ>7=
MU)0-GA'#_4R^;I>QOU.O[_=V3_1O0S_>2*[SW2'_ )DZ%O-4FM8;,_X-<<L?
M,.+.6<\E/2LG_P!&>)^C"'L;]3K^_P!W9/\ 1O0S_>2&\]T@_P"9&A=KQ_9)
MK6'5^QKTXLY=WR4:OA'^IGLV;(>QOU.O[_=V3_1O0S_>2*#![I"/_$G0M^,F
MM=K_ !:]0=(L#[H^"G^>:_D>>NZD/8WZG7]_N[)_HWH9_O)%=Y[I#_S)T+>/
M^$FM>.W_ )-?2SEW/)0-GA&@_P!3T]6I[&_4Z_O]W9/]&]#/]Y(;SW2'5)&A
M:'_M)K7YJ:AYK,#[E*%*#_WS_4\]8>QOU.O[_=V3_1O0S_>2&\]TAQ_N)T+O
MC*K7Q8?:TQ##)HY9WR6_YQVUJ*I..-*^F'L;]3K^_P!W9/\ 1O0S_>3='%$*
M]TB?&$+LF:%S@PXKL1[^$:M#^[ '7@%R\2F;PP[B\ [XX(1 M8'@!YZ]0F'!
M>!0@@I( OJ%TU&."!> H1=4"DUQ!($0;,^IV)21I!W9!153_ 'M:%F\*$$5.
MD9I6M;PH<*5H3')O/=(?^9.A=\9-:[9C_P!FOG:.7=\E&>/A''+^!NB?8WZG
M7]_N[)_HWH9_O)%=Y[I#C_<3H78_]I5:^O\ @TQZL^2SEG,/ ;P_A'+=X.';
MESU>QOU.O[_=V3_1O0S_ 'DC\O0^Z/NNB\])6A:ZZZ%WGGJEUK  = ,;B--0
M   ->JS.7=Q\%!KEX1J*G[3'?ACJ@;-^IUS-O]V3G.CFAF0__P!DU1K.H;G=
M+EZ6%1(EZ'HAR.<C08F_3(B3I5]25RQ.%#>?,N)/"-.0*DS<9T-PX>?@1HY=
MP7HA,"YG>3D#:V9-)DIIJ:G+,EK2:;JM,G,S+C+#BA6Z7N2;"W&QGR04E*R
M'+S96VK6SUD?4^6@PJ3DM+>[79SKZTLF=E]%="7G&PLT(:4O2-2&UDD>Z7%K
M0FI;"7+CB?#61YS/SE*:-.:KNQ4YE+ J'WXQF.;BQ3AI^)$,QXIHP\^9CQ8\
M4'HL2+'B1(K[[[XQ(D1X1?>^OM')\VO8=EVAWNU)]]23+HEF/K# I=#3(NI
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MRKUR;2W(E=M):<:EA+)#CLK)R:&9HS#CG*W>7>7<)-TI2D5^@T !T ="]@
M"XB\-@"V+SPB\\.T7A$1'$1$6X-QL\T=%CJ5X'WDDX#CL=YX785@+1G8$:P&
M(0O;F*_X(.@[<8CH_P!\A@_##%\&ORY >14H \+%Q)6BMQ5*I3B36EW8JA.
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MA'>.Z[]B.XK_ )F[!_\ ,6E43T:J.+QH#2CJA-=%Z#U J?)9"6E)?E DE*$
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MD['FYU]RS;,>GG9.2<"0EE^?6PJ=<6;H=<<>7+,E7++<Y.X V$54%<W!:6$
M"_!Q$(#KT>*[! F7WIR+'<B0XT0(>]"ZZ_&AQ8KD9]T!>B.1(CKXBZ^\ WBA
M( %T&AR*12IPKE3&I)\(5)-<R(U@FIF_?[X?Y100@KY5PK*4*2IM)5>J4H4E
M*D@FB2E)%* CB?($7GH[SQ(H^^8<BN&'GBT%YXPX8<A0X[D9X7+QG(T.! AQ
M0B"(18<&"Z^ NPW =FZ*UNC&M<  0<"#@<: 5!.K7#OA]/)@/O)#90IL!Q:0
MV6U+4V4 'P"V7%J24XH4MPIQ4JM=RZXXZXXZZXZXX#KCKH ZZZZZ%G0    !
MT L#H %@=  M8& >%K &%!3"A! PK@#G3+7F8I62:J42HE=Y1)J234FIJ25$
MXDUQ)K'$]A<!M@ 7RRU\?%8;ZQP:3XZ>;U\#9$?!J*XG7S]0VU%,:#&.)_V/
M*(8VRX_(%VJPPU4U=!XZ-T0CQNCKXSZ(LQ$+#GQ#LMR\6T<+;&F*J'53# Z\
M=N(%:BE37$91\"?=#L--/2:S^W+44/\ O@N9M]9=PH?WF3?_ &CM/I_M>S]F
M&6(ZHQ?JM#_?5W)#3'^QX[E)_P!2W\-9QZ<H@H:SZ,;".KMAGMU-VM.KG'Y$
M?+3GBG4:#?LH=?5U91DM)_MMTOR^V+)/+]DZ9VZ6Q;4^Q5IXT_M"<QP_P5[;
M$29_MV4R]],:L??".STYZH_J8M^9D?8<&0@R$1OTM?M$3+^$U*OTM2,WH-%_
MLW+?<]I?T7.QKK6]X/?;R_Z2S$8>ZE3&@R_0N08:X;X'X9K*AIY":29%]Z9Y
M,BE9*GU<4ILDB80JY1EV4)N1I?2%B.F+;DR+1TS!$XA)<F3&HK!:! ]-W,Y=
M]^VYXLHY4,V0^XY++6.]IL+G)%AJ5G9?V)MCON5>F'64N,F790E00^[.2[;2
ME*U6E*DB1E6U+#9>GV6T/5NN,$M/J4^R[WY(AEUI"5J#G*N*NA:$,.K6D"6.
MBPMI4QZ.U'EA$F^>9_2C4CI#A&>*EGTU6GJ;H!-Q\B$QS*KHSSZ2KGUAXL\>
M!638D8DJ%X\ ^6CF(1AV-$\MI,R[+V_:S+\I(R#J9UTKDK-;<:D90K(7WO+-
M/>ZM(9"@@M. +;4E2%)24D#:V0XV[9DDMI^8FFRPD)F9M25S#X15'+.K0 A:
MG"DJ"T^"M)"@2#6-^MHHV,02I>(CW0C2ON\\]:A&C(  ]!"$#@<*5?'<NOV#
MOAVXB]OPW$'GGH%[00 *E4\# #W/&BKQ/NCF)'P#3"[K "_A8]EM[_D)[G6>
M'=![HXH4A-/[E:#G _#!K6]7 DI/BB)VM3'&H,A!D(,A!D(,A'"8,0"L%^.8
MBN084,+O/Q'@==#4 7',1'   !$1$  !'!I2E2B$I!).  X[<A$$A())H!B3
M&N5>:(IX8A=/W1<O< ?BB%H\8+6U"(P7! , #]T$,1>= 7G!VC$F$XN5*Z9
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MEFI$-VB63)(+$[-34W,RZYF<7,H9,LREMM;?E6K*MDVBQ/34Y+J,L\66PRE
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M9]0UF+;C@;25'$Y ;3ZML8/$B/QXCT6(]NGXCPO/"-KXV   ,@  L  (
M %M>U2 @!*0  ,-NT&NVN)UDUK&J6HJ4":$DXG"NH89TH>;$4KMLQS#5;FL-
MQ'"^=L-NH+X@UPZQMIB=AH,>; \^.JAA/BCC?'X>"X<HC;#6 = 7OGAJY!5Q
M&NF>)J:Y:\:=(QPP.%7S]L<+V("%L;#J&XX#?',<M89WR &9$<]W&E*"M:8U
M.!RR!)&P"1F*[1%L.//R8>;JRU:FG&]3$D#HH3GT#;6IPS&(X';3T9#.N73Y
MXMQ[; ^AH%;U-FO7JI4Y[\QK&6$7%Y#<1KQRU[_IC@''R#;BPPMYN9I) 6.8
M4[1M]!@KQ3P<37&.-_V(XWQ###: \6.ODM@.NK'#GQILH>.>*$^,,-OFXZ^:
M+(<AOQCQ"'%@%M>P.AIBK&N>.5*C"NNE3742-N,? GW0[[M329]^6HO+]F"[
MZ/*WUGW"_P!IDY_VCM/]'L_I'-F!@=<8WU6?[:>Y)_\ 3QW*/R+?B"IJU^V5
MNVKI;M(S'1V(P\YU\V1CY:7XIV<VJHU",EI/]MNE_OBR3^<Z9K\VIL:T_L7:
M?W!.?HKT1)^_93[I8_2$:_1JC^IBWYF1]AP9"#(1&_2U^T1,OX34J_2U(S>@
MT7^S<M]SVE_1<[&NM;W@]]O+_I+,20;S\;&#(09"((TO$1[H3I7@+SSVYH3H
MR  /00A Z'"=7GMRX_;]\.W$7M^&X@\\] O:" !4H>)@!5NN"JU]T=%2/@G"
MEW"H 5\*.RV]_P A/<ZS_P"4#NCT\&@']R]""14>-4^%>..)3\&)W-3'&HC+
M,^C#+DT5*5*B&IKF."XLSO2*H9^572R!'17YJHX[$+()V$9,)+ZQ"@*"=WL3
M4B?"#\ 'BW?A1TN9B"^[!&(-<M5!OUYZ]N%.>.CV;W2+0LW1V6L!JR[.6J4L
M;2NP&+3+D^B<%F:7%+D\RMM$VF44XQ,!QZ7>[W2NCG).\HVD Q9C]S/HJ@)"
MD2BU!GUPBJ4D4*6&89IV63T9R(=H^LT0<FM$".A/OI2[!DA7?@C (BX1BG"X
M/OPX1$ZJDSQ#2EN I *@ ,J"M*8C.FO$DXFF[HCWU2^E:YF6FG;%L /2NE3&
MDS);]DV4N)9TMD]-%63-I;G@)N27;4H%WWKSR&7*7E/,RKS.'5IT,"<_+%39
MJE:HDVE%J<I+/23+4MS*=33,CR:EJT6FO",%%)ED V932#H4V(GR21!A&DQQ
M44E.,;*FP-;J%LD2(0E1"JK*0 2 $@A50<CD"=1K@,JQJM%?J@7['9T8LJTM
M&K*59EBVZQ;EIVA9C<TW;UMS$FWI*)8SSR[189F75*TD>:?F5J:F3*RTLAIY
MHM47>)NA!(9*?I;J2;G*<EF:$N8S,TS%$4H,K@F3<LQ:DJ=5"APTD$9?)IZ)
M%39G53+I)]!@D1AD7"SPW5R\)7=O=[(OI<*E%257C6Z HWKV(  34YA-,-^,
M:>:[OFD,QH[:>B[5AV))63-V8U9%FIE5VMWW8TBC1>4T1>8:G7[1>F;01-65
M)M&83:*WPJ84Z !).+DC^Y)T*Y:D:')/!U3*@GC-/5:FQF53:D7DIZ(20*8R
M-/M,T65(T(G*A,N=3CLD5#6TY143,&(O/J3A98+JA>*X!<*PS3]T635-"0BH
M2D*%WQ:8A1%:5&HY4BWN[M:ND"[>,UHKHW+M:2R>E#5L,RKEO)3,6EI7;^CN
ME4];#:WK8?<8F6+?T:D9J6E6EIL],JIV2=E'$*Y4["H%HTH>C[NB<I3E-*F@
MQ96DQ$.("Z5E<P7,J\ER%(M-2<TNJI67RLPEC9N5Z?H<(TCP5<$!T]%43L).
M=?C%G"=2&[BB;Y(( ND)I4!(O5I>R3E6F)PRIYSNA]U.?[I)Y>V+#LB4M%%K
MV[:#-HV>[:S;C4E;ND5OZ4OV091VT7;-=98M;22T%M3SDD;1,NB585-%+;I?
ME$7O=^V-MSR6&]MEAUA<0QXVO)KD*ZB:9X'5OY\.FD<L-,SO&._Z,<Z#=6.P
M@Y/<NO/G[>D85GZ\^G?P<:P&6KHRZ-T7+F8\GG!J%4ICE7Y^VE.F)B[@^R'M
MJ%J3XHR[:YC$98'.F66Z)'BJPU#SY;<>G+*/RH_R<H?U YS?O>)B+6E9'F/F
MBY+^^9;/&88I3+ZXC'9S:MQIA\+543 %M'"CKXC;='H#N>Q+5<[7V:N:P-]E
M]RD5T9L84!_N0SM'[J,CLUXXFFN.?_5;U_LF^[9B*^WFT^GP6=XQPYN:(E<*
MN^V'MVOR<;=2"=H'7NW:@<.G72L?/..T=7S\W!APJ'M_+J]#1=/D]%>T?/6&
M.T5U;MFOU0X5##P^3/JYVF[_  /];Y_3TPQVBG-Z:[(<*N^W\K1=-/%_UN,N
MOGQ@*[01N'SF'"KOM_+VP:;NU/2%>;T ])AX6HCI!ZL^V'"KOM_*T!!IB,><
M4\_3ELWU8[J?37T=L.%7?;^5IN_P?];T5[*](SACM'4?/7MIT0X5=]OY>VQE
MW^"1NO#U>G;NACM'4?ZVZ'"KOM_*T73Y)_G#?NU\W3#':.H]&N'"KOM_*RZ?
M)/\ .&W@0QVCJ/1KAPH&'A#CRL"3CX((Y\<-_P PRVPU9BNW5U5V;X<*A[80
MZ6%)V=HSW5U;CCOVL=HSV=8SSXI#A5WV_E9=.RG3G]&O;C35#'=U=>OZ-\?8
MYW">/WQH1GXE[_PVS\[?D1I-]/19OC7N\BFG#>%/[AV?^>G>,SSQ]&]RFOM8
M=K3[*S>7\1*1[--Q:.F09"#(1T4T?8S,7WB5_P GF&OROOF7_CV?SB8H<^MN
M?:*_),:VT<?N>J#^\S2_\R$-MA;_ -G;:K^^]I?ICT6)'WE)_<LO^91&YFU$
M94&0@R$&0@R$&0@R$=-,#PNI!P0??AC:"&Z<+@:>"YB" @$$0$'@> =R\]:\
M)T1BABX#7Y:G+(J 11>"E\F,$*IX6%*'$#X1\'7%B9KR*Z$@^#B$7SXZ?@D&
MM<B:>"/"U1B(]NV.KEMK%L@<<8:^:NH1CGCC'5STUF&>KCY;7OQ?5ACFRVG5
MJW4W]NO'#)QS^CZ-N;*X=(8_1DS.AZCA\^< :=.K'T$0UV&P;=>73Y;,U5%3
MLU9]7FK#LVYZN?'S#;#"^8<][>3'G &8TR/12OGPZ"8:\_/ZO1 ?JOT:[[.3
M4S@TZ]5-O/K@>S5YM^R'6'/;MZ6GL/17CU1';YCYH;<]FL!OCGUW =H\H1LR
MVZB*8?-0C8.8SE7/S<;^<Q:EA$8AV[[[P ;LZ#T ((..][%!W#KP!^^7+B+V
M_C<=V\] O:  -6L8-8 $MXD*O5-]T5.-4&E!<V4707S%M!Q=Q)HO %-V@N-F
M@-*.#$F\==4_! BZPPZ_/VOQX:J,<>ST<4W4(SKX/'&W#4[=NU[\;.,>/FIN
M@>*<?/MQAGU]M758,,F9=G&OMJ<<XG/MR]7JU"(I:#O\O:;']M"??T;4F;7_
M +H[]NK53X2ML=W[KOV([BO^9NP>G^^+2KZ,(GC$?<A./1'W@=<< 7GA'4 >
M4=0 &(C8 N(M4 5$ "I.  CBQ(2"2: 8DF,)/G'S<<7QN[#='<PG1_P7=HZ]
MT\.+XA?, #  OLVFPVFFLXD[3NW#5ED=9C6.N%Q5<@, -@]9UGHV4LAMAC?B
MV[<=7(..-\Q%KGHXU9\\8ZLP<\,J9YUQW=F<< CE8,1ZA 1PR 0YK8WQ%KA&
M)J2,2*[J"ASZ#JQR%1%2<ND^<\84C\/Y8:LQRRN.87#Z@L.I@!J*ZZ@5J21T
MTWY]1PBK+'<=^K9Q2.$;@#P7'+"V Y#;/$+Y#S8VM<2>CF%* ZP0#L IUUAL
MYQOBV>Y+<6H,Q"^.P>+9@TC.F8PQ-:5!IAJ&(WUPQQB3B=9R&\\VSMWQ;C?/
M;RZ[^C;Y[0!X1%,J;M8Q[:T%!AEE2M>S54>;LU9##6,17@>OKU!C8>;#&]\L
M\>8&E7C)ZZY[>*ZJUU0- DTUTI4;P<J4I4ZL,=ICB?\ 8CRAMXO0/%;%JCJY
M_0<^,Z12GQAS'T^CBD67;MT<N+3$FE1GG361G4X'$''$8YZS'P*=T.^[4TF?
M?EJ+^>"ZWUGW"OVFS9U^V.TR,LS+V>=>KYJQC_5:#^^GN2;/['?N4U&OQ+?Z
M:[AZ(@H:S[#JV6]/)M[4,QS_ /H&TUYMF,?+2\CD,$Y;,*<;:QDU)QO5NE^W
M]D62/SG2[!S8MBVG]B[3^X)S]%>A)G^W90XU[Y8_2$4'1NC^I@WYF1]A09"#
M(1&_2U^T1,OX34J_2U(S>@T7^S<M]SVE_1<[&NM;W@]]O+_I+,20;S\;&#(0
M9"()4P!X.Z$:5PO!% !H1HRBYOD4(CHN\*5?"\!T,8,+= \ PGL1C!%BY10%
MI53P*7<$"MT$$'E'#X9/C*I0@C"Z4IS28[+;U?V">YUG3]D#NC4J:C[%Z$>*
M/@BM:I.)5>5D8G:T1QJ/-#2"[H49H35*9J31:0G9F74Y\7I>.$9A>@D58M,\
MDIL:DT4_9$,/IL:H=8GUVD<& X)L$TXB\,#$-@<<3H<A*R<4X4J,ZD$$(S&%
MY0NUQ[#'T%H3W#6-,]%[/TI:TOE;.E'JIM!F8D0MZ2795LO#2_D@)UM,TG1K
M0WO+3!ZI85,R\WWI1GDC,*U>6TQ)UBSX8E=7E6#,A$K50Q*RW,2C-Q9/4$1-
MFG2WG/1MEDK+B"D2&53U8DAG4Q(4=PJ**8I/(3AB&H*ZXNPWE!1V35&E)0$H
M/NA0I9/A>$^ID4\'&E$FA(J*BM:$XEH=Q^RIRQ&[;:MIRS9EW1!NUK.LR6L9
MV8E)R9LGN-V'W4K47:$_.:0NS$D]/,3<[*UE)6:EO9$MK8DY"06)>6TW+^GN
MO*DRKB[')4_3Y66$FDJ.AI$Q5,*),I4O7)C-Z0:JMG*S3Q#D:,<D>;(Z93Q
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M5ZHYF/J<>[8 /[P;1&>'?]B[?Y3BG[91H.?TB)0&V5TN;\/^[F7HY;N41O\
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M-PDNH\K6*^ L' X8E)RWUUYF!^IQ[MHH?:#:.8H>_P"Q/]IZHMGNZ2Z#F/\
MOB9/' ?_ )NFP+YZ_4]?G''%J@ZWG4X4%"%=8 3V"@PR%,*C]3AW;<"- +2%
M*?\ /K%._+V3WZJ#<,0. >Z2:#H!?UQ,F_\ Y":__P#/>40SV-2'$7B;Q&L8
M*%<:^3E0XC.NS&)5]3CW;%"GM M*M:XSUB98T_\ B>>[..%[ND>@[GZXJ3;
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MU B3&7/PE!63 -P2LRH\.+&=)GDC?LZZ^S+LOF2HRY5"9EYI:VWEAQT^YK4
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MZU$DQP+26P;,TPTBMG2S25ERUM(=()UZT;8M)^9F6ESDZ^077BQ*NL2K-Z@
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M4?'%=P_M'?<Q_P"CG'^-RM?SB-B?LT=TC_&!/XIL;_9\9'['^B/[T)_"Y_\
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M2%$=>'%7W9>Z4VM;;EO7'$*4A:%V18R5H6DE*DJ2;.!2I*@0H$ @@@BL7DZ
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M\XAII"G''%!"&T)*EK4HT"4I )))R $4J4E"2M:@E*02I2B D 9DDX <\9
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MLRZD+ 4E26VRE25"H4D@4((H01@1';>IJ7!S0$4?_P *(_\ D-3WU-?X2_\
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MC>CEK.(0XAN3*'$)6DFUK)02E8"DU2N>2M)H15*DA23@H @B,A5H2J5%*EN
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=8(            !8  ,   #   ,  ,F\G&VC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g287237g28y66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g28y66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1-N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $U*^248X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              7T   =3          $
M                 0             '4P   7T
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   7T     4F=H=&QO;F<   =3
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   %]     %)G:'1L;VYG   '4P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      )/
M  $   "@    (0   >   #W@   )(  8  '_V/_M  Q!9&]B95]#30 "_^X
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M%)&A
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MPM3A\3=D9G)S=H*$E;*T&2A%2%578W2%DZ2ST__$ !T!  $% 0$! 0
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M\;!]TG4G][[G/\,M(_Y>\'8TO[?#]54?PL'K-1^P3_6TW\;!]TG4G][[G/\
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M1SQ(M5!(-4<\3 BX =22#S/,];\]Q8C;"'=75._4'8C?JD_!7J-]CT/PWVX
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M;%3LAQ"0B]_$@WVY&]S]_3?V8ZJEJ(^*(WAJHTCSJ.5%I*V/3'#F8-PM/4Q
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MLOS38<][=+_1CZ;H)A'60/\ ,[^DM>UM8*W)V\=S?8$G$/P>H)&VZ 2.VQ*
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M*Y5(U-B-3+?1SF3U-$F?5F6-E%"\,JT&5BM$E2U-I--%/-5$$01LB.0MW=E
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M#"T\^DA:E*6A6V$#=*E+6I2>RE+42#S*WD_RCIKC_P"S7#_=((&O-=B-@?\
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M_.CCB..+C'B=(E"Q+G-?I4;A2:EV-C?D26V%[#R&/T0X5[.7^3="K.TGJ_I
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M'992!8:J4C]&2#XLNQ\.8-_HY8Z:MSVF%*RTTC&8W5!H( 5@1<ZN5N>]C<;
M\\22XS](%B!U!WOL/>1[=[^SPXHL2"#;?#0ZPLA5/5/*3NEJQ6UN-P07HKRQ
MOMTV/D'J>Q2!V/%ND(UD;[J1UZ'>_P!YW]YQTG#3JM1,A^<\-P""1W)%OY#9
MAN>?*^P&.8T:D*:NK1D$#S:Y+I'KS-26FT';U'[(5N>P!._?B>IC#QN2-](M
MN0.Z?;S(8^WZ,7N)EO!3O90>T*["UQI8_ CZ0/'$AB222>Y.YV&W?Y<9JKI
M%AR ]V^W7E[AO]/&L3RZ#<>P\K^P'_GBG!Y@>)!OL;GEO>Q.PZ<SA 2#<8Y#
M-,8&45@8:6VS/C*+L)]Q)\OF("7&'2@<X:>0D#F3N6W$H<Y5A*D*L1U#Q@K9
M2G,#86Y7)(Z$<N=KW/,WU,KS#U"<.06CD 69>ND&X*^8Z=".>]L:+3["9.,>
MVS;%;2I\Q"8Z6F'/-:8CH<\PGG+;94ZZL)Y@!RH2A(!)*N'SSB4 ( JL@5QS
M[VHFX)]B[ VY^S%C.,T2O=%A!6",:@"MB7(9>9NU@&%[D"][ XZ/-G5,XCD"
MD;@FOD D']L06SZ^O. =O0G?MQ!3H@D;4""02.>]]AL-[F]CRQ3RU1+7TBOR
M:0<MB;7-O=;W<\1>QA2DY'1+2=BBXK%$_P#KC([;]=^H^)W._0\:<RDQL!U%
M]_ '?X V\\=YF.DT58A&_8R@BYMW 2?;\W?X<[8F7LG9(3Z)'-N?4=_R#Y#\
MG&1I9F4#^M8=!TMRY;W \/''FA-RWGRM[1]V(<99-189)=2FSS-.SY"6R3O]
M[9<+#9!V/T2VVE0(/8_+C92^FY'/S\E'W']V/2,L0P4<$#"SI$I9;V'>N;W.
MQ)))(Y#S'+I=(JA5]J;@]<$%Q*\CKI;H *MH]:\FRDJ4-_P?(B+W)W Z].O#
M_P!_XVO^>6,SBZM%%PUG4^O010R01$@;O5KV94#^UL =])M;F#CV0/4';U'3
M\O"?G\WQ\D88^T 'B+P-LE1)T7U8<4.8[?[M=&$;CKL.I.VPZ;D^IXT8Y?\
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M8!BM=B&1Q<UJY%=+<@7.,6(%K=R7F+2)[!E&0S?MAL;@-9>?4]5F.:4&:4%
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MR1MO'\>8J,SC2:*9CL^ML9TJHC2#7)JY7%K@!2+@KM<E;\P2!LU]C8;8J1\
M^C6>DRF!>(Z7+JFNA,>9568\2<.UU315\'%F9T+4=*F79M3Y932SY+!ES-7Y
M@]7E#QUT.80U%/#%5R1NII9KWKUE^<8=499HJ<>PV]FV5)9Y&*G/:J:P]'KM
M3K2GS%%?D=!!]S8M?0L!H%-U.1&)D%7,U'H:FT4Q90?(MW*[%E!78];';9B#
M<VV.GD0"+CKRYCB;@C@?*<FS:JROC#Y0S>BAIJRFR_UK(ZF%TDJ.&Z:KREJC
M+Z^?US,J&;/*\-54 EH:F'AZNJJ8/33]I28/#[K+X@,LR:IQS4?3"TJ<95%L
MX+V77U1=U>3.W$+%L/RAF?9LMXQ08JW42I.0V^-13!BP7'+*C<:"#(BS4.B,
MY(!&VX)(()MN#:UK';PY^6\G'7"/ N5Y;4YAP_Q+35>8B2FG3*Z*JHZG+EI)
MLSS;+'@IG;,J[,VJXHZ"DS*7MI)E6FK5:XCEA99CGD-LL'E*?=Z>9)Y>7I*W
MZCMVYN_P5\^)<>0Z3ZN& _Z>P:W]D$@$#\[$^.-4T1Y-1N1TEHVW/8%,X$CX
M I"0?B.4=MN%Z#VD>X6L/9BPRVFKP%LII1L%LI;5&38  7ON>M\9WE#V2_ZC
M;S#R]1MO[*QOL.V_-OV_&W]>$PU0==%L;Z%%M[V$DGOMIY;<O+"QTI%C'Z@'
MV!>_;H3)C=_AN-^_?A1^X_9[_P ^'/$=B:1[ _[5#R!Z))?Z.OV'EC0V=149
M!C+M!=P(5K2W9ET]M5S6FY$&RJK1$J#85\J.L*;?B38;[\:0RH%#K+KC:@4J
M(X569&5T)5T8.K#8JRD,K ]"" 0>G/$LJEYJE7!8-3,'# FZF%00P/3D-\1\
MC>#OP\5SV238^&W2YL^FO:&[FS=3=5+.9E51DF/SJ2SAYM*L<WEOYNE-=;6C
M=4[ESET_C[]C.L*!VLL)3\IR\<TK6"@RI9&1XP*>F41-&RLIB"Q 1&ZKJ[/3
MK"JKZE  II1P,:8-&Q$Q*R O+^D1I&5E?O\ >72[@ W"ZB5L=\=?*\-VBT_+
MJ_)I.(+][>W(OY:6,HS")5V]S7ZA2M5ZNPO\=B9 QCV1R*?4*ZN<DI57M59"
MED6]M"JA#K+.=!D1"NJA'V8D&C24%XXBRJT*T[*DA0R('A18VT,NL*I:Y4$.
M[!"D\A5KB95!#.$MJ=AJ0'0Q!N5+ D7-N>.>Q_PI>'[',=;H*[ &Y-([+K:L
MU=]E&997":IJ+(Z^[IZ",SE&1W*8F.55A35KL#&XODT,2-&%>S7(K77HCCGS
M&M=^T:<A[LQ9$BC)9U96<]FBWD8,VJ0W<DEBQ;?#O58D+H(R5]75[,6-K(A!
M%SLH(%@.Z/"V-[B'AZTWT^SI[.\<9R(W--IB-+*ES(<LO\P?AXI(R*?FDUEV
M^RZ?=Y7:29-R_&0VNZR&RC55=7PZZCBU<94U$MLU=430O"YCTO-ZPVB-(KRB
M,1*0D82-0%!^9&"S,S.6-BJ)31HU#*FK7=HK:BQ"B;4-V):Y+6%R0  % N;O
MF%#SJK90W4P^1L>JD^0V21MW'3<[=.GRXST!N=CR^[$S Z*TV/=9=[<B92![
M#S'CSPC<4H,2.4JY1;$H WY>M@U^#MT]3U'Q)Z]>)N?@.0^'YN<2* *F,D
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MQ8VPZT#6*X90E%A5PYR@D O,K7$<7ML.9:>20WSGKOR);1OT"!U/$#4R,Q)
M4'>P&FW+D!L+D7OX].N,!^&$<EH)B(R;I>[BW*U^9W!N2Q/GAO,EOY.36SUI
M(;2P5-MLLL)45I98:!Y4%9">=2EK<<6HI2"IP@ )"1Q;71K%E4+<= !;SZ<_
M'&S047R; 8P2Y(/>',D];<[#D!X<R3COM/\ /86/1'JBV:D&&N0J3%E1D><6
M5.D!UM]HJ"@US K0ME*_I*4DIW._%6HC#G0!M<M=1[00;<^8VOXWZ8R\]R>6
MIFCGIM)8H%=>0VN=5U![US8WY^(M;#JM:D86XG=5KY?7LN+-2H;_ !_8Y ^
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M+Z_WR>GU]>#L_/X?C@[>#]8?[C8/89O[F5_A)_C_ )^G!V?G\/QP=O!^L/\
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MF2-DY9!2!OT$2>!^80_7ZNOYMSY,S']D;Z^D_P 1A#74I-S,2?$QS'_^._\
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M%!7,3Y[FR.>,1F2:)#*L91-,C.2XJ2R%41K-&M+*2M];'0BKK8JHE;$YE #
MPCO7  +:H5TZB0!<3:PQ[ED;O;H6T.-_9%J(3<:J,PQSFN,]U,DX'B\7%/8;
M2+71)^JT_3+'+JRMJ_)K^JO*UN?886S>WE3,@T9?LI4FAEVHFTM?)D?(W/:-
M$_<@IUFE:34I)%,*B1%5HT9&LLNA&!>P =5TR%6BN31&74AY)I(P%[PL*CL(
MR0+VM=3(VHIOW3;3JGKI+EEAGVE6F>=6S$.+:9II]AF664:N0\W7Q[#(\<K;
MB8Q!;DORI"(;,F8XW&0_)D/)82A+K[RPIQ6-4QK#43PJ25BFEC4M;451V4$V
M %R!O8 7Y 8MQL7C1R+%D5B!R!902-]^9PX/$.'X.#!@X,&#@P8AWXP_$9EW
MASQW![S$<7K<H=OKZ_8N&+6/9*@PJ3',-O,JF2["V@38;.'TR35-B_SZX9MJ
M/":3V[(;6EL(<)U"-/+*&.NDE221H]"(5*Z=1:25(@%1A>5^_=(5*O*UHU92
MP.*E54-3B/2@?67!N; :(V>Y.X .FS,=E!U&X6Q9FR^R38<[C657>-Z4ZB.K
MI[K-<;HI65QHF)T-W=XU NT4\5<V<\N=$7D>2TZ,=92*YZ+ EV$"%.L6<@GU
M]!+M#(Y1)&DE1!WEB=Q&3(Z)(5+&RBQ[-"7/>N0&(70I<,-?&49ECDV+J-8"
M LI(522;C418&UKV%RQTXZZO\>V.V%L<7AZ:9#;99MAE8S64>7Z=SXTO*<KM
M=":AZO1(5D[$R%C]=(\0F%2(F6V==$K+^'7Y&]3MR?)H!D<9R:0+VAG1(OTK
M%I(IU*QQ+6-<@1D%V%#*#&K%D+1AR+OH?ZY'K5"&N7C0E2K %W@2^S7"@SJ=
MP"P5BH/=NHTM\?VGVJ^8XEBM3@&HE!&S/,<CQ&FR3+:Z%1U#LBC@^U0R6I$L
MV2IUV^B3#B0T0U0V'X,J)(MTVRX-5.2HR:>GBDE::!S%&DCQQ,7<!C8\AITJ
M+$G5>QN%TAF E9'(RJ%<:F*AG&E;CD!?<D]+"Q\;D \NSXZKC#L<UGR'5;3:
M0PQIGDF0B$K%Y56(\FC=UWU+T1P?&4-*R2_N\@S2<_I+EV1WEI#HJ2B9B>QQ
MHT%K9V4J0Y0LCTJ4\ZDSHEQ(&N&]3IZN60GLT1(@*F.-%+N]PQ)M884U2(LS
M/>T4KHK!2!(HGFA5E!N]SV(8@J-G%KD, EB?9'L-:LJBKO,(F0Y.7YKD^/8<
MS&RG'5OJH:ZIH;3&LCS/VJ3'@X.QD!R.L8DF]L8\2K:<=G(ESX[1"E.1S68I
M*K"**-Y24<#62XDCBL"9C'H:VA;L;"PO<1FNC73<'OMI0;@[A#=KBRV+V))T
M[$@D<]G&^R%8G,]GNZ_3G.[+%I^ )U'4T8N-TN28MB=3F.?XOE5KEE?=9;%E
M1[6O:PU,A_ FZN/F%!9+>H;R(BY%G!QYAR:1;HT\*R+,8+ZI'CDD:.%XUB*1
M$%29#^FU&)ULZ'3I,D@JT9581R&X+DG2"J"X!9"0P(96! )8:E!5=+'&USCQ
MR,:<ZPY=H]9:99IGF1IU)?Q' X.G=(N0Y+IXNE/AYRE;N165E8)K&+23F^N3
M-8E\KJ:R%C<=N7+)L(K+=\1909Z2*J6HAA0P"28SO8!S4UT0"*JZM(BH]1'?
M8R$@=TG1&:T+/+ R.S+)HCT(Q#*(::0ZF^:'+5! %U&E1UW/ Y]]DOPF+6R6
M=,L)R[);"YTVR_4/"<OFT:Y6GLJIHI&I]=2W-S*@6426U1W]GI'E;$?RY46>
MIB5C,MAIV+<2GZB2+(IKEIY8HUCGCAEB#@3AV%.SHH*L-:+4QDW!6XD!(90&
M45L;E0BNP<%D<+W"MY &U= 3&0#UU*1<$V<[(O')B]5I@]JLQBE^FNQ[475;
M",KQ)::*?E2#I;H-J9KD_%8=8R>%1U-ED%#A%7*II;]A<U4J'>5[C*G:BWBY
M/"@CRF1J@4YD35)#32QR NL8]8K(*0$@QEV5'E8.H5&#*;V9#&9?64$4LA1S
MH+J "H.J,:R2#<$,BL%&I=V5]106:5>EVH"=2\4.2&@L\6F1<DS/$K?'[>35
MS9M9>8+E]WAETR9M--L*R9%=LJ*3)@2HLI8?@O1G'FXT@O1F<^HA,$@36L@,
M<4JNFH*R31K*NSJK A7 8$"S C<;F5'UJ38K9F4@VN"C%3R)%B1<;\L.'Q!A
M^#@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8
M.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X
M,&#@P8.#!@X,&#@P8.#!@X,&(>Y)XOO#-A>2XA1Y-9.8];7FIF3:4:?SK7"+
M6L@W665>21L*S-6'7$NL9CSZBNS2;&Q;(K6G><939/ID20[4$V?&FF65\L<K
MQIK5((ZF95E5BL;QF:+M5#$JS1 R(K@$J#I[UUQ5-53AD!8 L[Q(2IW9'[.0
M(;;A7LK%;@&U\(?#CXLM.-9;BMQ*%BIP?.[3"J;)H5#&85.A+PUO%L/R)@)R
M!FFIX+B*B?GDBJ:J8Z'E0 S[PE-UJ,@K6)2UV6ST@=VD[:%)GB,A[I[7M94^
M869AJ6'7<VO?2-11B"GJ4F"670\D22Z>8"NBL+MI4&Q8CQY$@:AB6KF,XV]%
M=@O8_2.P7HI@O0W*J N*["5$CUZH;L=4<LN13 B181CJ06C$C1XQ1Y++:$YW
M:.#J#N"#J!U&X:Y.J][WN2;\[DGF<6;"UK"UK6L+6Y6MX6VMBUK%L98>1(8Q
MVB9D-18,)M]JHKVWFX=8IM5;$0ZB.E:(M>III4&.E0:B*:;+"&RA.P9'(L7<
MBY:Q8VU-\X\^;=3S/7!I7G87M:]AR\/9Y<L(S@V$F"BL.'XL:UN&_7(KSC]2
M8**^5(C2Y,%$3V3V=,.1+A0Y3\4-AAZ1$C/.(4XPTI"]M-JU=K)J)#%M;:BP
M! :][W ) /, D<CA-"6MH6VXMI%K'<CEU//&Q8QW'XKE@]&HJ>.];-AJU=8K
M(33EDT([40-6"VV$JF-B(PQ%"))<3[.RTSMY;:$I:7<Z078A?FW8G3N3W;G;
M<D[=23S.%L-]AOSV&_3?QVVWQB.+XR6JUDX[1%FF>7)J&C45Y:JI#AW<?K6S
M'Y(+RSU6[%#2U'JI1/"]I)WN^_>%F[S=X>#;[CR-\&E3:Z@VY;#;IMX;;8M.
M*8N9)FG&Z S%1%0%2S3UQDJ@K9B1UPB_[-YIB+8KX#*HQ7Y*F841LH*(S*4'
M:26TZWTWO;4UK@D@VO:X+$WYW)\3@L";D GQL+_3[A]&%,:@HH4Z7:0Z6IB6
M<]_VF=8QJZ&Q.FR?(3&]HERVF42)+_LR4Q_-><6YY"4M<WE@)"%W*A2[%5%E
M4L2H%[V )L!?>PZ[X  "2  2;D@"Y-K7)ZFVWLQ5FBI(TJ1.CTU4Q.E3A:2I
MC-?$:E2;-,)=<FQD2$,I>>G)KW'( EN+5($)Q<4.>0M39"[D %F( T@%B0%O
MJT@7L!J[UN5]^>"P%R +DW)L-SRN?$VVOB]VEIWVW&7ZFL>:>9LX[K3L"*XV
M['NGDR;EAQ"VE)6S;2$I?LVE HGO)2[*2ZL!7!J8$$,P(*D&YN"@LI&_-1LI
MZ#86P6'@.O3QY_3U\>N.>RC3S",SQB]PW)<8J;+&LEH58O=U?LXAHFT!#_EU
M@DP#%F16(JY+[\!4.1'=KI3JI<%R/)V=#XYY8I$ECD99(W[1&O>S[=ZQN"38
M W!# 6-QMA&1'4JR@JPL1X@]-L:_#M)M-L IJ:AQ+#*.KK\?BR(=4I<7WE9L
MLS;M[)IZW[RV5.NY\JQR63)R*RG6%A*FV5_(?N9TB19/.25++4SS,SRRNY<@
MMO92501KW5LH"Q@1J  %0!0 NV$6-% "J!:]MM]SJ.YWW)N=]SOCK8U!10[!
M5M$I*B+:JAFO59QJV&Q8*@*DKFF"J8TRF289F..2S&+A9,E:WRCS5*68R[E=
M)=BM]6DL2NJUM5B;7L +\["W+#K &X !M:]A>WA?PQC@XWCM9(;F5M#2U\MJ
M$NL:E0:N#$D-UKDI<Y=>V^PPVZB$N:ZY,7$2H,*E.+D%LNK4LJ9'869W87U6
M+$C5:VJQ-KVVOSMMRP!5!N% -K7  -N=O9??&KO<!PK)::7C]YC%-/I;!,9N
M?6KA,M19T>([4N-PYB(Z6?:8#B:&FC2Z]XKA3Z^NBUDZ/)KVQ%X5)I4<.CL'
M%R&O<@D,"1>]F[[$,-PS%@0V^$**05*@@VN+;&UK?8/H QL9&+XS+-BJ5CM%
M)5<2(,RV5(J*]XVDNL+1K95B7(ZC-D5Y89,%^3YKL0LM&.IORT;())!IL[C2
M"%LS#2&OJ"V.P:YN!8&YO@TJ;W53<@G8;D<B?$CIBC6*XPRB>VSCE"TW:ILD
MV;;5/7MHL4W"T.VZ9Z41PF8FU<;;<LA(#@G+0A<H.J2D@,DATWD<Z=.F[L=.
MCYNG?;3_ $;6MTMA=*[C2+&]Q8;WYW\;]?'%OVIXKSPU_:SC_/72!,KU^YJ[
MG@2T\_+*AJ]FWBR$^8YL^P4.CS%[*^DK<[23?](_>%F[S;CP.^X\CM@TKMW1
ML;C8;'Q'@?,8W;++,9EJ/'9:CQX[3;+##+:&F666D!MIEIIL)0VTVA*4-MH2
ME"$)"4@  <,))))-R=R3S)\3A<9>#!@X,&#@P8.#!AC=<M:]+M%*:LM]48UU
M)JK3WXV@TF"Y#GCD.MJZ6389/964#'*BXEP*2OQY$V1;S7XZ8ZX:7(0]HDR8
M\.3;I*6HJV9:<H&703KF2$%F<+&JF1D#.SD!0#>^^P!(AFEBB"]K>S:@+(SV
M 4EB=*M90H-R;#IS-L1YF^+[P]4V31WYN V\>$Y]MV1VV5Q]-K%=MAUWBE?E
M4#-?MWIUX_'O:G(V)F(7.(L-U7O^WO+*,[6H:2TN&)MU<MK6C.F9;@1QK&9U
M"RI(T;1=D_:%&C(E64EM"(I#7YZ8C4P K=3WM9OV9NI34'UBUPUU*@;L3<6\
M=K9>*S0^CJ3:8;IQE5Y:5EGICBV0TU5I-D=998G[UUR@:+5V,7)8QB08F5XO
MD3=_8XUA"4JD68QU"J5Z+#NJ6UE,7+JMVTRSQJK"HDC=JF-EET4IJFD0F0 I
M(FA9)20%+V<$HRAQFB4G2C%AH# 1/< R%%!LI-[ZBJ]0+BP()RP?%SX5%R(^
M14E?:3)<Q>.65==4VCN4/3K/,-2XNG?L6*UTN/C29LK4RQJ=3]/Y5WC3:O?[
M-9=(]X-D5-NU7*V6YC;0Y4 !P4>JB 6* SWD(,FD0*U/,$?YA9>[NZ:CMH/G
M6-[BQ[)[EF"$ 66Y<AUN!OSO\TVU<SQJ>'FULJRJK,8R'+L8R.EJ[&ZMX>F&
M43&$Y'>V.E=IAN">YG<7<<OL[L[#7+$+>9C25)M\>EWZ9<R*9B[4UZKE5:JL
MYDCBDC=E5341@Z$6I$LVKM!HA5:251)NKA+ VTZFM4PDJI5F5UO?LG(OJB"K
M;006+3+M>X-[C8V[?3O7;P]ZI:FV&D#%-C:-4X51G>1R<<D8XU(<5C>$YQ]R
M:WL53;"DKGDO!ZNHH$R,]#;CAI3576S[J'3.RFXIZ*MIX!4EG-,6AC$@?;M)
MH?646RNPY,[ AB?Z3!"]L+'/!+)V8T]K:0Z2N]HG[%CNHY&R_ $@8E(K'Z%:
MWW%4E0IR4B0U)6JMA%<EN6\](E-OJ+)4\B3(D2'Y"'"I+SS[SK@4MU:E9^IM
MN\VUK;G:P %M]K  #R Q9L/ ?1[_ +=\$C'Z&9*CSI=)42IL2P%M%F2*V&_*
MC6J8C5>FSCR'65.LV @,,PA,;6F2(C+48.>2VA  [@$!V *Z2 Q *WU:2+V*
MZB6MROO:^"P)!(!(-P;"X-K7'G;:_AMA,[B>+/F 7L:Q]XU<23 K"[35SAKH
M,Q :EPH!7&)AQ)38#<F-'\ME] "'4*2-N%$D@U 2. Q!8!V[Q'(MON1T)W'3
M!I6X-A<<C87'L\,96\9QMF%[L9Q^D:KO/G2O=[=5 1"]JLVY;-E)]D3'#'GV
M#,^<U.>\OS);<V6V^IQ,AX+0NY.HNQ:P&HL2;+;2+WO9;"PZ6%N0P  "P  N
M38  7/,^TW-_&^-LRPQ'2I$=EIA"W7GUH9;0TE;\EU;\AY24)2%.OON.//.$
M%;KJUN+4I:E**$D\R3L!OX#D/8.F%QEX3!@X,&#@P8.#!@X,&#@P8.#!@X,&
M#@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8.
M#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8.#!@X,&#@P8.#!CRG
MRG&\=@:LO3H%#2PIK/CGQ"M:F1*N#&E-5V6X?4YAE4!N0RPAY$+)LM<<RC((
MJ5ABYR)Q=W8MR;-:I1Z&.21J<JSNR_)$K6+,1JB9HXVL3:\<8"(>:(-*V7;&
M:X >X !]; N!8V8!F'L9MSXG<[XUF%8QC<#6/"6H./4<)JKP?2NSK&XE3 C-
MUUDG4;0G'DV$%#,="8DX4#SU&)<<-OBG=<K Y[$M3!?/([4T^IW.J:I#78FX
M[&K>QN=QK[UCMJ[W/?!"JB2(!0 (H[   "W9*+>%EVVZ;<L>M?'-XTL'!@P<
M&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8
M,'!@P<&#!P8,1V\1%-47..EFWJJVU:^U/4N/Y5E!BSF_(FX=+C36>24TZGRI
M<=2F)3>W)(946G4K02GB]0LRRC2S+^EISW21N)E(.Q&X.X\#N,03@$+< [.-
MP#L5((WZ$;'Q&(OY_@F$65D[&L<-Q6?&N=8-0X=Q'FX]42F+:'=U7B??NHMD
MT_#<;G1K=^9+>M&)276K!V5)<EH=6^ZI5V&:91=99 4I8"I#L"I1Z (5L=BH
M "D6*@ "UAB)T0@$HI/:2[E1?<SWZ=>OCUQQ6G.)8HBT\,LQ&,X\B9<Z,:<9
M/<2TTM:F3:Y(QXAM-\F8R&R?$8.SKQG(\ER/(&K:4MV>W=W]W:HD)GVLZ0_-
M/+)HKQVCV6KFC4:VLL9HJA"BB]@A2.-"HLI1$6UE4!D2KK@.E;F$$FPN2'!!
M)MN068WYW9O$XZ'!\ P2%JI!7#PK$HBV--O#5=,KC8W3,*9N1K9BU>+9I34)
M!;LQ PG#8(GH(E"'B6,1O-\FAJD1(Y9IC3V,LA!EK5(,C$:?59#IM?YMY93;
ME>20VN[7D5$$^RJ/T2'90-]48OL.=E7Z!X#&OQ; <$A:QT#\+"L2B/MX7X?[
M1MZ+CE/'=19G5_'HQL4.-0T+3.,?!\*CF6%"06</Q9HN>7C]2F)*\TS4L@:6
M4CM*Q;&1B-/JTAT[GE>64VY7ED/]-KQ*B=NIT+<1QD'2+@F1;F]NNA/[J_U1
M914XIB]1XF<@L:G&Z"LL)@QRSESZZGKH4V597GB\KV+NPDRHT9I]^;<,8WCK
M-I+=<4_8-4%*W+<>1504L,:61LO16D=E 8!6=BH"9:Q0 $D (9'TCDNM[6U&
M[8U45#D*H.I]P #WJ@EM_P"T0"?$@7Y#'J+Q@8TL'!@P<&#!P8,'!@P<&#!P
M8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@
MP<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#!
3P8,'!@P<&#!P8,'!@P<&#'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g287237g29m44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g29m44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1624&AO=&]S:&]P(#,N,  X0DE-! 0
M    %7:^5)0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              D0   =3          $
M                 0             '4P   D0
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   D0     4F=H=&QO;F<   =3
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   )$     %)G:'1L;VYG   '4P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      +8
M  $   "@    ,0   >   %O@   +1  8  '_V/_M  Q!9&]B95]#30 "_^X
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M6UP>&6;@T@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( +H"6 ,!$0 "$0$#$0'_Q  >  $  P # 0$! 0
M        !@<(! 4) 0,""O_$ &<0  $$ @(  04("0X%#PD)  4" P0& 0<
M"!$2$Q05%@DA,395=I33%S4W05%7=[2V(CAA<71UD9>AL[6WUM=8>(&8\!@D
M)28G,D1FA[&XP<?1V!DC.49'2&-YX3,T4E1SA):G\?_$ !P! 0 " P$! 0
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M76EA$F0=<L\I=A5?]+64Y<+#)4/'QI5>KCLP".:AO%BCWECINB<RV#)SI/\
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M:RB C ]R+*D=;I7"L4^FIKNOZM#P_HDTLD-G+);RWNHZK+"=LZZ7IL31O/'
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M4%M^+P?))]45->1U/66NW_60=VNU"]K>59R%4)#K (N%<G)],(U:<= YD9C
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M  &_\97'?_9IIW^O5/LB^Z ?X,/7O_.;LO\ <9QG^2?Z/OI_B_X#?^,KCO\
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MM9OM0FO8K1YX+*"U:=YQNSF=?$Z<4IQ2LC[,G$!?;/01&1L296:7$U/O55E
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ML,9?<4\]EEIMK+SRO]\Z[E"4^<<5X8\IQ?BK/A[^<\IY)[SGT?J]5<\ !G
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MFUFMU16@GN)[,M#SC"R6EK#G:O-#2[G;@Z4M]))]\-KAXFZQ>S+^UH2GQ#+
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MJ*YO(JDIQ2O*_9/6+L+9;/N@I5V&A0"ZV220K->SOJ]P4Q;JX$VP,KFYXI:
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M&7!/@RL]1\)NG<*ZMPGPWJFBZGIE]POQ;J;B:YXMU_689([O2M+N+-T:TU&
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MZ3C0D^D9D9>GONY97EU4E2%QP.@N86EY83G(9 X7E["XW[E8;=H4G/3 '=C
MK#A"RN]6XNT"SM],.J37NN6$+:='IXO$N%GNXUG@\12%T:,Q-)F-8@L:#<H0
M("O2U_<^L*YHRL%I6]=>CW4:N%$8EVO5U&69E<GV58F-60\IZT"2=I:2[G!(
MDTR<@32[6'6F2D-Y]$IN$R(SF1]NUGWNJ;(AAFR50!2D8.<* A5<@!2!BK47
M!_%^HZZ]K)P;Q%->RZJT-YI.G:'=:?.EQ)=E+BPMX(].DM],D60O;PQ^)M!9
ML%7Q8QQ\HU+H3O#I*[]>-2WG<?8CKY6]B7;659LM]#B;T"HS=:LYX)'GGJY#
MKA^\'[,'EU>?)D G4SBTH@N<-=EXQ%4\B(QE*T(ED$+$Q!B(RS!F902 Q(5/
M*QG&T8SCJ1D]'KG@=\(MIK^JZ9IG@[X\EMK.^FM;=VT#5-0,L4;[(IS?6>EP
M6<RW"@3HT4:QJDBKN<J9&XG0_L-K"^=?J2E[? B]75<RUI.XM^PV2]YQ)3;3
M:(31")8""3[3"1*1RAR'(R(RH*X[D3RF7$J5E<312REXS& 8X=PC18D$@AC$
MNV,*H4<W?Y*A<^3TQ6'A#\'O''#^M2?AG@K4]&W:=HTL_BFB&'21=OI%D;\V
M\VF0MI7X_P"-<U;24Q)*'50J@ 6+H+L(U9:%=+/N':6E42*_N7<%!@E:UA%!
M -5[7=Z+4P,^29L^R+PM\N8B!T61^:R8@P50S@^-$&8:C))$T_)1E$9.WE1,
MQ:1'[;Q*[@%50 *6V[3EAM.XY.!H=8X+UNWU&RT_3N&>)S-<Z-HNH^+SZ?=W
M=U.^IZ;;W[S6T<&F6KBTWSO! .7,?<'8W$A)5*PZ=;XTEL'8?; 92-P-W*>W
MV#)OC!Y:]V@[&17G:=4VW%T&+;B<F!BHJO3-]Q!]A4>S>&\,9'^ -=?RJ:ZG
MMY8[%83$'BM.7<<N)8F,XNKE@9"$3G/R&@!ER^0 I<LK =CX2^!.)^'=$\'5
MUJ7!][H@EX*3\)7 T%=/YNI?XQ<0RH=6FMK6(OJ@T271><=08WPAY*3D2I(J
MZ$UCO-[8FX-[ZJ76X M&E"E5&9-1C9TA)/KM(7)UIR2,(4BOC1'HL1<=&6X%
MDLN9#JW'$*;A8BRYOL]J(;:RN!(7-VD[E-J#E<F9H0,K*[MNVENW'#CH%#C+
M#A=:X972.'.#M?%Z]PW%=KK-T;1H+6-;$:3JTVE!5FAU*[N+CQAH7F)NK#3.
M6"J0K=+OE2.U'<-T-=O-QZ.(8'XH]%U'JZ^5]QK7UC&E'2]W+6D878F[!DW"
M=6S<&&FM,O#88^G!I4A\F5@JFO.4X@\2Q>&-;."< \R2>>(GGPL-L*0L/\G5
M>=&3SAVW8JP'9'7IC>:%';<&Z)Q%XM<K)JNN:YI7C1U2PFM771[72+AHTTJ.
MU74;2;_UM'NN+F[>"5(P88LN3'+GMTK:[)P>OGJBNJ],U#.VOZ\]MD)LC3,"
MT0ZNL9FA^S^751'GYS,E@Y[1I:6AF:UF E<9.7L>3'XKS^8_-Y_*Y7*7E[.7
MOYG.YN[=N[/+Y.,=KF9[-5/P59'A@ZV+V\.H#6QIC:<--B\06T-D;I;PZM^$
M^>+AI085L3I'+**TPO\ <##5\<KUH*RUN_>=PUCN;JYK<!4HIT)OF^VFFV(V
M_!L\EZL-UZEEKJW*AOAA\H4V](@ 2J5MFI$5"&&GB6%8@#";S-B&!98KF0R%
M#;Q+(JXC/,W2QQ%<O-&PQS V8XY3TP57()WVDZ1;ZCIO$5]+>M;2Z)IUM?V]
MN$LF%\9]2L].>%FN=2L[F/E^.),&L[/4F.PI)%#OC=M2\KUH:J'=FVD:7J(J
MVNTVQW=LK?M=Z]0*J\VJ02$<GLVY!Z#6Y[[MPL59&Y&XM-A!P)ZF)STR(S/R
M05$5 ASY,::&(3.RF6.';'+)NE$I4B)&D*CE1RMN95.W*A<^4RCK6XT/2/PW
M>2V?X0LM-,6GZGJ//OX]1DA=-+L9]0FMT73+#4;@3RP6TH@+P);\P 37$*D-
M7$["[M"]==26C;]AKUCM(:J*#8FAJFT->.2$&3@X$V[%;+D1,#*(KY)J3)\]
M.95B,T[YK#KWD-+DLK5KVZ@M$DBB>=PBR3LRQ*2"1O9$=@#C PC$D@8ZU:X2
MX;N.+^)-(X9M+[3M-NM9NULK>]U>:>#3H)71V0W4MM;7EPB.R"->5;3.TCHH
M0YR+<&S<$AT CAAZ+B?"BS<1I.$)D1\2F&W\,2$MK<;P\UASS;N$.+1AQ*L)
M6I/@K-8C!(Z'!QD=Q^#V5S[KL=TW*VUF7<ARC;21N4^E3C*GT@@US>>5C3BE
M0RL?;W8GSM'_ *"TWDC^3#\F?M9:@B\Y<_*K]A#4SY'4].*50?:;];ENG\G=
ME_,'>=1P3^5O#OZ6L_M5KE^-OR2XB_1-Y]DU7>-^UT#]Q1?YAOG.3^?F^5D^
MNU=)#YJ+Y-/JBN@N5PA4D2@K-$6LYE^8V/ABZ=5#UN+RIK[,A]EM4,%!F8&Q
M%IC.(=,FG1@&&ZIAN>5B*DQ\.>11&5MH:-, DM+(D:@#&>KD;CUZ*@9SUVJ<
M&O7<(-Q#MUQA$9V)^!0<#VG 'I(J-:SVU7=IQB3P,5;Q+PAU+!!BRU<D+C)>
M4_+CY9'V%MN943[[#T)]LA&KEA+R0[GFF3+(]]]AIR2XMGMRH=HFW#*F.16.
M, Y9#B5 01M,D:AN]2P&:QBE64$A77'0AU(P>XC<,HV".NUF ]-6CRO4M>;?
M?'L.[HTH#C@0UIF[$M6BMZ ]9S!@23+"(O=GL6FJA443RS:L,Q'6K89 -984
MG+CCY,6PCP5.0I&31OR9)AMV(R1DET#;Y-VP+&6$C9"L<JI VDL17U'P1\%?
MXX<9:"E]XNO#EEK-I<<2RR7=I')#H]A;WNN:GBUDG2[DC?2='U+,\,$D,)3,
MSIE0VU-)ZQ%:6U#K34P7*5CM>4FN5-J0G&<9G/!A<>)-)N^.,95(*3FY)&2M
M6,*<D2G5JQC*LXY@HP /4*Y+C'B2ZXPXKXCXIO,K<:_K.H:JT9Q[@EY<R30V
MRXZ".UA:.WC R%CB4 D"K0Y[7-TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*5"M;_$"F?-H/\ F+/))?.R?';]O[_>>^H+7\6@^23ZHJ:\CJ>G%*<4
MIQ2J)[ ;1N6GZ<W=:U4J?:A<.>/'GV[/;MAU\@Q)/F!%;JT&K@]9:1WC:+D9
M/6(S$$,!A]?BR\2)$3$7TY3[C<>Y96\5U+R9)98F()0QQ0.I"*SR&1[B\LXX
MD2-2Y=G(P#G&!F"XE>%-Z(C@$!MS2 ]2%4*L<4S.2Q P%SU&,^CI!VZ[79>M
M9W<U2HT8_>X-9OLD9KH2Y?WFI-TI96P5YZK/(MFM-?[*3(B'P3X\X.D:M'6E
MB7'(#A%>+S6X"2.;6D<=^EK),4A,D(:=N0,12JCB0&*XGM\%'#(PN&C(*LSJ
M-VW%9G:V,RQY<+(1&-X[:%E*XDCCD':4@@QAN\ $XSG?4.U>T=GV'IJ+<@]P
M&BYPW 2\"G]:$(-%L->$5O;,8ONR1<SFOJ8>J-JL.PJEK9-:UF215YH^EWU;
MLW7Y9<EJS5JY<V^GQP71B>)F!WPL)PTR.TEL4M.4DTB21I#)/ON%W@RPG$J@
M<MXHI+EI(PZL%[F[.%90LH,N2BE"7$6V/.X*_5<@D:5T;FR9LO8+-M2$0=^R
MX&]+377)[HC"?L'Z>]&]&62;:F95F-YK+_G48QA_+F&\Y;PG.=)5ZM"<4IQ2
MG%*<4IQ2O/ZK_P#I1=S?XC6@/Z\>P/.ZN?\ V:Z3[>-=<_J30OW^>M#'^4]Y
M^@]/_P _U&O0'G"UOJ<4IQ2G%*<4K%>PM0[_ "^]9=HI&R#]7UY896KG#&(5
MO:SD:,J0;:#%H##:@7K189']H31/7DN61@RF)DR#'.->>B2VX4AJ%T<L2K$
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M5\!>!^])Z,9_!_H$9([^IL=/L\=PQLP1Z_5FG<G4';B-O=96C':3=HXR5O\
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M4KP^SY/G$\FH)8 8R2 ,C(SGTC!R/6,'X#75GN/P5YG]1]EFK+NJ6,)V1FU
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M-BOO-PI>,YQ*BH6EB1C.<.MK\>8PW=W;J4@N;B!&=9&2&:2-3(G5'*HR@NA
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MB:7CB2+@F)%B.37I!1,-Y0YA,=O'ZK#LS#+><N*;83A7B^ZTUA3B<E +*"0
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MVV_(CQ'9#R,K:;D2.YW8>WNH2%.,\^VEA7/494,ZLP]2] 3BDB;U SC#QO\
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MY&S9 :1;RR\@0R'K7:+$\U"\VXF1(KWMPMS*C*TKB.)8S-.09YB&=M\N&89
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MQ6QG:1YU+PND:1(CQN[!E'C :6+=$H8MR^VKOM,B.BE'@GB,H0#;V6#$MG(
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M$-,M(6ZZZZM+;;3;:<J6XXM6<)0A"<94M:LX2E.,YSG&,9SS2=_=5LD $DX
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MU-4TSJ:^$%'7&&"2J?<:Q$%A(9_9 YF0X&B;+N9.Q2K$R*UPME,)8ID% LA
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M!ZG\WT_R338GO5^B/NIZI%?)@_Z%&^KXR=O>?*]?LIL3WJ_1'W4]4BODP?\
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MEJ\")D]E>_WH]0]E?/5(KY,'_0HWU? )QWG\[T_R:]V)[U?HC[J>J17R8/\
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8@+&@4  *H    &!T '05V',:SIQ2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g287237g30j85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g30j85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1VJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '8Z^=68X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              S<   /)          $
M                 0             #R0   S<
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   S<     4F=H=&QO;F<   /)
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ,W     %)G:'1L;VYG   #R0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      3>
M  $   "@    B    >   /\    37  8  '_V/_M  Q!9&]B95]#30 "_^X
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M_P!3_2*RLK"Z173UG(ZD^AK;[J:VF]KCM<_W?:"RDN_1[FUXW^8M5)?,0!'
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M"O\ NE)))((
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@!!P$V P$1  (1 0,1 ?_$ !X  0 " @,! 0$
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M;9K^G;;4)?3Y#=(%]/:VU^@<R?U98'%]1=3HVY USZLD"K-8X=7MTJ[2[G5
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M%*TJW+0W5G;+AU0^-KE[LS>V'+CF^C;F0TI#U=?M9439U>E:'T[HZPAYR-I
MHUQTHS;:ML )LM^+0(MON]^/S(HPE972)7UD5YPR.+A_LD,?1MG9:);HW,-Q
M-;N+VZO$8='?:NMN2![?,^U%"BEECTKP7M[YWN^4C[QEW%<PB%XHY5-M#;L#
MNKK@UI(DN(];R,<%\M=7IHU=9@-5WZZ.J9KIIKVT=R2;MJ^ACXFN\GM<5S&N
M]95DO+\VQ6;SK:OSKM>*G<[I)!0<&(Z$VM9<DB-9RA1J)QN)S)*;-!.+N6WM
M!#/<KND2R=(N)% >94ED$4$D,(=E7W,JN452>C91LG26,1@2:X,D4)T@HFS$
MC95"R(7D1Y-*D^WRW6+5.O3_ &T[?-):MN5GE-SK#9*2"*FIK4:/#1+(RH3:
MI4G$2(VU%CY?=\)U3,9IIAM2E)9:;;PE">95T??_ !K+[Y),1:XI0&5)A$I!
MNICDS(<2--DQ896V!!A20S'FQ9L12F1<N:YXR1%>:8PG,A:.S7?$D04OU\%0
MLAP20"5C9E!((/-@!R(SV5#<%UB)C)5B\2Z@ Q4/*BL0&#+R4L<D$#M/97Q^
M:5E^,^W_ #3K_P"Y?,ZX_B4\Z7UZUV9?E<WF6WX%/-*R_&A;_FG7WW+XUQ_$
MIYTOKTV9?E4WF6WX%/-*R_&?;_FG7_W+XUQ_$IYTOKTV9?E<WF6WX%?I1)!Q
MV+8(QZ?-*/B[46&02$^'!A290R,W$5%=6V-@CH3N,J==QA]B*A+G;MG*LISG
MF)0N5*@*&16*@D@$YSS))[V<$\LUFW,A$@D9G*2NBLRJI*C&#A%53V]H SSK
M.>1U/3BE8%=WC^95*& BD\,@W:GX!@D.@C9LF,+8J5I+)[>NPXG!C(>*#!C"
MI#L7*LY<Q';<0M_'>6/1B0LH;2@*J20"QDC7]4@G"LQQGO9[U5[@R9@6-V37
M-I=E5&(00RO^NKJ.LBC.._COT\TK+\9]O^:=?_<OC7'\2GG2^O39E^5S>9;?
M@4\TK+\9]O\ FG7_ -R^-<?Q*>=+Z]-F7Y7-YEM^!3S2LOQH6_YIU_\ <OC7
M'\2GG2^O39E^5S>9;?@5]M!FER%2$RCSK[Y9?ES<M^3&9AOO9C$ID9EUV-&8
MBQVEN1V6EYPS'9;5W\-",)5CF)0H<A<!>1 !) RH)&22>1)[236UNSM"AD)+
MG.20 3AB 2 % Y =@ \59AR.IJ<4J.YONLUOY.[M]9=?\F'O=_VT7\DM56]^
MQ?NL_P#5MZD3D-6J<4IQ2J_UCWSFY/D<T)^/_P"ZM^?B_%_OXK'A^?[!5@.*
MS3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5U7^ K]57[L\4J
MOO2=[VK2/R<UO^!;XK ^T]GSG\GQU83BLTXI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI4=S?=9K?R=W;ZRZ_Y,/>[_MHOY):JM[]B_=9_P"K;U(G(:M4XI3B
ME5_K'OG-R?(YH3'_ .U[\]K^_P#O[_VJP._\_P!@[?SV8JP'%9IQ2G%*<4K^
M?CJ4]5ZG:BZWHNN CL]W0FM2ZJ5N2$U5PLL^7L\";*C'B-8)2Y*)[(\$Z^B#
M)B+\G=(R0KRAZVF9*796RW-HD4L<EO+).6]CG6X"1Q   AK?8=I2"#S$T?@T
MG&3^X?T??\)$G==^B0]U-U?F#NP[H+-.+]R5NMWM\+AX=-$LEG#Q9.B2N]QQ
M!0)HI8)UCM(KF-9TDD5Q'_0!&DL3(T>9%=2]&E,-28[R._@.L/MI=9=3WQC/
M@N-K2M/?&,]LX[XQS6OQ#)&\,DD4JE)(G>.1#VJZ,5=3C(RK @X[XK]^*TIQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*ZK_ 5^JK]V>*57WI.][5I'Y.:W_ HXK
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MFE%U#K$$D*"1Q>Z+CW_+/";GC*QO++:-";>..0PL;B29(X3O*&,01V$AD +
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MR#"8LN5B-&PU'<F.QL+CXF/-.2FV7Y33;R$2Y*7=3([9#.QU8SDYR <@9//
M//'9G'@%2+!"A4I&JZ,Z=(P 6&"<#ED@D:B,X)&<$YJR!!;>QUV; O)#4\L?
MIXCT_P!"UH$V<JYTR2R5/U*W7.[RLXI\8JNWP8TI>P7@;#LP6VA,NN3)BUXA
M$!ZW+KS0GA<-N) 9UOKB=H]#\HI8+>-3K("9U0-E03R9#G.H+[RYXEPMOT=<
M)X,EZ'XS;=V/'.+SV(MKD"/AW$>#\#L;>4W;1+;-*+CA$^Y DCE8I[9PS,9X
MX+F\Y]>(IQ2G%*\2QV0!40LZQV<O ! QB&G)Q0G);BPX_CWVHD9"G7,XPI^7
M+?CPX<=O"Y$R9(CQ(S;LA]II>\<;RNL<:L[L<*JC).!D_0 "23R !)( )K5W
M5%+NP51VD]@[P^DG  ',D@#)-814MSZ[NIC%>#%2T,\XS)E0PMMI]TH)4M$A
M^#Y9. P+U7JY*L$")A;:I,X(T0B,(<:6Z\A#B%*EEM)X5UNJE 0"\4L4ZJ3V
M*[0O($8\\*Y4G!P.1H'4D@'F&9#VX+*6'5/8RG0Q1E)5U!="R=:I.6ZTUC.7
M'&V\80MW.5K2C&&VNV7',Y5G'9#>%)RM>?Z*/"QX6<=\<KX)[!GO?2>P5M7Q
MCR@PT.9*!R,$L,F-*<B$1DN//@RF\94C+D>7%<=COHPM"D94TXI.%)4G.>^,
MXQEE9"592K#D58$$'P$'!'TU@$, 5(8'L(((/S$<C4%])WO:M(_)S6_X%OF*
M#R\S_$_P[*L)Q6:<4K"KP=G"QT46"4UFU6>7ZRUQ#J,NM1I3C3CTTS+:3Z50
M  YJ25E85E*'UL1QZ5ID3H^%21J"2S>T0:G[Q(S@*,YYL2%'(XR21@&H9W95
M"QXW93HCSD@$@EG./U8U!8]XD!<Y8 ^Y7P<&M!1P,=ASR4?'PREU]>79,IY2
ME.RILQ[/])^;.E./3)LA7]-^4^ZZK^DO/-78NQ9NTG/+D!X !W@!R [P %;Q
MQK$BQKG"C&2<DGM+$]]F)))/,DDGF:]GFM;TXI3BE.*4XI3BE.*4XI3BE.*5
M'<WW6:W\G=V^LNO^3#W!S_\ -']:2_=55O?L0_\ Q9_ZMO\ ?5&:LJ?5=O;!
MNFQR^Y)MKBWAUNNQ=>=-6SI@^QB()H\PY%,S >D&Z&:&%:H]5*R&LLJRW&S5
M:*%E$8VXQL&T&:Y![,F);:&*!;01;76,_$+<-&S(ARJO>;ZLD@D=HQ'%'*6
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M;UKKN(^XG>N04_;!6(U=I976."9>-7C 6CV]@S;]BS]++.-IZT0@0U:*6ZK
MNOF+#T^6LA(V!%(&P !F.U5(0'NQ-$G"&$;$R2K<Z4,B-+%IBMQ=Z?\ Z2[I
M'*.LZI>QJ("$=R3(ST'#MQ :@ D9@+-H*H^J24V^K_KE4O&>JC-;.3)EE7V@
M7:QSSE=FG%*K_6/?.;D_3IS0GUJWY_SZ>._Y/G[_ .1]-8\/S_8/SRJFAO26
MR#^P]KV,9I2VU:B(V#1&"-"DVJA%L=3E.&;6Q>-@W2TDI>R)V'BA!XC)A4FC
M7- >"QJ\"[33)1J#<V*'1?1)>6Z06T;7<;SF";3/MS*.'RM;[4$42K ,*H4&
M::+4QN)#*BEHC--SFMGGF9BJ01M/;QO&RX$\*2(9+B?:5]0"]D>EY7CC8.KM
M+H7PX?3'NNJUDG8@$,[*M5AUUN!J5K8N8#SH0"A>>:[3JCIV3<1QN+-(N>;H
MZAZV5"@6/-8K@-K=,X%<8)2[5LY$D/$;25TC<HL4<]KB=$8,\VUMW-]LLC =
M=IK@,T>Z[=%1HRL3H8G@N=N,A%UQVMQ"L2K$A,)N9;F&"::,+)<2>R) 'DD8
MI KQK*$$.BV)(QU)FZIHR>Y6R]>E%%SU[E&:[CZW8LT!],=M%7PV+VG8# $)
M2RN4RI=W%AC]GOM<<?$!*\6)I8,V!OEJM@DEX-Q7"Z>BM.9S&1G,F6MT5WE0
M8$3,D<,F&=U&4C-MFN6C@.AE)!WUB$08'3A0%E9E5">; ,[KU5!/6:J9U.L^
MJ-:RT#5=?@8A^:8I6AQ8>I.@\]/A*S1]JANG34<&KU*S2+R7AUV?JT3MN/M8
M?8C4:5-V#.DQ*FY%/DZT_.(2.K(_ KB]DFD9%66]9I=?31&;9[ZY,DL8B0R"
MY:V-LT:$"$ R@HDFE14VN)0VXBCD5S%:8C*",N;A(8TCB.\J(8MP2.6/6*F,
M;FK6@SC86P^LG64ERP[!L"J[JB=L.8V8L(O&@X-EK%77=NJ"'5153E76="IV
M(Y.L!NE^;89-\?FFGHECM<"LRF+G*P'"PPP<+N $@37<B%=,;=,:.200\.,K
MR")3+D2/Q!4$("@I&SKM#6VTTM[&=;X2$OAB@A#*H:Y5-!E<IEPMLTAD;'7<
M1A20B2%TNG^MVSVZJ']ZQFQ>NS&H:&6DP,UFCC8Z[,4U;K4B9S+3%.PMB5R_
M1]ER]AQC@4A6I%+8!QHH\='%S8D4D5@X@G"8XI$LR6G2YF4'7*WL:W-PJ:25
M:&2$VX@*,'$I<EF+ D++;/?22AYU5(FC5@@50 3%$2#ES*KB4R@JVH!% .&
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MZ%5O8WCB&D6^I\7VU5NM(]9"=MIK%J8N&OIO426UVWAW1J=:D([E;M<?1->
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M!%TK(*08%"W:=KEC9A6O94LI9;W=*CN.NZ&J9'4$)4"U:_8W-K&P62>7EO\
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M.3@5D/*E6Z<4IQ2G%*<4J.YONLUOY.[M]9=?\F'N#_MH_P"26JK>_8OW6?\
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MWZ@&?;=N 0:C2V[RZ;*S1(=RCZCFF)\FX1*++J<;5C_KM6[&BYFJ/8XUK)1
MQ&NA(U0+UBR8,$L%Y@^;ZW0&:]*-/VFHH.6(K&^EF,1GC0"(S"0SKIDCVDE0
MQ+J$CF19(]*A PU,7"".71#))81QZQ:JQUB,HMODH^XT;!R$*J$9&#-J*\A@
MG6FJVOL6:T_\@4[Z."?\ISF;\WQC^<:N]$M?D\/HT^ZOJ@ZZH R9&(#J55H,
M^&ZE^),B AD>5&>3C.$NL/M1DN-.)QG.,+0I*L=\]L^GF#-*P(,CD'D06."/
M :RMM;HP98(E93E6$:@@^$'&0?'69\CJ>G%*<4IQ2G%*\TR,9-""H>1((0XY
M4=-&ORQ).>%*Q69T9V,[(&F!4F&4$SV4.J<ADALN+/@R$MRH<EB0TVZG96TL
MK  E6# ,H93@YPRL"K XYJP((Y$$<JPPU*5R1D$9!((SWP0001WB"#6N?U-T
MPX[1[%59Y,@7,U$+KX;(.3NH+?VZ8-U'LCC N!L>FBM[5&M9K- N;HB=+K9K
M79.ZT:TJC$((VWF?-7$IWN<>3$R2A51)7G8(+.SM6B.I6,$S6DCZYX@RB1)U
MBFCR"T2;@%<[AS+I>-7>01*BB1Y9VW5&H+,L<X.A)0-0:.2:-CE5E?1J.RKG
M!KI5U7^ K]57[L\4JOO2?[VK2/R<UO\ @6^*P/M/@\/B_P!_#SJPG%9IQ2G%
M*<4IQ2G%*<4J/+CJ;6VPC=/L=VI@.S'=?E%FZ25*Q,2)E7,.-*CN$PKN58S"
MG+C+=BKE-=GE1'Y,7*\QY+[;DL<\T2RI'(Z).@CF520)8PZR!) /;*'1'"G(
M#HC8U*I'2L>,<4X;;\3M+"_N;2UXU9KP_BT$$K1Q<1L4N8+U+2\13BXMTO+6
MUNUAD#(MU;6UP%$UO"Z2'R*N;3BE.*4XI3BE.*5'<WW6:W\G=V^LNO\ DP]P
M?P[T?\DN?LJJWOV+P=%G_JV_^:UU;RL)@1ZH?J)M@K39 .2!U*)(U:T/663L
M)R:?M&T(<0YI2L1-M5H0;%0<L(D[@.N4,RBE AX\](9LK$8A$ ]ZSC5^!W61
M*KA[EQ)&$$&$CMB4NY#;R,CMV6J;R[SLR#;)5I*-PY3B</-"K) NABVYEGF
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MI\(POSFL^EQ(\\QF"08-#+;<6M74![;V184ACN-FV:2();\.BR$9-#ZC9W"
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MI3BE.*4XI6(WXR<KM,LAZN!X)\P&%R"48.1EGX<:>U#QA^<UARJU6[V1Z5B
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M2,P<CJJ1DRL16(DMUD:Y,<LD,MS&C1LT6Q!-M2-)*K%U?*3.J+#)E8@,ZI5
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M*S3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE1W-]UFM_)W=OK+K_DP]P?\
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M()G5(UM<@PS: 2AZQZ@+5O;\3AF5G<&%>D201LX.EU5!-%(6QA!/"1)'J(U
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M*5N2)$B0ZN3.(SI"O#EDB4QW*GYQ"8[W=DRGU*<<7G&,>"VE"$Z,[.<L>\
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CR Y"IXXTB4(@PH^DDGM9B>;,3S+'))YDU['-:WIQ2G%*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g287237g30k86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g30k86.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1R 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '&2^<F@X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             P4   3?          $                          0
M           $WP   P4                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   P4     4F=H=&QO;F<   3?    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   ,%
M     %)G:'1L;VYG   $WP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      2,     $   "@    8P   >
M +F@   2%  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 8P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MXYMZ=U/.=BL+JM@M<UFX'<XM#ZV/]CG?F^S_ *:Z1";7C8S+'-:RBLEUMK@
MP2?=9;9Q_;>CQ=K4Y+_JPU]3JOVGGAC@&D"X1M'^#V>GLVN_JK9K8*V-8.&
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M0?2MQO38V;+=CC&H;LM?[=NW]Q&N_FG_  *"F:BY[&QN<&R0!)C4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MD-A3<:1*E.MJD.=<VG;16>T;VU@D,L%O=3112$JQ>-'948LG18E0,LH )R0
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MGX7::-YX3;[O45U[Z/1J"ZRNK5C4$Z1&<A>D>'&GS'D(!:!!*BIT,F+)PXQ
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M\@=GC/(9S)$%4'01,H/EU[#;1L;B_F\'$B7_ !90T6\B(N5N4:-Y[:YA)5U
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M!&=6!6YJ/45"NAK2+(>FF/<OO?6X_8M6//% RRP^&0JJ[@Y[>U*%(F$AP$-
M<#A#MM?DMBHUSM]+K0]!5PX[-'X2V1B6[U2KO+.=H)$TOI8K)NNA*0%9V8.Z
M1@:C%%+(2N@!LDN!(8"JDI/&)$;.& *:^DF,JH&%+'&'94QD\)(<HU8HXI1Q
M2CBE'%*1=(^U+!Z:6[YZE<DDYKV<?JBH8>4G;2^N:6G(ZFHXI1Q2CBE'%*.*
M4<4HXI1Q2HTFNKK1 *6:&S+26P6"6*14W!KM*N@OVRL$:QV>GOQ0A<Z $UPJ
M,CVRG6&N3;5%-*IXLM";C%K!!]FP%R;Z;,O'",(UTO&)=0EB;3&8XY075':1
M6,<J2",IO64Y5&PV*QNX!JZ9Z+F,Y1U!<.T9"LRJK .C*S!M"D'4P'&DJOJV
MA(G&QZM='6)#DY82@MRS@'#ELL<+<];Z>S0DW[7O$F:>R)VO; P_)/R]@B$J
MRJ;9Q?LM,-0UR3[6G"-OT(P'F(1\1QM:27J,F0#*6MHW8KA"LFF-L$DC$78)
M8",\RJ$LHU,LJP,K?U<2-C4-:LH+*2, _P!TEU>U[=6R"6M85.+5LP)"GYI!
MLH7%2B,4E3WZ6/M&' \+*WU5#)VY^YVGWQEYX/<S50O,6$S#;!QGBB[V8]K;
MK<&59%9T5=*L%*R"4QX<X&]TQ:Y82 \22PDDZR%170EE,6[92%8Y)'-- ;@/
MO<OI1P2'*28 "@F7_-95NCBE'%*.*4V^QL9RFG]F.W_G8Y]$+;R:'\)V?S^R
M1_\ G\U5KGE%VO[J6G(Y#5FCBE'%*.*4D3I<[',APH*&*?>(CC9)^06E3(S#
M#8B2#C)9;Q#B2EK=D*,^/CQ\(2E,=79E65=V:JI5F8D895  !)U!SGB1RT_I
MJ&1Y!(D:*IU([$L6 &@H,< >>L?-YZ^/E-B?ZE2_Y3.?\)X]C\K_ #+_ +TS
M<?U8?\3_ ,%?&2C8$N-(BO0J9EJ2P['=PDH<3G+;R%-KQA6!/:G.4J5V9QCN
MSV9YR#&"""^00>2]7YZ'P@@C3#Q_M/\ P4V]%T]#UO1H6N*EKS5 ZH1&A6'A
M/D92V2TP- $C8)<XCW/);+FFX@(.W[:3&W)6$C("&UMMPHK;,\UU)/,9Y)YV
ME.KIYP5#LS,J=/HH2['2,#I-PXDF-(GC3=I%;*G#*@M@D  $C1Q.% R>/ >0
M5IE=.U#6QF,O0W3JJ-F0Y*S'55(:F,ONL-Q'5Y:S5LMY\I 9:%K1E/DU!VTA
M\IR,QB)S+PVXSGPN[SC&=ZV< Y''7G@W2^-TO&XUP86/ P6A&2<$$C)YG!CY
MGD3SQPY"G2"!K76AK(>OU[7H85'=F/LP!THO$BHD$)L@D0D>29#I2J3/(RY<
M^=(5A3TN;*D2Y"W)#SKBJ[N)&+N\C,< LV"2  H&2W(*  .H  <!4BB=0%5(
M !R 9^LY/WG6>)K:^4V)_J5+_E,Y_P )YC['Y7^9?]ZYS<?U8?\ $_\ !6',
M,W42L<\3'5AR#+,AA4CVO(%G);2"Q*,.Q(:1(&-,K]CJDX=4E;B,*0A6/&QG
M.,\Y"HVK!8$*S#(&#I!..?76+/,FDLL95G1#I9R0'8+G!4#AGRTX'(ZL4<4I
M%7+[-3.[_OL+_%_@!;O_ *OQ\S3D_P 0^LM03\X.W3T-2UYA4]'%*.*4<4HX
MI1Q2C.>S&<_)CMXI3:@36P#P,*=:&5",T:$C2S<9XF;R]';(PV9B&'<I$^+E
MUE+V&UY3V)RI.<X[,<E98U9ERYTL5R N#@XR./75:-[B1$?1$-:*^"[Y&H X
M/0YC.#6V\IL3_4J7_*9S_A/,?8_*_P R_P"]9YN/ZL/^)_X*0&Q-:3]K#0P:
M^5FAV ,%L,.S,"9Q P\-EDH,(C CH)1'@KK,Z'A@I)4J,ZGQ,O89=QG"V49Y
M-!.;=F>%Y$=D,98 !@I*L=)# @Y4<1U9'76$D<LH"R) RA@VDLY!(! R"F#S
MS\.#U5EG=>KLXR.%L6N]/FQ,,<R(A#R<%^9%@BXTL80C#X++]>6F%#BSPH:=
M&CQ<,M1YHD9*92A^!$<:X2=XV+I-.K%BQ96()8AE+$AN)*NP).20S \"<F21
MAAHK=@!@ EC@9!P.AP&5!QRR!Y!6H!:>%5>R1KA6M6:9KUGABW@D4V$A2Q4^
M.'D3B91T4R[!!,>3'+)&B\_,-.,1TS"<Z2EO#TEU:\GNI9(S%)<7#QE@Y1VU
M N JACECEM**N>>% Y 4$<BL&6*V# :01J!"^0$1\!YA3E^4V)_J=+_E,Y_P
MGD'L?E?YE_WK/-Q_5A_Q/_!1Y38G^I4O^4SG_">/8_*_S+_O3-Q_5A_Q/_!6
M;5S!(LR7;+1(<2<(-R1#N(#\B1$?PS%A2D2&ER6(SV,+3,PA25-]F%-YSA6<
M9[CJJZ=))#*&X@ CB1@@$^3RUS$[.'#J R.4.DD@X56R,@'[['+F*4_,*EHX
MI2+I'VI8/32W?/4KDDG->SC]45##RD[:7US2TY'4U'%*.*4<4HXI1Q2DS:3!
M(1&&X$Q(DN<4,PA+29[[\>(SB4E]:Y#SD9B0]XK:6,XPE+>>U2L=JL8QS-%#
M$Y) "EN&,\,<...=12NR!-"AF=U0:B0!G/$D GACR5@^4V)_J5+_ )3.?\)X
M]C\K_,O\5<9N/ZL/^)_X*/*;$_U*E_RF<_X3Q['Y7^9?]Z9N/ZL/^)_X*;2F
MZC10W+9(KE'UG&(7HQ9S5O+/+(2"UC>MELLUS)0C!!8'$D@*8-6\]D:-EK>B
MP(DU<5E'BJ<4NQ+=//NA)+*5A2-(EY+&(HXXE*KJPK%(DU,,%B,GJJ*.%X]>
MB*W!D9V<Y<EC([2-J.C)&IVP#P . *U\O0]2GR)<N9I/0$F5.7&<ER'JVPMY
M]<,.0K\-:W,UCQO&B!"I,7&RG.,L0Y\MEKQ$ON85R+R=0 +J[ &<#>-@997/
MW_6ZJQ\I )Y4,+'.8+4ZN? \>!''V/CP)''JX4LP%-)U1;;E8I.JZ\MD #JC
M.0K<X9ABL5E9%RO5]A,,$RA@,$<,%7!8UI*(<)9&8J.RVJ0[E43RF3VR69^F
M\AUG5F233O'.6.7?2NICQ.D9/ 5DJ2)XD=NN%5!I+#")G0HPG!5R=(Y#)P.)
MI4>4V)_J5+_E,Y_PGD?L?E?YE_WK/-Q_5A_Q/_!6J.F=@@@9DVZ,I\EH,*(E
M7([),WAZ0@?#>EJ9:RH3XN''4LY;1G/=A2L9SC..9*L;,JY<:F S@<,G&>?5
M6$CW$:.Y6(A$9R SY.D$X'0YG'"G(3GMQC/RXQG^/'(JLU_>*4W&QL=J:=C_
M /%CGR_<A;?D[>30_A.S_>1_-]1UU6N>47:_NI:<?D-6:.*4<4HXI6FL-CK]
M2#3[':CH>LUX4TE\H=L!.$&##6%NML)>GDR+\:%#94\ZTUAR0^VC+CB$85XR
MTXSFD;RNL<:/(['"HBEW8XSA54$DX!/ <A6+,J*7=E15&69B%4#RDD@ ?"::
MYWJ!U?,3Y*E'%;8*+;B*9$:DCYV"ZEPCF-@6@P8 +D56G,$TRV7H96]6"K@\
MP_+D'BC(Z)+EL3^!7 XRIX,N3TKD[C@,ZBJ/B273@ZEA21P<+I+$ XF5!IQE
MRZ:T"*6U(69 P8= *65E#,P4E7&>@V$4-ZO](F:Q.M @N?(,B:77-AF13=4.
MQRXBEVKVCR#L<YN=#B0/:LFV<6X(EQB$EFQKKEUAU=9LA2[-#&3-LR[601LJ
M+JED@1C(A5Y8@^M%P2VI=(# J-&\B,FA98RT7A<&EFU, L8E<:'RB'&&88X:
ML]$<VTN%R48#7DNL76$&;/&1 .SSQ*,;#"X#%<UW8K'$,"C&PC6LLW)DN BE
M!(6HC[35K:U)GVR979TN!6Y1,,,*02M;?-\KLNX8!B]NBE'9C)/'&49($N-U
MI<JSRM')'A8A(H:0*S*5D"<-=QK]Y*Q+HHTQ.P(>0QA]2@JJ!E8DL5.%& 2\
M8>3Y8L+ BB9TX2@!@@4?,+&#!69''BQ0L=&<F$"1*?+<9BP8$&(R]*F3)+K4
M>-':<>><0VA2L4%5G9416=W8*B*"S,S'"JJ@$LS$@  $DG &:LLRJI9B%506
M9F("JH&223P  XDG@!Q--Y#W?J0K,!CJ_?ZY;B-D>PV(@4>;B]3GX^#$JOR3
M$B)3T&Y ZMC3D*:*-6DDW#K8.?$E1C!6"Y'=2B8VERH=GA>-8QTFF&Y .D.%
M!ET!I&0ADC7,CJ054@BH]]$2H#JQ?.D(=9(!P3T,X4'@S'"J>!(IN'NK'5\?
M AQV#>EL3VV<EG1].(G7JK*(7*UZ\KPPT*KZBILB4M5[I%FJE=@4\7:7YI4>
MWY9,6&1%RYL_VNN#JP8L@G3JD""0+%',[(SZ458X98Y',K1X5N&2K <;],@#
M43@$X7)7+,BZ@,MTG1E! (R.) P:<O4FQ7]HU659WJX_6$M6BU 8L%\E&,9E
MP !R8+@&4$A[*13^#$..S/=BBYA5@/)>D IA%9<82C1H+F 6\@CUB0[N-R0I
M72SH&9"K'4-)) +!2PPX72RD\Q2;U2VG3TG4#(;(5B V1T3D#/1+ '*Y)!IS
M^5ZEHXI2)N7V:F>FPO\ 0"W,TY2?$/K+\WU'74$_.#MT]#4MN85/1Q2CBE'%
M*.*4<4HXI20M^P:%KY@=*OMWJ-)C%YJAHF3;K('KC!,@F.[+5!'O&)D-N9,3
M$8?E*C1U./)CLO/J1AIM:DRQ0S3%A##+*4&IA%&\A5<@:FT Z1D@9.!D@<S6
M#R1QZ=XZ)J.%ULJZB 20NHC) !.!QP">0I%E-\ZU'QB\R$8DV6& /5RM&B-5
M&S38,<;LES'4-H4]9X[2:NZ9#V G';LE=BFI%D!14N29X=O&64O2K9SDJ"@C
M+H\B+(P1V2.)IBPC)W@1D4E'*B-SP5C6.^CZ6&U!2%8J"RABVC26'1U!N#)G
M4O,@"D&>ZKM?"6]@1X8RR$3%+&W28*B28<0(&NLBAF+74K&P-MQ2:U7*Q!&7
MRG%Z/..;"G5 4T;<$.QI$P98JY.+S)LZ9MR2T:K*T08Y+-$)ECD0M&H+R%H9
M5E"0"5M ;(!1PN!N8QKP&)35@'"ARC,A"LQ"C$BE,N5&K!!*D$R'KI=-AKX(
M^B,_#0<#C"Z(DIF5'E14DH3$U,:3'FQH4UA]C#^&GF9<.)*:<2I$B,PZE;2*
M+KH=T)!*,RD@@@Z21D$$@@XX$$@]1(XU.IU ,.3 $9!!XC/$$ CX" ?**2IK
M;>JJT8)UZQ[,U^ /A0[MB,!#=RKHHL* ,L>RGCA(=/(QY<$.U&[9#I*4RU#;
M8QEU3V&\95B1;:X=%=+>9T=@B.L4C(SDX"*P4AF)X!02<\,9K!I8E)5I(U95
M+,K.H*J!DL03D*!Q)/ #CFD@:ZB-9@!SILG+/1JZS1-E;'<L#]6/0QZZMJC
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M-J.@1#M=L4;2=Z9)U>9-(#<-W (@=)F2[.?NC#Y\*G:F ]I6#MEIL-BJN++
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M+'DN8EX6^TTE#B\3Y[Q2;A2L8[<^R2,A^:]_]N0ZMS/]\K.><EF(P22.'/S
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M9H9K9L/X-$D*%"8B"-VQFKQZ3>$":!F#RLT8DB9P"ND!(E59(Y5P-Z[,V5+
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M3WZOL#;X[XEF0K;*VQX)_P"C,P) ,%[X/O\ [>'!/M>]W1QX^[/BU(K0_AN
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MV3=XW>M]& P&C4=. Y+@:<8#DL!XQ)R:S35H77G5I75G3G5@9SIPN<_U0!Y
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M4%0XHEB9'?C9C>6:<0G1B&9F*K%*S!-Z5$;%A'@-O" ,Z-)!U^+@@YP:V)=
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M4E\';?GJ6VG]!CO%*V>\_>>V/Z)EOT=7)K;V^'M%Y_#^:JE_[CN>R;T52O\
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MR\J,-"EELM8B*4O+H^R$0]<?B*QC*)ZK 7$@V(*I$DN4'#V9$QB]LPD;0L\
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MJ1"VG&/%(4..4)>YM5R9]K<#Y4-B/:ZM&!G9=30=/9WEC';012JTA8M$CZP
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M*[G6% TJJ*% J6?*U=:J+'7)\#'JM_@\;@^@1WBOTWO+>^_WKOE_W)?3MC7
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M0NW$(N#&UKTMV9 8=)(U^,RNSEC%NP(E7>F5@BTC,@OUA,"ES#J$^5UA>F2
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MMG^WGLV]9:U6VO<8[9/5>JLNW/R^;.>_';_'_;Y^_LS\7-U75/1_YSU_Z?\
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M8HLA1A&SJ,E5?&DL!Q*@Y YBI=2EB@92P )7(U 'D2N<@'J)&#3::9^S[?\
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M'[.Y_;+BK9>?EM=PKSI-E>^-?_36U?>_[=G_ !?%S7U[_P#<Y]SVP?R-LO\
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MRZ@LVQ-FJJ@EF:!  !Q))/  #B2> J6-/Z5M"].>KLURD&]D:OU1KT8?-8#
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M8F-H&!$D2)((W\'02Q.\@?5(0R$KHY.STZ>'.'=F(8%QAUD4@AV92PWA*,
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ME"6V6&&6\);:::;2E#;:$I0A"<)3C&,8QR,DDDDDDG))XDD\R3UDU8 "@*H
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M_?\ +_!3?G\1-\\'\^CW=/\ W%6S\O3/UOXW7_43_/\ P4WY_$3?/!_.ZO\
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MX\ZXMQ:G7Y,F0\I;\J9+?<=DS)DAQR3+E.O29#CCSJUJP9BS%CS/F 'D  '
F #@ .  P.%3HBQJ$48 _.2>9))XEB<EF.2222<FMES&LJ.*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g287237g30r12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g30r12.jpg
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M 0$! 0$! 0'_P  1" $# F$# 1$  A$! Q$!_\0 'P !  $$ P$! 0
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MG$=8XD*XA&P^MO=1$(S(KU+':Q+5?;%)IMSKK1^)<+B_$-ZB.WDBXW&(T"4
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M 8$@"I 7ZH.FRONEV#V_],!7@#T2.:;*[-IH]8MZ>3?"0FYN)9EK,=<LY&E
MX^'.SOIJ+*$([HC'>C(@FFZ@X0I8W;AP2FVWE;=M4.V,(<X0ASX$(?XI!J;7
MUDA8-=VRE2 VZ:,;26*#.6Y9<%!^L"OQABOA#JAZ;1,4G-*;]TX.B!I4""4D
MS=D5"*Q!FE5VQD9#D.O%T(1*(R*%>H<&/VY>ESJ5;8#"')E;,L0BZ;J#%56Q
MNV9@Q4+;RDL%X18@!,D*)X2Q[ LT3'E(A(WUDH8M=VX"E0Q,T8P6XFT'K<B3
M%* .^8Y!VHP%4.ZD^GDO'S+$[RU(4B)C6>8J4.V'5)T9,.EAHECMTM<B*5=9
M1%K=>GP3QJ0I>&1X6;%*25MP9#+Z\-I]^APUG=*<QKAH)0=TKM'$N"N<R2*R
M(,99U*@;@161>VC#*W5NPPYRLT9&(U#R'(8C"(RLQ[RD,>1S67AI(<9'#S B
M?#*"2L**2%DQ\EF9 (CIS#<J%/@S(ZW(\J'+C.M2(TEAQ;+[+B'6EJ0I*LZK
M*R,R.I5D8JRL"&5E.&5@>8((((/,'D:V%8,H92&5@&5@<@@C(((Y$$<P1VBJ
MWD:S3BE.*58;588=1K%CM9%F7)'U@$7L,Z/ 0PY.?AAA\@C*:AMR9$2.Y*<8
MC.)CH?E1F5NY0EQ]I&<K3..,RR1Q*0&D=8U+9V@NP4$X!. 3SP"<=@-0D<1H
M\A!(16<@8R0H).,D#.!RR1^VL 43K(Z;+Y4:C;&MO4&J.6[4X#=C=2N]TI]>
MNU=UU8J+"V5$/6VO+/R'@$:+1Y[-C)OR7E0X(IN5/<E9AQ)#[>]/I.H02RQ&
MUGE$5U)9F6&&62%[B.8VY2.38 Y,RE%  +,0,9(%:D6HV4T<<@N(H^);I=<.
M62-)4A>(3!Y$WDJ!$=[$G 4$DX!-1VD=<O3S=W+0[[;X%1#4]V_M&[)>;#1:
MZ'9SKC<5GT>:D-I<M\@LL80NM3*>(#BA2 14>J+W!)HLXZ)8LFT:_AX0X32O
M*(2D<,<TCGCVD5Z@/P07<L,JETW%U.>J4 <QCU.TDXAX@C2,RAI)7B1<PW,E
MJV,R%B&EC;8VW:PQU@QVC(IKJBZ> +B&)NY->/REVVD4=4(3:!)J<S9=BV0U
M4:? E0Q,F9(BH,6&LVL8W,D-MPF9-1MK;\AI=:-)A:Z:=?OS%I.!PII@6C9%
M,=O&DLS L #LCDC8@$G$L6!\(F;6OK-.VYA)XD4>%D5R'FD:.,$*21N>.1<G
MD#')D]1L6NL=6O3Q8Z:+NTK;>N:H/(4J+L*5#M&Q=>L2P=2EY@80:-3!%K,@
M&!S>2PKOQ*&;G"VTE!J_#LHG15.RDTN_CF:$6MQ(RS& &."<AY1NZB!XD<L=
MK84HK':W5ZIQA+^T>)93/#&K1"8AYH<I&=O68K(R =9<L&*]8<^8K)E/VUJW
M8,EJ%1-CT>Y37P#=J9AU>U!#LIVLNGS=518$1QLV2\H/FSUNPUS)'"/!$G09
M82IW$\?+8:UY;6Y@&Z:WFB4/P]TD3HO$X:2[,L -_"DCDVYSL='QM8$W1W$$
MQQ%-%(2F_$;JYV;VCWX4GJ\1'3/9N1E[5(&0N45=3BE.*4XI3BE:S[BUAIB[
M;4U*;M5X;HFZ8E=VM2M8O"K-51=PMU,N@<*_M*HC:U:AYN-;A"6:[5[*2\"
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ME9;OKF_/3YE2M<EL:7U5M#8&V*9#&,.:KSC(<:>V=<1"8)-9+**K.@@XS\9
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MES["&G2:U+9BFTDI;I5B4]%DM)(X0\['>3A3:B/JJ8'=MDZ#A@Q/J>FF-TC
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M(B2EMM!1MA!"P%Y,S*OK" *NHVP 14 ]M=.(VH(PHYW)R0(85R>>V*-2=L:
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MDG_[0'_N_?\ M-T-_P"8:>Z]^QV_&'9]&&Y__'?%/Y)_^T!_[OW_ +3=#?\
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M$2GYA@?:2(P2<B880H0LE#F2\H'.+F-[*V%PS0IA%>>*29$=U0B*.(S&1MV
MJ-$K,A)ZVT@=;D:#>0 2MN8K%(D3LJEEXKR"(1C;DEA(RJPQU=P)Y9(:[ZD-
M-;24<Q4;G"<]KK3KQ5!MB75I,=J$[F(96H?96!1)":V42L)9<O0VL 3:%BB6
M8\S'>LI]/N[;9Q82.(0$V$29)&4YQEE^$7KQX)WIUER.=(;RVGW<.0'8"6W
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M:1D4R$Q2!(P2[E"J*QY5OF[MPL#<3<+D*T&Q7D,BML(<!%8A )$+.0$4,"Q
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MRX(+@J5X4/#D;20B0=TMB1E)S%$<(NX"+F#F, J-ISD*=V[B2;Y[<]3)NU=
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M6Z+5I8X^')&)\I*C-+)(2_%?>S-SZS#L&XLK#DZNI*FJ33HW?>CF'#QLHC1
M%X:;0HY<E/:< ,#S1E;#"%1.@2GP0U>!M;$M<D?7 U! )%F0U2LU8LPNDZC>
MT>_B[4:SB#-'-3CVNY<L60(#:Z!?FO-@EV+%DAU2LP!=S:W*SR.8(PTCSR;D
M>6.2-YKH7@X,T;K,BQW #JI=\ OPS&TLC-6-*C5543.558DVLJ.DBQ6QM3Q8
MW#1,7A)5BJ(3A-^\1H!L_;M2#K=<*[:I1:7#:!:\ONLW0\:-&\'*5S8]@UB;
MLK<B0KL=C/.QM7C@T5R$AE46$9,/-JQ-P,D#^=%=-%%)$$#;YX+@.2<K);QW
M*1D#L(!N6<[LY9$'9N#;LEN))$D+$;8982H PR3/ SY/:#B *,8P&8]NTBOJ
M%#-5VW7FUF+M,M*K?)B^!P)8 "-]KPH=((N" 48G C))SA8=@@^R.BRI*8[<
MJ69,/,/FCQ6?(C+,DD4,:0B+A Y8.[<1F"AG*GJAF*@L0,X"H"$1%$HXF226
M1I"_$Q@%%78JD[5# ;BJ[C@$XR68Y9F)\??->OV.KVH<5^.]12]70%KJG66]
M69R8T!JHB89)^+H$LJ2=CPVLN>"C1<!I^<3)3'.XB#Q\-EV3-FO,1F$*==3C
M*NIHFCWW2#5].T335B:^U2[AL[;NB>*UMUDF8+Q+FZG9(+:VB7=+<7$SK%#"
MCRNP52:\0?6[MCJ<ZT-TE=CV/4NUA53&9D!=9TC-*M3D2H5),C*V6G,-B\L2
M+ 84ALC92B<95-GY1&84V*'"H<17[/>PQT5]CCV'^AUKT>T_I3T8NM5N>'>=
M(]9&L:8LNK:J8PKLI:YWQV%H"UOIML<"& -*X:ZN+J676&E4'?E!N%5O-?U-
ML1!^FV(+:@;DS7EIE163-?(QBPM]^,H8A$EIB=$8>7'<SEE_".]/)6TM:%*]
MDZSKG0?7=(U31+_I3H!L=8T^\TR]6'7],BE>SO[>2UND207),;202R()%&]-
MVY"KA6&66++U1C;5F]5_3%HJUV]N<F_IMU<UE>1UA:M$^PC+,2FL$\]^D,1R
M)(1!2\-94@='A)DPAT6%'($$RE>+/IOL:W&E^TE_TOTW4]&]IX]".E:ATCT2
MXL&TR#3[G3;>%[8!(WD@M[N<I<.&N))N%-<2S/;P&.6YVSU<,NRY0K1#->(3
M[A;+K.+ .GAT:7?*WV*\/N\-HHV!5.& K2)D.A2@4.^.@8#Y2.@M0XS;:$L?
M=SKE#HI[%;)%%==-Y+^W@TC2]%@M;_I\MS:1VNARI<:+*ULUZ(;F]TRZC6\M
MKR[2XG-V#<3M-*S,;JWU!]?C<AN5BO;)6\W+_P#B=U6:=2Y7>^D'_:(ZTL*I
MIRDX=*D5>)E([YGPI:<S,I;82TK5;H#[!;(T?=W1X(T78O2:T0KJ&R!/;Q66
M\#+K.VUMQW6&VCA B$%GW=^'L7'1): TI/6?U,#.^[PNU>""=;5DF.Q$>UCK
MP16!E0 2I$!Y&'8-H(T\2+"0FI'=E =381')2G#1TVQ$5\,_[3'LRZ9>1'V'
M_8XN=G0O1K^]NND6HVUP94Z2:_=ZG<ZM?11SHVV?3+?5KJYO9FCQ:WNJN9+:
M)+.QLGE[N<XQG&<9[>S.,XSV9RG/9G'9[RDYPK&?Q9QG&<9]_&<9XKXRK"]4
MZ>-.4BH5F@UFF,P*;4#EFL8"O/&;&4'1C-QEV>?8IDMLN8G*,8GS[G9YS<8R
MLA$@32[\L:Q#D-QW&=N6^NII9)Y)<RRI'&\@2-&*1"-8P-B*$VK#&,H%)" ,
M2,YUH[2WBC2)(P(XV=T3<Y :0R%R=S'=N,KG#9 +$@ XQ80W2GH6NUW3-5 4
M=\,%Z>LSD:;;&7"]0B%''DQSX@E7X)N/9FSA"I$!+^!4ZG&R).JRQL09 D!W
M(@@6S#F^I7LDEW+),'>^P;K=%"5F96#K(R</8LJL-RRHJRABQ#Y=B8K8VJ);
MQI%M6TSW.!)*#$K*59 V_<8RIVF-BT9 4%<*N(I2>AGI4UVWEBIZD@0HRJQ;
MZ8[#(V:[V*#)JM^H^LM:W %,@V2S%XDT>>HFFM85F8S+9>[D=3A:6%,O9ENR
M;9M9U.X.9;IB>)%,"L<,;"6":YN(G#1QH59)KNYD!!'6E;.0% KBTRQAY1VZ
M@;)(R"\C@QRQ00R*0[L"'BMH$.0>4:XQSS1B^@SI0#RX!&%JK.2@N6H@-,3;
MULHH:'DU&=0V!):$9*7&84C&&3.A-/D(I9F6@E$?H8?P64RA4Y$N3:WJ;AE-
MSU6&UD6&W5"NRZ3:46(*4*7MTI3&TB9\@\L872K!2&$'64DJS2S,P8M;ON#-
M(2&#6MNP8'(,2X(YYX$= '2 RAEF)I80/C1H@V!%AB['=A4&)"#UK3M.&1(D
M$=9HL.)&A5CI_P!.!6&8[#3:8=#$IRG*WB2YSV\U0\S=LQRQ+-'"[$O+=S,2
MS1EB6EOKMR23SF;O!=N/:G3^];*  H 5Y5 ");QJ  X  2TMU   Q$H\.;W&
MZ.='D@\>-L*F5^_6%RZ6'8IZS/"<5A=FNEL<KRK.7,!ZS+@"I46S(J%35:*^
M^T_6[',KP^>6$R)#3>6X'5;Q68P3201\%+=(P_$$<,?$X:(\@9@8S++PW!$D
M8D8(P!J0TZU9<31)*YE>9WV\/?)(4WLRH0I#\./B(<HY0,RDBL247V-+IA :
M[#4B\U21LTH.6XHA<2MANX(L8;97L%H-!<8"W!MN & #-GW."* 07F@<.58#
M!R*.CF2<F8K:FZ0ZB\[2PRBW1@ L*QPNB<H-[9>+K.[6T+/(1O(1$+%5 JB+
M1;%(5BEC,S#XTK/*C-SFVCJR#"HL\@5 =H+LP 9B:RM*Z*.G5)&'8P5#;K]Q
M!%"=DI]DCGK;.34[80V!9MLH/#@$^Q/5]],79]OL%S2%ECG0;\XC)@O0,B5I
M@HUAJ]^5,<DYDB=4CEC*1#BQ+!';;&<1B09MXHXMX8.%4$-N&:O.FV88.D02
M169XW#2'9(TKW&X*7*'$\CRA2"NYB,8.*S=JS6U;U'10U"JD >.$BWC1%Q@6
M.8$#WC=H/$[59R,03%4J*+8+64V7*(&Q59BP,3/!(W] RWCFG<W$EU,\\C,S
M,$4%F+L$C18HU+GFQ6-$7<>;8R>9K:@A2WB6*, *I9B%4*"\CM)(P4<EW.S-
MM'(9P.59!Y15M.*4XI3BE.*4XI4 QJ^CX]M&$AG48NMQ%WZUX;,'&O'MJ#0J
MX-'D)_>R:>^1VAM1K8UT0GN LL<(BP9@Z1$[XRY?W1-\'UP>#$T$640[(G:1
MF5<KR):61MWQPSDA@>=5<"+K]4_"R++)UG&YU"*">MV;8T4K\4A0"",BH[C0
M.G\A+/6)%''$*Q<H^PHEFJY:66,5DK$VN<S9=BQ7:\5(3 [$:VGUNERL>)"C
MM+G2)3[*&5RI&7;.[KO?'()F62$VYCD0(DBFU3AVYXBJ')BCZB$L<* #G Q#
MN6WV/&8E,<@F#QL69&$[;Y@48E<2/UF  &2<8R:S#S4K8IQ2G%*<4KRB;2]@
M^ZF+KLW8MR&[.T7&'6V]VZS0(TXQ?T38\(]8"!6*Q,0QKZ0PF4TQ+;;D)9??
M:2ZE>&WG$82M2OU#Z,_[:/L<:-T;Z/Z1<=&^FTEQI6AZ3IL\D-IH1ADFL;"W
MM97B,FOQN8F>)FC+QHY0@LBG($$]P8ZI?.IH'YZV)_XXXKN?RX_8R\6.G?V/
MH_\ \Q4]P8ZI?.IH'YZV)_XXXI_+C]C+Q8Z=_8^C_P#S%3W!CJE\ZF@?GK8G
M_CCBG\N/V,O%CIW]CZ/_ /,5/<&.J7SJ:!^>MB?^..*?RX_8R\6.G?V/H_\
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M4O\ =QD> ??Z:;?UF\M/ <?"YWRI?[N,CP#[_33;^LWEIX#CX7.^5+_=QD>
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M((-3WE%6TXI3BE.*5XK^*_8BO3GU,/H<V)KH<_A;\#$BMEB ^((V\;9*J@6
MA@&*MXFA"I=)FUR18G199J=L>3)B@QP"XX!A\EC+!T&K\W/8Y0KT?Z07"82?
MAZA;6\\MWT3LGM1/80=VW6DW6N746LPZA'IZW-J\'1Z..6]N+_2.[;P6EF]E
M>[C6 ^$J@(Q9[*5@@Z]7QDTR;,DY#<0<+%#8[DN?/FR75);8BQ(S3CSSJU82
MA"%9SRR**2>6.&%&EEE=8XXT!9W=R%5%4<RS,0 !WS7I^"":YFBMK>)YIYY$
MAAAC4O)++(P1$11DLS,0 !VDUXMO9%.N,WUC;64D(_.&:4HDJ9 UO77N^1UD
M\J5WB;>3L56<=IL\EM/@<9Y/_N$+X.,:3B8Z8ED?H+HIT<CT"R^$"OJ-R%:[
ME&#L[ZVT3?-1'XQ'Y63<Y.T1JGU[T!Z&0]$M,!F"2:Q>JCZA.,,(AC<EE"W/
MX& GKL#\/-ND/4$2II#KFXO:\V#1K_&@M$Y5&M];N$0<^\N/'G2ZT8AF8L20
M\VAQQN/(D0FVI"FD]][RI>&U(7E*T^17=N+JUN;4L46Y@F@9P,E5FC:-F )
M) 8D9Y9QGE7F>H6@O["]L6<QK>VEQ:/(JAF1+B)X795) +*KDKDXW 9!&0<X
M .I15+VBO<]&IB0.QEW<[=?'4RP)-1O_ ,4F6)]BKJQ4@#'@R*^0$>,ZTB-*
M;?D8$V(ZF=)(KDQ/ >?+I(N+/VON9^):=S1V_#6(QM\#&5AE#B4L)4?9-N7
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M3M3>O''NYZ+_ $D?L6H>JT]\WH7]+/YNU+U2GN3G7IYE8GI.U-Z\<>[GHO\
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M*KQH=HY'!SG)S"K1TOZAN.)D@\%FR#A"G777\ZTQB;XZQS*;?[P,V+9 $J?
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M\L6,@(((*/N.^-@8WZN]&V)M^"^D+2(:7&F#P9=IR.D''<0]8"<R//&UH5J
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M$/-1U3S%7;D:LIQ2G%*<4IQ2G%*<4J+4K^[(W_.=_N,OEDOY1OZO\(K7M?\
M=X__ !_XVJ4\KK8IQ2G%*<4IQ2G%*<4JTA<)3#=PE+:<>-3N>QJ$Y 3E2CA%
M2E98=SE2W%JSE;TS']&1=4L@SC#4E&.2?M']%.TAOS%[X^X=JCJGF*KB^(<
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M(:"UP3[:\*E=YV.=@O?S#A:&[A7M4B/-J[%BA$EO"S3B<YQ.+,H@X[B,.?\
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M55OKM54!547$H"J!@  /@  8 '("O*(M7U58XU74K]55$556[G"JH4 *H$@
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M;W2_T<M?KKQQ3^GZQ]%/Y,O03Z5Z4_:]'_R.MVNCS?\ OGJ/,$S%DHVK:]K
M!AV(0-"ZY8F29@ZXSA<<,#>GVJ="PN(EUJ<7ENQ)2(L=4:)AK#Y!IZ/)79L]
MH_K->G/99]COV/O8^M+>TT[4=?O^DE]ME@L[J[TM[:TLE<B2[O4@TF";$I5H
M;2)9HFDD$DI;9 R2=B'BX?\  8?R9C^#DLGPGRFO0>Q/DK]4>BGBX?\  8?R
M9C^#C)\)\IIL3Y*_5'HIXN'_  &'\F8_@XR?"?*:;$^2OU1Z*>+A_P !A_)F
M/X.,GPGRFFQ/DK]4>BGBX?\  8?R9C^#C)\)\IIL3Y*_5'HIXN'_  &'\F8_
M@XR?"?*:;$^2OU1Z*>+A_P !A_)F/X.,GPGRFFQ/DK]4>BGBX?\  8?R9C^#
MC)\)\IIL3Y*_5'HIXN'_  &'\F8_@XR?"?*:;$^2OU1Z*>+A_P !A_)F/X.,
MGPGRFFQ/DK]4>BGBX?\  8?R9C^#C)\)\IIL3Y*_5'HIXN'_  &'\F8_@XR?
M"?*:;$^2OU1Z*>+A_P !A_)F/X.,GPGRFFQ/DK]4>BGBX?\  8?R9C^#C)\)
M\IIL3Y*_5'HIXN'_  &'\F8_@XR?"?*:;$^2OU1Z*>+A_P !A_)F/X.,GPGR
MFFQ/DK]4>BGBX?\  8?R9C^#C)\)\IIL3Y*_5'HIXN'_  &'\F8_@XR?"?*:
M;$^2OU1Z*>+A_P !A_)F/X.,GPGRFFQ/DK]4>BGBX?\  8?R9C^#C)\)\IIL
M3Y*_5'HIXN'_  &'\F8_@XR?"?*:;$^2OU1Z*T1-]=W3@!-%P<^RFV9P8H0%
M366ZF<<;:ECI;L.2VVXW$RVXA#S*TI6WG*%)QA2<Y3G'(;E'?^X^BO>5E["7
ML@WMG:7EOIMFT%W;07,#'5+%2T,\22QL5:8,I*.I*L 03@@$5:_= ^F7]*3W
MT0/_ &/C>OA^X^BMGWB?9'^B[+SM8?C4]T#Z9?TI/?1 _P#8^-Z^'[CZ*>\3
M[(_T79>=K#\:GN@?3+^E)[Z('_L?&]?#]Q]%/>)]D?Z+LO.UA^-3W0/IE_2D
M]]$#_P!CXWKX?N/HI[Q/LC_1=EYVL/QJS[J3==%W<))G=?R"TX0)GH&22! *
M0$1W)ZF$R7(L1<]IK,IR,PXPY*[SA6&,2HV%YQEU..9!!YBO!^E70[6^AMU;
M66NQVL%W=0-<QP07EO=2+ ',:R2B!WX2R.KK%O(+F.3 PN:RSS->+4XI5L"9
M6H,)4XIY3F1L'+BI$QDB^I>8S659?(1\8CSG<J[<N3&,89DK[7F\=PM/)-\9
MNSXQ[ 0.WO \P/ #S'94(L\./.<[$SN8.V=HSEUZK'PL.3'F.1JY\C4Z<4IQ
M2G%*<4IQ2G%*BU*_NR-_SG?[C+Y9+^4;^K_"*U[7_=X__'_C:I3RNMBG%*<4
MIQ2G%*<4IQ2K8(RO,1S*U/*5XR,XQE^8S.7W"3$[#:</L8PA#26\)3'B9_IA
M[&&X$C.7XSN>2;MY8^*G8,?FC/(]_/:?SCUAR-0CSM.<_'E[6#''$?',<@,8
MPO:@PC<U-7/D:G3BE.*4XI3BE.*5S1DI7(90M*5H4ZA*D*QA25)RK&,I4G.,
MXSC./>SC.,XSC^WBH2\XY,_(?_":DWBX?\!A_)F/X.9R?"?*:Y&Q/DK]4>BG
MBX?\!A_)F/X.,GPGRFFQ/DK]4>BGBX?\!A_)F/X.,GPGRFFQ/DK]4>BGBX?\
M!A_)F/X.,GPGRFFQ/DK]4>BGBX?\!A_)F/X.,GPGRFFQ/DK]4>BGBX?\!A_)
MF/X.,GPGRFFQ/DK]4>BGBX?\!A_)F/X.,GPGRFFQ/DK]4>BGBX?\!A_)F/X.
M,GPGRFFQ/DK]4>BGBX?\!A_)F/X.,GPGRFFQ/DK]4>BGBX?\!A_)F/X.,GPG
MRFFQ/DK]4>BGBX?\!A_)F/X.,GPGRFFQ/DK]4>BGBX?\!A_)F/X.,GPGRFFQ
M/DK]4>BGBX?\!A_)F/X.,GPGRFFQ/DK]4>BOJ8$%*L*3"B)4G.%)4F,SA258
MSVXSC.$=N,XS[^,X]_&??QQD^$^4TV)\E?JCT5XNN8K]BJ]J'%?CO3BE=9/7
M[U:?@V#2=-Z])]Q?[' [+27A/=C].KTYKWHC+S>>ZC6([&7GO&4JQ(%B7,D$
M89DSA4E$6; Y=I_ZS7T;[!GL6^Z&\CZ7:];YT+3Y_P#LVTF3*:M?PMSE=&&)
M+"RD'7!!2YNE$!+1P7,;=+.K8@J?LS7L$ZU#>!3+M5HIQH@IM$!860;@M%L3
MG'5(;9AX'KD9DR%N-ICLX6]EUKO??$U#F1W^?/O_ +:^P.DLMU!T<UZ:R:5+
MV+1M3ELFMPQG%Y'9S-:\%5!9Y>.(Q&@5B[[4VMNVG8&I5.CQ=F7P;?Q 2%K"
MUG+/5@]DBOQ%DZ*ZNP-1*?:@$6/B6M\5W^9$C2.^QGX1&O\ C>='4Y+&1G,S
M P3D#'[!R'>..S'A_8<]G/P75=4UJ3HYHESH=W>3=)-+LM-U.[T^5)5MM;06
M#2ZMIE]+)PE2ZX<4LD>V1)K:_P"Y(9 L5S*E3&HT2J1X)B+M&K:M8RWL ^P&
ML-;M@-#F)0BLW/ Z#XN9M#TDS4K);G:0,KB8P7(]X>-*$2DUMV7WXOG'A [>
M79G R1X/ /#W\UR=5UO5)9K.7HWJ?25PVA6#W>GZAI5YM,5WJ6D=T3]TOIJ1
MV>JZ=I2ZS<:AQ;T3I<7%M;VT)6(K:?NPT>H89(QZ13]4E69FS*FS4CABXBX?
M@F4 GTWR/9(4BY1)TNIM6>>S$#LQQC8F-!JY67*D=[6RDV('>"G)Y=GZ>W]
M\ YG'/MJ-AK.K;[=]:U;I/:O#T=U5]4LK72+F;C WR>TDFGS)I$L,6J-IL#R
MW327+7<D^I6L4498.UE#:KT^$-]=2=FHE#!Q:A4(YU\H8?'$85@$4RI+=:<P
MMHD-)F1DJ?*0[A@6*B&"#2"+V8'AJX0^9-8CMRV , 8S^@8_KY_]>&NMJ?3N
M#H/['FG:WK=[)JVK2626UHEQ;S6%WJ^J!67#VUQ;6=S%!$5,ES=26ENS6Z"?
M@K-<0POZ)Z+1*OK.FA:-4!J15<KH],&#%8[M3ZTXPIR3,D/-8P_*)3Y"WIDV
M7V9D2IK[K^?Z1?+0,8 _Z\O_ )U\!ZYK>I=(]5OM:U>X:YO[^9IIY3D*,@*D
M42 D1001JL,$2]6*)$1>2UT9:VV-[('K8)5K]9X=Y*3*ITC=0]ADUW=$'9$>
MLV_;XSJNIZM<46SOF2U;@1]M7C36+55M19<*--X?+@I$L>6BH9@R?-[BWT.X
M:2"-H4$NJ6$8DM&MS)%:-IDW=$\819&-K#=\.2ZZO8CA60DD>OH9M6A2*9Q*
MQCT^\=DN1,$DN1?Q<&*3<T:B>6WXB6^6'QE)## .=K=UG]:XO:^Z*10]%UK9
MT'4LP/#-B*]KK8GCVJQ;%HC4&V6216P#KL?!W ^%.7RP5QC6E5&1K==H@V+-
MK_@ZHLKPK2BTG2'MK6::\DMFN0Q1Y+BWV2E+RZMBJQM#&\2.D,<AN)6,4)8J
M^<C&W)J.I+<7$45JDPMV4.J0R[HP]K;W&YG$KI(Z-*Z"&->)* "@Y',U<V_[
M(&9*.*?JU/KE6KG4)TWTF<_5]![=G%[AJZY4O4UMVCL</)N-N&$X]5 VTQ?*
M.;&YUVT?KHUCN2Q4*5K!,F2J%KH:J,2S2226&H3*);VT58KF&:ZBMK=Q%$RF
M62)()D;CE)&(**R2JBV=T:LS',<21I=V<1,=K<%I()([>2>93)(K"-)&FB9>
M#O1>3,K1EVA,[JL]D0JVM*!>;1H2E2YMEU8O8MPAL:NV558>N",:,^S::E;<
MF-EF'PDG7T0/,O[Q$\X&SL(8>@4"K#H)NOS+.<M&F:%)<SP1WLP6.Y[GA8W-
MO*;A208I8MENH<3LX@"INX#(TTK%'$:5-?ZO'#%+):Q$O 9I!P)D$) (>*0F
M=BIB53,6?;Q@RQ1JK*7;&8#J@]D(NMLT5MD5J8E,H\T3(&&H%?U1M>+0-@4O
M95U]C>E^W5=7EVJ<8K=IUZ V5U=Q*3:21(J+, -3G[,@ 0"%F58V7TW0H8KV
MU:Z43!PR,]U:F>":WAZ0#@\01A)(IY+?2S-&JHRO<QQ\177%4I?:O+):W"VY
M,17#*D%QPI8IY=&/%V<0LDD*3Z@(I&+*R6[R;&1@:V8Z1MS]8)^GS0VU].EZ
MZ;HFB!)X'7K93]H1#NUKV1IE5*Q/_P"+]TL94#7Y8V]-[ H-GH5K9)7I++-0
MO+)7VNS)6)7.U2TTJ.4/;722)->LCO%-;,EM"LLBG^:PQJ[AH>!-'-$5@YRP
ME>( !NZ?<Z@T96XMG1XK5757BF#3RF*-A_.)'**RR\6%XI-TO*.7<$)W8XL?
M5YUY#!5!DUCIXD6^;9]1VB[V-#W3;OBJIJ-S5J'J7ME4HD^ 1M\N6X9$[3UM
MIG6]F@./Q/';&PFC56(/0+6&(5G932M$9IQ)?B(1W4<,>-0LI>+#W5IT4DZL
ML0&Q[:XO+B,@'8;?9(H:-EDI?4-558BEH9"\#R/FRNHQ'+W/>R)$5,I.Y9X+
M:%P2-PF#HQ$B%,;]2FU?9&)$B., T6SR)5:UCM>UPUZ>U5N>M!MAE[CT;=2]
M@IM=-E!6P#T@(0I^\(VH-:PP31P3?,; AP-ACYE9'6H570U^G6V@@%I)HAQ+
MFUB/=5U:2/ L6K:='-(BO @=9;-KJX9RCP& O RR&)I'IOI]8)"I$Y*0W$@[
MF@N469I--O7B1RLKE3'=BWA";UEXH68%%D5%R!<NJOV1P;".-U/I=&I>A&[=
M"&R">L-HVS# T*KK/Q4VG(XFZ@Y5E?MHC3O2\?=L8]^&,$3=[RZG,A.'EP$!
M:(=-T!F0RZBV"D3.%N+:+)?VHXI!:%Q'PFN]2CX9#.XLA*I";M]LE]K #[+%
M00TBJ6AFDP%]LN'R612_$6WL7WC"@W31D;MNR<4[J<ZY2I,:,+Z6HCQ0B[N4
M>BJ.5>VT2T1IE0#U*^ZLL$Z%:]@R94?7^R0D3:NI$VMD5+A#]M#:614^H-,.
M@H5,NG:,JLR7DX51:,9.)'-&1*\L%RBF.  SV[FVNN$64M:M,OQU1VLCO=49
M@K6T))[I C*2129C6.:!R'E)$4R\>V+X(%PL39VEU&+PG6[USR=HTC7!70E;
M8*F(5,LTRNXU;M"%9[#0IVX=0T+8MQ;:E7=U.L!=$K-VV.8C9NH\IBR$-90\
M#75M741"1LOH^C"VFN%O9"J&6,2=TVYCCG6UNYH(N4.;EIY(;=3P67AK<-N&
M8F:JEU+4S/%"UJFYA&Y7@3!Y(6N+>*:0 R? "))9F'%#;S ,'$BBL>6OJ%]D
MJVI1B[C>IKSJAQ_6>TUC&*AI'9H:S3KO!+='%DUJXO!$R4-5HI@3?-] ID!N
M;+!%$4"W!%3"1%F*1'7QV'1^VE4=TPW6+FV#&2]MFC6!EU6.XQM14E7=!9.&
MVAU,\3[57*M1)=ZS/$V()8,P3E1';3*YE!TYX?C,SHVV6[7 )4\%T)9L,-XN
MG/>W51?]C5RI[:H5'K@0C1K78C\@56+)7+%5#M!V;>:-+!64%8+X9)@U[/JQ
M?26S]7N2A2V'JZC:,>1**I;KI&/QK^RTV"WDEM9II'6:*- TD<D<L<]O#,'C
M=($5^YI4N[:YPV>)W,0%^$6NI:75]+,D<\4:*8G=RL;HZ-%/+$4=7E8J9XVM
M9H,K@IW1S;"$=@W.'76IQ2M%-CCMN.[+WJ)K6R=OUH2-U3I6P:^.#J_'/ AE
M_O&QM]![NT+B2:I*$6E%2KT#5,^;5,O2U"AL4)*-8:CV8O*-=F!K46]D\EO:
MR,US=I.C2,CM!#!9-"6(E#1&60W063 WL7"9,:!.9,+@S72I-.BK;VS0N$#J
MLTLUTLNT&,K((T%N2F3M 7<<.Y:)IN?5=@RJR2JI9&3]*); C;&U(/C.R:;M
MBM5^LZ1@ND=)7";V)!E2L@U<]A:>9*FX$LV10?U9>LB9\*<?H-O!TS;PQ+'L
MF6 V]TQ EMI))+Q@+R$$;T4)#;W95&5%V7,.X$1SU<6^W;RC[XS*)[=?R<Z*
MEL,VTASM9BTDUON8%CO@EVL"T/'3K3O>21<C2)NU'BHSJ'TW!@BBP8F%A$M1
M$-+=-*ML3LS2NN2PD[ !7RW[/FSH\H[6WT26;M&!'<F:(&#"<S162KD+;!6L
M;LED='*W2WFH=S#"W"LC/!%; 823D82Z!9W=T<ET3S,Q9;NV&TJR*8&MK/N@
MY,)5E662<X+IS$@5BT2HO8WS@5V*<4IQ2O))M7_YH;(_^_;A_P#N$CRANT_M
M/]]?J9T8_P#LUT>_^AZ3_P#H+>H%S%=RG%*<4J8Z_HQ_9=SKM%K$;PHW9"3(
M^(G.%=YCH5VN2Y\M2<*4W!'0VWY\YW"59:B1GG,)5E.$YR!DXKDZ[K5CT=T?
M4-;U*3AV>G6SW$I&-\A&%B@B!(#37$K1P0J2 TLB D Y'INU9K<!J2@UO7];
M;[!M?@(CKE+;2W()D'<Y?)%YF$=N,RR<YQ^6]C&<H:[XF.SW+#+2$W@8Y"OS
MCZ3=(;[I3KFH:[J+9N+^<NL88M';0* EM:Q9Q\%;PJD2G +[3(^7=B<@\5P:
M<4JU D]P$$([C*.Y&0$]QD?@1E'9%:QW.16,JP,RGL[/ ,*5B'V>#XSGO?;R
M3_&;^D>_N[Y_._._;W^VJXOR4?+'P:<MG#QU1RX?_=X^1^;\7O5=>1JRG%*<
M4IQ2G%*<4IQ2HM2O[LC?\YW^XR^62_E&_J_PBM>U_P!WC_\ '_C:I3RNMBG%
M*<4IQ2G%*<4IQ2K4'3W,-W'<91VDS:NYR/P,SGNS1!7=>#8RK#F%]UW>)_;V
MEL*P5SA.9F4XDW;_ .%>_N_-'?\ _+\WXO>JN/XIY8^$E/Q.'VRN<[>_GMW_
M />9XG+=BKKR-64XI3BE.*4XI3BE7T7$[,8DN8]_.,X:3G']F/[,N?\ ^??P
MG_T[5?\ /&>*TKF7)X:GD/C'PGY/[!VG].!RP:T-O^VK\/VS8Q-,W01)4-JT
M"J]L%EFL4@H6TGF#3MPG)9"NYBTOOWBDU=!VG]<2,WU5TDD2IPSBNN Y ^6^
M[W8+6%K6-I;14G,;20$R3*MYNEM8PKYFQO2)KJX'!$(5$3B;PPQX]-/,L[B.
MY+1;U2;J1,UKB.X<LF(^QI!;PGB\4LS,$*E36/C6^.H9G6&XK'4C1ZZ[4@:*
MKLPWJT&!UA*GZ"W"BGVD]?)P* 4:JTPR"KD_Q#6(H6W&=CEC%P9[L8(D"0MH
M@$;ULK'NFUCE1(K9KV0)<O)<A;ZTXL<<(<KQ0KR#?*7B6W58CUF#/$RTO<W@
M@N7C9Y9Q:H6@1(";2YX<CRE VPLB'9'MD>9VD'54JC@[0;6V7>86G&K)7R6:
MI9VMM=/-8(8@QPAHV%K]PVEJ$7L$5989(6;KL(S&J%IM""[PE18>%'I;-#3:
M'8N947G6UO";HQNO%C-K?R+N+HCR16UTT#1E620H9HH]H?8SME&3G@[L\THM
MPZ-LD[HLT; 5F5)+BW697!5D#"-WW%=P4==6Y9&K]OW/U,5>O[.%S[,<?CBZ
MGOB]:GW/6J?290D^+ [<J]2K5*N\:352H 9L2CQRDB*)S#&BPVS*<4'V&'$(
MV&NW-L)T8[33Y'@98T!:6RAN+.268/&SVLDLDL)$JR-!.5RV6=[>560LJ20E
M]*2YO4292[X"7,D%RD495U6X2-(I 8V19HMQ"X55FC(< LDFW)ELVMN07JCJ
MR-U^UD2<"@VFN1-&[2EU^K1IEAB$*[1)UH@1DHJ3E0M82OVPJ>KL*X#JG(B/
M-*F UY)V"I$2\S7BMK1KK3$DB5&FBE-Y;"24A"KSB-CF7BQ.\2QR&)I V0'
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M93S%TRW-VD;Q-Q=BBYCBA$&$=6$L9!8G?)!-1ERTK(QC=E81CM@1H+8NLB[
MQ,$CS&;+*RE'! P$3;_2V\+-LFV6.JV2FPZ^Z"JU-/QS  J[9:P978J^%*3T
MCS?@T"7%Q%G%'6H$.R :Y+,!FX-AKJK&-E%'0/)N[..WCCDCE+AY)D*NHCD3
MAR.B[DRP.0N6,;R!')CDX;!=_0MKEYI'C>,(4CC?<C<2-MZ*QVO@$8+$ .B%
MEVNF]2VS9;FA6Y6#+O8SEUL4K46O"4D5*C-17-I7\<I.'->A"+")46O )"DK
M97M&UCW4/"&>QQ-)K\E-Y-MX=E4D-;U>:Z-I]EH^GQ=*M>MX[J.1I%Z,Z%<
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M\XQ$:;CM*0RA*,"[LJJSLRH"$4L2J!CN(4$X4$DD@ 9/,\ZP%52S!5#.06(
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MDOY%_BJWB:_-B"QL1[$5EV- AQW6FI<N8VTXS';;6VW+EM>%2D(4G*42)/\
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M!G)'8<?< *J@G6.)497W#=G 4CFQ(_.\!J^^)Y/Y;'[3GU7(5;W5'\E_(O\
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MWYCM2^CVJ?=7%/?"Z>>.G2KS_JGK5/)NZ>_,=J7T>U3[JXI[X73SQTZ5>?\
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M:>^@=1^[..')\V_U6]%/?&Z<^/'2?^T6I^MT\G?IQ\RVGOH'4?NSCAR?-O\
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M_P!F,8P,[<YS_P L8X,;@9*. .TE2 /Z\4'LC=.2<#IOTG)/( =(=3R3X/\
M>ZYO)NZ>_,=J7T>U3[JY"I^^%T\\=.E7G_5/6J>3=T]^8[4OH]JGW5Q3WPNG
MGCITJ\_ZIZU3R;NGOS':E]'M4^ZN*>^%T\\=.E7G_5/6J>3=T]^8[4OH]JGW
M5Q3WPNGGCITJ\_ZIZU3R;NGOS':E]'M4^ZN*>^%T\\=.E7G_ %3UJGDW=/?F
M.U+Z/:I]U<4]\+IYXZ=*O/\ JGK5/)NZ>_,=J7T>U3[JXI[X73SQTZ5>?]4]
M:IY-W3WYCM2^CVJ?=7%/?"Z>>.G2KS_JGK5/)NZ>_,=J7T>U3[JXI[X73SQT
MZ5>?]4]:IY-W3WYCM2^CVJ?=7%/?"Z>>.G2KS_JGK5/)NZ>_,=J7T>U3[JXI
M[X73SQTZ5>?]4]:IY-W3WYCM2^CVJ?=7%/?"Z>>.G2KS_JGK53NH:_HFOHLV
M#0Z95J9#)2TSR,6K !8%B?-0PU%1+FM"XL5$J2B*PS'0^_AQQ+#3;258;0E.
M%<35M=UO7I89M;U?4]8FMHC!;RZG?7-])!"9&E,4+7,LK1QF5WD*(54NS,1N
M)-2_BN56"?*DZ9?C%Z)]+NO_ %AYV_<STC\7];\U7_J]<WVYT?Z5TW[=:_BU
MG;G$KI4XI7$^^Q%8>DR7FH\:.TX_(D/N(988891EQUYYUS*6VFFFTJ6XXM24
M(0G*E9PG&<\RJLS*JJ69B%55!+,Q. J@9)))   R3R%8) !)(  )))P !S))
M/( #F2>RO'+UV^SR=1A[J/):YZ 3D)C65/S+K4:P1-?@-@F=M6.&\XHQ9@T4
MV%-N1*I%RPN'66QD9M\I 9DV*>^XR3@P!'UST(]@[H_!T>CU#IW [:E=[+EH
M&OY["'2K=U BMIFAFA#W3;M]R9&*Q2%;>, QO)+Z$Z2>R9JLFK/:]&)$%G!N
MA646L=U)?2J3Q)HQ(DA6!<;80@!= TKDAT6/2B%[.![+*2B2IX[8S,^#")10
MTV9"T'KF5$B%YKR(\(5*D,4=QF.2ER'&V(L%U:)4AY:&FFEK4E.?,G]A?V+(
MW6.33F1WC:9$?7=05WB12SRJK7H+1HH+,X!55!)( )KQ]?9'Z;.K,MTK*KK&
MS+IEJ55V.U48B @.Q("J3DDX )KXU[.%[+&_,CCF-CL/$)<\D*BP&M":Y<F2
M289MITP-CQ44C+[T\4T^PZ2AMH5(@MO-+E-M)<1G(^PM[%JHTC:<PC6..5I#
MKNHA%BF)$,C,;W:(Y2K"-R=KD$*3@T'LC]-BP072ER[QA1IEJ6+Q@&1 H@R7
M0$%U RH(W 9%<3?LY/LKKJ!;K6S8;K9R<X,"N-Z'ULM!@DR^F,Z/%K32<I(3
MFI*TQW(D3+TA#ZDM*;PYG"<Y/L*^Q<#*#IK@P())@=<U$&&,J6$DH[MS&A4%
M@[X4J"0<"L#V2.FI"$7:$2,4C(TVU(D<'!1#P.LP) *KD@G&,U9/=[O9.L?V
M[MK'H=U/ZH<N]XSV-OH:Y\[ZIZW5?OF],/I"#[!9_@UW^^PT[^]DKZS997?'
M45M6#'Z; *B0&L!(NK-<UTAMJX(2N),7 +#JM$*1:A3G5+R2*C9,91.S-L H
M<IYL79H\?T3[+VA>QST/2+0^C^ENW2*<1SW,S:GJ%Q'I5H2'021273Q-=W8
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M>1@\TR[+>/;UUCG=F4(@D\UZ)])-1Z2"XGETV*SL8/@UG6>21IK@[28HU:-
M5C0[I7W=4M&H!W,4[<^>JZ\SIQ2G%*MHE*TQ7,.)>0KQB8SC#\:-$7E"B\Y3
M:DLQ<Y:4RMO*%QY*L^$S(ZFIDS"9;[Z<9/;_ %#PGO#P_?W@>0Y5A<XYY[6[
M0!RW''9WL=A[2.9YYJY<Q6:<4IQ2G%*<4IQ2JF'_ ,7&_P"NU_WIY7+^2?\
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M&ES;,L2W1,;<=8(V%U*;=!*02LDC$A^@(]0[JT[;&%M(7F-R>,8V9W@F#2-
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M2(-?"::OQHO*@P-B=0%7!)@E7-AB!9R0Y4JCIVX)=[FOPSZ;3(99E5Z$>@3
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MY#3B)\H5]20@*4E*9T-2E9PE*4R6<J4K.>S"4XPO.<YSG.,8QC';G/O8XP?
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M,!+AXW5)%EQKF>U$@!2438X1ANHBRJA;A3!-\\.\$$3(' )C)1T9D:)5C?\
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MF_.1'[5SF9/Z/(/179VCPM]=_P"*G@#'YR;\Y$?M7&3^CR#T4VCPM]=_XJ>
M,?G)OSD1^U<9/Z/(/13:/"WUW_BIX Q^<F_.1'[5QD_H\@]%-H\+?7?^*G@#
M'YR;\Y$?M7&3^CR#T4VCPM]=_P"*G@#'YR;\Y$?M7&3^CR#T4VCPM]=_XJ>
M,?G)OSD1^U<9/Z/(/13:/"WUW_BIX Q^<F_.1'[5QD_H\@]%-H\+?7?^*G@#
M'YR;\Y$?M7&3^CR#T4VCPM]=_P"*G@#'YR;\Y$?M7&3^CR#T4VCPM]=_XJ>
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M,VPT+K@JOX:.FO0))BJM[(WY!MMD(!F+BU",4BHPZ1:K]0))"GGAPFXYL=T
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M9>PTIF2DI3>;;A*<2'<8QC!\AC&,8POLQC&/>QC'O8Q[W/LS1HXSI&E91/\
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M -_#SJ*]G>^,W82?SCX>_P"$=@/(<@*N_,5*G%*<4IQ2G%*<4JIA_P#%QO\
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MQ]3_ %4[V0^%Q/D+OWAQR\!\H]%,/\L?4_U4[V0^%Q/D+OWAQR\!\H]%,/\
M+'U/]5.]D/A<3Y"[]X<<O ?*/13#_+'U/]5.]D/A<3Y"[]X<<O ?*/13#_+'
MU/\ 53O9#X7$^0N_>''+P'RCT4P_RQ]3_53O9#X7$^0N_>''+P'RCT4P_P L
M?4_U4[V0^%Q/D+OWAQR\!\H]%,/\L?4_U4[V0^%Q/D+OWAQR\!\H]%,/\L?4
M_P!5.]D/A<3Y"[]X<<O ?*/13#_+'U/]5.]D/A<3Y"[]X<<O ?*/13#_ "Q]
M3_53O9#X7$^0N_>''+P'RCT4P_RQ]3_53O9#X7$^0N_>''+P'RCT4P_RQ]3_
M %4[V0^%Q/D+OWAQR\!\H]%,/\L?4_U4[V0^%Q/D+OWAQR\!\H]%,/\ +'U/
M]5.]D/A<3Y"[]X<<O ?*/13#_+'U/]5.]D/A<3Y"[]X<<O ?*/13#_+'U/\
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M FM)R]K>IS4H?;!(2YCNH]E+(PU)L[_\UV$C#%?:PUB,4=):$\O$;:OQ1_\
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MYI"'6[M C('$+*(R0/R!X,5/+U+:&R]0F1H<C,G)BF).+AJ6Z^+U#5R8Q<)
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MJO:;;:&X20.)'N48,%C56MEA8[',AXA=9AM0K'*2IQ&596;92XS/+"T94QK
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M9(8;#L%(JA#N*6<-X*JE)BC0++<\^H.OOT=E)87,:&0H#&(HYC('4*%DCBD
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MCY#V T.RWF(4FM/0%U<JS.)Y0[,69M[;F8NDA8MG)8R1QODG.^-&SE5(R;>
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HXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g287237g31e28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g31e28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1U&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '2J^=&8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              V\   ./          $
M                 0             #CP   V\
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   V\     4F=H=&QO;F<   ./
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   -O     %)G:'1L;VYG   #CP    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     CA"24T$#      3%
M  $   "@    F@   >   2#    2^  8  '_V/_M  Q!9&]B95]#30 "_^X
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MN94(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,[+A)S4Y0D-&1U)89G*7P_%%8G."A8:CL[32UO_$ !X! 0 !! ,! 0
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M?%9OEC'&D\8>8GU:KU6#Q6_*R_7IX*:+YI>>^*R_+&.-)XP\Q/JU3JD'BO\
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M7%1TV)W4!E%BJ% I6[H> ] /$^F%+N&TZ_IC\9"_64O%:TBP)#MFGV (YX>
MI!R7C'\JJ)J8>TFN^H:FG!<)U9[-ENY<F,;H8-Y+H.)DL",!)#_)JKF\E;5Q
MA8^]&]+E?.SM A&U;65L;/F&=E[I?Q(+@HV:&[DXD7%0P&*Y:#P#IPYI-,+W
M<MIU_3%X48DZR]XJVDF1&=D4^TAY!Q,%0H(*2>*:/J82TBN^H:FW%<IU9+-F
MNX\%QOE@W91#LR&+'(=/&JDS>2PS.%>#4;U*>G3470-8:MJOWD5P(V/W/--R
M+D&/=#W3S 1,8XB=!R7G?4A$5OIAN)+F/K^F0=7D$?$N+Q8HY\EQOMG*GBQ]
MQDL .3(<=UR7&IBWCMY.H:G/UA"^RWLVED@P$.VX0,.$YWX"DDY5Q_)YZR4M
MQ8N>C8(:W;I 9(&@A+Q<&J\@6/=;E1L 24D58A&@MNCZ=WSB&Z!L=-8>(&X!
M'!8&>UFNNN6$7!XGVO/<B.ZEX:!_482I,F_.R/!&]P5Y8J2:_$-U#:]3OY>,
M(SUB&V,EK%Q'9/5I@P$93;NDR#M0JW/-"6TI[0>K][=N*8G'_& \&H6KFX,P
M>?23/3=&;B ]RA]2XB\ 6_:'.P; BR%[URP(/^B"Y7KH]4X?.WVY_P!IZ[V/
MN_<H+\&]-EU._!'^EFV;J1]3XG*XW8_\'K?9,IVU^(BXEEY:4B0K%QC1BRNS
M#(R\"JQB9#N1R5L)8M\98Y7AG/.Z=H!2%Z=L!E@X '#*W&GFW@@GZ[I\W',8
MX-O="6>+B(7S/$%!C"8VR$D[7(7OU2WU 7$\T'4M0AX(D/&N+5HX)>&X3$,N
MXB0OG?& !N0%N796FB;R66BYF4"HWJ."&0*L,?+5Q5C*2G.364Z*&9F7.9^N
M7H>89,AR<%%$2<1Z0!"^?3#!/;P=?TR;K#%>-!>++!#@J-UQ($ B4[L@D'D&
M/>JRWU,3P7$_4-3AZNH;A7%FT4\V59MMO&7)E8;<$ CNF49YU1.]E4KB]C[T
M+V0J#XK+TC4K:Q;&KSNA_A:$2*_2*,0Z;Z9P"@ '1+?2_4QXU.F$7:VGV0TL
M[HC+UD7BFT7&[U-I]F%E[GUA7OKSYT&I@V;7G4-3&V3A]6-FPO&];W:P;LF/
MNO7[L<F\%5>WHK*"BYT:C>G02BJB01#*MJN)V/Z,5@Z24C07*=FDIT/%,YE#
M\X%41X!TG52/3#)=3VO7],3@*&ZQ)>*EK+G;R@F*$2,-W=  8*MX*2ZF([6"
MZZAJ<G&8KU>*S9[J+&[G/#O!C4[>1).<KX:^DS=2PPPX#5;M)^G#=-P PU>5
M?A&=(*0=#,"18G<#A/I>*B1^>) 35ZQY@\:6^FFXZQ]O:;#U=V3[8NUBXVW=
MW5OE3Q4.WN6&,Y7PU=<:B+<VXZCJ,_6%#9M[1I1#G;W-QAAPF&[FISC#>"ON
M]MQ65C:UP:U;W0NA;@$XR@E'%<;]T<[K=2P+%(B"'-_A BF/1<2\>/'+([ R
M6<EWURP3A[_M:2Y"7C[,>L@*DMNSW&&[KG5TE^([Q+/J=^Y?;]LQVS-9INSZ
M^?< NW'=<CMR*_32VE=V1S6^]NVMS-NF_P .NX-1&MN.A3(I_!I<5C)K=)S^
M8CP3#I%"G*'#F\126!CLTO.N6#[]OVK'<JUXNXD=W %RN,9;NN0(-([_ (EX
M]GU._39N^VI+8K9OM /<3[B&SG"]R,D'P9K3Q%U++K3"(56ZQOI.@NN*LO7E
M6*,GT!U"]##J&6/W>NKT?.02*!!4*=,P"'.ZK[C3C;K;MU[39NL.J8M[L2M#
MN .ZX 4<)%SAB<X((QRJV#41.UPO4=1AZNK-NGM&C6?:2-MN2QXK-C*@ 9!'
MAKYQ]Y+(0LK-!4;TR"*$@#%2%;6:S4CSP*/&*CQ7,=Z!>=P.)3EYHE,'7PRL
MNF&*Y@MNOZ9)Q\^KQ7:O;0XS[/*$ CSCED'M'AJV+4Q+;3W/4-3CX! X$MFR
M7,V<>P1%B9 ,\\$=A\%#7DI:VE9.]*\F*J\%GZ1EKBIK(GP,H7NI6)!?I",Q
MZ/G N*@@)3ICS?INH-,)O#9]?TP%8^)UDWBBS/('8)]F#)S]:%[0>?*AU,"S
M6\ZAJ9W2</JPLV-X.9&]H-V1'RSOW8P1X:I)WHL9$P\L-1O3\)A,Z@1T96UG
MDM&<PB9^9,,BKE,P4-TG-(0YS\XY%"\0YHXATPS3W$'7],BZN0.-->+'!-DD
M9MY"A$H&,D@# (/?I/J8A@MY_L?J<O6%)X,-F9+B' !Q<1AQPF.< $G)!&>5
M:F6N)8F1B(X:Q<9(9<C4X/8F!5?1T;W4OT',EW95B%8G;_YYT4Q3]"A]4'B'
M5ED&GF>*XEZ[I\/5RXX<]T(Y9MB[LVZ%290_K4((W-RJ^?4!!+;Q=2U";K 0
M\2"U,L4.]@N+APP$13USC!VJ">?97Z6MQ4;.G6.]JWJ&4%,/3]&"44K!.D:]
MU<5)@%@3(!/K=012^E=?4>L?ILHM@6LC>]<L% S]JM<@7IQ)P^5OMR<^O'=<
MT[KLJK7X6]6RZG?L3C[:6V8V0RF_NKC< ,>M/<G#]SVUD+!\#\CHX,W[/N9^
M\8\U^V%L=P+-8R/=C8HF-TS!US>E9N0X NB8J@%* \,Q98N$4'$BDWQ1RYB<
M.$XBAN&Y &V5,[9$[48$9-944O%#GARQ[)9(L2H4+<-BO$0'.Z)\;HW['7!'
M*M=D52U!\=ZJ]G>W2/\ @[H>9/WN+\!OULE:T^SW7OR?LUO4X9C5LJ8I3%*L
MDQ]<0'W;)^BY3*CL;R?.*CD[8O?!^@]7O*5)3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*@^.]5>
MSO;I'_!W0\R?O<7X#?K9*UI]GNO?D_9K>IPS&K94Q2F*59)CZX@/NV3]%RF5
M'8WD^<5')VQ>^#]!ZO>4J2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5!\=ZJ]G>W2/^#NAYD_>X
MOP&_6R5K3[/=>_)^S6]3AF-6RIBE,4JR3'UQ ?=LGZ+E,J.QO)\XJ.3MB]\'
MZ#U>\I4E,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4J#X[U5[.]ND?\'=#S)^]Q?@-^MD_?O5K3[/
M=>_)^S6]3AF-6RIBE,4JR3'UQ ?=LGZ+E,J.QO)\XJ.3MB]\'Z#U>\I4E,4I
MBE,4JV34S%5R'EK!.R#6)A(*-?3$Q*OEB-V4;%1C55[(/WBYQ B+5FT06<.%
M3B!4TDSG,(  XK(L[2ZU"[M;"R@ENKR]N(+2TMH4,DUQ=7,JPV\$2+DO+-*Z
M1QH.;.P YFN*K4_HS?) V[NN,TQ#AL2 4LDZC6JA?;178V.I=EFWCE-E$M$C
M-YY[8HA.<=JIMXEQ/0,:D*BJ))/TL.H!<M# DCD,=G,Y([Y[,8\',Y'/E79[
MI3Z4'T6>B?0VYZ87G\'[Y=.LGU+5M#TS4+FXUC3K**-IKJ5A)8PV%VUE$K27
M4=A?7+!5<VW60I-<ILM9(*"?UJ,EY1K'R%QFUZY5VK@XE5FYUM79ZV+QC$H%
M$%'25;J]@F#D,)0!E$NU.=Q(!32K&[K(RJ66)!)(1V(AD2(,?<,DD:>5A75=
MG52@9@#(VQ ?Y3!6?:/=V(S>135D?["JL9L*LZN>OU$KG;ZA<[S Q_<;HS=U
M7*#-42OV9V>1*D+%LNSE-DU%N@R773=OBR"RK-)9)B\,C<(9&@DN N8HY8H7
M;(R))DFDC&W.2"MO*20,#: 2"1FAD02+$3W;H[J,'FL916.<8&#(O(G)SR[#
M4*07+'T)8C3*K":OK6&@;TWUM(7&?TAO&K:[/<G.P%]5DBXO9-FUU$4&>03V
M$W4JKN8@['(PC&1%(7LDW;+HKJ9;Z7>Q[ R0EWA-PL27=G)/PA +G<T$<[3(
M> 1*$>-7*]BD@BH!>6[;CN<*LG"+M!.D>_BF' D>-8V'%!3<K%<XYX()S2@\
MH_2&SYEI7:/L2$FK!(U!YL&(A#%?Q<M.T)C;YZB+W>O1\PSCW=@J(V>MR3%M
M8X5)]#O&RL-,-'B\+9*Y(2L<UA>6Z&2:!TC640,^594F:))A"[(S!)>'(K&-
MRKJ=Z$!XY%6^.ZMY6V)*I<QF4+S#-$':,R*K %DWJ1N4%3W)!PRDR#0[Q5MF
MTFI;%I$H$W3;S78>V5:9!F_CPE*_/L$).)D 8RK5C)LP=L7**_<T@R:O$>?T
M;ANBJ4Q"P30R6\TL$R[)89'BD3*MM=&*LNY2RG# C*D@]XD5?%*DT4<T3;HY
M462-L$;D=0RMA@&&00<$ CO@&LLR*I*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*@^.]5>SO;I'_!W0\R?O<7X#?K9*UI]GNO?D_9K>
MIPS&K94Q2F*59)CZX@/NV3]%RF5'8WD^<5')VQ>^#]!ZO>4J2F*4Q2F*5@FT
M:!$[7UKL#6$\NZ:PFQ*79Z1+.F)RD>MHZTPKV$>.69SE,F5TW0>G6;BH0Z?2
MD)TA#$YQ15N^C6NW71?I%H/26Q2*2]Z/ZQINM6D<X+0R7&F7D-[#',%(8Q/)
M"JR!2&VD[2#@UUJ]&>@0[FJ/*$JEAV3LO7+O4%'N,1: ?UAS83W"WLX*40E6
M,26">P;-E75I$[5)M+.33\@6,346/'&E#E34RP+SYYP/#@@@Y&!SR,#MY <^
M7N>BO37T[W1#5N@6J:?T=Z-](8NEFM:1=Z9P-3CT\:1I,U];26LUV;V&]FFU
M!+=96EM8A86YN65!<"U!9:[!&WN3A5-PW75%UFINX1;O65P=V<[."O.PH!G.
M-'&M]E4%.,2;5FY0#""?)+[#].5;*Q8K3+QK$&KKA4\7*+]!L;6_EM8;F%%B
M87$0CR\,#E"+BWGW$R1.S@B#8(RP4%^(.Z49\Q9[5)Y()&9P89#)A9)%##A3
M1!<*ZA3F7<6 +$+M/(\H8Y6_(U-REGT1),Y^#A)"JZ%W9K*E2$]$NYV1J>P-
MCVC1UCIVS8=^9T#ME,48^I7QFTDW63GDWTRU?1\DU7;+**Y6FZIU ,K([K)>
M6EQ*J,$$D,$=Y'+;N,8*S=97*GN"$(92"!4=U9BX=&W ;()HDR"Q5I6A82 Y
M&"@B(!]=W7(CGG$FGH?-/8Z/VAJB/0I,58>4#<]CI[XV1%UHR%FMVH=G[CM^
MP;-463@ZJBB-F6IED"B1=C=**$K[PZEICVRCN.CV9I3K<IN[>Y)E9+** V<#
M2 QQ75O:Q0QRL,8,8ECXS1@=V/4B=K,:C.G1FWF@[@&Y>87$@4AGAGF>21%.
M>3E'V!_Y)[L#( K30O("._D(61V#L$%[#0-&:ZTWJ795 B4:?LC7TAJ:Z;<=
MT[8<(_Z)Y",YR0U[L"&J]WKY8E>EVY1K:8N8KSRF6(U<2JVM;5=8( (YKR:Z
MN;>9C+;SK<Q6PE@=>Y<H)X&DB?<)8LQLCB6/B$-/#8XDAW)!%#%+&-DL9A>8
MI(I'($I(%=<;'PP92C;1O&Y/^KE-(:-U#IM:<"S*ZLUO3=?GL8, B_3TU2@&
M,&,N,85P[+'C(=Q=U"R*Z<E;"J*)5U2D YM7?7(O+RZNPG#%S<2S\/=NV<5V
M?9NP-VW.,X&<9P*R[6#JUM;V^[?P(8H=^-N[AHJ;MN3C.,XR<=F34O9BU/3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I4'QWJKV=[=(_
MX.Z'F3][B_ ;];)6M/L]U[\G[-;U.&8U;*L7NMTK&NZI/7>YRR$'6*S'+RDQ
M)N"+K @V0  !-NT:).'TC(.UC),XR*CFSJ3EI%PUC8QH[?NF[=62&*2>5(8E
M+R2,%11@9)[Y)("J!DLS$*J@LQ"@D6.Z1HSNP5%&6)[P^<D\@!S)( R36PAQ
MZ(2D]J$3LFJZ4LDGKV&T[2^4!NF2G[5%UFR:NU7?K=;ZO"N(RLIQDXC>KI%L
MZ!=+7:ZH2<K+.)K]?<)QECGI]]#0DGN5T0\5K>2[C6=[J6RM%2-Y([BXABBD
M8-)E3#$QGABBD*.7>0%D2,.ZZ]M2PG%%N_"2$7%P7=4>&-I'0=QW6]U$<CNN
MY0JI@.S$*>027'BX@!#L&;((?BN4S1CL;R?.*SY.V+WP?H/5[RE24Q2F*4Q2
M@B  (B/  ZQ$>P \HXI6UZD<MCDD;)VG(:2H7*)U-;-JQJKMNM2X2X1;V4<N
MX\#&D640=-;N*>?QI4U32+"$=2#R/*@Y,\01!LN*?);WH;TJT[3(]9ONC^J6
MNERA&6\FM)4B5)/8WE!&^!),CAO.L:2;EV,VY<ZBWZ0:)=7CZ?;:K8SWJ%E:
MVCN8WEW(,LJ@-AV49W*A8KM;(!1L2"IR@-*I[8+HH^S*D&X3)I+>#H)1(]I(
MFO"*61 RL:0#*(]- )*2Z0*B05&!>Z"@)!*(Z3J5WU;KG5Y>J]G'V'A<G$9P
MW8<2$(<=C<NVMEQX>+P>*G%]KW#?ZW=ZW.?6]UY.=2;$S4//-57L'*QTPS0D
M9:(6=Q;UL_;(RL!*/(.<C%5VJBJ9'\/,Q[^)E&AC X823)TR=)I.6ZJ9,=D=
M" ZLA*JP#*5)5U#HP! .UT8,I[&4A@2"#4@96&58,,D9!!&5)5AD=]2"".T$
M$'F*N>6U6K'-V:MUI$7%CL,' -P;J.Q7FY9A%(@U1=L&"KD57SA @-TGTK%L
ME%A-T9'<DP;&,"SQN12](Y)#B-'<YQA%9CDAF PH/,JK-CMPK'L!Q0LJC+,%
M'A) ':!VGW2!Y2/#5\RRJUIR.VBCI=DFY;G>-46[ART(LF9TW0>&<$:+KMRF
M%5%%T=HZ*W44(4BYFS@J1C"BH!:X. <'!) ..1(QD ]A(R,^#(\-4R,D9&1C
M([XSV9'NX./)6HRE5IBE,4IBE,4IBE,4IBE,4K:]RHN6!I7D?5VKVC=<G.QD
M3;YMS7X52!K[VP+*R31B>16(N@R$#MT@:IF,54_TIC@! ZQRA( R:^E>AIZ$
MW3+T6=0U+3.AMK975WI-G'?WBWM_!8(MO+.+=&1Y^YD;BL 47F <]F:V5_W[
MWD$\/59L3V/!M.\?S\/RY;O'@/YODSFOL7^)CZ.?^J=!_P!XK#Z:?W[WD$_;
M9L/_ +MIWJ]GK];V<;QX#^;Z?W'/LI_B8^CG_JG0?]XK#Z:?W[WD$_;9L/V?
M!K._O^?$,;QX#V9Y8/+W<'E3_$Q]'/\ U3H/^\5A]-7NM>C.\ANV6.OU6&M-
M_5E[--Q->BDU]=S;=%22FG[>-8D67./,12.Z=(E45/\ 2ID$3FZ@RNX> _F\
M&?#X#6'J/I0/1KTK3[_5+S2M#6TTVRNM0NF3I!8R.MM9P27,[(BG<[+%&Y5%
MYL0%',URM9=75^F*4Q2F*4Q2F*5!\=ZJ]G>W2/\ @[H>9/WN+\!OULE:T^SW
M7OR?LUO4X9C5LJBW;FF-=[SKC"I[,B92:@8NQ0]L8-8FWW*F.&]BKRQG4'*!
M*4BP5R5.M$O3$D&":KT[=M)MV<DDB5^Q9N$,BVNI[.1I+=E1VC>)BT44H,;C
M#KMF21<,.Y;EDJ2N<$@QR11S +("P5@XPS+AE.58%2#E3S!SR/,<Q6V".]#O
MT;#5FCTN&L.VHVH5>F0^M[772WKTP9;EU[7KK.;!@J9MMS-1,G*S<)%V>T6=
M5 M>D:L^5A;'.5-V]<U.17A#; ZW>-)-*R6S2R2M/$_!VFUG>)('EM@K*J.T
M<<8/$60!XTE4"50]8OV/@PJAI@@01NG%+":,2-*$E+AF8!V;FK*Q5F0L4.VM
MZTO]<0'W;)^BY3-0.QO)\XK*D[8O?!^@]7O*5)3%*8I3%*B3?U(L^S-%[EUS
M2; -4N-]U9?J=5;,"SAOZ06*RU:5AX:7%PT_A;<L?(/&[DSAK_"D"IBJW^K$
M)FUT*]MM-UO2-0O8.M6=CJ=A>75MA6X]O;744TT.UNY8R1HRA6[EB<-W)-8.
MIV\UYIU_:6\O N+FRNK>"?)'!FF@>..3*]T-CLK97F,<N==$CDB^A3^B$LN6
M1JB(DM'[)U(GK7:M0M%FVU,QYHZDUV(JEBCYB0F:W=4UAK]Q>&;-#)Q$?5)*
M86D7:Z*2I$68/7#;N[TK]%#H"_1'5)8M;T[53J.EW=M;:5"_$O;B6ZMY(HX;
MFR*BXLT#.#-)=1Q+&JDJ6?8K=:M!Z#=*X^D%@'T^ZL5M+Z&>:_?"V\<=O*LC
MO%,K%)F95VQK$SEV8 X3>R]R&4Y,^P(O;_*>Y05*F52[.NJ%>/HN)?;<VK Z
ML3EHK2L/KPDAMS6E=>)TFPE865![)HN'U:M,L>+:QIF3Z.?MV(1W25;^%K;3
M[*5?M>'B"\86UN]P4:[:<K;3NIEC+1X7N9(U#%LAE+;NRQMY5DNYHV'$EV&
M&201JRPK%F6,=PP##=C:Q( YJ<$?'D1<E?:/)&1OFOY[9%:VCK2SFK]UA)9A
M6Y>DS\/LP\:2 V4M(5^0M%[;R*.QC1$)LB<L3>S,5Y'9<WL&7>5]-2Q [&[5
M]1M]3,,Z026]Q'OB=6D69&M]V^W"R".$KU?<]ND9C(6W2!%?$>*LL+.2R#Q<
M1986".IVE'$Q!$S%<L#Q2%E9MP)F:5BO=Y&U?2N@.5Q=-+5V>):Y_7[^:U'5
MXJRUZX;MW2M:-L6&.W;0KK)C:33, $IH)ZZU35;_ *C&:HH3\VHUVN>362Z"
MBUU-YGW=[ID5U(G"CG5;IWC>*TM!';QM9S1#A[7VW@%S)#<[)MB9MMN<SR;<
M2UM[Y[>%FD>-N @D62:9GE?K$<C%RZ[H3P4DARFXCC\NYB3-ZLW(:Y0%FNB5
M]+8H6'EXF*Y1L54$EMS;2LCNHQ6U-@\DJPTN 93<G"H.G$5%UW4NVV<LV4;E
M:,GTW6DF#5^D8KR M35[)(N#PW96-BTI%K;QB5K:'4TE=D5R S/=6Q4YRP23
M<5['OZC<ES(9 K!KC8#/,Y1)9K*14#,N<!8)@5P "Z@9!.W((_D;\J5>RR[B
MV;TN<U%2NU:O/6%RWWU;XJ+N=&:\H6"V-)MV]+@M;0,K096+U5'/]<QT9 [-
M=PKV-E9"K2*;R%3@YB&C.J:<$ CLXE86TL: V<;M%,;%X$8RO<.LRM<LLS,]
MN'#(LBX<NK7FSNR1FY<^KQNWJS*K1BZ$KKM2)64\$&, 2%6#%&RN")MY(W)C
MV1IF]W6_;2L#2T6"SZ<TYK<)HEUM]ME'3O6]QW<]<GE%;*@W[H1+4K=KF/82
MBQG,H[>Q<\=X*2RSE_-XFI7\%U#%#;H8TCNKN?:8HHE"W$5F %$9./58IV91
MA0&3&0 J9%K;20NSR.'9H88R=[L28WG8DEQSRLB $]T2K9QVG?QFGK-IBE,4
MIBE,4IBE,4IBE,4KKX?1"?V$.3]]]>=_4]UEC]@\OTUWU](1]VG3S\5K'^UX
M:ZH_7U=?9V<>/B\0</\ 5D?;W\>#G] P,8'@[/)CU#I\_'U_ZNKY\.IR\OPX
MR.^/W_/2J93X?^/[^[2I8T-]G32P>3;6N.SCQ]6,+[OB]GK'APR[X .1]T^M
MYY_?D2?!BN+=.?N)Z8_BITB[>S^)[SMKT<,FK\^%,4IBE,4IBE,4J#X[U5[.
M]ND?\'=#S)^]Q?@-^MDK6GV>Z]^3]FMZT=IWP> GI.!A=,[OO7I([[AEYFOU
M6OUZ!0< W1=']*9':%NUYWY-4D7"7/D:&C:8SNCI6!'AY!LZ:(WQV>]%=[JT
MAW@E5>5I'QG'=K;QSF(DYPLW#; W8VD$Y;3[68"&9]I )"!5SC/<F5H]X QS
MCW DX!)# 2G2[='WJMQ]GC(ZS1+20,\3".N%5L-+L+1=@]<1SM)[7[/'1<J@
M0'3586;T&QXV79"WEH5[(P[UB_<X\L30R-&S1L5P=T4B2H0RAAAXV92<$;ES
MN1LHX5U91)&XD0.H< YY.C1L,$J<JX##F#@XPPPRDJ03E.1U?452FO81/8,+
ML$).YC-*R)&AHP]^NAZ85,*_(,.D2H1YT:8DYZ%,%.ZDX,KCNLRC[I.[5#+C
M4=C>3YQ4;]L?O@'_ /%_WSVU*N4J2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2NOA]$*?8/Y/WWUY[]3W66/V?#\QKOKZ0C[M.GGXK6
M/]KQ5U1^/5P'Y^+M\G#\P9'V][O#\WN =F.WY?#ZAU3\'S]SY^/';\/[][_Y
M^=51'B/C\?Y?'^;C@^YV<\#/9W^_^_EY$JE?0O5O32WWVM<>7[<8;]G7U>7
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M$3BK,P9@F5QWJKV=[=(_X.Z'G%OO<7X#?K9*Y ?9[KWY/V:WKC$V-J+5^_\
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M]$*?8/Y/WWUY[]3W66/V#R_,:[Z^D(^[3IY^*UC_ &O#75']D>'D\GN<./\
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MMN@?^Z6@_P#L*_7]V'RM.OARG^4%U=G'<FP_+QX^J$./9X_+P];*GW,>7O\
M?[>0SV9[/<[33_DD]"O_ +MN@?\ NEH/_L*?W8?*T[!Y3W*"\0_9DV'XO8L(
M\.(=7L]8]H\:?O\ N,?F^:G_ "2>A7_W;= _]TM!_P#853^["Y6O_2>Y0?\
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MY!I(%0.<#"0JQFBRH)&.!3"0IQ*)@*80 0 <5BW-E>6107EI=6AD!,8N;>6
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M=X(!VQ# '<X))I':WB7LEP^ISRVS;ME@UO9K#'D +B=(%NFV$$C?,V23NR
M/,]Y2FU+*RY1O* : VA' -MV;5;E569.04,"-ZGDP4,"+]%/GG O.,!2 3G"
M/-(4O  [>:1Z G0;4-)TJ^EGZ0I+>Z=8WDRQ:G;"-7NK:*:145].=@@:0A07
M8A<98G)KGL'^$@],-T:ABZ.6%GZ'$EAH$2:)8O<]&M7>Y:TTI!86SW$D?2:&
M.2<PP(TK)%&C2;F6-%(40F&W+,!1#N*!$1[#"R> 8O7QZN;(@4?_ 'BF'-B?
M2\] <C[8Z28&.7V3M0#C';_S:2/#RYY_-+_E._3(X/VCZ&6>\?X+ZUR^#^%7
M>[U/"Y9>: =Q0'$!_P ON)X)O8X#)"3AXO\ ([/'E1Z7GH'N_P"L])2.7(ZI
M:#M&1_V;\_/W.5/\IWZ9'&!8^AD#X?X,:U\G\*J#MRS"  #*! 0[3 R><3>S
MQDA+_1*7'^+ST"!YW'20@\P/LI:C&3GGC3,GRG.1SJA_PG7ID2 !8^AD".T_
MP7UDD_'TIP/#R'?KM>_0WTA<+[2.4Q((VQ2IM(2^:L![$P<'".FT\DI$6M=1
M)^XGVDN_:<Y-$[8#Q;EB8J:ZAP$5RIJ)_%/17Z%=&?0]FTJTTRSN]0.K6M[*
MUQJNH3/+:R6[0Q1FW6R2RB9<S%V6=)LLJCN5)4\8Z0^F(]$WTR5Q8:KTYN]"
MTR3HEOL[.WZ,Z,;.&\M]2>*XN1?'4[W5YRV;-(XGMI;;8CR9#N49.S@K 64]
MJ2FT[W+(P!!(*E,+"U@\8J!60MS :64B#6$@*.1"0'F2A1!8 1*)6O%$?CBW
M5F+%K8Z9 UT<XU W%X)ES)O&(!.+0X3U+G"<KW1[ONJTK6MX;Y;D:G.MJ,9T
MX6]F86Q'L.9S ;L9?U7E,,-W([CN:K&0%D9V&1E7][EI>&=E=@RJ[F&K+5A%
MF7<)*MSH2+"(;3;D62)%&R0/9!<%B+'4<@JL1,Y$UU9R6D4$6F06]PG#XEZE
MQ>/+-M1E?=#+.]LG$8AVX<2[2H";5)!0VMY'=S3RZG/<6TF_AV+V]FD4&YU9
M"DT4"7+\-047BRON#$ON8 C20U9MD>UG4)+9$W/.)-J*$2]=P%09*UQP*;HH
M/&247!LV[]4#K(*=%+I/6XF9IE%+F*N"J7W%Y8RO;-#I%O:K"X:>..ZOY%NT
MRA,<C37$CQ*0KKN@:-\2$[LJI%EM9W\4=TL^KW%T\R;8))+6PB:S;#CB1K!;
M1I*<LC;;A9%S&!C#/G8SZ)*TL]3]#EY7B\A<W]KE&VK)R1;2<K#UY@=)LBI%
MB>+%I!1L8T4;+@BX*=P9+NX@/512<IF1;BER/HII^D]*.F.@:1-I_4-/U&[2
MRNHK.ZN6D(D$OJ\<UV]RR2J2A5<-%ZF-T;!G!SM'Z7])/0NEAZ<Z+?V^H](.
MB]U'K6ER:O80267&MC'MM[JTL38F:W<<0/MFBF]4.V9=J8\\0=OVCF@7N6#
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M[O=>M8]%U*/I'I4VH6SPV[K>K<0I97^ER0W#2QX;U5X=C$+$IPPZ@@[@M F
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M0M+%)&L@4O&Z@J?3%/6+::LI0Y=DS9)PCP7"EN" IXR*S83J&!@:+-!# D1
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M:K+%*]^M[>,)";%(+9)+=E97"0G>S2 RJPN6 A4':RG57<\D<SA)61T6U:"
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MSC[8M.5?>?0=!%EK>01FZL\9]R&;/Q9'QUVE>D3_ )0G](O[\ZS5]FITB?\
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MCZ>WL]P=\4P? ?B-3-R<8V1+RAM"F,P>E*7=&K3&,+1< *4+S!"(B(I@
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M#JZ@\F*4  #CP  XCQ'@'#B/E'RCU!U^MBE5Q2F*4Q2F*53@'$#< X@ @ \
MX@ \.( /: #P#B'CX!BE.:7J^E#JX\.H.KCV\/)Q\?#MQ2@E*/$1* B/ !X@
M'6!1$0 ?+P$1$./8(CPQ2G .OJ#K[>KMZN'7Y>H #K\0<,4H
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MOQ&9DPZ; .&$:8M<9SE6;8J!0&KE%SC];2F*4Q2F*4Q2F*5!\=ZJ]G>W2/\
M@[H>9/WN+\!OULE:T^SW7OR?LUO4X9C5LJ8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I4?QEX9'L%VAYJ2A(PM=G(Z.C2N'B+-RX9NZM 32B[@KIU]5.#
MV4=HD41322!%)-,2&5(HH>5HSLC90QWJQ. 2 0[+@8'@ /:>WX*QEN%,MQ&[
M1H(G15RP4D-%'(2<GGW3D#  P!W\FLL9SD)(K"WCYB+?+@0R@H,Y!HZ6!,HE
M R@I(+'.!"B8H&/S>: F* B B'&,JP[5(\H(^6IED1CA71CVX5@3CPX!K9-R
MH>6XCR7-IZSJ-HU%=9[6MO@YJ>N6WH5I8WL11D(T'R39BVC8:G3K&PS*[YLP
M:+0;VRU>9>+V.M,*?'W&=E20J>WT_2#J-M<2QW,27$3JD5JQC#S%MI)+/,C(
M@4L0ZQRH!'(96B1=YPKN_%I+$CPR&)U+/.H8K'S( PJ,"Q..Y+(S;E6,2.0M
M9<3EB4&M\G&D\H39O<D<WO<O"UJ"INII!;?$W*WBW3[B%JFLZP;74?(!<K^J
MN5*+G8VN(/(N*L#2=;DEG4/$GFE8OL7/)?36-OEC"CR/+<@6:+#%&'EN).L,
MO"A RR-(0S(4.T,VP7F]CCMH[B?N.(R((XLW#&21MJ1((E)>0G 94!"L&YE5
MW5 ^KO1'(7?O*PU9H?2M!L$QKFTZ:O\ M2^;*MU8V#4)6I2E,O,]K%S1#5N1
MJ":$3/P-]K,O7;>%NDX,C.4(G$QW=<@=JF^SKG07LM-N;R\F1+B.[@MH((I;
M>5)5FA2Y$_$64EHWAD1XC$KY7NFPN2,:'5%N;R"WMXV:&2WFF>:1)HV1HI3"
MT.QHP%=9%8.)&4J1@ G&8^UEZ*E#S=CY4LCM6GU"BZGY,^R+5K.3D:A9MF[+
MV[(RL7OEAHFK2CW6<?I.)@RQ=LEGI9%-O4-@W:P1XJ-&!X-R=959O+<='71-
M.6WEEFN=0MX[A5ECM[>V"M9M>2*+AKQGW1JI4F6"%&P6W@8S;%JZ$W;S(L4-
MK++$60SRRL4N1; \-;95.]R#MCEE9=P!%?7E ^B_:'UIHBV;&UK [&OFRHFG
M;5L;35LKJC:$+)5)WJ.XH:\M1-UE2JZ[S4T,SO3IK61F+,DT:JOW*9TE>XDW
M3MLLNC%Y/>QP7#P0V[2VR&Y6YMG6474)N(^J9D N7, ,FR/)"@C&XJIMN=;M
MHH&DB6624)*PB:"92G!EX#F?"'@J)<IN? )!.=H)$Y3GHF_)*K=AO4!.6>\Q
MZ-%3V.D-L6U3L7O$NTYJ"88UW9]2UE<BUT8*_P!KI-AD6T)-0U==NUB/P=D;
M'<I1TBLTQ$Z/ZF\<,B1PMQC;^IBYM^-"EVK/;2W$7$WP13(I='D !7!.-RYG
M.KV*M(I>3U/C#?P)N&[6[*LR12;-DCQLP5E1B=P([0<86KZ+CR,6 5$E@L6Q
M:LYMUIM=7(SGM571%:N%I.P$M46.SV]9E&OV,!3&.R3KTT+*Y=G8KS$9-] )
MV<'+NV4@Z-:JW$X<<$@CCCDRES"1)Q8#=1QQ!G5I)FM\2\,#<%9,X9U!M.LV
M"[=SRKN9U.8)>X$<RV[O(0I"1B9N'O8A20Q!(4D90X]%&Y(4=/;(@)RT7VNG
MU@CMXTS,3FI-CLJW8'^C+_&:RV5 Z^GRUQ:-V'8H.WSU:C"0E/7EW[Y:RPS=
MHDJ^5=,VE@Z.ZHR6[I%"_63:[$2ZMS)&MY UQ;O.G$W01O%'(V^4*JB-RQ P
M37[,6(:96>5>#Q][-!,$9K:58)DC;81*ZRNB[8RQ8NH7)R!J6GHFO)87B[0]
M>R6Q:[*46D[YO=\IMMU=<JI>J1&<G" U]:MF1UHJ<_&Q\M&3J%9VG19^O1YD
M3ELD7.H.HIPL5-8$Z'H]J0:,!8'6:6RAAECN8I(9FOWGCMS'*C,C(9+::-V!
M]39"& R,W?9:RPQ+R*42ZDD1X9$D1;-8GGWHRAE*I-$R@C+JX*9!J9=1\KW3
M&\=L;(TWKEW;I>U:HC81_=9!S1[-&5".<3T37IUG!I6U_'H0KJP%B;3"/SQ*
M3D7"S5PY78]V)1DH=GB76F7=G;6]U.(ECN2XA431M*P1Y$+F)6+A-T3C=C (
M ;:64&>&]@N)IH(B[/!@2$QNJ LJ.%$C*%9MLBG )[^,X.-QCV;AHU4B,C+Q
MD>LH0%2(O7[5JJ=,3&*"A$UU4SF()B'*!P 2\XI@X\2B 8 5CV*3Y 3\E9+.
MBG#.JD\P&8 X\/,BM'WV58>RRP'XYCO[3E=C^*WFGZ*MXT7ML?GK]-:"DV)6
MT0SJ45%F8I++<8ELHP$QFRS" MDS!QS@IQ67!11PQCVZRZJ:@(JK***(II)&
M(F2Z1 C!1GFD;'/:"Z*Q'P$\N_C&?#5L$IE1G.WE+,@*]A6.5XU/:<DJH)(Y
M$GD *R[(ZFIBE,4IBE,4J#X[U5[.]ND?\'=#S)^]Q?@-^MDK6GV>Z]^3]FMZ
MG#,:ME3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*L+VJUB2<J/)&N0,@
M\5 H*NWL/'NG*H$(5,@*+KMU%3@1,A$R@8X\TA2E#@4H %P=P,!V '8 Q ^(
M&HVBB8[FCC8GM+(I)QV<R":^D?6Z[$KBZBH"%C'(IF1%Q'Q3%DN*)Q*8Z0K-
MD$E!3,8A#&()N:82%$0$2AP%W889F(\!8D?$355BC0Y2-%.,95%4X\&0 <5&
M>WM#T'>H5=CLM*6G:Q5GDS*ITDLCW'5IN<DX5S QT[86K9!.1DI&I-)"4>5
M"RC=A"S[Y&T@R<66!JLM Y%M>36?$-N522150R[<R(BN'9$).%64JJR]R2Z
MQY$;R*]DT$<^P2 LJ$L$SA2Q4J&([25#$ISPK88#<JD04T]#^Y/K'D_Q7)T9
MDV"RJM>V PVQ6[A'7^=BMH5K9T/+$EX.]0%WBE&3V,GH55)%DQ%NW+'GC"'8
M/F#Q%R\!SFG6[XWK7Q,!ED@:VDB:"-K>2W==KPR0L"K(P.3GN@V"I! QC_8Z
MVZNMMB01K*LR,)7$J2JP9724$.K C P1W)*]A(K*](<BW1O)[M4-=-<1]H0L
M41K6PZQ5D[!;)>T/9^,M^T)/<ENL=GD)M5Y)SMTLVQ)F5GYBQ/7IUG"C]9LF
MBBV*BDE%>:M>7T;Q7#1F-IX[@*D21JC16ZVD4<:H J11P*J)&JX 4'MSF^WL
M;>U*&)6#)')&&:1W9A++QY&<NQ+.\N79R<DD][E4=L?0[=*,?"E'C<MY/:;M
MO8JNU[#K61VE).]<Q5^<;JK^_'5BJM6.R!K!/G5_KC51PJBHJ=2&>RL6)^8^
M.J6=M<O&ZLW#M!+:P"VCG6V03M MH]D(Y)<[G40.0,]C!6'9BHOL;;8E7,Y2
M:0S/&9Y&CXAG6Y+JA8JAXJANY [2.PD5B&S?0JN2GM8]M5GR[9AU[\YW$:\K
M4O;%JIXW&)W?<F^P[A5;.A!N&K2=J;2[M&ED@(&3;N6;!X@+9T60C'3YBZEM
M^D>IVPC"&W<0BUX/&MHI>"UG";>*2(N"8Y#"3&[J02#D;6 862Z192LS,LH+
M<4/PYY8^(LTO'=)-C+O3B]V$;(!R!R)%87OGT)W2^S:IN1K0;1=:-;]E$O#N
MKDL5KN%YU5JN=VQ=8&[;EF*#JI:RQ$/6Y#;;R'=L[6_C':*[5.>F%89-HW?2
M$<_FLNDMW;RVIGCAFBM^")-D4,-S<I:PO#:)/<B)GD6V#@QA@<[$W$E598;C
M1;:5)A$TD3R\5EW22R0Q//(LL[1PF0)&9F4[V3:>[?':0;'K#T(W5$?4-.([
MON]HV'L72R]AC*G:Z,Z?:OB6FM96Z=_$-J%Q",'\JK,U"KR_2+L922?=]*SB
M0EQ2E8^.D!BD;KCI-<F2ZZG#%!;W0C:2*95N&-PL/!>Z5V51'+*N-RHHC 5
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M#R-9+1QN<O&CG&,LBL<=N,D$XR3R]VK?WCTK[3ZO[WXG^R97B2>V/YS?35O
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M+]2J^%N@^>70!Y1K]E /PC#@'L>7Q<<<&3Q1YZ?6JO7+?QS^3E^I0-M4 ?\
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>OU^3_P!FI_HY<?6+Y?IJY/7#X?D-9EEE34Q2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g287237g32s77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g32s77.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1\84&AO=&]S:&]P(#,N,  X0DE-! 0
M    'OR^>3(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              JL   40          $
M                 0             %$    JL
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   JL     4F=H=&QO;F<   40
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *K     %)G:'1L;VYG   %$     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     CA"24T$#      4Y@
M  $   "@    5    >   )V    4R@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M0.Q3+'..LHD=-7__T>PS/2K^O.):ZRMH.#8Y^\C<-KC]'U;6;&;=[OT%-O\
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MX\O'Q ^D"N$]^)X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@H.%B)68I*7_Q  = 0$  @$% 0               0(#! 8'" D%_\0 8A$
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MM,-<6EE>2-P)&H4:]VJ4>Q[1Y,/X^O6)\DP<+1<D@WHD$G-,%+:U :@>JYD
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MGR$OC.T>O;F*LV1/9&]1J-T4-&*%QZJ9U'>Y%UAR Z4(@H+LKQ+U?N(D455
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M)((WU$B(T@@:G2OI]K'&&)<#\'W6/X4W:O73-U:LI:NT*6R4W#H;42$+;6%
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MY8ZZA$F)'BZ7Q<<N,'91:(QAA+[3C[CEN%-%T(>M;9ZY4N E124L-O$$)))
M$:FN7NQS"^T+$<8XB>[->(W>',>PWA==U<.,XDC"U8GAUSQ%P[A)POTIYUFW
M2EW$L1PRX4+AU#1%L8/>EL% YG(?9U1,(K'R4-2G43-^Z$6WCHG&T].K32QV
M^(* X:,6D=7W\A)/7K:V8AKS$C9-5Z\0-"D:BH2(<G9:4KX9#*D!%NIM ?0J
MU[LK)"UVS"PAI*5*"U*7:H!0,Y_)P#ETW18X7\H2XQ5;MMBF.V^(H-A?.W3O
M$%O9IMI7CN-6UQ=WC]XS9MM!RVX@Q!:WW0VT3=*<(+HS)RIDOLPY2J,9EC!P
M5=9O3EQ9!3[7$MKA7\)]<Z+EG[1XS<2-,(G&L)5O<YU9E:WR)HI%Q-3S9)V8
M5Y- _P XO<(%IA]M#;!4RYA[*DV[B7$-WH4H H4T02OTA2T.NHB7CZ\*4*W1
M^+ORH48G=V=S=8OBCH6KBV_LE\38=B=I>/<-NV33W>=UB3@??M_P=AS;EBTY
MWP[BT*F@MMHCQ,40>P7'N&<J7:AU=_F=';W&S^2IR3N5,&,MKIK-L7S10U<4
ME:O4(!_#RI\?2<2R6AV'N(61KSI?TII<KATK=EKAVSLKMQEA%VWAW>2%MC.E
M%\6FGEG\FTE:/53E5E,PH9C$UKN)\1^4#Q7QEPO@F.XO^*@[3;W#N%,/9PO$
M@O!UFT=M+ONL33;WM_<EZT9XH:O'S=/&Z;M+U#24]V0TE0_KM]FE)+2:CR-Q
MN53'<V=ZD]=8ZF2ILINEUU-D7W#=F@"H3Y&T5B;W%A21*KYE,JX[+&Q9'SJ"
M02+J$8CPBZX<B+,K;4M3P5;92E;00 E)* %*";<$9<X)8]7,4 #;(X=^4KA=
MLTRQ>\5,VO$&%^CI::QQ"T/X3C%T_=NIO6D72G&&G'N*7;NX<?[IRU:XA"WR
MTFZ7F\^,LG9UWJ[Q>)JABBB724O.5W-4LS=G1@CV3"SQ-8RS8/=U^>99QH3\
M(#FIY%JWI8()1@G,O9B)<)D;J/"'RLN8'<7EK:6EG;J<7<N9B&%-]TJT2^4]
MX2$YDDH?;(!4@^N@_I ZB]1\HKAW#'.*\=XKXDPA&$<*M7>&7#F-"\?<PF^O
M<&MQ:-N6[[Z;5:DWN%7Z$W7=/ACT9YL:I6E<$]]=/C;!3F+O']HBL=6U]D2,
MB\H.WE5:UB-:8Q6NJ$Y,R,4,X2RH5Y!"@R;M[-(PRD3"LY.LEDG39>8(@CF/
M$EJ%V>9IP,7;=ZXE\%!0VW9.73;BB,X44'T8%"DI( <0%E)4!6S/U$L==L\?
M=1B^'/\ $.#V_#5X_P -)9OU8C=/\4M8*[9V+5VFU<L3B;@X@LU(MW7VUW/=
M7Q82OT1V'';?,ZUO<7C.$RI4F$I%P,](VR/:1\\W(SFT!J=MFZDY5?LB*K"R
M,[<PIWB+1<Q7:#9TBF[21<D623^CA6)6^+V+5];!8:=4ZD!Q.18+3BFR"DF1
MJE6^NTA),#9?:+P%C'9GQ;>\'XX[:/XC8V>#WCC]@XIZS<1C&#V.,M=P\4I#
MR6V,08:4X@%"W$N%LJ1E453M%;KUPK\O5;9!P]FK-@8.8F=KU@C6<Q"346\2
M.B\CI6)D$7#&28ND3&3<,W;=9!=,3$53,01#7T#J#Y5LCX^/C[*J7;'H3<F]
M[2I,:WM<H+.@5C.UV:WB]4?:_M;@=O.+L95UQN,J98_$&X+'7I+\_NJ\6CM_
M]:8/I1]=G%JE,GUZVP->@H=-LCE9([E9)@D'8G4Z["=021R.FLQK1WU%I$:D
M)@Q, CP\]SIL.<"W<4.Z4I0\ * !\P<>?7Z=8Z@" !X>5<Z5-1O;J)!"-WR=
MFR^>'*BT8V#=HX<+G,'<2;H[;YM5=94>?XFFBF0QU#FX*4A3&$0 -5*T@Y=2
MK30#J8Y\@-3YCQJIF"I0(2DSF'K3 G4 $B=?=6PH=J9L <MD73;=!CAR@X2(
MNW6;+3;A!PBL4#H*METH8Z+A%=,Q%$ED3G25(<ITCG*8HC\)?%7#3:G$.8_@
M[;C*U-NH7B-HA;:T$I*5I4Z"E0(B% :U]YOACB1U#:VL#Q-274)=039OIS-K
M 4E8S(!2"DA0S 2E04-"#38=M/:-;*ZM-;GE[%G^G1"%NW0W.V5M5ZA8$4YF
MMOJ!C./:3<>8T+_',:Y>P\HU1<%  .LQ<E !]$(C'XV<+Z#\8L%$IS:XE:;'
M8_LLB1&AUFH5PWQ"D C L5(DI)]">T(.4_H3OMIK4A.$]W^V_<9.3]<PIERH
MY$FJO&L9F>BX)P\"0C8F2<KLV4BX9OV;-?U)=VU<MB.4B*H^G0.D8Y#\%U]&
MPQ.PQ1+CF&WMI?LLJ2AQVTN6;A*'% E*%%I:PDE()$P3!T&DZ&]PZ^PXMB_M
M7K13P4II-PGNUK2@A*E!"H5E"C$Q!TUUBJ1W;2F#[*%ND/XIBGA,>0X$P<8)
MQP \E\0+P/41X 0\!'7=_P"3^0>!KB""?P_?ICH1;6&AZ]=.7C('$?&OYRMN
M4VB8)T!_*.Q!, @Z#0F/HJ, _'>XY#Q @!R CR <<\!SP <<#[!Y\N-<X5LW
M8;$:%1G4:DZ@C2.E.DV+& N^+9EP(?=38-[W>^#P7W_1 B(=[CD>2]W@/'GI
MX#KCKM9 5V><420D)LFW"20!^2N[9R"3$%66!YCF0*W!PQ^>K0;?/@Q.N6 (
M@G68D?;5C[ZI=4#ZRNT40Z\;A;'T\1'G#UX /#S$#<].?#V:\X>)-<.!$"'D
M[>?3KK.W336OF_*(;*^S:\2085B>&))V BX*Y*B0!JB #OKTJI(8W>,) ^W
M1Y#D/#H <!X] #D>?FZ==;!D_2>70^)']^HT%=!0D90X20@I "@DJ$Y2O<:;
MJ@$$B!XQ0!@#OE+X@)_M@$.\4$S> @ AS\(>GQ>S4U52"$(4L>H4M$E&4Y5J
M?2 #J-/5&IZ^^[1A)0 ^IY8$H" D^QMV3NG^+ZT,UU$ Y'Y_#C@.?(.5K&3:
MVJ8U+*('701[](ZS&\3ZN8.E:<&PI+B%!?X+P\J2CUS*K5J F"9,08TWVK3(
M_HR9CQR!F3(1#K\'ALF4?B'P ?Q" #QK4Y"=2%")!Z@[Q/AKY \MJ^L$@I"Y
M7E!_* ,NJ4@#>0$'43S@>(G3/YZ]?F\@\^H"/Q" ?DY#G5,HF)R]5*(2D[0
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MM[53ZD%980'0C/D"UQ)^@-71T$4P?'(JFH<RBQ44^52B102E'C@P=WKR(F,
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MN9L=5F#;:IV3+8FF-,;2"Q(4,IU9N-;".D(=5B9 72R#[W2,3U\#-@;]_P!
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M-/T92@ \]TH@/3CO"/=Z\<CW>.[T#J  /'QZ^^=3/G'@"9BN%PF !.P'A)
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M=+L5 3;XMF8_!#C=+@T>JA/+($,(^)@Y^( ZB/ !U$ UQSVM_O=\3?Z+:_\
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M':/Q%\V?Q4N1NE6GX8PHF #,P-"#H>1U%=:OE1D*X%P;>1Q7:'4*'_9.,<R
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MU7^!+QP$9'<" AU#@41Z<"(" \AY>&N[/H=I$>BV\?S*/'^+_?[JXQ]/O_\
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MG]G,F3(E1$:S'.=!.QVJ'YRO<C#&VD0$C;?3EI/AK5LPOVI? /@AT#CCP\N
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M20-)!!,'':PY K.5.T-W$Y!IRLNM7IQ/$1&!IZL6>FRX^Y>&J#&NO6ZS<H>
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MPTE7=CT7%L#NGBXX $Y;>Q>[U>QU[M;:-W"F0HRQ>L7+H:91<@D2KOF7VD!
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MF'%@"":^C:78+KD;\. 5.51<JAFJH$$4O1]X14(*I2GX. E(<2F4 # 0#"'
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MR,0N6%/?,4%Y H()&8C,@+YR1<-,6MH'0[^480E/=,//ZI:23G#*%E($C4@
MB>A(HBU!ZR+7(-LIW_2LX5(Y@%(RZ8%013*MW%6YW"*PB4Q!2*F8_I0Y%$52
ME'CA/B/@_',#>6]?C#"S=8@;9IRTQ[ \04MYU2UH*V;&_>N&6SE5F>?89:;4
M E:DJ*0?-OM PC$[7BG'[U1M.XOL;O$,FWQ'#UO95/+4V'[5#QN;;20X;A"
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M]RD54A/X_./Y"ZV%703F/Y(YQ^DJN4_M@_L@_(;2JK^:K^2?J/7^ZKM&#?\
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M5T4 . Y !X$!#D/ ?#GGP#CGQ'RYU"MCY=8I$QYZ>XU3TVB3V \K=IK07,%
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MC7:9)'NUJJE0H= TM1D1JD$Z&0.6YDG8GHON)-UN3K]EZI;?Y6'IK7*]0O\
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M4LX56JT^*M]SD$F\F=\:-K:[<'H**%4&CJ5?DFT:I*&UK,ZCU4E0(G34Z'J
M/&B"%J>48!#KJ$#3]%:TIB-#L"=CJ3H=GY[;LVUG<A@C%6<:D4R<+DJEPME*
MQ6 0=0TBY;%2G*\_(8I#I25<G$)&!DD3D3.B_C7"1DR"7NAD)2HDB""20>H/
MP*KE*/45\Y( 5M (W&FFGU12W< '@ !\P>7AI Z? VJ:A8W4;[-Q>)MS-_Q?
MCJ/ICVMU&8VRU>KP$[A#(<ZPO-MSO(R#16 MFXEAE6JXVP@=T+(K"JOK94IT
M'$FLU;MF=@DY&.@7<M +*9V7<N6_*9:MD7!C23HYR\HG6JN2-I_82J8V.=21
MSW.733EOL*6+;EV@S'-N]7-NVY=.J!4(5M;0P=.1"<R6>L+["$U!4;/;.V.G
MJQH18Z-XLC<*$C HI*/Z]7+1(O@6(S25#&@YDA4;DGK^D8^.1JR@4D#JE!@Z
M'5*3/B8/76)$S4HO >P/H#5Z5'[OXW%93V^Q^WY#$Y8U*4RWFI[CN=D'6&KW
MGR3BZY%X6R[E!RZKN,<=76B66;E%'V/(YF=1O,JHL(MU).C1[I4J0%A.KH!V
MR*D3 TZF#'@8WTG6H68:,:G.D".1TY2-?;H.7.F>XT[1?/D[C6+7M55Q<XRC
MG[&E4F]H"T'&SD;5\AV*PYWE<'.GMOKQ+W;GU=90$?/X:S!<:62U&LU+KENM
M-8F)(\S4)%XA8I#@0B?T 5QHHMJ40ZKKZ@RZSH3O59R%:B) 6H)G4=ZD M)Y
M?.)5TT&H(J;IF10B)06,4ZP=T%3% P$])W2B?N%.90Y"B<3'*0ZAS%[W F$
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M[:FU<4>0 0\! !#CPZAI4USI2NISE3(8YS 4I $QC&$"E* =1$QAZ  >8CT
M.HZ4I!\LX%P'G1]6I3+%*JMSDZ8281JLC).ED)"#0GS1AYMNP?1SYD[1:RRD
M+$*/VPK';N5(UBHJD8[9(0 D3!B1!CF.A\/"H(!Y Z@Z]1L0>1\?97IQ6','
MPD?CZ*BJ51F$=BFT3-VQRU:M&*1*;;K"UL[&=L4$8#^D:2\PTNEL0E7P',O(
MEL,J9X991VH<6VU3KSU/,[Z]9.M*U[I1W]?LO\*0_P YI2O/EBUZ<BI*%ECQ
M4C%2[!Y%R<>\6;+-'\>_;J-7K)TB<QB+-G3955!=(Q1*HDH<A@X,.D#I2/CX
MVI'76WS;J_G<:V=]C3&[FP8>AHJNXQEU8N,,^I,#!+L7<+$P+CH=JQAG<:P>
M1#8>^E&/&B3MB5NY$RNF\3K!D>!ZCQ\=Z@"-M)&4QTF8Z$>!'NI1JU5\?T^0
MN$M6(RN04GD&R$N-W>Q@-&JUGM18"#JWN_+F3.'K<H->K4#$&=G#TIV42R24
M,840,*3 $Z"8'(223 Y222>I).YH!$GF8DQJ8  GR  '0  0 !6V>Z4=_7[+
M_"D/\YI4TDLQAS!]@0MS6;I%$E&]]NU6R3<2.V4>H-@R!2$JDC4+B_-T44L5
M;3HE-+"RI%$WD>-9ASMU2':$-H/5,I]4ZZC0^MHK;^$ )ZQK4$9H! ($:'4#
M*?5@$:1)B(@DQJ9KWZ?0\64"5O<[2JW3JM,Y/M 7;(DG!-(Z.>W.WA#1=>]\
M=A<-^XI)RHPD)$QOK3DQU/5F*)1,)A.8T  "  !),#02=S'4\SSYU.NY))@"
M3O V$[P-8$Z28K>_=*._K]E_A2'^<U-*\R:;U:R0\K7K E!3D%.1SV(FH:6*
MPD8N6BI)LHSD8R28.P6:O6#]HLLU>-'*2C=RW54163.F<Q15!U^/OT^BDNP]
M@[ > &,Q&X9H-"QPTL"[!>;)5F;*/4E1B6IF,.D^<@<SEPUAF1SLX9D=8642
MT44;1K=J@<Z9E (GQ]NV@^.LTM23ENN F0626*4W=,9)1-0I3=T#<&,0Q@ 1
M*(#P/7@0'CJ&E32?Y)HN,LP4R7QYDZ$KMSI<X>.4EZY.'27CW:T-*LIN*643
M(NFH1Q&S$:PDF2Z2B:[5\S;N$CD52*8&Q!&X((/,$;$'D1R(UH=1'([^(Z'P
M/.DXKVVC;15J?>:!"XSH2%/R9!^]C($$Z(25;7"N^@F&Y(2P*RSE\[DXQ%*P
M31&[1RX41;%E'OJY4O3& 4#4QJ=2>IZGK4<@.0F =0!KL- /9N-#2]-G40S;
MH-6[QBD@V23012*[1[J:210(FF7O*"/=(0H%+R(CP :5.U?89*/$!XD&7/'3
META_UQ_(/R#X:4I 9W;5MEL\!2JK8<58RF*YCFPR]KHT.^B8M9C5Y^>>/Y"<
MD(A >"-CS3^4?O)='X3>2<.#*/$5A(GW'ARB(\)!CRD ^8'2FQ!&X,SSF" 9
MWG4B9&YUI56%:H,5;K%?(V-KK*XVZ+KL+9[&V]41E9V+J1Y@]:9RCDA@,\3A
M!GYD(\RW>4;IR#A$JGHNX0B3 $Z"2!R!.Y'2>=1&L@#403&IB8D\XDQTD]=-
MJ&2CN!_C]D/RND./G^&/Y-*FDPM.*L-78,@%MU.H]C+E2H1N/\C$F64=($NE
M)B!L QE8L)''>)(1$>:UV0[-HL4Q$%)AZHF)3JB8 TVTUS:?PM-?/0:[Z"H(
M!F1N(/ET\C)GKL9K*K^-\2U2Y6?(=<K%-AKU=(2JURV6]@UCT;%8X.C(OV]/
MC)F6#E[(-*XWE)!"*3<K*>JI.CID$2D2!-)Z[F3XGKY^-(T .PB!)(TV/+7[
M-YI1?=*._K]E_A2'^<TJ:/=*._K]E_A2'^<TI2"X^VX;:<472:R'C3%6+Z-=
M+"C*MI:Q5J$AXN17:3TLG/SS5N=N4J<:UGYY)&<GFT8FR0FIA%&3E$W;Q(BQ
M0T$#0::#0:;:>'+I4'4R=3)WUWWWG?G&Y&M+^@Z;..\"#E!<Q  3@BLFJ)0$
M1 !$$S&$ $0'CD Z\AXAI4^SV:??'TUT<.69 %)RY;HB8H@*:ZJ1.^0P&+U*
MH8.\4>OQ<AP/@(:5'OZSJ/[0?=]=-GQKM.VKX>F(J=QEBN@4^2@7*SNOK1G(
MIUURXBI6#66KK1T\<M(%16'G)B+.:(09&]SI)VR ?55C(Z?<![!L/(<ARJ F
M#IM))ZDG<GK/,G7Q@Q2UT^LT"@1KR&I<;7*Q$OI^RVIU'0WJK)FM8KE/2%HM
M4P9ND<J0/IZQ2LE,R2Q"E%T_>N7!R^D5,(P !H-!TY?V58R3/7<DDD_'7V5M
M?NE'?U^R_P *0_SFII236K#V$KPWR,SMU+HMA:9<CH*)R4C*,8YT%TCZPFHE
M7&\\*G(O1@2+*^XZQA!Q&G,55FJ@NDDJ4-""-"%%8(T(64A)4(V44@)*AJ4@
M F!4;R#J"(]G3RG7VUWAL082KS+'$="TNCQ;'$$E)S&,&[%HP;DH\K-Q4Y"3
M3^OBF8#,G,O%V6>:2:I!Y?DE7AW7I55 4!4ZG?[]M!]&GT4JWNE'?U^R_P *
M0_SFE*U2PUJAVN3J,U8HZNS,K0IUQ9Z6^D09N7-:L3NO3=3=3$0LH)CLWR]:
MLD]!JKI<&/'2[]N/)5QTYSSZ\_?4$3IR.X^K0Z==Z3Z-P'MYAY*FR\5C3&C"
M3QY=[WD>AO6T-$)N*=><H>[7UQ;16SE*7W&E[I[XYX]@<L 0"16E7B[@AUE3
M'%SGG!$\X,$CR) )&Q@4@=-)G7J- ?,"8.XY;FEK"1C0\'S$/D=-P_(?3QYG
M<]8T'N&E30,E'<#P_8B/ \ +M  $?8(]\> ]H\#\@Z4I![_MQVTY4O<'DW(N
M*\8W*^UQ"*;15JL$-$R$NDU@9;W?@&KI=4.)1I 3HGFH-I*E>MH>644D8U)L
M\4.J*!TYS[>OGXU&O7V<MYWW\^NNFM+R$E'B(%!\S$QA "@#E$1$1$    #B
M(B(B   !R(Z4)BLW2IHTI1I2C2E&E*-*4:4HTI25YQFY^MX?R5/U6\8]QI9(
M>F3\C"9"RRB=SC*ER;2.769V6^-TIRM*+U6)7*1W,I)V"&,=DFJ 2+3^?%JK
MYI\OCXU\CM3I\?'TU4O[+ZC4J_\ :+9!R3-9/[(>;O\ B?<K>ZFF_P 24^[J
M9KSJ^M&((S($]E7!#JT;H;[#Q97$KD*7A)*1B:;.^B;UNY-&KYH"JJ3%;F&U
M1(RE03&N65'YIY [F(G60=:J_JI T 4E!4!.L)@2-C$Z;[>RKD9>.Z''AP''
MR<?('Y ^35JM\=:YTI7D6" @[7!S%8LT-%V&N6"->PT[ S;!M*0TS$R+=1I(
M1DI&O4UFC^/>M556[MFZ24;N4%#HK$,F<P"I32_L=.P3[RO:P//MP/C+\VOT
M^740.@J(\_>?OH^QT[ _O*MK'X!\9?FUJ8 V%('C[S]]'V.G8']Y5M8_ /C/
M\VM('2D#Q]Y^^C['3L#^\JVL?@'QE^;6H@=![J0/'WG[Z/L=.P/[RK:Q^ ?&
M7YM:0.@]U('C[S]]'V.G8']Y5M8_ /C+\VM32!X^\_?1]CIV!_>5;6/P#XR_
M-K40.@]U('C[S]]'V.G8']Y5M8_ /C/\VM32!X^\_?1]CIV!_>5;6/P#XS_-
MK40.@]U('C[S]]'V.G8']Y5M8_ /C/\ -K4T@>/O/WT?8Z=@?WE6UC\ ^,_S
M:U$#H/=TVI \?>?OH^QT[ _O*MK'X!\9?FUJ:0/'WG[Z7G%>#\-8+A)"MX5Q
M3CO$M>EI,TU*PF.*;7Z9%24N9HW8FE'S&O,(]LZD!9,VC07BZ:B_JK9%#O\
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MCCD1 >.O/'7CCKQP \\"/0.NE)Y_5K]5<]\O/'/4?: AY"//4 Z=/$.G/3Q
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M@S"6AZ^;-FCO%)28$1F$$08L2Y<:;Q5[,@? \_MJC*;[E-P=-\N5')\Y9AG
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MOQC](^W50/65[#'+40=-OHJ($1&F@]VWG[:^I"@4>G/AYB(^11\Q'CQ\M0@
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M3*(=P"\"'(<#R AP/3J'(#T\!$/#4C194-\J1/.$E4>Z3%3]Y/M.Y]M=B$(
M% "AQR8W7D>#=X.H<\\#SU$0\1$1'J(ZA( 2D#8 13G//[ZPT(R.;O7C]NQ:
M(/I J 2#Q%NDDY?^ID,@T%ZL0I5'8MD!%%N+@R@HHB*:8E)\'4C4#R%*S@(7
MJ/ <\B/T"/'T>/'ASU\=3\?'OJ#L/ C?7F.M=Q#D!#KU#CH(@/7V"' @/Q@(
M"'EI]M37S,F0>1$H"(%, #\1@X$/D$ #GV^/CJ")(\C]@^VE:I=J14<C5.RT
M2]5Z+M5.N,%+5:TUN:;%>1$]79MDK'2\-)LU/XFY82+%PLU=(' 2JHJ"0W0
MXJXD*:6@SE*9T4I)!2-"%)(4"-P000==Z E*DJ&X)&H!$$&1!D$'G(K86;%H
MR0;M&C=-NV:H)(-D$@[B:""!02122* \$323(4A"!P4I"E*     7!)F=9*C
MKXJ)/TU6 (CK]04?KUKZJI)F X"4!Y(/(\CWAY$.>3<][V!X]   #@ #4'_^
M23[0H$?3RVJ8'O"@?$*$*GK(Y[\]ZY302 .A Z= YY'V"'B(^'D/B'@' :J
G $1I @:GH3]?7[30['R/VF/*>59'AJ_VU.U&E*-*4:4HTI1I2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g287237g33b33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g33b33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %H:^5V8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!O AR@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              E,   3M          $
M                 0             $[0   E,
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   E,     4F=H=&QO;F<   3M
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   )3     %)G:'1L;VYG   $[0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      ,<
M  $   "@    2P   >   (R@   ,5  8  '_V/_M  Q!9&]B95]#30 "_^X
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MM*[!OLIK9]H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ Y@'H P$1  (1 0,1 ?_$ !X  0 " 04! 0
M           '" 8! P0%"0(*_\0 71    8"  0!! P)" 4'"P4  0(#! 4&
M  <($1(3% D5(5@6%Q@9(E17E)67U-4C,34W09:VTM,D,E%2=X62\#-A<8&A
M"B4F-#9"L3A#1%9D97-T>(;#D[>XQ=?_Q  < 0$  04! 0
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MN>.G@U9N7#-WQ0:.;NFBZK9RW6V/6$UD'""ADED52&D ,11)0IB'(( 8IBB
MAS <IJ.T>,+=(N1/E>FCCEBY-=M9(I6-DCD9L]DG,?&]H<Q[7"N0YKFD%I'
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MU/:?&4W&?BM\D>A/-L=\09?-4/X>-3VGQE-QGXK?)'H49:+  U75@    ";
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MI:-=EZV[Y@X2=-E0 >1@*JD8Q>LA@$BA!$#IG 2'*4P" %5=E^+\>$74,;!
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M=43=8@#(EA!9)$3"/\E;ND6I2B*9$2I? S".=BW2;YH71J==P-W6?0T2 @>
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M3(QB*<7*)H!U"(@0CJ6=F3)S$$R'*F7D4H &T\J\$,6U0FB8V-U[%TK<X:
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MSQ,'OUB_3=)AMII,?3LP8.YG<,[$UC7FK@ACV-O3UJKVLDA@ED+2QPC8TAH
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M:IW$1KI_6J7G]9Y*VZ_+4-.@.K[;XA>6</7:5G\TLFLO*-0<@J_C86!WO;;
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M:R;=JU;($%19=PNJ8J:221"F.=0YBE*4!$1 ,HYS6M+G$-:T$N<2  !Q))/
M #K*O5Z\]N>&K5AEL6;$C(8((6.DFFED<&1QQQL!<][W$-:UH))( "HYL?B2
MTAL9E(5!;75ZVQ H. %1_ 5X_@D'B13D3=QKU1\QE6JY"G4*DZ31:F42.H4I
ME$%1!3!V,C1LM=":\]N,'BZ.,Z!PU +3O->#H3H= =#V%?0&RW);M_LQ8K9N
M/:?9[8W)21$-K9+)MZ1) \M<Z&U7;7L4YHW%K2^%[Y@US6N(;(P;L3Z]NVA]
M62_LD@N'S<Z<JW[AD)J;B?.BT2DH0R:IV)7<F5JT-VCG(9T5,KOM'.F+GH.8
MHQ:\U"L_G&8^YOC4A[V;Q8..I:"X-' GCIKX5N6TV Y1-KJ7W+R/*5L*^G)N
MB2A0N]#9<>UP<QM@PU#+,-]K7")SC#OM:[FMYH(G;?/'EH/AUX=/=*[%D)YG
M3W[OS)5JXE$"6YW.UJ^-*UJU<B73ANV>/U_-SY91Z=^G#-&3)X^=2*;=N<V=
M%V-V;R>W.1@QV#B#GR,?/-/9)AKTZT;PR6S9> XB-KG-8T1MD?(]S61M<X\/
MDS;^$\F]J]3VBEKFQ2?%'N8^>.X+$L\0FAB@+2PB1\1#RR80OC9JZ5K!IK0/
M5GEHJ RNU#I&^^$;>O![0]GRQ8_6^R]B5TT?K^2>S#@SALO+G/ UPD*A(N70
M+O)"."?9L3NQDI=TUC?$2:?3<KR09"6I?O83:S"[7W\;%SF2Q]&SSN0CCA:&
M%L7\_9,SHF,W&1R&![A&(H6NDW8CS.AMY3AFJU+^ R&SU.X\BG9L0"*HY\KR
M[>>!%"(A(]Y>][1(T.>7R.#2YZ]S $! ! 0$!#F AZ0$!_$(#^D!SBBZ.O,/
MBWGT[UPQZSWX6-;P5XKUPK\Y7WK%0RKB*,O)/6RS-)Z<B:QVJKEA'R(E$""#
MMBW.7D!3]?9]A*IQFV69V6,S[.-M4+5:U'( UL^Y#&]LCHP2UKPR6:($:^XD
M<#KJ-.-;=6FY+8W#;4"%E;)5+]6S4DB)<Z$NFD8Z-LA <6.?##*>K1\;". .
MOIDS6,Z8M7!O@F<M4%C=/_=,LB4X\O1R] F]'H_1^+..2M$<LC!Q#)'M^<-<
M1Y]%V*-Q?&QQX%[&N.G<+F@\/FU7Y\O)\[NBO)VT#=/"OQ-Z^W?$[-KN^]E7
M&ER--TAL_945O:M6Q2,6@Y^E6&CUJ>B'<F_(Q,1=">D88C1$[!N[=I/D9)I'
M]XV]PLNW]_#[3[-W\+)C;&"QU2XRYF<;C9,)9J-D;/!<@NV8)61L+P6N@CF+
MW"0M86&-\G,]F,@S9>KD,-EZN19;BR=N>NZ#'W+;,C#.6&*2O+7AE8Y[]W0M
MD?'H-W5V]O!M=>("L:^2W/Y3SW8W#WLC9VV=RUB%)P-S2ND;SLY7V.N:%--*
M?6-66*OUZP16M;16;.\@@M*AI&MJDE&KWOO':I7*3O8<#9OG#\FO\D,_CL9B
ML18F.VT(S5+&M%AEZ)]NSE*]BQ!+D:UFLR<U@([+3&]A#&-+2W%9*&J,AM?]
MW<9:N7;T4?\ )V0XZS</-.K/;!#2FCAD94GBF='SVKXB'M=JYVCMZ2=*<)<U
ML3C+X+Z/QFZJ4V>-.\E?&-+HWV)#NK16VNPH_9J[2/A;.[=IN(.7M,! RYD%
M&<HL_51E&Q9A %'[)E(I8W,;50X_8_;&[L?DQC!<Y3I'TG8^9M:PZ@_&A\DU
M9K2V>*K//"'!\8C!C=S+M(WOB,RAA)+>>V?KY^ETWH^QK18%N,S0MMMN:-CF
M+@8GS11O(W7EQ#VB0>[:UXJYJ6D7&,X8/)QN>(36>RKIP<ZDXG>*)MOO7"M$
MN-T0AXY>0DD-'3-RUTPBY*>GZ#7)YQ+.2)&A9..2;N'+$S1V:68LG&SY6[4D
MVEY0FX#)8ZGM=EMFMF78+(-O5*;II&QQ.S4-/(22QP5[UB!L321-%(7-:_>;
MS3WMPU*M.W#[*G)U+<^!I9C,C)U#6GL-C87O&-DL5&,=++6AE,A YI[&M):6
MD/:T_.U=2SDUPO>4;G-&:FV-1N%3:7%5PJ2'#C0DJ';J,JN2%L,&UVG=J%KQ
M[&1T_5JO*RRC-XP=(PT4@FV:M6Z;9D>#5:,:XO*P0[2\GT.:RN/N[48S9;:F
M/:&\;U2Z&F:O,_&4[U]DDD%JS%$'L>QTTI+G.)<\3![Z7:4DF(VIDQU&W6PU
MS-X5V)K"M8K$B.6-MZQ6JN8R6&!\FCF.$<8  T#>;T;=;CRX.^%CAVV'Y.ZR
MPO"_73</5(V[>(W>1H/3\MMP@UF<J392 ;7J+8P5RL]EAE[&62DT&3YI*M_/
M:[Y^@U&4?J'<:;L-M=M/M!0Y0*\VTU@9^[B:4F$Y_+18H])@MN$[J4KYZE:M
M,VL8XR]CXG<PUD9=S48#<_M)@L-B[6RTS,/%]RZ]ZRS(\U0?>_FI8 8A98V*
MQ-+&9@]^ZYKQSA<X#G'$GUDXPMM:XU3PJWQ_81G(J'N^N;-K^C1U>UY>;.]5
MG[3K^P)UB$&N4JL3DK7VZJ3<6IG<M'1D1$G*FTD7C%11%,_+-D<5D,IM11CK
M\S++2R%:_=DGR%*LP5ZM^N;,XL7+,,5AP+MX-BDEFE&KXV/ )&[9R[5I8:RZ
M7G(V6*LU:LR.K8E<99JTHACYFO#))$"!NDO8QD?!KG-) 5;_ "-U^KL[P*:8
MUJU3LK"[Z<JC:M[%@;)1[M4%H*9EIRR2K!HV=VNO0L=82*L.2ZKRLO)EDU,8
MB#MR@X.1(VP\KU"Q!MOF,BXUGTLO;=8Q\]>[2MB>&*&O$][F5;$TE<A_N0RR
MR%[N)8US02,5L'9BDV<Q]0"9EFA V&U%-6L0&.1\DKVM#IXHVRZMXET+I&MZ
MG$'@O5/.8+<DPB811)N+\C5#^U'6_P"U3#+]?X4G9S$W[,J'=^]Q?XJM^V;^
MM2R8I3E,0Y2G(8!*8I@ Q3%'T"!BB @("'H$!#D.6.OK4T$@@@D$$$$'0@CB
M"".((/$$=2XGFV.^(,OFJ'\/*:#L'B"O=*L_*)_STG[RQVX*)P-1M<W'-6J#
M^(K4]),UB-T2F3<LHIVY1, E( ^A1,O,.?I#F ^@<DTXF2VZL3P-R6S!&[3@
M=U\K6N&OS$JQ:M6!6G<Z:5X9%(\-?(]S26-+FZ@D@Z$ ]76OSF^2QV'*Z#\F
M%7=[5"*@)39.[N-2CUK8D[:&;V17G&FQN(&BZ?EWCAPSDHQ\K(1M:EY%] F7
M>+,F4\Z7D'#!\1T]:NOH7E.Q\6=Y29\);EGCQ^&V.O6*$-9[(Q"_'X&]EHF-
M:^.1@CDLPQLG#6![X6MC:]FZQS>1[&6GXW8^+)0,B?;R.T%:*U),USC(VWE:
MU"1Q+7L<7,AD>Z+5Q:V1Q<6N!<T_IASYR77%0JZ7!;>L_P"4"X9]@P5<D=9T
M/4%!CHY))B[++RC;;FL;Q*V0)MTXD'3-95B\B6:E?7CH^+7C3%%8ZKIT1!PC
MO%.H,)7V$VCH3V(\E>RU^21Q>WFHW8K(THJ_,M;&U[0]DSQ8;))(V0'= :TN
M:=:L3G)2[3XBU%"^I6HUF, :[?>+U.P^7G"7N:2US&F(L8PLZR7.T(K/Y!JP
M2L[Y-74*,H[4>%KUJVG7XPRIC'.A%-[_ #;]LT QA$12;*R+A)N7T%2;E21(
M $3* ;)RX5XH.47*NB8&=(JXRQ*   Z5U&&-S]!W7"-I<>LNU)XE8CDVE?+L
ME0#W%W-378F:]88+4CFM^8;Y [!H.XO8W.1K?%YO\0/!#:=QG\H"I%W.MPZG
M&)PRZVT/5E)"/D5STZ5I$7N%@]FIXS<HF>1;]79,<JW;1PBY($6Z[H=1T,S]
M+,1U?N&'0R/&*R%B[)NN:.=;,^JX,9KU.:*[@2[A[H:=U8BUC7V#E")&-&0I
MP5F @GFW1"P"Y^G6UW/#0#CP.O6ISM_!EHO9+^/L.PH:YRMG;UZ @7CZ W-N
MVDQBZ4#&(1K<R%?I6PZ[ MQ%-'F=9*+2<N!'N.U5EA$XPX<O=K-=' ^)D9D?
M(&OJ4YG O<7'5\T$CS\Q=H.X %)DQU68A\S9'/#&L)98LQMT:-!HR.5C1\^[
MJ>[Q736/AWV)K&CUB#X,;_%ZQ?5^^.[C/5C<I[UNFE;+CY6!/ R5:L4_9K=(
M;-JR;8R<9.04A4+2W9L):+ K^ EFDB\3SU'?@LS2ORT#[(D@$3)*G,U)J[FO
M#VR1QQQ-KR:^Z8]LL9+F.):]KF@KR^I+#&QN/E;"6RF1[+'.V8Y@YNXYCWOD
M,S-.#FEC] YO%C@2NYX6^'NS:6#<5WV5=(F^[FXAMEDVEM*;JU?<5.CL9&/I
MU8U[5ZO2*Z]E)N2:0%8IE.@HP)"9EY";GY$C^:D5D3O4V33SDKT=SHD->%\%
M2C7Z-69)()9G-,LD\DLT@:QIDEEE>[=8QK&-W6-UW=X^J51];I$DTC9;%N;G
MYGL88XP1&R*-D;"YQ#61QM;O.<7/.KG'B +6YC%.3")A$PB81,(F$3"*)=&?
MFLJW]]_M'+Y?L_?W]WX/'77^@WNJ'C_P2'\I^U>I:RPIB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PBQ<D/%ENJ\^$ASFU*NTAU(KOM_@1:$L]>I2'A
M@#Q8=QVX6;=\3>'-VNV4.Z4PX15?XOW+^7:ZBUD@]681NSMDQ$'.K-S"116.
M(\CFP-C"'/FB#F41>F((#U+,6_/F4#%-A\L7/%2L'%K;-EK'D<"6@M&GS:N#
MOG:/F/<>12*O2EVUVLD@98M[)[*W<ACF2 .:RTZ"U*90#IH_FJDD =J-&6)-
M.)!%@J@YJM=F7FJ*O!^96]/K5>F2)MD4$HXS*>=S3%L1,Q53.5WX*P3E9^X<
MI]:YETUC+KK'5$L^$Q1O=4B9N"&.-^@ #=)"\#NZEVK"7$CB3KJ3JN:YJ+,9
M.E!MCEK_ $Z3-Y7)T7/EDD?:$^.AH6)7.!8(HZ^YD88ZT<3]V,1N8(XV-8#(
MV25K"\-/+8T*YM*_P@<3,!19+96O>$CB+@MI[@H4(T!\Z>45"3K<L^F5(SI[
M+B.8^QAQ$R2ZP';L$K&5_(D+#HRCE#M/(U=I&?:S9N:Y%C;VU6S\^,Q%V5W-
ML9>='9B9"'CB))#:$T8&CI'5RR,\\Z-KN><H<%LLP699!)>KX3*PW;]=H,CW
M5F.A<9"TZ[S&"$QDG4,$H<X<V'%M,?*->4&T!Y2C1%.X/>#J#NFY]X;?V'19
M"+8.*)-P26M4(*0\?)S,Q)S#=!LU<HM3K14E(1BDA"1L \GI&1F6K1!$7>X<
MGVP>=Y.\W<VMVNFIX?"XFA>CE>V[#.<B9X^;CAACA<YSFEX;+''*(YI)V01Q
MPN<X[NO;5;3XO:W&P8' QV+^2O6JSXVFM)$*@C?OODD?( UK@W5CW,+HV1ND
M<Z0- WO>J];,V7HR%UU3:WIFZ;O4:4N*83%EKR[Q,B4E"M&L4J9Z*4%+"9S)
M&0._ZE%43\E!YD'^=G',1A,/M%)DKMW:/';.ZWI'05;;8RY\4SG2@Q[UJ#1D
M6\(^ <-1UCJ6YYO.Y; ]!JT=G,AM '56\]8J.>!%)'I'NR;M><%SP-_BYIT/
M4>M4!OLQONZ\.D'H@O##M&/7AW48Y-931TLY2<!'2#Q\)0B@KZ!TA5\4"8"+
MX_1T"?D8# 4.JXROLOCMK;6TYVSPLK;#)F"GST#',,L4<6IGZ4X.W=PG[T-=
M0.'6N3Y2?:C([)UMF1L;FHG5Y(7FX8IG!W-2R2\(!6:03S@'WT@::\==%[/Q
MA#I1L>FH4Q%$V+0AR& 2F(<B"93%, ^D#%, @(#Z0$! <^>9R'3S.:00Z60@
MCJ(+W$$> CBOH6$$0Q @@B-@(/6"&@$'P@KG9:5Q,(F$3")A$PB81,(F$3")
MA%$FXOR-4/[4=;_M4PR_7^%)_<3?LW>O4H=W[W%_BJWGF:I;RPIB818U<XQW
M-T^UPS I#OI>M3L8R(H<$TS.W\6Z:-RG4-\%,AEE2 8YO00HB8?0&2*<C8;=
M69Y(9%8@D>0-2&LE:YQ '$G0'0=U6;#'203QMTWI(9&-U.@WG,<T:GN#4]:_
M*GK#@F\L_J7ALJ?"S6-;<,J^MZ9M>J;BB7LM<TG5J4M=/V9";6BD'DFWLK2/
M5ASV:!9(/&B<2@Y6BC.&R;U!P<CQ/Z?R>V7(_E=HK6TUG);2-R-O%VL1*R*F
M6U15MXV?%RN9&ZL^03"O8>YCS,YHE#7%CFC</&:>SVW]'$0X:&KAS4KW8+\;
MI+&],9J]R.\P.>)6L,9FB:'#<!+-6AP)WE>WV:?\H4^2+@A^EI3_ /TG-'Z%
MR"__ *OMG^9B_P#\Y;)TCE0^0[.]S^LD^D_A7=ZOIZM%(O!GJCRDJV^>)6[<
M8M3T74JMO[4T'!/)'64HI*.FEVHK$*K3 9QAK'*+-X@]9L5J=S8.%%S.Y%M&
M>'<L"=:*\#:_*<G;<'L[2V2MYNW:P65GG9'DHA$U].Z_I-S?D%:(.E%BO5;#
MNAH9&Z3>:\Z%LK 4MK#DLO8ST&-@AR=*.)SZ;R]PL5F\S7T897Z1F&69TFIU
M<]K-"T:@W \GGPAR' [PRUSA]D[TSV,[@;';YX]H8P"]:;N26>:6EDVQ8IQ+
M32J1F9500.J+]0%Q+W (F ](:GM]M9'MKM'8ST=)^/;/6J0=&?.VRYIK0B(N
MYUL4((?IO <V-WJU/6LYLM@G;.X>'%OLMMNBEGE,S8C"#STA>!N%\A&[KIKO
M'7KT"N_FEK8DPB81,(F$3")A$PB81,(F$3")A%$NC/S65;^^_P!HY?+]K7GW
MZ]?N?^!O82H>/_!(?RG[5ZEK+"F)A$PB81,(F$3")A$PB81,(OGK)U@3J+UB
M43@3J#K$@" "8"\^8E 3% 3<N0"( (\Q#"+ZPB81,(F$3")A$PBQ$E<7+?'-
MN%RD+9>HLJX#/H/WRKM9E_)F<B?_ $8I&3=E2*0/A@<AA'X(AA%4SC"F6U:L
MO#M9GZ3M6-K>R G9(&2 N7(,8I[7'[KL(]1 46%!NH"*9E$P.IR*)R@(B&%R
M[Q%)CY7:[L=C?=NC4[K3&3H.[P"[_P B5&7*8KE-Q-=\++64V6^Y]4SR"*(V
M+E?*5XN<>0XMC$DK><<&N+6ZD-)T"Q:,XM]6M-J6ZXJLKGYGFZ938%F!:\F+
ML'T#*6QV^[R R %31[4TR[*@*G%0_=*)"= ">RW*U1:FF(FW'PPQM_F^.\QT
MI=J-[@-'C3CQX\%EK?(QM=-LAA<&RQ@NFT,[G<C/KDR(37R-/"PU^;DZ,2Y^
M_C['.-+&AK=P@NWB!.+OBXTM#Z=V)OBS34C4M;:N;K.;9,6*-,T70*F@U400
M8,FZ[Q>1>2+A\RC8MDV SN1E7;9@U14763*;9]GZMK:>_5QF'KRV+MRPVM!"
M0&%TA;ON<YQ.ZR*.,.DED<0V.-CWN(#25PS;[9F]R;EO\I;%!C'477^=HV3:
MC;"V9\ :X\U&[GG2L+&1!I+RY@:27:+R1K7'EY5CB\:.=@<&G!;K.IZ!D57)
M:;<^(R?4:S=YB2*J-DY1I&)7&IIBS? FH<?-,=.PR)P4:)V61,F90>XV=A^3
M#9-[:&U^V&2MYV,-Z73V?@#H:,I <8GRFI:.^S4:<[)!,1HXUH]=!P^':7;/
M.--K ;/U(,8\GH]C*R[LME@) D:P3PC==H?@-EC!! F>MBNCY<JE/)"5J7"1
MY/>O2$F)E95Q6$VL!(3!^?<,5Z]8;(9*.E%#A_/=KF#KY&,<OXPK8]A6XR.*
MUM3M[89& (FV2Z=D0ZAN,DQ[PT =QC>K@ J1>R+7<Y\&#V8B>_B]T.[&Z3P.
M<RTTN_VBK#<*7E,MAV'?+3@^XZ=#*\+W$I.,U)#7JC1\I*:TVHU2(Y,9&KRY
MW<H@@_6%A(EBQ:6"R0TNNP>1R,PUG$T8=S@-J.3BA7P;MK-B<XW:79R%XCOA
MS!%D<6XENAM1!L;G, DC,N_7K31->R0PO@<9FY3"[6VY<D,%M)C?N-EI&E]0
MA^_4O-&]J(9-Y[0_W+MP-EE8\M<T/;(!&?8C.2K>U\G.5,AU#CR*0ICF'D(\
MBE 1$>0<Q'D #Z #F/Z,=:=2I1J;RAG"OO:4A('45SLURG+?3K7==>L#ZRV1
M3VFS6%' "VV)US:-A5:HTNW6>N.%$&5AKL995)*NNETRV!&+2(NJCE[6"R5)
MKWVH8XF12Q0SGI%>5U=TVO-.GB@EEFBCD )CD='NR :QE^HUQT&5I6G-;!(^
M1TD<DD(,,L8F$6G.-A?*R..1["0'L#]YA^&&@$C@)<9U\4533'@ XZ$@44(F
M*JM;X;022 Q@**BHDXFSG!,@#U'$A#GZ0'I(8W(H^CB80"?NWACIW!)?U/S:
MX\#C\_SZ<=/(R,I/_9>3'A+*>GT^_%!'&GQ,[BU?OJHUEE;]A</_  V0FJSV
M/:7$7%<.:^YJ5$;$M]UC8*FURWS[Q@[AJ36ZY7XN=F+78B&5:1!K+75;"XCX
MTY'B<S$X^K9I22&*"[D'V>;K4'7Q4F?!%"7RR1,!#YI))'L9%&="_FY!&'.!
M"C9&Y8AM1L$DM6FVOOS6VU#8C;-)*UD;)'D%L3&L:]SW]3=]A>6MXKU0B06+
M%QI7$B287+'LP7ETTD$$Y58&Z8*R*:#43-D2/C]3DJ38QD$RJ@1$13*4<UQ^
MF\[1NX-XZ,U)W1J=&ZGB=WJU/$Z<>*S;==UNIWCH-7: ;QTXG0<!KUZ#@%S\
M\JJ81,(F$3")A$PBB3<7Y&J']J.M_P!JF&2*_P .3LYF;]F5#N_>XO\ %5OV
MK?7]2EO(ZF)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%$NC/S65;
M^^_VCE\OV>,[_P#8_P"!O'APXJ'C_P $A_*?M7K-9J8FXYPF2-JSV=:E2*L[
M<M9&+:*)@8YR]AFV?.$3O')"D[IR'.T1Z#IE3<*JF,D2PIBCN_3SR1KT4J6&
MM<8W6NE7CU6B:XPLW+M7+H2O6;/P4JU<H%6*8&Q%%GS(%EA,9-0J1"+F(NQ=
ML6OM<VHC:/N-?!NPEY!!.;L,JI-$>,H[Q3=TA)(6.5>$9]Y!+DU"1(@H9-8B
MS04U5.\19C#H%E:;$(/572@/JY& Z62>/&KQ05HY RJA7S5=%ZDN<PB85TG!
M%P,(F!0#"(X18[KV81:ZVKTM/2J:"*<>)GDK,R $(4#/ED$CNY!^MZ3&,9)(
MIUUA,<YB$ PF,4!(L-LDBPG+TQ\,E9[7!K4DKUHE1;(NT;"Z+8';51^HM'62
M#;.B 4AF@F!PY$JA0(*8"01*1999DO#R6L7;9288G/8&T4HT5E9#D9@M 2SD
M[24:E?K,W[HBS1N*KEUXQP"J1A(Z,!SF4(NVN<3".4@F+3*.V]>AV+HZ\<D]
M=Q[55VL=($GRZD>NW=NW2)"BVCF93' 7#D3I)'="CT$6_1"SA:=$%G?%>=@0
M=>B3-U/P:^-=#$%DS%$3"_+%^!+("815%T"W<'N=6/7UZT71QVP%Y%.L)I1I
M#2,BE8EK$R34.<\,6JD59RB:11 ICJJSIF;!F5?M@HBN=;TBD(81=;2-AR]O
MFFC8B574BG$$:<='AY5Y)/X8RBJ*36(EA%JBV;2QA7 YVY^@QDVSPQ"@"1.X
M18Y<C^<HG85M$YA;-9"MU2&4(!A$&,'9HM2;62!/F8PN9Y=ZT/T 8RI(IN
M/H*!%D[K9#LD"PL*36%8QMAFRQM??3<J9FP;QP-'CCSM8'*22Q6(NCL5DVK
MG-5(RK=-ZLW7%9) BRJB3\K9H'SO*MHYN=61D6[,T6JZ79NV#%T=FB_06=))
M'60?*(+.6BR91269*-E2B!CG*4BS+")A$PB81,(L(3BI<-D.IPQ3^8%*0PBD
MS^)()/.Z,])/%B@S[G<*<&2[<1<BB!#@() H)B"4I%FATDU.7<3(IRY\NLA3
M<N?X^74 \N?Z>64(!ZP#\ZJ'.;\%Q;KUZ$C7Q+;\*V^+H?\ Z*?[N-!V#Q!>
MN<D^,?Y3O2O##_E +AR;A U12T'*[*#V1Q5:HJ%K08J"V&1@U(>ZR_A%13
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MQX$%30EY/7A314353IM_ Z1R*$$>(3B,. '(8#%$2'VP8A@ 0#F4Y3%,'H,
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M"<X@)C")A$<PCWND>^1QU<]SGN.@&KG$N)T' :DG@."RK6AK6M;P#0&@=>@
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M)&"5ACEW'N;SD9<UYCDT(WV%S&N+7:M+FM)&H!&8=&Q^YOL8[FW![-YH=N/
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M*PIBX=<NY+&^.Q+5+O""1NHX\78ZXO$L3 F=,G8(Y464*9P?N=1$NGF8A%#
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M&A>]K'/+ W>U:PL<7%IWP 0ZS.R:1F[!,('EPUD,0E(;H=0UKG!H<3IHYP>
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M81,(F$3")A$PB81,(F$3")A$PB81,(H0DQ-MV><5UN)QUG6GW:L[U(_2G=+
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<B81,(F$3")A$PB81,(F$3")A$PB81,(F$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g287237g34c81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g34c81.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1,&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $NJ^2$(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              <0   ='          $
M                 0             '1P   <0
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   <0     4F=H=&QO;F<   ='
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   '$     %)G:'1L;VYG   '1P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      (TP
M  $   "@    )P   >   $D@   (MP 8  '_V/_M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ )P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 0,1 ?_$ !X  0  !P$! 0             " P0%!@<("0$*_\0 5!
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MOM]_B;9_R9T_1WA7_6:__P"'#_Y>GM6J_P"BHO\ >2?]M3]I?5S_ %5]OO\
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MQT^/7.,@\'H1D'C/>OK_ /);X!N/\(I+_P <^%M2@T"TL;BU2WUNQN]+AO\
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MFD2&&.2:61@D<42-)([L<*J(H+.Q/ 506)X -8LRHK.[*B*"69B%50.I9B0
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M2TLJ2^ZH*X:8CLS7'W5DD (0VI9^B=8RZ7J<(,DFGWT<:C+.]I(@1>F3Y@#
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M4CA*.WW!&L?CR2IQZ^G49Y([].?ED*IWD*)2$\$*Y2 H!1X]^>Y0( '!)]N
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M?Q^8^WZZ^=>OS^[@5]'MC^KP>NYN._W5E58E2H$?E?\ R)"N>WY>U0!2 ."
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MI5R,@E' )5AAD895U(925()LX9X;F-9K>6.:)_LR1L'4XX(RI(R#PP/*D$$
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M@X$Q3*HR-!*O5L!D9HQ[V3@HQ]X?9PP :[2B/A9)()'P[Q(\@D>FKQ]""?\
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M4W^9,DC(T8X(GU4,!,K$">VRJ+;JAB:"(3DN78J4G,K.%#E@GEQ$!UDKN?U
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M=WYZ8(QS\.3CI4/:CA(X\ CE/T( XXX]N.>% <<!0YX! )R#HNU2PR5+9 8
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MSP\[5-+F,LR0IHN2;74-5N[J2.UM1+9)M#+ BLLS3*"IC8+@AL,<+C& <@D
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MLKO'/<,9+9V<,D,;898W!3<YPK[??Y 7.3FKJ'QQ=-<VZ20QF#R?UX*,)GD
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MY2)[\IA"3#1+DR5R*XN.QV"78R760GPL+2VVA# _?G'P]/GQG- <XX''RSU
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MLP@[\_A^>WI]:O== 9K(;4)A3BVVO4(6\I*G%J=<6ZM2RE*$\J6M1X2E( /
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M&QM0@DE+,TDK>7!;P1(TMQ=7,IR(K:VA1YIY6X2-&;!( //=7,5G \\NXJF
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M61$?:[RM9,JRHY!]X\0KD$1.H(!\PYYQ#)M92FYFDC96==ZB,709HW7(R/\
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MS@>Z>,9SCJ,]<C@BE38X)DQ@/)^)8X'Z_F)Y _B1S_\ /4J>?CCX=./3]@)
M^9-0>A^1_95OS3+,8PNOL[W++NNHZ>");CLRQDH:]0,-O/+8B-$JDV$];;3B
M8T""W)L)CH#41AYY:$'=%#)-((X4:1W8 *HS@G R3T51P2S$*HY8@5M26*&W
M+S.L:*226;KA0< #EB?Z**"Q. H)P*N5;OEMQ74C:9.X^W+S4"+,9-O/W#QR
M*E3E>TU-G-S?4DNB.Y6UDV)(FNJ4ZI##C,R0VRU*2ZC8+.[8@"UN23MX6&8G
MWR53@)SN8%5/](C"Y(Q7.9K=02;FW !;),R 97EN2?Z((+>@.2 *KJC<C!KN
MWC1H6X6&6=GD;@735$#+J2QDR@Q2UUK(B4<9B:J38-M5KS5TX8K!6W G-V#B
M$QGVW%8-:W*HSM;SHL> [/%(JI[S1*78J-N7!09_I@H/>!QG'-!E56XA=I"?
M+5949GPN\A #EL(P;C.%(/0@UG:@?4)(';PI':4\@GGU.X+/D#R H>RE #GV
MYT<9X/4\^HZ]N>?GT&>!@FNFI0!X^9)Y"@I'(()3] !SR3X"?/'T5P01J0.,
M#(P>.F?Q!]3Z\=^:D#.>0,>O?Y5-0KL7\R>.0KP#W$ _.H*/ "#Y'''LD#@\
M<: 'T'<' Z_ ?OZ#D]Q4'D$>M8UE.)4V5P_AK-D-K8!^'F,EM$R*L\CEMT]P
M4VXHI[V'$J:7X)2'$A:=\=S-%@1MB/.<<@X&>P&/PYSUY%<-YI]O>*JLB@JF
M/,_]PM\3C&T]3WSCK7.MYM#D]4ZIRK#5U&!46U1UM,3.$@GA4-UWE:NT<A$=
MV0M7D]H2.=6L=_ 5&XE& YW8YZ>]QZ].G45XZ[\-7\.Y[9?:8R<C:V&4_P!3
M#XZ !N,@Y]:P,LY#C[B@47%,Z3PH=LR >_D$]Q'I@\$#SYY^GZCI0P2,,+"Q
M;D=F;C.>@Y/4\YZ]\9JR+FQ]P"[MW(/+/(%!)RQ!^P >0O.",8SD5<&LYS!H
M$)R6X4% !07,<?Y2GR 2ZISP"? ]@/'MK<;:%^L*+@8X(&>OJ?SFLX]3OX@W
M\\G&<=A+T!'8';U__+Z&O3+ITLI]OM-C\^RDNS)CLJZ2Y(>X]1:6KB:TV#V@
M#Y6T)2/'L!R2?.J:Z18YW1.%7& #G&0"1]YJ^LYI;B!99F+R,7!=AM9@K%5)
M'&. *WCKGKJJ3(D1X<=^7+?9BQ8K+LB3)D.H8CQX["%.O/OO.J2VRRRVE3CK
MKBDH;0E2UJ"02)56=E1%+,Q"JJ@LS,QP%4#)))(  !))P*@D $D@  DDG  '
M)))X  Y)/2N/-LXTCJ3W J^H:_8<&SV$O34=,>.3&E):R67+BR:NXZD+2(\A
M"TO9#6RY^.;/1I#175X%*MLT0Z96XT>'C_K-19?#UC+H,#?^K7BI_A'<(>;=
M%=98O#T3 D%8)$CN-6=3B6^6*S(VZ>SW%/;!M2N$U"0$6<!8:9$P_P :Q!1]
M2<'',BDQV:D'9 6G!S<!8^R=>2JYII2FE*:4K6.[.TN)[QXNC&\G%C DUUC&
MR#$\MQV9]TYC@>65R'D5>78;>H;=>I[V B1)C*<]-^#:5<RRH;R#:4%M:5<R
MQTO5+K2;DW%OY<BR1M!=6MPGFVE]:R$&6TO("0)H)"JMC*O'*D<\+QSQ12IS
M75K%=Q>7(74JPDBFB;9-!,N=DT$@Y21,D C(92R.&C=E;RDZT;+JFPO8/<';
MA2\$Q_.[^BL<8Q3J4LHT^GV1RVKN&A&GKSWX)FX8Z>=Q':Q<V!$E9BIO9N3=
M3X=G1;AU,]UG!8O==>&K/6UDO?"1=[PKND\-7$JMJ-NQ(W_HYF"G7+8 L8UM
M]NIQ#_*+)XHFNY?3^$/%MEHVJZ?%XY2YETF&='.JV(_4N5SY9O8]Q-MM;RVE
M$C"VEVXCF+ND"^$DK:_=SIUVZZA+W*\8R7 </Q:CV)R?:2?F=C&<Q:H+E:-P
M]PJ3"<AQ.RK\?SV=4Y#S2PLAQUZTA/UXB4S5B(;#$:)0B);.*XMYH6B>W8(J
MN)(I5$?OD3+E<.LK2!O<7"@*5!&3]_DUFQ\27>A7=CJ-MJ]Q-=7DEP+")6+1
MRQO;6KE9I Z1+ %:59$#Y =2JD9Q//NI"ZZB\TZ9<'M:&K>VWPV!B4[/[1^&
M;EM$?&L2W/KSD-]=42'*6[FRZO(\8MH\N73EN=;26&Y2Y$)^15H06MW/JCR"
M-)8HX0X82!TA\R-E8[5Y+^]P23M.">%P>ZYTW2_#>EZQ=I<7"3WEQ)IUF+=X
MU=Y UO((T0Q,\(9!.9,LX9 0H4\GWSF[OX9CW3-N)FV#6U7>PZW&,NOHU%L]
MCXS>'+OUVDVCE,4];34$.>S(OLC/QV1PY?9^&+)ZYE7CD. A^0GCU!GFG1U$
MLQB ._AF&P%0KD#G .!TQCKC./G]KILJ7T5M=0FU,[0$M<N\<2HS%_.D<G.T
M8P2& .05'&*\+>DS;[K;&*;P9-A.3XAL%@FX>WD*DW"WYWUIKW;;'<LO<ED7
M<Z UB>4R8U9(LLRQ:VS++9,)&W-*7GK(_=,T/-2<<C#.QT6^U<M8V5A-<RRB
MW*Q6L3RW'ZMU:X=PBML1%W'S65(U&XLVU21ZOQ=XG\%Z&MK+K-['<2V<SF*V
MM;VWF1%A1?(A1"IV13@"-FFE=G!(B0NI ]W^C?H8Q["]JL-VUVLQ/(=GMG*F
MFDQ\XWRR:HEX/U*=1+EVB*<G;QFJDMP<KV.P+(#75E?*R7)45VZ<S$:R!BF,
M4.&54*FS%_W,8T_PPIWRVNL:X-HBLH'CO-#TF5,!)KN9=]MK-]']J*UMS+ID
M,H5[B>[97LT_.GBCQ3K/CS4);J<3:=H[,WDH0T%W-;M@B&&/"264!  >:18[
MJ10RQQ0@K<-Z@2=TNF_8^AJ,1G[E;+[3XYC-;$IZ7'K+-<*PNLI:JN:3%AU\
M&NFVE<S#B16FTLM,M-(0@)[0.>=5"Z9XAUF>6Z33M8U2XN9'EFGCL[R\EFED
M)=W>1(I&=V)+$DDFJ8W6FV2)"US96B1J%2)IX(51%& %5F4!0!V&!@UA3_6A
MTXJ[1CN<6^Y/>2&SLSMMNCO>APA2T?EO;187FK"AW(([@YV#E!*@E:"KL7P?
MXAQF>RAT\#K^E]1TS1B,@'D:K>6;="#TSU]#C2VLZ<IPDSW!.<"SMKJ^)P2"
M?YG!/P""I;[(8;20>*B9ZF+6[;+F#],W4]F"% >D[-P/%]ID**DE25.1]^L[
MVIM&4#@!?=6J>05 >BI?*-0WAR*$XO?$?ANT/<)?7.J8P<'#:'8ZI$Q[C$FT
M_P!:GZ2=AF#3-3F] 8(K7CU/MT]J1R",$;AC)7:REJ<;F=65RL#'^EO#,<86
M2/6W6ZBJVEF,H^4A:ZW:_;;>"*\YP5 LHO&T=R2!)[2E2LOT=X7A_P ?XEN[
M@@=-+T"29&// DU+4-)91T]XPDX/V<C%!<ZJX]S2X8N?_NM012!P<D6MO=C/
MV@0'P"%P2"2L^14]:-Z$EO.NFK;9M7'JL1=M=R]W9B$]R21'MIFYNS\-*^SO
M3ZC^.2$%02OT0%%*<1+X/A_^R\1:B<'#/J.G:4F<'&Z%--U9R,X.!<J<9&>,
MD$UE_M3Z;;CT2VN;INHSAVN;5<XW 9B.#M/(RI^L;);Y6:.[+NK_ '+:<5QZ
MD7;3;?8_"*M0_II;&5;?[GY"R%>0E3>3!U X*7>X!6C:SHL1_FOA33B.S:EJ
M&LWLH.>I]EOM-MSCT-L1QR",@A97S8,VKW/;*VUM90(<8S_C8+J49P<[9@1D
M[2N!BG3TAX)/6'LPW)ZE,[>)!<3>]2>\E)6OGM2E0?QS;[+<*Q9;:RGN6Q]Q
MA@J)X:">$C+_  KOHP1::=X=L1V,'A[2)I%Y/V;B_M;RY! . WG;\?TL\U!T
MB!R#-<ZE.>IWZC>1JQPH]Z.VE@B(.T':4V EB%!8YO,+HZZ5XDA$U[I^VHO+
M%M7>BWR[#*;-KL.#L/JJN\PC7ELMWEM"BZN:IPJ'<5%1).E_%OB9E*+KNJ01
MGK%:7DUG#CGCR;1H8L<GC9CMV%;!I&EC!-A:R$?TIH4G?MSOF$CY)523G)(!
M))YJ_;F].^UVYFV-UM5*QBKQJ@M$1I%?)Q"O@8Y98S>U<EN?09+CLBNBLIKK
MJALV&)\"2AI20XVIA]IZ*_(8<I9[B>Z):ZGGN6/5III)6Y!&=SLS9]#FO9^#
M?$^I>!->L=?T%;>.XM#)'+:20HUCJ%E<(8;W3K^ 86:SO;=GAFCQD B2,K+'
M&R^3&1LY]L1D\;;G?MJ/%7/D_ X)O) AJ@8!N:V2H18\AXJ=A85N"MM';.PR
MTE--SY 5+Q67:0WDQXGGKRRV$RQ#<I/^+&<G 7./0DY. >1]GJ57]DZ'J.C>
M/-.EU[P>69[1#-K7A.6?S=9T$'),RQE?.U715; @U6W61H5*QZE%;3*2V-;A
MX:+FHLXL.595T6T8=BV#]2\F+8QFG.U,AR'*])Q47XI@N,+D--A^+ZBI,5YA
MX-/,TLBJLBS>6P*'<4!PQ7U!'&1SGG([=<CTNA:L8IHO/$$SQ,LEKYQ\R%MH
M)0.."Y1MKA3E6VE6!!(.*5]?"J8,.LK8K,&OKXL>%"A1D):CQ(D5I#$>.PVG
MY4--,MH0A(]DCZ^YY&D$KNX!&6Z'KP .W3T ] ,<5Z%I9IV>:>0S32L9))C]
MJ5W]YW;_ .3.6XR<# XZ#'\WQMS+,<DU<6<JIN(TN#>8O>(;2Z_CV54KPET-
MTP@CYA%E)]">P"$V%1*LJM[F/.=2=4D$$YC$J *J/"^W@R12$[@QZ[EW9C.>
M& Y /&ZQG%G=K/+&MS;O'-:WMJQ*I=V%W&T-Y;N>F9(FW1-_[-Q%!.A$D2L)
M&!YBWFV/"Q<AIJKROD2*3*\>]3U7<=RJL4EFYJ%J(2IR.B1_+*F6?EL:.966
M39].8G6XQ2Q+")029=^V1L9?RV"DG&>2"CL,8#R.%!C"9RU+3WTJ[6W+^T6\
MJQW5A>J,1WNGSQ,UM=+P CE/U5Q"!N@NHIH2!M!/9D&2Q08HQ*L7$QXU11B9
M.><6E*([$2$9,IQQ7/"$1VT.%:CPD!)//'G5I;*1Y*DY(*YZCG<..1@Y)XX.
M!P>]?&+A6OM4D2 %WN;PPQ*%)+R23"&)5 .YFE<@*%!SGCC%=L=#%3.IND'I
MYBV3"XLR7MCCUX]&<2I#D<Y*RK(D,N(6 I"VV[1"5(4 I*@4D CC7J1T7O[H
M_8*_/G\M-Y;WW\J_CZ>UD$UNOB2_M8Y0<A_8'%B[ C@J9+9]I'5<&NKM37S"
MFE*UANANSC>TU7'M,AC6DU,IJUDLQ*D5*92XM) 596CZ%W=M207G(\4!3-<Q
M-=M[!Q8:K*^:M#P:Z+>VDN6*H57&T$MOQEVVJ/<1V&3U8C:O5F%:9IT@4,X8
MY#'"[<X49/VF4$XZ $L>P.#C"YO4QMK7V>3T\EVS-AB5?;S+6%$^Y+*P$K'D
M1EWM0U3UMY+NT6%:J3Z'K3*V)464B/)9I+6S6UPK:+"=EC8;=LI4*3O5</G8
MY=D";6QT#%U!!=5R*UF\A!<$G*!B0-I.4QN4*K%LC/!("M@[6.*CO^I';[%8
M!DY(U;T=DU;W5-.QZV<QNNN(#^/U]-;VKJUS<C8IK!+-3D5#81H=);VMM9-V
ML>/65LR>W+B1B6$TAQ&4=2B.KKYC*0[.BCW8RZDO&ZDNJJNTEF5<$FNXD'OA
ME.YE*L4#*456;.7VGW74@*S,=P 4G(&^HTAF9'CRXS@=CRF6I##H"@'&7VTN
MM. *"5 +0I*@%)"@#P0#R-<9!!(/!!((^(ZUU Y&1T/(J=J*4TI32E-*4TI6
MLLAW5H<:R<XS.J\B>4P,.5:W<.OC.T-(G/;Z=C&+JLI;L]B4KX^\@+A.IKX,
M]<!#S,ZP3&K?7F,="6SR1^8K(,^;M0D[W\E%DDV@*1[J,&]YE!P0"6P#I>=4
M?85<X\O<P *+YK%$R<Y]YACW5..K87FL33U"8NY7JM&,8SJ1#167^1.J9IZM
M;S6)8O+;K[W+%Q3>"2:J)8K<AQH;;2\BN51I,JBH[.N;$Q6SV*0-M,D(.43!
M9O\ &R LD6=F-Y49)SL7(#NK'%8>U)C=LDQAW^R,^7&0&DQNSM!. ,;VP2JD
M<U;)W4AC="YE)RFCLJ*)3YXK!L>FR+K#68N7/(Q:'ECDZ'+L\FJX-4VU52%3
M"W=RX ?CR*J-#>DWLYZDA9BP=_*\MU<O!YS@)*3$/,:(*0L;,WO#;E <$,2!
M& Y@W:+OWJRA9/+0EH\2'8),KEU ]TYPQ&> ,L2HKX>_V/3/7>KJN_R9F?<P
MX.,1<=ITIGSH<G:_&]T#)F"[LJR-&[:2[6_ZDIVO 6AJK]!5F4(E8&SD& S)
M&51C(9&.%(N)+? V*Q/O(!QNSG=G;TD7*'H&?+!4"KR085FR=S*!A#DYVX(V
M\G&=U4MQ7Y#35-_4O_$U=Y60+BMD]BV_B*^SBM38;_IN)2XWZL9]MSL<2E:>
M[M4D*! Y75D=D889&96'HRD@CZ$&MZL'564Y5E#*?4,,@_<:N>L:RII2J>7S
M\+)X]_AWN/'/GTU?3QS_ &?74-T/R/[*E>H^8_;7(*@5**>4GM4DD*'D<=WT
M'L0H<<'D<=P//CGFX^?7IZY!(^??L>.!7I%ZIU_Q*=>F,D<#CGZ_4YS185P4
MJ[.%CD$CDD^Q"?;A0 ]Q]%>="<8QW;[L\_3UP?V<5F<=OQJG4/3:*PH+[2>4
MK/*SP4J6I7Z+2E(7V<) !X(\Z>H]2>V?D3W X^IY!Q2IJ4I "B$@!7@\_-]>
M."3Q[$$_7CNX\'@L8'IZXX'QZ8].I[>O-#Q4#@^;@(4.5)!*AX !]0<=ON@$
M%!!/'<KGV!Y'[\ _>/7'\/NP*5#RD+"2@\*[AX/=P DJ;^;Z>$!78!V\D$$^
M^I_=U[>A^/;XX/?X*F*"AYX2DJ0!PD<+5ZB@"I1XX/MW>!P3X( 2G4=, ^O4
M8(R.,<]/3U^.<TJ$GD<E2R1R#W(X(0>0I7L.X\(!X"21_1!\'3'7  ]>X/J,
M<#C]O!QS2HNWR3QR5%/("5$]Q]UCD@$<$$IXXXY() T/?I\S\#\,?,<YR>HQ
MS..,]LX_/Y[5@CO=ZSW<03ZKGM_]H_P'UY_NXUE6U.GU./E_?FHK;_2Q?]0C
M?W_*K6!QD\@8QCZ9]2 ,=>WQ!!YY9?M?0_\ ,W]W&?G5JU& <'&>?4\@#KCX
M]\YYX/)-:Z:= >GH<9 QQQT[C)R/4GN*5\*0>.?IJ<D8'J,?'C/..YY&>N<'
MJ,&A /7L<_6IT993+C=O[PD,'R 1_I$\?]?'TT4'J>./D>WP&!P>GKZ\U!/4
M=3@G&/SG-6#<#;S#-R&T5.;43%[60K46,:$_,L8L=,QKO2V^ZBOF0_B0WZBU
M(9EE^.ET(?#0>::<;Z(+B>V+/!(8W*E2P52<'!(!93C) R5"D\CN0=@MH+F$
M).@D4/N"DL!G QD*1G P0#D ^I&:X9J,=SBQCUD^PZ1JS\2WVWN)W,6SG/9_
M/+EUN1E3M7G.'Y<Y(R7_ -'7ZN ]*RC*IEK?39#SB(N67D!O*9*:.M]$TL"A
MD767\J.XEC**L _56T8>WFA B'FAVQ%$L<:J!F%&\I3(_GU2=F#-I,:R2VZ2
M;G:4YEG<B:"4LWN$ >9(6=F)P[+YN4'7^T>W&&*D'+%;:(Q.VQ#+\TK,+DR*
M[.L<DLTLUNNKK&V8QC*Y(36P\D77ID>I$1,KK]$6!EKJ*[(+*?65-/=7$X'D
M^T^:D\4+S*#!("Z[G5&EB'O-%O(P=K1Y>'WHT5FMK6"$D2F#RWBDF2(XE0A&
MVJQ$;L0HD"@X'#8$A"NS*O2?:I9"CVE/!"?UY)^;GCP01V\>/'!_75=Q@D8'
MQ/'Q&?GG/QS7?\JDN#Y4 DCTO8H!)X0#P/J.%'P>X$ *41\W!$\=>/A]>/X"
MI(&!ZG.?O_/YQ0\#M 4@I4CGN^7CN4"I(X24GY@ HD@$]H/'D\1^//?CT&1G
MK@]\]#CG %14U* %=I X*22 1R H I*@23[_ +O@\<'^&A ST&<9'X@8'&.3
M\ 3TYR1)QGC./CUJ4/"E+[ "E*@A*N?=9"CPOD)[DK002 #V\<#R1J2< 9 Y
M(ZJ#_''?&3Z]N:CC/(!^!Y'W?6O@2ESN3V>JD>W<E/8HGEM1\\]PY2>20?'!
M'\&\CW@S ]MIZ9Z< X''WCCX5K:&-\E\N>P;# #TP0>!V&.*M[M-3N$J?JJM
MXI4>0JOAN=I2I*$I^9E14%$DE2@>WG@'GWR,DO3S7'']8GG[NN.< _(=ZQ%O
M!SF&)O\ :C4X^7 Z]ZZAVUBQX>(5S$6.Q%92[.4EF,RAAE)5,?4HI:;2A""I
M1*E<)'))/UUM4E@"Q)) R3UX&._RY^.:IKM%2=U1510%PJC &5!.!\ZSS65<
MU<:[DOO=2VX%KT_4;SG[&,%E05]2V1PW5):RVU=CQ[:HZ<*F8PZVM'WK"DUN
M2;S2F5N"'A,FKP!32Y.X%I*QOUVG!?#MC%KLP'Z8O5?_  =MW'-K$&:*7Q!*
MC @^4ZR6^D(<;[Q9;_(6PB2XIKDG4[B33T/\R@(&IR*?\:Y =--0@\;E*R7I
M&<0,EO\ :G<Q]BL,,QF68T9EJ/'CM-L,,,-H:989:0&VF66FPE#;3:$I0VVA
M*4(0D)2  !KR1)8EF)9F)+,2222<DDGDDGDD\DU<          8  X  '  '
M05-U%332E-*4TI32E2W669#+D=]IIYAYM;3K+K:7&76G$E"VW&UA2%MK02E:
M%)*5))2002-2"00P)# @A@2""#D$$<@@\@CD&H(!&" 1C&" 1CTQZ?"N3<CZ
M+=F; 358-^*]E_O)QQZQJMJ+MBHP&T?><4\_*N-F,BKLHV0N9LAY2G95C:;;
M2[*2XHK=F*4$J3Z1?%6HRQ^3JL5AK\(4(!K5JMU=*BC:J)JD;0:O'&J^ZL<>
MH+&HX""N"/3H[687.FW%YI%PN=LFF7,EJBDG.[V8;K0L23ES!N;."Q&,:#M/
ML[PN0^JLR_8VTC2*./C#JMP^CO:6]LGL;ALQ8T*DD/[=6FT-0Y7PXD&'%CQ&
MJ!B,U'BL,-L(89:;1G'JWAP;F?PQ+!(Z[6_1NOWEK%CG@)>6^IR;>< -,^ !
MSQDV'Z1\6!%A_P *KZ6!9#,%NH5FD$I4H'#QRP1A@"?>6$.23[P7W:RG"^A[
M)\*J+BHQ;?.HVD;N7[.=(=Z=>FS8;;!2K6V3'3-LWCF&,[MO.2GQ%B^HZR_&
M?<,6,5/GT4<(]8\.VTB/;>$+28*X9DU35]5NU;')!%A-I(][OO#@]"IK1>7'
MB;4P?TAXJU.5O), >&.!7$?.T9NQ?#C/10JD@''7-OQ[[-':N#E$?.<SWLZJ
M-U\XB.N.P,RS[>>2G*:7UT*1(CXOD6'4>(WN'P'TJX=KL4LJ:"K@'X?GN*KB
M?^474WMFLK/1O#&EV3*JR6=CHZ^RS;2&5KFWNYKJ"[D4C(DNHYGY(W8P!21>
M&K5)/.GOM5O)\EEN+F])GC+!E(BEB2)X5*MC;$R*,!@ PW5O=GHRZ<7$=F18
M)8;C ^7#O#G^Y&\WJDI4E1<3NKEV8-D*"E!2 VEOSX0.!Q2-XO\ $ /\WO8]
M/]!I-AIVD 8((Q^C+2T.00,'.?C7<-&T[I) ]QU_RRYNKW.0P.?:YIL@AB".
MA& <X&-G8AL5LCM\4JP+9S:S"5(/<E>([?8ECBTJ/'*@NGJ(:NX\#E7/<>.2
M3JMN];UF_P ^W:OJ=YGK[5?W5P/NEE>NJ*QL8#F"SM83DG,5O%&<G()RB Y.
M3D]3D^IK:FJRNJFE*:4II2FE*:4II2OG'D'D^.?KX//ZCZ_PTJ,<CKQ^/SK&
M<PPK$MP,=M,1SC'*?+,8NXZHEM07\"/9U4]A1"@B3"EH=8<*%I2XRLH]1EU*
M'6E(<0A:7W'X$ CZ@Y!^M6&E:IJ6AZA;:KHU_>:7J5E*)[6^L9Y+:Y@E4Y#1
MRQ,K#KAAG:Z^ZX920?-K.>A7.\#6_/Z;L]BS\:3ZBT[,[PR[:XJ8B5*6KX+#
M-S(Z+#+,9AA +46NR2OSBOC\AJ+\!&[4-<DUA!.2<F-L<8.$^0&<9YZD' &
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MJ*,*JA5'7 4  9/)X'>KKK&LJ:4JGE_S25_J[W^[5J&Z'Y&I7J/F/VUR"VD
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K2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g287237g34p78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g34p78.jpg
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M 0$! 0'_P  1" $$ ED# 1$  A$! Q$!_\0 'P !  (" P$! 0$
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M=+G$GNU,S 2,+":L?,@75Q;I7(P\G'?FA%MRHR&)7^KX<2O,9;K#V'//L_\
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M==<4IQQQ2EK4I2LYSTVY\SF$W+N%$RV21$SF65$6]:555;]@*JJ)0%50
M   !QJ&PN.Q[8;$LU&FS-C*#,S5H2S,:L1))*<DD]R3W)[G5W?(CICZ(M8?
M-4_9/(/W<S7SQE/RA;_/:D_<W'?(*7T6#\WI\B.F/HBUA\ U3]D\>[F:^>,I
M^4+?Y[3W-QWR"E]%@_-Z?(CICZ(M8? -4_9/'NYFOGC*?E"W^>T]S<=\@I?1
M8/S>GR(Z8^B+6'P#5/V3Q[N9KYXRGY0M_GM/<W'?(*7T6#\WI\B.F/HBUA\
MU3]D\>[F:^>,I^4+?Y[3W-QWR"E]%@_-Z?(CICZ(M8? -4_9/'NYFOGC*?E"
MW^>T]S<=\@I?18/S>GR(Z8^B+6'P#5/V3Q[N9KYXRGY0M_GM/<W'?(*7T6#\
MWI\B.F/HBUA\ U3]D\>[F:^>,I^4+?Y[3W-QWR"E]%@_-Z?(CICZ(M8? -4_
M9/'NYFOGC*?E"W^>T]S<=\@I?18/S>GR(Z8^B+6'P#5/V3Q[N9KYXRGY0M_G
MM/<W'?(*7T6#\WI\B.F/HBUA\ U3]D\>[F:^>,I^4+?Y[3W-QWR"E]%@_-Z?
M(CICZ(M8? -4_9/'NYFOGC*?E"W^>T]S<=\@I?18/S>GR(Z8^B+6'P#5/V3Q
M[N9KYXRGY0M_GM/<W'?(*7T6#\WI\B.F/HBUA\ U3]D\>[F:^>,I^4+?Y[3W
M-QWR"E]%@_-Z?(CICZ(M8? -4_9/'NYFOGC*?E"W^>T]S<=\@I?18/S>GR(Z
M8^B+6'P#5/V3Q[N9KYXRGY0M_GM/<W'?(*7T6#\WI\B.F/HBUA\ U3]D\>[F
M:^>,I^4+?Y[3W-QWR"E]%@_-ZJ" $"US1/A&PU>$"P(>&6V)Z(*##X@L;%](
MZ::5E/\ HT&"RQ%8\_)>>D/>::3YQ]UUU?E..+5GJ8YYK.6\.IK$TL\SPT>N
M6:1Y97Z=Y9I5ZI'+.W2JJHY)X4 #L -0;Q1PT-WQPQI%&LEKICC141>=O8YC
MTJH"CEB6/ [DDGN3J7 ]+Z=4%$*5J?6BE*%CU*4JB5;*E*S$:SG.<Y%>/.<Y
M_'G.?QYS^//-F?+Y833<93(_KLG_ -]L_P"6?_UNH1*-+H7^XZOW*_\ W>+X
MA_X-93Y%M.?1-K/X#JW[*YB]V,M\Z9'Z;9_.ZN]!I?(ZOT>+ZFGR+:<^B;6?
MP'5OV5Q[L9;YTR/TVS^=T]!I?(ZOT>+ZFGR+:<^B;6?P'5OV5Q[L9;YTR/TV
MS^=T]!I?(ZOT>+ZFGR+:<^B;6?P'5OV5Q[L9;YTR/TVS^=T]!I?(ZOT>+ZFG
MR+:<^B;6?P'5OV5Q[L9;YTR/TVS^=T]!I?(ZOT>+ZFGR+:<^B;6?P'5OV5Q[
ML9;YTR/TVS^=T]!I?(ZOT>+ZFGR+:<^B;6?P'5OV5Q[L9;YTR/TVS^=T]!I?
M(ZOT>+ZFGR+:<^B;6?P'5OV5Q[L9;YTR/TVS^=T]!I?(ZOT>+ZFGR+:<^B;6
M?P'5OV5Q[L9;YTR/TVS^=T]!I?(ZOT>+ZFGR+:<^B;6?P'5OV5Q[L9;YTR/T
MVS^=T]!I?(ZOT>+ZFGR+:<^B;6?P'5OV5Q[L9;YTR/TVS^=T]!I?(ZOT>+ZF
MGR+:<^B;6?P'5OV5Q[L9;YTR/TVS^=T]!I?(ZOT>+ZFGR+:<^B;6?P'5OV5Q
M[L9;YTR/TVS^=T]!I?(ZOT>+ZFGR+:<^B;6?P'5OV5Q[L9;YTR/TVS^=T]!I
M?(ZOT>+ZFGR+:<^B;6?P'5OV5Q[L9;YTR/TVS^=T]!I?(ZOT>+ZFGR+:<^B;
M6?P'5OV5Q[L9;YTR/TVS^=T]!I?(ZOT>+ZFGR+:<^B;6?P'5OV5Q[L9;YTR/
MTVS^=T]!I?(ZOT>+ZFJA;#B!_0+LV#@"AL$*Q8^W$%@/#@Q8PMF$K;^PV\PV
MA[+2(C<7*%*1F.AG#64*4G*/%G..;KRRR>(&VYGDD>5H=HNTKNS2,_N3CCUL
MY)8MSWZB>>>_.MJ!$7:&7C5%5 <^H15 0+Z9<]4*  !^#CC5O?(MISZ)M9_
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M:U5@224QB?S'F5(_,C23S$V.WG>]G&?!\=C[U<:X6T]M4#H7L(03$ 67,<H
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ML\':!X2PF@T"R!FJS((-BC\(9.B13$!,QAM],4BU)9PKRT^1Y#KJ5ZE@D2U
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M3(8;@7@%;(LRP*>U -;4B1=J\BG!AUDB-1FY&R@:$LXQ]96(G6CY4JS4//\
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M/BY/'M.HB#>&[8-MS;0KY_+IM>:T]V7!I;F]S?2I55)IEK]12(SJB"P(^A+
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M?&TYKBTHTDM-$5(KPR,(DDE+,O1&SL(PYX3K94YZF4&EO(T:!A6Y8CKFR[)
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MGTA-,Q/P1@NCHTFPN$_1AM7\T9GLNMX;+1='1*8P7Y"B1@!S\+=_\CGGX^>
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M>I=6MF9);EC<6?N5YXK@ZDI1-#@\,QE0+$'!AD"GH+-$R0AC)PUCP9/<W8%
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M@?$/9Q[![/B_>_!J*?+Y65F>7)Y"1VNC),SW;+LV1 "C(,S2DFZ  !:)\\
M"3@:P!PAK'6H<62LDVB4  *?R*"SSDFOU4.-E%_*1D:+E3UP(4-\GY"TYAQ'
M&W)ODJ3YMWR<XQ0E$ )*HH[ DA0"?@'/ '/Q?#J2Q];=NZKUNKBJ^XMR9*Y&
M+E^MCXLGF+UJ&ETD6K<-9;$\\=3J4B>966#J4]2<C69Q5ZF^RC":[77HZQ;
MIO&! UQE85J1B=%&H\4?*%"VY7DS&(:?'$1(\4AMO#GB7RO"_$/9P.P]GP#]
M[\'LUHG,9J.1B<IE$E6W)<8F];607WC->6TWVT,+;P\P23G[<T?,;,5]76:B
M1(D",S#@QH\.)'1AN/%B,MQXS#>/'XFV6&4H::1CQY\24)2G'CSXL<KK0FFF
MLRR3V)I9YY6+RS32/++(Y]K22.6=V/PLQ)/QZY'&L6G&FM9I'Y"W:#^UO;?]
M<6PN31^_S;/^C[1_HC':NB^]+,?YV?\ YY;ULSR%U;IQIIQIJ,D+I3A-B#U
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MU7>G-!%)7:'A0\#0S2[.<SZ\DTXTTXTUK8U^1G4O\5.NO^897>24_P!]U_\
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M!$9H@I3UFE =0%'+K5G@-.U76H[J9KJ)K)S9T#8=%@V7911&R(X;,6T0BQ^
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MO2YU>T_M>18IM[H] MYC9>ES&B]UUNL#0A%RPGZH0M,&0Q*%"?,8DD!1B 7
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MKL:MBG6V1MD-/0Q<F,']7AXA!]N3Z.T;*/1%*3/5(CMS5(&%)ED'1&'#QNQ
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M>*2,E6*DJ2"1P==M737\DCK+_</JG_)(7DA7_O>#^!B_Y%U\6>.W^&KQ:_\
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M@(>"C+<(6(%16H0X?$;SE641XD1EIAE.5*REM"<9SGQ>/FVJA5"J.%4!0![
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MY5$\^:2.<J('N *&=5<]/##CE) OCU[3=<]RT,_0B.P*);AVU]AZ2L79/<@
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MXO(RK&<8SX_Q<<'CG@\<\<\=N?B_?_!JO(^/\/\ L^/7UY333C33C36LLO\
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ML#FE;^[J?Z2FOK?[&'[UOLF?_(3=_P#,[.OX\$7^1_#_ +T=E_\ O3?*8_\
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MO')6BEJ- \"*KND[2OT-))(R.L:=$+(Y$BPL&!MP0JBS5PZXZ*DXZIG2=X[
ME65F**T(C7K$:(&5G8&0,@*-(AG@J]C9JN:W8[1J0Y(=Z[^$!T"P8GPS1)^N
MI[6;8E;0U;<@D>56&L*D:_00(ULL"9D!FQC,^63K9>6A]X0Y8VZ:PE$D<5M
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MVW9,&T9O<)VSBYXA"E4L_#A58-R4DCI)'!.S59>M_2(H)4EBDQ,&.GA*+-$
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M8J>7I$X:A'8E>"MYK*I:(1&,LG'2).KCD<:["J]7PE3  ZM6AD,)7*T'&5\
M&',ICCQ 0-"8'"AD&.C^0Q#@08S$2,RG^2TPTA"?Q)QSSNS8GMV)[=F5Y[-J
M:6Q8FD/5)-/,[22RNQ^Z>21F=C\+$G770Q101100HL4,,:111H.$CBC4)&B@
M>Q450JCX  -9CF'633C33C37\K6AM"W'%I;;;2I;CBU80A"$8RI2UJ5G"4I2
MG&<J5G.,8QC.<YQC'*@$D  DD@  <DD]@ !W))]@T) !)/ '<D^P#XSKPA^@
MS_\ [A.__P!.3_\ U<^]/,C_ &Q/]Y?^NOEC@_$?Y#KVD]7?R9NNO]Q6H_\
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MH%!4M"\T$TK D#EQS'TD\]CQT\@GC*R?")DK*[UGNP37^P*90]KQKW=QL0K
M#*&;1I,'J)<NP==@^ORP5,P-+%30CPBR2*CDC'&6T$R.BE[75BSA#%!AU3TV
M)Y8I):_E1L5+]4$AOQ5'/0K<.&#AD$G23&Y)6.1>G5?3RWHSB-T24.X! XD0
M5'L*.HCL01TMT\\.O 9D/)_NG>%5KEAFT;)S2U@K0&X%NMT229;N(PX^%&=I
M=$V?>>N2?JF*%BO$7Q8VGFP=T&M2(^1<AP1-!R[+Z;-A"J28%T$G391V1;A"
M^6R]34;4=69>HL0H9I$:)N#U#J#B/@%J)DU8IU0LJN:XZNL,1Z3 T\9( ')
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M5%+$A!Q5#3*Q21FOT K%"RM'T]0)5$0@\%@6944<L"S!>['FTQ&D^ODT2>"
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MW5+9PTYGRE^'';JGLV()+$#8B.G+%#,L$ICR6U8\<[QRO#.B/$MHRKU0NK%
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MVZ2'92HX8=RO;N..1P8_L[1.\!/<.C]Q=.ZH1*>?L8;3N_-8O6*E"5[6U2,
ME6@?8F%,EW9%=;V#K0H9G :0&+MLVLC17IHHB2#ME&X 2Z"U5;'2XZS8( 1K
M%2<)(WD3EEZJA B+^3,%#2LI,8D *JW'+6R0S"VEN&/VL(9XRR#S8@IZ; ]8
M+YD9/2@/KF/D$CD!:XW3UPWIOF[;]LC?79>M"^9O7 1K:UR=D:R=B7K5/6SL
ME6]Q,TF-6JP8FOB[#L/+EXLKI:WD0PL>[&UW3Y#<1L8</R\]6[5J1U$-OSU
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M:<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::I/LM^3EO_\
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MY<10)U"3J5$*J3*K(Y^Z)'JL0JJ5C3VJ@.L@BX4*7D;CIX+,"0$(903QZQY
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M<1UUD(Y/):29^N5S\7)"HH^!44DEB=9HX0DDTG/+2E.?B"1KTHH__P F//\
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M9Z8P@<*ZR=0"D!&,B*[%0.IARW/4W58E2)%KJ.OIK$F$%RW3RK)P2>[ (S*
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M @^:AV6.Y7\=(TV]8<-9R]S=.9J-%'5F@Q\F6R1O6*UJ>.%+;QB<"I7;S4>
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MV%6:]-8QB[YFJ'KL]B"PX &,VZ0$CL$&<BH E;S$K)TOUH2&(6=WY+#LAC<
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M>%>6:&?#/$\5+W10O<QPCN4O<8[A,^*F]+\G,*N% R+KBI+CI7:,LH>2-6@
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MB"2-+N-MQ7:KO&2!(BSP1LR$@,H*DCG51'](3;?0[)1K;>YI1!O55HT_$,Q
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MA6F+?8;G7J[7D62.<*TD;4YMI/A@"09;+L*L$E"FG$/CP9 26$*P(8C@<$<
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ME60AR3<B,BP5^: N<_(=D\R:'9'!]>0('G!KI=!YUJM-11WEQ%QB.&1]HE9
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M-<.?O)%'E\YT+/AIK3WUCCL91:"M9KR2*+<./:6</#2=XI<J@ZD UPFKV$H
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M:=:#=6Y(:^/R,N8H019S)QPT<O.9#/E*<26@E;(S&64RW852S(99"\I+MSD
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MB0Y."-J<2)9L)8D,5&41.8L<4L%P-[)L@V44V1) #K,X.@K$SI,JND9I+K\
M#IU.5"A+(M#3L+8\N9<IQPX(23:-IE@",1%9\X94ZF,C<E^D.!R.Z]X0/+Z5
M/L#\N69>0WJ_<ZVJ>,PF/VIB[<-/:L>1M8E;5@7:T463JP5?$O)7FWE3R&0Q
M*LZ3[6A@P5?'X^\U1Z#0Y*K.V6"T%MWKC4+O5196KV9FXP@2=;:;CC6+ ?*$
M$CK8Q29 ?8,"ORGBDV0#BP9L(/C,$(X/!1IRGIE>9QEZ6_F^!74%6Z@O1%P"
M2>&"D.%Y)X X'8<+SSQ\>N)\4\WM_,W*67Q+X*?('=>^I;<F,QM2L;6%DS\5
M[;5G)PI3@CR,UBO8O'TG()9R,M<1P9-R$@C%+U@'V()1M?PK5 W"-:CU3J<(
MN\O-V<CNR[-6'=GB]^3TOU^X/D\L%8SM2?+D8J(ZK%AL>6@YDSD1Y><*K.?+
M#>8.$K!_7'=E\T3'E6Y[\IR1[>Q'<<Z[S+Y#PPJ2[EGP]C8UIY<SXS7<!",
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MH"QSRP5!V(%08'DB&#AP"9KF8*HIV<-QI'-RK-UB0BN2>KU?5 $P8!BK$CJ
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M->RV.NV:36*[?=03M6EB,L+?#%(60_"NL[RNH[3.,9QG&<>/&?Q9QG^;./\
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?33C33C33C33C33C33C33C33C33C33C33C33C37__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g287237g35s94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g35s94.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[10:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $_Z^41@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              ;P   ;;          $
M                 0             &VP   ;P
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   ;P     4F=H=&QO;F<   ;;
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   &\     %)G:'1L;VYG   &VP    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      )Z
M  $   "@    *    >   $L    )S  8  '_V/_M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ * "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 "
M P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
MC@(R P$1  (1 0,1 ?_$ !X   $#!0$!               &!P@" P0%"0$*
M_\0 21   00" 00! P($ @8' PT! 0(#! 4&!Q$ "!(A$Q0B,15!"18R42-A
M%QA8<9;8)"4S0E*!D35BH2@T-D-%5G.7L;/!T=;P_\0 '0$!  $% 0$!
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M[:/]83<7^Q!W'?\ &/:=_P RG3ZAM'^V?3__ "G5'_3VGMU9_J6O_P"/:?\
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MS[6E'78SKO,XV/=C$?)L%QZGCF)34F(W3.^46&.U=-$4N)3PJE^)'JHKKT>
MW'9>=0O(:* Q2P'Z0;489W:2>(IU:8YG<Y=Y4-AVNSGERP)8@%LD#5@=@Z2#
MIVH$D:JL<FZS;T500H1OK#*A02!@C ) X)TL(%\JK54+K/X96Q:Y= YG#U"J
M!&[)H:J1[9TM4_9+M0J/W -FM<V%.6N9G"X995EDM:I%\;!Y16<36NB;=NZ[
MLS;_  =^Z'JP[O9QM@W9L'O> ONPYSX0X3:-9/:9QVL-9QO(Q):.\G,F/\8=
MY#R_]H_:SJ.=+V_Z[J=Z7F^Y/\,K:U_D3]%I2BP+'KZ+V)3<2THC1%?E=9AD
M_3=<-VM2L%G*AY46YJJR<&&C18^JK8KC6M=3VCB:C2B'7EE2,/5O,Z1=7+)5
M^V&)I5JC]18F7,7&X9.]PQ;<=1@K>TM5-8*QY"D$:!Y+,R1"G,C1M"#7YC;,
MIR5(^RF -H)=W.\=PG:&.RL2V-_"=R3.,7G9E9;%F8_E-#V-7=1*V!=%1NLX
M?@6&^GXSN7W/FM-ODBVS<6B''&YTR0AQ:518:&"G<20?2!:H9!$L >-.K480
M)C9"&6P@B),#9']A<>Z!K-)(\HVR]/5,B[VDVNUF8>(P(9\-<"-[ D%OM'/)
MUO8+M56)KTUO\+7,Z]-3E.,YS5IA5/8[%%;FV%X_'Q/#LQ@!C?;?T>58GBL2
M)C6-9#'^.WHL?C1Z:KF1:YEN,FQK;2-NW=>VAMT<D+;H^K3NBE?Q)8FS8.8Y
M)"9)$.5=SO8%CG5_M$PQBPU8(97'[2SC#H-J,/\ &'VE7W5;@J.!@:=O_6$W
M%_L0=QW_ !CVG?\ ,IU&^H;1_MGT_P#\IU1_T]K)[=6?ZEK_ /CVG_U+1_K"
M;B_V(.X[_C'M._YE.GU#:/\ ;/I__E.J/^GM/;JS_4U?_P >U?\ J.C_ %A-
MQ?[$'<=_QCVG?\RG3ZAM'^V?3_\ RG5'_3VGMU9_J:O_ ./:O_4='^L)N+_8
M@[CO^,>T[_F4Z?4-H_VSZ?\ ^4ZH_P"GM/;JS_4U?_Q[5_ZCH_UA-Q?[$'<=
M_P 8]IW_ #*=/J&T?[9]/_\ *=4?]/:>W5G^IJ__ (]J_P#4='^L)N+_ &(.
MX[_C'M._YE.GU#:/]L^G_P#E.J/^GM/;JS_4U?\ \>U?^HZ>G5>S\;V_A==F
MN,ILH<>3(L*JWH;V(*W)<2R>CFOU62XAE-6'7_TS(\;N(LNKM8J'Y,8OL?4U
M\N=6R(<Z1I[G;:BTUDE'4F-V58Y8IX'\2FJJ:9%EIZNEEP/%IZB)EDB?"MAM
MLBI(KHLJDJHZR!9XPZ@ED>.1=DL,L;%)894R=LD;@HP!*DC<C,A5BXO6OU)T
M=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--'331TTT
M=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--:3)<BI\0QS(,MR*:U
M6X_B]):Y%>V+Y(9@4]) ?L[.:\1[#46%&??<(]^#9ZS4U/-5U$%+3H9)ZF:*
MG@C7[4DTSK'&@^+.RJ/B=622)%')+(P6.)&D=CP%1%+,Q^ 4$GY:Y?M9;G6/
M2ZK85C"IJSN=[@L3@Y*J?F1,M&G]6W<V3)Q/2N#/*8D4U(,3@0V;;8<^Q=C5
MF3YR+S)GS/;71UE%+ZPO+4\T72]DDC%NM\C)'(%95NE>A:"JO$P _:33R)(M
M&*@8I+=X%/&-_CM+ZE]$/T>VF]T-?UUU?%<*FWTLYIYZ*WLC2TX2&GJXJ.8>
M*M5[(4J88C%:EDJ:NX-))*T4*QD\@=SYSM#/]J,Y?&RG$)T/%I,R)0G(]MZM
MER+AJ2GZ2^L<F@2<Y<;?<R^,DP;>G>4XPQC*:_$G5RH-6AU[1P1&! "Y>3.Z
M21F!:20X#,<G('95'&U0JCMK]">EK1TU9^FY+7):[I2R7**&2JCMO2O4L,-!
MX3>-04ULFBLJ%!:I3[13UB!9)+FU3=@(IJIE23>,=S\F-?:5[<NXC)V,VP7N
M(RS&:[M^LX&2+RG>FK<]F9.SB%7DF&;7QL6M&U)U7E<Q+J,@R'(&;^50/Q'H
M+<U,RTPT;BUW:JM%6M32LC$J8IZ>4>+35E++A9Z.MA)"5%+.N5DB<Y( =<2*
MCK\S_2S]$_1O4UDZDNEDME?9.J.E8*BNOLE';C9;%.E+2-<:>Z16RX"EKK7<
M;A1CQ8%M5(]-!7+44U5$].T=?+W&[=\^R7-L'LJG/GH#^T=6Y??:IV>]5QC"
MKK'*<7$.5 RB# *G/TV#L#"[C$MC0*KY7C40<NC5:WG7(:W%3[_0TU'6QRT
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MP"#_ )\]-Z^OY'^6GL=+Q^SD_%?SYX_+6;_/N2\#_K)85Y<$!MI0">""KDH
M(2?SQR>1QQ^>J;USC</E@YU7V.E/^:?CT(\N3DY^/SX[\<6QGN5>94;1:V_C
M/ 2PSP5A7(4%@\GD I("5?CT23QTWKZ_]OUG5!1TOG$__P"0_F/T!\=6!L+*
M>$I%FZH^1/G\4<I('D5!?^$CQ\$@#@J \BE7DH'DUWKZ_O\ Y:>QTO\ HY/F
M6 /'\^WRY'GJZ<_RD.A(LW% IY],,A \B/$GEOD\CV$^0( //D3QTWKZ_O\
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M-1Q[Q*&XRCM-[F,=H(KT^ZNM#;9KJRNC@E^SF2L&O&F:MD#V7;-2A!;3^ZI
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M;W<+WR>?+R\_E\_/U/& D)!X'M0!')_/!//')_;V/WZH<X!S\^<=CSY _#
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MP"/PXQZ<9QCY ^6/0:OXQWY]/^^J@?ZR'"/%9^T *(^SDD)'!)Y/DA(/OA(
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MEG@:.")II21M1<Y^)]T@X [_ *(YY.XMDD8!3E):-\\\!,&0KT 5<E3:%H]
M<^U<@#D_CK9&HA/ $2DX 5@"<X&,MP#DX\N^."!G6E:@N )=X:A7 #$J) %*
M@8.?$[J .<<$:H9N<DJ5?$BRMH7X'T[K\E+1''H&.\2V4_OQ\9'X_OSU0^'*
M,2)&JC#93 Y[8./@3\,CXZHLM?3D2-/5)Y*2Q"EN^.0<<#SQ\_+2^I=L64=:
M&KN,U8,E(0N2QPQ*2. DJ4WZC/<  ^(1&40"/D)*>(LE/"7.S&TCN?E\_7\?
MAWUO*;J.I3:E8HJ4 R"KJ#ZC+E2#W[!>.!Y9T]-9:5UU$$ZL?3+9!'"P%H4A
MW[@IAYK_ +5MQ''D4J3[2I*DE2%)6K621-$<'MSSC'X9X^[]V,:ZFFJ8:N)9
M87# CWAD H<X QDYSZ\?NUG>UGE+;;@2KE?DC@I*$*/^&.?O7Y'USZ'(">2"
M.L63\.>W?S]>/F?+([@<XD:\4E2ECS45) 1PGR+?'BODK)\4J)*5)Y ] CUP
M>@\CW[^>>.>Q^.!R<>?F=-)?/'J2+@693<HL5U./0L5R*7?6?*?.!4LU$UVR
MGCR*DE<2$'I"$J!\EMI'BODI-\6%82 @",A\,.,*0>><[21R>.#\!B9;[=4W
M>MI;71(TM;<:FFH:2) 2TL]9+X$8!\L2-'N)[!BW93GC'C#&/0;&DR1G3=C]
M!%RO&MC0\9LMK0G_ *+(:3!9.+1$-J_T>M2ZAJ?.LG<DR:IJ[1%?86T"BK8[
ML:EH8<9627K'>9(#@.8Y:0S*C -&]0KL2<E6VH@BB=@S*C.Q+/*S:]Z?^Y<H
M*>=B.NY7\*I65MW3$GLQD@B:)G247SQ#$[%IV 11(1&-BJ@775GMOETUGHW7
M-ACJ7&X%C32;1UE<=B&Y$N9]Q8S,C@RH,%9@0Y4'(WK>',AU:8U3&DQWF:J%
M7UR(T"-;45'M$\DI!4.$(RQ8A0@15WM@L5"A=YR[<%B6RQ\1Z@Z:J.CK[=>E
MZN1)JBS5LE,]1&GAQU*.140U<<>YPD=5!-'4(BL559 JG:!IRKM*DI8*@.!(
M4D* \>20"01Z/KD'GC@\>CSR3C&.X.?O_7GG'ISC6H'VA\Q^_6IFI AP%!7)
M490(_MXN)]\?Y\_G_+C]NK6Y./W=SQZ#X'S\AWP>+9CR?F/R&-:OJF?3MS@#
M/...,$$Y [G(XXYXU@T=4XSP>^>1C)R!G.3P.#G)SSCUTUGUQ(<ED'C_ *!(
M_O[_ *01Z!(]*YYX_;_/JY/3[^,X\O7SX/RP>-6MGC_>'\>_Y>6MM0H(?>'*
MUJ^! ))'W#Y?8]\?C^KGGG@?C]^KO0_'GOZ$?'C\!YYU,88QSGC\OA\._P#(
M#&566D!:E^2?)9']7!*4CD<(Y]CVKW^QYX]<]4R/ACGCC .1CD @=_X^NK=4
M@@.@J*SY*\4\<A*5)'Y/B/'GA''*E<CCQXX'JG.>XX]<Y\\G@C.2/3G!('JU
M0ZWY!PA?B!QZ4/,%*>5<I!]<?<H<\'@<\G]^J_GCXGG'J1GD>8P<^7H&AE*@
M!Y<I"N24<)\4J\^1RH#@J'Y*4I ^[A:CZ($\G_N21\,'(YR,XQYZ:NI3^ /+
MXQX@>Q]QX\5+*ASR'/( _CGC\^_3G!/GCOC[QQZC\CZ\ZKCOR./S^6O>0M12
MI)^XA) !'@GGTM1(2/7)_!Y*?$<$ GJ@QW. >2!D<=LY\\G')^?8ZIJV?(*"
M!X%8^UL<'T@<)^]1Y*23Q_22I7XXX/JO;D>9\N^3Z$XR.Y\_P&FJ3R4I3RE/
MB0I2&SXH'B@A:$G@(2WY$DE2O7B/Q^.F<?+C'<^?KSG/EY_OTU<90 % A0!0
M .%^03SY<A*CSRI/]P"!Y#\?O0XX!QG)XQWQR1@'SX/)Y[GTTT_&JP$U%@E*
M4A*9X">!P3_@-\D\< GRY!/YY!Y_'K/'RI/J3YY]/B1^&M1<?Z2/_</_ )CI
MT>LFM=HZ::9#>.IYNR:2FN,/N(V);=US9N97J;-9##\B'49&(JXLRBR6+$=8
MEW&OLUKU.8YGF/M/M.3Z>2F?6O0<CIZ"VK=S9;HENFFBJX6J[5<(Q2W2C5E5
MY:?<&2>F=PR0U]')BHH9RI"3+LD#T\L\4D*NI6J41X7$573MXM),02JR8PT<
MH!!>GG7,4\>060[E*R)&Z[/2^V86W<2=MG*F3BF8XY:R\1V7K^SD,R+K7^>U
M+;"[C&[%U@);F1E,RH=SCEXPA$#*<4M:+)ZORK;B*HX[O:WM54(A*M525$2U
M5NKXU98:^AE+"&HC#<HP*O#40L2]+513TTO[2%M7456M7$7V&*:-S%4T[$%Z
M>= -\;8QD8(>)\ 2Q/'*HVN-.YUJM2]'331TTU'W?^_J?25+71XT!G*=C98F
MQ;P7"%6:*AF>*IIEVZRC*;M4:<G$]=8BU*ARLPRY^!.,(2ZVDI*R_P PR#&<
M9NMU9K,US:>>:4T=KH0CW"O,9E,0D+"&FIH R&KN%649*2D5U+E9)II(*2"H
MJ(<#O425%-04%,]==*]S#0T,7VYI  6=V"MX5/"I#SSLI$:X 5Y'CC?COD^S
M;_)LL;S2UR-[-=EMMR6XN>S(/Z5#Q:/8,_#.I])8O+DSXNJ\8?83])+LF)\S
M8^61TI<S/+K%OZ6IKNV9D2F:@HH?J^U$KNHXY!)-6%#E)KS5(L;7&?)WI$52
MAI6)%+21Y:5_;>DOHOHK2R73J8QWF]J-RB2,FWVXD+NAI*=\KN0Y5I7$K2C[
M;N I$9YV:M+S@8@:VSDRYS#LV?9N+4EME];,B8II\*<D.R/)"8_S24CX?FGQ
M&$+>>#Y9S^R$4AJ!(J[6"*@/O,,JN01@9'O85L' 8G  S[#3L<>+L'A18"((
ME,:C.W*@((XP".  !E21WY<JIL,@H' *'+\AQ]$IKXG8T"UE-P)B"A32T/L1
M)D>,XV \KA+S;I1YJ\4<KYZ@-'&Y]^-92,X+ LP[<Y8$@]AD8/'?2K2AK0OM
MUJMM3X14I)+24S2QE'$B%7:)I 0RJ?M#C&XXXUA8O11<61*115U="2^V8K\B
MNK*:.)+*2VKX)3CE8X])8\FV5!I]7@?CX 4>!U<[LY =F8C! =WW XQD#?P<
M$CW?7/8'5*^6.N6$3LQ2#:88CO\ #C8$[6C",J(P' V@'MZ:5&-9-?8;:V%Q
MC19HK2T*FK1-)'AQX5W'2A2?H[JKC--PK6O>3)D-*K[*,_!+3CK;;9:<">L;
MQ)*(UDW,(R#&6+;HRK9#1R9WHZD AD8,#R3YZ@7"TVV[4KTM; EPA= ':KR\
MJ!CEO#FD)D0CRV..Y'8D%1X)=;%P&Y.3=IN33-6W$12Y>8]K3T.%D>@ME(D.
MAZ=:Z;UY:W="YK[9*%+7,E:_PC)\%HL^D+^"MM:>Y(:MMZ*VWW:$4/5]*E>7
MVI1]4!VI[U0L!MCANU?'%.*V@8;46NK::MFH0,R1S1<Q_,?77T95O2,KWGH^
MKFEM!#O4V9HS400C*EY(("4$;C+,(Z>:G24!@VR3WWZ?:][SZ"3B^-Y)N:A;
MUQC64LQEX[N2FL)>5]O^1J?6N.M$K.W:FENM56L2:T]67..[OQ77DBHOV96.
M1K*]L(4A?7&UW2$Z5-136F<W"II2PJ+3,B4M]I\ -E:(2S0W2)D99(:BS5->
M)H&6H:.&-QKB:>\QF**2L04\4H7PZU"TMOD);;@SE$>ED#>Z\5;%3E) 8PSL
MIU-6+*C38T>9#D,2XDMEJ3%E176Y$:3'>0EQE^.^TI;3S+K:DN-.MJ4AQ"DJ
M0HI(/7(,K(S(ZLCJ2K*P*LK X*LI ((/!! (/!UN@0P#*0RD @@@@@]B"."#
MY$:O]6ZKHZ::.FFCIIHZ::XJ=\F.PZ?NBC3(S;(_TF:!_4+ME+:/"1:ZNSMN
MKKY\A)'^([(IMAJKGEK\BN/5PV>2TPE*=+?4!I4DY'AR+C!][(.X$''!R<<8
MXX^?VI_<^W"6K^CVKII2S_WO=;QQ4K,3^SI>I+/+4S01D$%4CKK":E%& )*N
MH;)+$:C+A%AJG"-BZ$L=L/T6-Z<QO-[ZUL38LM1\9@Y%BVOKFTUS&GQ6F_B^
ME@V4.5.IH"&5I<R"!1M1&%S4PVEZ^Q-&\TDDLF7&1E_/"':1G@ <>Z>YQC&O
M3>MZ7J:Y=*]:4?2<-?<>JKC:K=1P)1RN:Z6W7.^T=)U 8')&6DHI(H9W:1#'
M1S5$K.$#D-9E=QLC.:#;F,83KO)+[$<QWHC9F)9MEUO PM%G3Q&LSK6U'',B
M6<M85;0K^JDL&UHJE81#<^8<*: W3W*FC,B[N8RPP3C[)P<<9QQP< $8QQC6
MUL]FLEIN/2MUNMTH;9=;7T,>F[Q:K+1_6305]0EJF=Q74@2WS/234E5#*:>K
MJ-P=#%,X#,=GANR=K9+*VQI6ZC9A@TC9E['SG<#KEXS)BLZO:-R(&(8Y;4MK
M,89.R[>;*JK>6RJ#8,XAB=Q 6PP;&.IJE57QBG+PR!7;+*W.$&1SN4_UN<$<
MX5NW!UAK^C^F:&;I?JNF%KNU/TU12VKIJ+V*-99^I6]AC>ZW*EGIXW*V.DIH
MJJEBG,\,]RN--("!3,KIW<FM6]O1,-UI@^-/3<X?F2:/3V+XY75Z&UN-US3=
MS&L693D&MKL!8J/IE9=-FS8=;5PDP VZY;"M8?U%LFJYZIV#9C?WR7)8 #W2
M% [ A>0 J@'@9QGI['U-#T4MSZ@OM?'!9T2&JZGKJZ:69I(WJ&2G$:+OEJ[I
M)4,XM\$2O-52F4L$@\1U^B'M3U_L?57;WJO7.VLD@95GN'XRBDN;>K=FR8*F
M(DZ6*2O:G6#,>;8FCQY=31JM);++]HY7.3W&TJD$#J3Y9[X&3]WZ[G/K@Z_.
M'Z3+]T_U1U_U3U#TM;9;18KQ=):ZAH)HXXI(C-'$U9*T,+/# *JO]JJXZ>)B
ME-'4+"O":D-U37#:9S85M+N[9G7M7)D0XSD!JWS6RANN1Y3-')>?C5V/PI;*
MT.Q)N2/Q9GU<IA8D0Z2!.2TJ-+LJZ8S$G8R.*=25!4/,PR#L)(6-2""&D(.2
M.0BMV+*1V_35)#04<G4E7%%/*M0]%8J6=%DB>X1)'+4W*>%U9)J>UQS0>#%(
M#%/<*B N)8:2J@DU=OBF-7V+V>$W-#4V6'W-%,QBUQF7!CN4D_';" Y5SJ23
M7% BKK)5<\[!>A_&&51EJ9\/ \=2*:>:BGIZFDD>FJ*26*>FFA)CD@F@=9(9
M(F7!1XG560KC:5!';6"L_P 8BI%?FL]M$PJS4L9FJ34;O',[2%FE:;>WB,Y+
M.22Q)UR2NJ3N'_A[UTAM63;.W/V,8G!'Z)*PZ;@DC>?;?BL99#=/=5F;8].7
MN#76/L+:AT4RFN(>94%.RB ]4V4&LB*>]@CN72G7"F:IH[#8NM)W+U<MV-SI
M^G^H*A@,SI4T-PIHK+75#@O4"HA-'/,YD$Z/*X7S2.P]6V:LAH+34=37VQ/M
MAH;?8*:WW"_6]069:>.AJ;57UEWAC3W8EI7-4D:!! X4'2MQ?NIRGNR$K&^P
M[8.49G7USD&#FG<%L>NQ*CP'7[LN.F4Y#AX),P6ESS-,R3$*O@JS5T%!%F+C
M.S[1Z"IT#S'J+IV]V&Y2P7>@J;1)*YGAIPJO0M [;A]7U3>TK64J@A4E2LJ3
MCAYF<-KZE^C]_HM3I:@ZEZQN?3W4*)"]/3]*6&LN4W7=UK:0FGD;JIJ:Y4UK
MZ,WU"&2KCJK?#7R1^*:*U0_LLSYT5I+'-#X2O%:6QMLDN;BZL\NSO.\D>1*R
MK8.<WKB'KW+<CEH2E+DV:MMF/&CMCX*ZLB0J]DK1&^5S4#\=<IUKUC<.MKP+
MG5T]+;Z.DI*>U62RV]&BMEBLM$K)0VNWQ,25AA#/)(['?45,LU0X!DVJX%9+
M. 9)&?8)1AV7VK4&W@I]1J#*K:0EJNR"(DJ"(T+(;%QNIO(S*?C<N9];<A#3
MCUY)DX0?9Y 0,0S/AQY1RN0%D'/"R-[L@'&]E?@ERVFJX1U%:Y8Y/>OEEHWJ
M**H/,MQM%%&7JK;.<$RSVRE5JRWRN=RT--54)9U2WQ1/]U.UYSHZ::.FFCII
MIANY;?\ B7;+IO+MN9<%2VJ.*B)CV/1W BRR_+[(F+C>*5* EQQV;<6*FVEK
M99?5"@(FV;K2HT%\IM9@H+,0 !G).!^/EKN/HYZ$NOTD=7VGI2TXC>NE,E=7
M.I:GM5JI\27"YU1RJK#20990SIXT[0TR,))D!^<N@Q_;5I=76X,AW3MO!]X[
M$MY669M=:VSVWQRM9F3@TFNQ=-(T[)I9U#BU8Q!HX$29%E($>"&6WU0T1FFN
M3FO,XGD:$KX6X!0R\D#@L2"#[V,XS@#'NY!S^D]32](4]LH>DJ7I#IB\=(V&
MCCMEHI+_ &2DN-08HMQJ+@:QT2LAKKE4O/6U$T,L3&6=G9!*TC-)7$N[;OQU
MHAIAK8FL-\T\<@?1;5PY_$\H5&2>1'8RG )$.)(F%(\$SK:CD!:B%/(/!)EQ
M7Y>!-"R^I4AQY\X.T@=O-CC/<Z\SO7T(?0IU"7DCLO47154XXDZ;NRW*W"0C
M&][;?8ZB1(@>3#2UL6 ,(1GB6&M_XJ%=-R;#<,W?V^;"U5;9ME6/8339+CMW
MCFR,!7D&364>HJ$6%O#D45Q4QYDV2A(^2CF.,("E.\H2I8VE/<::I(6-QN\U
M.5(QW.&"G \R,XR/B1XUU1_<LW"@MMWO/2/7%BZFH[-;*^\5E!7T=?T_>A06
MZFDJJLP4TBU]'5210QDX6NA#G 7!(4]:.I^OE'1TTT=--(C80!Q>:"">7(X]
M$CCET>_7]OSTU,H/\JCY(^UV)'E\"/X_+4:B![\@6C_0K[5  DE)X4DGE)4L
M)3XD?:%G]N1'<'<>_<$>\1Z>F<#T\^_;C6Z7MC+$988+,1]H\').?0ZLOQ6)
MR/@E1XTEI24A3;J&WT@#W]R'FUHXY\AY!/D3Q[X X+(RDX9@<<@D]O/[1Q]_
M;T\]&1'!5XXV##!#1H?P)7(/Q&#IL\GUE F,NRZ%M4&<$J7]"23$DJ ](;"E
M<1%K\2$$++'/ +;?EYB=35*CB0YQ_:]W&>0,_ 8&0>/3MG05]AIIE+4A\&<\
ML@!"#'H6R"6[G'GQIK,3R&9BMVVM?R)C%],:SBK*@GP\_C<<4WS_ -O$4I:T
M>2?+R2IH@)<5U(FC,R\C.?>5L<'GRXQ\\9 .?CCG+=624%9NSQ_GXG.SAB,[
ME.-IQY#! R>W&G F]P.IX5C(B.9,X^J.\Y&D6=9CV3V]%%<;<*'0]>UM1)I%
MM-%!$B0Q,>8BK#B9#S1;<2F"E#58)$19=Q(+AE/E\!VXYY\^?3K6OELC8H]6
MH8=\*9 <\\,AQ@9QCRQSY:=V%-@V$./.K93,^!8QT2H=A&>:E1)$5]/E&>CR
M$*6Q(CO!?+2VBI+B2D\J'OJ/A@2"",<'@CGT''\3K;1D2()$(9,!BX^R 1G)
M(R!]YU#_ +MLXI;76&9ZRQNZCS\KDOT*KW'8U;D%@)U%"MJ^VO<4DVE%3VM9
M2V>1U,5=4W%NEMLF/9<3FXD"4;"/F2EJ9X:A88R6:(KN;*Y!.2HX/!']D9\N
MXUV'T==8]*=)];66Z]25$RTM&]4T,M)&E4**MGI9J6DKJF-9!))#0U$B5+PQ
M$5!\-7A#E2IYV2=QZ_KL6FY9<7K./PJIQ$2VA7"%1+NMLU@^--(I#YV"[5X\
MB)$BM2#/;XD5[DF(I,D\:G3]WFK(K9344U763N/"2%)97;<V!B-/*/@MQA0"
M6)'?[HI[E9ZFT"^T]WM<]@$#S_7QKJ>"S"GB"AYY[C4>'3TL:&2-9O:3') [
MK#-&DS")I;=A_<+K>ZQE_7DS+&:?*+_-,HR; <"R:ERO%K]..7?TEU/K8B\J
MQ^AI<AO7,@<RC)55F&6N1J@4MHS\\@KBS?A]0K^A>K.GK9'4W:T5 @AC)J*R
MF\"K@B3*_M*A8)W>$$O@NRA Q )!P#\+_2A]*/T:=>==F3HWJ2EN3Q6JWVRX
MUP@GIH;I<;:LE+'44"50CE>F% E%1I-)%#)424CR^"BNA?H3=H);8X*CX.CR
M)Y\5 (X!!XXY4L>AY$\>_P $#KFR,'.W /;S[X[,,@C'IGMR>#KD%)&"PVD'
MG/&,'G.<8'GSK1S4D1(!(('E+2.0>"2MI1()_P!_X'/L'W^PM8<'^9'IW\B!
MWSZ?CJR5E)]UE.3GA@?+X$^>M6/?X]^^/7OW_;_?['_KU;M;A<,"<X7:2Q'!
M[<X'ZYSG6, GD D>H&CWR!P23QP/W(/!Y _<<'G_ '>_QT"D@\$*"<D=@<8P
M3G'/?!QG!QQV8/H?P.LZN'*IO]7'T+_/B 3Z4P0/?]^.#^Y3SQU<!CR(X\P1
MGD_KM_VL?W0">.?ZW;L?E_VUNJ4(^=\K/ #!Y/ )3RL#RY/](XY!//'^_HWE
MYC(R/Q//!XSCR_?J:_D<\XY_?^>=*A0!4U]W"0CD<< %0!X4L\>TD*'BD>!*
M@#R0>!3&0?,G]V>.3Z>OP'!X&K-4K!22 4G@^9)/ ^XJ!  !^X'R"B?20HD\
M<=5XR>>?(]_+R'.<9S]^.PT!QR-"O7OXU#[0O[?N\SY>*FU'T#R#_A\_V!Y
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M^)=25$IY!4E*0I1 _;UR.NY/X#CO^N/@?7Y:U+]P.V!V_7E^';2@#Y0' IL
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MXII(67>0MP%*%-@?(E  2@< E)- 3C/.#V!/EZGR[GL,XP<>FL2LK#<SIN9
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MT[&ZF04(;<L+.14Y-9S7Y"XT-G'V*YIV9Y[/65%\,@CAF&R0K"T\W@1F*-F
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M8@BY'.!6&KB:%<J*BW820?+]_)25\@D>R#P?[GCUD7:AW*L8)XR%'.<^O;D
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M.%<JY6OU^5>U#C@_U #U_EQP!U@<MN;EB.<C(QV'PR>Y^_@^NMRJGUX!;@!
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M-4,8BHCC^THB16+D +F55RSA]G2+K1ZV.CIIHZ::.FFD3L'G^697'Y+\3_\
M>3S_ /#GG\^OVZ:FT!Q5)\B/Q&HX!20\0K@*4GUP2?M'_B3S_5R1QZ)*?0/[
M=1Y/M,?+C.?/A?RQG.3CUX&MTO;[V_\ ,?U\.VL?V$\DI!5]R%A)\ 3RHI/E
MP2?'GE7KRX\?'@\BSL!C/!/!QY>I[  ^8SY#5=5I4M*@./))2H^7! '!3Z"?
M?I1*E)]^12>2".#U7&>YS^'YCL..#Y$9QW.J@9./X9UZA12"2HJ45)! 21PD
MGP\B%JX\1^0$*!X("DG\=4)&,_/&>W?OV)'X8SWR<$TU:Y05$^OD/W>:P0 E
M2E  H\CPE0"P@\ >O7OCFO<=NX/8C)''//\ ,C'?/&FJO(E((#IX2"4*]J/*
MR!XJY!\PI((X!'C_ )$=.3\!R>.YY^ ^?;!.<<]RU[Q[Y">20KP*P4^*DJ/"
MBE7I*_22%*')!Y ' '0]N3P#SGGCTXY//'//KD<%JATDHX !2?))4OC]BI/[
ME7W<\>S^W*CQS]M<_#/RQ]WISCG]#5<\8P/GSG]_Z^6KS0(:\5 !2?7L\I_)
M( (]\?D?^(C]^>J>I'GV^_)\R?7T [^6F#Q\>W;6BNN#&C@#@"0L)2>3[ *E
M$>_7 \N/?X2![]#H."?CCS' &?OQGC/<Y^\@,,!\1^_2>FC_ *)!(XYYE^O7
ML_(C_/D_@<G@ $D<GGHV./+X_/CS!'S&>PSJV;OY=_X<_P#?XZU@YX]_GJF.
M>.!\LY'P^&>_D.".^HXSCD8.O>K0>2<XSV\^20?(?('S\O@*ZSJXE+DLCSY$
M&3QX?GV&A[ Y)3[^X#_].>KU'KW\_P 6\OCY>NK6_J_[WIGR/Z_/6ZH21*?)
M!42PG@<<\ O)Y\N/M) Y/YX'H\\_D<\#@#SX'W#]#[_+4LC'?SP1\N?U_#T4
MW]R!P2"?_%Y+''CR20% 'RX5S_[R2%  6X/EY9'!QV\N>?SQQC&.=4VEMO&0
MC%E!P5R<!@0>X9?=(/'9@ R@CEG::-N*JZR]S",_T/&UL<AF6N,2<AV',A3\
M?K\BL''U4,RMK<8FU34.MR-RYI<=2SD8"ZN%"@?$W,BR&1$JK!)4S>(T<R%\
M%DBC<,P7$G"LC D;@6\MA!P 1KZDLW]T!TS%8;2E_@ODUYIJ6&AND])';'IJ
MN6E'LL50E1/<X9&EFID@:8^R_P"4E\L5)Q+/MIU5+UK49O96^4XOE]YF&4QY
M$N=B/U!IZB!CM-74L+'&W)$F7(?D0+)J[GS%+,92)5R\R8C1:4IS/3T@HH_!
M'B@;BX\50&PX!RO"@H?M*V.0>!VUY1])OT@T?7]PM%1;:2KH[?9[=/1^!6U$
M4\LM95U4\M?._@)'"F]#24ZA#(0E+&"Y*DF3"A]RUE2?$)*5I*22D$*422"
M./M_;W[X_OUEYR._&/L\\X\\YQW/)/8COY>8@8 &<X &3\!C7A*@.0L*]>D@
M<?A0"4E0!^Y"U<\<>@3R0D ]5'Q!QGC]W/GVR3GX^>!JO?6'8UE?<1G8-DRB
M3'7_ $I6DA;:DA24N-.\\MNH"U%I:2E225<DA12<L<K1L-I!&X9!'9>_8?ED
M?Q.L4\$51#)3U"!XWSY#?&<8#(?[2GWE!R-P&0><LO=:JF,N+>HY:)C"N/"%
M+4B-+23SXM![A,1\CP/*E+C@E(Y"BL$;**JAR=_8CL#YY\SS\<]^?(=M<I4=
M-SKN>CD$J?V':/Q=OJ25 ^!PO!T@)&/9+5N>;M79QW$*(^H9;>6CE/KU)C^;
M1_'H!?X3ZYXY$I6IY%WAHL'/##WASZ _H'6E>DK:0EUI:J.;.&*2G;YX(5/=
MY '(').<YUXC)<DC H3<VS)Y\2A4V2#Z/X\%K]<?Y ?Y>O73=3D>[&A/'?L>
M<$CD<\CC.J>VUT1++55 . /=:9R,_#8O?UR",>NIT=L%G/L\2OW)\U^:MG(?
MA:6^X'"AO]-A+\$D<<#R63_F23U!J=N4*@+D$8''8_OYUM:"HFJ(W>>625E8
M*&EW!@,9P-W.,DD=QR?CJ3'4;4[7BE)2DJ40E*05*4H@)2D#DDD^@ /9)] >
MST[]M-0RQ;GNKSZKV7+!=[<=7Y")VH*Y?N'N?9%#*4T=SSFN?^EX!@UDT_"U
M!&D(,3(<DC3-JLMRJ^#K.X'7U/\ \,4,MN3 Z@N5/LNLG]>SV^=<_5$9_J5]
M;&5>ZNOO4],R6PE9'N,6M-%_C6H2I/\ \NI9-U(H(*UM2A(]L;&=U/ P(I!G
M$DH:I((6F83.ZY#6YT=--'331TTU0XVAUM;3J$.-N(4VXVXE*T+0M)2M"T*!
M2M"DDI4E0*5 D$$'CJH)!!!((.01P01V(/D1IW[ZYK;>[')U<Q)F]O[U8QCR
MU+?<TU=2XU'7T:1_C.LZ8S9ZCR9G7D:2Z'%*P#(\7RO6SSSHC8]&UJE^?;N]
MQ1=3T];M2_B450 5+W31^//+V4&\49E@%Q*C'^'05%+<0HS.]PVQQ"39+S>^
ME)";)*E1;G9GGL5;),E&<Y+&@GB824#DG(B >GW'W$ARS:@GMJJ306T2%D#=
MWI&<W$$<U.W:?%M7Q5R5\GX&=DLM2-%9U*4\V PWB>R[VQ6VZT),"NDNA*-Q
M3VVJJ$:6@:"]Q!F;Q;-+-<)-N  9+8Y6]4B@<GVFWP1Y!*R.%)/L/2_TO=+Q
MP&FZCBEL]7+(@(NXK&I0V2":2OADEIQD'RF=L ;@?LZSJ+'MDSJ>8_08(,ZD
MO-(576=6RE^ @%OXU.1KO#_JJMX*^QUIQ-?-8\"XI3;WR!P0I/"@D5*J26E(
M8[DE0QN2,G:T50 ZXY!Y!X\B..JFOW35;X$MMZFM,-.6S(&N4=4&!)8;DEVR
MX\B#(,  G@$:0V=X2[4)@VN;WD+5ZXKKR')6PM@8=KBM42II:GG1DUKC[4IA
M*N4-Q?CEOR"@\QPF2(YGT2U-66BH:*IN.X#"4=#5U\B@Y'!IX9BN>,D% !YD
M+G6&IZYZ2M'C>V]266)!'O4PR(^]E!X7#R$/YY!4#('ED4TN2UU_90*K76L]
MO]Q%T^"EN=K[56SJ;2-&ML*6T<DW7/P-<.Q:=00J-%P&HR2'8*2F.K*Z%A)G
ML[->GY(8VFO%TM/3\*'^AJ[I;9KU-V!$%J2M#1@'[;5LM.\8R5IISA#Y;>_I
MP@8/3=(VBMNLTH8-<JF@J4MT>X?;0F(^(_.]&4LCX]X(&!,^-)X!O"@MZ[,W
M^V2?D&QZR#*K\;R/=FQ-<:CUIKJML&DMV<#3^NM66O<MD6*-7#82W>9%E(L=
MEY4VV(V29.BK;@4E=H;K56)X'H8NH8J6W.Z23TUEM]PNMQKY$),;W:X7.+IR
M"K:(DF&"FV6ZE+;J>G,IDGD\G>IO=QKFNEQI9J^YR;O\*N553TM/2JX&Z.AI
MJ4W%X$884LP:=P&620(%34J1CG>+DCY7:[/T3JZK<5]]7A.LLNV3DC#94.4Q
M<XS+.<1H"\$\A+TG4[S?D0I4521X'G/:.DJ<#PK;>[E(/\Y67*DM].QP<;J.
MDH:J?!.,A;HIP,!N<B3X=WD;WJJAIDS]F"FEJ)0//$\T\<>3Y9I" 3_6 Y]5
MVRS;M[Y]A]QG<IG2%*2M=;"V%7ZBJ!P22TTUH7&]66RHYY(^.;<SG"G@+>61
MY%_?&D*[:#I_IVBP,"1Z"2ZR_P"\QOE1<XM_Q2%%!Y"C5/JUG)-1<;E/D@[1
M.E(@[^ZHH8J5]O/9G=N "QYSN*;M&[9J6U9R!.DM?WN3L+2XUE^;T;.P\T0X
M@ )<&9YZ<DR@NCQ'+AMRM1 *E$^^L4W574<T9@^N:^"G88-+13&@HR/3V2A]
MGIL? 18^&LB6FVHP?V*"212&$LZ>T3!@,!O&J/%EW#^T7SWYY.I#,,,QF6X\
M9EJ.PR@-M,,-H:9:0D<)0VVV$H0A(]!*4@ >@.M S,Q+,2S$Y+,222>Y)/)/
MQ.IX      X  P /0 =M7>J:KHZ::.FFCIIHZ::" 1P?P>FFDSD^&8GFM/-Q
M_,<;H\JH;$)3.I<BJ:^[JI:4^TID5]E&DQ'@#['R-*X/L<'WU4,1V/'(QP00
M<Y!!!![ZEV^X7"T5<=?::^NM==$P>*MMU74457$RXPT=33R1S(1@?9<=M1H?
M[ ^S"0^J0KMMU6T5K+BV(>.LP(#BE'D_)5PEQZUQ!_=IR(IKC[?#Q]=6;5!!
MVID'(_9Q_OV9X\N<CRUZ7%].7TOPTXI4^D3J@PA&C'B7*2:3:V01X\PDGR<G
MWO$W G((.I,XGAV)X'0UV+83C5%B6-5#'TM708W50:6GKH_FIPM0ZZN8C1(Z
M%N*4XX&FDEQQ2G%E2U*4;M>;7&Y7&\5L]RNU?67.X53F2IKKA4S5E7.Y[M+4
M5#R2N>!]IC@# XTI.FH6CIIIGMR[]U#V^X^QD^X,UA8;2R19.,/O0+FXE.1:
M6 Y:7=B*O'JVVM14T=:VJ=>7"H0JZ:*IIZSF14/LER32T=36.8Z:)I6&T$ J
MHRYVHNYV5=SMPBYW,<A0<'6*6>*$ RR+&"&(+''"#<Q^2CDGL,@9R1E)67=W
MVV4TO*H5SMW&*=[":E-WE*[;]2K8E17)GT=7/6]83:]B ])H++)L>@9971),
MBQPZ7<US&51*=R4TE61;=7,L;+32,)6V1[0&+,0[* H)8;UCD:,D 2!&,98#
M5IJ:<%E,J H&+9.,!2@8Y.![I= V#P6 /.J9/=[VVPL9QS,)NVL=@X_E-CD-
M763)K-Q#?BR<0LVJ;,'LCK9-8U:8?68A:R(D'+;K+H5)38S(GUJ;R? _4H!D
M5%LKS(\0II"\:QLP&TY$J[H@C!BLC2J"8UC+M(%;8#M;%/:J;:'\9-I+C).,
M>&VV3.>5"$@,6P%R"2 =20Z@ZD:.FFCIIHZ::.FFCIIJ.-AW=]M=3:YY2V>W
M\5K[#6--G%]GC<Q<^/'QNNUHZ&]@?6SW8*:]R?A[2X\^_IXDJ3;UU1-KKM^"
MFHLZ^=)FK;:YEB=::5EG:)(2 "9&G_H=H!W8E(*HQ 5G#(#O4@8#54X9U,R
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M1_7Y$JX]%2@!P2..!P"/?5"0,#/&,?'CMP1DY\^XX],C303XE8X!! (] <$
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M!.!S@''SX'GCR/KC)!.JGD8/(]#R/P[:]=8;45>;:7?M'(<"5>: V4A 21R
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M[222.TDDCL7=W<EG=V8EF9F)9F)))))))UME545410JHH554 *JJ,*J@<
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M"R-BKDY#00K101&D6U;9Q5N4BTRP"&'>E-)1I4?M/%6FEJ'J7CV^)X18R22
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M!(D <\\\\!SCG_/\\>OQU38O]D>G;OCU]?GWT]KJ/](?UY_KCX:J. XH>/\
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MGI)HX8JEXL03,Z1R HRET"ED8*24<*RMM<*Q5@P!4YU07"5G:(3G>@5V7&"
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M9GA=[CN#VTJGQC)KW7JYS^6V..P8R\CJ-<ZRT1CX8=KZK'H*KG,&L%QAV?\
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M$"YUM:X_DOD_V_XQ=RH&2TUO42<AR/,KE=>)UE6.TU#U-<6R'$,BL6)1C4
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M,:7VF4!'M-*\8$8 *T^\>&* 9$AI&8G-+4,-^X$UC!U=4(D-;IR2PKIU8[N
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,Z::.FFCIIHZ::__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g287237g35t95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g35t95.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[17X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %=R^598X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              IX   ;^          $
M                 0             &_@   IX
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   IX     4F=H=&QO;F<   ;^
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *>     %)G:'1L;VYG   &_@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !CA"24T$#      +Q@
M  $   "@    /    >   '"    +J@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M9M+.I-ZO0S)NJ?D_90
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5ADV\;'$9(D>O7*:N02, ],XQXXSTSTS[>E&"EWV A 6(#-N8("< L$4,0,
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MC+K,F\FP,X 9R01QU]9?9P!G)/K#@9/7CU6Q'H\FTMF(!4[PYG@5MN(C@*9
MS/\ CD_%J#(2) %S#*$LY/M3=&63<O&75VKX#8.RZQRIT]?MMT#;]9U_L9]3
M(II2[%#U8S"RLVM)7D8MLTEW[]*^RLDI%H:N]7LR79*-/8H47$>1XP=Q'(SZ
MH#'()R,@@+QZQ]5<L"*+ [*'!B )E&'GA1OQ,:ROE7D5AN1@(L@=_(##!WDJ
ME!Y^M^U$T>SX[\?]H;QN,8_ONY]4V';ZL%QSU=O_ &I$M=?5.6<1UIV2G76>
MNGFR*OK*N#Z&WF+9?Z[7V+=^9PD154B?4#%03C(7)V@D,<>&2H .!U8  ]0
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M:QVO9Z\)F>MI#4+?C5JXFO96[PVRI&!&#,HH\O\ 76H1\!<%YI5P>P'GX2,
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MUK?BQI;G3(-A&@U9,H6R^IXT\LW30[SI9H1<RGC&44.\,<8X\!GC.,'J!SR
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M*+=6]@[<QY$44T(YZD@B9N!DBHF54.:0 3R<#!]OAD<#GK]77RJ-VW)V*W!
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M_/N%.GUC]GE^KK^G( ;Q;/U"IJN6I3%*8I6M>T>6NC=1;BTOH&W6],FW-\V
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MY\_#G% "Q*@@84MDL%' 8D98@$X!P =S-A4!8@'&6V.T$HFI=H)T20UU?[!
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M3U.V'6]X:?A8^)LKW[I,M8ZG(-FCV<;N*\NZC47*J2BKQ@LY9(*M]S3];O\
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M?!0Y(46.8R$M<WQ:_'/+ULBITA)C&V*R2ME8ZI?C7[A*C&0,-(NDQ8S\98G
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ML>9_%>!3IK;8UC;Z[<LU=AN1]:/=:DD0K+J8346.1.;/'^FE432ZK&%,I15
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M'R"<<!R3X>''%2TI=# F<1,4PAT$O0  1 H]0$ #RZ 'M'I[.@#GALARK;F
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M5&BJ-88#8$EJ*JN4ECL:E;=K1;2$D]DRZB9/%/8INK02BQDE"-4W*1 <*6<
M'@,%(!4LNQF4]&*[G S_ -UBI\*V;R...;;"DZP%$:"2XMVM9KF%@2ER\!N;
MM(S*.<0SO#QZA/4R<96M6F*4Q2H(NU$3XC?=_P"(BLJEKGYWY.4_%@E>=+-Q
M-L<FNS;&?"Y3:.# 8I(8Y_22J@F/BB452G $3#CY^?MJ >?9SX>.3GX<#V\]
M?"=P/8'V!BIZ57%*8I3%*8I3%*8I3%*8I3%*T4YZ]/D7I+KY!\Y[1GTO/H'^
M5Z/3J(=?:/0/8/XNN>J[*+NN=1'B-+N3]0*'[JX>N?[.VX_[2G/AU'MSX5O$
M4>A_(!_TL.G40]_0?>(?L/PZ]/+,"$., [CTZ<\GJ/AX?LZZGUO_ )1^H?=X
MX^/%=O?'[WW^?TB>S_\ E[<Q?C/G%9:IWS#_ +4 ^T2__5]OU_UOQGSBE.^;
M[T/B'F7\@_2]OL^'ZGXSYQ2@*&^]_24/A\3?M^(<?C/G%*=\WWH?E+_]7]8_
MBQ^,^<>SZO']=*Y"<"E[Q@Z!T 1$1  \_CYCT_3F0=!GKXTKF @( (>8"'4!
M^(#BE,4IBE,4IBE,4IBE,4IBE,4IBE0F]K'KWCU4:56M@7#7'!^R2%KVHI8[
M'1N4]%N,V]WA:X^C(5B*:4&1UK$6JW-=C,J_&,(="02H=T(>%2;-%HXI$$R.
M+HN[=D,=J,V5 .W:."P./5)PI.01N! 8@(VU:6XN#<!DN&$5K<7!>W19!"8E
MW(\ZNT:BW=]D$C]XC1-,LD:W$B):7&V79H.:<_XLUR3H_#29X)0LG.S3XVB9
MJ#8P"J;Q4C BMO8,FC2+='B;$BFAZN<S<'7YI5!EW7<,T330%2&.3^5OX4 G
M/0* %];D;  F!E1MPI*@$X[ABTN3<-<@10*LK=YN$:0QI%"1*-RFVC5;8HI:
M&/N=EN\D CD:0#*UAIBE,4J%.F;!K-U[:>)BX#4&PM8NZ5PKY&P4[.7?6H4*
M,V3)?.%T>![72Y3O":]0*RC9=4MB[I2J ];J!U]+ZXJ<>KNRN-VW&X;LXSG;
MG=CPSC&>,YJ:S%13%*8I3%*8I3%*Z56Z"Y>XNBDL0?:15,JA!^TI@$H^SW@.
M!Q@C@CH1QCJ./+@D?6:@JIZ@'W@']=:D\S=06G;/&W9- UQ#1,E=YE"OJUYE
M).VT(S=KPMN@IY5!:64;KIL 5:1JZ1%SI'*4XIE$O0<]#V6U&UTW6K.XU%[@
M6,2W2RK"S[@)K.>! H# 9$DBM_W?RATKE:Q:/<V,L5LH](<1A&X##;(K,0>,
M94$,<C(X/!JUV7)C<4%M#36N=K<=2Z^8;CLL]4H*SQNXJ[=DV<M TBP78Y7D
M-&UR-=E:KL:V[0(J5R4I%E$@.'0W=-<:%I]SI^J7^GZ[+=OIL$-Q)!+IGHX*
M3SK" )!,XW(7!P1ZV,#CD574+J*YL[>YT\P"X>2-7[]90=L>X':HX!Z\XV^
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M (-V\"RW4<<C?2%^24?<I_*NRH )!X];@8P"2*/:WD,,\SZKWFQ"Z@V\*[,
MGD+%SCD=2.:VYXY6Z>ONB]27*SOO6=@L^MZ3/S4CZ*@S![+2]<CW\DY*W:HM
MVJ157BZIP2;(IHI=>XF0A"E*',U:&*WU.^@@01PQ74Z1QAS)LC61E1=[%F.
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M4S)NCVW\J-IVMC#<8R1NQC.>@))Q@8Q7//86[%CVFF^EM);5.R*W,VMZ$IU
MWMO:6FMV_9^XN$NS8#2)BNH7=L4MXM1>>2VE$R(6#1"])#:5<B+A9*Q,.6<-
M'5"IU>T62U3$HRBX2,-=)Z;@JW$JKO#I)@[?+5Z364446230 \8ET54D4NX+
M@,0>  I+$X&6) 'OXY\LCSKD0=FM0NM)T_4K2.:[GU75-3TW3],M+::YO;D:
M/8V5]J-TD<*LQB@2_ME551F<BX;*K;MGF;<>HR1$98%-I:[1@II5^C#S"]TK
MB$9*K12X-9-&.?+21&SU6.<B#=\FW44.T6,5-P5,Y@ 7>)@'>H!S@E@,XZXR
M?#QJ!V2[5&ZN;%>S6OM>V:P/=VB:/J#W-LETAEMGN(5MS)"MQ&#) TBJ)4!:
M,LH)JTY_=#N O=&J)M=6*4AMCV%&OU*\1,]1WL')":K2-N>2_JY.R_*-.$C8
MF(D#NY T.*9CI-P; OZ>Q](@NP8+L)5C@,&7'3)..N!@C/WUT['LA%?:)K6J
MC7]/MKOL_8/?ZIHUU9:S#>VX&IV^E0VGI#:=]'M>7%U=P"* 788*TAD*=Q/W
M=^:XO+/8].BK:R9.8STU65CY")>'34=P\Y7IB0KMAAG*J/\ @EEHF=BI&/46
M2Z)+"W\5, (<H9=6# $>WZB#@CZB,5Q.T&C3=G]6N=+FFCN>Y6UG@NHE98KN
MRO[2"_L+N-7]=$NK*ZMYPC99.\V,25)J^,FN-3%*8I70N B4H ( /?#\G0WN
M^&89D>0*$8*0X8DYY !!''O'7BK*<$GV?=\^'OK4+E  EM?$L1'J \GZ[T]W
MF;7.S1Z^?0!\@Z#[?/H/MSO:3GN==4C@:63GJ 1=6WU^XX\_?7,OCF?3& /_
M %G!Z9_V4F,\X\. 2#TK<(!]OUB ^[X!]?N]_P!N<>NAD#ZO:./+R^K.*Y?H
M^W^G%1N''M]H^_\ 55.OGTZ?T?KZXJ=W&?#WC[Z"/3W?C\OZQ#% 0?\ F/?X
M$TZ_4/[!U]W7_M\@ZXIGQ'/N(^^N/B%Z&'W%_??5T'I\?/\ %Y?7E=ZX8YX4
MD,<'@CKX<_5^T5/E[?:/GY\J H40 0ZB ^P>G^?"NK ,I)!Z':WZB,CZQ3V?
MMS50, CTZ#[_ '>SI\<G(]OP/W4KEDTIBE,4IBE,4IBE0VUYYO%WVSE9#;\!
MK*"@6O"+D0AJ537UCLUAE9ND_.$TD"4G?49^O0+."LHH)Q?B1<$K-QX*+O )
M)B1NB*]R(]@*L^_@,I0!?')5PY)\."@ZGGBMN1+$6L;PW%RUWN436\MM&D(#
M"0L\-PES(SA2(UVR01%C(Q! CP\R64K4IBE,4IBE,4IBE,4IBE,4IBE,4K5C
MDIQ^M6Z'6GY^@[11U-<M-WU[>X"><TAG?63I>0J%BISI@]@WL[7TC)'86)TL
M1P#PQDEB%$$Q PB';T75[?3!J,%U8?2-MJ=H+.>%;I[1DC66.5622-'92KQK
M@!2/97,U"RFNC:M!=+:/:RF56,$<Q)92C!=^ N0QW$ $^RM:=YGYCZ"U\IM"
M1Y6U.ZQT+;==1TI65..D%6?6D9:K_6:G)$+--K]*+QQT6<TLX3718KB"B8?1
M 1ST&ECLIK%S]&KV=U&VEFM;YDN(]?DN&1XK*65"(?HM=V'C!&&!&2<UHWC:
MK86S7#:A#.!<6RD-8F,!&<*P]29L[NI.,8SC%24A,Q7T2A(L#"/0.@/6PB(^
M7L#Q?,1Z_E\O:(!GA_1Y@/\ 8S8'_<EZ >[_ )^'E7=[V/\ /7^FG[WS\:]3
M*5DIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE0V=I
M_:=QHW#B75&.J(5]IESS+XM/Y/;"U_0;SD=9RW]WW*^WUWZ@.X=LSHE0.,V-
MC02(90>C,XD[AWS\_/C\(\2<GI]0Q[<=?/FIDP]@=?;[\4&,#'3''NK36/X:
MT-B\I4T#*HDM4!M_:FR++<&5)C6%IM\'LQOMQH:GO)]!<)<B46VV7')"^=/7
MZ+HM7;@2/; NW!AA$* [MJ;BSLS!0&8,6."V,GJ <GG'NKZY/^%S6YHM9M.^
MU0Z9?]E.S'9[3M)FUFYGTS2;WLY)V4F&JPV+IZ(S7,G9RX;N8X8'C.IR;IY-
MDG?_ %H\;+?(UZF4VX[)AYVL:LJ]A@==>KJ4ZAIU61E-?3FL(>?O,@I;9./F
MG,%4;%+(G9P416VTI+NO6Q_0DT48XCNV( 9@54$)@$')0H"QR0<!F' &<YZB
ML3_A"TJWO]7U?2>SUW9:EVFU*POM?](UB.\LE@MM>LNTEY8Z+ NEVT]G'>ZK
M86SK+>W6HR6UI'Z*.^9WG/A&X<)!*6-\G?7/H4K&Z\"#@U88IXFKV*"F-<2&
MQI^/2+(D.H?8R&IZ8 MS'3&#D?E#(E6D!L#M "PA?'^2H \ ?5#'Z]BGC'.2
M>N:W1^%IS;:? VAQ=]:SZ_Z;>I>%;K4K"^M.T,&@6,[&W(4:!)VIUC\8 WIM
MM]'VY2W] B<Y/NG'*#N5@J+LUGML-7*Q)VNUK14?9K(YEW]VGX<E8CY=O.S,
MS*#$Q$76)2XQBE>8,4V;M6Q).4S-/0!2=#"I(P6499B QR6( !!).T!=PP,
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M&FRT-Q+;1VO8^)M:%QJBVY->N9"PR[Y*&&KO64N:),HP;PZB<OZ4B0Q >"Y
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MJV Q)P/  ^73FMN<Y==.F*4Q2F*4Q2F*5#=!53;%;[9ZJO-E;8C]DP]BX/\
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MLQQ;!V*N+>297%*QIU]."(4R0*Q*M86?&[IS^L2 )1QQSGJ>G..<C.>#GC/
MQS@YP"#(VX?<&8E<*0P 5MRG+C:VY2FY=J[#N97+$*4>9'%5'0>ZHQ8WEYLH
M6^H$GE<M"JDWRAY(:^M,\:IQ3>KVBC:Q;<H7=:KE;DTW*JQ)U,NLZ>V5=I1Z
M#IVM$RH+K*"Y<"O](D[*:=NU8I<6RB'LUV?O[:#TJ5KFVO=2?LTEQ<7$94 P
M'Z2NV"&1E198MH&U=OFEU:ZV6#%6)FU?4;68]VH22WMDU9HT0Y)#@VD&6 !8
M*V3ZQKO<[TWA4=>:&VI)W^&N/SBJ%<YAW46M4@V,)KV93X]WG>=9E:*^9)%G
M9*!@5::2K6%&Z2=D4F?6[:7;NX0Z/JMS1=%T:ZO]<TR.QEM/X/WUG"MVUU.\
MVH1'7K/1;F*]1SW$<\XNS<P&SCMA#W+1,DP8RK?TZ]BMK"Z>=)3J%O,[1")%
M2!_09KZ)H2OKLD7==U()7D+[]X9,!3C)7F3NI;4FLJNTG:^7?]:OU;2WY)C7
M&@LC:R):-9M8^<CX4Q1CHI_M: W3JAZP\(H)1Z$I<@ARE>5T1:=->R.CC5=1
MN7@G.A7%C<'0XA</O^DC:ZD\D,DV1)+'I<^C:HDF?6D,5H924N!OTY-8OEM+
M:)9(OI"*ZA2_?NAM-J9[9%D1,[4:ZCO+4C&0N^8)S'D;!\K^5QJ?K-NTU';H
MFA;+MNP5]?5FR[CJL[1ZI#R%9@)>]61^Z3V/%U9K-PKZ'K:E3CYN*6>Q)YZT
MPOH;UPOW$C<'LOV7%WJ3-JMI-?:=:6"W]S;:1<PWMU-'<3Q65O&IT^6Y>&9)
MK@73Q2!)1!:S;T5<FNCJ^J-;VRBTEC@N9Y^XBEO(VAA0QQR7$C,)Q$&5HXC$
MK E>\E3FL3;B[0B$AT^-MQI5YI%=I=HHM2WUM.,LSN("7F=76VU5BB!5JV5\
MZ1=%L,.2:OUY=J12;A\!M1N8)1($YHP#U-)[!S2MVBL[RQO9[RVO;O0],DMT
ME[J'4[6VN;WTFXV*5,$IAL;)!*53_6JSYS#6G=]H8U&FSP7%O'#+!#?W22LF
M][2:1(.ZBW,I[Q-T\Q* M_HA0C#\Y9D=\[<"]S>B(4\:^VJUY IA#OUV+!)J
M]XYN::MN9E854"I>B$:.$6;OC\:>!+QT[,!)H3>GF*N/+CT/2O08=;F$B:6V
M@DS(KR,Z=H%O!I#VX.=^Y2ZZZ(<E3;?B<;,J-QK^[](>QCV-=+J "D@!3IQ@
M-ZLI'3#;38%QSWOKCGFOOXM;CV[;-A3NO-K!:%Y=KI;6FS)YO:]<I:\=TN^V
M:>ND!;Z5!$;-VZ%BH[9S74!J4V9:?77,PFQ-<K*D=([#'VFTC2K6PAO]+]&$
M+:QJ.FP-:Z@=06\L;:"TGM+R<LS&WO62X/I4($"KWD.+2W(/>7TR\NY9F@NQ
M)W@L;:YE62W$#07$K2I+ F#B2'*#NFRY)60=])_(M/7O(B[S[+4^QK9=IZ);
M;V?7]G3*!$ZZK\AKB%6@X39,W"TJ8N0G+=&.R8R&U\_E;+)OY%>M+R4=)PC6
MLQPN61V^U?:!90/JFGVME!*VB1V#WE_+J$\>H3">;3H9KR*S_P"J/I\LM_'%
M;Q)&MRL<D<S7,FUP<4&H2O':7,UPT?IS3K!;K;HT"E(KB5('EYF6X1+=VE=G
M[LNKQB-,KC&4+O[<Z^CN+5MEK[NYG-;SOU&C+?+ET[KF7L*49-<?=E;(?-M4
MU6L4"7)+03RTUN&$9"9@IB6:0J;D1>,TA<O$^C-H6CKK?::TBL=':'1;&^DM
M8CJVH10&2'7=.T]&U.ZN;^(Q3I:W$P[N&>*)YBIV.=J'6CO[PV6CS-/<]YJ$
ML G;T:!F ?3KJZ86T:0ME6EB3EU=@F1N&2PV=F]C;GA>.&H7MZ31IF[-C773
M&NK O&L(SK77E^V+!0,])IQJSFPPS.:1IR\D](P])FHR.LBB;1-1^U0**OG(
M=/TB;M#JJ6)-YH^GV>KZA LCRXN$L;">>&(R!;>9H6NUC3O-L,LEN"QV.V1T
M7N+R/3K1KC\5>W$UE;R%5C'=M<7,<;-L+2('[LD[ 9%60X&\#GA\[]!O:9Z)
MD]93,75XZV[GU_#7-[;Z:T93]QTI7INVSK91K(2+!*MP$E7Z[-*,K+9)&-:-
M).-<M91NSC#LIMY/\$V-M!+'J44MS+:Z/?36B6EX[P6FLSPVL#!XXY#<3QSW
M$(>VMXY'>.16B9Y \*576 9I$:U>.%9[VV2=IH0KRV*/))E2R]W$T<;D2R,H
M5D(90NUSB6\<R9NY42"D-3L7D?+O]NU6BR43KRTZ2W+LZ>A9>L7.PR26LXNN
MVVZ4=*T1B=:2FY)._G8QZ='C+=(,B*R#)D)>I9]D8;.^FCU1T>)-*NKV.74+
M;6=(TZ":&YL[>,ZC+/:V=X;:0W)AC-COD-[+:1N5C=ZP7&KM+#&UGDNUY# Z
M6\MG=W+H\<LC"W5)9H1(HC,C]^5'<)*R@L%KY=)[_P!EV3>?%EE:K<TL$-OW
MB;L^:L<%#L%HZ%A=J::O]'1>RZ<:^;-Y&'FUHV]S-4N48J1%NVG:VW:HM6X-
M"E-?6="TZWT7M-):VCP2Z%VITV"WFF<233:9J]C>LD1D1FCFA62QANK20$LT
M%PSEFW&L5EJ%S)?Z4DLJR)J&D7DDJ(,)'=V-Q;*[ , R/MN7BF3 "R1 ;1@U
M)CGSFO34Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2H2:)1
M-<T_MJ(Z0HVT[=L.4M7"WD=,W2'L^W939K2@SR_(C2:JM;KD-)2DD3742@LL
MZ1)561&#5N1JW12:$(S*4ERQ95!V )P,(BL<\DLRJ&?IU=F(Z# )K9EN))X8
M8W%LJ6H,<?=6EK;SN)"69IYH((YKLJ4 #W4DSQ[MJ$*S"IMLI6M3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8P.F./*E4$I3?OBE'K[>H /M#H/M^("(?8/3(P,@X
M&1R#CD$\$@^'''%/,>!X(\QY&HWZQKCF/I^][X=ZSK/'FTT[:VZ9_:T.ZN=^
MOM?L+ D]7JM"'BWD=#4*8CR&;C7/%*HA(N .#@>O= H!GKKC4.RE_:Z.^I2:
MY:W>G::NG3BU@L9(7D$CN&5I+A6.=P!W ' '-<)+75K66\-L+"6.YNN_19&G
MC*J548PH*C&,C&!Y@^&0_7W:$_\ !CQ2_.OM'_JQ#^O[,=UV&_GO:G^S]+_\
M_5LZY_-],_XUS^[[Z>ONT)_X,.*7YV-H_E_V,1\_R!CNNPW\][4_V?I9_P#^
MA3.N?S?3/^-<_NUCV];WYEZB)2Y[96LN/(5"P;3U?KB56J&RM@R-@8EV3=(.
MGHR+%A*4"+CW1V"LRF[51</VY3$3,0INH],S66E=E=4],M]/O]=]+AT_5+Y1
M=65C'%_H%C)>E25O7?U@A#;1PO0 G%8)[W6+4VDES#IP26\MK4B-Y\YN&"@Y
M8*"RD8&0<D], U)!GC*]%3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*AN[3S7%F?7'B-LA+<M]9U5CS.XL0CC2[=*L&U[)R!]A/!+97:BE>/:QF
MD1,D!2)6%&-(*"8BU.83%.^?GS^RHY\?B#[?NZGSZ5,@ ]0Z_6/Z!$/<(_#%
M36/6VI]<LT*PV:U.,10IEVLFQZND4''<AKO;S6\UEL;4!7'_ $=+FOMP%T"O
MB-_\?//"13Z(>#OMJFH.URS74I:\LK?3[DG;F:RM/1/1[=O5_(B]!M-N,-^(
M3+'ULZPL[8"("% ()Y+F(<X2>83"64<_E.+B;=G(_&-QS5IP/&W1U8<2#B"U
MS"1_I\'/UDC4BDBM&PU<M9B&LT#4XER^6BZ5#V Z:2DS'5!G!M)%5%!5VDJH
MBD8FU/VAUJY5%GU":39-!<EB(Q)-<6N1;3W4JH)+R6 $B*2[>9XP2%(!(../
M3K*+/=VT:C9)$%&=L<<IS+'$A)6%)#RZQ! W&1P*](^A--G=SD@.NZV#^RPV
MOJ]/OB,S)O)>%U5(GE=>1[YTFH5=="J2!_2(WO*>('AH).#KHMT$TZ#7-7"P
MH-0N-EM-?W$"%P4BFU./NK^1%(*JUU'ZLF!CEBH4LQ-C86;-(QMHBTJ6Z2-M
MPSI:/WELK$<D0OZR ]#[.*OQW4ZX^M$-='D2V<VBO0\[ 0DPKXAW,9$6=U!O
M)]FT(*G@)EE'%:@SN5O!%P)8Y)(BI$3K)J:"W5PEM+9K*RVT\T,\T(P%DEME
MF2!VXW'NUN)@HSMS(202 1G,49D28H#+&CHCGJJ2%"ZKY;C&F[')V@9Q5C0>
MB-05N,N\+"4" 8Q.R&<C&WB.*BLNSL49*O;+(OXIX@Y7633BEWURM3H(QJ#=
M@BM/RAT&Z0NU.N[/K>K7$EE--?3O+ISQR64F55[>2)+>-)4954F4):6R]XVY
MR((@S'8*P)8VD:S(EO&JW"E9U XD5FD8JP)/JEII6VC !D<@98UZC'4>MXVX
ML=A,JC%(W>-UZWU2RM(@X5FD->-9$DNA5O35EU%5(].33(][RHJ.C+]XYW!N
M^<#8WU74)+1[![J5K*2_;5'MO5$+7[1F)KK8% $AC)3C"[> O JRVELDRW"P
MH)UMQ:K+@F06X8.(=Q))0,-V#SGQKOHNKJ)K;URI3H$L:\L*[1Q/2SN1EIZ>
MF31Z)VT8E)V"POY6;>LXELHJVB&#B0491+=99".;M4E5"&K>ZG?:CW(NYS(E
MNKK!$L<4$$(D8-(8X($BA1Y6 :5UC#RL TC,0"+0VT%N7,2;6D*F1RS.[[%V
MIN=V9R$7A5+849"@9-6JWX[:5:6PUV:Z_B&\_P"N9JR)F16DTX=M:+)&R,/8
M;8QJY'P5B/ML[%S$NPF+4RAV]ADFLK)I/))8K]V"VTVOZPUKZ$U_,T'<PVQ!
M$9E:UMI(YK>U>YV>DR6D$L,4D5J\K01M%&4C&Q<8AI]D).]%O&'[R28<':)I
M59)9ECSW:S2([J\JJ)&#ON8[FS=K?6%!:1FN89O6(Y*+U&X8.];LB^D>#4G$
M759:DQZL9U6$W>:U2=EH1/TDS@/1'RPF RW<5)JMJ5\\NH3-<R&755D74']4
M&Z66YBO)!)@ 8:Z@BF.T+ZR#^3D'(MK;JEM&(D"6A4VRXR(2D3PJ4R<@K$[H
M.OJL:^+;&ND=H5 M;&4-!2#"STFZ5Z=(R)(FA[/K^X0EUKSTS$[AF#QMZT@F
MS:1:%>-#O(QP\:%=(>/XA;:7?G3;OTCNN_C>VO+.> N8^]MKZTFLYT#A7V-W
M4[-&^QPDBHQ5L8*ZMQ<Q=WNV,LD,L;[0VR2&5)4;:2,C<@##(RI(SS7U,]6Z
M_CY*.EV=6CF\E$W"T7^.=I^D^(TN-TCY2*M,^F!ES$]-FHZ:E&KL#E,CX;U7
MPDDS=PQ8?4[^2.2%[F1HY;2VL9$.W#6EG)'+:P'U<[(9(8V3!#909)&02VMN
MC!UA166:6X4@<B:<,LT@Y_*D#L&/DQ\Z[;YK6D;-CHV,NT$G,(0LNC8(-RD]
MDH>7@9U!D^C4YB GH-[&SD')^K)23C#OHF19N58V2D(]50[-ZY05K8ZC>Z;)
M))93F%IH6MYU*1RQ3P,Z2&&>"9)(9H^\BCD"2QNHDCCD #HK"T]O#<!!,@?N
MW$D9RRM'(%90\;H5=&VNR[E8$JS*>&(.*:[QIIU5W34MKP!VT/#:\TK,::U]
MKR*B$64)6&UKN4=;[I9"/2NU%7DG8SUVK,#D,S040",D'KE[(N9I7T7J7':*
M\N='NM+G#2RW^L1:O?W\DI>:Y:UM)+2SMRFT!(K<7%S(,,P8R1JJ1K"-VG'I
MD,=]#>(=JVUE)96]NJ@1Q+//'-/*#DDO(88E.<8"L227-;(9YZNE3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*@NU9:..$]VU[B/T33HZJ
MV>!X><CH_=SMEJ*=UFK9=@DY%Z;*XEW4U,U6N-]C+'=%F5#VF%=V&/6.Z,L,
MH(O$A6N7=E"LS,B\*&;(7J<*I)('))P ,GQ/39DN;N:WBAFN998(-L<$4LQD
M$"KWC!((W9FAB+2R,5C"QL[DME\8G1RE:U,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4J@  =     \@  Z= ^ 8I5<5&!Y#X4Q3 \AQT]E87WQH^M<@*$- L\
MS9ZZU3LE4MT?.TR3;P]DB+#2Y]A98"2C7[EA(H)+-)6.:K""K-8IRE$H@'7K
MF_INH3:7="[@2)W[J:%DE4LCQ7$9BFC< J662,E'&<,I*D$&M6\M(KV'N9<@
M!TD1@1O21#E'5B&PRGHPY!Z&L)?-"LP?^5]R]'R_X1:5Y^?_ +MO?[?\^=;^
M$:?[N=F/ZC=>7_YSZO?[,5I?1<OZ5U;_ (UM_P"7JOS0[*/_ )7_ "]#[=BT
MK_JV']@Q_"-!_P#ASLP?_P"ANO\ S@I]%R_I75O^-;?^7JGS0[+Y_P#??<O0
M]OF.Q:5Y>7_NW_S8_A&G^[G9@^ST*['V^F<>613Z+E_2NK?\:V_\O6*>(?*+
M6T+JN7K>ZN2]+>WJG[9W/4'#K:&RJ5&WA>%J^SK7!UL\\V6=0IS+A ,H\2+E
MC&I7"?=6*F'> 1WNU&@WK:JEQIF@W,%C<:5H]Y&EC;74UJ)[C3()+M8W D!4
M3%B07.TYZ]:U-'U*U6SD2ZU.&66&[NXG>>5(WVK*2H8.5. IX)\.G K;B%Y+
M\=[/,QU=K6]=06&>F'2;")@X795/DY:4>*]12:QT>RF5G;QRIW1[B+=)54X@
M/0HAU'//3:-K%O#)<3Z5J,,$9]>:2RN$C3H<.[1A5/AR0?(=*Z\5_83MW45Y
M:R-P-BSQLWL&%8D\^6:SGG-K<IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4J#3M.
MX'C2IOGAY/REDA"<GD>6?&!I!UDVP)9K/.:(>^R15GI=>ISJ<2^:)'.Y_P ;
M+0*ZJ?AB<CE,R8'(^?O^?UU ]^?JQ\^^IRB^SS'KYB'7IT]@B'3I]7LZ^_IU
M]^*#YZC]?S[ZKBIIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K7OEILNS:8XO<B-NTMJB]MNLM*[,O=
M::N6YG;96<JU.F)F+]):E,0SANF]9HJN$ .4542*$ZAWNN/GCK^H_J/NJ00"
M-P)7(W $*2,\@,58 GH"5(!.<'&#'OQ WQN^ION3E)G[ALGF[]R_7W%O:-1<
MQZ>KVFQ).8WO1%9BX4J,D6H:[HJT1'/&!+G6V<H[;2476)D&"C^3Z10N+A5.
MT[U7<Y4@A\(OJX=L*Q*G<>%W/ZC>KRN=A8HI.X8W,%OW]S)%(CK=%;.(& K<
MRE(IW>W;O9 JP>DW0%M+NART/?:V7'F+LJ.[4C3MSG^"?+E@^:<&]Y5YI1(B
M+U%;;E)MI+=FDY!Q9V[2N;8?13>O12D8E&/G#Z6;/O6$FP3;L%D#J+IY.Y3(
M N8#P23B=0,$#!WP*<G.1@$8!R1QG?.EVAE$<>OZ-(#&[M*%UF*.,JR*L;>D
MZ/"YDD#EDV1NFV-][H=BON U[59N]V-,:C9\$^>;C9%?J,)?)FHIZKH'K2/J
M-CE)>%A9Q<#;5*W]#?RD%+,TO#7.J"K-3Q$R$,F8]O1Q@-W\&TD@-^.VDC&X
M ]U@E0REAU 9?,5F.AH$64ZUI A=GCCG)U,0R2QA&FBCD.F8:2%)8'F0<HD\
M)/\ M%KE ]JB2T7"^4& X'<]I2WZQ5K:%\@F^J]?>F5M6W1 SU<3?^)M8B7>
ME8@HOF_@J*AX/F<2&$ R/1QU,\(4G 8]]M8C&0I[KDKD;O+(\ZCZ$0*)&UG2
M$B9F2*9CJ8AF9 IE$3_1A#F(N@E'!0LN1AE)Y5'M4$K\\NL?3."7/*Q/=<W!
MW0+PWCM6Z^.I6KDPC(J9>5Z1\7:R12R#>+G(EZH1(54P1?H""@B80"6MMH4F
MX@ <;EYEY7)7/^RZ94CSXZ5DE[/K (&EUO1$6YA%Q 3+J/XR$R21"0 :;^3W
MD4B\X;*GC!!/&@]JDAM""?V:@\%.>-F@HRR6RH/Y)AJW7_H[:QT:>D:Q:XI0
M5MJI'%Q"SL5(1SKNE,F*S<QDCJ)B0YAMP.&G@4X!PW? X(!5L&'HRD,I\5((
MX-4?0TC(6;6M'A<JD@24ZFC-%*BRP2A3IF3%/"\<\+])(9(Y!PPKS*OVMD)=
M=5M=W53A#SKG=4O:Y)6UK=V&KJ"I#+UN(*\/)2Z9S;3(X,U:$CWIE!\#Q!!N
M?N$/U+W@MU) %Q;DDX !F))/0 =SR31-$BD=8TUW17=V541'U-G=F.U551I9
M+,Q("@ DG@ FOF?=KQ68W3A>0;[A3SF;:7/2&6R2[$4UA0/D\-%D8U"8868%
M@VF+CU:ZC'39ZD?T?Q?!73$R13=XI96VWLJ+<0%F8*JYER6)P!_LO$D=?KK)
M;]GENKB"UM];T22XN)H[>&(2:B&DFF=8XXQNTP ,[LJC) !/) KT[WVK\?K&
ME&V+?^#'.^K4@KJM,ALLIJ[7Y(X75PFHNNUA #);555\2:FYJ*C68>%T,X?(
M H*91,8M>X7^<V_QE_P:P_0UO^G]#_XFI?\ IE?1>.U4;ZU)5%+YP4YXU=.\
MW>N:VJ)Y35NOB%G[U;5EV];K3#PMJJB:1F%FZR;0B@)I"9,W?4( =<=PO\YM
M_C+_ (-/H:W_ $_H?_$U+_TREG[5-*F6.@5*T<#^>L-8MI3LG6J!%N]5Z^!S
M9IR'KLI:Y*/CP3VN<HK-8"&DI%3QC)%\%L8 ,)A N/1\Y*SPL%&6(,N$7( 9
MLQ# +%4!&?691T.1(T-6W&+5])FCB7O+B6-M0,=K"72)9K@MIRE8GN)8+9&5
M7)GN(5("L67G*=J@E"7JJ:SEN"?/!C?;S$V.=J=76U=KX).=B:B6/-97[),N
MU13,A#A*QWI9CJ$$!>(@F!Q$0+;T;*LXN+<JK*I.9>&<.5'^R\0C>SCDCBLJ
M]GU:WENEUS1#;PS06\LO>:CM2:Y2XD@C(^C<YD2UN&7 ( B;)!*YZB]JL@.S
M/N.?,1YYALP:*.RRU =6Z]]:FHI;!\EALA2?=7\(8\L^)8PQA5 Y7)R ) */
M>RIM\ 'OX=K%@'S+M++M++GNLY4,I(QT85C.A!429M8T@6\K2QQW)?4>XDF@
M$+3P*WT=N,L*7%O)(-NT)/&=Q+8'=&=J<69O%JUK%<$.>;Z]4B*K<Y;*RAJW
M7II*"BK>$F-;>OB&VN5,J,MZFD_11(H<3>B*]X"] ZSZ-A0YN(-K%E#9EP64
M*6 _%9RH="<C'K#!/.+G0%6&.X;6]%%O++-!%,9-1V236Z023Q*!IN[="EU;
M,^5"XG3:S'<%X5?M4T+K8-@56J<%.>,]8M5V)C4MAQ+#5NOS.JI8Y.MPUO81
M$H"FU4R$=.JU88682*B=8@M)%N83@<3$+'<+_.;?XR_X-8OH:W_3^A_\34O_
M $RN%%[59OLQ.VJT/@ESRLY*)?+/K&W&C=7:].$%>Z:X2:6:MO?$VNGW9"(<
M+HINBD[Z93*%[IS>?2!"IS_I$ P<<F7GVC\5TJJZ1 V[.NZ*NUBHW2:CZP'\
MI=NFMZK>&<-YJ*XTKM66>Q:238])X+\[[%2%#6 A+&PU?KTT>8:M*2,-/=#J
M;63.'JZ2B9%JOU('=4:JA[@ZV-MM.&G@4D!@"9/R6 9&XB/#H0R^.",@'BLL
MF@B!@EQK.C02-'%,J22:AN:&XB2XMIALTYQLN+:2*XBR0W=2+WBH^Y%\R/[7
M.NRFH/N^Q_";G.ZTT%(?;)'8:6L* -?"BQL:XF'ME%8=I@X&-;Q;1P^.<&XJ
M^ D<P)";H49>VV,R/<0*R,RLI,N0RDA@<1=0015[CL^MK<3VMQKFB17%M-+;
MSQ-)J):.:%VCEC8KII!*.K*<$C(X)%=EK[6V"H^KE]U6SA'SJA-5-8&(L[B[
MO-74$(9*OSPQX1,L8Z>TU%_1'OK1AX1@0$P@Y3$2!U'I46ZGI<6Y]QE_P:Q+
MHD+'"Z]HC'!.%?4R<*"Q.!I9.  23X $G@5ZEY[5)'6L/&6&^<$N>=8A9BRU
M:G1<E):KH'H[VSW>;95RJ0R(M]JKG]*G)R18QS,3D*CX[E,5E4D@.H61;!CA
M;B G!.!WQ.%!9CQ#T506)Z  D\"K1Z#',Q2+6]&E8)+(5C.J.PC@C>>:0JNE
MD[(88Y)I7(VQQH\C$*K$<;CVJC;7TA1(FZ\%.>%<D-GW1OKN@M)'5NOBJ6F[
M.X2<LC:NQ@);55 \@M!UN=DB%5%)+T>,<F%4# 4IH[A?YS;_ !E_P:Q_0MO^
MGM"_IZE_Z959[M5&]6N-#U_8>"?/*(N>SU;$C0:^ZU70 ?6A6I1 SMB)'@EM
M11'K%171XY](51_P9R^'XANH!(MP02+B @8R1WV!DX&3W/&3P,]361=!C=))
M%UO16CA"F5P=4*1!V"(78:650,V%7<1N/ R:XN^U5:LMC1&HG?!3G@CLJ>J,
MU?8:GGU;K\9>0I]=E8F$FI] @;5%#T&/EIR*8K"HN185GJ7AI'(!SE>CC!/I
M$& 0"<S8!.2 3W.,D X'C@^1J!H<)1I%US1>[5D1I VI[%>0.T:,PTO:&=8Y
M&12<L(W*@A6QCI7GMIZ=VK.ZM<]F!RNE=KQ]2B-EV&ON^.^F'<ZG5;3.34#%
MV5\NOL,_CHR<Y7YIIXIG"JYG#)8RP )DQ/OIJ.JQHL::W=I$JA4"7U\L0"@#
MNT48 V*5]4  *1CKBM)NS.GEB6O>S_=/N87+0WGH\LV1WT0<Z7EYXU>*28%>
M$FB)8EP!K_LWE37-K;(H59TMV</*>&O_ !AY":@V1MZ/C]&:L@IN&K;VNS\P
MPB"KQ%^%163G(B48RD>T5619+-@*JNY2.F4,[&B:Q)#!KL.IZO)/'>Z'J%C"
MD]U=S1BYG=&BD"2!AO39PX&0#ZIQFN;=]F;9[FU]$U/L]"+2]M)Y9%6\C66-
MD?O%0IIG>%D(!<.B*"5Y.21N34.U13OSZ[QM-X(<]+"\UQ<7>O[LA'ZMUZ8U
M>N+&*B)MY O_ !-KI]QZWC)Z*=*%)WR F[3$#B @.>8-MC!:>!0PW(29,.N2
MI9<1$X#JRG(!RIXQ@GT#Z"(UC>76='B2=#+;.\FH;;B 220F:+;IS'NQ<0SV
MY[P(_>P2>ILV._&B=JHWV=#25AH/!3GA:H6'LUIILI)16K]>*MF-GI4T\KMJ
MAES*;73,5Y"34>\CWI"E,5-PW4(!C"4<EK;80&GMU)56 W2'U74.AXB/Y2,&
M Z@'# '(J\_9\6SK'<:WHD4C0V]PJM-?L3!=P175M)F/3G&)K::*95)#JKA9
M%20,B^54.UP@;]JMINZG\(N=<[JE] RUG;W=GJZ@>ICP$&I()RTIWU=J)N ;
M,31;[QQ%#OAZ.IW2&$  :]POC<0 ^()E!'O'=5A^A8AP^N:-$X_*CD?4ED0C
MJKK]&'#*>",G!XKJ==KM6V>G1Y NN%'.9#3 49OLL-B*:QU^6O#1'46E--[/
MXX[4!<L8K%+)/@4,@50J!P,=,H@(!*VV]E1)X&=B%50T@+,QPJ@M$ "20!D@
M<\D#FLL'9\74T5M:ZUHMQ<W$L<%O;QRWZO//,ZQPPHTNGQQ*\LC*BF62.,%@
M7=5RPEGB)-":BHR7;$53;2L>RDFZ:Y2E6(@^;)N4BJE(=0I5"D5 IP*<Q0,!
MNZ8Q>AAUJ\]7HXI3%*8I3%*8I3%*ZU!. !W/:)@#J(E   ?+J/4!Z]/;W0Z&
M'V (8I417'7G/N#:>[=?)V9M2B:;WC:N4%/H<%$0LJC=:>YXWV56$+*3LVK(
MN&4ZWM:49,'420B8X&*IH]-)10PJ%.^?GY]M1T]O3R]WA\?;T%:O=HES)XGV
M(>.%@;5BYK7BH\S>/#AW:Y3CALQO.HP$!<W*\K'Q%D7I";QV4"&5]"BVCY0C
M\_>!NW<*&^D^?GD?/A3_ #\_O^?#%2*?NF?%\Q2F\?=28& >@&XX;R$3=TPE
M$P=:&'EW@$ Z=0'IU#J&1GV'[/OH,^SQ]GCY?YUQ_=,N+_\ "]T?S;]Y?W$Q
MGV'[/;[?GQJ?GW^_CY^RG[IEQ>_A>Z/YM^\OA_["?M]>,^P_9]]/GY^?NI^Z
M9<7_ .%[H_FW[R_N)@GV'[/O_52@=IGQ>'_=>Z/YM^\O[B8S[#]GWTI^Z8\8
M1_>.-TJF .]X9>.&\"F,4OF8"B>BE+WNZ B "/41#H "(@ O'H??QC]>?LI7
MDM.U8X>/Y^7JK&=VN[LT"RCI&9@&^@=T*2L9'RHKA'/7K3Y#@H@W>BV< V4.
M/=7%LOX7?\%7NS3Q]GS[/V_57KCVF7%\!'_1>Y_;[ XX;Q-T\_<(43H(!\0]
MOM]X9&?8?L^^H^?N\/\ E5/W3+B__"]T!]O&_>/Z?\A.@8)QX$^['WU/S\\>
M'A\FG[IEQ>_A>Z/YM^\O[B8S[#]GWTY^?J_S^RG[IEQ>]GI>Z/YM^\OL_ 3&
M?8?L^_Y\?'#GQ_7_ )"J_NF7%[^%[HZ=?XM^\?[B?IZ=,9/D?L^^HY]GS[/\
MZZE.TVXO)%,8SG<_AE3.<ZGS=-X)BF4A!.8_TZ$).Z0A1,<1-U  Z%((Y.>?
MGV>W/C\\4.?#XUYE>[5+B);X..LU6G-M3M>EVWIL;-Q?'W=+Z->M/$,W\5JY
M0HHD6)XR9P Q!, ]#AU#N]"R002""""001@@C@@@\@@]15W1XW>.1&CDC=D>
M-U*NCH=KHZMAE=6!#*0"I&",@UZ_[IEQ>]GIFY_YM^\OK_\ 03ZARN?8?L^^
MJ\_)_P O/[_93]TRXO\ \+W1_-OWE_<3_M]V,^PGX??_ )^>*57]TRXO_P +
MW1_-OWE_<3&?8?=\\?;2J?NF?%[^%[H_FW[R_N)^+&?8?LY^VE/W3+B_[/2]
MT=?+_P F_>/O_P#@3I^P_#&>O!^SG[?UXI7C2O:K\0:^O",YR<VU&.K+*!"U
M])_Q^W4V5F98[9T^)&1J2E%(+IZ9DR>.B-2=Y8S=JX5#O$1.8)J.??[S]P^?
M/R]H>TSXO#_NC=1/_P!7'#>(]??[J)\.GY<5-4_=,N+W\+W1_-OWE_<3S#[/
MJR,^P_9]_P!?^?%1S[/GYZ\^ZJ_NF7%[^%[H_FX;Q^W\!/+]?E[?+&>O!X]W
MMZ<_Y^RG.?9_RZ_;_GX4_=,N+_\ "]T?S;]Y?W$_;WXSQG!^S[\?;4U7]TRX
MO?PO='\V_>7]'R$_;VXS["?A^TBG/S\_;]6/&J?NF7%_SZ.=TG'H/T2\<-XE
M$?+W&&AB " >?F AY=!QGV'[/OJ#GW>VO"C.U=X<S,S9*]%6/:DC.TYVP86J
M(9Z"W.XD*^\E(]&6CD)9NG1^^S5>QKE%VV(L4AE4!\4H"0Q3&FG.?9_SS^RL
MLZXYWZ#VI<X"B5,VTAGK$Y,UCO7FE-K5J*%0$UU!%[-SM08Q,>02H_14=O4$
MQ.8I1.'> !4Y_5]7GS_E_EN9BIIBE,4IBE?)(1[&58/8N39M9&-DFKAA(1[U
M!-TR?,7:1T';-VV6*=%RU<H**(.$%B'262.=-0AB&,45*Q5IOC]I'CS"2=;T
M=JNBZI@9F3&9EHJC5V.KS.1D_1TF:;MXDP12!=1NR0;L6A3]4V;)!%FU(BV2
M32*_9TJ26( +$A1A022 "2V%!SM&XLV!QEF)Y)-6=*<?(.3Y8TSE"K9GJ5DI
M^A[]I!K3RMVQHQ]#7J\T:[.[ LY.;TTCU@ZI+6/103 6JJ+U910X*)$**H&W
M!&/6W [O(8?*XQ@Y+ YZC;CG<:S6VIE3:VR0OK>M0*%VEX*.K$I;48EBG8Y"
MN1#U_)14$\FB(A(N8B-D)22>LH]9P=HV=/W;A%$BKA4QG^?VXS\<#/N%3DX"
MY.T$D+D[06"AB!T!(503C)"@'H*Y1=/JT+/V6U1-<@XRRW(T4:UST?%LFDQ9
M303,\?"&GI)!%-Y+&B6!SLHT7RJ_H+4QF[84TC"7%1EL %B0"2 3P,]<#C&<
M#/N'7%*_3ZK5'-C=UFN0=?<V^?<6JU+PT6RC%K'9G;-C'NK!.*,T4C2DRX81
MD<R7DWIEGBK9BT0.J9-!(I%223C))P,+DYVC).!Y#))QYDGQKC6Z95*;'.H>
MHUN"K,0^F)N?>QD#%,HE@ZF[))NIFP2Z[1B@@@K)3<N]=R4J].0SA^^=.'3E
M1194YC/GX=*@DG&XEB HR22<*H51DDG 4!0,X"@*.!BODAM?4>N4Q'7-?J%9
MA* VBG,$WI47"1[*K(0;U-<CR)2@FS=*-)'NRN7!73,K<$%P77%0AA64ZNG2
M@)5@RDJ5(92."&'0@]00>A&"*^9UK+7SW7YM4/*35'6L35M"G&U\Y@(M>F&J
M;9DG&MZT-:5;&B/4:$>BFR1BP:>@D:)D0!#PR@ NG2@+*0RL58$%6!(*L#G<
M#GJ#R#P01U'AZ-GI%/NE>^2=MJU>LU8%>(<C7IZ'CY:$](@'[.6@U_5;YNNR
M%2(E(]A(1IA1 S)XS:N6QDUD$CE4KNL=/JMO+"%M5;@K(6M6&*MU>+.Q3&5+
M"6F".HK"V*)!\@N$=.1*JJBD=*M 2?,CG.9NLF)S"*GS\\_\JPWMO0\1MG:'
M'39;VR.HE[QOO]IOK"):MVCAM8'%IUM:->+1THNJH"L<@V9V=24270(=519J
MFB)025.H6ZN4610 1*@1LYR )(Y<CGKNC YR,$\9P1M6UY);0W\$:HRZC:)9
MRLP)*)'?V6H!X\,HWF6QB0DAEV-(,!MK+EUU4:A,V*!O+NOU^1ME<CY:-K5M
M6C6+J<A8JP"R&<8P\P=([Q@RF1C6'K-NT<)H/O0FWI)%01(!:?/S\36J"<$
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MZY$A[J:BJ:953$[I>Z)_( #H 5K!7LXI3%*8I3%*8I3%*X*%$Q1*'3SZ=>\
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M5;GCS\<^74>>>HX!K5C2''^<U?OSEWMF5EXE]$<B+KJ^S5R-:)+ ^A&E$U3
M4!\WE3*HD0%9[(1*SYL#=14H(+E\02JF,0%3TX\N>?;G[/U"MKBIE\A "AT'
MK_I92B'Z.H#]>*<YSX>6.?C]?E7;BIIBE,4IBE,4IBE?FKV,WMINTP.@W9W@
M>3A^T,T?*41^BQN0QZ?9[(<:D4MDH(32" U-#6!KF6W$L$6N\3!392T>HHU4
ME%8T3SGC''3'09QDGG'.<^)];;@9V\5D+OM52(\&(H,1PEMO?-)EF5=XEW@@
M.Y$W<[8MWHY1*_2ID5CIBE,4IBE,4IBE,4KJ6(91,Q"*"D8Q3 "A0*)B")1
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MA&JSG7KJ+C;SL20DCJ,X?6E4E9,AS1\A9Y9PV1!VS\)9N5NHHHX:MDUURJC
M\OG@\?KX\?;4-M^WORIJ4-J[7NT>1DW3):H\#]_<ET+E4[%7G+RZ;6I^SDHN
M@4>VV2-;.8.Z/*?2W4;'V6&B>ZC.33MRX62,5-,31_E[?GWTZ^7!^?<:_19J
M:?E[7JW6]HL#7T*=L=$J4[--.YX?H\K+0+!_((^'Y"3N.G"I>X(=2].Z/F&3
M4UD#%*8I3%*8I3%*8I5.@=>O0.OQZ!U_+BE5Q2F*4Q2F*4Q2F*4Q2F*53H'G
MY!Y^WR]OV_D#%*  ![  /L#IBE!$  1$0  #J(B/0 #XB(^0!BE4[Q>H!WB]
M3!WBAU#J)0Z=1 .O40#J'F'EYABE5 Q3>91 P (@(@(#T$!Z"'E[P'R$/: ^
M0XI5<4J@& W42B!@ 1#J @/F B @/3W@/D(>T!Z@/3%*KBE,4JG=+UZ]T.H^
MT>@=1Z^WS^O%*J  'L  ^SRQ2F*4Q2F*4Q2F*4Q2F*53H'7KT#K\>GG^7%*K
MT /8'3%*8I3%*8I3%*8I3%*8I3%*QI?=.ZNVF6)3V70*C?4X)Z61ABVR C9T
M(QZ42&](8^GMEO13F,FD)P1$I#>$F)RG$.H*C!^/7[_KQST]G3G(R*)&Z944
MB$313*0B2:92D(FFF0I"D(0H 4A"@4 *0H 4I0 "@    J:[<4IBE,4IBE=:
MR8+)F3'V'  'S$/+J CYAT$!Z>SH(#U]ABCY@I6+8+1^HZQ=IS95=UK1X785
ME362G[I&UR,9V283<&(=<LA+MFR3Q?T@Z+<SDQU#&<BB3QQ4$H&Q48\/G&#\
M?KS[>:RL =  /@'3%33%*8I3%*X&/W>O4HB!0ZCW>AA'V^0% 1.)O9Y=WS$0
MZ".*C/7@\>[GW<U:=GJ57MJE=7LL'&RZM3L#6UUI229MW2L-9&;-\Q9S$;Z2
MF<K:3;-9%ZW17()%$R.EB=X.\)14/0@?9CK\?+GPXZ5X+'3>JX[8C_;C#7=,
M9[-E601\E?4*U$HW!ZQ\%)OZ(ZGTFI9%=(6Z""!_%<&,9%!)$QSI)ID(ICVD
MX^>?/[_&LE'.!.GD(B(]  !* B/4.H )C%#KTZCTZ^8 /OZ *A./^?7D<#YQ
M[?+D ]0 >@AU !Z#TZAU]P]!$.H>P>@B'P$<5-5Q2F*4Q2K&<ZUH3QS<'3NF
MUATML%LW8WH[B&8+FM[%FR/&LV=C!1N8)=NWCU#M447WC)I(CX92B7IT5&.?
M\S[/#W?#K@UUZZU=KG4=?^2NL*15J!6_2UGXP=1@X^!C!?.0(#AV=I'-VZ:C
MA;N% ZZ@'5,4I"";ND* *GS]OSQ5^XI3%*8I3%*Q-MW16G]^0#.I[IUI2MI5
MB/E$9ME!7JOQUCBVDNW(LFA)(,9)NX;D>H)KJIHK@0%$BG,)3]XPXJ,#]E6J
MGQ2XVI5:GT@FBM5!3Z ^=2=)K1J3 JPU5?O7 NGCF!8JL3H1JCQP85W0MB)E
M75 IE2*"4HE4_P _GW_Y^^L_HHIMTDT$2%321(5--,A2D(1,@ 4A"$(!2$*4
MH !2E*!2@     =,5-=F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*5C7<U"2VIJ/9^LUG3EBGL'7]PI9G[)91N\8#9Z_(0I7S1=%1)5%RS.]*Y14
M352,51(H@<O3J#)'(QD<C(!&?:"""/800?$&K*Q1U=<;D977<JNN5((W(X9'
M7(Y5U96'!!%?C1USRFW&HWT7VB4_<-D(:X[,"*TGPMY UM0)X\5>YN6JNQ:;
MO6X/HDQWCZPRE>LLQIX4G1SN%%W2CHRB[MTB@9/=,!+]Q&H8S%IH6*;3)$$+
M0]V6=W7O ''=DY+; S.P&WUDFCR/=-HEE;)--J<D^J:9.;0127NGI:R7&F"R
M>>YN+F%+V(72FQ9FE:<6D,TDTZ8@VUJ',+F?Q?U9IC1U&+7V-N@.&%:YI7^3
MVFA2)5IL;8F^]F6*R2U%LEZVAN_3P4:CU493Y-R=FK3*WST=+OH<7,>T:)D9
M2.(HLA1QE$DF:/8JAS'&BQ;6]79WC;6(/JJSE"Q8LS%>7+;07TEM>1]Y:V]Y
MJ,UB+6" 74EC:6L-AW+CN!;&^G,%Q)NW102W,EK),\KRSR-'MNKVD/+>>Y?V
M>B5NHTJ#U[KGD=I'0-AU99%-7QSVRQ&RJ%5+?:;K'[0LV[JM:5+:R5M;@^O:
MQ4-2VRN6Z,JL@DE-.Y!ZN>%Q*H.,DCU';.">5#D#A3P2H&>@SDL #C1@MDD(
M[QY%#6=W<!EBE<"2".X:-,+"Q[N1X4C:1=T<1DW2S1JDO=8![/3F]OU'8FZ.
M/YFM?H5-H\QSWVE0K?O$\DHUY,WBI[;LJZM:I-U6FVL71*#IU*4@G=^=2"$G
M+O6L@\5C&D9$0KZ1S)<* ZE0H!AMB5 VD$VT18D8&=[9<L,YW98[C6]KD$4=
MQ;M"L42-I.@%X43NW25]"TUY)FCVJI])E9[COD+B1I#)*PDDPV]G9E\VMW;^
MV#>-2\CY]N?9##5-.VU&UMEJ>KUNOA!SLJ[A)*?U]M;6^Z-NT/9FNG4D1NSK
M[AU\G;8FHDZ6>HOFR@&;5DCVEBI+1!RBN05).,@%3@A@/RAR > 2,$ZM[8-
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43%*8I3%*8I3%*8I3%*8I3%*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g287237g38i49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g38i49.jpg
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M 0$! 0$! 0$! ?_  !$( 04!X ,!$0 "$0$#$0'_Q  ?  $   <! 0$!
M        ! 4&!P@)"@," 0O_Q !H$  ! P0!  ,'"0\,#@@' 0 % P0&  $"
M!P@)$3$2$Q05%B'6"AI16'%XE)>Q%R(X.4%45E=A9(&5MK?!&2,E)C(V17-T
MEM38)#4W1E5B8W)V=X:UU_ 8)S-"1$=EH4-F=8*#A9.1_\0 '0$!   ' 0$
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M<[X:-03;-R3E0>@S'K#LQV:'O-=V?1QQK&_MA49X#(I7,"X.P542YB.E/DL
MZ"L6!,:2S[RU@X71DD<4D<;3OQIC/,I9GMS=9O9!,K%-8@Y/J[1VM=:D4(+X
MX7W([A#C9FV%R$B8KV0:(PF*%8]>5YE)BO&XO81)\LG*KJXU%PS8EEV1,+JN
MFP]>C1;39)M;LVZ[%L<=]WW,>HBNAZWJS(\ [.<KKFTBV'DM(]0.QL^]5J(-
MHTDN'<R+<XXA)'R AYJG<$2.9A-$RER'EHF)B7[*);WE)N*C)8Z:>6"SUL#A
M3@"]*3OPYHS+A@>*A5,0Z:,R*C-\?L?'X^&8[9]BUM7!?+#M&IVL)LS=ZP<N
MJE6DH!K71ZN':R:H1?)+ EG7(YH8M)T"FB3)JMBNEB*4#2V?V_SO;R_5<K1X
MWHRIO,I1GJB+:;V:[ Q][$"TTW'LW."Q5HW:%5"U[E+ 6+_97D_(0+9\IKU8
M8<>M1=C(KOSS_P!OL>SP^/\ ;F6:GV(OJ=GJW]H;ZLE16-VFSV_7!3IX;6+3
MZCK:7=F0AHK8O",LXP-=[_ G$ V_9)A!+)6)*Y+R+<Y-0""K$(IY7'Q*BF\0
MS#8*+$ B$E!CC5#[2K;+IAW905:XH=BW)!$Y'=@-C3N6#W8UFND+48$W+X_'
M_#V<Q!G8MMDJ*:8U*J#*:W2YAZ%YI[YM;$[1;9:S5AGX19/[JD*2/,=7=>19
M"JSBD%&Z2T\8=9Z Y51W?Y\S&QT V%!"@C6NJ-KXHS=O%\;/8EN)B;(13/'*
M,2B2V'E<$ 3RQ(08\7/F^5\,D4G"5E%<&6G>^S"PT2##L9%[0W<67L6TZLKZ
M9]FO1M=1/"CVC5\I5M=WB*Y\X7=I<3O "(BH]PW*UJY2TS66*8Q3&*8Q3&*8
MQ3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8
MQ3&*8Q3&*8Q3&*8Q3&*8Q3&*8Q3&*8SY4QOGAGABIFEEEAECBJG;"^:=\K7M
M93"RN"B=\\+W[K&RB:F%[VMW>&6/7C=GK51'(JM1R(J*K7<W*Y$7BK5Y5:[@
MOF7E<UW#S*B^.6 CO'*(1&'SR'Q>3[%C^.QMB$MK2*3!Y8H.F.4Y-&QQ\T5:
M'FC)%7!L7=BVK-^%<I.PBP/OL>Q'8 U<V%WQ^/QX9G5AV@VUK;4=M9UU!/77
MM?CZO7ULRK;(J4I8<*1!AQ2P3&>U2112BE!,&\4QLWDGK(6:U#Y(YGQ&U!/X
MY)HA*,)@_C,O%%&T@!X3,XT%D9,8/NI,]V2X8M7"35;9&!IS@Y'299)6X=%@
M(8"&C$>('-6S*ZG[5=LHK&MMJQU2"RJ9<8L":ZHA%DQZZ)!%6AUT9BC<1FNK
M#&HY%:QS4EO/+/+*>1+D%)<2:Z6A6Q85'(!-+GI#'(Y)83++)$SY%T\/&("?
M82@%>4/EE<W!UED>&,2)$>[R\#?*-TT<T<6N&*%F8_3;A<:_<6%[3]Q@6%A6
MW-4KX\&.,4&)>P3UDY*T+&H.$9(,D\>.<2=4+2.>UZD57K:5IPFX_MG#-TK'
MCK]5L-WH-<W>RV09V,8<CBUC&V'AKO#UO<B2/*XX-$7RM[+#QZ+1JVOC9@PS
M;,RHO;)O96&&V?""TDC29 T#50$[HO9[%6)JP8?.$G=X\%JN*\#$Y)!WE*5%
MZYT)&->&VC$8ZUCCL&4+-T7.F,G3\F764)%1/'YR,=ZHB9%1JFT:7A\:="6K
MS*-LV;,:5(K$BQ=)Z7+%'[MDHG:[NS[ MB*;&BD>/<$$"-$8V/&E;X.2+:+2
M.TKBE2VLA2RB2Q*8LF+'9'BQ'ABQ8P!5ZEH6#M-QR#>(YU*A4QEP6)@Y>U%R
M4@RCLH;P90EG$G!@4CE;)1<-B6?(8)-734<0;+9(EV)##+.V3+$_>+HNHP-+
MD#K)514S+2;4DDUT<UA6DNVQVVHXDIZ*C62UB@(KR"+(CD8CXAXZHG"D=K<3
M-1;F.3^139&4K$ME:G':6DN0J5%!2&4$&R$G)TV#%LU4LBU7<E"SO)^I?%5!
MZA?!-=ME>V6>;+KJ_:GM>H0J&!3/K&1]<VF1N-<DJLC2GI>2*^-6N.<A&\Y1
MCBQ1(!J*QX7\SF$1%1&P!/AIH@Q+59T3!GW4J5FD'G-S5I=(6Q#$GKW7Q/6$
M;&X/FC]N]QCF$1-%V9,'X1=D9=%'[XIBZ<NUL\WQ^/\ 7D^-VN[M$JFTD:;!
M%5MI[JD[GY*KR1UC7]_&V6QD."4! K8.MH<0T:=T^O#%& ",X0Q,:DAQX6ZL
M#:CB^I@*LU(QS6DGCDYUD!/[$D:(P(>@A-W(84$5?#TU':<98G7&*CI>[0@?
MR03:*9$':XD3BU96KVP[-+VNSVF<VGCV&QUMA2[).@4%>Z3-@W<85?<S&A.Y
MHG61X(U:-G5CP$>XK4 (<J5U:UTGH]2$RW9VY9BB,3V[NU_%S$W81XR2.0V*
MKQV!P^#Y X2]+"0)!P-(VAS0R3*/@@TD2=*,V;M+-J$&Y699]RW-MS5:WJ%0
M^2[5-,!9Q*4]A#C0KBS987EO=)-N0Q94X Y$?RN6'&C FR(\833%$]"S9"+*
M5.'VGKG"$H;6ES&3/MS']\HG6TH>9/1.PI/$'T$-/1"3M-TP:,W,7(+C$$,F
M:S@?@B,6'.VBX0(H.95M[6=M[D"L(M4>M#I\'1GP2U@4!*H*VV#=PPRG"<(Y
M3#LP,DO>AF,D*^2R0(K)LULBJY3QGT_*=$X\;LXXL!U,@SCC)@#BY-^&>#<8
MK(Q<L#.69E)90G<BG(0[,J](NG#EZ5>W=.2B[Q=XZ45*G'X_V_<\^6NL[1ML
MK-W7M#2P9.VEYK QYUG&!,%(6TKI55,&:&YC8W=W5\LT4,<0Q@BAZ8XPPL")
MK+>,.$.D0[T&6!9SX(?C6W)[ND)(F4[-K&F,PV<Q>"IOABZ)*$$UQAX4]4'.
M<'*"Q+%NFWS3*8.4$W%F7\_;/N<L,V+.2CFP;'5*/3IM>:DA,AGJ=;.*53*H
MHS0.')A2@MD#<)[(ZD<1'1E&1PUNN1X_:H,2Z0SHQ&;EI/)]7,--E2A(J7>N
M,X /SE.6(M!5P^46;OWF,R/HD9 FI8^]0=]Y7)9)VRMFS%H^][1$JH%)$LDB
MUM;LI]NBQ8\6($;;TZ5B+)>P86L( 2T\!\> YO<0O%SLCHY45* $\0=4BXOI
MR(*$-@EPFAI/'93K9 O.2Z_B9S$(V:B<7'9IM[M&JPT(#//FK;N6R1)?+%LL
M_)/%4,<KLOLKM7VB39[=;("ABS=XK;"LV(D6EB#[X.VL8=K92$<]"$9)F38(
M2DXD='8BD8".)KU1+'[IX*!'>E9)KC1(X4./R(8>U\.*SB5F&[/7NI]H;-^:
M#NX)"<V$=D*R1*;)O"XR[E\T4).TUQ#,I(\PH!B,IF::=VVS0[C7;#NTB5(@
MU\F%?2(U+5Q"&OMIUG6_(.ES+E#V$!KXU,X420@PE;'$K)9HU>V;/-)S,K7>
MI8;K-:2D(ZR6S.S-T(=RJ0$54W!8O:/!FL=C8_+)NW9L6 6-@F3<6#!AV T0
M/2\+=I,;$B95Z^9J*_VJXV-E='L#,2%4"EBK( &N9%B+83"V%B=$(\ISS+&<
M8DF;-EGD2SNZ0G&[M&BA!<RF8YBF,4QBF,4QBF,4QBF,4QBF,4QBF,4QBF,4
MQBF,4QBF,4QBF,4QBF,4QBF,4QBF,4QBF,4QBF,4QBF,4QBF,4QBF,4QBF,4
MQBF,4QBF,P*Y^\D9-H[06V2&K\GB&P 4%(%;RO",') "@=W>;0<*4(/!PYT%
M8RLLN134C+.1/& ULW0=2 GX8BT& ),S>/87V>5NZ[UJT?94$^BFW<>+Y+6R
MA0)UX@D*>2V.*0<4PU7%9'<VR-7B/)(]XX$;I/+)G5M!.=I;7SW[)5(/XRG(
MWC;QEU:.E,&,['*0F+3#<FZ#K4DB]DY'$;*<'I.):TC[DPR[Q%9 >)%)FP'-
MV>;MX-7P?'X_']'&^"UG5TT2M;==VI)':)VC;-)K+N)KT:YLJG4=.@DC/#6Q
MUDU:AC6NQSQQ#<]I @QHU.>00[1"DC=;+D=RSVUKK9^NI$]@Y)@8TSQ],;=V
MMI6*[3*K1$Y.-SS<#J#36N9/+6T69L#9-N[SE!,2TSA;U1>4Y"\QZ5@S->4M
M?/C\?R^OYOKIF2=GO99JNPZWL%>&ZCGB[?OL34]7W&SUB,VUA4NGTL[;=OV&
MMJ269CPXY!)61I16W(6LK$DH=_>S,K"Y-'>9RB<KFXN&ZQ?RB&Z?D$EC^ZMB
MNS;H)%H*M!]9$]@SMTD1QC)0>2;Q9\I$XADW7?C3)PV;-*@PSP5$"Y&_OQ^/
MK_V9K>#V0M=5TLFXV0%9;[; KI^FZ^*&*;9W;+K9(U!2#='6QC'COLPMM;9"
M#!)B0H4*&V;+#*MHD=,6$^?$HTMK>,M4]02[8<@,:.AO(8HQF6YGTBE  YR+
MW(G']9Z==F\=9=_?/5$#[K&.-&PW$D.$Q]J#L \5-'DF8OC\?CX?6\,V<O8;
M6;CL-D5VV55! B;I<:#&/4:>&OK9\+L^U%T_9-N%"79.0(6O@C6>4DE8\B5/
M)-[_ -Z**N-?T7SY;D4';+YE)A67F=Y[HU'K*+ S#R4KS6/Z'$,GT_V$LL"B
MSITT;CBRCR)(@(^-EBK^6>*1XTJ]%$7!X<S!9/882.\1ODHB-J8>DZ?M>R6<
MV(&L933]XE&#14#&3;,8BDD16AM7SI\BJ:"K[T>1$#)CC@R*WU=R;VUL?:CS
M5ZN@&(%U"!&H'FYR:FU&3_'6AK9FN2\Y*QF[7&)-4Y,8BSM.,ADD@KY9$NUD
M"QIRX!H#D6I-]SX_'_\ .679NSC5=>U@.RLWLTX=U+VP6GQFZP8"['#US8(E
M+%LNJMJ1U;$LQ.LI;GS -?$+ 9#&.:^0\L:01[9\PT'MB <<I:X/[")[G-SN
M<QK94^F#]8,U=$9\N;+:0C9I.*NU'AK6FK73B41UE(,8XWDX\6@%#XA_#$&X
MQE?/UNIWG5KWM!JAP*"-I\*DI+'7:*I"V804>B9"B[I8PW6@T%#V/9A#K; T
M!;!];(E/F2UE]%Y),-R0Y8RK4NT9?$Q(2,K0'4O&.:<B-JR%X;*(G\U%,I#%
M-:P(,R9B;M6123RL=F\;K9FF[QZS8.+H+B\FJ"$@9,[/>RVLVG6JFTE3+)E[
MM7:13Z!K%>&%&?!1K4@6FQ7DPQI2%-%K:N0T)&-AD"$IV<[)74>^!9KCUR[F
M, UAEK39L6DLNV5 C/'/3 R22>>.R9W;/(#?<6M.Y& D#LF#66@X_7;8HD5-
MJKO).["0M'-+(6T,B,HMB^/Q^QF7[]V4U%[LJ;%K=G6U.NWD+M!W"175M(*/
M"U;1-&LO(E?/@"C36-NI&P%BOBPVL#6CF7#D<DDL.6EHM1+](ZZPBL)E;74
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M)^UOQE^.S:?]7^G1U'VQV/\ $U9\.XZE]_L=1^,IOP5G*V8]30\HBQ8H5RY
MZ#0R)D7Q"Z%D-AJ61N]<JN;I64O%<+YV3NKW%L[X8WRM;NNYQZ^JW3HO1&ZT
M(0A>0;QW3&P?-S0$X\C4;QX=Y7AQX<>'%>'LYI5_9#<O>]_E2L3G<YW#A*7A
MS*J\./0\>'')=ZV1Y0^V&T)\&V'Z+U,^61UKZG[SW<#WSD/I/W/MK6>YE?L<
M>MD>4/MAM"?!MA^B]/ED=:^I^\]W ]\X])^Y]M:SW,K]CCULCRA]L-H3X-L/
MT7I\LCK7U/WGNX'OG'I/W/MK6>YE?L<>MD>4/MAM"?!MA^B]/ED=:^I^\]W
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MS=G<+6Y+K;)QG4^D,DZ5IUPGT;#)M+DL6^O1DHN*<Q\&?-BE)DP;"84,QDY
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M+TU5:IK<G<>S.$>%3=TNM @VUI4OB2$-96$BJM))9R$%$6.+YM%"3D2;&Y$
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M1T\B93=RC78YKH1'SE>]# "Z1!CF'W$:#):!;SQD0CW)Q1O*]ZHU:G,=(9)
MF[;:;>Z%Q0>#-U"M0RO-;8)6\D$A\=**;HENZ T19:P?/9!J(.S:D(O'Y,NZ
M!I24TBUS?WB^+M9NQI@Z!&-3>5V7O,PE,6VBHV +NQ3+<)3Q*<TM]F-@+8SW
M#DGC(TRQ@JY&=Z5J.?.)M9AV/D]U9P<RQ9 .JRWJ88TKO*)[$<=L-[BP!M1X
M!&5PT,1&\_0YE:VT+KI>1C35DCV3?13G-:W$''FEK^.Y;%LCE)-8I;?5U0_
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M$>6)3I*XOB@BCBL/WEJ2>]""R4DCF.ANJYSEA90U0QPA-C.5M>;KPW/DRRF
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M/)/+RUAP,1'L@C(:#0&87"^3:3(>K<687:CH![(\<";P[R.XEQC5+I45T2'
M6CE*PLJ(6#%B"ZAC2$,\AG$7K=Y5Y$ZH6N)&^G8Z5'5>B^  PYZ!.T\B4ED!
M%8&0R48Y.0;!=-C!(Q.GT4:Q>0BM99-WPDV#ER-E&[PG(K;419RK<L/V@4B\
M7V9+VNO"D<C0F$1\MKJ1Z3*8F8>=RET;AV<>+36TB'*M&Q-!X+BC54*Q;97E
MFZ0$UZ-2FUZIEOBT\NL%)DUL1]@*1(+,.*QCW(NC+!W21+[P*%W<B.<-6$E.
M0Q'9;G:Y*6V-9#MIP&GL 32!#,.D1X0CC"?$+7/ZD<G7#'Z1)'68J->CF :H
MVHM]&G";BRRC4RAR&G(]>,3W7KC4L@#.'\B>,TM8.3AR39P",V>&5U(/$4I#
M(BQIF!A.<>',"2K5XQ;MUA8O-E9';GL[Y$.6MO([S!L&VL<S61V/6S: ,9)\
MGD"U)LM8\<07GFI((02/8]SFE*C[DW7:5H9$=*\71E15@E$KBN8D-2D-W4*.
M(O=@(4KR-%&Z3&O5KFHBL9R^(CA+QJ #I4,#P0TP0G)4><F+I':&VO'$E+#(
M(7UDW?&3^<ZS.OUUX(>*QHG=<CGB:8NNZ,8OG2#9PC$;<]C.2*4TX)'0A$#$
M:ZLJNC&$2<&R<P($@H ;6S@"D"1HTZ+V\ \C7.:[P>NU F'8.,1B27L)(<DV
M=U#$9&)#1Q"]YZCE6,5X7\7_ #1J\2<SD:J9)1N.@H?'0,2BXID"C,6"BX['
M08U#%L.# @C% 8(%#VV%K8-V0X>U;LVJ&%K8I((IIXVZL;5CDF0>7(/+E%>>
M3*,61(.1RN(8YGN(4I'+XN>0CG/>Y?%7*J^OEW"$4<0@!8T00#8$(F)RL&(;
M48-C$3P1K&-1K43S(B)DZJ3DS)4="CI(&*Q\NFNL*-#W8LDBV?/QBZS%\AFV
M=(IOQCEF0:9*HJ9I]_9NF[C"V5[IJX9>>IH#$CF$<2M:4)&%&YS&$:U['(YJ
MJ,K7C?P<B+RO:YJ\/%%R HV&&\1$56$8YCT1SF*K7(J.1',5KV\454XM<BIZ
MRYC.-X0\80\<TS$1>M%&4;X]2968Z7$(3G8V+77LE6=+O<RP3KEUU+K6<.G=
MTDGRCQL@D\=MT$4V[IPDID9-TV4TBXEEL4?(OXR1+@KH5<KY\9K6L01OW)PY
M>5K.*L1CE5C'*JN8U4L[-<IAAKP,AJT-499%<-),M&Q#*Y7*\?S?CQXN=P1R
MN1$<YJ(C7*BQ>'"WC&FQW((MJMAG']_+R)YM:*K2&8KPZ1$I?DBI*C+"&K2)
M2+Q$])%VS5T</0L1'C)1XT9O'KY9TT;+)0KN.R*^H*MH]#T+8[*N4D>&V9''
M$14BA),;'25+!':YS0@F%D!$Q[V,8C7N18OD>IT;8#[DSI6BF=. I3K',^1P
M4Y&QU*H0%,J-<4L<8B$<UKGN5S6JDV#\3=!Q_8;3:P2$O1<_;Q0#"G<A9SC8
M**LD Q7!7"+6G##&5>*M@&8S=;)>/2B<,)!)PCO!N]&&&KQJV72E&VJ]/7OJ
MS36%@.E'F,COA0')'/)5%D]R(L7JP R43ED1H1(\8[%<,H7L<YJQCHZL4M)P
MXSF2D *.XS9$I%,("+T>\MZW3E$#QXB-):4PW<',(UR(J?8+B=Q\C6J8;I(%
MKIJ.UIKN6,YU 0")^69.X5,1\B>RME)(K)E3RDK %VQ\D2?)/!9QJKCB3),^
MOP @\:K^'VJ_DVDRZ/8/)96$5\*>=P(J,FPR1V17QI49 )%.%P!B8K"@<U>F
M-_#G&QR!4=4&#'K11&LAQ#MDQ1(4_-'D,,X[3 ,I5.(B%>]R.85%X/>WYQ[F
MK2Z?!SBVW=1U\/U?8.\B6OI!JV.N@$UV''EQ<'EQI[(Y@(15"2T?FHYF1PD0
M)S$ZO=60RMR\<Y2$J2LMGC>J7==G<R0,EGUF2IX+.0V1#KY#2S8H61XAG(>(
M1$;$ (8X@&\(\5K&I'$/@F24UNE1PGMA=-P(I80G"D2A*R,<CBR!HHSL]5((
M]SY!5XF.YRJ8C^*Y3S[B]))9KKDNUF<C@3;=G)'79K4T@VC!H6<C3&T)8,)R
M#UMF1#)S'(\Z/1H+.B>#X@SEK#-57P5!DJBB-;JJSV;-'BV&MNAQYSJ77; -
MK'K)TP$E_?2$@GL4&98: :"2:"+IL?$>C4YG/17$<B2G4I3Q;A)!HJ6-O$)!
M+-C1RA;W=K9(X?./O"E<0(Y+^9S3M55X-:J(QJK1NF^#2<52-C=N[0VMN2(Y
M$=:26!PW9VX)EM%]K#86MB)T@TV/ ]G%&42FT6,D\"@YA86 L-;CV@EU@X(F
M43SILTK+C=EE*$E365=1+0=C&G3*VHAUC+*OL1@&ZNG5HGRX<H(U$0BED=5Q
M'E:K1A4#7.IZ_6T A&3YLZP!SPS18\R?(FNARX;RO;,C3'M!) 1Z/8SD$K6M
M:->+R=5R)<R2\$>)LMCL-B9K3PO*/P*(3Z!1P<*D4TCML8?M//%?8H XYCTD
M%O):QF3_ !\<'[2QP;5?2#-:1**^/5UB&=MC;QM461,E!MR]>=+@SI!"QX<A
M5EUB*VO.%LB,5D5\,:]$'=6A1@$2.B=%K1I6&UFC.*. E>SI102HH6,+(%^Y
MYJHLL15$9CCMD.3J%ZZD5Q>)57J*KUN!'^,VDHO)89+0\,5P.:Z;H(055_*9
MD:8151OK]CJO B%"&I"0!LCF>NAS2'N) D.L==A,56KHBMX4ZR6H)&R7,F-,
MB&F(H+!SG3D'%AA)*1T]]HHS'#'&=X$L"/EMCJ3H,,J.8-O*U$JA4]<$T<XX
MZ]2(B)&5YY!&@5(K82/&,A7C:58C6QU*C.JX?%KGKQ=QOQ5CRYXIC%,8IC%,
M8IC--^X^4FP-4<\^/>PRAR08\3-JG)=PY+CW49DXV'QS9;X@.*:^VEC)WPU&
M+F7\QV$#D^O?"!YE=B(A0)$SG:ZQ5QBCMZHUB!::-?UX@QUVJK!$VX)&28Q)
MDBN8,@I]9W89'2A#B5YHT_E(%KRS9"@3P$U5P"PNI<'9JJ4\I?(4XIZ C'!,
MR.&8]S"1)O6>U D?(E"-$XL(K1QQH1?%ZHF.)_4F^]_<[>DFUKH_9"NK3&O]
MI='Y+8ULA>>3$0KIX*_U:\EFR4H'"@+!\*DRVT/!7K:4Q,N_C<5D+I?QG)%W
M[E%"ULACVU'1:/V=6-W7I9BGUF^Q)-<D&(9ML8=HV+6K.F'(PL9*WF8Z++".
M1*CL;THZ#:JY:"P;2TV;;X5;,6$^+-U60&6LJ0SN WPG2)B18PFN&99JM<TX
M'O" KE5YE<Y$RH('(CNTN/72X;8Y"R8^"W;IC<G)2-04JH?* #W'N$ZMUJ(D
M6CU-4*-G;1>'-W3QQG(FY^.>!Y[-=KW7-.)"BM=/.GF@#67W9354$<!Z6XJ-
M=DS1)'$<%]-L[(T>Z2T1S'MF.8QJ1W D<Z5K&HT+0*B*DV*8LVJWN=:E**QK
MK&X#&>IGA+51H4,9JWN3FN:L=JJ[K(8/+WQR\2*9/#+0!)[R*V9R%X#DYK$$
M)AL[8_1N'9SLC7<I*$8J&D<H0D(IHGL(I%& EZ.(; 9QMSF>%@EQP199^XRC
M3<S&D,DKMKN6#K];0;T*'+=#K*_M#!"KK"*-DDT>,X!'+ %*>5A!P'R&H IT
M(=&C;WEP9+D7GH12K:7:ZN^2!#S)>H$DS(ABO ,QFF&U);P,8]CY;0N4K!*P
M:JYRA0@4X<M\^D,Y"_,EUUJ33^IUM_M==07<G'!FYG41U[M>=!-B,A6^!X4_
MK17<8N/% []Q&F\7?""$5\H7,YV%)W80"GW]!D48S"R:!K_E6PM;>U2A?/G5
M&PO;!EV%5"/7O+2/,"R\D%D#,-LETIA1RN[LA0(S32%Y5()\2X[7;=QB08$%
MUHV+%L*EKI0(LZ2.4T=HP18:SQB(Q[@H%XW@4JR99G#&G%&N;(E_2-2*2&].
M["W< ,EF-R?-_CSH> +LC90#@K ]2S)Y"9P,7<#[Y+-&Y_<1S<P.0W1;N4RX
M <#P?-GN#%LW2C[/01P6]?2G$)_3TN_O)Z/"(ZI.M8;)L(C6D]2]P*@%.:/Q
M<U1'(=6.8KW.6';"F) EV0BD8K]DJ:R*K2O%QC09*Q9+%5GBUI9Y; 1?!R$$
MT?,UW*C4RSFNR'O'G4,OS'02?Q+;6Q29/.?1G1L/V'OL?H\;ACL4;&9V' QB
M)%5Q+&1QV!H"8Y)2$7C\0?R/%G-CT:1Q\<A2^+PJYFPV\3J3H$NJKQ"2!)NY
ME?1$NB+Y/))@F/)EB:4D>1/4LB,.3(ECC\\($E?F)@WV5,=50)#FQI89TM[U
MDAK02[-E<Q.]L#)&(,<BC:445!B,X @.-RR"!3YH,ERNBTF1*?='YQ9DYI[)
MR9M[K%@@:+2] TD<,%F#\@Q(%UW)]/ @6:DG3=1X/.WS<-#C%5N48.W3)T@X
M4MG:;#'!WS9HP61AA99/<$41P5 $1!C>,2- JC$\;7(P@.#7A>CA$8U[7-2K
MTJ0^5JU(8CC/(Z$Q"$.A$(1[7.:\BJ5$>1KW(KF%\6D:J/:YS7(JY^U@F91B
MF,4QF&?.9_/S&BIIJ+3TBD$4VYMJ%3L1$Y1%X_)Y&9B;07'5EGT@3:1)@^,,
M4'II]%X%:0-;MUXP_G8^2-\U5!'>%,PTD< 5W#MK>."5554R":5&DGC1PRG%
MD-1D=72R,"1S LE3N[NYFR1P21W(B%YDQ_972B5DB! ,4$^='DC 8(C&(!&"
M57%1H&N(U'$<"+U6\%"Z2TR<59P757OCE*9Y,\"N ^XFMW0?9Q3F_P ;M1[E
MC:!!W%GB$[&28U$=MZ]D5F6'A0V.2PH,P?/8^^;.VJT>)!E7X]Y=%'"VSZ/6
M0ZWO.]5+N4M:+2]BMJ>2HV2FK!+&#+JI\?G7E))BB+TV'8YCDD#,C",YES";
M.[)<:SK%@WF%-?LE1 L H]P7ME,.2//B%Y4YF".]G,X3D5JA>/G8[@B9-);!
MN4.@]H\,=%;EVF3*Z%Y)\Z=^RJ6B(_,ID>CNOH0M'A4CXW\37&QY(V!R:3PH
MF;0DGAH @R%AY-=ME%\!3D&QR1?2HD[6;VLW"[J*L0KS7-)HHL0QX<,$B?,:
M<L?8MI;71W'C1IHPNC<D@;RFC<W>5*P[T5D9XUU5S=>K;":\E9;[+:'.,4B0
M4,6,H1FJ*)TLS1F/&>5#<PGM8,W#H=-PFJCJ,Y93.?0:<]+/J'6Q4TRT3 >%
M\*VRP9B2#Y 1H_D&40;8CQFO5VJV'D$M+XFFXFCP "5'M,23'QZS8M7!-^N^
MK-5AP9L+LKMK$07W<[<)M4]Y1L<:ZH!JY2$L$<U>_)#EJV&PYT(_ID0#WO:(
M;1T][(E1I.\P89"MK8NO1I[6C>]&5MJ]$Y&Q'-5.ZJ<"+(<(2L;SMZK6M5[U
M=FMH69/M.\?!&X3NMS.6VR&G]=CHA"=78; W 0VA!'T8T*DIN(Q!8M'K2J2/
MXU.MBO2>P24<B^9\6)>&Q"A&48#A1?/#KV&RXORU +$/DH=M8$ES+-8%2.LG
M#E7BI4!G2Y'=8[),&O8. .3*0!BL 9!Q5(429'6R70*MD\T0JSG0(C(\>%WJ
MP=-BN#5HM@2,$76,X,F6Y\IX@J9@W%8KSHQA,Q[X3;8DV\X?,]4%Y%M*0&9M
MTF6\7<B.;'C<FB$G2TKI4\/V6J/?!S@P+80R7>Q77FH)I!FC%EA#_FBYQ4B'
M$Y8J,TK]N=5&I)<.T%'K !A=F]*R.&NDQI<9US<!)6H1A@%-UGHR586T.<XC
MUE^3^]#.5.#W6G7)QK*/)@E--,23N-DXI)831S)75Q6R^5PRL'TV*\$6!(BM
M:WN_>U \;/%J0G1PHOI2]W&;V6U2P@T'YN\CF,4VVZGQ[RO$3&.;DU)&M6:;
MLP79I-V\',L9.="AHWB9-CCF;YR-;@0+QB.>OX^T-S(HZ@%<]RS9NF:\^74M
M@@[H6'(J+619V_.UZN=-"^, QI/1 0"#:1QSL>1C/-2YSNL"3$3NL;8[=@)S
MI9>N.0&P@A@UZ-<B-2,]IB#$'J$817*QHA.:QS\EM/""D$Z3679 4)B2U!OK
MB=E.8A+A6[Y+M;7TUEL&V4"0F<UE0"16<-(;*LV,[BL>AZ,-(J1!&-H/<1UE
MU33@;%,<MS"G=F\1#NACMZ+:>XRXA:6-5SX42=7'=#A13QN5TR*A(,J1+=,&
MDQTES5(K4"TDJ[P&$C;B=1I(? M*/O,<X[(TZ+(/%F#21(.(W%L<ZME@%'2.
M]8Z!:Y&(JD5@-L5:LS.,4QBF,@"I4<#%DC9AZV&B [!X5*D7BN*#0>.'MU';
MYZZ6SO;!%LU:HJKKJYWMBFDGEGE>UK7J8(1#E&$+'$*8C!"&Q%<\A".1C&,:
MGBYSW*C6HGBJJB)D+WL&QY".1@QM<][W+P:QC$5SG.5?!$:U%55]9$S45QVY
M%[.#<_MK:3W@[DV,(Y:Z_%;UXX!YG$9/$$X:7@8%C$ME:.:#Y8,'7+&A\-81
MV8'W 1!6/KOF9\HDY7=FG'7M?8->K3:'5W-*R,LW59Y:38BPY<:8LL,X[Y5=
M=O)%(3I!),)(A@:9R'1CP"5K6!;PP.IMIH]IG5UDXR1KR*RRJ&2(YHZ )%&T
M$RM:T[&=0C8[0R"J-%$KD*]'*XBYA7Q U_RMFL3)[]TY-UAF.@M]\^L#(MY.
M9K(#V]$F7C(;J/2SW7V;*T4>1,#(F3/,65-2%<A',%$DHF);++*.$LQVV?J\
M*6.AMX32>7:/1>B5L*''!2*]1DM;AEAS]Z9*/'>]""#'0<A4591E1J-7'J&+
M>20$M($ES/)5IM"/8Z3),6R1O.R!7.B*WH. (K6\CR&5P>*( :*Y7)XGY_/(
M_P!$9H#EOKJ92D_S7D&T=<$ATVS*D'T\VCMF6;M<Q28Z<DC:R^"DCB?BK.0Q
MK'5#AO>,!F,:9)C00Y4*U6;>@@09':M>ZI80XH--!66 R0D$-D&LJHM,V7$M
MXSN54C2NJ@)*VC7=Y,^2]2G(AG([PLN4+1*N]B2#EV(TV(]DA7O?)FSSV2@D
MUYF\44H.3K!2"J=$30M08V*-JI>J%BS$\Z23I(M?2@4W(:7#E>+6,Q/O=A&8
MX[X^QZ3<2=G30W,=:IHM/%\?7D&R T<6E9YB:C62#M1N7?,SMEG63&T32B@=
MG79W/BE<.Y,+9NZ 9 %(9?R(VV5L,,2Q5S^I(;'K32$BQWAD\S$<(;P\&<]Q
MBM+*V_;X9VH^N&^E201TH@758CT4R021#:C>42FF,$IRM()4<J/>TJ*Y65CM
M_EJ7+=([PK!ND]Y0C586:<G!#X*:U'M"*P&8M0>D"H\7M7*4$HNQCL\!HO2I
M4J@0!E#L>@4"183(\[#.I 4;":2IU0(NSS<CM6DFVAX6M%88-M62IT-YKL3R
MU?=12B2()W,$$2C.($B=.4D,##-CB<6?/O2/VW71.2RC0A2;ECAD@30Q9#1U
MI&LF]9P&BDC1SWD1PWD%%BHV05PW%>C+&\@7VUL-S]&')HV!RET\Y&VY_;G,
MZJE\F+QJ/3-20ZD;;-T]K>>8MAYM!YAJP*6CL;C[$@%>MF!L+EFBJ+7(OC"=
MYH&5:T_:5&D'[I!U[Y!*<-I$CBD2(:1[1];;6,%7$"YBV9Q2),AXS,<0)O%I
M6C8%;;:/GI8Z88 U/*MTVFP+".<@!25) ;,KXDI&L(CNY#>(0FO&YK2C544:
MO<1,E.>.N='Y<?8GK6,[_*ZAVICL8B"T;)W_ "+D>N(]JN>O)XUV)M*7&G/E
MB %'A6KHX9("DQLFSD6<8;8@M:PM()*CZ:3W'=&L;KR]*L95"*VJUKAGNXP]
M?C6,BT@L@NKZR(!JQ#E :SDA&121N[I)<I[&:IXH%5EXV>)7+5!AAM'P)W>W
MBK3OMC1!093I*2YARKW@+"CA"(YB,-UE"B"B1T&8J([<6 =MGX(*_9%+&V;T
M2-=M#5K)VL7;.6:*R!2UD<$D;6?I9X.^I)--.W?OG,,,>K&VHCL<,YAO%T7L
M*1CPKQXB<UZM<)>95=\S5%9XJJ^'BJKF?"<UPAN:_J-<-CFD\/FC5:BH_P .
M">K1>;P1$\?#)M4K)F*8Q3&:K>D^VSNV#ZRR-\>7LAQE/'U_"N2<\# XS*3#
M*=0Z%2YL\>:MD!T$+(C8Z#D,3%SR5'U2JS)=5&'@QS>_@\@671V?V:U5--L5
M#?LC]UOAS-=@&/)BA?"F3(KFLLP .499!X\HD&*!!->U%F'(Y%<!&KA6Y3K*
M-#ZE2XW7JW1[>2,03D;*CQCHYT$I1,<T0S 9),57JU52.-B+P*JICKRSG-^0
MW*#HO2^DW2,BBO);1O,<Z/#OYO(-?QV5(YZ,B)_7[N8%8LQ.$F9"!$S;HN,7
M1#$C45/)O<A.+,IADKAD.J0OD?UKM,%<M='DZY=:B AAPH\^1%<EY+CSVQ!2
MGA&\<X86!(U3##* YG55XEX+:;R5Y5N=+)7/0H+BMV C1NE&BA.GDR.6(Z0\
M#2.1T5Y7D8J#>0)4?T^4B9^\?XCO<%S>TQQ!Y?[-)[JBVK> SN;QQP?6)N85
MN;<"^U1P*6RTZD9RZ]D2#7<3)MXF&QF"1 H/&(ISQ04,.'')#/R^ET9M+N-L
MU*M'32K/>F0I#0-$V;3U+:LAXL0#@I^]T>PE#=*.L1PQ$*Y8"%* #1HJP68]
MCKZ&_F/L0PM862%2J]8]A/=.:*0<J$7]UEB >T T.CGM8B2E&,I'.7##8^SM
MP$./NPP&,GE!^ :MZ9R.Z0X_R\S*3J;XUIS*;/&!?5^<YMD0.2;7(9[?.+XO
MWF<A1<#$[A5+$D(XS8,\QKZVI'?5Y^[1@3[/L?D75]$#% K V_<V/#9I"^9A
MC6)F)WE1L2.YI%ZWS-TEY'X],G6#ZN6-#&)%A=H(:ZJD/,5'D@=Y<TL-9/JB
M'B#<J@YG*5%8BB7G0+6-V]R;4@B9\?-IZJ4!AP.^=B#3<Q5X]C=_S77<80G^
M0(['(N, RF,8,)!A%TQ4/L?:H#P;2/'R G"<E8V(6?Y$V>IHUL:'?U=HAS2*
M.O(&&V_+0P["2Z!UP2)13Q9*O LE2S%CN4AW2 #,L$4@J,Z;\\/"')JYL%1C
M'9RF$D>2FVLF(%)73*$#!'"C2H#DC]5$8)!%>Q)+PL5_.W&?5,RDVX^(NH&1
MM?82#G2'1^[!V=/\I\=4)31UM20Q&8Z:U@=+2!MBUN=Q7%PC?,F%DU,/#%4G
M<)DG?<7_ 'ATIDEG#C5&V6SPM@.;=;[ K8'< =*&VKCRX=Q9@%'<KD K2S:*
M.4:+R(K)D=$Z?%J6>%(-/H8#2++:ZMU:7,E=Z)SR'3BQY%?#(0K4:A45D:S,
MQZIQ5'1C<>;@Y9MT;&#$AQAT+L?=[YMKY\>T0% 139R.U3;0SM=O+@,F-;!-
M30R^3!793($C$D'+-UDZ*&(FU&)&Q,TPO)G(]"5VBJ0>R7E?2L?8,!>&D2JQ
MU6%X:MT0\8, ,,+%/U(9UEN:]O((4MQ%"6&O=FD=,U!4?2U<NR>D5Q:P8@3.
M_%0DY#B.24201W2Y9(D CFN52$ T:/'(3K*Q+X='D#ENNMG<ZM.2:-S"-#8;
MON/2N",".TY'MZ -H-LC7XDJ&;0243%JWE+9^X6%/I'-@)2]\!)22,$6*6+;
M/%P[LF_GB6-9I%O&D1))9=%(BSGCJX]3/=-KIY1&=.C1'.C/&U"LCPCC\2CC
MD5Z\R<K;CJ@CQ)FRP#!D!9'M!'C-?--/BI&EQ1O&D8\AK3H]58XLD3U7IO,Q
M&^I5%7:#6M,S/%,8IC**V-,T-?0F0RY5DN47%,\<!(5I@X5?2&1$G* J,1D>
MFT;/'*A&2R%\,!#\$6KC/)X00M9+.W7:JVOANGS8\1'M$TKU4IG*U&1XXVN+
M)DD5[F-0<:.PIR*KVIR#=XIE/+D)%CE.K5>K&^H&U%5Q2O5&!"Q&HY5>8KF"
M8B-7U3T\,TM:6WELK+3_ $FW%+?$L.27;VDHSO+<FO)F> 2&#FIAIK;D=EL\
MB$E# I(@SD ?. 39<D'0LE9)O$T\XH'!K8-A3%:^XKBDKDMNS?:*.*"-4W4F
MDJ+"&"0":&);U4B+!EQC'CJ\!4GPFC*[BJNEJDHQT5Q7IFO*ZREK W&CLSD-
M/K0V5A$D%$6,217SQ'E ,,1D:4?=9+GC3AP0"= 8U1K&KF*(P3S:U7T?)OFS
MJ;8Q(4.?]'!IF.,-?AIA+Y](9-LQ]+8T2V'RD-CSHIJ"ADUC&J2<@QP<@5I
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MB"U60J$T1CE57-BU9 -<JN<Y55H@,15YG.=XIYW.7SJN5_Y713[)X]^.AO\
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MLFWW/\E7CB$X+ZM_F7^,[]>4KYDM%\)4E/#_ %Y?97^5DQ1#"+]HH;V7_P#
MM?9_BJ@<4O%WS0GG;_'=["_7R2^;,3APERD\_P#Y@OUOY>1R(8/?JZQ0V_GO
MVL6OL?Q53.H3_6/]T[]>4I9TWQ_=DKYW_:"_7_EY'(A M[VZQ N_GOVL&GL?
MQ5.J3_6/]V[]>4CY\[E7]VR_6_\ ,F]E/Y>3!$&$Z_[3B^V_\'M/8_B:=0G^
ML?[IWZ\D]_G?[;+_  DW_P#WD>B!!]?]IA7;?^#F?L?Q-.H3_6/]T[]>2GV$
M_CP[[+X</-WDWLK_ "\F&  %\[^P@CS]77^QK/S^[^LTZA/]8_W;OUY)?83T
MX<)TQ//_ .9-];^7D<G'P/5C^P@CM_P:R]G^)IU"?ZQ_NG?KRE?8V',O[NF>
M'#A^ZC^Q_OY,$8['_P# 0;LO_!C+V?XBG4)_K'^Z=^O)#[*QYE_?";^%']A/
MYS)@C'(]>UNL"&OYK]HMC[/\13J$_P!8_P!T[]>4WE.R]L)WX7(_:9,,(S'.
MN_[7PG9_@IA[-OO>H6E)RI\T?Z_\=WLK]?)+K.RYE_?"=^%R/8_XF1B,:CG7
M;]KX3MO_  4P]C^(J+J$^G?[IWZ\EOL[+E7]\9WK?^;D>RG\YDT3B\:O?SQT
M%?SX]H@??ZM_O>G4)]._W3OUY3/M+-.'"QGIY_\ S<CZW\YDQQBL8ZK?M< ]
MEOX''_T>C2/XIZM_G3^,OZ\D/MK1.'"RL$\__G)'UOYS(]&*1:_;&@';?^!A
MWL?R:G4)_K'^Z=^O*9]O:\>'E.PX</-WV3[*_P [D:E$XK>_GC4?OY\>T,._
MHU36D)ZGU;_,[^,[V4^ODE]O;>'[Z6/K_P#G9/UOYW(W")13KZO)F/=75V>)
M1OLV^]J=0G,OS1_G3^.[Z5?KY3.N;?F7]];+\.E>Q_Q<F2<0B=^KKB\=O\]]
M4(-O['WM47._Z=WNE_7E+Y9N/;6R_#I7[7(_"'1'N;?M6CGU?X#&>S?[UIU'
M\>/._C[/,O'\N0/N;?AQ\JV7'CY^_2O87^=R*2AT1OW/7%HY?M[08R_L_>M.
M=_TSO=+^O)7EFW]M;+\.E?M<CTX9#^O']JD:\]O/^P0OS^;^2U[U'_3O\/-Z
MI?#^W)"W-PBKPMK)/%?-.E?M<CT87#K]L3C/9?\ @$7[/\EIU"?3O]T[]>27
M75SS+^^UG^'RO8_XN1R,*AO7;]J49[;_ , BO8_DE>=1_P!._P ?/ZI?'^W)
M#[NYX\/*]GPX>;O\OV5_G<FF$(A=[7ZXA%[^?_  G[GWI47.]$\'N^=^F7Z;
M[.4OERZ]N+3\82_VV1Z4'A7<V_:?%OJ?WOB?8M]Z5,<]_*OJW>Z7V?LY(=>7
M7%?WXM/.O^D)?L_\;(Y*#0GJ_>?%NS'^]\3_ $2H6D?P=ZM_F^F7Z_U\ENO+
MOBW]^+3S^V$OV4_GLC\()"+WOUPV*W\WV/"/9M]YU,YW_3N]TOZ\E>7+M?/<
M6B__ ,A+_;9&X0*#==K>1D3ZO/YO)T/['\CKWJ/\_._C[/,OZ\E.O;OF7]^+
M7\82_8_XV1Z,!@M[6ZX7$[^:_;' _L_R.BO?QX\[N/!O\9?83Z^2%OKSU7[]
M6WSWMC,_E?SV1Z4!@E^KKA42OYK]L<#W^K_(ZC:YW!/5.^>5/.OFY5\//E.Z
M_O4<O"ZMD^Q8S$]9/Y[(]+7\#OVPF(W\U^V-AK_5_D5>,>_BOJW>;Z9?93Z^
M4WR07WMW;_C*;^VR9X:]@/5U^0\0Z^OM\F@OL6^\JF\[_IG>Z7]>4_R07WMW
M;_C*;^VR8IZ\@'5C^T:']OV,A?9_D536N=P^>7UO77Z5,E/V"^XI^_=OYO;*
M;[*_SV3)'76ONY_>+#?YL!/9O]XUYS.YD]4OG7UU^E3)+]AOTX<+RX3S_P"D
MYOUOY_)BGKG7M[^>!PR_GQ[8N$O]6_WC4?%?97^M<DNV+8/']_;CYUW^DYOU
MOY_)HCK?7?<_O"A?\U@?LW^\:<5]E?ZUR2NQ;!P=^_MSYE_TG-_;Y'HZVUU?
M'SP&%?S5!>S?[PIQ7V5_K7*5^Q["G#A?72>?_2D[ZW\_D<CK37-^V 0GLO\
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M#]S;\/RWID#_ #)]G]"Y%)?]W\/Z:9*R8I]N/N?HIDAWG7[*_ER8(]EO<O\
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5JY5XJJJJJOG557BJK]E<^J9YG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g287237g39b55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g39b55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1/R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $]:^4'@X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             6\   =3          $                          0
M           '4P   6\                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   6\     4F=H=&QO;F<   =3    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   %O
M     %)G:'1L;VYG   '4P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !CA"24T$#      )H0    $   "@    'P   >
M #H@   )A0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 'P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
M 0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $#
M @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                         /_A
M0'YH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I
M;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM
M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E
M(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU
M-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @
M(" @/'AM<#I#<F5A=&5$871E/C(P,C(M,#(M,#%4,C Z-# Z,3<M,#<Z,# \
M+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R+3 R+3 R5#$S.C Q.C(W
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C R,BTP,BTP,E0Q,SHP,3HR-RLP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z
M4')O9'5C97(^5&]O;&MI="!H='1P.B\O=W=W+F%C=&EV97!D9BYC;VT\+W!D
M9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.G!D9G@](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F>"\Q+C,O(CX*(" @(" @
M(" @/'!D9G@Z05!42U9%4CXQ,2XQ+C N,C(Q,SD@4')O(%!R;V1U8W1I;VXM
M,S(\+W!D9G@Z05!42U9%4CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^
M"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS
M.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @
M(" @(" @/'AM<$U-.D1O8W5M96YT240^=75I9#HU-68T-V-C,BTY8V)E+30V
M,3$M83AB,"TQ-F4Y93ED-6,V,S8\+WAM<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,#$Y1C$V,C)&03@S14,Q
M,3@V1CE#-3 Q-#,Y1#$P0D$\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @
M(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F9R;VT@87!P;&EC871I;VXO<&1F('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CDV,3DX030U140X,T5#,3$X-D8Y0S4P
M,30S.40Q,$)!/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(R+3 R+3 R5#$Q.C0X.C4T*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z,# Y1C$V,C)&03@S14,Q,3@V1CE#-3 Q-#,Y1#$P0D$\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C(M,#(M,#)4,3,Z,#$Z,C<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV
M97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C Q.48Q-C(R1D$X,T5#,3$X-D8Y0S4P
M,30S.40Q,$)!/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(R+3 R+3 R5#$S.C Q.C(W*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-35F-#=C
M8S(M.6-B92TT-C$Q+6$X8C M,39E.64Y9#5C-C,V/"]X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T
M86YC94E$/GAM<"YI:60Z,# Y1C$V,C)&03@S14,Q,3@V1CE#-3 Q-#,Y1#$P
M0D$\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U
M;65N=$E$/G5U:60Z-35F-#=C8S(M.6-B92TT-C$Q+6$X8C M,39E.64Y9#5C
M-C,V/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/G5U:60Z-35F-#=C8S(M.6-B92TT-C$Q+6$X8C M
M,39E.64Y9#5C-C,V/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D
M93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M=ZEXYJ!D:ZDY0?#<7KM.,=J\DMBW@HC)C &@6N48VKTE(0<>(.&:5(/+>T*
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M7LBR%3?HC26M:]=U8=/+B4*>G9%US,I91J\.X)&XZ[CVCH+=]L1S45&IBH0
M$Z18ZNNQ\P=P/*^]L8J<QE> \=\D2OFADF"SJ:80Y0&;* XT>1Z#>YJ]#P-*
M=4*-RL(YKFHU4]$H9!2MS8B@U6L65NFD!3V/N)4W(\UQU+*-,X"R$7O:R]"2
M3OTL/81M?;IEV<&(<KX;12H0E\%Y6@,CUD*U%Z ,4B.*QFSGD,]@V)U-$B*Y
MKE17J2)83/R6M>TA"$C_ .8CKY#?VWPGUJ1R3!$TPZ7B4N !<]5#"W7>_<;X
M^D7.%5@DLHZPGNW:IBQB,BN>GDC2J]SAJ3=%:PPQKWV17;*JH-%J8B"1);"Y
MTNK$?Z.W]>."N11:4&-M04*P*]@>A(W\_HZ= .66DVQ:"'%CMAHU2O(894,H
M&N5%D>'UL42'>GA1&N:XA&H0[VM8QJ.!31B-C(X$@-E&H;^=AWW^NPN>_?67
M9CI4GJ+$'R%KW)]UK]ST!PY/:AO@P?\ -=\T_P#6<1='M_?V==[7_JQ(Y_L^
MK_CCTEG(WVZ!)NJINJ/[^??[_P"7_P OCMS2.Y[=;@6Z=0?S ];7M? )KD#8
M7[G8#YP<,VOSF:N26.-6@(T<_0DZE*C2,9.KG)LYFY"^]*C/:]I>CW",:\C&
MM1C]K":A HEK8'YJH=-0B'6T;$[:E4DJ+>=OI-L0H*V];)1SHT:?*AD(*K(G
M0E&-@W6QMYV(VPJNR:<S(0U'A1O5STTFP1R,*A4/'FQ8[D5WB]/A/#+&K$Z4
M<CF.=NK7)M$,*"C>J4LQYR1A=ODE 6;N2%LQ.U@!<]R91J%];2'8*8&E\5@]
MPQ0 W.Q;:WG<=3L%Q+0Z>3!]MN_2_M]/W^^VWT=_CY\-:18'4#?RM\]M]_WZ
M87SNQ%C[1T/MW[=\)]IE*5<?QSN KE=TB"B;$*[MNC44B;-:B]9"+[HQHI'>
MZG#T%,9FMXE4B^HBRCN+MN!?L#8GMWPB:H,0%@"YW5!<LP\PH-R!W(&POTPF
MQLCR66!3,@UX>EO6C9#9(WR55R>Y'8YZ*-J,1R,-(5JF7I<H L<BJ^U-3QFS
M2EC_ (++8;;DFQOO8"WM!-P<(2>=A<QF,;6Y@*D^=K@7M]6Q/48\KEMFI@!\
M $5Y"#&X<V+*"Y'/<B;",USXQ5=OLQ6EV553I5R[-5HTZ&Y1RRB]SL;6ZWL+
M=O;[<25F0"SJY8'_ *,76U]NH._GO_4)&1=T1?FB+Y*GFGR7NGYE[\1,. W
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MDQ%C&=+SL!(1K*!0=[DKIJ(4I81RN8V"WC*I;6L:1:PP&H7$:G3>P-[;;8I
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MEOTL'W,F@W\F>/\ Z[#^^\'V19W^$JCZ4_1P?!U%][I]+?I8/N9-!OY,\?\
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MS43MTDV3?;?BDJ0! "+V;Q6[&XZ[W%[@@[;VWQ-I?!.^G;XNQU7:V[6()WW
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M^IA1F=F$CZ4KP-<C$LQL3<DDL<='!&53-%,TV9N^E"&DJ8G8!0"JW-.256P
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M39P#O#(#[+C3>_6UOK&^*+B>AROB'**W*I:VF0S1<RBF-13NE/4QG7'(0"'
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MMUUZ.:O:A4CD-E^AJ8)CN"76'BEUFIN1W>&9+K''D_8VIJNLR;%:D^:2L I
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M3<V -[WZ[;E535F55,JU=,R1RF,![GJ+WL"NX 'G<'8]R))CG!*"*3&,,X)
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M+#,C7,"C/(6F@CC3Y+X$R"Z0*M:,:RFA)LUM$4J<NS1<SAD5WBFAG3FKS+/
MRDJ_1M%P0--BMR-QCWN/.,JXYRC)^&9,]I)L\I<N;*)HV:HBH<RY[,L%1EU5
M4PP,U4T83FF6 !V =93U-=-$-'M*]',*N=-=,,FS;+8NI66U29?D%A5Q9$FE
MK'"?7@JX8QQ::CBV\]&K55PI!$D6-E/Z4\3P(M>FEXFXOS+CZOI:BN@@I/5*
M5J0)3I* XNTC2R-*6L?&UU6RV &D$$M6<(\ +Z(Z/-<P0I5U*0S9E2TT]=2F
M6KK(X@E-)'24PED:AI59JJI<#5*48.RJ08^JFGE'66$8$P&/1Z/'Z,;J/',?
M-$"!D$5810/F$BL<\99SY7K;2G,CE"1%]7>5[C'<._JE-#11M=[B6207# E;
M!5.^D!0+JI[V;'@%9+4YEF-3FM?/#7359.HI)K5OC&9693&I:Q)T@JNG90+*
M#B5I%-42F*R155IV+ONTT*.1NZKY[/8OZ%[+Y[IVXK5J)U(TRLI!VTM)<=3M
M=R+VZBQ Z]P,,&&!@0T$1![:!OA()A>-.7<=4R&Y$WZJ\\JO5-^W;U(P-D[^
M2=T7;945.'Q7U9MJGY@O:TB(XVO<C92#U%[D6O8;X;%'2CY$00VL2A8&UR;;
MEA;OL!OT[W0;RF?CM>^TKK6U4<0T594*;+)9Q20BR@QY3VDG*>8!X(Y7G&\,
MIK44:HYJL<Y.)=%4M43+%+'$=0.DHO*92%N-@6N;BUC;>X\CB/5P!8FDBD>/
M0MR&)<,+BX^UM[S>P[X8U_3#IP5 QN:1$@AB%*UGAH4T0+!O,C.IZM<=.E[D
MZG+UHJ[JKE5<]FZDS,VHVD<@!CJ(T$1@ZMK]-@0+#:YZGU;@:JDFR]J%V414
MRI, %T_WV9F9;;6\9)U7)))V&*QZV6MY '2,K9DR# D+*646*0@'%DC47@A(
M83FOV1CBD:-7(TG2YW3U#W9%I>6JFY'4@GO<=>N^XZ;^[<G'K/#M-%*9=2K,
MZZBFOL26"GEF^KH!I!%]A<7!PP:[+KXNE&M4:R/)L*^OTLSEX9<MY9! K)Q.
M[$>*ISN(0K""<IF,>1_A*-48YK7=*7N2E/A;+"A ?X2H+6N20:J(%1?KL?;8
M7/?>J](664;9)F$<85)7H:F1HQV>.(RJX0$:;,NGJ;7\@,=9<9*X%)5M0+WC
M2MKV_P &K7*U[(86.5456KTO:UC]T39'*Y%VV5>&JD!II?$H/,D/BN+@NQ[
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M$LAE@G294T!RL!?3KF8,J'T9<%*8J5:L@ITB97)4$4UA(K12)('*JDB,FJY
M9/G:IZU2I.4$?RU<N0DP;&<XNLV;6R+>Z=B<_3*SP.JSO$;J%C^-VU@S*L7F
M:FX:MP&)"F4D.+8R9I;UL2FNCU\RF]'F2P14L2\<\7N:NIHX:0RI'":M<RCK
M9**KB>HK43U:H3+ZKE%I$F8QJO(U31*ZCZ=\RNU_1QP2/54GFET(6$+4[0I/
M%*L="Y,J&HB#*%>-02P>RO:Q7HX_2?2-4^8C0GEV=RPZ)8J/(Y^3UWVPZ.$1
MN7UOJ&)9;E'K$(SH ]BR'5_LPJJ=/XE)*WJ<J=*N<<^B=<@X6S?.?LKSRO\
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M[E<641CB+MU*KE5J=T3A%*&JJU(6WU.6 ML4%KL"-N@(M<'SZX:K)N5#,][
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M2;_-_P"U3#LU0_\ LVM_Y\__ +._C.58\$9\IH_K88VW"?\ #*C_ *O_ /\
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M<&VUM[]NV'3DV<1L25K[*NM'PV^*I)<.LFSP> @&F%(]9BA)'BC;T2@R%F/
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MI3NOAP )ZGG?F/[I4/MVWRD?7Y'V##.K,]1<2T/32?[6G[=-O7+_ %]SA?\
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8<&#!P8,'!@P<&#!P8,'!@P<&#!P8,?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g287237g40a28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g40a28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    & :^85 X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              :\   =D          $
M                 0             '9    :\
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   :\     4F=H=&QO;F<   =D
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   &O     %)G:'1L;VYG   '9     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      -\
M  $   "@    )    >   $.    -U  8  '_V/_M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ ) "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 "
M P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>G
MM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"
M(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$
MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M  P# 0 "$0,1 #\ [SJ.-B7Y%K[,BR@5[6Y) V5AH8Z_>ZRT-;] >G?94[^8
M_5;42UG3J\REC\N]EN6XV4@7V>F[4'TV#?Z6WW?HZT#K(L;@Y[KBRVMM=I<T
MC8-:;"TOLW^W;7^B_P '_I%C]$&)9@_5X7V^T/N=0;"&O-K;?8UKO?N;_@_2
MW^_]'[%+$>F[.AX=/+B_[E;*1L#PMTL?,Z/DX]EE65F 47G&M8;W[VN+_2:Y
M_P"D<[TGO;^CM_\ ,U9>S!9;=6<K+WX]0M?%[X+8=8"SW^YVBPO2NIJZU7B!
MK\^VUMOJ<ML<+'.HI=4[:VJWW_\ ;G_;J;_G!>,VFU[3.91718P AU$^LUV0
MQL>YNYGJ>D__ (M.,22>$FOQ0)=WI\#JG3K,7$++X^U",=MSOTKB!O+7;CN=
M;M6@O+\7J-V1@549M0K/3<H%F35(+J[6ES'5U[F,=[&>_9_P?\S9_.=?T#=^
MV>I.JM+L2YWK"IP@A[X=Z@]OT'L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB1U"K&$$4\V.;E5R5@*CODR.JXQR96PE^*?S'7\"5%S:X3++#2UEX#DS8*3
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M$L$HOT;7&LI7_"U./K&M%7:>KN$#R6;6Z;EL\<+025Q-$AO;9*1/(HC:LZS
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MR3+]\Z8.JH8]<)]O_*I--E>WN'++#OP?$.^F-HCO&Y]-S&SH+M@*QBL-;C)
MD /"T[6%^4Q$H\X##KV"B2K&I6)4,%)AC)7E&(FXY4XS$.F<>J>3W21K[!?'
MWAH2N%()R3GPR@<P5A"MAJJB,.(\&@%<J#,T@U%Q'@H;FQQE&AG]OJZ5<HA/
MC;[*7>+;EM]WIY3,^Z7VF9&C,C6I2YC>\NYLA8MG@VX(EUE]#9592.8!UZM*
MFJA%JP!0P8*(DQR6$UPV,>H@)B!/I&2H[=M<+^"IXS86I4VO ..Z*JXY96)
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MYBNW*\;106[,,3N)&BBGECC9P  [(CJI<  !B"0 !G&AHHG8,\<;L!@,R*S
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M<9+\TY,V<R2[[;?KZBYK$]DQF>:28PPQ5XC([.8X(5XQ0IR)XQQKY40851V
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MCS#)$[/4BO[G2IS%A%8G6.3@0K\2"3Q8A@#V]2IQ\M/K\[U:=BQ&%+Q1EEY
ME<Y [@%21W] PS\QJM;QI^*O!>;345?3?EV47P];71)5E-<KRZS8V+75*/\
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M0B&S$MNUG$5=KYH"/,S;,)9SV9\D,&FYC$Z>8PTC,A),TDTF^^S6LQDL3NV
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MRY%>>;&";GP$K\P6FO,UNHI)BRT)[[8Y%TI K'.PQBW;56%%L/[ZZPX'QIM
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MZQ.'$G# *RH0CX?MR5-YBK0%UBM.L<R%^2,#&7!XE<AD)\C!N0'8E@6!?_\
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MT5+&TDV,9'$%8FC1"8.*SG:(42>6*8@K3(,6NQVT8TE@N>%-^H5'O6:+"K&
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M;:.36.:'?762/;;3?&,;:[9QG&<_0>UV$LRR6(PP2>(3(K@!@LC\@'7O@@,
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M/J)KZ.1WI8EL,%&B,UV.E8R,-Y!FI4)L1#$*4DELNDW%4N^%[V[U7NTHEDG
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MQC;2Q\]GB^I!/'+ 3!)C&GU1289A#!]]H"89AI9(]W--V7949'9&%3 >-RK
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M&8'';^%",@C!!'J"/C]^K,? KS^YOR_L)DUHI-% K(C!M3[<PK7/% MQI[.
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M:0>;66H7(P8L,H<X$X ZXT,L!BO.#EG$.7L YH2@S!)I1R()=)(]\XSGVL\
M.(2RLN8\@.I4D  =@P]"0<'T/SQJ%E*EG*L"0^"58,/X1QE20",C(]1GOJQ/
MC/\ Y_<?[5=_^$V]1F[#$Z#Y1#_6;O\ I]=/J7XMO\;_ ,M4D^&/(K9W&D?%
MLY_17-=0W#/Q<K'>:\RMPK(VM:L>3=@X]UB$)R.GDB:;@M<4G95)L#)I/%][
MK+KOC$><^K+NUF*I+X9FF1WB_P &4A=8RHDXV8+E<LA?R\DZO(<A@E<?(ZA]
MOB>;\-)&4#_A?FI<'CF(59,'CW[\,9'<$YQ\-3W>>*WFR_(ZLQC\UF%497.U
M(65+BK:-E,HHZ!I/>4_0 0E3=@4%$4EH-\%5<R&&&PJTO?+:!TVV#L'IUB&E
MA$W':D%=3M*R+%&ZRF1P'F=1"T+,R $AYX2U@Y#=&Q-!&54(1)M6N-U"+I0L
MRE"$R$4LXD 4^4D1N%BR"O4C21U)+#4V.$TSHE#YA7D'6^@[=1Z9M(W<7:Z1
MB3K%+!Z^<'." :REG()W15)#&;"AK"C,TL@B5:'@J4@W<HB:*N2P36'>M#[/
M7PJQ1$AF5$4*&D< <Y'(+R-@ LQP H #R!)$C599.K)W+OC +$DX5<GBHSA1
MDD =R3DZ=[TVTKIC*-_/Q[Q_O=R3_H.Q>GDWY'2_QK7^O'I)/QLOW1_Z&TC>
MAT>OW7R;Y'J^P[SA%QSK[E=^%M=JJW^KQ^@\(Q%D[-7=)LMP\>_\=8VR<LF_
M?,'OGTI#*\5"QPX>>U65@\<<G8PV^Z]1&XD?G+AN_KKET5YDY9[1OC#,OJ\>
M?=(SZ#USK+O\7VCVVK^6_>[$_0L%B*_JZL^IC<B'/XZQ*EU)H==8D+2M<[0S
M;+W2HY>>-G;4H66.+>>#2$L26?=OHJLUYX]J@21'EK&['8B_A(9#8D3FI[E7
M1P5895O,H/)6 RWQ[%+''N,K*RI*M5HG^#A3"K%2/BK+@CLP['&""4S\*+IG
M0H?*;Q[$BN3[01_8G]8>BX,S]%S7XQ+%%HJ::YTSE@+I^/ FQJ7M+O@L(4W&
M_P!W!'-K??I,VJA-X WFW+ )+%&2.2G([R,:[_AF&IF(%BJ?N:1XC@=U8YR>
M^J1X(NV8?&&VUXI>G#:5TL(BJHF0[:]GC)A?,.NJR#)R& Q@9&M(WQ$VG*Y.
M<5>C=:48P@OK%\L7WR$[[$_FCD5/KD6RQ9^Q-Q.!M&9..VAFUV$R)_&+'EAQ
MD@/Y8V.&26>9X[!@Z48+CAU%D1B0RNO-/*,9R#D'!&,9UOVYRK'$@:$2EW/'
MS<&5E&05/!_-WQCL",@YSC4=?&K:"*\]+$T)CGW##2Z;;QZ[:130R/+3(*9!
M\_OG<8R'/U89-=ML8SB2"3;4F B**9G26.Q,)E*,S-(,J4#"1W;*@DGB<D#)
M;XJ22"=,(61HHBA\J\5.2"5*JHXL0!W [Y[ CO\ $#5H4#@JO<1A?@1C3&H^
M6Z-PXC(Y)1)2EM4P8/&5%%+!+*-O+#IK-''/#)O%G;726/;.-\5!P&L,I. T
MS D>H!<@G4\#B,$>H0'^I<ZSY=TX_2I)%/7>+4 JMJ'%U@8==0)0C]:Y4+;.
MRK!.Y*6"20@46LE0RY,SNNV& 7Y*AUF6I]-M@A+S0W&T\<56[,\BUL+6E=5]
MSRY1Y>Q<A40#J9(5<!B?6LVJD*NT]>,(9@3*B%NY\V&5/1<DMD(!DL#CL<)3
MQT5JS:79935:PZ71E'KI*8N#+FCUQ7%>V-=)2())--,;;9VQKKMC7&V=ML8^
M;WSF<C1&K3\D5CPD]Y5/;I9QD@GXYP"/B?LU'.S">#!(\Z]@2!GJ?HU,CXC/
M/I?)47NO'5==(9]A"JH8_'VX$E?4 [*0C*+:GU5MIQFH19 AIXVTB0HE@8.&
MR:9^496+$<4?5/"MW\$[EM]YWD]F$I:U&G$ED\REE5\#*^1NS(S!..3G&IS>
MZWMM6S7"IUN Z+/D>;RL 2I)(/<=P5'+)'8XS-<IIEDIEHI-/O-8:5UXML]P
M <UZR+)0RX)PP[M#-"4";%C$D<9HF?DWSK)#M+!B2+?;Y--_6]-9J7[6WRUI
MH+<#I,,QLDJ$E[\@1U[\7"LCF-P'4%25!QK,C%/6KV5ECDAD4QD!U9&Q^YT+
M*>V5)#*&4E6P1D]QJZ4WL0'(/ -377%&JERYQTSR(NM0O-><*I99!E$?/:P[
M':5C8!BHW5/UK0?1B&<//"3I/'G84H(O?0R.@[AMM2SXXMLYFKBKME.RC4G2
M!PY"QL3]6RN"A(9&4K(/(WE/:RT[EB'PU $Z4AFNSQ,+*M*I7NX[!U92& (9
M3E3AE'+56GE*> 1QFP#BB%K],=#ITP QV--99%>T=_DADB^0DOZN(="1H2?>
M>24>;;76?/M./*1:=DI6:?B&T;"N%LU[$T,C]/,P:>-V9C'A.HO,"1%"\3@A
M0C*3$W[$-C;8.F5Y120QR(O+$;"%E48?S<3@E"220.[9#$/-\*:X->:] MG1
M*U"OS8:=X==@MJS# 78@$EI7Z0K> Q-1X)A9S09& (^Y8^I4&\VNN?EFCDQK
M)JY^DRM!-X1\/1F-%%C>]DBD>-460I+0O*^'"YR0<Y.06 )!QI#PA/+'ONZN
M&8]+;=QD1&+%>4=FL5''..V,?=D#4$//>N2]]/J/;.5\W@4R_GV<?2:52%++
M JRUV JMSX95M)&2?'LA(E@BS,,EA$C!W-CDPI&'^ZU!DO"D<&U=!&LVC4AL
MT^<]^6NR5U@EB:0O8$<1$:PE3U)\A%0#FN#I+=)9+?6!B@6:6&P8XZJ2*9NI
M'(J@1%Y0)#)R\D> Q)P">.JQ>>8SJ25GVSKOJP7YQGV]MM=M<8_7&?WXSC./
MWX_7&<?T\>M5\/00S4]V,D44I!/$R1J^ :[^A96QG[.W^?53W=W2Q3"NZ=CD
M*Q7OU1Z@$?;K4Q\2_E=\I/E5U>\69 6)4NKU1 ]H]B^7,ZMZ.L1\T1-Q-#-<
M9BC;+&*V?5@KGVT-@'F!.S%D)@'//\S^!KM:?9EJ1RJ;%."PL\1[.HDNI*C@
M'NR,KX#C(Y!E."-:AXDKRQWS,R$16)83&_JK%*[(RY] P*YXG!XD-C!TVWB!
MY&%\FZ51WK&R6R)I782"$$,]@N;6N/8,CMQC:T\1+V4FNH&JN/ZH<<0FP&-
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M..RB.;RA0I0)C)(^ ^7?(JU\L!2%1]OCGD*Q(;=DC=6:0M:I-VH&\'3Y]&H
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M$40?VL*F)CD@P+$@L&A8NT]2\>^(K4M78=GL[;%!3K[MMEI-VBW#KPO[''-
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M?C9?NC_T-I+7JFU"X>3G*=;;5:W:-4O%^P-DV+$C5N\*6L'0>$?09K,,Q2L
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M_ESG&,^^/LYL?IG.,_I[^GU ?4W.WP ^&1F-_G\O7]'RTUM_C:WW_P#]@_\
MGJ<_Q-/'_I%)\ANG]C.4_D><]2K2!@ELJ?$QP2D]:HYV@-KMFVTBQA(ZQ.HD
M.#A*S]NR6D03@$SSPL1@,Z\#;G5DVI*!<QV:\$Z".7"&826TG5H"3B3"E@ZK
MYU*.Q7CAC;/$E29;K60H>*62%N2>;I\(&C(E [IW"\2?*W( $L"!1_>/(AMS
M+HM/0:)5)L:RNPNDQ^R^2=G@HXJS G+CB-6JV:=1,MBVTB@C(BR+O''M%K]7
M$,P^S^'-LV_<8XX9X;*VW:45;5)X$G1A$[2*PLJ\#KT@Y!E5P#V"\N++1MTG
MLU5::&2(P^3KP6%D:)@70*PZ)253SX<N+!NY/(#D#MF^$[U?EG:?$)#?.54M
M_0 CK=8 +C6W[?=Y]O?E@:41\2D9REESD5XP?180JU)S 4/'O(,5#L1%(21\
MU?2+MFY[/XKW"ANUL7;$2UVBM=*"!Y:<D2O5,L5;ZF.98B$E"%AS4D,00=:O
MX5MT[NRUIZ4'LT1:59(><DBI.KD3<'E^L:-GRR%L$*0,#&I4W?QBY)?+F5T%
MFF+6VYDL%4.&Z(S"[=T(!)MN#NU'V@(%*-$UWR/&Q^AH=N)K &01,,&%$/6*
M>[7Z"E*L_!&.>+)'( ?CQ$BMQSG)"X!/?U)U,6*-6TP::/DP[9#.A/W\&7./
M0$Y(';TT\]9KRZI5Y+6%&)M5:!8&I P3+]<C[4&#2"'ZTWRZ_4ESIIC.^^-=
M<;;9SG&NN/;&&,LCS222R',DKO(YP!EW8LQP  ,DDX  'H!C3E$6-%11A454
M49)PJ@ #)R3@ =R23\==SUQKK1Z-&F$\E_YTI7_#_BO^6GGWIW2_*/\ W%O_
M &2?2<ONC^<A_:IK\>2B-/9N;JD+]<(W3->P^/@C%:=%K.(:-OW?G.=X"(=_
MXLD>V=<>^N?TS[8_?ZZH.T<[NC%76K=*LIP0?8Y^X(]#I.R T: @$&>N"#Z'
MZ^/_ )_TZ@;\3OD#PCGG(;'1ZY'BC<C'MJAZ(IB]L5I.^CI<*0O0&/7.=$86
M*T0&:3IGY%^9P=YM,"[SD#RNPVHTL3K-(1)9"<&;N'<%RRECZ,W+*Y]X@KG)
M ++<X':*)HURL+$L!ZJIX]P/D,=\>@[XP"0X/AK-%+U!Y].6.3.*(XSGZ>^N
MWMC-AJ7MG.-<Y]L9]L^W]K]/4UXP(->GW'X^;_47^O[_ -'PU&[ ");&01]6
MGP_[1U9(> $T"+6LA!SUYX\PAH1<,9 I8I&FT4XY$$NNT<L,L>VVDD>^N==M
M<YQG&<9]4,$@Y!P1W!'J#\]6?U]=9GOB;^)]GY;UGEG4*BH9L>*QKHZQ(VVE
M_(RTVPGW6Z6K*AU+K!I.,F-DM6@U=;,)29"98I%AQ^[#43=AKGT?;O58+M\\
MRQVQ<-B/F519HRD2MP8G#21]-F=< \"& (5R*+XIH3#E;B0M :XB?CEFC8,Y
M'(8R$8,JJ<GOE3C*@S]^$CMKOSOKVVFVNVO[;I,?-KG&V/?"#WSCWQ[X]\8S
MC.<?OQC./Z>/4=]*#J^]42C*X&UH"58, 1:M=L@D?H_J[:<^"E9=MLA@5/MS
MG!!!QT*_?OJAOXC?DF_Z3Y?]WYS;EJXIKRFSOJ516R1 E7,S*$&Z1'X06!D/
M"*<XF7,-8)5,S.<S:/8DC060&,EADO1/!7AZDGARO9JM96_?HK9D5[*>Q.1/
M"LF8YL+#(QZ2*\3KS/ 2 *A+5;Q%NEMMWDBDZ#5*UAX>T#>TJ#')QXO'DRH
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MX(()!['X'(]#@Y&M"WPBL8PJ[Q[8]O\ 7#G/_P"&NOK.?I6_?3:_\GO\<_\
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MI2R-&H*H7);C@? D'B3V.%+\59OX(;D>P.H@VKS4Y3>Z@1&5QGN;] /.AL;
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M[>WOG&N,8SGV_3WS^OMZ, >@QHUA&\^:C<*-\2WR))L*1U6I;'8GMXJ1I4)
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MMRN2.S((SB2.HF %9L%.&5?.1D@@J6#42^3.6%HYD=9 Y@F@PO0%WYR%8*=
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MKP7'DEG@I;?78*A3V(OA;C@$$L[3J$0,BL%?S J=6'8[=H-O4LU<1I'--9E
M+<A85 &KJ,8(58B2W<Y9>W?.K9JA\5KC[0F[$W:FWF@HJU:'M72#,:?TN7I=
ME(0UGCMD*GSR@_FZ:R)8XQNHLS"(V4VA<=?J6UC$$/5M\3+JU+X<M*(1#+#.
M\D22N5E@$$8>2W&![0)V1SFLH'$8ZDHC)#+YIQ=T@+2APZ".0QC*2<W(CAD)
M$90,!B4YSWPA8 J<Z=[@?Q!^+=P,Z*MWV:TP^B6.<4/\RHL?X^T4T]Y:$]1M
MREK/7P02)76*BXW;I I3YJP;#JM8&2$;ZYRUN;+;J+7;"RK/&&/!XRT<H2-I
M(F4.6'#JIQ9@HD!Y*,:6@O0S&0>9#&Q'F5@&7DZ*ZDJ >1C;('=>P/?4\O4/
MI[JN7QU\D'W2/.;S1XH7Q"_4P?D@?-(FO1'I2F2HO,RKS=J;^ V%DV+,VNE<
M8SV<33Y-<J!%I0+;,+#:&'>=O4$K[/M-L6X)3:-@I @;JI@CK=3(PO1D41GN
M>98,O;.HZO::6]<KFO+'T!%F5N/3?D"4X$=SR4\NX&,$'OZRB<?RG>=_W!^R
M_P"4'A'J.7\@F_IE;]C:T\/XY?YI_P#7CTI'W:><5GK%"XDZL,(?1NEH[38*
M>CVAGVPQ!J$0Q+.*0S33(H9Y(6[)@F *DB)<@5JUEKHYXJXUV'32K/)6FMHA
M,$#QI*^1Y3*2%[>I4'BK,!A&DC#$&1<C31K*D+-B20,R#![A,9[^@.#D G+
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M>IT^DP9@T?'B02",'&HYMHVM['M;;=2:UU!-[0:T76ZJD%9.KQY\P5!#9R"
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MEK+W3&?F5&XAB^A,$$G2DX,657X-Q+*(V8 XP2!+&2/@)$/\(9>]1"Q4.O(
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ME=-5[;"L0V#!_$4GD@+VD*ZCAF2S#MC7PM:RZ=1H7D-<+.8SU&600I)E8XI
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MBC#JA#E00,LJC2QU>0Z^2A'<I8.ZL:[/00:>'2V7C[Y)9*K)0DS*0PFLR ,
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MSU;@HY007J7-L;/.3,@CK$MU8X-O M9$7*Y5<UU*21D*69F[K(6'%E"L!@8
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MP'7O^Z'KGV.3^-J?VRM_Q=>]=?S)O_ E_P#1KQGR%J^N,[;43N^-=<9SG.>
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M"%UC#-^Z.PYNB_>P'QUR;<2E0RS@NQ5 :UC+,%9R!]7W(56;[@3KJ?P@Z/\
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MQ82C;K&Z@/MU,L",.J+R"CGY0)$D7"\@4!5EY#,BRJ0H:"FRL2MF;!&.+,Q
M/;S95U.3C#$]\>XR'+'Z^:^%Q/.1^:J-.W7Y_5^;+JR,'6F4S;52Q.JU^"O
M!LR?6SR5>';34&-/"9O6RK- /,1IFSS*]%Z5?Y8W43FPYJ0I)8:0F1>/)1)
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MFNV^8L:!;MV6T68X]-LY+D^IMO[:?*D78JJ$Y5"S*.V 7X\C\^_%<Y^0UT%
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M=<8H*+(:EN(WC*KKAT.1'<C=>ZBKQ/3LV&F5)H7B$419!U59@LG%<F1G4,K
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M$.TV\LVT080T \>TLLDN=(\9DWWWSG;([M([R.>3R,SNQQEF8EF)Q@=R2>P
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M\?JV);.KPG5N*M(3UTK(%C'+8EFKH,G2(]=@#)J/#$ -X5/NLK[ L-VX@F4
M':9<T(ZLMJ-+DABK$/U'4@,N$;B1D'EQ?BQ0>9U!1#S*ZXF:18R8E#N,84G
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MFI!'#+366*]'+'*)& 98RBY(0N[YQ*S<25&8UBY N&9NC#-)(Z3,CUFBDC*
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M+EKBP):F6JQ>N'/28G.5P#C/Q .0.[=AV=QYVXB,AC0RC$F/-]X[9^'J.YP
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M<AV)'8Y]"=.%Z1UWH]&C1Z-&CT:-'HT:/1HT>C1H]&C1Z-&CT:-'HT:@Y/\
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MD1VPF,H(!G>=]5K-829Y^!]QY*#5D"L 1+Q+1<3P'+F@8$<I$3*Y\Y*#+*P
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M=3K+?5&JO?G-/V7:JG-EUG;K-0MDV1L+VLV,3,@L18&.EQ]0J*7?]?3\7;G
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?Z-&CT:-'HT:/1HT>C1H]&C1Z-&CT:-'HT:/1HU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g287237g40b29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g40b29.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1C>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &,*^8S@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              C    7'          $
M                 0             %QP   C
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   C      4F=H=&QO;F<   7'
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   (P     %)G:'1L;VYG   %QP    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !3A"24T$#      .K
M  $   "@    /0   >   ')@   .D  8  '_V/_M  Q!9&]B95]#30 "_^X
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MY8Y7_@/_ +SI?LS(_P#+'*_\!_\ >=6X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MW]M3]G)O_E_2',]KC^2_G^"/:_P[Z?F@>&+OY'#.//\ [00^XKS[=#T4^_\
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M&.V-9(B&V=JB/U?=ZBW$UPR.E?(==LM:K]E%DBXY4U%GQP5G+>?!#.0%(DB
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MZZZZM+;333:<K<<<<7G"$-H1C*EK5G"4IQE2LXQC.><L L0J@EB0  "223@
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MVJ9!67$UR#E)N2%$%&(*(!C WC"61V"7!QWGW&65I:;??9:6O*4N.H3G*L?
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M#-]"'5)%ZM:E2+J9J:>;CQH-+ZY<N,2L9RT!QS8N,E.EEU5$T,TP-A1#ZG?
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M^Y)$4C<^Y+[$]3_3%M7-QU#=;;F8UJTO7>B8&Z:[A:)3QP@H^J*B9(\.)3(
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M&Z#I6P1-/J,!,V.Q056KD+8+B2"9;IV)A(R.F;47&">(1I5CDPQ639PF/!_
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MCQ TDDJ:%84]ATI]AA*W4SV]M<7<HAMH7GE*NXCC&YRL:%W( ZG:JDX'4XZ
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MC Q0WFG7(M5E (622,M#"74$CFR'> 6\<;CFG83ZUI4CS6?@^M[9G&)'MKN
M3%"<E%;:[!<X.Q1M.!XIP*ZI=%7=$=7=8QUPH.:I;]+;^UMW_LB:)V6)D"VP
MC#+XXC\M%/*9$\M0HYI0X);SH,7+1Q+XV).&"&D(LD_S'C'@#4N$4M+[M5IK
M&A:CC\GZWIS;[69B&812J&?DS,BLZ /+%(@8Q3.R2K']=H7$MIK;3VW)FL=2
MM,]JTZZ&V>, @%TZ#F1AF"DE4=21O10R%N@O/@Z^DK1=E;-H.G:3-;'V?:8J
ME46N8CU3MGFW5L144B5E080!PU]#;F66B)22!#PZI/@VUD(6ZIMK"W$S6]O-
M=3)!;QM+-)NV1H,LVU2[8'3.%4GZ!4<LL<*-)*ZQQKC<['"KD@ D^09(&?WU
M"4=UG: M- F]E:PLL_N^N5NWM4:?'T50[OMZSP]B>#Q(MLR-/HL!,V<4!<>X
M,>W,.Q28E\$Z/-'-=%/%>=MOI5[%.EO<QI9R/%SD-Y-%;1LF=N5EF=(RV<@J
M&W A@0""!"E[;R1M)#(9U1^6W(1YF5B <%$5F'0@YQC!!S@U[J-U;:[O,J=&
MYI'4%0A(N"F+)*VG;_3ENG4-&BHB!%R;)$R5VV)2J[6 5,BI<?0R3)M//-LO
M*90O#3F4ZRZ=-$H;FV4Q9U18[:^M;F9F<X4+%!*\C9.!T4XR,]];+<QL2-LR
M !F9I;>:)%"@DDO)&J#H,_"ZU^*7UM](VPPY RH=1.J)1,7(QT4:([;8Z*EV
MSIDUB.A&FX.8<CYDE$\<2,+ DB@/#3;Q#*8IXSPJ.^VFTC4X"JRV-RI968$1
M,RE44LYWIN4;%!+@D% #N P:UCOK.4$I<PM@J#XZ@C>0$\5B#XQ("G&&)&,U
M5/J>ZU=DZXZKZOT[4BUZ3U36CZ+49.0VCOK5>Y[E4)C9U]MLM"UG5D7;Z!:J
M71Z?.N0D2S,*3=[ P])OV&O@Q+#[Q?>*Z-AI,$^FR7TL5W<R":55MK.XM8I5
MMH8D:2Y:*:.6:5-[%,PQD+RY"Q 6JES?/%=BV#10H8HR)YXIGC:>61D2$.C)
M&C;5W$.X)W(%!W5U.1W_ 'B/"93ESO4^$RC&4HROLQW^4)4I2DIRKMRG"E*S
MC'9C*LY]//G?HKJ_37ZXI3BE.*4XI3BE8V9_H>5_1IW[J[S*]X^D?C6K_ ;Z
MK?@:TW47N6:[_4NM_1(O);CI/*/^8WXU7LOU2V_@Q_VBJR=0UH@J7U =/UGL
MIV(V#B1+>]('9')*P.T\)@5M>6 V2"G.^??:1V,L.*QWW?YQA*5*Q\[J,L<-
M_I\LK;8T$I9L,V!@#N4%CU('0'[*_0W@TTG4-=\''A'TG2K<W6H7DVBI;6XD
MBA,CI,96',GDBB7$<;MEY%!VX&20#[J5U+Z2B;?M>3D+L@<*QVJ&D85[,%97
M?'0A:77(I]_#;,,XZQX,\(H?*"4,N*RUX1"%-*0XK,&I6237;-. LLL;(=DI
MW*((T)Z)TPRD8.#Y>ZM-=\%?'MYHO!UI;:"TEQI>CW]K?1_E#2E,$\VO:I>1
MH6>^5)-UM<0R;HF=1OVLP<,J[QN7K'Z?]$Z'D>HV^W/Q;6HCK@$80''&KG+1
M/X(+#%K-9@C6@#I&<.+!+:'8<2,*TP,3)G%AQ(A9['V?"^A:CQCJ-OIFA1"Z
MGN-S;V)B@@AC8++<7$C+F*&(D!FVEF8JD:/(Z(WA7%\,_ DMW;\3Q'3KFR$)
MFMN9!<2%KF%)[>.-K:66*1Y8I$<!9"$!)D*!7*\A=@=975CUBT?#,1W' [<6
MA9]QB6K7LYVVN194R/A*E1ED#@9^%"S&O/,.*="D88L]*&GU8"F2&7,NN>R6
M/"'"W"-[NE\+D>DZY &BN?R):W$BPMTYEN\\$TG,4' >.9$RR^/"K#"^8W6N
M:QK=N!'P.U]I\A#Q?E*:)&D'[$JPR1KL)ZD,C-T/1R#UQ&H-^=8G21 RBZ/W
M$:/UG0W7$25P;T[>Z\9:I)D-"\Y,?'A(6>GK$^"/E[(K)3)?@$J6EI;"%KSR
M75M"X3XJGC%[X97U*^ ,=F=6LKA+:-G(\16FF@@MP[;=Q4IN(!.X@8TL=2UO
M1HWY' 2VML3OF[#<Q&5L>4JD<DDI49V@@^8$9Z]>NCGK4TQUN:W)O^IC)0$^
M D$P=]H%I%;C;K0+%EM3GDNP1S3Y+"F24-NN1DL 25&R"&264/M2 ,D #Y1Q
M;P=K'!NHK8:JD;I/&9[&^MF,EG?V^0.;;R%58%<@2Q2*LD9925,;QR/]IHFN
MV.O6IN;-G5HVY=Q;3*$N+:7Y$J D=<':ZDJP!&0RLJVXY\K79J(-Q;]TUT_1
M,#.[HV)7-<P]GFW:U7Y&RDN"C2T^S"2]CS#AN-LO>$D'8>"E2A1<XPZ8L7Q,
M1+YKXPSUJULKJ]=TM()+AXTYCK&,E4+I'O/F7>Z GR9R< $B&:X@MPK3RI$K
MMM4N<!FVEMH\[%5) [SCIDU'$GUBZ:11Z%LJEL[.W11-D,33]8LV@=.;/W=&
M][ &,QTFU.+UM5;$[62V)%QZ/P%86HTQ9\=+!88\:BCVAYAIEUSIK>;D6LT!
M021WES;VC>."R[!/(G,!7#93<-K(<X92=.UPF-)8R\T<F2CP123@X.#GE*VW
M!R"&P<@C&0<?76NK75$W5KU=[%';5U#3]<Q\=)VBS;[TSL_1T*T)*$/B#*BS
MMG5:M,SKR2F4#/C0V3B6"#8UAQI+TD$A_#Z;<+)#%&UO<RSLRQQV=U;W;DJ
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MQ;IVF<)\7\'6-K<W-MK6LQ76G:E-*D;1V5G>6DEOVB#DJSS306BE]IB57D^
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MH\5!IK7!AF6\+F\61^>#GE L 4[+T"F IC&W+;]XD._-5'I.JMD6/N-VHJS
M4:PSEVHTMKC:1VL% / 66WP^H>J6-VM9*6+$R6!''9BQU:KR L-&$I;Q*'D
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M*J@5 H"2%792B@%\ L&?QJZV]76G;[NKH(-UQ08)JQV_S:TC9TT"3+9B1]A
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:&DE89!R"59R#@]>H\@\PJ4.15:IQ2G%*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g287237g41l54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g41l54.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2.^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (Z*^D2(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              ^8   ./          $
M                 0             #CP   ^8
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   ^8     4F=H=&QO;F<   ./
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   /F     %)G:'1L;VYG   #CP    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      9C
M  $   "2    H    ;@  1,    9<  8  '_V/_M  Q!9&]B95]#30 "_^X
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M\/\ @_-/_F.D6,)G:-4QKKT]HY3[
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M16-D9G)T&1HG6&5S=8B3I<999VB#A8>FI[2UM\73_\0 '0$!  (# 0$! 0
M          $# @0%!@<("?_$ &$1  (! @(%!0H("@<%!0<"!P$" P01 "$%
M$A,Q009187'P!Q0B,E*!D9.AT2-"<I*QP=+A"!4S4U1B<Y33\21#8W2SP]06
M-)6BLA<E9(*C)D15@X2DPAB%1597M,3%U?_:  P# 0 "$0,1 #\ _NW=8SKC
MQRX=JOKL55TNLX5*WR3D)HW*HNH94X(-6MF1;-D0,802;MT4D$2;)HID3*4H
M6B9@ -6++*YAB)RYR4-^LYGB<:QI8F)8M/<DDVJ:@"Y-\@)  .8  #<,?#T*
MJQZH7S[J&2?TKU.V;R8?40Y]?@?1;$=YQ>54?O53_%P]"NL>J%\^ZADG]*M1
MMG\F+U$/\/M;KP[SB\JH_>JG^+AZ%58]4+Y]U#)/Z5ZG;MY$/J(OL8=YQ>54
M?O53_%P]"JL>J%\^ZADG]*]1MG\F+U$/\/#O.+RJC]ZJ?XN'H5UCU0OGW4,D
M_I5IMG\F+U$/\/#O.+RJC]ZJ?XN'H55CU0OGW4,D_I7J=LWDP^HA^QAWG%Y5
M1^]5/\7#T*ZQZH7S[J&2?TJTVS>3#ZB'[&'><7E5'[U4_P 7#T*JQZH7S[J&
M2?TKTVS>3#ZB'[&'><7E5'[U4_Q</0JK'JA?/NH9)_2O3;MY$/J(OL8=YQ>5
M4?O53_%P]"NL>J%\^ZADG]*M-LV?@P^HAR_Y/IOAWG%Y51^]5/\ %P]"NL>J
M%\^ZADG]*M-LWDP^HA^QAWG%Y51^]5/\7#T*ZQZH7S[J&2?TJTVS>3#ZB'[&
M'><7E5'[U4_Q</0JK'JA?/NHY)_2O4;9_)B]1#_#P[SB\JH_>JG^+AZ%=8]4
M+Y]U#)/Z5:;9_)B]1#_#P[SB\JH_>JG^+AZ%=8]4+Y]U#)/Z5:G;-Y,.[\Q#
MZ?$W^SHP[SB\JH_>JG^+AZ%58]4+Y]U#)/Z5Z;9O)A]1#]C#O.+RJC]ZJ?XN
M'H55CU0OGW4<D_I7IMF\F'U$/V,.\XO*J/WJI_BX>A56/5"^?=1R3^E>FV;R
M8?40_8P[SB\JH_>JG^+AZ%57]4+[T;?[J.2?TKZ?/TZ;9_)A]1#]48]F'><7
ME5'[U4_Q</0JK'JA?/NH9)_2O3;-Y,/J(?L8=YQ>54?O53_%P]"NL>J%\^ZA
MDG]*M1MG\F+U$/\ #P[SB\JH_>JG^+AZ%=8]4+Y]U#)/Z5:;9_)B]1#Z/R?W
M].'><7E5'[U4_P 7#T*JQZH7S[J.2?8]=?7IZ=3MV\F'U$/V.W'C=WG%Y51^
M]5/\7#T*JQZH7S[J.2?TKTVS>3#ZB'/_ )/HP[SB\JH_>JG^+AZ%=8]4+Y]U
M#)/Z5:;=O)A]1#]C#O.+RJC]ZJ?XN'H55CU0OGW4,D_I7J-L_DQ>HA_AX=YQ
M>54?O53_ !</0JK'JA?/NH9)_2O4[=O)A]1#]C#O.+RJC]ZJ?XN'H5UCU0OG
MW4,D_I5IMF\F'U$/H\3[^G#O.+RJC]ZJ?XN'H5UCU0OGW4,D_I5IMV\F'U$/
MV,.\XO*J/WJI_BX>A56/5"^?=0R3^E>FV;R8?40_8P[SB\JH_>JG^+AZ%=8]
M4+Y]U#)/Z5:C;/Y,0_\ D0_7&<.\XO*J/WJI_BX>A76/5"^?=0R3^E6FV?R8
MO40^C\G]_3AWG%Y51^]5/\7#T*ZQZH7S[J&2?TJTVS^3%ZB'^'AWG%Y51^]5
M/\7#T*JQZH7S[J&2?TKTVS^3%ZB'T_D_NZ,.\XO*J/WJI_BX>A56/5"^?=0R
M3^E>FV?R8O40_P /#O.+RJC]ZJ?XN//H")XUQ>XA)_+NV43=E&<?WWFI:<=-
MVJE4JCXS<'\P\?/SH@[>.EB)J.3E3,L<" 4H[:F4WV;64%H[G555!.NXO90!
MN &[AA2C5[X36=E2H*KKN\A V4+6UG+-:Y)M?*YMC+&J<;6&F&&F&&F&&F&&
MF&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&&
MF&&F&&F&&F&&F&&F&&F&&F&&F&&F&&F&,75#Z-Y-^S\?P*I>K9/%A_9?YDF-
M:G\>J_O)_P "#&4=58V<-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-
M,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-
M,,-,,8NJ'T;R;]GX_@52]6R>+#^R_P R3&M3^/5?WD_X$&,HZJQLX:88:88T
M9L@/(OLCV'4V,[:D8VX<'_$.[L5<-<+4O37\A2,L\-+6K2Y*0XF%:>PG(EK<
M[0U).QL&SF7;68<MG[YT@1NFCUH[-H.JND1:/2="$DV48E59::O,B;8)M2C&
M*,ZC.5!0%5&>--G85\,8/@/35#LO.\<E,J'G%ED<6! .L2038XUKX[[7)91R
MGP\XYQ$VC,\M7M9XI)VR8GC^(&0P72)*4Q@VI56-:)G+%.>.7#FZ8ENDX$ S
MQNHS>*L9.RR]PD5:W)8]:2*/1T/$M-35T]5K4;+)HY8ZAJ(5<JK.TLNS6FE4
M 0U,*;0SZPNL:Q*)%G(QH:1=I9Z6*"TZF.M9XA4FGB)B5$UVF2Y,D,C:@BMD
M9&D;5,0(W2X'+D_R%P<\,=REK?-W^9GL(8Y=3EVLC(&$]:9Y*LQ[6<G)5 CN
M02.\D)9N\<*O$)&2;2(G"0:R4BW=)/5^3I>)8-*:0B2)($2LJ D,9ND2;5BB
M*2%-E0@ %5*[BJD6&]HZ0RT%'(TC2LU-"6D8 ,[:@#,0"1<L"38F^^YWXV%E
MY]>) @C"2+P5G96K8&R\647'^#N')U@%T_;E223(W,407,FH8YB@1,W.(:J0
M!U++*A*KK.MI-9075 ,T 8DL"=4FPOBZ28QD!HGLS:JD%+,=5F)MK7  7XP&
M9  ._'C>&KSUH3OOVM>SZN=1YNG0P$?&'H;Z;6^[/GMCWQ?^J?TI]K ;H]#I
MJ$[S?\^K7Y]T$%]SK\U_LX=\?V3^E/M8>&CWUH3GOZM?GW38_KCYK<]APWGA
MAWQ_9/Z4^UAX://6A.>_JU^?=-B?*'S6^H$X=\_V3^E/M8>&KSUH3OOZM?GS
M38'RQ\UO=AWQ_9/Z4^UAX:/=M_!"=]_5K[W?W?0P$&VL#U!OIM;#OC^R?TI]
MK#PT>>M"<]_5K\^Z; ^6/FMT='3[#AWS_9/Z4^UAX:/?6A.>_JU^?=-B?*'G
M5NG+=T8=\?V3^E/M8_ WAV"@)^"$[RS$,< [MK>W)()"F'E=_.3S"H7F$P&'
M<1 ! #"$][FVMKJ0"%.37N;V-M7=D;GJRSQ'?68&RDS!-[I;(@6\??GY\^;'
M[\-7GK0G??M:_/G-[>FP_77T-[L_-B>^?[)_2GVL1X:O/6A.^_:U^?/-UW#4
M; ^4/0W/U=-^J_$'#OG^R?TI]K$^&CSUH3GOZM?GW38'RQ\UO=]^'?']D_I3
M[6'AH]]:$Y[^K/Y]TV!MXXZM5K_1AWS_ &3^E/M8>&CSUH3GOZM?GW38'RQ\
MUO=AWS_9/Z4^WAX:/?6A.>_JS^?=-A^N/FO]G#OG^R?TI]K#PU>>M"<]_5KV
M?5WKT=.FP/ECYK>[MOW8=\_V3^E/M8>&KSI\$)SW]6OO=_=]-@;VUAUZK6]-
ML.^?[)_2GVL?@+N[$YB!4)WE$ IC!W;6PYCB8"[",YR3;\@>8HB(>, W#>33
MD '74W)%@&N"+;QJY W%C?GW6.([YS(V3Y &]X[&]]WA]&>/WX://6A.>_JU
M^?=1L#Y8^:_T:M\3WQ_9/Z8_MX>&KSUH3GOZM?GW38'RQPX-E?S>G#OG^R?T
MI]K#PT>^M"<]_5G\^Z;#]<?-?[.'?']D_I3V^'EY\/#5YZT)WW]6OSYJ=@?+
M7YK_ &<.^?[)_3']O#PT>>M"<]_5K\^ZC8GRAQ^*W#S<>&'?/]D_I3[6'AH\
M]:$Y[^K7Y]T,!'Q@>I6]V'?/]D_I3[>'AH]]:$Y[^K/Y]TV!\L?-?[/;CO%W
M?/\ 9/Z4^WAX:/?6A.>_JS^?=-A^N/FOT_J]N.'?/]D_I3[>+IB)$TJR*[.R
M<QYQ453.U=&;'63,D<2[B=HNY;G*<NQRBFL<.28 -R3@8H5NA0@$@W ((ON/
M." 01Q&+HWVBZVJ5S((:UQ;Y)(W=./3UAC/#3#&+JA]&\F_9^/X%4O5LGBP_
MLO\ ,DQK4_CU7]Y/^!!C*.JL;.&F&&F&/!7JM9=6:-NCFOPR]OAH68K<1:%H
MUFI8(RO6![#2,[!L)<Z(OVD3,R%=@'LI'H+D:OG4+%N'*2BK!L9+,2R"-H1(
MXB=UD:,,0C.@=4=DOJEE5W"L1<!F -B<187O;/GQBFR\,'#9<JP2DV[ &%[/
M3T[9.7Q.K3^,:7+U].[V=^\D[+;TXA_"KL$[+89"1D'<Y-D0+(RR[YX=^X<"
MY6Y>RFD*^*3;1UM5'*8TA,B5$JN8HP%CC+!P2D850BDZJZHU0+#%#4E*Z"-Z
M>!HP[.$:)"H=R2[:I6VLY9BQM=KF][G&:(Z.CX>/8Q,2Q9Q<5%LVT?&QD<U0
M91\<P9(D;,V+%FV(DV:,VC=--!LV;IIHH(ID22(0A"E#49F9BS$LS$LS,269
MB;DDG,DG,DYDYG%X 4!5 "@      "P  R  R &0&/#L^_)BMN7L,@IOR5BI
MD$.]S[_&)F 1<!OSE3*(&(<"K;\E,0'9IK?#7M^36UT+&^UCW,/$Z2<B+K;.
MXUZG^JW^.?C #\FYS!S;=D!F#GN&+?U=BC#3MV[?5AB>OC]WIZ?B]OICWY[L
MNCJ/I\VZ>W'T[]_L\^^-3B,.OBZ_C\OCT[<>WU<W###3#$[=/[>H>?2_;=S^
MWHP[=O?AS_BZ_B^+HTR^OM]?MWX?R[=NK&)ULQ8Z2M9*\>;==U)R1ZNM+EKE
MG/3F]H</&K9&KN,@$@CT=O9%7O)CBP*UF1E>^QDH@S$TFL@V$'759;YZZD"Y
MS 5[DYVL";7*G?<$"]_.MRIT$ND.\#62;5:G\7O4"AT@VBTT@\B(NCWTT*0Z
M(2O:6T HWKTJ>^"M,83.R1G+'3Y Z]?Q!INYSV[?6<>BW\P[=OJ&(TPPTPQ/
MFZ\_7G\FG3VR[9<^'1VS[9\V(TPPZ^33MSX8GG]OX_VZ9>;V?RPQ'7V=.W5A
MVZ\4Y/GIP.W2FW\0!XU_&! ]SEFV\0%W]-E\1?E-]"=/U#K/"/C'J'TMT?6>
MH<:C6.)Q/3^O\OY1\OEU&[[O=[A]&&_F^CV^_#KU';V?<Y]3V["_5Z<L.W8V
MZ_1GA^KI'R!U^\&H^_<.<]OI.';T;_3_ "P\_7]GW_=VGH[?S^CT7=/;MU^_
M$=>O4-.W;M[@[=NPPTPPTPQ==>^<3\VW^%N/$ ;^F+S\Q";^3<1..P?RQYBE
MUI_''R!]+=)Z^'5Q.U!XA^4?H!YAY]^=\^&/=U1B[#3#&+JA]&\F_9^/X%4O
M5LGBP_LO\R3&M3^/5?WD_P"!!C*.JL;.&F&&F&&F&&F&&F&+5M')_@<!%,##
M(J\D#E.)Q'O:_P!P2,4.04W)W$PJ"!1(!BE$3B4!VZ6]I\FMLUO8BP^%CMK#
M>1?=JY@V)ROC4J;7@W7VC6N#?\F^X[ATWRM?C;'@ZMQ5AY=.;#MV[?5A]_XN
MO1I]'M[;\.W;V8GHZ^X/7G]CF'4;^WI'OX=>8P[>[M]&'..P>Y[>IR%SZ?-A
M?AS?7AXNOW^GV@]G4<>WT;O.>K$\.WT[_,.O#R>3XAV]SR^SIS\_M%_3S=6(
MP#?<-N<=^C;\7WMN?3+CN'3].>?3?+$_7PM]WHMCF1A?-RV>H3,O![0ZJDM7
M\>3UFJ-@S0]EDT6"M2F;K."29BH)&/=.W^0G)$I0L:X4D&\:XEF(W-U(-A43
M@E:MB05D^*;$\;7YSE8$ FV_>!NN/S[R5Y4ORSI^57<ST-HX-0Z#KJ_1E=RJ
MFJ L+:/JM*U;+4TU&L$DD^FI M2(':=()*F$Z5>9-9:1NFXCN._1N(^UN.X\
M_3S;]=]6@6ZP!Y_Y]MV/T%O])^_G/T^W$=?9^+K]^>W5UY]OHCMU^SM]+3##
M3##KUZ_K=NW;[G;MV^][&G7AU8GKS_E\?7FU';+W<.V>)[9^_CVRQ&IQ&*=/
MYZ<;"'^+;!TEWZ5]MPY8B ><2E >< $VWI<B? 7+XSG<>9,KVSZKD] XQ\8]
M2_2W3EVS-LJGKT^+IZ_EUCVW<=W;W8G$:88=>O7[VG;MV^G#$]?%[/4/QZCM
MQZNQ^K#$:G#$]1\O7K[#L.;MVZW7Y^?#\7Q^R&X]>G4?7[.HV';=B?J]O6+G
MMOP\_M?B^]X_Q[:='G^OZ>'U7Q&+JKWSBISA\]N.@0'QEYAV,;8?,;DCMMZ4
M V$=>?QU^0.%N+= OUY]? ;4'B'Y1^@#'NZHQ=AIAC%U0^C>3?L_'\"J7JV3
MQ8?V7^9)C6I_'JO[R?\  @QE'56-G#3##3#&G<]<[_#\>>+L>(7J:7QC?.%S
M.%SE,=.8RGF@F-SQKDS <'!6B*F$:PA>$G[J(R58F$JP>VU_7W"9(Y=I#,GC
M51RXZ:10MH>HG,*"HATC21+.&EUS%/3UKO&RF0PE0]/&RL(E<'6!<@V&DSR+
MI"*,2-LI*6=S$1'J!XI:=5<-J"2Y$C @N5.5E!%\69QH9TRY6)3'. ^&^GVV
MXYGR<#^[6%U3%Z SG,>8%H$Y6FN2;C!N,IR\'0G=SF7MC@*%1XR;?J(IR]E<
M69>/D6=7<QSV_1-'2R+45M?+%%24^K%&)MN4GK9TD-/"XID><1*(WFF9%!U(
MPFLID#"C2-34(8::DCDDJ)B9',>R#14T3+MG4SLL6T8LL48<D7<OJL$*G:K#
M66J?G;%U*R[0EI)6IWN%2F8DLS'+1$RT_?EF;Z,F(M?=1A+Q,DU>1<FUY:J:
M+YFX(@NNB":RG-JZ66BJ9J6<*)87U&U&#(<@59&'C*RD,IRNI%P#EC>IYXZJ
M".HBOLY5#+K#58<"K+P92"K#@01CU+;*)()LS"A+&*UD^0L#:+D5RJ=LCWP%
M,0B#54[Q$IMA$[8%")*<@ZABAL.K:>.RR,3'X48*^&I<?"QY6#70G<0X!*WM
MBBI?- !)X,A#61]4@QO^J==0;9K<*UB;$#%H>$K'ZCL'P8L7YLU98]'SE]^*
M==>9_5R?9P\)6/U'8/@Q8OS9I8]'SE]^&T7F?U<GV</"5C]1V#X+V+\UZ6/1
M\X>_#74<']7(?_P^C#PE8_4=@^#%B_-FFJ>C/]9??AM%YG]7)]G#PE8_4=@^
M"]B_-G7V-+'H^</?EV.&NIX/ZN3K\G,\WHP\)6/U'8/@O8OS9I8]'SAS=?L^
MO#:+S/ZJ3[.'A*Q^H[!\%[$/_P#6:6/1\X#Z\-HO,_JY/LXP7Q,9V8X:P1D[
M(:)91I*PM8>H5M1] S+-N:US(DAJP0ZSI@BCR0G)!BJH0RA1,@FKMS!J"I.0
MXD#Q@<MQXGA?@>?IQX[N@\ITY)\C.46G@VI/1Z.E6BUT8!M(516DT>+%1?\
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M0EB#J&A@AJ%!\5JF3B2<;_&M%9[L2'PD@.2#9<!'OU'<@#"JV$H";NOD<H0
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M8G'Q]UN-QYMQ'<O./I""(^+<1./-_+$-BEUI_&'R1YLVZ3] ZN)VH/$/RC]
MZ!]?-?'N:IQ=AIAC%U0^C>3?L_'\"J7JV3Q8?V7^9)C6I_'JO[R?\"#&J6<>
M(#BSI\G?7]$PWPY5#$V.7A&\QF+B3XFD*'#/VYF\>MWP[Q4NDW0:I'*GDFB3
M1:ZV&%DW!5VRYX1NF[:@O[30V@N2]7'0QUNEN4%7I32"%HM$\GN3C5T\;!I
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M<3CS[=#Q+HL?W1%L7 +R@JN15;,S%643C7Y4U7*:J)C.S$Y9BI<_+3,?MG*
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MK$$BV9RZ3GEU] Y^;'Z?AIX*>**"&&..&"-(88U50L<4:A(T4 6"JBA0!:P
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MM;![NHOYLA_+FOY[GT8GAY^W3[/IQ2&^?4></G5SS;AN/[\TWV#E 80\X)B
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MJ*"ERS45=-+1U,U+.%$L#E'U6#(;9AD89,CJ0Z,/&4@\<6T\\=3!%41$F.5
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MTZ691QVK59RNJD=4^EI&K%=6U%4$V2RLHCC)UBD4:+%$K-8:S+&B!F  +7(
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MQLX"DEN(+BOXE^+B22%:';R"M&H)W "?M;=]W,W:*-C"  FZB:1 PK)SR>2
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M<8\!I3\,7N[Z1U^]M.Z#T*K7NNBN3= VJ#P5]*G2DJVW!MH6&1UKV.-KZ;P
M<*]"*@%:X?.'=)5OL*#R:PZE:I(@@;<#!*VNV34D)P,&X'%V)N;81VYM;T>B
MM%Q#P*""XXLJ.UN8LT3,25RN23GS8^7Z7[N/=DTX7_&'=*Y5LLEP\-'I:LT7
M3L"+6--HRHHZ<+T","^9OB]Z_P ,5(K\TT=M4FS]C7P45JE2LCW)-LQW25'Z
M+MHLI1<;V7*4I1Z:=-DLYCF)J[!L0B8IV[B88L;&.W31Q<E!11E95BDN&?41
MYY'BC!"CX*&0O%%925&SC354E5(4D8XE=W2.6FD*:HI9]*4<,E8L(TCI/1^A
M=$Z,T[I<0L'0:9T_HZEI=,Z6#2QQ3S]_UU0*JIBBJJH35$4<BY)4Q5 +;BM6
M<3J[_P!+BIHIN/-ON)K*/M^S[EQAIVWP1DWWE8SD;VR,?U^<Y@^?7E'RF0>#
MRATNH_5TCI #V5@QYB^$:2ZW[IH>%7&^^_;\-Q2V^_E[9/FW]OV]1WO3?H\?
M#/4C\^6SX]'/Z=A.5W+"+\GRJT_'S:FE]*);JU:X8\E7ARQ6OOV_%/#ZMOOO
MVW!%=4WW\O+F#=>;HUB:2C;?2Q'K2,_Y>>=O1SF^-M>7O+Y/$Y;\J4^3I_32
M_1I$8H%N%S"RX;+X5X;50'?<%.'RJJ;_ ->4'RCOMS\_/Y\.\*"Y_H<'#^JA
MN/1%](]-CB]>Z-W1TS3E]RO4]'*33HW=6DOHS^OR%N#[A\<;]OP!PNJ[](J<
M.5/,(]/2(R0CMS[;!MH:"@-_Z%3Y\-E#;=^RY\^.-I.ZKW4X[:G=(Y;K;=;E
M3R@'_P#M/HMZ<><IP3\-"N_;.'+A4.(](CPVTP1]G?OCN ^<-A]OGUA^+-&7
MN:"E/_R(.G^R)Z<;"]U_NN*++W3N70ZN5?*'_P#ZENV>/,6X#N%AQ_C>&WA:
M'?IY'#U6TO;_ 'F:3Y_8VZ/%J/Q9HS.U!3#FM%#YK_!?5Q.\YXVH^[7W8X[:
MO=0Y;_\ FY2Z:?TZ^D#?GS._FQXSOL>_"XJD<T9@W!55ED]E8NS4W%056U5V
M22'MC"=K5@A;8TD(2=B7147\3*L5DG3%\@@Y1-RTPUBVB=&->U%"A^*\:1QR
M1L""K1ND8974BZNI!! (L0,;<7=V[L2,HJ>Z%RBTG3$ZM3H[2U?5:2T;7T[7
M6:CTA15<\D%715,9:&III5*30NT;"S'&R^,L.3S.PP]\R;ENXY@LM2:3D)3!
MGXBG5B$KB$R#9M*32<'3("%0E+;)1K9&)<V&77?"SCU)-I7F4$WG9U&1K:D$
M4R.T\TY5#LQ+L@$+G5=K0Q1*SD+JAV!*J6"!0[ZW%K^6$59HBIT1HCDWH7DS
M2Z1J*:HTNVBY=+U4VD7HR\E+3;?3.D])2TFC*>:5JA*&F==K4)!-63U;4M)W
MOLEJS'D<-,,8NJ'T;R;]GX_@52]6R>+#^R_S),:U/X]5_>3_ ($&,HZJQLX:
M88:88:88:88:88M2T\G^!]Q2W[XJ\GE]L[8(]['^_:>0 DY7)W$W;1 G:^5R
M1%3D .W2WM/;6_)K>VKJVVL?C7SM>UM6YO:_@WQJU-KPWMX[6O>]]F_BVRW7
MO>PMTV!\+5N*<4,I)L(6,D9F5=),HR)8/).2>+&*1!FP8-U73QTL<1 I$F[=
M%190PB %(0PB( &^H)L,N'/?/HZ;\_/SXIJ*B&DIYZJID6&GIH9:B>5B D4,
M*-)+(QX*B*S'H!../W8U8U_F/+W$MQ@6)N<'%PL[NEU0%B";N-DZ<,K#*LTC
MGY]HF%0H\.U43Y@03=H"8.2<@2<M5<_!%SGO+7M?CD+WW;\LL?F+N"T\W*CE
M-R][I]<C:^E-(2Z*T;K"XBAD>&MJ(E8YGO:E31%+&POX"R)>]QCL@'W_ #;]
M1T/T=-NPQ^H^V[MVXXC3##3#$^3\GG^/J&HY_?T>SL<3S>[I]O88Y0=D#[)1
M$\-BJ&#\&1A,K<5EQ,VB:_4(=LK/MJ,ZF"]JBW]CCHXJ[J3L;M19!6OT= I'
MK\JJ4E+&9Q:C)*9X&E]-)1_T6E GKI+*(U&N(B]M4NJW+R&XU(@03<,2!JAO
MU!W"?P>*KNAJ_+/EI4GDQW,=$"2JK=*U<BT4FFHZ1M:I@T?45!CCIM'QA76N
MTPY,4)5J>E66I$S4EJ<-6.N,J1X-:]CGB@FZ,G@J5:3,3DA"NUPPY8]#.3G'
MHS=;7L+&WM*JWJSALN\BK%8(6JGL4?4E9!&KI.5DXRUI]NAY+5#4\.AZ[2U.
MNEIH@7T7'12,&VZ;9=&/I1:A8DKYHW6)HXZ%H$D?O;OU)@9$\WW1N[#W.*7N
MC:6Y?]S7D=IV2FT;5QOH7E/7\HZ==$KI71R)1KRM@Y)3Z#FTI/04E3!W]1BM
MY2QO520QZ2JM%-2O)H^7>&G\#?!S0BH^#'#)A-FNWV[4^?8\KD]*$$@B)3!+
MV!C*29C (_RS/#'Y@#E;  :U(]%Z.CMJ45,+ 68PHS'("Y9@6)L,R3F-][8\
MAI;NT]UK3A;\9=T;EC*KDZT,.GM(45,;BQM2T,U-3 $96$7/NOGLA#5ZOUQL
M5G7H.'@6A  I6L-&,HML4H   4J#%!!(H     !=@    #;6\J(@LJ(HYE4*
M/8 ,?/:S2-?I"0RU]=65TI-S+654U3(3SEYG=B=^9/''LC[?GWZ_L\^LAYNB
MW;^?1C3/GZ;]OY=.'1[GL]/N<_C#R>/GU&_T]6[TY<#S\,L3N[7M?Z^.(U.(
MQ/L='1^3R?M#4=>_?[^?^1Q/5NW>[F_F,.O7S;\^W[=3V[=-LK_RQ&'D_+Y_
MBZCIS^[M?L,.;W]/L['%,3G=.>??]Z;;\X;ASK[?YXCS^<A=]N83@'I9R"KP
M\)[>A.CZS:^X7\*-[-G<ZJW]+6X\;'APWFQM4:C$X:88G\77;F\OFT^OT]>?
M-TX=NUL1UZ[==^GGT[=K]K;LL,3UZ/9Z_LU';F[9=A?#MV[9^;$=>O7[VI[=
MNWTX=NW;Z,3U#X^G;Q_?]S4=C[-U^'T>G$[]W4//?CS_ $^;$=>?KUZ-3V[=
MNG$=L^W;=BZZ]MW"?8=_\+<;\X#L.Y>;F4/MY=A!,>?G3#?<VK/XX^2/I;H'
M5QZ^ VH/$/RC] Z3[;9\+8]W5.+L-,,8NJ'T;R;]GX_@52]6R>+#^R_S),:U
M/X]5_>3_ ($&,HZJQLX:88:88IS.VI'*;([EN5XLDHNDT,LF5RJ@D8I55DT!
M,"ITDS'(510I!(0QR@80$P ,V-BUCJ@V)L; G<"=USB+B]KB_-Q]&*C48G !
M 0W =P'G 0Z!#RZ88M>S\ODQ7)[;R>^"G+Y ;I[#'/MNW>0G*Y/('^EY >36
MU36M-?5OLUU;^-?:QDZO3:]_U;XU:F_P-KVVAO;=^3>VMQM?=TVQX'7X_8]O
M]?-JW/F]/#+KSSRQ3V]O5Y_ORQSZ[)GEOT+N%>V1K-<4IW*3UIC:+!,_)5!E
M,)N'MH6Y!?3F0-68Z4C3F*  1Q*- $0Y90')1=E'-X1SS%K6]MO;CXKW?N4O
M^SW<ZTG3POJUO*&2/0--JFS;*J5Y=(-JVUBAT?#40$BVJ]1'<B]CFK@YQ&.$
M>&W%E#<MB-IM*O)V"T%Y %5&S6E52P2Z+@VP&45C%GY89-0WI@:QK=,/2)E
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MGZRA#*/'*ZR[@RBJIS&@LS$%F8D  $DD@* % )-P%   W   8D*H! 4 $DD
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M">^:^KF!WH]1*8^.Z+6$8&_<H&_'6AH:.GL8:6"(C(,D2!N'Q]76/#>3C9P
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MM<__ $^6[#YK;$?J'Q$?V.>+_P!W_<*Z/'M^/3\7U'ET7_%-&>C_ 'S?PO\
M5AWU#Y-3^Y5F73_N^[H&>'S6V(_43B('_P!3GC _V%!I^+ZCRZ(?_NFB_P#6
M'#OJ+R:@_P#T5;_IQA\UMB/U$XB/['/&![O^X5I^+ZCRZ+_BFB_1_OG;/#OJ
M+R:C]RK?]/Q^@9X^!.+/$H.%SC!<1'(.1 I3?,<\7OIA(*O*W ,%<L.3RP_E
M"(<X\G;GWR[PJ-4#7H;@L2/QIHW*X7_QEN' 7Y^B.^8KDZM3:P%^\JSI)O\
MT?F/.1D;=/W^:VQ'ZA\1'L_,<\8'^PO\6L?Q?4>71=7XTT7T_P#C/KYNG$]]
M1>34=?>5;T9?[O\ 5QZL/FML1^HG$1_8YXP/]A6GXOJ/*HO^*:+_ -9AWU%S
M5/[E6]7Z/YL/FML2<^T)Q$;#_P#0YXO_ /84'1I^+ZC*[T5Q?_\ BFC/]8=^
M)[ZBX"IL3^A5O^GSM?[MV'S6V(_43B(_L<<8'^PK3\7U'ET7_%-&?ZS$=]1<
MU1^Y5O\ I\/FML2>HG$1_8YXP/\ 85I^+ZCRJ+_BFB_]9AWU%S5'[E6]7Z/T
MV\^'S6V(_43B(_L<<8'NA_X"_O\ Z]/Q?4>71?\ %-%^@_TSZ/NP[ZBXK4CA
M_N5;E_\ ;[]XSZ>O#YK;$?J)Q$_V..+_ &__ (*Y]_BT_%]3Y=#_ ,4T9?\
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M'758XZ5:16$125G4RE[RQZPF"L+&/KAKS&.YAIAAIACF1QQ\461L%9>P0%&
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MZ5T8S,%5=(4;,S$!545,9+,38   DDFP&9Q^'=(!FH*U5!9FI*D* "26,+@
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M0Y0.K1.8Y8Y4*21OJJX#*>#(RNK E65@5)&,RZU,;&&F&/R)R%'83E ?()@
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MLA88U&_[VJX8O_&$XA/ZV//T/UZO_P#45RC_ /Y?T!Z*_P#U6.'_ -D^B?\
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'#3##3#'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g287237g42p95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g42p95.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2$X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (1R^A'8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              1L   8.          $
M                 0             &#@   1L
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   1L     4F=H=&QO;F<   8.
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $;     %)G:'1L;VYG   &#@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      7!0
M  $   "@    '0   >   #9@   6Z0 8  '_V/_B#%A)0T-?4%)/1DE,10 !
M 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94
M     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                        $6-P
M<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M%')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4
M    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D
M  /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=4
M4D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="
M($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M  !865H@        \U$  0    $6S%A96B                      6%E:
M(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M   DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                             &1E<V,
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@                            !D97-C
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0                                  =FEE=P
M$Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7
M'^=M96%S          $                        "CP    )S:6<@
M $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X
ML@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!$P$9 1\!)0$K
M 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I ;$!N0'! <D!
MT0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"<0)Z H0"C@*8
M J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-: V8#<@-^ XH#
ME@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$?@2,!)H$J 2V
M!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&
M%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9
M!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1 ))0DZ"4\)
M9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1
M"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-#28-0 U:#70-
MC@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L
M$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02
MHQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4\!42%3055A5X
M%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W&!L80!AE&(H8
MKQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;8QN*&[(;VAP"
M'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I'Q,?/A]I'Y0?
MOQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\BW2,*(S@C9B.4
M(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H)Q@G22=Z)ZLG
MW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K:2N=*]$L!2PY
M+&XLHBS7+0PM02UV+0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            _^% ?VAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N
M,30U-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R
M,BTP,BTP,50R,#HT,#HQ-RTP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @
M(" @(#QX;7 Z0W)E871O<E1O;VP^5&]O;&MI="!H='1P.B\O=W=W+F%C=&EV
M97!D9BYC;VT\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I
M9GE$871E/C(P,C(M,#(M,#)4,3(Z,3@Z,3,K,#4Z,S \+WAM<#I-;V1I9GE$
M871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(R+3 R+3 R5#$R
M.C$X.C$S*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M
M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY4;V]L:VET(&AT
M=' Z+R]W=W<N86-T:79E<&1F+F-O;3PO<&1F.E!R;V1U8V5R/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F>#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P9&9X+S$N,R\B/@H@(" @(" @(" \<&1F>#I!4%1+5D52/C$Q
M+C$N,"XR,C$S.2!0<F\@4')O9'5C=&EO;BTS,CPO<&1F>#I!4%1+5D52/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P
M=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA
M=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @
M(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE
M;G1)1#YX;7 N9&ED.C,Q13DT-C%!1C(X,T5#,3$X-D8Y0S4P,30S.40Q,$)!
M/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)
M1#YX;7 N:6ED.C,S13DT-C%!1C(X,T5#,3$X-D8Y0S4P,30S.40Q,$)!/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W!D
M9B!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#HS,44Y-#8Q048R.#-%0S$Q.#9&.4,U,#$T,SE$,3!"03PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP
M,BTP,E0Q,CHQ.#HP.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C,R13DT-C%!1C(X,T5#
M,3$X-D8Y0S4P,30S.40Q,$)!/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 R+3 R5#$R.C$X.C$S*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E
M<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H
M;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#HS,T4Y-#8Q048R.#-%0S$Q.#9&.4,U,#$T,SE$,3!"03PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP
M,BTP,E0Q,CHQ.#HQ,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#YU=6ED.C4U9C0W8V,R+3EC8F4M-#8Q,2UA.&(P+3$V
M93EE.60U8S8S-CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C,R13DT
M-C%!1C(X,T5#,3$X-D8Y0S4P,30S.40Q,$)!/"]S=%)E9CII;G-T86YC94E$
M/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C,Q13DT
M-C%!1C(X,T5#,3$X-D8Y0S4P,30S.40Q,$)!/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z
M-35F-#=C8S(M.6-B92TT-C$Q+6$X8C M,39E.64Y9#5C-C,V/"]S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R
M;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H
M;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @
M(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-
M;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\
M+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M/#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_;
M $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( %L!\ ,!$0 "$0$#$0'_Q  >
M  $  00# 0$             !P4&" D!! H# O_$ %T0   & 0(# P4*!@L-
M!0D   $" P0%!@< "!$2% D3%188(9?4&3%!4U99D[;2UA<B.%%Q@2,R,SE8
M879W>):A"B0E)C=B<W61E;*U\"<H4M'8-$-7<H:2E*?A_\0 ' $!  $% 0$
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MF-N.P5YOT\:<1!<TCK&+IB)I1C5EI?9N-BMK$-B#;+]993D62VVU;U+B,B9
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MJ*+@@N=LW<;M[Z.I=L8E/6ZZP;ZJWWAFPW&-#:E,2H=RD.%F.T6Y33:7T.O
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MY7PH)B[*@(F,(HE<=X"7$QAY +Q,/OC6E:6>RC_*2[63^F?9OK?E+7L?2?\
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M4[DA:59#HRH$JVDI*2<8Y]M3#(XTK$OCQYC60:$& DH!*!D!8I(L%URIM4D
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MVO9])_M2](WXW:O[S#J$7C[[]-?^5*_L/5O$UXQ4WJ!-T^!HS=)MNSGMQFK
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M=GQ?^(\?\W]/C\8IW,NW[\N?S?\ NIYO^Y?^%9,_U;)[=JO=[3GM79^49_\
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M^O2E< <@^\8H\>/#@8!X\/?]X?@^'2F1Y:"8H!Q$Q0#CPXB( '$/?#CQ]_\
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MMWAG3#FGT6X0N&SP0L71*I)D\7CEPI]*X?"VC=NJ_2%SA^",2J*XO_#KX$H
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M,83>'^']!P  !WU'$11X41Q.?$V>+&P*'ESG<3YL8\];FKE='RC [PV]8-I
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MEY;X@S.TY;6E;"LSLE?GG*LZX:2 )F>2)$SN5S6M-* P4.I6EE:592VE"E*
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M5![OS(H'6$6K3V%;4$-<1E*''0D@-^EI6I201L20-R0@$#/?LP,UYTR@^SG
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MFE0Y@\P17,S7H"QHLF]A@X>>;QTHPFX]"9C&4HBPFHI8'$7+LDGR"Y&LI&N
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M5:,FRJJ#9%))0Q!+F2W VE<J2M++KCS25ONJ#3SJ@MUUL%1"'75@+<<3A2U
M*420#0,,)*BEEH%:$MK(;0"M"!M0A6!X2$I\%*3D)'( "OE4J'1J"S<1]%IE
M4I;!XOU3MC4J[$5QFZ=<!#J7#:'9LT5U^ B'?*D,IP$0YN ZK*FS9RTN39<J
M8M"=J%RI#LA:4YSM2IU:RE.>> 0,^*C3## *6&6F4J.2&FT-@GRD( !/G-77
,K5K+32E-*4TI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g287237g43r46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g43r46.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1/24&AO=&]S:&]P(#,N,  X0DE-! 0
M    $[:^4$8X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             3(   ;C          $                          0
M           &XP   3(                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   3(     4F=H=&QO;F<   ;C    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $R
M     %)G:'1L;VYG   &XP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !3A"24T$#      )@@    $   "@    '    >
M #2    )9@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ ' "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
M 0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $#
M @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0'_P  1" !B C0# 1$  A$! Q$!_\0 '@ !  $$ P$!
M          <%!@@) 0,$ @K_Q !G$   !@$" @,+!0@)#@@/   ! @,$!08'
M  @1$@D35A05%AD:(3&5EM37&$%16-47(CEA<7>!M@HD,C4W.$61H2,E-$)2
M571V>)>QL[3P)C93692UP=9$1E1796=R@H63I;*WX?'_Q  < 0$  04! 0
M            !0$#! 8' @C_Q !H$0 " @$# 00""0T)"P@'!@<! @,$!0 &
M$1('$R$Q%$$6%R)14U1QD9,5(S)589*4L='2T]7C-396='6!H;/P,S0W0D-2
M8F.RM,$()"97<X*CX41&1W)V@Y4E)T5FPN*%EJ+#QM3Q_]H # ,!  (1 Q$
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M^0K@XQIC2PV&TRC^AP,J];6^O-'[>QJUY>:8OIT3)&%_9%:E'2+&(.JH4IW
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M_=UV""*6?L(G6&*25D[6ZS,L:,Y"MLZT 2%!/'*D$^KP]_4NV.Q5_P"ZI3U
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M/)&LE(V0:RT<PE&1S*,Y)DUD&BAB&3,=J\03<(',F< .0QDE"&$A@ Q1'E,
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MQCN=QQ1IJ@U*DPKFK4J4JT(_JM<<JKXX!1>$@'3)6+BUE >NP.JR:H',#IP
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M7:P[(B&Q7=XE92C-*&8=VGNWX4\ZE(LK4EI39!N^@K5PYE-F&2!U$:AB1'(
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M>]#AA6XYJV3(X8&=+.//9A:V['[%\76SAJ9ALI>R.8QC8VT[Y*U%5N5Z-8Y
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MN^IQ-S[<R^\Y]IYC;'<6L3'M_$T7ECN5H4PEBFS^DI;1Y4DK]R7#LP0L2C
ME5YN8G)T\)'F*66[R*VV0MSA&@E<W8IPHC,3!&$G7P5 8@<,/'@GC#"9H4_M
M]VZ]$U'9RR'<-L8HY8W&W"2NK%GU=OP]7[DD,Y7D@CY.%G 9R:C&19HN8Y["
MNUF83+ENNV0<(J"AM\5Z#.[@[49,-1J;BYQ6 IQTY'!J96Q4)AL'O(YH0\8=
M'*R)*JOW2L&*D<PS5Y:%#:JW;$V.XMY*9I54][3BF*M&"I5^ENDCW)0]/41P
M"/#9IFSI%<8;<MG6,I3%F;G&Y"]93E;;C+&6:\CMA81Q9F/E$0M=WR0[CJU"
M"A#T%";C$^]\373/)P[6,:IMUD@?R"'.<-L#([@W;D8LIAUV]2QD5;)9'$8]
M@\AB>(^BT\>KV)@TUXPR'O))^F'JE8L&Z$;9[VX*^/Q%<U+C9&Q:>6M6N3J5
M4.K RS6&$:<) '4=*IRY"@ CDB&Z_=<,8 Z*";QKM(RRQS1>LE75+ #2Z0K.
M8BS67<)G-S&-[,>,CY9DP?,TX6JRZ\A#IMVZ@HQ</'F654?=U*:EYZ>7SO:A
M#D=TXM\12QU,YUJ<SPR^CX'"K(U82R1.Z.9K42I*68<R2R!1T=.L-)J>/VM)
M6Q=H7+%J<4>^170RY"\5$I57",.F)BR$#P"*3[KG7NZ2''M+VYXGZ,K'!<CS
M&'*-B3-59K3O+, @@I-TUI!8^>-GUT:)K14RV/*G=).94X*Q+XBKIPL86JG$
M0"WV?7[F?RG:-D3CXLM=RN'LV$Q=AB(;;SWE:.DY$D1$?05B'$B\(H]UQJNX
MJT./J[9K=^U6&I=CC:U&O+PA("&G Z6'5U<N?<D<D^YU>>1%LC[A,&;<H7;)
M-SW2*80JF8+)/[@)VU7^H8LLV0I&C.(ZT8_H%BD9RNUQ@XK#*P3D?)R[2/K+
MH9)C5HB.<N$@<K+GQ,>,=@<SN"7<<,&PLS:Q->#!0UJ-K)UZ,=T25KUZ"."Q
M89;+P0/%$SV%$<EF615/ 47['I.0IX^/&O)GZ,5N63(/+-%6DG:'HEKUY&D2
M,&,.ZNZJAZA&BEE!U$&R#<==,!]&7NNRC8*$-46I>4\PCCI[X21DVI9\DWNV
M+P;6N)1;)!)RT-5+O)0\4=RJ*J<\BHJ_8))MT#EU+;RV_3SG:+M?&P7O2UMX
MS%?5!37EA%;'4:PF:PTKL5<6J<<TG2.# P$<A+,#K"PN1FH;:RUJ2#NC#:M>
MCGO%<R6+$G=K'T* 1W4K1^/E(#RO &KKW.;8+9@KHX=G-::5"7OT?M\S7AW-
MFY"JP+!>8E;(P4<S\_E"15C$R'<3J,?:+0H=R@NF=,D8D#UX*;2-452QMM;D
MJYKM!W;8>U#2DSN&RV&V]:GD$,5=U6"OC8UD)"PF2M6'21P3)[A.7D :[D\9
M+2VYB(Q"\ZT+M2[D88U+M(K=Y):8J/%^F24@CQX7Q/N5)$G;W=Y>W7='L,W=
M1."+8\OBU=PY$S<Y+M*A:(J%A4I"ZUQJV@'LQ.0\8V+83J$.X5@6YUG*+9JJ
MY7*F0A!-&;.VEG]L[VVK+FZJ45GR\T,,3VZTLLQBI6&:=88)9&-?@] G8*K,
MP4$\GC*S67Q^4P65CHRM.4J1.[+#*BH'L1 1EG11WGKZ!R0 2?+4347&4?MR
MW72=#QQ8\@&K65.BXN63L@L[3>;/;S63),7+HQK>ZN3STB]*SFP9*':)!&)L
M6+)NHLWCF31!=5,TK<R4FX-LQWLA7H"SC.TJGCJ#U:5:IZ/CI8C(U11!&G5#
MU\,>\+NS!2[L0",2&J,=DV@K26#%:VQ-8L"6:6;O+*L5$I+L0'X' Z0H )"J
M 3K&YMA>)QQT3^*<X1%IR3+Y&SK>=IRUWD;'=IJ9:I,ZME5:,K<378Y94J$#
M&1<2]"*20:!Q<,V[--RHJ*!!UL#9B7(=I^3PLM;'18_"TMSK2CKTX86+6<8L
MEB6>11S-))*AE+-]B[.5 ZCJ.6BM?;%.\LMI[-ZQBS8:29WX$5EE1$4\=VJJ
M2I'/B/,ZFFZ6.G5SI98YT6P+;C[7<LS5FJ(4N/L&<Z?E7;(V:U=-E).6\$W,
MGAZZ8601*I,32SA$':A'JRQ5N=-R[5AZ=:W8[+Y$,"[>K5,19MFY)#AK6,W&
MSV"\2M,W.5IY=CQ%"%/2"@# @K&N9-+#'NI2'.0DFNQPB)6NPVL=TQ]+D(.*
MDM,#EG)')!)##Q8]&T.A8YPQDWI1J7AN#FH+>#4)3/PX-K2[[($A)#AY:$J[
M^FOV#:9?/:U,G>7$8=:(F97NRSR"B[8B+QQ&+'*/K==Z_F,=V:V\M-#/M2W#
M@OJU85*$<8RPFL);21XD2Q"%J=Z)88^BM'TN619!SJF)@@J6-T0TTDCR\4F0
M%&,FPS&IT1F%E#DQN3+W91F+2-[D@E2=8])/]L$ET;NXEWC*W9<L.Y61VMP+
MS=(QMTQE*6B$K^3)=!"><6Y"Y==6X^](V)61:5M*!50=KU7OLJZ07*4S@)XI
MN2+M"P*Y*KBH-NQ[DLIMN2K%C8I#1^I=\P+5:KQ8DI&N(VL&P&5;/=*C#['4
M?SC7V]>-:6Y)DGQL;9(3/99>_P#3*Y<RB4&-;'>%A%W?!,/7R#YZRZH>'RX,
MW:SN)\13.1G\9F?HNK9?[9"V*[VBYNK=EI.=3@(VV&&=D7PMK"Y17+'MR19&
M#)JFNHVCF31%=1,VK7<M]6]L093*PX])<1VE5:56:O3K4TJXLP]_)5 AC0-7
M0KUDR%W;A6D=RH.I:"H:64>K5:RRV]L2SS+)-),TUOJZ%D/63Q(0> %"@<D*
M ">8-VT[@:OD2>Z&K%M:G+4_NF()O*U7S2Q=PMICVE;LPXSGVC&M6&7DV36,
M>SRQ860D4(I)V]=(1Z0.UTVX' HS&XL%9Q\':UD[$-6.GE8<78P[I-5D>Q7]
M/@>2Q7BB=I$@7ODC:0JBEVZ 6UA8V_'8DV?6C>8S5&M1W0R2JL<AA(6.1W4*
MSDHQ"\DA>3X<G4F;3,16Y+;?OFW18TGLH3NY6-L^\+%>+X\+5+R4-!0Z%G\(
MVS&H4U03L2V ]A[JF&#HJ:[Q286ZIN7^JBD:/W1EJIW%LS;61KXV#;KU]IY+
M(OZ+%'-/*U80,]NV"&, AZ89%)""%?='PYUD8FG,,7FLI6DLOD@^6K5E,KLD
M<8E+@0Q>0<MRZD<DOQQSX#6-5N=;4Y#HS-P"N"+=EFQ9>D,*X#=[DF]KFLFS
M$*UR0;+M%";=SX73KX*/R.>>4FD.HK2Z9%8!OUJC<R)$7!]AJC<T?:+@_JW5
MQ4&*CS&<7;[58<=%,V/&)N]RD!I\328X0"%N;()$[ !@>5$?(<6^W+WH,MR2
MV]*@<B)'L,@L&[!UL_>@HMHN7 [OP[L$]/K.RO;!C&*VZ])7=\/8[GKXK0+I
MLEJF7+3$W"\6>[&F<FIY32K#BZNGEFD9%8DW(QG=)7IVQF[8QW;@C=LW; @@
MCSO<F2ES_9[2RU^"D+]/>%K%5I:E.M3$.-.--A::I7CC'<QR=/1U=3<(O4S-
MU,VR8RJN/W'/4KR3FO-AH;4J2S23==D6!&9B9&;W;+SSQP/=-P #P-S.N1ZW
M'3333335A95_@OR1_B%</U>D=9V,_=+'\^7IU3GZ>/5BU_>UC_L)OZMM:AN@
M$_B%'_/9D/\ %_)E1_W_ !CY]=5[<_W[CQ__  ;'_P WURUX>?Y/DUJ.POW"
M/\>L_P"S%JRNC+_"-]*[^=5#]>\@ZS.T7_!]V7_R8W^Y4=8^V?WQ;I_C(_KY
MM;Z]<0UONFFFNLB**9U%2))D46$HK*$(4IU1('*45#@ &.)2_>E$PCRAY@X!
MJI)( )) YX!)X')Y/ ]7)\3QYG3@>/AY^?W?EUU"S:")A%JV$3K%<'$4$A$S
M@O[E<WWOWRQ?[54>)P^8P:KUOX>[;P'2/='P4^:CQ\C[WEJG ]X>)Y/@/$^_
M\NO3KSJNNA-LV1.HHBW0246'BJHFDFF=4>/'BH8I0,<>(B/$PB/$=>BS$ %F
M(7R!)('R ^ _FU3@ D@ $^9X\3\IUTJ1L<LJ*RK!DJL80,951J@=4QB@  (J
M&3$PB    (CQ    ] :J)) .!(X \@&8#Y@>-4Z5YYZ5Y]_@<_/KTJHI+E B
MR2:Q ,4X%5(50H'(/$AP*<! #%'SE, <2CYP$!UY!*GE20>".02#P?,>'J/K
MU4@'S /R^.H6QW@"@8SR7FC+D 69=WG/$S7)>]2LW)%D>5.I0A("O0D$F#9
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M^JBUOHUQ#6]:::::::ZSHI*&3.HDFH=$PG2,<A3&2.("43)F, B0P@(@)BB
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M^"C^\7\FG@O6>SL%ZHC_ '?3TJS\8G^FD_.T[F+X*/[Q?R:>"]9[.P7JB/\
M=]/2K/QB?Z:3\[3N8O@H_O%_)IX+UGL[!>J(_P!WT]*L_&)_II/SM.YB^"C^
M\7\FG@O6>SL%ZHC_ '?3TJS\8G^FD_.T[F+X*/[Q?R:>"]9[.P7JB/\ =]/2
MK/QB?Z:3\[3N8O@H_O%_)IX+UGL[!>J(_P!WT]*L_&)_II/SM.YB^"C^\7\F
MG@O6>SL%ZHC_ '?3TJS\8G^FD_.T[F+X*/[Q?R:>"]9[.P7JB/\ =]/2K/QB
M?Z:3\[3N8O@H_O%_)JKMVS=HB1NT01:MT@$$D&Z1$44P$1,($23*4A $PB(@
M4H (B(^D1U:9F=BSLS,?-F)9CZO$GDGP]_7L * %  'D   /D \-6#DC+>,<
M/Q;&;RE>ZQ08B3?]ZH^2M,LUB&;R2%NN[[B;KNCD(JY[E;+K]441-U2*A^'
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M^"C^\7\FG@O6>SL%ZHC_ '?3TJS\8G^FD_.T[F+X*/[Q?R:>"]9[.P7JB/\
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M%@05%NLNBLHTZERJK]GN;ES=K;UBSA\=DZYK"*'(Y%*ZY 6^37.-94D-P2
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M%ZLG#T0#X$<CWCJ*AR%^M<&1KW;=?("2287H;,T5P32]7>RBU&ZSB23K?O)
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M4<*.U(ZO1$?"L3NU2)IJN3M(UNV;F<*)HI)J+&3%0Y$DRF,)2%   '@  />
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M]P:Z#V09AG[7ME9;.Y1GZ<Y6>YD\O=+<1QUY(E>U=N2GA$14C5I9>E5"H"
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M "<D9VN8:CFM>:>XCR1TTJN;71$/KLAB?H*P@\=$C$"4%3&&) UX[/TH6V&
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M5YYC"8W2-S&RS.5+ E01QJ)IX#+XP8ZS2DH26ZU&:A9AL&;N'C>U+9CDCD1
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MH*RJJYC+"9=5143G-QG*V:UW)7[E.HE&I:N6)ZU)""E6"65GB@4@ <1(0@X
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MA9MF=DF[WO4M;2WUYFQW0XC@<;UJ/&.?@I4G4-33U@7TKU7!%RQ.L8'"2#
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MGC-W'-':J[X'Y&2(-CIE3%NLLKS\R92C<D,@'UH(S<^(=F4<<'R*JQYYX\"
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MXXK$=ALN,Q\F8WCOJKEI*==\E6I[;Q\]2"ZT2FS#6F>VKRP1REEBD8!G0!B
M3QK(VYR666>,%Y*BUFI3.6BQ,*JWK,]./(VHGF5EH\)YHI.-VRSPK)F@I)'C
MW -N=RHW:E5*0%CB6ZW7TGI"E^!P&)"\^OD@$\#Q]1/W-<_Q%?:\NY$KYK(Y
M6IM8VKBR9&E3AL95::).:,JTI)%A,TSK76>/O.F,22%2>@<PSB:U;S96ZL66
M9L3X7J=".TD#2$U2\@3E@GT'B;50T8DWC'T8V;JHN'@)I.5#+%,BB8RA0,8
M#5M#.6^N)$%X/BDCLP/J'#1J/Z=;?NG&=D-7#S3;0W1O#*9Q98!!3S&"I4:+
MPM*HL-)9ALR2*\</4T:A"'<!20#JN9KL>ZZ&L$6A@3&N)KI6E8<JTN_O]VF*
MS)M9ONQT0S-FSCHYXDNQ!B5HL5R=0J@KJK)"0"IE,:LAF!'=+&1QX]X[+X_<
MZ4;^GC6%L[']F%RC:??&XMT8?(K;*5(,'AZF1KRT^YB(EEEL3Q,DW?F9#& 5
MZ%1@26/%_P"')7,LO45G><JI2Z== EWB2$31; ^LD*>$(@T,Q=J2$@U:+E?+
M.#O2+M@2%-)-) Y3B*A@+[3KZ?K@4-[R$LO'RLJG^C4%NVMM&IE5BV7D\OEL
M.:D+M:S5&''W!<+RB>(5X))4,*1B%DDZ@S,[@@!03C2>\=(B$F=)/!6W0T2#
M\R9')LJV4'8QP.!*5<R(0O(#D6W!04@'E!7B3CP\^K/-KG["#CD_Y1PW'/AX
M=V1SQ_I<<^O71!ANP/T8,V]=_BWW 8QC;&.,0L=WR4#^F<F/O/<]7GT^/GK)
MK,4IF&(J .\'U:G7"[=]6*0Q%YGGM<@PASD<C(.^^+!L[<=V(*%:@W;]5R*E
M45$QBB0.-Y^OI^MA2WO.2J\?*JL?Z-<YVG6VG:RO=;SR>6Q.&]%F86\+1AR%
MWTL-'W$7H\\D2=RZF4R/U=2E5 !Y.HZPI9-V$S9)-MGO&F):75DH15:)DJ!=
MYBS2KF?!^P(BR=LI&.9I(1YHY217.Z(H90KE!LD!!(L8Q?$9F)/>+&HX\.AF
M8\\^L%% ''O$^/AK8-XX_LOJ8^M)L?<6Z<QDVN*EJOG,-4QU6.B8)V>:*:">
M5WG%A:Z+$5"F-Y'+ J ;$W&26^5T\LE:VYU+$K6 ?0C)*!R+9+:NUMD/,K)D
M/(.$ZT]@Y:!<D:+%,DU!ZFNDNF<3J) 8H:\R^DDD1"( CP=F8,#Z_<]VRGCU
M<_SZF^S^OV+QPX_(]H&4W3+>@N3-=P&/Q:2XNY41B((VR,%VK>C,J$-+W+1N
MC+TJW!.LNZZG,)5^"2L*R;B?2AHQ.<<(]7U*\P1D@6362ZI-%+JU7H+G)U:*
M2?*8.1,A>!0OCR'/GZ]<IR#5&OW6H(T=%K=EJ2/U=:5#,YK(W6SMU+"4#=3N
MW(/+,>2:SIK$TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
MTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
MU0Z[6*U4(TL+4Z]!U>'(X=.R1-=B6$)&E=OESNGKHK"-;MFI7#QRHHX=+ D"
MCA=0ZRQCJ&,8;UBS8M2&:U/-9E*JIEL2O-(50!44O(S-THH"J.>%    &O$<
M4<*]$4:1)R3T1HJ+R3R3TJ .2?$GCDGSTBJQ6X%6:<0=>@X9>R2:TU8EHJ)8
M1RL],N4DT'$M-*,VZ)Y23711216?OC+NE4DDTSJF(0H ELV)Q"LT\TRUXQ#
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-::::::::::::::__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g287237g43z47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g43z47.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1.$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $VB^26@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              6,   =D          $
M                 0             '9    6,
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   6,     4F=H=&QO;F<   =D
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   %C     %)G:'1L;VYG   '9     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      )40
M  $   "@    '@   >   #A    )-0 8  '_V/_M  Q!9&]B95]#30 "_^X
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M%)&AL4(C)!52P6(S-'(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%R4S-%17<K4F-4)%8G/!PM;Q&.%ULL7_Q  = 0 !!0$! 0$
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M8+8[@C8VOWVWRZ6@79%69$]D55\DG;NOT1%5B?5?9._957V[=_;IHJPN-)U
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MV.#6#L-R>W?\^OR%\>8_34U8V)YA:1,F69&.]*9Z*L \Q,O_ $<;U3RQ0/\
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M3(W-\D>;Q$NP/W5#5V+V^=K+726!5".-7O3U%KXCC'L:.R.1?4LUT9=FN?\
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MP2<K#:FJ.<^-M8<EI7+:>K$M? 2CT5:"HR>K@#R*.;&CO&VEEYBLA&J\!;G
M+T+:"H)M<=,6L68T\I52VB1@" 0Q&_\ YU!3Y>+],;28IXIVM?#(V1CFM<U[
M%\S7->U'-<CD]E:YJHYJHO9S514545.JSO;N.H[C$[';T8,'1@P=&#!T8,'1
M@P=&#!T8,'1@P=&#!T8,1'=?ZK67_B!_\Q$Z,(?H/G^AQ+D1$^G1A0%OWO\
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M*WKR9(RACSJ^O,3X?2T5#D<B293EZ^[-4&R-*O*FDJ=@)9)26C>)C=6C9HV
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M5@JCT%/"0Q";0I['>DK4[N6(&!G^DG'O;Z 8<,\SE>YB1.J:>B>6J19(V6E
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M<BWV.(QQ[9'9.\L<];U+*-VFE(OZKT[44RM,MF>B[2U57&.L+!1V>6"ZK@)
M1IV#3VJ0LF@ E[)L=O"?7;OO]?RZX3[PAZJU_DO3RZG<#;O;ROOB=XRV61^@
ML"IG3W95_85]I,]&>G"-5F%-H@ V(J^E6PU9$-B-&OJ2NFM2"R9I9RE<WEFZ
M:3]A_?>WU[VPX)4(!L=Q\A;RVW/EO??&5U%E71!Q%$-&0]DL$(R2)"Q2HVR(
MLX\CI7,;)#$*I,\3GN:@4Z-EC5))^SI1W5@ /A-]S>X&QMZW&W<CY869EL2
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M6Y9)\5E :S  ]3C*>U;V2<4^S-LM3-IZVJRW-9!'[]5TJTK1!R=#/$ 0XTV
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MW8K# D<,8)-],<:*.P&'XXTBC2- 0B*%4,S.0HZ LY9C;S9B?7&8*_ZM/_\
M*?\ _P"J],84W0_(XA+Y8X(9IY5:V*&!9I'/5%8UD;'.<Y_F[)Y6HU5=^KZ_
M5>I"$>%#<\Z2.(6Z_B;6)[$]+_6V(0!#2N.L,3S6W M'<WL/*^POBOG$=%^F
M 7_*=I EDCTQAE_FZBP9ZC10[?TW"7),$[>RV<M0P"H DD8YXM%7"R1H,5;6
MD:WF=3>[:<KI9R?=42*6=#;25)=H%V^!69GL=R\C7NH4XS^50M4__%JJ$*U3
M+)+!3OXA=@J+.0=BSJBI?IHC6P&HC!R#3QX2_H^1:$9(J6JOQ9-M3U[6,C!K
MK0.>B+U48L359$T4*R^(OVI&U2QJP"P16.KBG&N4$JYC1UF75#NS20D9?.3K
M,LB$.L!-_A,H?1U*LS*0=2A3,(&RVIH\RIZ>.%(ZT#,(HT5$6*9-,E2RJH4M
MH8:R020 UQH-W+9:[+TSQA[724%9.6R)XH]C:@@S$LD1GD<-"43%*]'JYC6*
MUKN_F:B^_MU0-0U$ZZ>3(P0,KD+);P[/?3<#^:_:WKMC22UT%,=JFB EMRAJ
M760Y&@ $[MI(MV[>6,@8H,ZI5EP-)2P%+<X>2!LT,PH[QF3MF\Z.B?$KS(8T
M1ZK'(DKV^[7.[\$<T962%E$L.CE,S,@7059?&I5@5TW!ON1T/=@,AC:*4,U.
MY8N@"R!M8*-X7##>]CL1:Y'0'"-LJB/BRT%NZ(W-/S48M\'59*ULBJ64$_16
M-/8F,SI%347I%E&:=5*X3.0U,A?QIY:"%RP/$KPKQYWS&!DJO>!,TL<TU6D9
MJ-?(CDC7FZW6VD2G\0N ;*"MR6:GDIHLLJ8VI>4T IY(8*-I.08S/)%(2NE6
M%KQ :%2X).DD !<V)RY-4STT/)N;EX_;HFHE/9OM&7&<4Q[))4J;FU^$ DH;
ME\#%GC@LA65L[4D@"M""XI1T8;)O>HY#EU8M8U./QZ>.(PU>DC4K1H2PDC&D
MJY6[@VU* 02I<W]WEC.:4_N$<QM!.TRS4Q(*AUG<!>6_B4IJ(4^+2Y((&;U=
M@.R&6>4F)HL$4LTDR2-]%D#&^:65SVJJ)&R-'.<Y5\OE;[KVZB4<.N>,(6L'
MT2*X&K6H\2DW^(;7&WSQ8U3DT\LD; KH+(Z?#8]&6_8]=OIOBE& *)DJM842
MU\9%GLCM!,-+YTE%ETU#G-#,+)YE[HHLUC(/Y/?RJQR^95=[7_$JA:C*UM_V
MZ<0H .D0D(TB][CO]^G09OA]F?WW4VKF3F9R;6:6P\>UC>P ["P&QWQ'=#4K
M(4&2A$LT@Y;"I"22IW3Q-@>CU''@B2(5D937.BG18T:R)/9LLKHY1Z(D"]QZ
M#Z6^1!'8];$V)O<WCC2#;N";GK\O^?/"OW&HFI8JL:",=YU_<P4=>I32W!Q%
MD#%EK,4@,4Q<K(X 9?2'A9&D\SV,F+!'68P<MJMOOO\ :YML1<B]K=K7Z8C%
MF(.^QM?Z;]!;N =NO3"K+V%%959AT>DISK/*2R%%$B,^7Q0D1=XI8X@R3"Y_
M@[(=LU?!,AA4!BS(\8LF0=K44+;;=;=-^^QVL .]B!UN-P<(N=OTZ&YMU] ;
MG;?J.AQ"W<V91[9Y6!;%(HB9!'.7'WKAVR1/\DR2G1!R5XSX.RH2,66.:.YK
MHY163>6-W?OL>_?ZF_G]Q;#$P\2CTMWWOVN0=SV[?TQ]#<N9ZS58:,>QN3>R
M(T43Y8*])5[^2.5UG9A)%W7LCT^^]$[HV-SNS5[AD@CK\OU^6*\W'*(OE(/C
M*6J=\S,T<UVQL;&U1,B+&//72V9(S4#'KD^$GEL!FP6D<\JDC0QE?#MY8]O,
M]1Z]>W8?6_7$U;Z1VV\MOM;M]O4]<3/-[IO*@]36RZ.PMZ.Y(AKI;D5U2-2R
MM=#,IWK0Y]JQ./L)(H*ZKB,LS:ELU@YR@2%!N%>6MV';I\]OL?EZ"^.VM?H/
M+;I?8=3Z^E]]KG%T:0<6IKQ*RK%BKZ\ :$4(01%BB''B1K6QQ1M7LSMV7OV5
M7.55<JJYR]<-A\B=S]-@?3_C>YQT&QN#8COZ6/7TW.)52['./L(ZAFAIY+1\
MZ0)6Q68CSG3M:Y7QO#2;U8Y&LC>Y62,8_P K7*C51.FRH(.Q:_38[7W^?I?S
MO>VV'$8L3<WVO_3?;MOW[X>504OF:C7>55_/LBJB=O9$1??Z_P"4Z2JJ+W%Q
MMZ]_R_8ZD8FQ"X-P#O?>^U[WZ^6^QO<[WPZJ$UT4#I$CE)=#$Z5H\'I_$3OB
M8Z1L42RR10I)*YJM8Z::*%KG(Z6:*-'/:A[$A?Y.NDVL//Y7()O?OVQ,6VCT
MW\Q][;CY>7VQVKR+54&YH3->$N+>;BM5&)+=V^=1UNX*URAL-5#*!<%PNM!H
MY#B6!(^=CXIT>.9*WUXX;"AH:K,<OJHJ2%IUCS*G70H=M!D5B[$*-@QU;W-S
MY"UZ3,*ZERW,J>:JG6G9\NJ3K8JNL1LBQ!2QZH /*XOU)-GOE;EV@S.?O9%&
M:^ZIZRR5@<[21&R6 4!;HQYT[>M"QTBMBD5J+(SRO5%[HB5]73-!45=,"1)3
MU9CN19@@8J00;;@=COO8'KBUI9EJ*>EJ0HTU%)K'<%V6X;KL;GL0.IMB5 ._
MTV%O;[R.553LU.R>1WWO9>_;O]U.Z>Z_AV[+U$9)%W9B1WN.]A;Z[W]!MA^,
M$.-K;'J=^N_Z] !YWOB6=)Q*PB^8>%,3RM)3EZ0>SAN*6$^&FNZ:S*K;&M8:
MX92&1I&YP9,4KAXG/A/%*B56=T8GF=WN,HXCS+('F]QY30U00U44ZAH91#K$
M8=1^(2.:^DQV(!.XO?%3FG#F69^L?OX<24NLTTB7)C,NGF;;J;F)/B!Z&PQ4
MV^\+UYGI9)JS,\:\Q5+%25P&JSM;B=UY$3OZ8.LS@C*<XGRIV1UE55_JO>BR
MGM59.^QI.-:2L!%1-FF0S7(#TDXKLOD;8\QZ2H9YHD:]B!(^D*-L9"KX%KZ8
M&6ECRK.XA8<JJA:BS-%ZZ(*N$1P,J#=!(@?6TA9BI6V$S>:X@)O&9F0'D7B#
M==D6'(G;#79<HEJ*J.FH'C:">@O0T>R18IZN4I'MB5[QX57LLN2ISUX9J]9,
MMSO+XV.J=,OH*P1BVW.14::!F!%UF"/<[$[8KHZ?)H7@HY#GV19C(O\ \M4Y
MG5Q1E@2"*<L#%,EQLT)8$$VW! ;;^,]! GEJN;>:*X=.W8=^FJK=BL^BM8^Y
MH32FJ[LK?/\ $^9%5?*YKFHJ4_\ %Z%D9JKAWAN73\314U8I4]0&Y$T:*UR-
MC87L#<=;8T%?&X]WXAXDC*V&B:>E(-NPYL9=@3<#;41ZFV$?8I39;2V]#DK.
MQK&4Q84_*O*UF7^D&\T-N]D)@.#H[2SCF3YD:.YIMLL$4%=3UTWDBBA-F=VM
M,QS6"@RB/-<ZB1DJ(9%R/):55IZ..(,(O>WIQID>&/4W+>^IG35(Y12<=X5X
M.S?B[B)N'>%S,TM-,)^(.(JQ)9JBE9@97A%0%,"/)I2,H]@%DLJ!M.JBGBH\
M5G,=WS#G.(>*JCC42X(X^O\ E,@SEN]O*7)04-+>CT7RVM9GH9;2TU1!9#B[
M,V:2*LH*9L9DT$[)VQIYGE]'-Q0E5+42'W=9.3!%&I*HMBZREU%K*HT%KD78
M=S8_4'$.<4WL-H<OR_*<MAS+,LQB6:ISFN=88Y5U\N2F$C$! Q D4:@?"+@D
M"U8>-\KRCR_00>([@7D@#AAOB(H:>ZY&QFMQ4/)%=4ZZA"EQ4^PPMG#<YN6$
M]];2!CP)91&T%N.!5W$@$1$DC483.X<E$U!+30UK43B*D(D^!6N91LPO<JA\
MA8B^^]IF7LQI/::M-Q:*R;*%SW+H_P"(9:!J5I4L%=687()+BZD!@05&X."
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M1*2MJ9O$!U+C3=B/$3$  H^*YOJ/A5DM(825XF_$V/QK8Q,\-6KLN0XJ/6#
MWH5+OXP%T@%/4OI)69>RXL DEL([&ZF..!?8PX6PIL[9B93DO5:\B+(-=%!0
M&=?]=&L.J,E6> G06;6.8M2?#I0 -IYRO(IDIXX@9<(%14:-Z=B_B (UV! %
MB5:-=_$20K,A56"R-(51IS:^)WF2!==1A^'&VDTN7K!RC9PM'H+^L"^=;+28
MC-&.JJ+C*QW=C%:S878ZB..LPYD$64,XSNC2Q*O;WY_'[2T%*>4YKEY<C$ ,
MB(QT11S2#4]0L*Z1-%&=4RDR"=5!:)%F4:B8!AR#K50=F9E&IF53M'J-RCFP
M4D+RR;!V*8>X\2OB5K,A M=X6[:RV!69W)%;(>=OD!,N\H[85=+)8UE!Q+:,
MIG:.PR@5W-17-_0^IG]KDFXJ\VMC/>#YY:4% TIU9@JQ"2$$*L)8))RV<*SU
M*ZN6LA0.J/\ B12\U(5"%TM45*QW%*6?0Y&[V+*'"BPC)%RH)4E?"ZZ&D;4%
M9_'O/G*>MWH>1TWANVF"IB=CR3EYM=96%H?6B@XFL .H-,]68P*L6GW$TYP5
M42^\B"]: )E38:$DFR$I(\U'3Q0F6.NBF<102")54$F9F5X_^\6UP@!F&@FQ
M.I4 !9V.>5W"M3M&"\BZB6-@@!5C:/2 ]R ==MK L386KZKL2<'1@Q$MU_JO
M9?\ C _\Q$Z,(?H/G^AQ37G#G+Q3X7F*VIN,^(Z[?<;4=-@O2#_0W9RZ'7:#
M:9/GVU.BJ-Z%>1Y6D"R>@XSX\J;=AN8M_*G(P49UA3S$U+S-ODV2\,UN4Q39
MCFLE#F,TU==O>Z,4])!256111F:A> U4SU4.8U\L12IB_P#D'*1S!9=%365>
M9PU+K3TJ3TZ+"0.7*9)7EBK6<+*'$:+%)!3JUXVOS[$KX2:_TOC%\9\6'SMW
MI>!$-N])'MP*YF:X'\0P;&Z"HU?A\ASX6DSEY!\WQ8\V3VW-I!%E:6!>:M2>
M.J\NNTXI[+C*-OIN$^#VK:B&GSPI#3M1/(9\ZR%_]/+2Y\:AZ>HB/*K&6JH\
MF58XHUJ(UKY%DI6C,-48 S3.!'&S4(<R++ITTE8I$BRY>$62-CJB_"GK&NS%
M'-.I#ABT(DL7B6\;X=C@VVO#U$5#LM&1.)3U'"?,4TI-$SFRMXUGQMUJXM<=
M2<9Z"BXZ'N^;".0MT /E='56%9FZ+.-6DLKVVC-P[P:\==R<VG4TE.JM--G.
M4 +.<GES$5<-*:2.;,8)J\PY.M!12-4P2I+435%IHX8GA7YPIBYE(AYLA(1*
M6JN(_?4IQ$\@E=(9%I]=6TTJK&R%4$8T.[++3>,OQ\Y?BF312>'GY[OSLOQA
MM*.JSOAUYGMZB&3693EVVTW&NGKP>0YM%5:&HN..LS7IKQ1S@JPWD*FJ+_(5
ML<X5_-8TW"/ ]5F8IQGW(H$J<RHYY:C/\HBE(IJK*HJ;,*9WH!3RP2PYA4R>
MZ,R/(E!+-!52$/ (TV:YW#2O+_#^9.8XI8HXJ2I==3153O32 3%U8/3QIS@+
M*9T5HQL6V&>%PS?'XG>%<BPZD>VEY_\ $(ZE'UL=G&>/B?\ E?UWZ$05S;6.
M,A<W#F/EL>:= Q*]U(T):[N&L/6#XD2A2LHER]J9HAD>0B9J4QF-JS^$TGOC
M2&(E?>#4\PU 8\P3%^9X[XO<O,YBF,XD#FLK"HDU7$1J9#"%U;Z!'IT6VTVM
MBR?6>Q.P=&#!T8,'1@P=&#& T\-R12&PT)@5?9R-C9$<>&\^ 6)TC4)E:&R<
M7X@AHZR(+')/' I"QK.JPH]KEIR@P,R/(B^+0C!2Q'0%B18'OOTPS/S3&PA=
M8W.P=U+A!W;2.I Z=1>UQBJVYQ?*!Y-'>H;F+Y<)%?65<]XQ8YNAA.@@B+J+
M.CC#?7NGL*:*>JBG%LH!VG$LM4!8L,0+-)EM9E\:S0<J:!:P10LAD#+3LI?1
M.I5QJT/N0 Q*%DZ,;Y3,*#,II*:03P3&C,LVLQ$-."%U0.K(;!U!WU+9E#=0
M,3?C@,H.I K?E-=9YLJ%Q-/J0;. Z ^D?&U:!QPAS(#8YHJE@(:-'=9#,]!K
M8YFC]FMA5DB2RS6?W>2-S&8 C($9%!8(0-+!V8N6&UV.Y:X%C2)4+%%'*D=2
MA4LE8K("T;%C&)%;2Z,B_AVTMT\-E(PQ["CJ+<)*^RK@S0T:Y/AR!X7Q(GMV
M\K/)VC5OOY71HQZ+V5'?=9VKXIZB!M:S.')ZBX-[VZD6(MZD'>_K,FIX)%Y+
MQ*ZC^:X(-]_ZW%QZ>6$?MLN/CP+&W8V$_-D5DN7*I+DB<JO' T)H0*!RNEF1
M8:J<QP4:E*^62F8Z>5(21YIWQ:"CJXJO1#.G)GC;GBIC7QR&,!CLJL&<J&V-
MM9%S;O35]')1NU4DAFIG5<O,#&RQ1S@+$025;3SF1;BY0$L1I!85O*YMJ,A>
M9;"7&L.+V=I0N$KYJNNN393!!UG)" 2]B+(GAF8T2+U995M;%Z2Q.L4)81$I
M2&EHYJN5*2G9:>ZR&6>:,(DA(5]4#%'<Z6:P5 .A) 7;>4'LQXAGR1<Q&900
MU*0!GIFT\Z2G!&CESZ^62"58@2%BJD$'<8>&$L]= 7<7E_@=;L![,1JU&A<W
M"#V:!BRO@CIBJ^76""0#3.1YD!T< TDWKJ+9"H2)'8'/9O!05)I:6#,J:DT.
MLO+5<P*K(RZ3,TB4S<TH9-'*!<6\2BUU3 T4V9TC52UM%-5&)G02JU&"Y5R-
M#"2=;(54DML2Q"VN-38JB%W?+\<]DRLI<!A&GSQUM6D@=R^XFKBUB=;EBT1,
M=1:H^<5K07SW!-/!..\A]7?L0 ]K]4U!DRQ11U4F:YBL2--(Z&%(UE6ZI#SP
MLJ!@6U\R-&V &DZE6!1KFF<R5$LD*9=EK&2&%(W$IF(/B=P@9&TE5T\MV0ZC
MLX"MC7[XOO"1F.4GUN8U8]U'99HZXT 6PHS0J\ NFNCI&M98MD$,CI59",T.
MT^,KY !6 BF170D7E]>OS#)YLYA%;E<D*U#:8Y:*5=(#J!J<3N!"^NZBP?4=
M/PJ2+_1WL6_Z@LR]D$M7DF>2U53E-5!RJ6O2):AJ2(DZ8Q3H'J@HL0+1F,!F
M-S9K+?'<8TU;1QYO-R0'5F&R4T5+7#+,6U?D%=(/1#$36:@V1S2BA8(T/K:X
M\$ASE:AL7JQM? @X2KJ!5S"L9(IELRPTTL51&YZC4:>218NFZRE#>]\-<>>W
M?(>,A7Y3E>754IS"9WJ<SJTDID@+G<QI.D)^&QM&"+^MQBTP=;2@U0C*18IP
M2X([!MBWRS3W#S8F3?-RRG+ZAA1[7M)D*>]9)O41WG\CDZ([N&(ZKN;[6 O>
MP-B;7(M\L>*/:Q -Q;KV.W7?YG;;"^*,A((.K)%^$.C1KO06>-Q#A9O4CC+@
M\B(KHED8]OJ*QKH7L<V2-GLK^W\SZ]K>?47[;V__ -'KB-??KWM]>O\ 3]=R
M;8A A3B@H8)W]K <89ME#(BLG82D+&S2.8Y$5T<LOF?'-&CX9&N[QO>B>Q:Q
MN!O87'3Y>G8CZ#H+G#,PVO;N+^G4#]B_3[^*5BM[M<G945%7Z_3W[^Z=U_7[
M(J_E[^RO(P4,#WM^5_3]1B.#_4'[7_?4?V@3+-0A+:R(?,/19]=,=),]WH(5
M (XF1ZHKF/66 4<<XE)')%'WF%9ZKI(I&M<YB[B]K^0/KMTZ;_EYW.%@B_3?
MN/J1I]; _*P%[ 8A^'IPK:C9IM<# <EC-,\($X28P>.6QGD./.C"E@5)CKBP
MF*FC\L<TH5= &#_!SPG.D4"#<D]1<&UM^QL/EU%^NYOM@[G>YZW(L+]!V['_
M !;<',M%;BMKEYX8?)D-*ZPH@W=E]"AM+=@AHHJ.[1) !9EU PM3&]J(.;8%
M (UD:UL21/MZ#IMM\^G]NF'F=64J&\1OM8@7\C?;\[7[XL8&K49''W3S+W\J
M*OE541WOV1RHJ_14]NZ=_;OW[=!(L?[=>W<6)\O/IA,<;*X+#L>XN+;>?]QB
M3+1U6@ EJ[H$6Q!G]-91"HV31.=&Y)(Y&K[^G-$]J.BGA>R:%Z>>&1CT1W7"
M=@1T\^_7Y=]K#O<7V!!F1G<VOTOY6L0.XOW],=N:"LN-YRSB1HK/,5]'49Z@
M<,8,-;"5]:7;D!51@U@3"E@2Q+6"JJ7USR"SFC1Q.!8>1)')&EL2.@-CM]21
M_;MZ;6.)2?"1TWZ^EP.HZB_D#O\ +:RF"WE7:6@E!;@VN1U!0B&AY_3-KAR[
M(1JL1Y-436V%C5V31?.J6$0EC*;6JD?S($)L\;W-8?",0"-P-@"1<$G?<BW6
MV]OEZVI!LQZ6@M;HYZ1#U5<;83O=W1/2"%>3*C51%3U/)$]$1?R_!W;N]$.;
M)%$MF:1U0*"+DABI !L+@_%Y;DW7H[*R04[3NZ!$4@D.C$%5WU*I+CR.WEM>
MV(_P2,<!QQ6UUFLBGU]MIQ2W2(BN^*9I;9Q/=6*[RM^(?(C$=V5$1$7LOMU8
MYZ(AF,AIR&C=5=; VT<M"+FU@UNQ(ON+;;4N0K4C+(6JD96%U-]P'+-<$_/S
MW\\.T#_KD/O_ .T[Z]^_\5_=/Q_;[K_7WZI&%EZ ;]NGS[;]NGTZ6O8MW'^.
MUORV^GKWE?3>)>,59?6+]C__ +?\_P#ZZ;D[?7],2*<VU_\ M_7_ )QC/S1?
MU_A_:GO_ #]-XDV_MM^1N?/?8VZ=L']O^>_Y]&#Y=N_[/]/*_GBK/.$#I^4>
M"HF=F.)_Y5(VO^GE=)C48URN[*O=KI'.1?P[]T1.M;PZIEX>XM5+Z7BH2J=[
MU$VA1L "=:DG>UB/EC(9N4@XJX+GF90E/6223N02.5 %J)2>I(Y2G;K>^*(&
M@FU9A=46.^ L&><4R*;[CFN:_MW:KE3S,3RHY')W1S51S>Z.3KR&H1J>JF64
M$.;!%"FX(%K&X]+CTOTO;'Z'T-;29C0TE?2RK)354,,U,\?B4J$O9M-])V(L
M3UV.->/VB&:M[/CO'WU?!,55Y>]G;>,@1'QB0W L8X=D1Y>Z-'A*A8$Z5WM&
M\^%7JUDBO270 ) VN0 ZV8@WV!*A0=KZB2.UK$7/08]K]C%?24F?9C#4L%EK
MJ(1TI9@@=TJ$=HQK(U,5&L "Y"26OI:VGKLO=4[+]._=$7MV_/O]%_J_J7M8
MF-N6) +KOW&]OV+];=3Z?3EVYIC<,+ $-8E;=]Q?R],6O\+N8VH!>XYPSU(1
M8#<0\?[_ $%1 Z,CX?3:\;(6WRC,1-@8Z4MTOKNG+B&5)&(HT'G;,7 CN1(*
MDK32$(DT@1E_GWV-_,68MMNNU]-QCP_VZ\4P99P7F%!1JM7G$L3S4L"Z&>-8
M&$IE==5]):-40;ECJL"%:SFT8%MQ_P"&;->+7/>(7DK7\OE4V,V4EA9;FPLN
M/.3[C4EU<9_%@_&#U?DA*PTJS+S=!7YZF!OZ,X84AQGK!&LZ]#FR?+7I9J&*
M@I^5?2*IR590% NS7L6/<K?Q=KWQ^/64>T7C&/B"BS 9E4SYA55$AGRY%,D9
M0NUQ'$-UC%@ ) I^]\;U..* 6DI3N5=DI5+F<W6R'#L^(E"((*BC\JH-,.^&
M9RQS.4,7X69'E6;X88E7R.<S+\+9#59A7+&%+PM.JP,S-I>S"\IN+K%&H+NQ
M  121>PQ[7[</:)EV69-+DT,<%1F3QB2MD:.*4T>J,D4R%F#"LF)58; Z7*W
M*WQ<K(Z_7%YVELS@R9H;:L#L"<[?3PLT%,I<#"O@F7<$;!BIPG/1LD=@)ZOK
MQ/CELF^5W;35>7+!53012QL(6<:TU<M]!*:DN VDCITNIN+@X^:J/,)*BDBJ
M)T8"95.@VYB7&H!R/"2#L>^J]Q<6+=SV_I;2>"I)F?67,C'*/7VR,"*,9$B(
M]PG=\@YZL]UD?73EPM[?](B]F]5%1221>/9E)).@,=/4[[; >>V+JGK(I? +
MJ0!NQ #7-A;>Y)/6U]^O>S [HOT5%ZA7!O8@VZ^GSQ-_8]?48.NX,'1@P=&#
M!T8,'1@P=&#!T8,:0=U SAW[7VY0J)1:#QC>%BJL*R9SG)#:<J>'Z\*#,K(>
M_EB<6-QF:MC(WNY[($9(C/;SNNH2)LLNPU"@E,C)_,R2$VT]B 3OJL!]=Z>9
M"N82=A4P*JL?@5D[-TZV&PO<>AOB!_:+<4^ W]#TYN\6^;C?;T8C:/-'Y>\M
MJ#D/:31/E+#QE.+3V(#=%(YTI$R/M8Y1J()Q1I!U97(20WT+V?YYQT*E<IX2
MG+4TDJ),9H'FIZ1&=5:=]43IHC'4QD$V/4C&3XFHN'P)*S,6!GD4E8X-/,D-
MOA0,5N3?:YM\SI&)WX2=[Q-F/ ;2\P\+<6!X/$U_'N_W\?&]*<7=G/NL@NAC
MMZ\V\,1UIH;X\[-.#GN;-LQDS5@:Z%@[(!&5W%F6YQ4\=MEV?9K-4UR9A2T3
MUDCLL)I:D!B:>( *(-U(!566WA%S<V643T<&0&JHHS'&JL\<953(KQWL)0NH
M ][DV[DC'YPZ+[7CQH0<H1[R^W@6ERI5E(1;\0397-)A3<]._P!,C,"1MJ?G
M8S)0Y7AC6?S>>V616RFDV#%D@F^C:GV1\()D\T%/!44]7'125'\3CD994GBC
M#+*"UD.IBY1;$+8V -L>6KQGF3YB[NRM%-/'#)3,MRR:G 6W0 @V<V4D=+],
M?I$T'V<W@ZVF\QG,:</5V0UF=T.>W4:9(A<Q3W!=46-=#A:G)AQ.RQ(SBX8W
M6B"TX)\ZQOC?8)$Y\<GSK3^T/C'+*.IR2/,I,PIJB!Z*4S_BU2IK>-7A=4+
M%0% U7O<LEB#CTAN&LDJ76O]SCH633(R+\!N.9K<,;!R6L;; *M]P+8]O,7
MGC.Y>Y'\.F5Y1V9L/&.(EL[V[X[*HX*4716-NS/&2Y>_-%M6W-U0-FC$MC1J
MTBGA0\0:MLGFMLFLS6?>SS.:'*<LXASNG>DAK:IH*6G=]%3=]<B3RQV 19!=
ME\7, (V!O?V'V;^V*/@N:LI^'\LRFNS8SP32YAF"R2QM04J1/[@BQ2+JCDE7
M6^JP)-S<*@Q4+Q,9"M^ROX9K.6N$CN3^4+VXY$ HH#-MH<_69O!FVF=T<L%U
M-14&7>;:0W4P3*BTADN*1ASIX(%)9(0_U7^!O9U1<7Y^,NGS6?+1'![XT2.2
MTT4+ 21* MM;IJ)%B&'7?;&X]J'_ %8<0Y_E20YSP9PS44-?0ST50E'!4P3)
M)J+TL[,T[AO=I%66/<%2A(N2,,+[/CQ8<U>.:0S1\P>&WBL7#89KQP.8QV6$
M3GZ]/A9?DV0S^E$U<LYL#7-.O+$'2U4%.CQ6/8040P5N\]H?"62\#1TM%E6?
M9HU17O$7RPSA62FDE5%ED:%@51CLJZ YON"MR/EW(,ZJ<^:6?,<KH%@1',52
M(V#$A"P.H@@ZFL+7N2;^5Z&$?;Q<LY_:ZZN.X9XWUN2 U>D$S\U5:ZK,74V;
M#MSH*EY9I!NJ ).DJHX/BBX*@6&:5ZNC#BB_@TWT/L.RB>BI:J/.LTHZDT@J
M)(WBBFB:4T[2,^J0JX0&ZBY8V-SOC-K[0:V">:$PP3+%.8DB9!?1J(NN]NEO
MO;# ^W!J^5]AQ+X8.1DH;(+C\8>WL=]4 RSV5=D=QJZ/,E4R7I,4 \;HH86Z
M*@J;@L$2%"WFCI\-/:0"OKO8A)E&59SGV733))FCR4WN=34A%::+77+.(220
MKC3$67HP8=;'#O&HJZNDRZHY8Y#QR221('LBS"'3<*-(:][,6&X(!(!(I?\
M8JY3DVV\8E9J\G%9MPN7R&R@Y.LX6RLI?D]S1%BT-*>0SN(19&:_]'K*LKW+
M\5Y*@JQA1T0!+XME[;*O+4X4EHZV:*;,9:I#E<5U:=6#+S&!B).D*&6]@!<;
M7Q2<#TM6V:I)%'(E)$'5RP;3K7L=0L=FZW(!/6Q%][7VA8DG)UWX-_"L ]93
MO$+XI<.9I041TCY>+>&6R<C;\J6/R/=&(*\&BE?*]GIN=&Z)LC4<O7RCEZFG
M6NJI228*,HC,06UE?AU"X+!CL;GRZX]D=S/,D3$-(U[N!93O8&PV&U[V\C;8
MG&^EJ=FM1/HC41.WT]DZHL78Z#].GTQ]=&#!T8,?+8V-<][6,:^16K(YK41T
MBM:C6J]R)W<K6HC6JY5[-1$3V3MT8,?71@P=&#!T8,'1@Q$MU_JO9>W?[X'M
M^?\ SB)[=&$/T'S_ $.*P\U^,7*<3<K8GBJ.IM+$PS594+DK43U%FW'<?Y?4
MX_D_6 SEWXS'POU! 7&MC8#4R031)3MD()G@*)JQC-=D_"55FF65F9F6.-%I
MJI\NIEEB][KZFEJLMI75(&(84ROF,<;37!YOA52JRLE95YO!2U,=-9F;FQ+4
M/I814\<T-3,K,X!&LK3,VC_9N2"5#*^N^U-\*%SG\?H:.WU]U!M]N7@Z8&NH
M 9#OFH;^-DE*F=-=P5LP2,Y<P4TT%;8V%T RULF6E0"1E==#164GLTXGBGJX
M)HJ2(T=&M;*\E0P0QO\ Q&RJ!$9 ]\JK@#)''%)RHS%*ZU-*TS0X@RTQQ2!Y
M2LSE(QRS<D>[>(;V*_ZN $J3IU-JT\M]/95?:D^%._QSMUGK+=Z+/Q$ZCXN:
M@Q95S/7TN/S%'M[[46,->81\!1!8^^AOB$*?%<A(#94EE4!:@9E%-R7V:\3P
M5?N4\=%3SE:;2L]8L(>:KJ9J*"EC,B+KG>KA,*Z08GUQS1RO3L9@#B'+6A$Z
M-,\1UL&2!V\"0I4/*=(-HUB<,3U!!4@,+&3N^T:\-A&EW^.H#MIL=1QYMJWC
MVQH<;DB-%;7&ILM;:X-M=0UX)3BY7"["G+I2/FL-1(]KA;P*,S,EP73XPX X
MA6GH:N=*.DIJ^BDKTGJZI8(H::.DBKM<[NNE==)*DR\LR@'5"Y2H1H0O^.4&
MN2-6ED>.=:?3'$SEY6F>GTIIO?3*C*Q;2 +/NA#8C;OM)^'+O4U^,XZSFOWE
MX_D^PXMT2UOR!P&0L8./^1-Z!>VY==<VT<M08+QKI8B@('-TM0)4W!ME20$A
M@UEM('L]S:&FDJ\PJ*6AA&6IF5/S.?KJT-?E]"\$220Q$2JV8TY5V_T\KRPI
M',5=Y8FVS^D,JPPI+,YG:GD*J-$3"GJ:@.S*6U(132*0EW6Q9E 7?TT'VDG
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M5?DXA4KWN-L/BP1VPL*;+ K?>)L;U'%*&+%":YO=K4$B@<D3E8Y[T5WF=#@
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MQ"VML8U7$XA<S2--43U$,4K65!RG+!UC5=E!!&JUR;7U:A<3JVJ0@*N$82&
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M7LEE?.RG:CHY>SIHX8DD6XJ,DR^.AAES.DKD4D)+F66M39K1'5>TCHA0Q;L
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M_K7'L90;B"'[R?Z5DS)5J;A4:[TU2GMX29^WG0#S*UK;:.KX;S=UBCK),@K
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MN;4KTQ0C<.)%.DI* >620+;DD6/4=+@B^N;PI\?^#[[+0JZS?.?.W&B^(?D
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M-/(Q9H8@H#(H! =R06TZ;@*VJGH)H\QFGS*715PU4[)202Q7A6GB5=,DB/\
MAMNIT@+X2Y(%RI#OU/'PN@K4.KQZL#2( Z.*P@@DBK;0>1')/37 [71OLJ*Q
M:YT2PS^M*#ZBEU[FEQ,67/468O3S!':62 @QF.5B[BY!YL+M<HR;6ML2&4W!
M.+NNRU*J(RI'#%4#\1988UB1@!812J@4.I[J3Y6W&_1PQKYK.-^2N?5%U&3=
M\"2*>]TIY-5!VC#+(F5&-*)&B?$#8E1H]A<J"737-"N@$D=S6B$ 6HA6]#,+
MQD$D),0-0U$D@:M1"L21<I?4AP917-4:J><A<PB8K(" .9 I(1@@"K<+:[*
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MSZM0#W(F=;%W;0=@0'L@RJ7/*U<^K08LK@EYF19<XLTHWO75Z6 :=;6A475
MI-O.W+?=W?\ /]7[5_F[?AV^B(B)[(B=8,$ABPL&8 ,0!<VZ7VWQZ*5"H%4
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MM-Q'#74^:I&:V*9E:=1(1^'2&QTH6($H !,9<G?&P")E705U<'!$P4(:,2L
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-1@P=&#!T8,'1@Q__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g287237g44x77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g44x77.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1104&AO=&]S:&]P(#,N,  X0DE-! 0
M    %#2^47(X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             5(   ==          $                          0
M           '70   5(                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   5(     4F=H=&QO;F<   ==    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   %2
M     %)G:'1L;VYG   '70    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      *      $   "@    '0   >
M #9@   )Y  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ '0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
M 0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $#
M @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MC;>OT&UV_7YI_P#J>J/^]?!XM-_-3_3O_=P:)OTO_P!J_P!W!]!M=OU^:?\
MZGZC_O7P>+3?S4_T[_W<&B7]+_\ :O\ =Q16#Z[ $_AYI^PW_P")^HV^P_\
M"L_N=^ RTUC_ )L1\_&<V^=M.^,%)K&TUC;8Z$-CZVL+V^OW\8Q5XCKFUN7=
M>Z1([;[Z0TPZ=QON>K+ 1Y$[$;GX;\ E@/%#(PWW\9U[7]&W!L/AM].<8"S
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M3JGW6+VJUE+8I3"ER4R*_P :(Q%B4]E DPK!F2VTT^^MF9/#\BCRR &5%+V
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M_F7U)I-1< K,'4^6IR40WJ>SMZRZLBVJ/1.U>3-6,J6'5M1U0X\V5$73RAY
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M ^').DM@;;K)<-WO]A/FZ &//.LD?RN>J:^4JU@WAS) T3L-R-:[K?D7XQP
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M'@1&Q^,?DOH9;1U?DI4IP@;K/9"1[RU$!()(!W0T\LSZ$B>1B+@*M[D<G:Y
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M02$=+"DIS5/8*6C5KR-P$"F_F)W'FX^9L,/L^S]8+S5# 2OJ6*([F0L"I 4
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M1RM89CO*AS&G5 M-I1XRDI<)0VLI]UTCH)4DI44JZCFKAGI@TDOB4Y<W;6+
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M5\!46]R"[:4D;'?FOM9ZJ'4G5,T=.VO*<F4Y=E[0A5AJ+2,)JC3&-]4A*AR
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M'#^CJ$BG0S"0J1H=5D*!E)MJ(TL"RWN W%B#ZA%13RU-.^@QKX9#"1HTD<,
M2%75)&0&%PUCZ$@VL8;A9/@#US-3E^"LX[?1)[49V1(J&9D1*WEI;C29-@RP
M8["I+J>EEU]/AJ06UAU?4=IB:CS)(?%HJLU,+AW6\ACD'=E4>9G" C< &VY
MM?$)35V633>ZUF6U$%7'I1_#4-"1^0X8V +KN1N 3IU'8E\W%?(A9WA\M+[#
M,"6J;&B+9BH3+;=8JISDFH4^R4*>BV4='M!HO!P,2*H!&X>2$L(7UT%:KJTD
ML:K*SRMX@)=A<!" 5TDV-G((;=; 8=SPA*ZC>%_#BE=HEC1=#!55O,[AB&+
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M+#?X1ZV[&^&M51TU9 U-4Q)+&P(&M5+(;$!T8@E76]U(X/8[@O:KNFIO2RX
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MK:JL8K<N!8UTEB= L(KP2IJ7$FQ778TF.XDDI=8==;._NN$#<:#L2-K7VWW
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M:V7(MXD(UN)YUF-#/U!=B6##UJW59%%B8NQ(0VJOF/6B9"(ZU8J0!W)!.I0
M#87W-SZ"PWWWVQWSV7='9YU%TKU%4Y;U15Y/!-.V7R93!T]U#FL6=-!#353T
MLN995EM7!E0D2H$8?Q!.;W>-$,;/P%Y\=/=4:W42#JWEVKL/F!PG4UN5]"]6
M*J=62:[IJ2VN9@<NKQZ98XYBEWB?KC2)>/TLQRKVD+FP5*<<G-1HNM1M?B%B
MZ,;(;BR\>3;;@$@[ F]][@>^OY/'5'3=7T]5](Y7TJG0N>].A7S_ *:J8:E:
MNJII $I<\AEKJ>FK9TJG*L9JB(2W.X*-&[:43L>OZF.Q+M*.WK8TN-%E1I,^
MLFPV),2<EXPI+#TEAMMZ/,3'D*BO(4IN0&'BTI?A+*6/F MN!<'N-QQCO%+F
M%'/))'25M)/-&TL$R4]1#-+')#H6>*14=G1X3)&)48!XRZ:PI9;Y#6*93(FR
M*YG&K]^QANSX\J"U36+LV*_5(;=M&)$9$93[#M:V\TY/;<0E<-#K:Y"6TN))
MR2S>IX%OV 6'W#"),URX11U,V8T(AE2G:*HDJZ<1R1U)9*5HIFDTLE0R.L#(
MQ$Q5EC+$,,('"</@2#M<$8VLY*]8WM$^8K <C>F>K8[?V+6$9>E;G0PNAR>0
MQ!$IX!)/33VAKKGQ/[A$!QH[(?6H.*9E67S"X<:"3VN;@GY!K$GT&^U\<M]L
MG28ZNZ#S>G1=5?EL;9OE]@"[5-$C2-$AY'C1:XC8D6:]M@<?6$C8)2 20!MW
M.Y[=NY^/V_$=^'&YY%C<[>F_'V?\L?-=26 )%B1<BX-CZ7&V/7V<%K[>NWWX
M"0 2> "3VV&$>DOZ7):N/=X_<55Y3RU2&XUG33XUG7ONQ)#L26TU,ANO1W%Q
M);+\24A#A7'EL/17@B0R\TA,L+T\BQL[.21?5>XYV_9W_MQH@J(JB,O3OXJ@
MC<D][>O&WJ>>^^(IU*UH:PK*<1TYQK"<GU+U2SF#9VN+X/C+]+5J?JZ9;#=E
M;6V0Y/:4V/U%;%<E,-N*?FNRG%KV8@ND))V(NIBESJLQ \NX%@QNU@H!86.Y
M/VB]@R[)/?LOS'.*W-:7(\DRN>"GJLSJHIYP:F>.26&CBIZ:FJI9994BE=;)
M$-,9 E+'2<=V?SEML"<OE+IG6 @R?4(G,7AAN@R@A*DB/*Q2%3N.C?<M.7[;
M:CV2_P!BOC8*=QL0/S?CNV^X.]EO\["PVW[-ES/V8FRCVASJ^AR=?1N:M [
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M5)2"R_.B,,23U+ /@.N'\H[%(*N,S4KPJK.]+("0H$%0LI!W-V4;@ "VH[7
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MKI\MHJW,9 8,JIJ4"FI<NI[0PO//=0U6RF,DD:G!D)X.)\D3]<D@^+48ZVV
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MY;8GU\NDTTKI6/9#%R*FRAJ^E2Y>EN-R:>SCQZ_+,9IH<'&*C(7*ZO0^[%)
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M[XS3M9;6%2\%@; J=@/QW%A!V6 5[I4 I.Q /#JCJ?=IB]EMH)NRZ@+$$<W
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M&HQ5V5,L:ZKHZRH9M+22J;8ONU4"-7,V%H^6FU3)4UB*VNQD%"2Z\MQP-I
MXC**LT54LDK,J3,PV\S#6Q(-S8 KL"3MWL.34^I>D7K\MAEI_P ?F5%$$ D*
MI'5*J %G)8V:P.E23?8$]\.6@FW%=C;5BC+*^AIUN2U.1G:AF:BODB;)8DQ:
MV3)FH0J&Y.;D&"RXP\Z L):\1(".+C41T\M9+$T#5,BQ0.#J\-2K!2LCR$6N
M%V9;C2UB2,</0U5-"\QG%-&99(74@2-%(GQQI&NY4L-*FW!V';%]N@R;+$A;
M3]TY!62#995.D5\=Y(.W7#Q2F;JUR&U#I+8M)$-!"@"%;;\9EJJ6A 33"S[W
MCB17*;?E3D,K$;W"W/<8TQTU36_C#)+&A/\ I'<CQ!\H58%1W!:USMVP[:C2
M?&J];;U@PB[DIZ%],EB-%JT.C8[M4T*.S"<Z3OTN3!)D ['JZNYCJK.JQXRM
M-:GWMY"5.F_)8D[CT  L.2.'D.3TL<BRR:JB5>'D.P%_AT;@CO<D[GUWQ)2(
MS+32664H80D;-H90$H; \DH0DA*/D D)&W;RV BF,D@(>9V)^)C<%CSSZ#@"
MYL+;V)&);3$54!%C*]T4 7OV &UQ:^UC:_?'L);<1X:@' D%"PM)(5N.A8((
M(4%=P=PH'?8#;?A .D#8FVRE@;FVP-SO?Y ^IN21@&Y*@ZM['Y\\WL#W^7H<
M)[5)3,R/6V:FJ8E'SE-5\1N2>_<E]ME+VY^:E]]N_&WWBK/Q2$CN-;;_ $!)
M!X';G[<)CCAC=7$*$J3L0-P01V .U[C>U^V^%/8]6_5[NQ'3YCL=]SMW^?P[
M^?"3OYB/-;[1?L"?[3_7A3$EB;G3V7\D?,"]N/\ G;%2D?,=]SL!O^]OVW_<
M[^?;C )X )MS?G[;VWMO]?OQC&.9; F>H!15($;UE:0A72VT7/#0I:Q[J5N+
M"@TDG=P-N'\E!/"PCLGB >6YMYA<GTW/SN>+;6WQC4"VF_F]-_Z[6_;C(.P\
MSMY]@"?KV^W?YJ/?M\!QKU &QY]3Q<7OO^P67GZXSWL?MQ#%C2MQ,@F8XTH&
MFR*%.OQ%;Z@]364:9"1,D,]0Z41+.1-#R(^VZ)+<I:%K9<<XE9#'F>7 2Z@T
M+K");6+FYTC?<Z1>[;7!MOQA.5ULV1YV):4*\$@:8Q:M-T0KJU<:1)V!O8@W
M VPTI^/4=6YX5CEM3#?2DDQ93L1IX'I)3U(=L&'-U$!()0E.Z@>Z=E<1:Y$S
M"\8E47MXC$J/I:P%C?:Q)('>UL=%_P"DBD6 N] _B*0KB&?<?+4$/RV-KFP-
MMB4&MJK&Z>BBKA.KA*=2W(L77:Q,9EHKV<=2J+8S52E-I"^EIH(6I0Z1L.HH
MV39 L44K2U 9P%\-0921OYR"$"G8J=R1\]M]$/M,@J)%5,HGD&]WFJXOQ9L2
MI"W+78JU]K@*!R=G_B&$5^2UK<^Z0W88Q*7*,#'I307#L6U*7%59WT974U.>
ME(1T,U[Z%PHD4@*;?DJ+H?2,N3CW2@4+4 1M451NDJR.FIEB8DC0JZ"#8-J9
M^ % H%76S=45WX5S*4K3*A@I*50&'A132$,[6OJ+LX"WT@*&N=5AX:T]R_3!
MUR?HA90D4(4MR7HWEDR4G"7T!.P;P.^;CV-KIC)Z@ BLAP;O!0VGP8V)5,J3
M(N6]9FAJRJU[RE[_ .O*JM,#>Y,T2Z5GL/RB5DL%&LBPP:3 +T@LES>GD:X?
M;\B0C\7OV(*BYV&YQ*&!ZQ8SF=A)QF4U:8CGU:WXEK@&6QF:W)([""A#EE5^
M ])J\JQX..(91E&)V-WCYD$PW+%JP:D0V6M122TZB0%)X6MIFA8.AN18.!9H
MGW!:.549=R187P[BJ$D N&1_RD=;%3N.1=66X(#*S ^N);ZAN!N-R2!]HWW'
MVC8[CSX:7WMOMSMQ]3QAQ<>O/'SQ7C.#!P8,'!@P<&#!P8,:*>DJT'G\QO);
MK;IS01UOYBQ10\VP0L B:C,L M(>74K%>XDA;4NV74NT(=;4E:6;5X!0"B#;
MN@\XCR/JW)*Z<@4;58I*Z_PFDK4>FDUC@H&D1FOL NH\8@NI: YEDM;3*FN4
M(LT*^LL#K*OKN=) V.YXP^N1[F#@<T'*YHYK+&E,2+/)\-K6LM98)VK\YI0Y
M1YG7N(("V2QD5?8*80X M4-V,\ 6W4+4PZIR.3IWJ+.,H86BIJZ<TK;E7HYF
M\:F=&X93&X&H;$@VXP[RBN&99;2U8(+/&(YAW2HB 29&%[@AK'Y@[$C?&V (
M.^V_8D=_F/\ 9Q 8DL5X,&#@P88^H^*85FF%9!CNH>,U>7X=.A%=[C]Q5-7<
M&?%AK3,2%UCS3_K+K#S#<B*&6S);DM-NQ2F2EM0P;6\UB#M8BX/U'?Z'G$ED
M^89KE>94E;DM=49;F<,H%+64U3[I+$\GXL_C]2B-&5BLA9@I0L&V)QIGH'R?
M\H.(Y<K,L$T"Q?&LTJ/4[RGM7;&RS-FKBVWC.55C33+.SN:>@NE,-.%^%7)8
ML*O<+B2':^3$FRDJL:L2J(#8;A5[WX/WDCC>]M\=+ZR]J7M-SS+5R;/.N\VS
M7*Y-4%12E_=1*\.D.LT82.6HIVN-%0^J.4%E\L@=<;T7&.4.2UZ:K(:>NNZQ
M%I3734"UAL3HJ;7'+BOR*@LTQY#:VDS::_JZZYJY 0'8-E B3(ZD2([3B=RR
M.C:D=D8JZ%E8@E9$:-UN+'2\;,C#@J2#L;8Y 51U *J5NK6*BP96#*2#RP90
MP/8@6X&$>OTYP&I76.U>&XU7.TE9EE+3N0J:#%<JZC.[:MOLTK:];+*%PX65
M7=/4VU_'8+;5K8UL*7,2Z_&96A33S,&#2R,':-W!8D,T*LD3,";$QH[*A-RJ
MLP%@3C C1;:54:0P6P (#D,]CR-3 %K<D G?&1A&!X7IIC4##=/\7H\-Q2K5
M+76X[CE=&JJ>"J?+?GS518$1MN.P94V3(E/^&A/B/O.NJW6M1.)II9Y#+-(\
MLC6#.[%F.D "Y.YL  /0 #&41(U"HH51>P&P%S<[?,[X=2E)0DJ5V VW^\ ?
MN[;<:B+_ +#]@W/[!C)('/\ %]A^W'&?+)(YI/2[Z=XK4R18Z>\@&EMWG>8%
MK9R"-:]7H[=3C]%,6$EKUVKQL5V00NHJ?8F5%O'2II34E''3((ST][-JRJ-X
M<PZSK4I*9"-Y<FHF:2HFYNJ/60K'?\L,K*"!?%1=QFG5B0C\939#3:Y39K)F
M%1I,:*UM+D4[DM8V1A8[[#LRG?8;^>W',U!  /-A?Z]\6_\ >?NOM^S"-D7>
MBNA\ZFP'_P ,OA4?QC_;7_TX1)\#?3$::"K4GE\T96T??3HYIXML@;GJ&%5!
M00"._?8@$?41\.'%;_KE7_XF?_BOC%( 8J4'@QP@[VV*J#OM;;OC0C">=C6*
METVQRKR?3B-DNH-%H9ISJWD^09#?,XC#N\6RZLTVHXM[(7)J*NE@Y99Y[=ZF
M0$8BW(A(DM:</-QY4)^_@-L1GC.J7*@D1J]R2 0P4 DVM<N6V'9?4C'J+.?8
M]TC5]0YA4Y;U!)EV0UO6O4'2N6T%!1/FTM'F655/45;+1QB.KJ:R?*J;(Z/I
MR<YJR3,C=0HSQ3)0S%Y M^=[.8LK*VZS1Z ^U1T3MHQ#O<FN<0NX,=FJTVM(
MN295%RW$J*LQ_&<G.=VE;B*+"XAV-I<8J]5R3"F2[9O&,F=O-9!L+V)((^$W
M:X%@;V7N3R!O:!I?8WDLL65M4=63HU;6I3/+19=29M1S2/5=14TF799+E6:5
MM37YCEPR2EJ<U:GHY:>FI,S6IC$\45*V98[O/+G;C62R*S13UTT^(R<@ATTJ
MPS&GR9I4?'].+JNN,FIK/ 8[U!B>82LYL:7&)1,NX5-QF7X]6[)-O7X_CQVW
M\@V6]B64CC=@5!"L3Y3:^Q)&Q&-B>Q?)%;+HZGK'P?>\UCH9:R.GRFKRU@]=
MU#1U%)EU739XZ5^:95'DE/69C$/"I!%F46BI6/W2>OQ;_G;U@Q:'<BVT#JY<
MR+:7-/ F4^:3&:&(<7U=R_2>\OLHM<KQW%:RAH9LC&(]U0R)%LEIR+=UC4^<
MQZREU.&J'0&\8) V*DVV=D-]04+Q>U_2Y%\;*'V.=*9G+2&EZXJ8HI:6DJYX
M:K)XGKI?PGTIE/5%%0Y;397F&9U-=70)F4E'71QTI<2T=0T$+^&5,W:1\T-A
MG&:W>*9WA4/3U46CTOG4_J61HSH2;C46GJI!H;*WQN"]2UEC"OITZGC19LB*
M[8UU:SE$ S**S1)A;$FU$AETBR6W+;N!8&PL+DV&^X%^-Q3NJO9M!DV3T>9Y
M)G$V?"2LZD@J_&R]LE\.DR"KJHQ74])F,R5E33ST,,-7)+$DBT]14/ELXBK:
M8QS;@<;\<HP<&#!P8,'!@Q\EGIM-_P#=A47O;?U%</[; _\ K+FP'<[_ "VV
M\AY_$\1U;\2FW_5CN;'SN.!]/[?48^G?\C(?_#',[,5_]\,QX53_ /E.1>H)
MN?3N?J<<@2-]^_F?/8 D?([ =NWE\.&6KY;6.W&Y%K\F_P!O;TQZ^8 ^E[+=
MPB*Y%A="R@$H?2_RQ7A.,8.#!@/] /,_4.#&1OZW[  DD]@ .Y.V.B?H\>5J
MRUJU-KM1\GK76=+=-[6-9R793 ,7*<KKE-S:C'8RE@(DQ(<@QK.]4VIQI++4
M:K="7+%?A.H$TGQ&74O"7VU.;6VY*KN3V)L.2+>>?;S[2X^F.GYNFLOF Z@S
MZ)J69(ID,N6T+.$FEG"W96G0ND*[-?6VXC88^EM)*@"1L2 =OEV&WP'PV[;=
MOR=SMQNL!L-]S_7]O]9QX*6P%@;@$CN;6.X))))!VOCUP85@X,&#@P8:\G"<
M/FWD?)Y>+T,G(HD^!:Q;Q^JANVT>RJJB_H*V>S/6R9+<N!1Y7DU1$D(<#L>M
MR"XAM*3'L93;NX5$ZQF$32"(JR&,.P0J[QR.I6]M+211NPM8M&I.ZC#=J6F:
M43M!$TP=)!*44R!XTDB1@UKADCFE13>X61P-F.$M[2[3B0O$EO8/B[BL#N[#
M)<**J6!_P4R"V7-<L[J@ 9 J[2P596)F388:D2!834NN*3+?#BA5U($P$\H$
MZ+%-YV_&QI8(DF_F1=*V4W L-MAA!H*(F FE@_S65YJ?\6OXF6347DC %D=]
M3:F%B=3"]B<([VAFC,A$YM[2O '6[.19R[!M>*4I1+DW-W2Y+;//H]3Z5N66
M18Y07LXD?HFWIZZQ>ZY<5IY.P9C7C3:LJ1I"*MII!98T>) /-PL<DD8]$=EX
M-L:CE.5G7?+Z0^(SL]X(SJ:22.9R?+RTL4<C>KQHQW4$(3/+9H8U8W%BYIEB
M,SVU046+2*^?1ULRIC4&.X_G.*UU7 K7XJHT2,<;U+SNAEAM!5,I\FLZI]2Z
M][U9.PYKF!1$]ZF&B228,LC!VDDD@F9W<&['Q::"07X>-6^(7QK7)<K5Y)/<
MH#XL44!1HU,:Q0Q5$*(B$65?"JZB,@<I*R'R[8?=)IOI_C%[.R?'<)Q>CR*T
M;GLV5W44E=7VE@W;7$C(+,39L5AI^7Z_>2Y-M++ZW%/SWW9+A4ZLJ+>2JJ98
MUAEGEDB0J5C=V9%*1B)-*DD#3&H06V"@##F*@HH)6G@I8(IG#J\L<:H[!Y#*
MX9E +!I&9S>]V)/.) AQ%S)C,<))25)6M8.P\-)W5]I'N[>8W/RWXU4Z--40
M(EP2S:CSH ') WW(L#:X^W#7-Z^/+Z">I<^98I%1 0'+L+>7_9^+CL,2:.PV
MV V[;#X=AL/S#8=NW[PO2; K8C19;]C95-QWMOW^N/-S,79G;XI'=S]6=C]O
MUQ%^LV9*P73;*;^.4JM! 55T# V4]*R"X(K:EEEL>\ZXU+DHEJ;0"KP8[JMB
ME*MI3(J!LRSJBIG*I3K/[S4NU]*TL$8:61B/A5@C1[B]_J,0^?UJ9?DU;4+Y
MJB2$4M.B[.U1.Y5$4'XF4%9+?FG$PZ::;1M/]%L-T\?/XZ)0Q&;EQI70IVUF
ME5E=R00DI5XEK*D+]Y!2I"DH4E21TFM9UFC9AG^89HI+B2=UIP>!3Q-X<"VO
MM^(51MP?MQ8,ERP9=D>7Y<UE,<"O4$'=JB5?$F:]N/&9CO< "U^,(MA46%7)
MJ7G);KD*ILD3:Z2MT(BMO>KR(JH\E7A/NU[4F-)>86I/5#?4I"=HKA'6XBJH
MIHY0J+&9DTRKPS"X92M[*2'5"3L0+VN<:9H9EDC8RJR0MY+*=KW6QW.QN%V!
MYWL<(V=S6GG:Z;!J[2!F<9<<5]G"+:H[,#UQ*WTV<MB48TRJEH#S#462TI]^
M03ZJA)0IQ&[*XF)9:F2,T3%_$C<D,3I(72+>5P2#>XLH()N;X;YM)&%'AQRQ
MU^E##(IVOK4V>QW1EN"O=K<@;+\VPFR7T3S$0J<X] ?CL./M-&,B!+<>:CR$
M.J"T.R5*==7T[AOQFQY@\1T3T].&HEE4+&\GXRQ;Q Y-B#;\A0$WV)WN.\S[
MEFM9&E::&1@(T 46!30NY-^=9\UN;<G&))LLG8DR55MS+]:;<,E^JO8M7.J&
M(JDE[K:LZUNMGL,M)/A-I<,MQ3@0GPWB>E3U*>G*QJZJT+LP$\#/XUR>#&68
M<W (M;N=L1K5-6K2&%RL\8 -+.MXNPL'T@W(.XN23QN;#.PB4P]9ST6[$J)E
M<A!E+B6*!XCM<I(\*97.)3T2HSFX0^8X\2*KHCOL,%"4J;9DIATBEE$E'& C
M2%K$E;B[@"VL@ D':Y)QMRZ7QIM-9%X=5/\ C#"H&F[6OX9O8H#<*5-P+;6V
MP^[BUI:6&J7=RXD2*@[ OJ02M9WZ4,L EU]U2@0EIA#KJB=DHWV/#2GBJYRJ
M444DCW %T< =MRP6P^9LH];DX>5$M'2H_O4D<4=CJ\\;,1R;:;[_ $[\@6Q#
M%IG4C)Y JZ5FSC5I4D/PZ5E4C);%A>Z/#D/-%$/$X:PDMJ?GS$6+@)2/4B %
M3'N<="RRU;Q-4%; -<1QN;;VW:0BQ/ %ORKC>!FKI:R+PZ6.;W?Q5N5 \21
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M9^)3O21RNK5;#PXXG1#^+*$E6!7S:FL 6!WMN ",*.&:>8G@59"QS',3@X)
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M ,B^E\2QPWQNP<&#!P8,'!@P<&#!P8,'!@P<&#!P8,:U:L%(RAL$@$U<7L2
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M$JT<!8C1HS"Y#K8D2!(6RVIMZ3I_P?015%>[S3RQ*HI%DC*!G8MJ:--VE\,
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M@N%0EK)_G4J(IO3Q'5*RDVD?8H@8>5E4[R 7M;2>6 V90D(0A V 0E*0 -@
MD #8? ;#R^'$=SSA]]WV"P^[MCUP8,'!@P<&#!P8,'!@P<&#!P8,'!@P<&#"
M=+J*N<Z'YE="E/! ;#LB*P\X$ DA(6ZVM02"I1"=]@23MW.Z&1&-V4$VM<CM
M_!QOBJ:F%2D,\T2DEBL<CHI8@ DA2!<@ 7YL .V,7Z-T/ZCUG[7POY#A(@B'
M_5I^J/6_I_%AC9[_ %W\\J?Z>3^]@^C=#^H]9^U\+^0X/!BO?0OZH_=?]N#W
M^N_GE3_3R?WL'T;H?U'K/VOA?R'!X$79%'K95W^NW\7P>_UW\\J?Z>3^]@^C
M=#^H]9^U\+^0X/!B_,4_8._/;OWP>_UW\\J?Z>3^]@^C=#^H]9^U\+^0X/!C
M_,7MV';[._\ RM@]_KOYY4_T\G][!]&Z']1ZS]KX7\AP>!%^C7]4?=Q_C\\'
MO]=_/*G^GD_O8/HW0_J/6?M?"_D.,>!%^8OZJ_+Y?(8/?Z[^>5/]/)_>P?1N
MA_4>L_:^%_(<9\&+\Q?N'S_?_&^#W^N_GE3_ $\G][!]&Z']1ZS]KX7\AQCP
M(M_(N_\ V5_=@]_KOYY4_P!/)_>P?1NA_4>L_:^%_(<'@1?F+^JOV=NW;Z8/
M?Z[^>5/]/)_>P?1N@/8TU61\C7P]O_X.,^#%V11] /W8/?Z[^>5/]/)_>Q=9
MI:AM*FVZRO;0E9V2W#CI'D#Y!L#S/RVXWHS1 >&S)=;'2=.UR/R;>F&DSO5;
MU+M.4)"F9C(0/D7)(Y.+_LJL_4^%^Q6?XG"/>JC]/+^NW[\:O!B_1I^J.WV?
M\^^#V56?J="_8K/\3@]ZJ/TTOZ[?OP>##^C3]4?LVV^S%M=56;I3[.A;*)"A
MZJQL01WW'1L?S[\+6HF8W,LA*\'6UQ?D@WVX[6P,D8\OAQZ7V8%!8CBQ%K$;
MG8BWWG%FBQV@Q>"*O&Z6JH:T/.R! IZ^'60@^\07GA%@LL,!UU0"G' WUK/=
M2B0.%S3SU#!ZB:6=PH16FD:1@@O90S$G2+FPOM<X(H(8 RP0Q0JS%V6)%C5G
M( +D* "Q  )M<@ =AA3,:,3N8[!).Y):;))^>Y3Y\:L;+#MM] /W?3[ABTY
M@NCI=AQ7$^\-EQVE#9:2A0V*"/>0HI5\TD@]CQDNX!(9MAMN>VX[]L8T+O<
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M%V_Y[?N^W!ZK&_Q=C_,M_P 7@QC2/X _=Z[_ %P>JQO\78_S+?\ %X,9L/X
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g287237g45b28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g45b28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1NR4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &Y:^<&(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              UT   6.          $
M                 0             %C@   UT
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   UT     4F=H=&QO;F<   6.
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   -=     %)G:'1L;VYG   %C@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      1?P
M  $   "@    80   >   +7@   18P 8  '_V/_M  Q!9&]B95]#30 "_^X
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MT@K#OYNZK_7^;1! UW/91%Z77C_+A:3?K!T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M  #_X4!_:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @
M(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(R+3 R+3 Q5#(P.C0P.C$W+3 W
M.C P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O
M;#Y4;V]L:VET(&AT=' Z+R]W=W<N86-T:79E<&1F+F-O;3PO>&UP.D-R96%T
M;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,BTP,BTP,E0Q
M,CHS-#HQ-BLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z
M365T861A=&%$871E/C(P,C(M,#(M,#)4,3(Z,S0Z,38K,#4Z,S \+WAM<#I-
M971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @
M(" \<&1F.E!R;V1U8V5R/E1O;VQK:70@:'1T<#HO+W=W=RYA8W1I=F5P9&8N
M8V]M/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP9&9X/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9G@O,2XS+R(^
M"B @(" @(" @(#QP9&9X.D%05$M615(^,3$N,2XP+C(R,3,Y(%!R;R!0<F]D
M=6-T:6]N+3,R/"]P9&9X.D%05$M615(^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O
M<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @
M("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F
M(R(^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z-D%%,C1#
M.#%&-3@S14,Q,3@V1CE#-3 Q-#,Y1#$P0D$\+WAM<$U-.D1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-D-%,C1#.#%&
M-3@S14,Q,3@V1CE#-3 Q-#,Y1#$P0D$\+WAM<$U-.DEN<W1A;F-E240^"B @
M(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F9R;VT@87!P;&EC871I;VXO<&1F('1O(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C9!13(T0S@Q1C4X,T5#,3$X
M-D8Y0S4P,30S.40Q,$)!/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 R+3 R5#$R.C,T.C X*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z-D)%,C1#.#%&-3@S14,Q,3@V1CE#-3 Q-#,Y1#$P0D$\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C(M,#(M,#)4,3(Z,S0Z,38K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C9#13(T0S@Q1C4X,T5#,3$X
M-D8Y0S4P,30S.40Q,$)!/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 R+3 R5#$R.C,T.C$V*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z
M-35F-#=C8S(M.6-B92TT-C$Q+6$X8C M,39E.64Y9#5C-C,V/"]X;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O
M;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E
M9CII;G-T86YC94E$/GAM<"YI:60Z-D)%,C1#.#%&-3@S14,Q,3@V1CE#-3 Q
M-#,Y1#$P0D$\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z-D%%,C1#.#%&-3@S14,Q,3@V1CE#-3 Q
M-#,Y1#$P0D$\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU-68T-V-C,BTY8V)E+30V,3$M
M83AB,"TQ-F4Y93ED-6,V,S8\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L
M;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^
M_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_\  $0@!% '' P$1  (1 0,1 ?_$ !X  0 !! ,! 0             (
M 0(&!P,%"00*_\0 41   00" @ #!00'!0,'"0D!! (#!08!!P ($1(3"105
M5Y86%QC1(3<X=WBVUR(CM;?P)#%!)7%T@9&XP28R-$)187:5LQDG,UAUF*6Q
M\>'_Q  ; 0$  @,! 0               04#! 8"!__$ %D1  (" 0," P$)
M"@L& P8$!P$" P0 !1$2!A,4(2(Q!Q4C,D%14Y'2%C0U56%Q<W2BLR0E,T*!
MDZ&QLM'P1$529;3!%U1U0V)CE+7#DI7A\2=D@H6CU>+_V@ , P$  A$#$0 _
M /V\'=5.N,F:9)2&F* 6?(%$'&EOP(RWRC"WED$D/+SCQ6Z^\XMUQ>?TJ6I6
M<_ISR\3J;7XT2./5[R1HJHB+.P544!551\@   V]F:QIUB23"I))).[>T^9^
M7/E_"/UE^1^N_I\7\N>ONIZB_'-__P"8?Y]_[_\ +V9'@JOT*_6WVL?A'ZR_
M(_7?T^+^7'W4=1?CB_\ U[?/O_?CP57Z%?K;[6/PC]9?D?KOZ?%_+C[J>HOQ
MS?\ Z9V/]^/!5?H5^MOM8_"/UE^1^N_I\7\N/NHZB]OOS?\ Z]OS_P#<_6?G
MQX*K]"OUM]K'X1^LOR/UW]/B_ER?NIZB]OOS?_KV_P!?Z'S8\%5^A7ZV^UC\
M(_67Y'Z[^GQ?RX^ZGJ+\<W_Z]O\ 7^7R8\%5^A7ZV^UC\(_67Y'Z[^GQ?RX^
MZGJ(_P"^;_\ 7MCP57Z%?K;[6/PC]9?D?KOZ?%_+D?=1U%^.;_Y^^^_LV]OM
M_P#U\_;CP57Z%?K;[6/PC]9?D?KOZ?%_+C[J>HOQS?\ Z]O]?*?+YO+V8\%5
M^A7ZV^UC\(_67Y'Z[^GQ?RX^ZCJ+\<W_ .O8_P"OD^H?-CP57Z%?K;[6/PC]
M9?D?KOZ?%_+C[J.H?QQ?_KV_U_H_.<>"J_0K];?:Q^$?K+\C]=_3XOY<G[J>
MHOQS?_KV_P!?)CP57Z%?K;[6/PC]9?D?KOZ?%_+D?=3U%^.;_G_\=O\ 7RX\
M%5^A7ZV^UC\(_67Y'Z[^GQ?RY/W4]1;;>_-_^O;^_P!N/!5?H5^MOM8_"/UE
M^1^N_I\7\N1]U/47XYO^?_QV_P!?Y_+CP57Z%?K;[6/PC]9?D?KOZ?%_+C[J
M>HOQQ?\ Z]O]?*?K./!5?H5^MOM8_"/UE^1^N_I\7\N/NHZB_'-_S_\ CO\
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M_'-_Y/\ V[?)[/\ 7Y_G./!5?H5^MOM8_"/UE^1^N_I\7\N/NHZAVV]^+_\
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MOP7Z-JWJE.M#%I[V:4T=*_&T5NT0U6Z8978B,B-" QYL!]#LR:X*<\IK51/
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MTTO3;=BC8N$E$CL5M998;M>=.4(C2Q%%Z =K"G<U&TU^&550U:^V\:@,UJU
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MFD*[-*;.G3ZA/JDZ2(=.O0O7C1%@CCN>GM]1 *%K R^'/)3"O9,P@M&5A+W
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MFB/>FEE!212LCEU(;8B)=.I3/(\M=':;;O;\N,I550&1 0CD(BINRD\5"GR
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MNL;5V+1$2!0^^Q977;TY&L>Z!TYHMF.K//-:>2!9Q)IX@MPA7>2,*TBV%"R
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MCCEXVXUL#L.!*%*DD\U=1OQ)REJ[C:2J5,J-W,F#9(&Y,BOA1,&F(D['%I*
MQ((1/Q#<RAV*<;;SAEY#CCF6RO%G].<>;BC[G_4=_4;^FQUXX9=/9UDGLF>&
MI,4E,1-6P:Y6<$CDI &Z>K%WK[IVCI]'49+$DT5]4:."MV)K<'<B[H%J 6 T
M) ]+ D[/Z?/VXG^XVDJ]KZM[%)F#38VS%-""P<4F(.MD>MUF0>2Y,P29E#T<
MPE,<ZA;CCJ\)<?%1G']_C.%7W/\ J.WJMS2$KQQS4HVDDLSF>*C*%:)>->R:
MY65B9E( 4;JKG^;YK77O3M72ZFJO/))%<<1QUH.Q)=B)65^5BL+ ,2 1$%BQ
M +1_\0.5D.XNDHW6D/M!V9,?BIH[W!BOB8B'[D*Y[S(B^M(5[$SAX07SQKKG
MK*>5CT7Q'/#P(QC"'H#J.;6+&BK7C2>M%W6M2>(33Y!PA?C%;\.5D?:91Q"C
MU)(-_3YI>ONG8M(KZR9Y&@L2]I:L8@?4(VYRIREJBQR1-X2>7(^3QG^?Y4SW
M&TEC6*=J9F#?A*CO<,5W"8C-UPY\1S&>OFN?&?6P+ZN/7]?U_+[IX/\ A_ZO
M'_A_U&=9.B>'C[XB[IM[S^]VW:$W'Q?A^//B>/'COS]/Y<?=[T[[SC6N_)V#
M+VO"_ >^'+N]GD:OB.03<<^7+;M^K\F5 [C:2D-9RVT6Y@QF)B#L /5XK$0S
M<R7,F1X?K 5W,SEXH7SR+3N7TO)Q[NP6[X?W&<92] =1Q:S7T5J\;3V(NZMI
M/$-IZ#MS2<9;?A^*/M"R\2I];1KOZO)%U]T[+I$^LB>18:\O::K((%U!CSBC
MY1U/$<G3>4-R#?%20[>@C+8+N/I*?U[8]C#S!P<96BW RH.33$!6R06VW'NY
M=AX)<RIZ0'SB1:2EU#J,*6P6GP_N,^*S[G_4=75:FD/7CDFN1B1+,)GDHQ F
M5>-BT*X6)@86W4J?)D/\[%;K[IVUI=O5DL21PTY#&]:801WI2%B8M7JFP6E3
M:8 ,"!NDG_ <K5NXVDK92K;> Y@V- I[9+AD1.8B(VR2F!0<'K3 P[DRMV46
MXWGT64MN-Y<*QEG'AG^UQ>]S_J.AJ-#39*\<TNH,BQSUC/-4A+R]H&U8%<+
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MIK/7;4C2\* WAT"U4E$<<;EBP8-(OJO2U4?1.OXY1WOF9:$#M>&6T>D%%)M
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M%<66XM.3!'"EF-;=&E1#0U?"5%AY@UXFK0M6BLL_**4P=MH]Q*>7,1LR.W=
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M#P5;AHAF58;0^VAF2:CPAVSFD())0ALI+J$H(?3A.,.N84AHTJXD6O3JP+*
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MQC'&,<8QQC'&,<8QQC'&,<8R->K/V@^TW_ZAIO\ RW:YNS_>=#\UG]]F&/\
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M )Q4,VX*@^2D'R'RY33GM$NG>_M8[BW'J;<(MKUSH*#,LFV;$BIWJ)34X4"
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MLG&U1D?+1M!%D"5P,BYE+B5K=.)=>GAV7\N8<*'&DV\.N-IRTXPA;S;LBZ_
M;JK2JCQI,2051^>X*#TLP[CA6/L#>8/%2&H=*5-1ZRK=;V+=SWVKST[?%3"(
M);>GI%'3G9>UNO:6"'>-"(Y#$I<'E(''=$M%.ST4?$1LE7JZ'A/Q.EQQY#L-
M-J0XMS.2"SW2YD1).%)8.0%(-8=8;1@?(;V77W"W7 4LH>5%98Y22"@;<^:#
MTMQ9F920/,[-S4!1&N])T^H.J:/5M^U;.I4GIR%8S"L-A]/<25&D41<E[95
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MA-L5 R78;,,2CG<2:(2AO2164TBO%"CUY@E7N1M,;4D:=Z-K2]Z)H3/((C*
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MI+3N/149'@%K:\/360$(\I.7!V5(L-.DD2'5"CNFVG\O2Q79A=I@-Y$>8#,
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M'2=232;MJ?7*GOK6EK&.*$:E8@[<YEC;NEHT8GX-638C;U;[^0R_V,_4+O\
MZ6[G;RN'9>Y3]AUU2*M;M0RXDGN<^]A#[.GV]*[5@O<J\5-2+>6L42RL$)F6
M6<MA/%E1.7\/X=0KWU7JFBV]*IQ:?"D=B:2*T&6HL)-=/%UW#2!0=^\GQ=SN
M &]F5NC4-1KZC9FLREJX$L2QFS)-Q=VAE38. "%C/'GY'?<;>>?J*Y\\SJL<
M8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,T%V:UQ:-LZ<M5 JQ 6'K(QB-G(F1=
MPP#:*N8V\)/5@PA2%H0),!$*9+9>3[I(#(>BSE)".(5C:IS+!,)"Q1U7>*4
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MQ\( [)2-8B29"0<#C!Q1UG'D*4^:6IO+Y3RE.ON.+SE7/5I56U:"@*/$3G8
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M'@!GD//ICYX8 MA_ RFI5@AIK+XF1S7[6Q3FNR]^HAEB988F8@(8WA@AC<2
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M 0.7Q2^S!BOQ>/\ /+^C/4&O>(Z_?W.(],U$]1):FH=GMQ<#J%>![,U3^5Y
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M26MOW);I_GK0W(^4?F/]ZXS>/)QCC&.,8XQCC&.,8XQCC&.,9@.UOU7;)_\
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M-U.^-E^W&Z<ZUZPZE[.OM7.TQ^VI@2'%U/4S=;R.WZ<LH&RG>^W6LOW\0&*
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MT$<E-AB[:%:I+*!;+-M9:F)R097[]E:VU.,"K80ZWJE>[/J,-MDN65*SS]J
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MR;6*\++!*X<K*\9E7BKA1MBM1':V0KE?/LVQM)5ZR'0D498( ;1UOF!X.;)
M8>E8=B78[%L,RC,8>L@)J1:99:.0PDEMIM#N$8]>KYQ]1_SRDRVLQ':^1K\.
M=9MBZ2KMA*CQGYF"'T?;IEB)D'&\*)!:E6.QC#)Z!W/%"2FVFT.XQY\(QC/A
MQZOG'U'_ #QE]?A^UAT8DBP;'TE!R>399E4</HZWRC:0AI8X:(,]\:[&,HRN
M3B&09-X?"/,"\8L%:W%C*<6'+Y=A_0?\\96"A^U9@3[T[LC24*:B8L0C ;.C
M;?)H>AP9^3!KLLHAKL8REIV>KX\9.$1^4Y<BGY%R+>=>=#6\X]7SCZC_ )XR
MD)#]K"T2>9O8^DHA8\U)"1B6='6^1Q(PH[_DC9=Q3?8QKW-Z18_OG(Y?J.AJ
M_NUNN9SX\@<O/?8>?S>T?/[<99#Q/:\HRR-3&Q-(Q(<?.I"K1;6D+=(+L,%F
M"A#%31 [?8MM40^F=,G(7$8\IYW+$.S)>KZ4DTTU/J_)]1_SQE8N([7$R-D'
ME-BZ2C8V/E11JW(-Z/MQKE@BG8*(,+DR!&^Q;:XAT:=*EX5(3RWG'V(IJ32X
MEH]MIMZOG'U'_/&<@<-VJ=F)D4S9.DA(<1N,5"RJ-&V\AZ6<(9(5*-O1Z>QB
M7(_$<\@=II;CKN#</J<1AO#6<*>KS]GY/(^?]N,H/#]JW)^5!(V/I)BOC14&
M3%3B=&V]U^3E3"IUN<C'8O'8Q+H+4,*% DLG./.-R2II]EIMI48ZIYZOG'U'
M_/&6-Q':Y5E+CW-BZ2;K34''&"6'&C[<L@J=?/E&)&&7#X[%X?89 CQHLYN2
M4\IHMR2<%0TA83BW'JW^3;Y]C_GC"HCM=BR,QZ=BZ256EP9)CU@SH^WX(:G&
MSQ&1H9,1^(OUG&2 '2S526'\-,N#(%RTI;Z5ICU;_)MM[=OE^;;?&7OP_:M%
M@C 6-D:2?KY$1-%2<XK1MO:?CI<,N":A(MN+SV,R\:U,!FSQ3QS;S;<<N%88
M=;=5)M*:GU;_ "?GV_L^-C!</VK:FX8039&DBH0L:6<F9A>C;>P]$DBX!S$#
MLQRNQBG)!,IEX[#KS;K6 ?<T9<2Y[RGR/5\X^H_YXRDE$=K!Y.O#QNQM)2$8
M<<:S89%S1UO$<@@68@\H(P<-?8Q:Y59DNR!%K&96RH=HUP]2U-BJ;6]7E[/R
M^1\O[<9;+Q':X4VMLQ&Q=)2H4A..!V4MW1]N 77H-,!.FMS(X[G8MQ4N\Y/A
MP4'F-94RZEB:>E,NY:C76G7J^<?4?\\96:B.UHBX7$+L;24N@N;%#FEO:/M\
M=F(@W!RUES#*7.Q;N9%X8AH1A,:WEIU])2W4NIPPI*H/+Y-CY_-[!\_MQET[
M#]JPQ!78+8^DIHMV9@1"AG]'6^,2-"FS0(D_+I?=[%NI?>A(5XZ78CDI2Y)O
M!(CVG6G"4N)GU?./J/\ GC$]#]JP@&GH'9&DIH]4M #.A/Z-M\8AN)-GHT*?
MD\$N]C'4+=@X$B2FF <(PY*/Q[<8TXTZ6AU#U?./J/\ GC++)$=KH^#D3*UL
M725@G6&,+C88C1]NB&)!_+K:<LN23W8MYH1.&E..>HMI>,Y1A'AXJQG \ODV
M/]!_SQBSQ':Z.K=@D*OL725CLH,+*%U^ODZ/MT,/.30X3[T7$/R[_8M]F+9D
MC4,!NR+S+S02'E$K:<2WE&7J^<?4?\\9],U"=I1(>6*A=FZ4EYD:,/(B8E[1
M-PCF9239%=< CG9!SL:ZV"V:4EH9PQQMQ R7<OJ0M*,IR]7SCZC_ )XSG3 ]
MGLQ^'U;3TKB0R'AW(.-"W'+>#/1\^1,%?B.\F48?_N?>/)Y<X_O/+X?HX]7S
MCZC_ )XS@A(3M*9#1!<WLW2</,E1@!$O$,Z)N$DS%R;XC3A\<U(-=C6FSVP2
MU.C-FMM-H*0UA]#:$N83AZOG'U'_ #QGSUF([72%<KY]FV-I*NV0V%BR[!7Q
M]'VZ9'@YLD%AZ5AV)=CL8PS*,QIRWPVI%IEIHUME)*&FTNX2D.6PW(W^7R/V
ML92M1':Z0@X\RR[%TE7IQ]I:I"&'T?;IAD!W#SJ$-MR3/8MAHO"V4M/96AI&
M$Y<RWG&<HSG,#E\NP_)MO_WQEU?A^UAT<I^P;&TE!R.).='2 QHZWRK:HP.<
MD0X*1][:[%LHPY-0;$=,O!^3SQKQ[D:ZMUT1;JY]7SCZC_GC*P</VK,%*<G-
MD:2ABVYF>$%&9T;;Y)!,,%,G"0,LIYKL8TEAZ:AF099^/4E3D8\8N/===<&4
MXIZOG'U'_/&4AH?M87F7Q,['TE$X%FC1(C+.C;?(?%(5I#&0I=W#?8QOW%XM
M:WT+CW/4<'PRE2G%8=QC#U?./J/^>,LB(CM>4;969C8FDHH*/G6PZR8UH^W'
MKL,$JOP)SLT0.WV+;5#O-V V>@\1KZGW5L0K$IAW#4FTRT\_G'U?_P#6,NC8
MCM:1)V(>3V-I*.C ) -BN2+>CK>8Y/QSL-&EF'D!H[%H7$N"31$E$(%>6\LA
MF/;D$K2T6AM#U>?L^KV_M8RX.'[5NS,R(9LC20L*(S%+AI9&C;>^]+/DMEJE
M67H]/8Q+D>F-<:$0TXXZ[@W!2U(PWAA6%1ZMS[/R';V_VXSP!Z]>R&[WZJ]J
M19^Y4OLW1#=%DMJ[WV"S*MD7RQ/F ;88V>-$A)U<IZNK8)!5: 7S(<C9B@:^
MB00N.L5K>CBV2._U#J;3;73,6CQ0V5N)4H0-(\,(@,E8U^\P=9VDV<1-Q/ $
M[KRV\\Y2GHEVOK,FH/+":[SVI0BO(9.,[2E%*F-5!7F-_40/8-_;GOVB([7Y
MLI,>O8ND45IN"!,&L.-'V]1!$Z\?(,'0RH?'8O#[+ 8#$><B24^IHE9S@J6D
MK%6M? ^K?Y-OGV/^>=7AR([7)L@D>WL722ZT[!R!A=@SH^W((%G&#XQB/ADQ
M&>Q>7GV3P"),YR22\EH1R.;%6TM9B%MO5O\ )M\^Q_SQFC+/UMWW.[VJVU'=
METLB7BHYS ]O$I\S$1U9'#(B5N5 .C.WN6ESH&UNAB&SH@U^ %EEB23L@]&/
MLPK1=A':5:IAY2J>W*C0JN\$TCB01SR[RCX2(2#CO&Y':3@Z<CP^=:ETEK=O
MK2AU!!K)BTRN]626F9)Q*BUU*R5H8E4P/#;#/W'=T91/*"C[+RWN9#]JFIB&
M%#V1I(N'+;E%34LO1MO'>B'!V1UQ;;,>KL8IR1Q)/+(:=6TXU@+#"7%X<P[C
M&*_U?D^H_P">?1<XY2([7#R5;'B]BZ2DHT^4+&LD@[H^WA.5^+:@I8P22'$7
MV+<7+N%3HL1"K"96RXPQ*.R:G%- N-./5Y>SZO9^UC(_;SU3W-M=VU#,UZR:
M8ML=K6UL7F)(&A;'JY8%M1'S400[-AR%DVF](PA-4.EZBLB#.!E%"WJ:&=C'
M!$YDA*/5(M9DE4Z?VNW' &C#7IZBO<6Q%,@M1Q5YA8J**Z(T1?9Q/*W!9(H9
M!("G;D/8?+RW(\B-Q\QV)W(\]O+S!.>AZ?'*<95C&%9QCS8QGS8QGP_3C"LX
M3E6,9_1C.4I\<?I\,?[N7H]GGY'Y1[=LC*\8R&7>;]4,)^\&'_P"T\Z_HK\+
M3_J$W[^KE1K7WHGZ=/\ !)DS><AEOCC&.,8XQD/K"WM+/:>IK 3LC-9Q(1N2
M5A/S.-18U9]VFQTV%N;8P]BI+OWWO9HRQ7"6%7GX-F*Q!NXJB;8G'5USIGW-
M60_O?XGA+Q#K#[Z>^?OAIWAS"VWBA1]ZO&\@K"EW^[WAXDUMZQ_%^^"<>YV>
MXFY'/L^&\-8[G+S$?>\7V=B1S$>P7T\LF#SE,L\<8QQC'&,\T]OQO8@-[=+,
M?+[TG@GMGW(S4A5,48!("V$_KUK(G4<>A%4'B!5:@@]JNW2+F_M"T53")L9H
MC:1,H,J9.>^AZ3)H#C1S)%HL#C3JB:JMOC(C0)KVHKJLA\4TKC59M+%.2'PY
M6VL+%=,6)Q$HH;*ZB/'!'L.3/.:97==G.GUO"K\$%'ADM]\/W/06 :4L#N=U
M]:T;41<-F9OF-B8$RP#B6S>7IMV#<V/B];-S,N:O1,O.",T)5%5KKX>BHH9I
M^&<!88;3:TW#'*?J$Z8:FG^!\#RY/VA3$(F&G^"T[LC4C".9N^-\?W#:)M<N
MYN?"^$S:T_QG.7Q//XHY<BY3O^(L\NP&.PB[/8X\ $VVV]7+)@\Y3+3'&,<8
MQQC(U[:;W5'[#B)[5JY*P,8T[M, 2F2;X$=KQ&P<6#6JJA.SYR F)%^5^'E6
M7(<>9.L DQT5)!QN(@L\^6YT&EG2'HRP:EVX"=6TUWMQJ\E_P'A]1\5! A<Q
MK'W%K\Y%A9UDEC>3NI&D6:<XLB97@9F'AYU$3$" 2\X>V[D+S+!>YL.6Q4,!
MQ)Y"+>FV^RGVWT\G88V\&)H4M8THY-2II]&)I \OOABW&;$7$8#HS]N/5C5)
M==]:.8FV67:TFCLBUMJZ,M]-JYZ=\'JQH-HS0LO*(11(EU;C1:&U1* EYW5J
MI_&:S\9#"2+)N$V#4)K*WOAW:PF\5NK(&9FWB:(>-[K3<0L?<;^#E1P# F()
MLHDV]..?.<O\<8QQC'&,TEV" O9^N5?=U,V>'L85NH)RT5)H-R4F(1JZ0;=@
MAGG"0#B1HHB&>,)EB(K(,E[@(^RW(#C/%8<N-"DI1W_X?#6EKO5O(#:+B*&8
MU)C!* KHK2K*$6)9><?-U8QLRKM@LK(T1[3NCAD;T<=V 8$H>0.RD?&VV/'<
M C<YY[V)KLS]M-F*F&^QCU ,V):R#&:"1L 2=B5(SV!1K &GD,22W)6M$K?T
M83)&ZM;A=?!#"QL=M".D7V]CS4AWE<].>#TX1'0!?2C55&O+1:"4'WA.I/;4
MQ@16%VUI8TU+NWW9I7TZ1%-"%*1S?[LW(7>R7F)$1D#*0U\0",@[LK U#O"5
MC $8E!/<8^K=;Q-XKT#BRY'S8\0L7B?R)Y?=,S?N+'Q7(OD_L>[Y.]?T?+_9
M]/R^7]'ASYC8[/B)_#<O#]Z7L<]^?9YMVN6_GRX<>6_GOOE_'S[<?<V[G!.Y
MM[.?$<MOR<M]L[KF'/>.,9K?<!^(O6-V/4)L602- EK5':D&)+V5))SY4*C:
M:@)M9K,W(85D,<\-8A<8E]<B-)13XK<D)8:4G<U*FG*@G*=0)-495TZ,^9$E
MLN0C0Q[<V1PZ2%1&T<JL8WPV#M!*=ICZ#Y5Q\,=_+:/YF/R'RX^W<;;CS=,/
MW87$0L=1#NT0FPQ-5;4E0Y"=K^ZW:62]*1.U\473P+^PZM$1)UTJ,@;6RL;J
MW.S#W">?I-&'"64-L*P!0OT"-=&6:5[L?3;4'U+3(W2&;2!<412Z9XW59%H6
M998Z=M(["^\^D--5@6Y=+A&HUWFIG6WVF$371.L,[!CW6C+2+9,5>,RH%=X2
MZ?PB959C%#ZCS=5GOUZ3/(H)6)9-X1$?;"W9HJ-F.V9[8*:'F8>S 8M;MU=?
MN*S/')>8W[5NJL2:_F'1,>!R7DXXG7C ;R&'P?=\)4\;[W"NM$WA"O?\,*@%
M0+\3N>% KFQWC%Z"";2GW.T_/N\>]-VN\6,O9YGASYDO[>7 /ZA'QW\\WGRE
MS;QQC'&,<8SR4VF5O&>LU^5K,_LY7JIC8Y,?:PIZK;ND)&1%C8C:SL;;==YA
M7J6N+I4C?'=<52"KFHK..-BKQL9?MH R4&9;H\_ZCIBZ+!6HC44Z=GM> 62L
M\%G1TCC:2;3!)5U#O+;$MR.B-0M3V-3K,?$R24=->.=*LBT%D7&=F@:XL32N
MLBLL[.55++++%VV1DC:9H8HTB8'@JR2J5YC)*]=?OD<V7<"+\)LL!IX&Z.7(
M2Z2,C)4\>PN;/DW-3C:P(?2Q67@A-0*''MI.O00( J33%/6$9%QS+)3SVO\
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MN?TOIO\ I;PNGZ.02='J>T#[YU;YQ_S+\N/&V?I?V(_L8^\;=?SNN?TOIO\
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94055"(6'-M@6=SN[,%0+)#G/YO8XQG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g287237g46z92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g46z92.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1IN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &E*^9S@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              UX   2P          $
M                 0             $L    UX
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   UX     4F=H=&QO;F<   2P
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ->     %)G:'1L;VYG   $L     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      0.P
M  $   "@    <P   >   ->@   0'P 8  '_V/_M  Q!9&]B95]#30 "_^X
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M:V-Q DP)TDGL@#/P"6@9-1+W%C1O;JX.;4YC=?I-LLKK_KV)7+N5+?LSIO\
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MMG)R152\XCW/L8'6,8^O]&X@%U;G7NIW[9_<2U4QMZ5TRZEE%F+4:*[/6;4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$              0,"! 4&!PC_Q !@$0 " 0(# P4'#0H,! 0& @,! @,
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M-O-6QQY^SBV^J./-V\7W4I]M*^LTT)5@7%8=[#,+*#R #,O89H[ #<5@6%R
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M8JC%I'ENZ@Y78.[96875=!N-ZD@B69YP@YV3+FD(!8!5" *=ZC*+D ZG7P;
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MUP5.K@K)1@[10'C([)<X5@@ (5KH8S(S*%5CS<A&:18U3*C'G"S$+:.V8AB
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MO%Q6$2%$"MO+RG0WT:5V7S$&WR5WSX/#U[.+;O#S53Z>KLOP=>K?5GHZ^VW
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M>R$01A", @C ,-A &&]A!$$5MH1!%:][""*U[7M>U[VO:^VU]E*V000""""
M00;@@Z@@C0@C<:^5*FE*4I2JF:]?H(=7?V-F:OO>2&O4\A_YY\E/[P['_3X*
MXW*+^0-M_P!E8_\ 19:TW4N'3;")A#7C*T1RD^2'*DG01<A7!_S^W9"E$G9%
M@BEBQ%C=2H9T=R4K*4G"UHTI;TY"-&X)T"PI.YJR>;L_N^6*5,-+ATCP\;2$
M2G!(3=Q< XBS'5R2Q)50+$@E0=K%'"QNC31RLTK!;HN(<"RG4\T"HT6P71CO
M -C5V6Y(E;V]"@1 ,+1HD:9(D+-,4'&EI4Q("2 &G*QF*S3 E  $9BHPQ0,5
MKB.&(RXA7Y+$EF)L2222+6N3<VMI:_5IU:5O    ;@ !>][ :7)U\NO76945
M-*4KDV<\F'X?Q5+L@HF,N3.S,G;44?CQ[G9D1O,GDCVV1:+MSD]W2.'<1H5R
M)Z;"GAZLW.(VEK$K<0-ZX:8*0[9PF'&*Q,4!<QJY8NX7.5C16DD94NN=@BL5
M3,N9K+F%[U3/+S,+R!<Q4#*I.4%F(506L<H+$7-C87-CNKF6/\MYDF;)DYB)
M@F.%.6L.99#C"7H13N2,6/G@A7CZ%9.;)+''RT%DS^2-3&,BQ9.K8')BO="]
M%OB4+TK2(T*UQLQ>'BA.'DB>1X,5A^?CYQ5650)IL.Z/E8J2LD#D,NC(5-E-
MP.9B\5M@8:3U+P6SL7CX<4L,D..VCB=G87F3$)3*F(@V;M.4R /$!"<,%-Y"
M9AD4/\GE_P!3PAD=L8JP<5?D#L"P,Z3DS;\T';>__F_AV;-UMFS?MY]U51?A
M9+G=>]NVW5V^3R\&;&<N[KFY/\E;V.[E9M6V_MY'"O&[NZE_J7X1YOJX3CP_
M]0/D]_9NJV[]0\O9X?-XZI[LY=?!_DM_JS:G7_<[S^*G=W4OO_8OPCT_W\)Q
MY/[P'P>2EWZAY?MIW9RY^#_);Q<K-J_[.%8RA\U*WL3RL88*ML4I[V[8S;-Q
MAN()H;@L586! 6"HN*VP@=KC$$VX1!+'>U@WS0N,_>L;QN#D;*;%2#F(O[&
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M-HFC6,C$ZV.DJ%K$RKCW=,:8J1QN2,;L\,TF*:%*<Y*L<&Q2-&/E)CB##"U
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MDGW>UO'ZWK+'K_\ 5?R9O!Y?+-MVK7UZK'JWCRDW\.IJ.YHOIFZ]/]TE=/\
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M9@;KIX'V[F[-:&!2W-<RJE3(>:*<W'=T!&9NHJ,B6L?T:KAUTJ4I2E*UA_\
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M^"N-RB_D#;?]E8_]%EKENH3(F+GC+3?").IU:8MGT2CT[;&>>8?PA.IPR2B
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M703DF9N;E0 ]XP<$M6NFSHT=FSZ,,0K6C3OC/B^Z0S9PX;F[<VN9&.6[#*;
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M58@!3F^.CB>3,RJYCCRF9U7/S:,;9B+J#H&(!9;D6N-X[K.%L+C.U\BDY<Q
MO:]C;HN;&U]W0:>,.K^9GZ$)[JS?8%$@S>"-V>3%$!03(QMB3@\8=RC/\<HV
MY),9$WH5%R7P<.3GD&*&E*N<%BX+>WMA:Q4D1VZ3[-B&UXMF)-(8I7PBB8Q@
MRA<5AX9RQBC9M4YT@V=K 9F:P)K27&.<"^,:-0Z"?V//9"T$LD0 =U71C'I=
M1>X &ZN9XFUV92R$YZ;"E^,H.WQW,6I#,^GB6.YC[,(_-6!SQI!,J3=B<#L0
MR2-)Y! 7%^;\<E*GJ*Y#?TTICB5X;N6R*R70AP1W8C94,"XXB>5I,+@<)C44
M)&\4BXB;#0N%Q,<I294;$=Y)"AC<HP#@J16$6.>0X?V)0D^*GPQ)9UD0Q132
MJ6A:,-&S"+6.0JZA@2+$&LAS^2$2.2R;\[3&>%W]AGKKJ1<]/T==LT-4MB<)
M"!AP"^9^=9$\"+8TCB6\W:XXM8"(0C4"6D =&&4J7:[>O"W#@;(1(^Z)\4C0
MK@EQKKA6CEE.?&I@513G*9<TBN96%N]:,)F7,,CCF+B)(B';$G#*TV9$&7#M
MB2Y[V^Y"N1=;D,38VKV<H:XYFPZ"\;:UX!BXAT]&N(XQEUP@;LFG;^%J2/D$
M!-CF);(X1%7)NBK&GL!6@<\NSH4=@D42$D/3X4:!84WAB#94;[8FV5-B IBQ
M4F%$RF%0Q27F@XCEE5I'8V*8:$O-(3E0Z$E)C2N 3')$2'@6?(0[6S('RED0
M@*/PI7R1H!F:PKO.)\^2Z?:ALRXA>XQ#FR,0;&.$LI022Q:6+I6IE4?RZY92
M;2U+R8:QLK6@-*'CGMI"E93'M&)"XDJ+OJL9UTZ34GPD<6#PN)621GFGQ>'E
M1XQ&(WPRX9K+W[LP(Q !+!2&4C*+7-\4[OB)X610L<<$J,KELZS&9>^&50I4
MPFUBP(;?6A3C6'?'><LG0IYB[M(H?#%.F?&D;9H4T(ET_E&;]0[G.3FYOLJD
M,JC<8115,R-<,2$J%IR,*9U=G9:Y.I3:CV$6Q;.Y_"02I(J2R#'SR&5RL,>$
MP2Q9FM'')(92[2FRWNJJ N<U@V+$<\D;*2J=RH@109&FQ+2 #OG5,@54M>VI
M8DVM6"V_)'M.JYNACVK5/,=8)C"39\8ZRI[Q5'C8HPH+OX) *3QIPR:5-.V(
MR9&'LMVO'(S(T1]T!IC&M>2+6-N;8^-5Y8PJN\4PAM&L[B1FR9.;<0&.TG.+
MDYQXSWW?A#1<= R)("1&Z&3,YC7(HS9LZF3."N4WRJP)&A:J^8K^21SW*L/*
MFK+CO%5VP&MK"6G%[1),G'/;U&\;9W/PK:(2,U+'VQW:G>?(K97<VB2(@/S3
M%VN00I\1-JY_$E.)MO8C8D6'E,33XC,=E8O'H6PX17FP8Q9DC[]U986[E!1L
MC2,DJEE2M:/:+R)G$4=ACH,*P$N9E2?F,KV52#(.?LR7"@H0&-7PP1EU_P C
MRG4G#).C:D[K@O/CEC5&J9B52=*[11XQUCG+,,6JBE2Q<(+RDCN2D3"^&DG%
MI5SFRJ'1,B;B%X&Y+R<5AD@CP,L98KB\&LY#$$K*D^(PTH%@O>%\.706NJN%
M+,5S'>AE:1\0C  P3\V"+C,C113(3<G7+*%-C8E2;"]A8JM.KZU=^B\;?US0
MI>XPT/QZ(Y19*K<VY"M$VA&D46$,%U1!PK .O?L-BP7L&QIH3;_- M>MK#XG
M$018A(<5+ LB)GCC=U$Q$L9RW4@ K;/<ZE4*]-JUYH8I9(#) LQ1W*NRJ1%>
M)QF(-[AO: :V9@W1>MIOX]NWC\ONWK5\(XX_<*V*CIZO#3H[>JE?:3\]+^N
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M:21IF<2,&<2&1F?G<P<,20PO:I;"X=U*-$N0A04U"E501A2JD*4R +DMER@
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MI2E*4I2JF:]?H(=7?V-F:OO>2&O4\A_YY\E/[P['_3X*XW*+^0-M_P!E8_\
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MY MB11_P[8=:W8;6M>Y.W==78BUM][;+$ODF[V,@(MRX(87D0>Q::,38-O\
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MEC(!D1FQ,1<XB*,$9UB0S1P,6%[<XMP3HX%52*YNR,"0K6B?*(G:QREVR/(
M#8]X>C<:Y]I;QGD/'..G5/F4B'K,MS"9NLXR5*(=)WB6-,XE3FV,K89)>6]P
M7'YD>)(;&9MC#!$$3(K0Q>(1R-M('Y\4D*EYMVT,1!/.IPAE7#11+#AXY8UC
M>&)69A'WDLP<EF:1Y2X,DKNV1 0HJPL4D<1$^1IG=I)&5BZN[ #,,R1Y18!5
M0*0B*HS,;FNU/Y!-C$VPDJVT!G,6"W_&#S[OR51#KFOK:V_7K]'14S#5;6&A
M[.FM?["5_%%_S _!5]AU#R>/Y?/5%.Q%?Q1?\P/P4L#O \G'&E*PUI1')3W&
M X-NWD>SM0L/*N+M@')"?LMN2"OLLJZ.PW%T5G&+9P!'_%2_QG5D-RG7)_V^
MMP-:KDM9;F07DC_B]]\XT;_RS_XE@>]OI69V$K^*+_U8?@XOS5A9>H>0<?9O
MJSCCC?NI<DK^*+_F!^"EAH; ]NGEW>/PT-.PE?Q1?\P/P?EI8=0W]7'EZ-].
M..-:GL)5_P"U%;]F_D!ML]KUZ$#JW7TL#V_NM:IW]6MM=UN.FH["5_%%_P P
M/P4L.H:=@XZ_/45/82OXHOIV?, V^Y^7FM2P'0--=VGA[-WBWF@XXXON%1V(
MK^*+_F!^"EAU#KW=.F[JW4IV$G^++_U8?@I8=0[=WH\GS4IV$G^++_F!^"EA
M[D>04J>Q$[OT(NW7R _!T=5+#J&[06';>WA[:=71V\=794=B*_BB_P#5@^"E
M@.CCYMU*GL)7-V(O^8'VK[/Q4LIZ!X+?*.@[NW=4]G'B/ KB&,]/>(L7RB73
MB#Q)P8I1-%CA>4.*Z53)\N^&C5) V6GH)!('1L";<EI;4Z!82B*5I&A(D;$Q
MQ3>"R:NUM/;>U-I8?!X+&XJ+$8;!QPC"QIAL'"(%YMCD5X,/')HTLAD0N4:9
MGD8%SFKFX+9^#PLL^(@@DAFGDEYUGEF<R'G+9\LDC( P1,C*H(C"J-!:NX!
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MFV*PV_X-_P _R=W16<9]O<OK'(!S>GX!]M?_ ,,G^,_J7K"0&RV"?QD=^<U
M&<7R[O9 /:?U[>"LOW_QVX]>J^OL^P\>,59\_P!HX\M/!S^'R7V<W7X?Q7IU
M[NKQB^_LZOM%.K?Q8:=O'14<<7J>.!44XXX]JG5T\?)Q>G'''FIX?@XV>2G&
M_B_CI4VOLW_!U;-VSR]?CMMJ"+Z>GMOK?Q=G@-JG[1P..RQ%14U%*4J=W@Y_
M#Y.;9LZ=O54:]>[J\>^]^BW;4\?)NMX^RW;4<;_<J>/MJ*F_M=>SKMT>7?;G
MOOYZ@>?LOX>GQ:'<--U3N[?#X[V[+WW'MWTW>Y^/=N\FR_N[FOR]/D-R/+O\
M/6T^3[>GY_ETQ$=Q=C.Y7:VWMQ;L[5_:<GMHVP.R[K?IOD[EG^4=EM?IO?-P
M+K;/I'%_&;[\VI.7_P N^L0_[>0]55QWRF^3^,E_BSWMN<:U]W?V_C/Z^;PG
M*\?M;_?K'P>?3YJSI2E...+4XXX-...!2E*4I3Q>O\%/#Y/32E*4V]/N;O<I
M;H^77Y:4I2E*5/-U^]X]WN=/->HW]GS^#7Y>C>*G=V^737I^3YZPE%K]L(-@
M$HK6/-Y0C]G9R[=J*+6$B_YZ]]@#=F_M81_1MJU+9)=9!WBV"^U/LD>DO]2V
MH_\ ,"54X[^'2,V=KE_;K[&^L7]8[FL?XLO695=64]SCQ<U/EX\.^GR<>#=7
MV%?/2OK@/NK5!W'P'Y*;NWCR_(?!71*T*Z%*4I2E*4I2E*4I2E*4I2E5,UZ_
M00ZN_L;,U?>\D->IY#_SSY*?WAV/^GP5QN47\@;;_LK'_HLM6RO:U[7M>UKV
MO:]KVO;;:]K[KVO:^Z]KVY[5Y:NS4   L 2RPA   0@   ;!   ;6"$(0AM:
MP0AM:U@AM:UK6M:UK;+4W[Z5\J4I2E:#-YI9A2.3)&#X>]955QI\>(%CR1S)
M'$CI<XMJ,\Q(0:KLB>G9O8AKBRD[N_H(X^=R$HCU5FY:839*;=%%G*O()4PX
MD59IXXC)S:DBY S(K/8W5&D3,;#,+WJMWR@JF1I2I,<;.$S$ VN;,P6XU8*U
MA<V-K5RO3IFR39DQ^^R*01!$TR6*Y'FF.7=J8ESF24I/B#CVF%Z$S3IIB$PB
MG=1.8G6E1V7L;<\A1J$CLA[JQQU9'QRV,=A8\+,B1R,T<L$4ZM(%N!(MRF:%
MI8I,K J7C8KF!5@DBNBTX?$/-&S&,9TEDB95:U\AMFM)D9 PL0K@-8AAF0J[
M=<<S7I:,D1<;7@L6$5K\M<Q[[BO:]MEK.E[=&_;LJB-E3-=@;VW9NB_3E[>.
MB9!(Y!$9%ATLA_\ =7E]K/\ Z7EGL]E\O_*56\['[J_A#>+H\^_PU7S<GN#_
M )D^ETU/:S]Z7EGLYE_K+V_<Z(YU.EAX@WT?-YZ<W)[@_P"9/I5CJ4+\;8JU
MHR>;8"E.=L.<&>U@=B-"/LH.2X"VFE;.66&^P(AVM85[6JR.:,9LTA3V.0=Z
MK',2A 0Z"P<V4D^U!)K"2*4A;0A_9(R0S1]Z%8'..^U*VN!TD6K([6?O2\M]
MG,O]9;_:V]7-5?.I[H=NC>;O=/#XNVL^;D]P>SOD\_?:T[6?O2\L]G,O]9\>
M"G.IUB_^+Z/S>.G-R>X/^9/I5':S]Z7EGLYE\G_*53SJ=8W=3>3VN[=Z*<W)
M[@_YD^E4]K/V_9'5FSHVKV7;_P#Z51SJ6'?"_8& \&XZ<=E.;D_[9_S)](5'
M:S]Z7EGLYE_K+CJISJ>Z\S=G]7S>FG-R>X/^9/I4[6?M_P"MY9[.9?ZRW4YU
M.L;_ .M]'S4YN3W!\J?2IVL_>EU9[/9OZR^'Q4YU/==/4V[_ "^CPBG-R>X/
M^9/I4[6?O2\LV_Y\R_UEQY=SG4ZQY&^C^_LMJYN3W!_S)]*G:S_Z7EGL]E_K
M*IYV/W7F;T4YN3W!_P R?2J;)G[TNK.O]/,OAZ/U2Y_AO4&5/=>#1NKITW>@
M4YN3_MG_ #)YN^J.U7[=^MY9U_IYEW?_ ,E3G4ZQ_P#M]'KIS<GN#_F3Z53V
ML_>EY;[/9?ZR^#;S==.=3K'9HWT=//;MIS<GN#_F3Z58R9"_E ,#>,GE<I0I
M-V$KV>]A6./,,L:/E.(?T8VPNRG6MM#8T0K!$*UK"O9)-$2MI"]HXQ=E86(C
M4%!I[5""BGI4 VK".&4 @PA._D-E9+$-(S!SWWMG!S-_6)K([6?O2\L]G,O]
M95ASJ>ZT\#>C7S>.L^;D]P?\R?2J>UG[TNK+^-<R^\Y5'.I[JQ\#?.N_Q4YN
M3W!\J?2J.UG[TO+/9S+_ %E4\ZG6/(WT:<W)[@_YD^E3M9^]+JSV<R_UE4<Z
MGNO,WT?-J-U.;D]P?*GTJGM9_MS1Y9M_SYEW>+]4O%OW;*<ZAWD>#OOH^46]
M%.;D]P?\R?2J.UG_ -+RSV>R_P!94YU.OS-KOW][Z?-3FY/<'RI]*G:K]Z7E
MGLYE_K*G.I[H>1NWL\'@UWTYN3W!_P R?2IVJ_>EY9[.9?ZRJ>=3W7F;Z-.;
MD]P?\R?2IVL_^EY9[/9?ZRISJ=8\C?1\' U<W)[@_P"9/I4[6?O2\L]G,O\
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M8:D[JZT0I3*K&"3*"% 23SDQPB#2SK%*4X[E*$YERQ"L \@P(BSBA;#"AVN
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M*8R8S%&A"H>U:LU(@96!,F;BBRA6-6C*,='4U>]KG)S6U8G%RXME:41@J9&
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MIYI6+R2RR,7DDD=B2SNQ+,2;DFNM'''#&D42+'%&BI'&BA41% "JJBP"J
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M_P"]]E?%\5]=KXW_ #0MK>MO] VFSIW>@7(>SFO?ZK.WH\-/6&Y&>_>4/QW
M?LNI'W2]OD_]/LKH_H^*ZP/?O;7R^6%=;WI&TV?:+D/\+5/6&Y&>_>4/QW ?
MLNH]<S;_ +WV5\7Q7UVH^6%=;WI'TV_:+D/\+-/6&Y&>_>4/QW ?LNGKF;?]
M[[*^+XKZ[4?+"VM[YJ_H&TV;N;]8N0_!M^JSU^U3UAN1GOWE#\=P'[+J?7+V
M_=?X/LK7_P"WQ761[]J?EA;6]R=OH&TV;=FW]XN0_!_UM4]8;D9[]Y0_'<!^
MRZ>N7M_-;N?96^W_ $^*Z_\ \VI^6%=;WI&TV?:+D/\ "SY/Q[Z>L-R,]^\H
M?CN _9=1ZYFW_>^ROB^*^NU'RPKK>](^FW[1<A?A9IZPW(SW[RA^.X#]ET]<
MS;_O?97Q?%?7:CY86UO;-OH'TV<^S]XN0]_S6SZK/@\%/6&Y&>_>4/QW ?LN
MI]<O;]_^GV5NO_T^*]S?W[7R^6%=;WI&TV?:-D/\+5/6&Y&>_>4/QW ?LNH]
M<S;_ +WV5\7Q7UVH^6%M;VVUO0-ILYK_ ,!<A]&S_I:ZZ>L-R,]^\H?CN _9
M=3ZY>W[$]S[*WC^CXKIO_P#>]E!?FA;6]:VVT&TV;O\ U%R'O_\ %JGK#<C/
M?O*'X[@/V71?NE[?) [GV5\7Q75_^;4_+"NM[TC:;/M%R'^%FGK#<C/?O*'X
M[@/V74>N9M_WOLKXOBOKM1\L*ZWO2/IM^T7(?K_V6?Q=5/6&Y&>_>4/QW ?L
MNGKF;?\ >^ROB^*^NTM^:%M;VRWZQM-G-Z1<A_A:IZPW(SW[RA^.X#]EU)^Z
M7M\$CN?96A/]'Q7UVI^6%=;WI&TV?:+D/\+/&SQT]8;D9[]Y0_'<!^RZCUS-
MO^]]E?%\5]=J+?FA;6]MO^L;39NOZ1<A^"U_JM4]8;D9[]Y0_'<!^RZD_=+V
M_I_!]E:CWOBNLCW[V4O^:%M;UK7OZ!M-G-Z1<A_A:IZPW(SW[RA^.X#]ET'W
M2]OD@=S[*U(_H^*^NTO^:%=;V[]8VFS??TBY#\%_^EGPVV_BW4]8;D9[]Y0_
M'<!^RZ#[I>W]?X/LK0>]\5U@>_>VI^6%=;WI&TV?:+D/\+-/6&Y&>_>4/QW
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M^\H?CN _9=/7,V_[WV5\7Q7UV@?S01K@<]C<")Z=VT;AL1!<4$$FXER 2O\
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3UDED<EG8[R; !0 .H5S:VJ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g287237g90n36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287237g90n36.jpg
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M ?_$ !\  0 " @,! 0$!           &" <)!0H+! (# ?_$ %40  $#! $
M 0L/!PH%! ,!  4#! 8  0('"'<)$1(3%!8V.%:5M H5%S4W.515=':3MK?2
MU"%XDI:UT]4:(C%76'.7LKC7&!DC,W(D==;8)S)10?_$ !X! 0  !P$! 0
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M&[R1:E!AELH4 R=+&L/%E),"B "$YI[S*VBS(RD)#'7TQJ?\E8W'3$(CYDN
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MCB)@;08PY#0LDC$2,3+IFD0M(AD8!7:--*Y5*R8?%,0\SRO)E*I8.4!6160
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MRB8@7L<2#(!XT&F8A9+-Q=S@'/;6WKK)F&.HK99XI'VF.E;FR&2.2"*3B1N
M.#3+*.*%C$&]L5M8XG60N7D>%P<LB\=M97#/&<@3&W/-"Y@DB,.3[H$2+:W3
M7$DB,FD*BR*1GGI>>ZA"MU>G MM;999%RF72:FY&"20?(N2.[K#VYYO<)JK1
M0)[Z^Q641>RSUA/.2MEUQ%Y,'$6D ;/MF/<<B W)1\CUL[CRCJR2G8>9HVCP
M^SU%#KN;UQHECDR5H,/R#[MWT/PXQOID7AJ49BOV)P]Y<Y!QI@M5.N-TS(EO
M,RNM5UKW'34A^)C6=#DBC\88^N<E.!X\-[<FW]<#A-D)8]T*VRNDAW6_7;H=
MN5MAG=-+MG9YVPROCC?L;]:6@MY[E]W;037$F1;=P1O*^D99MHC5FR&8S.60
MS&=3$DL4*ZYI(XDS U2.J+F>H-3$#,_$,\S4.]F74']:VMOUYB_\4J;^P^+?
MR7B/]BN?\JH'/['^.VG]IA_;I[,NH/ZUM;?KS%_XI3[#XM_)>(_V*Y_RJ<_L
M?X[:?VF']NN0%[0UH<?MA078D%,%'N>2;,:+EH @_=J8X9JY8-F;0@LX7SQ2
M3S4RQ23SRMAAGG>UL<;WM#EPS$H(VEFP^]AB09O)+:3QQH"0 6=XPJ@D@9DC
MB0.J:])>6DC!([JVD=CDJ)/$S,>KD%5B2<N/ 56?J@'BSD^F'B[_ *G]/5)5
MFGD)[8]K\T^4O_Z:;75=&E8?I2E*4I2E*4I2E*4I2E*4I2E*4I2E5RY/> (C
MYWL/V*?J<L>NM\F?.2J;BGW.GRR^9)5C:DZJ5*4K%&R-':HVV\C!/8$$C,D,
MPR01J2Q<\1"BW1X(0BDH$3 8F-,.6BQ!DP5. QZY%BV72;D44LD'.&>&=ZF;
M>\N;42+!-)&DJ21R(KL$=98VB8L@(4L$=@K$$J>(XBH$UK!<%&EB1VC>-T<J
MI=6CD65=+D%@-:*6 (##@>!J*/N-&M32[4C),#4F/VS=8G9(7>L\2TP'OU-9
MJ$ TIP&#1HEX*(VTUJY$B@R%CEB#>'-&[QPLD5D>)J*N(7"!ECT1(0-$:!M,
M3*+@*\99F=67G=SI)9@IE.0&F/1#-G"Q#/J=^(9V(U2*=SJ5]*JI5N;P:@ -
M6[ )(9PWW\B6S=?7+519NBLHWV9I!1NHJDFIFAG?=NO+7S1SSQODEG>UK6OE
MA?&][6M;KU^6!(N" 2 ;>\S / _\'/U>[7JZ ,0S .4UL1F.H><Q<16<ZDJF
M:ZJ&YO5(\LU1N#:^K4.),>-HZUV5.H"B95W(28*ETH=*"D=3)J,<-;N\&2C_
M  '6=YM,73G%ODK='%PM;"RF6T&#]#O:8IA.%XFVU5Q"V(X=97QA&$1N(C=V
MT5P8PYQ!2XC,FD,54L!GI&>0PCB/*[/8XA?60P**06=Y=6HD.(.ID%O.\(<J
M+1@I<)J*ZCEGEF<LZQK_ "H:8?V-HU_C>4_VPJH_P:;/^=US_<T7^I5)_;HN
M/YOP_P!Y/^Y4_E0TP_L;1K_&\I_MA3^#39_SNN?[FB_U*GVZ+C^;\/\ >3_N
M5=BWC!S C^\.'VJ.66PAPW4XC8[1GD]$YEG<@'@B9G8B^MX\-P+8"1[E]F8/
M9B6J"EQ3;%-T3334MBBEDXK7/;'9]-EMI<6P!+IKU,,GCA6Z>(0-,'MX9]1B
M$DH3(RZ<A(V>G//CD,Y["IBNWEIAKX3ADDV(XC9XE?+A]O(LCK;X3;7U]?R+
M)+N%9;>PP^YNY,PIT1.JAFTAKF5;51Z4I2E*4I6O;JKWO<O+[H>->F#ZOWDN
M[8.R?C>#S7JU=N.Q+'_%\OZ5KS8*Z)UJ#2E*ROH;W<M,]*^N_K>'JEXY\"XQ
MXKQ#T2:I["_A+#O#K3TB.O51KF'6[5*4I2E*4I2E*4J(3?VE9?._7WU^C51(
MO?'Y.;ZIZ@S^\7Y:W](BJ7U#J-2E*4I6,-J3Q_KX9$2+$:T)]\.S];0-ZF[<
MK-NY&$[EPR+N"37M**O=#MA<DFX1;*W115MAGV:UNQQPSF+:%9VE5F*Z+>XF
M&0!S:&)I0IS(R#:<B1F1W/CJ#/(T2QD '5-#&<R1DLLBH2,NJ1J! .0K%F_]
MU3[2^3J1BXC')E#!D)F4@-#T2I,=*PZL?CA,H+DA%WDQ<!&T1>R5 '"WS3%-
M8TA>0J2QHHZ&QPT,PF;*TAN\HVEDBE::%$8JK1N'=5>-1F',JQZYE/O#N]T0
M&D1C+W=S-;9NL:21+'([#4PD4HC,KL=)01EPD1'OAK,@S5&6L<0WE^2D>T4]
M<NX<@BF+V7EJ@\6;J.\,RAEQ*^3T7922.,5<UNU@V^7''!V68KN2.;7*8%F>
M)C)77SK.3S$N%K';&<2GIK?G**<NE418=(8Y#D.G//\ )2 N>Z1M&4ZZ(,>(
M,\^Y,8&F?<.PSZ9C)>H'0<>E',]3 DY;QAJSA.O+VVI(/2V_Q@BN3<]<HYVQ
M(3*;I.*RA:-XM$^/'(1MDBXF20?.(-"MU$\LL 3HXB;5;WP=IC\VJJ:V<K:Q
ML;7$I<TTBUC0@RQB3,W]B<Q$7WI7+JN$* \"V?"IBX<"XLH\GU&=VSW;E,N:
M78R,@7=AN'O2P;+CED16>RQ0>#%DC99U@R%!Q[PH3>*VSNFT'CVRCMXZ4LGC
MFI?!NV145SMAAGG?'"]L<<LNM:\I%%)/+'#$I>6:1(HT&6;R2,$11F0,V8@#
M,@9GB:F9'2)'DD8*D:,[L<\E1 69CEF<@ 3P!-:Y/^<-U-/^UI /-,X_^*5D
M'[4O*-_-6_\ I;+]ZJTO]_\ 8_\ EVU^CN?\BG_.&ZFG_:T@'FF<?_%*?:EY
M1OYJW_TME^]4_P!_]C_Y=M?H[G_(I_SANII_VM(!YIG'_P 4I]J7E&_FK?\
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MD<LB".%09CQGT8,3&),=>C6R8?)CB/QP?G+]I'C48.W'QY3+,IEDZB+-#6D
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MTDB=9(W'=5T)5A_2"16,-VD9<,#P-:&YR"SU?<NHV!G"/"W!55:($)P(9R_
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M81QNW(*ME&P.+"9OLO8(H".Q0;(9Y(CS^V)6W1=.<U7:H1&/L':CER)5(O\
MS<WLMTD:2!0$9I"5!!>5X;>!Y&S)&;):Q$@  .9&&08*OJ"UC@=W0L2ZA "1
MDJ"6:954 #J/.XS.9*A <RN9X""16,1?DCNV\:C@&.WD&J=%2(]<$''B+FY
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MJ6SZW+Z'#L1QKYQS>K,-K7/EC^'\-\3Q^FWM=<*MA:Q'2E*[8/J73VYYL?\
MMG'OTK=%:M]$OUK8WY3'_-P:LX\B_7-H_P 3"O.Q&MU4\ZG)A,>33':#;<,S
M#Z++,)L^V!I1L3(V5+R&:2B&RV3 X])K+>ND>UQL.10\/(YW'&3U#*Q$81'
M[MQ<W+XA]4ZZ%8'T0C81R;S[,R;)8/=[:VL^#0X#ME);6^FTP_!\-Q?"\.O;
M_#2G-L0VAP##\7N\/P/$9H7_ .'N;>XO=Y<X+:&[V>6M:UK6M;K6M:UK6_\
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M:LKCGES*BBE\D[M,7 ^Z=L;9]OR[+L;4;#E0S2%W*L+:\**$U!SS.XS!;4-
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MR^=^OOK]&JB1>^/R<WU3U!G]XORUOZ1%4OJ'4:E*4I2E*5P!R*1B3XI822.
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M^GCH)/O5^1SYOXA^L>-5+ZQQ6U%*4KN8]0O\1E+I?V#Z/':5R!Z-GMUO\T\
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M*+($[UPP.M%.0W2Z7E+!4=7TAI>X>6./5"(V<,.D?5[IF>MJ5(T,W$[PAE0
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M*N\]&#R^ 9G;"R S S.S&S &9( ''">J20!W20*^G^3_ '#O^M'D[^N&IO\
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M=):R&Q=6+715M_2FKVO367:U+=:_7PSZV5NM^6U?IY?N4$=5L'&?4SPPC/\
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M^&>66?#.N>_D_P!P[_K1Y._KAJ;_ &4KQSF'^(6GEWW[[7K^%_R^_P [[/\
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M:^>6-KXQYQ">IA]H>J??W_4 S)^[?B'$_P!%;:_PP.7S^>%G_P!L;,?'U/\
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M8B0!#Q;\@]8BQQ#7A1CBM(/6HJ0<7671"H"<!A4SXEMMW:VUR)DD%Q)<1F-
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M7,4=NMRDXA@.K0I>5%N)92I8E5B0(#*TLRT$K7Z2M"BP1G>(Z,H=YV@:$RS
MKJ(2-C#&BG( F1BQ"*EOZI=5&E*5QY4HS"CG11^IDFU:)VSS[##)597///%)
M!LV03MDJY>.W"B35FU1QS7=.ED6Z&&:JN&-_U06( ZI_]YD]0 #B2> '$\*\
MNZHI9CD ./#,GX@ !Q))(  XDD <37"QL6\PS=2 VGC@?-8)=N;6SP5P""T;
MYYCX^W5PODGG9GVY1<BY3RRQ?EW#QPGE9E9@V:^G8<%7WJ_'^$QRU,<^IGD
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M8CTTKI;Z9E_X:T?2NZR6XTELWC83@N[\MTB(\:,Q,O-+B/?JK6(R1'FSB/\
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M.I]6%WSHH6UIK\H2?+YN7Q$C#8Z]?/'*M^R4<.G;D:JX<+J9?ES564S4SO\
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I4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
